STUDYID|DOMAIN|USUBJID|ISSEQ|ISTESTCD|ISTEST|ISCAT|ISORRES|ISORRESU|ISSTRESC|ISSTRESN|ISSTRESU|ISSPEC|ISMETHOD|ISLOBXFL|ISBLFL|ISLLOQ|VISITNUM|VISIT|VISITDY|TAETORD|EPOCH|ISDTC|ISDY
e|IS|35f5401f-575a-44dc-9141-8084716a5b70|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|pmol/dL|[?]|1|mL/kg/min|EPITHELIAL CELL|MICROPARTICLE ENZYME IMMUNOASSAY|Y||1|1|Visit_1|10|2|TREATMENT|2020-10-20|10
e|IS|35f5401f-575a-44dc-9141-8084716a5b70|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|deg/mm|[?]|1|s/h|SUPERNATANT, PLASMA|PHOTOMETRY|||1|2|Visit_2|25|6|TREATMENT|2020-11-04|25
e|IS|35f5401f-575a-44dc-9141-8084716a5b70|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/cm|[?]|1|Log10 ELISA unit|ERYTHROCYTES|HANSEL STAIN||Y|1|3|Visit_3|40|6|TREATMENT|2020-11-19|40
e|IS|35f5401f-575a-44dc-9141-8084716a5b70|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Bq/g|[?]|1|10^3 organisms/mL|SKIN TISSUE|CARDIAC THERMODILUTION||Y|1|4|Visit_4|65|5|TREATMENT|2020-12-14|65
e|IS|35f5401f-575a-44dc-9141-8084716a5b70|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|NEBULE|[?]|1|JAR|STOOL|CRYOSCOPY|Y||1|5|Visit_5|90|7|TREATMENT|2021-01-08|90
e|IS|8a863a88-67d8-4e50-bafa-c3146591f046|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mU/g|[?]|1|log10 CFU/mL|SMEGMA|RADIAL IMMUNODIFFUSION||Y|1|1|Visit_1|10|6|WASHOUT|2020-12-29|10
e|IS|8a863a88-67d8-4e50-bafa-c3146591f046|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|foz_us|[?]|1|umol/L/min|REFLEX TEAR|NUCLEAR RADIOLOGY|||1|2|Visit_2|25|7|WASHOUT|2021-01-13|25
e|IS|8a863a88-67d8-4e50-bafa-c3146591f046|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/cage/day|[?]|1|10^9/dose|SERUM OR PLASMA|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|3|Visit_3|40|1|SCREENING|2021-01-28|40
e|IS|8a863a88-67d8-4e50-bafa-c3146591f046|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ft3|[?]|1|tsp eq|SMEGMA|REVERSE TRANSCRIPTASE PCR|Y||1|4|Visit_4|65|4|SCREENING|2021-02-22|65
e|IS|8a863a88-67d8-4e50-bafa-c3146591f046|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|fmol/L|[?]|1|days/month|EXHALED BREATH CONDENSATE|PET/CT SCAN|||1|5|Visit_5|90|3|WASHOUT|2021-03-19|90
e|IS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/g/min|[?]|1|uV2|SUPERNATANT, CEREBROSPINAL FLUID|INDIRECT IMMUNOFLUORESCENCE|||1|1|Visit_1|10|2|TREATMENT|2020-08-03|10
e|IS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|TABLET|[?]|1|U/animal|VENOUS BLOOD|FLOCCULATION||Y|1|2|Visit_2|25|4|WASHOUT|2020-08-18|25
e|IS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/kg|[?]|1|tuberculin unit|ARTERIAL BLOOD|HIGH RESOLUTION CT||Y|1|3|Visit_3|40|2|TREATMENT|2020-09-02|40
e|IS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cmol|[?]|1|vp/dose|BILE|SINGLE-SLICE SPIRAL CT||Y|1|4|Visit_4|65|6|SCREENING|2020-09-27|65
e|IS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|fmol/g|[?]|1|ug/day|PLATELET RICH PLASMA|INDIA INK STAIN|||1|5|Visit_5|90|1|TREATMENT|2020-10-22|90
e|IS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 organisms/mL|[?]|1|uCi/kg|KERATINOCYTE|MICROBIAL CULTURE||Y|1|1|Visit_1|10|6|WASHOUT|2020-12-20|10
e|IS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|LOZENGE|[?]|1|nCi|SERUM OR PLASMA OR BLOOD|NUCLEAR RADIOLOGY|||1|2|Visit_2|25|4|TREATMENT|2021-01-04|25
e|IS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/L DDU|[?]|1|APL U|NAIL|SPECT SCAN|||1|3|Visit_3|40|4|TREATMENT|2021-01-19|40
e|IS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|F|[?]|1|BLOCKS|LEUKOCYTE|FUNCTIONAL MRI|||1|4|Visit_4|65|2|SCREENING|2021-02-13|65
e|IS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log10 PFU/mL|[?]|1|ugEq/L|GASTRIC CONTENTS|DC SHEATH FLOW||Y|1|5|Visit_5|90|1|FOLLOW-UP|2021-03-10|90
e|IS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MHz|[?]|1|mL/cm H2O|CIRCULATING TUMOR CELL|DYNAMIC LIGHT SCATTERING||Y|1|1|Visit_1|10|6|SCREENING|2020-07-03|10
e|IS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uV|[?]|1|mg2/dL2|BONE MARROW|OLIGO ACGH|||1|2|Visit_2|25|1|TREATMENT|2020-07-18|25
e|IS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|LENS|[?]|1|amp|INFRANATANT, SERUM|ANGIOGRAPHY||Y|1|3|Visit_3|40|4|TREATMENT|2020-08-02|40
e|IS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MBP|[?]|1|VIRTUAL PIXEL|ADIPOSE TISSUE|SLOAN LETTER EYE CHART 100%||Y|1|4|Visit_4|65|1|WASHOUT|2020-08-27|65
e|IS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mm/min|[?]|1|Mile|BONE MARROW MONONUCLEAR CELL|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||1|5|Visit_5|90|7|FOLLOW-UP|2020-09-21|90
e|IS|0389257f-50de-4a05-8f2a-69c068374337|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ukat/10^12 RBC|[?]|1|log EID 50/dose|SUPERNATANT, PLASMA|WESTERN BLOT|||1|1|Visit_1|10|3|TREATMENT|2020-10-08|10
e|IS|0389257f-50de-4a05-8f2a-69c068374337|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|PELLET|[?]|1|Gravitational Unit|MIXED VENOUS BLOOD|QUANTITATIVE COMPUTED TOMOGRAPHY|||1|2|Visit_2|25|3|TREATMENT|2020-10-23|25
e|IS|0389257f-50de-4a05-8f2a-69c068374337|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cmol|[?]|1|Bq/ug|SMOOTH MUSCLE TISSUE|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|Y|1|3|Visit_3|40|4|TREATMENT|2020-11-07|40
e|IS|0389257f-50de-4a05-8f2a-69c068374337|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|km|[?]|1|Pack Year|BASAL TEAR|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y|Y|1|4|Visit_4|65|1|FOLLOW-UP|2020-12-02|65
e|IS|0389257f-50de-4a05-8f2a-69c068374337|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|fmol/L|[?]|1|s^-1(%O2)^-1|LEUKOCYTE|NUCLEIC ACID BASED METHOD||Y|1|5|Visit_5|90|5|TREATMENT|2020-12-27|90
e|IS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|aMFI|[?]|1|Anson U|MUCUS|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|1|1|Visit_1|10|6|FOLLOW-UP|2020-12-15|10
e|IS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Anson U|[?]|1|U/kg/h|SMEGMA|IMMUNOCHROMATOGRAPHY|||1|2|Visit_2|25|7|SCREENING|2020-12-30|25
e|IS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug/min|[?]|1|10^8 PFU|SUPERNATANT, PLASMA|SPIROMETRY||Y|1|3|Visit_3|40|5|WASHOUT|2021-01-14|40
e|IS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|dpm/100mg|[?]|1|U|PLASMA|HPLC/MS|||1|4|Visit_4|65|7|TREATMENT|2021-02-08|65
e|IS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/wk|[?]|1|PFU/dose|EPITHELIAL CELL|PHASE CONTRAST MICROSCOPY|||1|5|Visit_5|90|6|FOLLOW-UP|2021-03-05|90
e|IS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/U|[?]|1|min/day|EXHALED BREATH CONDENSATE|ECHOCARDIOGRAPHY|Y|Y|1|1|Visit_1|10|3|TREATMENT|2020-12-22|10
e|IS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|umol/kg/min|[?]|1|DNA copies/ug|VENOUS PLASMA|PULSE OXIMETRY|||1|2|Visit_2|25|7|TREATMENT|2021-01-06|25
e|IS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL*cmH2O|[?]|1|nmol BCE/L|WHITE MATTER TISSUE|WESTERGREN|Y||1|3|Visit_3|40|2|WASHOUT|2021-01-21|40
e|IS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/animal/day|[?]|1|mkat|VENOUS CORD BLOOD|ICP-MS|||1|4|Visit_4|65|5|TREATMENT|2021-02-15|65
e|IS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ks|[?]|1|Anson U|COLOSTRUM|CLAUSS METHOD|||1|5|Visit_5|90|4|SCREENING|2021-03-12|90
e|IS|ad402b62-0625-431b-9bd7-ffd6124610f3|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|log10 CCID 50/dose|[?]|1|ng/L|GASTRIC FLUID|CONTRAST ENHANCED PET SCAN|||1|1|Visit_1|10|6|FOLLOW-UP|2020-09-25|10
e|IS|ad402b62-0625-431b-9bd7-ffd6124610f3|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^7 TCID 50/dose|[?]|1|BE/mL|WHITE MATTER TISSUE|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|2|Visit_2|25|3|TREATMENT|2020-10-10|25
e|IS|ad402b62-0625-431b-9bd7-ffd6124610f3|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/min/kPa/L|[?]|1|Ci/ug|DIALYSIS FLUID, PERITONEAL|WESTERN BLOT||Y|1|3|Visit_3|40|7|SCREENING|2020-10-25|40
e|IS|ad402b62-0625-431b-9bd7-ffd6124610f3|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Ci|[?]|1|dL|KERATINOCYTE|MYELOPEROXIDASE STAIN|||1|4|Visit_4|65|7|TREATMENT|2020-11-19|65
e|IS|ad402b62-0625-431b-9bd7-ffd6124610f3|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|log EID 50/dose|[?]|1|Coulomb|LUNG SURFACTANT|ERGOSPIROMETRY|Y||1|5|Visit_5|90|6|TREATMENT|2020-12-14|90
e|IS|d76b0f55-541c-491d-9162-4c133c9509f1|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|pmol|[?]|1|foz_us|AMNIOTIC FLUID|FLUORESCENT MICROSCOPY|Y|Y|1|1|Visit_1|10|5|TREATMENT|2020-05-24|10
e|IS|d76b0f55-541c-491d-9162-4c133c9509f1|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/m2/h|[?]|1|Enzyme U|BONE MARROW|IMMUNORADIOMETRIC ASSAY|||1|2|Visit_2|25|3|TREATMENT|2020-06-08|25
e|IS|d76b0f55-541c-491d-9162-4c133c9509f1|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/h/mmol|[?]|1|log10 TCID 50/mL|LYMPH|HANSEL STAIN|Y||1|3|Visit_3|40|4|FOLLOW-UP|2020-06-23|40
e|IS|d76b0f55-541c-491d-9162-4c133c9509f1|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|km/h|[?]|1|cmol/L|SMEGMA|MICROBIAL CULTURE, LIQUID|||1|4|Visit_4|65|6|TREATMENT|2020-07-18|65
e|IS|d76b0f55-541c-491d-9162-4c133c9509f1|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|% INHIBITION|[?]|1|s*kPa|LYSATE|HIGH RESOLUTION MELT ANALYSIS|||1|5|Visit_5|90|7|WASHOUT|2020-08-12|90
e|IS|146059d8-5652-41cd-b484-c6e5d8ea540f|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|WAFER|[?]|1|cmH2O*s2/mL|LYMPH|IN SITU HYBRIDIZATION|Y||1|1|Visit_1|10|5|TREATMENT|2020-08-26|10
e|IS|146059d8-5652-41cd-b484-c6e5d8ea540f|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mCi/kg|[?]|1|titer|VENOUS BLOOD|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||1|2|Visit_2|25|3|FOLLOW-UP|2020-09-10|25
e|IS|146059d8-5652-41cd-b484-c6e5d8ea540f|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mm2|[?]|1|U/kg/min|KERATINOCYTE|IMMUNOCHROMATOGRAPHY|||1|3|Visit_3|40|7|TREATMENT|2020-09-25|40
e|IS|146059d8-5652-41cd-b484-c6e5d8ea540f|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MESF|[?]|1|rpm|ATHEROSCLEROTIC PLAQUE|SURFACE PLASMON RESONANCE||Y|1|4|Visit_4|65|6|FOLLOW-UP|2020-10-20|65
e|IS|146059d8-5652-41cd-b484-c6e5d8ea540f|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/500 WBC|[?]|1|ppb|GASTRIC FLUID|ICP-MS||Y|1|5|Visit_5|90|4|TREATMENT|2020-11-14|90
e|IS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PIXELS/cm|[?]|1|tuberculin unit|MUSCLE TISSUE|SMEAR|||1|1|Visit_1|10|2|SCREENING|2020-11-04|10
e|IS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/dose|[?]|1|DAgU/mL|PLATELET POOR PLASMA|NUCLEAR RADIOLOGY|||1|2|Visit_2|25|7|TREATMENT|2020-11-19|25
e|IS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/L|[?]|1|uIU/L|STRIATED MUSCLE TISSUE|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||1|3|Visit_3|40|5|TREATMENT|2020-12-04|40
e|IS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|%/s|[?]|1|umol/L|CERVICOVAGINAL SECRETION|IMMUNOBLOT|Y||1|4|Visit_4|65|6|WASHOUT|2020-12-29|65
e|IS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mIU/L|[?]|1|10^7 CFU|SKIN TISSUE|ELLA|||1|5|Visit_5|90|1|TREATMENT|2021-01-23|90
e|IS|129dc836-068a-463e-b789-a0d05c60605d|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|SACHET|[?]|1|Enzyme U/g Hb|GASTRIC FLUID|DUKE INCISION METHOD|||1|1|Visit_1|10|7|SCREENING|2020-07-06|10
e|IS|129dc836-068a-463e-b789-a0d05c60605d|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|TROCHE|[?]|1|kcal|MIXED VENOUS BLOOD|LIQUID SCINTILLATION COUNTING|||1|2|Visit_2|25|1|TREATMENT|2020-07-21|25
e|IS|129dc836-068a-463e-b789-a0d05c60605d|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|DROP|[?]|1|pt_us|PLASMA ULTRAFILTRATE|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||1|3|Visit_3|40|4|FOLLOW-UP|2020-08-05|40
e|IS|129dc836-068a-463e-b789-a0d05c60605d|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|pt_br|[?]|1|mmol/mol|EPITHELIAL CELL|WRIGHT STAIN|Y||1|4|Visit_4|65|5|SCREENING|2020-08-30|65
e|IS|129dc836-068a-463e-b789-a0d05c60605d|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 PFU|[?]|1|mg/kg/day|PLEURAL FLUID|FLOW MICROSCOPY|||1|5|Visit_5|90|2|FOLLOW-UP|2020-09-24|90
e|IS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|TAMPON|[?]|1|h/wk|CERVICOVAGINAL SECRETION|MULTIPLE BREATH WASHOUT|||1|1|Visit_1|10|2|SCREENING|2020-11-07|10
e|IS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|SBE/mL|[?]|1|/cmH2O|PERITONEAL FLUID|NUCLEAR RADIOLOGY|||1|2|Visit_2|25|4|FOLLOW-UP|2020-11-22|25
e|IS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/kg|[?]|1|nmol/L|GASTRIC FLUID|CELLULAR PROLIFERATION ASSAY||Y|1|3|Visit_3|40|7|FOLLOW-UP|2020-12-07|40
e|IS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/dL|[?]|1|10^6 DNA copies/mL|INFRANATANT, PLASMA|IODINE STAIN|||1|4|Visit_4|65|4|WASHOUT|2021-01-01|65
e|IS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/g/min|[?]|1|lx|BILE|AGAR DILUTION|||1|5|Visit_5|90|1|FOLLOW-UP|2021-01-26|90
e|IS|b91c4469-b3be-467f-8512-b73cf561e168|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|CCID 50/dose|[?]|1|mEq/kg|INFRANATANT, SERUM|IN VITRO GENE EXPRESSION ASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-05-18|10
e|IS|b91c4469-b3be-467f-8512-b73cf561e168|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|dyn|WHITE MATTER TISSUE|X-RAY|||1|2|Visit_2|25|7|SCREENING|2020-06-02|25
e|IS|b91c4469-b3be-467f-8512-b73cf561e168|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|TCID 50/dose|[?]|1|/2500 WBC|VENOUS BLOOD|MACRO BROTH DILUTION|||1|3|Visit_3|40|4|TREATMENT|2020-06-17|40
e|IS|b91c4469-b3be-467f-8512-b73cf561e168|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|dL|[?]|1|ag|SERUM OR PLASMA|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y|Y|1|4|Visit_4|65|2|FOLLOW-UP|2020-07-12|65
e|IS|b91c4469-b3be-467f-8512-b73cf561e168|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BEAM BREAKS|[?]|1|g/U|BONE MARROW MONONUCLEAR CELL|ACCELERATOR MASS SPECTROMETRY|||1|5|Visit_5|90|7|WASHOUT|2020-08-06|90
e|IS|3637e1e0-8c0c-45cc-b139-e812a589f940|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|vg/dose|[?]|1|g/U|ALVEOLAR AIR|MICRO BROTH DILUTION||Y|1|1|Visit_1|10|1|WASHOUT|2020-08-30|10
e|IS|3637e1e0-8c0c-45cc-b139-e812a589f940|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Pack Year|[?]|1|GBq/ug|CIRCULATING TUMOR CELL|RAJI CELL RIA||Y|1|2|Visit_2|25|6|FOLLOW-UP|2020-09-14|25
e|IS|3637e1e0-8c0c-45cc-b139-e812a589f940|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|HOMEOPATHIC DILUTION|[?]|1|mmHg|BREAST MILK|MUGA|||1|3|Visit_3|40|6|TREATMENT|2020-09-29|40
e|IS|3637e1e0-8c0c-45cc-b139-e812a589f940|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cm2|[?]|1|U/m2|PLATELET|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||1|4|Visit_4|65|1|SCREENING|2020-10-24|65
e|IS|3637e1e0-8c0c-45cc-b139-e812a589f940|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|v/v|[?]|1|/LPF|TISSUE|IMMUNOCHEMILUMINOMETRIC ASSAY|Y||1|5|Visit_5|90|1|TREATMENT|2020-11-18|90
e|IS|23385974-5fcd-4c36-b9fa-2fbb3841f182|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|PA|[?]|1|Watt|DERMAL TISSUE|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||1|1|Visit_1|10|5|SCREENING|2020-11-27|10
e|IS|23385974-5fcd-4c36-b9fa-2fbb3841f182|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg2/dL2|[?]|1|ug/dL|PLEURAL FLUID|ENDPOINT DILUTION ASSAY|Y||1|2|Visit_2|25|5|WASHOUT|2020-12-12|25
e|IS|23385974-5fcd-4c36-b9fa-2fbb3841f182|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Gauss|[?]|1|L/s|BLOOD|OBSERVATION|||1|3|Visit_3|40|5|TREATMENT|2020-12-27|40
e|IS|23385974-5fcd-4c36-b9fa-2fbb3841f182|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|TRANSDUCING UNIT/mL|[?]|1|Farad|INFRANATANT, PLEURAL FLUID|LEAD CITRATE STAIN|||1|4|Visit_4|65|3|TREATMENT|2021-01-21|65
e|IS|23385974-5fcd-4c36-b9fa-2fbb3841f182|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|in|PERSPIRATION|PHOTOMETRIC CLOT DETECTION|||1|5|Visit_5|90|7|SCREENING|2021-02-15|90
e|IS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|kcal|[?]|1|Torr|PLEURAL TISSUE|HPLC|||1|1|Visit_1|10|7|FOLLOW-UP|2020-12-06|10
e|IS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|log10 CFU/mL|[?]|1|mL/cm|INTERSTITIAL FLUID|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|1|2|Visit_2|25|7|TREATMENT|2020-12-21|25
e|IS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uV2|[?]|1|IU/kg|WHITE MATTER TISSUE|ENDOSCOPY|||1|3|Visit_3|40|2|TREATMENT|2021-01-05|40
e|IS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg|[?]|1|ng/day|GASTRIC FLUID|LC/MS|||1|4|Visit_4|65|1|WASHOUT|2021-01-30|65
e|IS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/m2|[?]|1|kDa|REFLEX TEAR|SINGLE-SLICE SPIRAL CT|Y||1|5|Visit_5|90|5|FOLLOW-UP|2021-02-24|90
e|IS|f1327e16-08c6-4ef0-852e-13c095a94c00|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CYLINDER|[?]|1|mL/min|BREAST MILK|IMMUNE REPERTOIRE DEEP SEQUENCING|Y||1|1|Visit_1|10|5|TREATMENT|2020-05-26|10
e|IS|f1327e16-08c6-4ef0-852e-13c095a94c00|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PFU|[?]|1|mg/mL/min|BUFFY COAT|TELLER ACUITY CARDS|Y||1|2|Visit_2|25|1|SCREENING|2020-06-10|25
e|IS|f1327e16-08c6-4ef0-852e-13c095a94c00|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log EID 50/dose|[?]|1|g|LEUKOCYTE|MICRONEUTRALIZATION ASSAY|||1|3|Visit_3|40|4|TREATMENT|2020-06-25|40
e|IS|f1327e16-08c6-4ef0-852e-13c095a94c00|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|keV|[?]|1|kDa|MONOCYTE|TONOMETRY||Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-07-20|65
e|IS|f1327e16-08c6-4ef0-852e-13c095a94c00|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|keV|[?]|1|g/animal/day|CORD SERUM|EPSILOMETER|||1|5|Visit_5|90|3|TREATMENT|2020-08-14|90
e|IS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|DIP|[?]|1|mmHg|SPUTUM|GC/MS-EI||Y|1|1|Visit_1|10|2|WASHOUT|2021-01-15|10
e|IS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|DNA copies/mL|[?]|1|POUCH|SUPERNATANT, SERUM OR PLASMA|PERIODIC ACID SCHIFF STAIN|||1|2|Visit_2|25|5|WASHOUT|2021-01-30|25
e|IS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|dpm/0.5 mL|[?]|1|cmH2O/mL|EPIDERMAL TISSUE|PATHOLOGICAL EVALUATION|||1|3|Visit_3|40|7|TREATMENT|2021-02-14|40
e|IS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|WEEKS|[?]|1|10^3 RNA copies/mL|MECONIUM|IMPULSE OSCILLOMETRY|||1|4|Visit_4|65|6|WASHOUT|2021-03-11|65
e|IS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/10^4|[?]|1|deg2|SYNOVIAL FLUID|IMMUNOCHEMILUMINOMETRIC ASSAY||Y|1|5|Visit_5|90|1|TREATMENT|2021-04-05|90
e|IS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|CFU/g|[?]|1|VIRTUAL PIXEL|ARTERIAL BLOOD|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|1|Visit_1|10|5|FOLLOW-UP|2020-12-08|10
e|IS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dL|[?]|1|VIRTUAL PIXEL|CALCULUS|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||1|2|Visit_2|25|1|TREATMENT|2020-12-23|25
e|IS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^6 U|[?]|1|ug/g/h|PLEURAL TISSUE|MIGET||Y|1|3|Visit_3|40|1|TREATMENT|2021-01-07|40
e|IS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|HEP|[?]|1|V/sec|EXUDATE|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|4|Visit_4|65|5|TREATMENT|2021-02-01|65
e|IS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ELISA unit|[?]|1|10^8 PFU|ISOLATE|NUCLEIC ACID SEQUENCING|||1|5|Visit_5|90|3|FOLLOW-UP|2021-02-26|90
e|IS|854a9218-995e-47f4-87ab-e58d20f56d19|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MET*min|[?]|1|vg/kg|SUPERNATANT, PLASMA|IN SITU HYBRIDIZATION|||1|1|Visit_1|10|6|TREATMENT|2020-11-23|10
e|IS|854a9218-995e-47f4-87ab-e58d20f56d19|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|CIGARETTE|[?]|1|PHERESIS UNIT|CERVICOVAGINAL SECRETION|LASER CAPTURE MICRODISSECTION|||1|2|Visit_2|25|2|TREATMENT|2020-12-08|25
e|IS|854a9218-995e-47f4-87ab-e58d20f56d19|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/g|[?]|1|usec|SERUM|IMMUNOTURBIDIMETRY|||1|3|Visit_3|40|7|TREATMENT|2020-12-23|40
e|IS|854a9218-995e-47f4-87ab-e58d20f56d19|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|100 IU/mL|[?]|1|cd|SOFT TISSUE|SPECT SCAN||Y|1|4|Visit_4|65|6|TREATMENT|2021-01-17|65
e|IS|854a9218-995e-47f4-87ab-e58d20f56d19|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/week|[?]|1|DDU|DIALYSIS FLUID|SCINTIGRAPHY|Y||1|5|Visit_5|90|7|WASHOUT|2021-02-11|90
e|IS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uL|[?]|1|DNA copies/ug|BONE MARROW|MANUAL CLOT DETECTION||Y|1|1|Visit_1|10|6|WASHOUT|2020-06-21|10
e|IS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mm/min|[?]|1|mEq/L|SKELETAL MUSCLE TISSUE|DYNAMIC LIGHT SCATTERING|||1|2|Visit_2|25|5|SCREENING|2020-07-06|25
e|IS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|umol/mg/min|[?]|1|umol/L/sec|GASTRIC CONTENTS|MAGNETIC RESONANCE ELASTOGRAPHY|Y|Y|1|3|Visit_3|40|3|TREATMENT|2020-07-21|40
e|IS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/m2/min|[?]|1|log10 CCID 50/dose|INTERSTITIAL FLUID|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||1|4|Visit_4|65|3|WASHOUT|2020-08-15|65
e|IS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL*cmH2O|[?]|1|mol/L|CELL PELLET|CLOT DETECTION|||1|5|Visit_5|90|6|SCREENING|2020-09-09|90
e|IS|08944dcd-a62d-4932-bb15-a8f15cc73229|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Torr|[?]|1|10^3 RNA copies/mL|MIXED VENOUS BLOOD|HEMAGGLUTINATION ASSAY|||1|1|Visit_1|10|6|FOLLOW-UP|2020-12-23|10
e|IS|08944dcd-a62d-4932-bb15-a8f15cc73229|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|beats/min|[?]|1|mgEq|MECONIUM|REVERSE TRANSCRIPTASE PCR||Y|1|2|Visit_2|25|1|FOLLOW-UP|2021-01-07|25
e|IS|08944dcd-a62d-4932-bb15-a8f15cc73229|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/m2/day|[?]|1|/2000 RBC|URINE SEDIMENT|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|1|3|Visit_3|40|6|FOLLOW-UP|2021-01-22|40
e|IS|08944dcd-a62d-4932-bb15-a8f15cc73229|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg|[?]|1|mg/L FEU|ALVEOLAR AIR|FLUORESCEIN STAIN|||1|4|Visit_4|65|1|TREATMENT|2021-02-16|65
e|IS|08944dcd-a62d-4932-bb15-a8f15cc73229|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|DAYS|[?]|1|GPL U|PLASMA|KNEMOMETRY|Y|Y|1|5|Visit_5|90|1|TREATMENT|2021-03-13|90
e|IS|1d7df560-695a-41fe-9226-4cc206b05f48|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|log EID 50/dose|[?]|1|Bq/uL|VITREOUS HUMOR|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|4|WASHOUT|2020-12-09|10
e|IS|1d7df560-695a-41fe-9226-4cc206b05f48|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/mmHg|[?]|1|INHALATION|ENDOTRACHEAL FLUID|PERFUSION MRI|Y||1|2|Visit_2|25|7|TREATMENT|2020-12-24|25
e|IS|1d7df560-695a-41fe-9226-4cc206b05f48|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mAmp|[?]|1|DAgU/mL|BONE MARROW MONONUCLEAR CELL|PERIPHERAL ANGIOGRAPHY||Y|1|3|Visit_3|40|6|SCREENING|2021-01-08|40
e|IS|1d7df560-695a-41fe-9226-4cc206b05f48|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mEq|[?]|1|ug/m2/h|URINE SEDIMENT|ENZYMATIC ULTRACENTRIFUGATION|Y||1|4|Visit_4|65|4|SCREENING|2021-02-02|65
e|IS|1d7df560-695a-41fe-9226-4cc206b05f48|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mmol2/L2|[?]|1|g/cage/wk|PLEURAL TISSUE|LISSAMINE GREEN STAIN|||1|5|Visit_5|90|4|FOLLOW-UP|2021-02-27|90
e|IS|12c802a8-862c-45a4-b12c-a6f920772534|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|INHALATION|[?]|1|kPa/L/sec|CARDIAC MUSCLE TISSUE|THICK SMEAR||Y|1|1|Visit_1|10|4|TREATMENT|2020-06-17|10
e|IS|12c802a8-862c-45a4-b12c-a6f920772534|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/m2/day|[?]|1|Watt|PLEURAL TISSUE|FUNCTIONAL MRI|||1|2|Visit_2|25|4|FOLLOW-UP|2020-07-02|25
e|IS|12c802a8-862c-45a4-b12c-a6f920772534|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|TROCHE|[?]|1|ug/dL|ABSCESS FLUID|MAPH|||1|3|Visit_3|40|2|TREATMENT|2020-07-17|40
e|IS|12c802a8-862c-45a4-b12c-a6f920772534|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/5x10^4 WBC|[?]|1|ugEq/L|BONE MARROW|PANENDOSCOPY|Y|Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-08-11|65
e|IS|12c802a8-862c-45a4-b12c-a6f920772534|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|vp/dose|[?]|1|mU|ALVEOLAR AIR|TURBIDIMETRY|||1|5|Visit_5|90|3|TREATMENT|2020-09-05|90
e|IS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/min|[?]|1|PFU/dose|INTERSTITIAL FLUID|DROPLET DIGITAL PCR|||1|1|Visit_1|10|7|TREATMENT|2020-11-23|10
e|IS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|AgU/mL|[?]|1|nmol/mL/min|PERITONEAL FLUID|CYSTOMETRY|||1|2|Visit_2|25|7|TREATMENT|2020-12-08|25
e|IS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cm|[?]|1|10^6/Ejaculate U|EMOTIONAL TEAR|TEMPLATE INCISION METHOD|||1|3|Visit_3|40|4|SCREENING|2020-12-23|40
e|IS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|dmol|[?]|1|mL|SEMEN|DARK FIELD MICROSCOPY||Y|1|4|Visit_4|65|7|FOLLOW-UP|2021-01-17|65
e|IS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|10^7 CFU/mL|EXUDATE|PHOTOMETRIC CLOT DETECTION|||1|5|Visit_5|90|6|TREATMENT|2021-02-11|90
e|IS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|VOXEL|[?]|1|mg/kg|SERUM OR PLASMA OR BLOOD|FLUOROSCOPY|||1|1|Visit_1|10|7|FOLLOW-UP|2020-08-16|10
e|IS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uIU/dL|[?]|1|Gy/min|MIXED VENOUS BLOOD|DXA SCAN|||1|2|Visit_2|25|4|FOLLOW-UP|2020-08-31|25
e|IS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|bel|[?]|1|ug/kg/h|PERIPHERAL BLOOD MONONUCLEAR CELL|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|3|Visit_3|40|6|SCREENING|2020-09-15|40
e|IS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|SACHET|[?]|1|mL/animal/wk|LEUKOCYTE|THICK SMEAR|||1|4|Visit_4|65|4|SCREENING|2020-10-10|65
e|IS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mol|[?]|1|log10 PFU/mL|FLUID|FLOW CYTOMETRY||Y|1|5|Visit_5|90|3|SCREENING|2020-11-04|90
e|IS|96114171-59a0-4543-b3ec-c7796ae8ee92|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mph|[?]|1|CUP|EXPIRED AIR|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||1|1|Visit_1|10|4|TREATMENT|2020-11-24|10
e|IS|96114171-59a0-4543-b3ec-c7796ae8ee92|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/kg/day|[?]|1|Bq/ug|DIALYSIS FLUID|GRAM STAIN||Y|1|2|Visit_2|25|6|TREATMENT|2020-12-09|25
e|IS|96114171-59a0-4543-b3ec-c7796ae8ee92|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/g/min|[?]|1|mg/kg/h|PROSTATIC FLUID|LAPAROSCOPY|Y||1|3|Visit_3|40|4|FOLLOW-UP|2020-12-24|40
e|IS|96114171-59a0-4543-b3ec-c7796ae8ee92|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6 copies/mL|[?]|1|kg/cm2|SEMEN|HEMAGGLUTINATION INHIBITION ASSAY|Y||1|4|Visit_4|65|1|WASHOUT|2021-01-18|65
e|IS|96114171-59a0-4543-b3ec-c7796ae8ee92|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|APS U|[?]|1|BOTTLE|SPERMATOZOON|CORONARY ANGIOGRAPHY||Y|1|5|Visit_5|90|4|TREATMENT|2021-02-12|90
e|IS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kV|[?]|1|psi|BONE MARROW|CLIP||Y|1|1|Visit_1|10|7|TREATMENT|2020-08-15|10
e|IS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|copies/mL|[?]|1|10^9 organisms/g|VITREOUS HUMOR|ENZYMATIC SPECTROPHOTOMETRY||Y|1|2|Visit_2|25|3|FOLLOW-UP|2020-08-30|25
e|IS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Arbitrary U|[?]|1|log10 PFU|EXUDATE|CORONARY ANGIOGRAPHY||Y|1|3|Visit_3|40|4|TREATMENT|2020-09-14|40
e|IS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cup eq|[?]|1|PRESSOR UNITS|PLEURAL TISSUE|ANALYTICAL ULTRACENTRIFUGATION|||1|4|Visit_4|65|6|TREATMENT|2020-10-09|65
e|IS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 DNA copies/mL|[?]|1|10^8/L|DIALYSIS FLUID, PERITONEAL|AMSLER GRID||Y|1|5|Visit_5|90|6|FOLLOW-UP|2020-11-03|90
e|IS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|OI50|[?]|1|pmol/L/h|ARTERIALIZED CAPILLARY BLOOD|IMMUNODIFFUSION|Y||1|1|Visit_1|10|2|WASHOUT|2020-10-17|10
e|IS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^9/dose|[?]|1|msec|SMOOTH MUSCLE TISSUE|DIRECT SEQUENCING|Y||1|2|Visit_2|25|5|TREATMENT|2020-11-01|25
e|IS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/m2/min|[?]|1|IU/g|CARDIAC MUSCLE TISSUE|CONTACT SPECULAR MICROSCOPY|||1|3|Visit_3|40|2|TREATMENT|2020-11-16|40
e|IS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|PUFF|[?]|1|nmol/L/h|BLOOD|ELECTRONEUROGRAPHY|||1|4|Visit_4|65|5|TREATMENT|2020-12-11|65
e|IS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|JDF Unit|[?]|1|min*mg/mL|CIRCULATING TUMOR CELL|STRESS ECHOCARDIOGRAPHY|Y|Y|1|5|Visit_5|90|4|FOLLOW-UP|2021-01-05|90
e|IS|cc562042-9641-460d-862e-d6923dd4207d|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BOWL|[?]|1|P|SEMEN|CENTRIFUGATION|||1|1|Visit_1|10|7|TREATMENT|2020-05-27|10
e|IS|cc562042-9641-460d-862e-d6923dd4207d|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|FFU|[?]|1|mmol/g|RETICULOCYTES|TRYPAN BLUE STAIN|Y||1|2|Visit_2|25|7|TREATMENT|2020-06-11|25
e|IS|cc562042-9641-460d-862e-d6923dd4207d|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mAnson U/mL|[?]|1|L/s/kPa|ENDOMETRIAL TISSUE|HPLC-FL|Y||1|3|Visit_3|40|3|SCREENING|2020-06-26|40
e|IS|cc562042-9641-460d-862e-d6923dd4207d|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/mmol|[?]|1|in2|GASTRIC FLUID|MAMMOGRAPHY|||1|4|Visit_4|65|7|TREATMENT|2020-07-21|65
e|IS|cc562042-9641-460d-862e-d6923dd4207d|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Ci/uL|[?]|1|dyn|EXUDATE|ENDPOINT DILUTION ASSAY|Y||1|5|Visit_5|90|1|SCREENING|2020-08-15|90
e|IS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nmol/mL/min|[?]|1|cm|SERUM|CLINICAL EVALUATION|||1|1|Visit_1|10|4|TREATMENT|2020-07-30|10
e|IS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|log10 IU/mL|[?]|1|U/m2|PERSPIRATION|FLUOROSCOPY|||1|2|Visit_2|25|4|TREATMENT|2020-08-14|25
e|IS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U/animal|[?]|1|/10^4|STRIATED MUSCLE TISSUE|PERIPHERAL ANGIOGRAPHY|||1|3|Visit_3|40|6|FOLLOW-UP|2020-08-29|40
e|IS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|msec|[?]|1|mg/g/h|TISSUE|GC/MS/MS||Y|1|4|Visit_4|65|4|SCREENING|2020-09-23|65
e|IS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|km|[?]|1|mEq/mL|CALCULUS|HEMAGGLUTINATION INHIBITION ASSAY|Y||1|5|Visit_5|90|5|WASHOUT|2020-10-18|90
e|IS|d90f2824-692e-403f-b1ca-5b6462c93a75|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mV/sec|[?]|1|mmol/day|SEMINAL FLUID|BIOIMPEDANCE SPECTROSCOPY|Y||1|1|Visit_1|10|2|TREATMENT|2020-07-15|10
e|IS|d90f2824-692e-403f-b1ca-5b6462c93a75|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ng|[?]|1|uV|CARDIAC MUSCLE TISSUE|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y||1|2|Visit_2|25|1|TREATMENT|2020-07-30|25
e|IS|d90f2824-692e-403f-b1ca-5b6462c93a75|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/animal/day|[?]|1|Ci/uL|MUCUS|CISH|Y|Y|1|3|Visit_3|40|6|TREATMENT|2020-08-14|40
e|IS|d90f2824-692e-403f-b1ca-5b6462c93a75|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MPS U|[?]|1|ft3|DERMAL TISSUE|SCINTIGRAPHY|||1|4|Visit_4|65|6|SCREENING|2020-09-08|65
e|IS|d90f2824-692e-403f-b1ca-5b6462c93a75|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uSiemens|[?]|1|TCID 50/dose|GASTRIC CONTENTS|SPECT SCAN||Y|1|5|Visit_5|90|7|TREATMENT|2020-10-03|90
e|IS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|umol/dL|[?]|1|cd*s/m2|TISSUE|DC SHEATH FLOW|||1|1|Visit_1|10|4|TREATMENT|2020-05-25|10
e|IS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|BU|PERITONEAL FLUID|HPLC-UV|Y||1|2|Visit_2|25|2|TREATMENT|2020-06-09|25
e|IS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|L/L|[?]|1|mph|PERIPHERAL BLOOD MONONUCLEAR CELL|REFRACTOMETRY|Y||1|3|Visit_3|40|1|TREATMENT|2020-06-24|40
e|IS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/MBP|[?]|1|C|WHITE MATTER TISSUE|POLYMERASE CHAIN REACTION|Y|Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-07-19|65
e|IS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 CFU/g|[?]|1|10^7/L|SALIVA|FLOCCULATION, CHARCOAL ENHANCED|Y|Y|1|5|Visit_5|90|6|TREATMENT|2020-08-13|90
e|IS|6aa37bb3-85aa-427f-9e56-a776257f1548|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|DRINK|[?]|1|cal|MUCUS|CONFOCAL MICROSCOPY|||1|1|Visit_1|10|3|TREATMENT|2020-11-14|10
e|IS|6aa37bb3-85aa-427f-9e56-a776257f1548|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|BEAM BREAKS|[?]|1|SFC/10^6 PBMC|RETICULOCYTES|TELLER ACUITY CARDS|||1|2|Visit_2|25|1|WASHOUT|2020-11-29|25
e|IS|6aa37bb3-85aa-427f-9e56-a776257f1548|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/m2/day|[?]|1|FINGERTIP UNIT|SEMEN|VENTILATION PERFUSION LUNG SCAN|||1|3|Visit_3|40|3|SCREENING|2020-12-14|40
e|IS|6aa37bb3-85aa-427f-9e56-a776257f1548|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Ci/mL|[?]|1|/ms|PLATELET|MICROBIAL CONCENTRATION|||1|4|Visit_4|65|3|SCREENING|2021-01-08|65
e|IS|6aa37bb3-85aa-427f-9e56-a776257f1548|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PUFF|[?]|1|mEq|URINE|TRANSVAGINAL ULTRASOUND|||1|5|Visit_5|90|4|FOLLOW-UP|2021-02-02|90
e|IS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/dL|[?]|1|mEq/day|PERIPHERAL BLOOD MONONUCLEAR CELL|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||Y|1|1|Visit_1|10|6|TREATMENT|2020-05-18|10
e|IS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|PFU|[?]|1|/h|SWABBED MATERIAL|LIQUID SCINTILLATION COUNTING|||1|2|Visit_2|25|4|TREATMENT|2020-06-02|25
e|IS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/dL|[?]|1|Ci|PERIPHERAL BLOOD MONONUCLEAR CELL|GC/MS-CI|Y|Y|1|3|Visit_3|40|4|TREATMENT|2020-06-17|40
e|IS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|gpELISA unit/mL|[?]|1|cmH2O*s/mL|VITREOUS HUMOR|DISK DIFFUSION||Y|1|4|Visit_4|65|3|TREATMENT|2020-07-12|65
e|IS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^8 PFU|[?]|1|uSiemens|DIALYSIS FLUID|AURAMINE STAIN|||1|5|Visit_5|90|3|TREATMENT|2020-08-06|90
e|IS|940d4614-b41a-44d3-b878-6e19ee22f24b|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|steps/min|[?]|1|uL/dose|EMOTIONAL TEAR|WHOLE GENOME SEQUENCING|||1|1|Visit_1|10|3|FOLLOW-UP|2020-07-06|10
e|IS|940d4614-b41a-44d3-b878-6e19ee22f24b|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^6 IU/mL|[?]|1|U/L|SWABBED MATERIAL|JAEGER EYE CHART||Y|1|2|Visit_2|25|4|TREATMENT|2020-07-21|25
e|IS|940d4614-b41a-44d3-b878-6e19ee22f24b|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/mmHg|[?]|1|umol/min|PLASMA ULTRAFILTRATE|TRANSMISSION ELECTRON MICROSCOPY|||1|3|Visit_3|40|7|TREATMENT|2020-08-05|40
e|IS|940d4614-b41a-44d3-b878-6e19ee22f24b|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U/cL|[?]|1|mg/cm2|CORD BLOOD|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|4|Visit_4|65|7|TREATMENT|2020-08-30|65
e|IS|940d4614-b41a-44d3-b878-6e19ee22f24b|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/dose|[?]|1|mL|DISCHARGE|STRESS ECHOCARDIOGRAPHY|||1|5|Visit_5|90|7|WASHOUT|2020-09-24|90
e|IS|e2edd4f0-926b-4514-bf3f-7449f248343f|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|IU/dL|[?]|1|umol/min|LUNG SURFACTANT|BRDU CELLULAR PROLIFERATION ASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-11-01|10
e|IS|e2edd4f0-926b-4514-bf3f-7449f248343f|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/dose|[?]|1|umol/mol|AMNIOTIC FLUID|NON-INVASIVE DIELECTRIC SENSING|||1|2|Visit_2|25|1|FOLLOW-UP|2020-11-16|25
e|IS|e2edd4f0-926b-4514-bf3f-7449f248343f|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|%(v/v)|[?]|1|mm/2h|INTERSTITIAL FLUID|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y||1|3|Visit_3|40|2|TREATMENT|2020-12-01|40
e|IS|e2edd4f0-926b-4514-bf3f-7449f248343f|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ng/dL|[?]|1|nmol BCE/mmol|PLEURAL FLUID|CONTRAST ENHANCED PET/CT SCAN||Y|1|4|Visit_4|65|7|WASHOUT|2020-12-26|65
e|IS|e2edd4f0-926b-4514-bf3f-7449f248343f|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|MnFI|[?]|1|JDF Unit|ARTERIALIZED CAPILLARY BLOOD|AMSLER GRID|||1|5|Visit_5|90|3|TREATMENT|2021-01-20|90
e|IS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg2/dL2|[?]|1|BOLUS|KERATINOCYTE|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|1|Visit_1|10|5|TREATMENT|2020-06-28|10
e|IS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|dyn|[?]|1|amu|PUS|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y||1|2|Visit_2|25|5|TREATMENT|2020-07-13|25
e|IS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pkat/L|[?]|1|PFU/animal|LYSATE|DIFFUSION TENSOR MRI|||1|3|Visit_3|40|5|TREATMENT|2020-07-28|40
e|IS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ks|[?]|1|Tbsp|AMNIOTIC FLUID|CISH|||1|4|Visit_4|65|2|TREATMENT|2020-08-22|65
e|IS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|min*mg/mL|[?]|1|fmol|PLASMA ULTRAFILTRATE|PHASE-CONTRAST MRI|||1|5|Visit_5|90|5|FOLLOW-UP|2020-09-16|90
e|IS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|SQU/mL|[?]|1|NEBULE|VENOUS CORD BLOOD|CISH||Y|1|1|Visit_1|10|4|FOLLOW-UP|2020-07-13|10
e|IS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol/dL|[?]|1|kat|HAIR FOLLICLE|HANSEL STAIN||Y|1|2|Visit_2|25|2|TREATMENT|2020-07-28|25
e|IS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MPL U|[?]|1|hr/day|AMNIOTIC FLUID|ELECTROCHEMILUMINESCENCE|||1|3|Visit_3|40|1|WASHOUT|2020-08-12|40
e|IS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/h|[?]|1|log EID 50/dose|FLUID|PET/CT SCAN WITHOUT CONTRAST|||1|4|Visit_4|65|6|FOLLOW-UP|2020-09-06|65
e|IS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mph|[?]|1|h/wk|CELL PELLET|OSCILLOMETRY|||1|5|Visit_5|90|2|FOLLOW-UP|2020-10-01|90
e|IS|ba33de14-b676-4389-a863-a7fa3edb8543|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Gauss|[?]|1|uV2|SEBUM|SPIRAL CT SCAN WITHOUT CONTRAST|Y||1|1|Visit_1|10|7|TREATMENT|2020-11-03|10
e|IS|ba33de14-b676-4389-a863-a7fa3edb8543|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mU/L|[?]|1|m/sec2|VITREOUS HUMOR|JAFFE REACTION|||1|2|Visit_2|25|5|TREATMENT|2020-11-18|25
e|IS|ba33de14-b676-4389-a863-a7fa3edb8543|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|umol/L|[?]|1|ug|CALCULUS|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||1|3|Visit_3|40|4|WASHOUT|2020-12-03|40
e|IS|ba33de14-b676-4389-a863-a7fa3edb8543|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cpm|[?]|1|TUBE|PROSTATIC FLUID|OPHTHALMOSCOPY|||1|4|Visit_4|65|7|TREATMENT|2020-12-28|65
e|IS|ba33de14-b676-4389-a863-a7fa3edb8543|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Gy|[?]|1|MET*min|PERITONEAL FLUID|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|5|Visit_5|90|3|SCREENING|2021-01-22|90
e|IS|24801f05-79be-433d-8124-85580bc14c4f|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ppm|[?]|1|/day|EXUDATE|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|1|Visit_1|10|2|TREATMENT|2020-09-09|10
e|IS|24801f05-79be-433d-8124-85580bc14c4f|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|hPa|[?]|1|TROCHE|VITREOUS HUMOR|DISK DIFFUSION||Y|1|2|Visit_2|25|5|TREATMENT|2020-09-24|25
e|IS|24801f05-79be-433d-8124-85580bc14c4f|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|g/animal|[?]|1|anti-Xa IU/mL|CERUMEN|MICROSCOPY|||1|3|Visit_3|40|6|TREATMENT|2020-10-09|40
e|IS|24801f05-79be-433d-8124-85580bc14c4f|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 IU/mL|[?]|1|g/animal/wk|PLEURAL TISSUE|RYAN BLUE STAIN|||1|4|Visit_4|65|2|TREATMENT|2020-11-03|65
e|IS|24801f05-79be-433d-8124-85580bc14c4f|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nm|[?]|1|cmH2O*s2/mL|STOOL|NEPHELOMETRY|||1|5|Visit_5|90|1|TREATMENT|2020-11-28|90
e|IS|02df80f9-2337-4abd-9452-41cd83dec8ba|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|min*mg/mL|[?]|1|/h|INFRANATANT, PLEURAL FLUID|DNA MICROARRAY|||1|1|Visit_1|10|7|SCREENING|2020-08-04|10
e|IS|02df80f9-2337-4abd-9452-41cd83dec8ba|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|P|[?]|1|CIGAR|LYMPH|TRICHROME STAIN|||1|2|Visit_2|25|7|SCREENING|2020-08-19|25
e|IS|02df80f9-2337-4abd-9452-41cd83dec8ba|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ppth|[?]|1|IU/kg|CARDIAC MUSCLE TISSUE|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|1|3|Visit_3|40|7|TREATMENT|2020-09-03|40
e|IS|02df80f9-2337-4abd-9452-41cd83dec8ba|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|hPa|[?]|1|mEq/day|CORD SERUM|RADIOGRAPHY|||1|4|Visit_4|65|2|TREATMENT|2020-09-28|65
e|IS|02df80f9-2337-4abd-9452-41cd83dec8ba|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^9 CFU/g|[?]|1|umol/min|BUFFY COAT|ISHIHARA COLOR PLATES|||1|5|Visit_5|90|5|TREATMENT|2020-10-23|90
e|IS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/5x10^4 WBC|[?]|1|NFIU|SUPERNATANT, PLASMA|DUKE INCISION METHOD|||1|1|Visit_1|10|4|TREATMENT|2020-08-03|10
e|IS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/kg|[?]|1|days/month|LAVAGE FLUID|DIGITAL PCR ARRAY|Y||1|2|Visit_2|25|4|TREATMENT|2020-08-18|25
e|IS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/animal|[?]|1|BAR|MECONIUM|ECHOCARDIOGRAPHY|||1|3|Visit_3|40|7|FOLLOW-UP|2020-09-02|40
e|IS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mol/mg|[?]|1|m|CAPILLARY BLOOD|PERFUSION MRI|||1|4|Visit_4|65|1|TREATMENT|2020-09-27|65
e|IS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/g/min|[?]|1|Sv|AQUEOUS HUMOR|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||Y|1|5|Visit_5|90|7|TREATMENT|2020-10-22|90
e|IS|35a59f6a-2712-4d1b-a954-f1418d4b9168|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|rpm|[?]|1|amol|TRANSUDATE|CLIP||Y|1|1|Visit_1|10|1|TREATMENT|2020-11-05|10
e|IS|35a59f6a-2712-4d1b-a954-f1418d4b9168|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|genEq|[?]|1|ng/dL|SUPERNATANT, PLASMA|JAFFE REACTION||Y|1|2|Visit_2|25|2|TREATMENT|2020-11-20|25
e|IS|35a59f6a-2712-4d1b-a954-f1418d4b9168|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|AFU|[?]|1|umol/L/h|LEUKOCYTE|DYNAMIC LIGHT SCATTERING|Y||1|3|Visit_3|40|2|TREATMENT|2020-12-05|40
e|IS|35a59f6a-2712-4d1b-a954-f1418d4b9168|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 CFU/mL|[?]|1|CCID 50/mL|SUPERNATANT, SERUM|ACID FAST STAIN|Y||1|4|Visit_4|65|5|TREATMENT|2020-12-30|65
e|IS|35a59f6a-2712-4d1b-a954-f1418d4b9168|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Enzyme U|[?]|1|CFU/mL|PLASMA|IMPEDANCE CONDUCTIVITY|Y||1|5|Visit_5|90|7|FOLLOW-UP|2021-01-24|90
e|IS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6/Ejaculate U|[?]|1|10^4 CFU/mL|CEREBROSPINAL FLUID|WESTERN BLOT||Y|1|1|Visit_1|10|2|TREATMENT|2020-11-10|10
e|IS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Hz|[?]|1|FINGERTIP UNIT|SYNOVIAL FLUID|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|2|Visit_2|25|1|TREATMENT|2020-11-25|25
e|IS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|CUP|[?]|1|damol/L|EPITHELIAL CELL|MS/MS||Y|1|3|Visit_3|40|5|SCREENING|2020-12-10|40
e|IS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mmol/L|[?]|1|mL/animal|FLUID|RAJI CELL EIA|Y||1|4|Visit_4|65|5|SCREENING|2021-01-04|65
e|IS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ugEq/L|[?]|1|ug/m2/min|PLATELET POOR PLASMA|SICKLE CELL SOLUBILITY TEST||Y|1|5|Visit_5|90|5|TREATMENT|2021-01-29|90
e|IS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|uL|[?]|1|gpELISA unit/mL|ATHEROSCLEROTIC PLAQUE|DIGITAL PCR|||1|1|Visit_1|10|2|SCREENING|2020-05-13|10
e|IS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cd*s/m2|[?]|1|ft2|BILE|GC/MS/MS|Y||1|2|Visit_2|25|5|TREATMENT|2020-05-28|25
e|IS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/cm H2O|[?]|1|STEPS|MONOCYTE|DOPPLER ULTRASOUND||Y|1|3|Visit_3|40|5|TREATMENT|2020-06-12|40
e|IS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ukat/L|[?]|1|nmol/mL/min|HAIR|NO INFORMATION|||1|4|Visit_4|65|5|TREATMENT|2020-07-07|65
e|IS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Gy|[?]|1|HOURS|PLATELET RICH PLASMA|ANGIOGRAPHY|||1|5|Visit_5|90|2|WASHOUT|2020-08-01|90
e|IS|d041952e-4aa6-4b37-9cec-127adce2eabb|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cd/m2|[?]|1|mIU/L|CALCULUS|CALIPER MEASUREMENT METHOD|||1|1|Visit_1|10|7|SCREENING|2020-10-09|10
e|IS|d041952e-4aa6-4b37-9cec-127adce2eabb|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^12/L|[?]|1|pptr|DISCHARGE|SLOAN LETTER EYE CHART 1.25%|||1|2|Visit_2|25|5|TREATMENT|2020-10-24|25
e|IS|d041952e-4aa6-4b37-9cec-127adce2eabb|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6 DNA copies/mL|[?]|1|10^6 CFU/g|PLEURAL FLUID|TRICHROME STAIN||Y|1|3|Visit_3|40|2|TREATMENT|2020-11-08|40
e|IS|d041952e-4aa6-4b37-9cec-127adce2eabb|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|U/g/h|[?]|1|PFU/dose|TRANSUDATE|HPLC/IEX|Y|Y|1|4|Visit_4|65|7|TREATMENT|2020-12-03|65
e|IS|d041952e-4aa6-4b37-9cec-127adce2eabb|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|kN/cm2|[?]|1|mL/animal|SKIN TISSUE|TOTAL BODY IRRADIATION||Y|1|5|Visit_5|90|3|WASHOUT|2020-12-28|90
e|IS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PFU/mL|[?]|1|Absorbance U/min|SALIVA|DIGITAL PCR|||1|1|Visit_1|10|2|WASHOUT|2020-06-09|10
e|IS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^11/L|[?]|1|10^6 organisms|SUPERNATANT, SERUM OR PLASMA|NUCLEIC ACID SEQUENCING|||1|2|Visit_2|25|3|TREATMENT|2020-06-24|25
e|IS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|LB|[?]|1|Weber|AQUEOUS HUMOR|RAJI CELL EIA|||1|3|Visit_3|40|2|TREATMENT|2020-07-09|40
e|IS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|PACK|[?]|1|genEq/mL|STOOL|GC/MS/MS||Y|1|4|Visit_4|65|5|TREATMENT|2020-08-03|65
e|IS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Sv|[?]|1|BAU/mL|BILE|AGAR DILUTION|||1|5|Visit_5|90|3|TREATMENT|2020-08-28|90
e|IS|9fc393da-4665-4be5-a869-856c45ddcf13|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/min|[?]|1|ug/g/h|NAIL|INDIA INK STAIN||Y|1|1|Visit_1|10|3|SCREENING|2020-06-18|10
e|IS|9fc393da-4665-4be5-a869-856c45ddcf13|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^3 DNA copies/mL|[?]|1|10^6/L|SUPERNATANT, PLEURAL FLUID|PET/SPECT SCAN|||1|2|Visit_2|25|5|TREATMENT|2020-07-03|25
e|IS|9fc393da-4665-4be5-a869-856c45ddcf13|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|GBq|[?]|1|nm|LYSATE|ENDPOINT DILUTION ASSAY|Y||1|3|Visit_3|40|4|SCREENING|2020-07-18|40
e|IS|9fc393da-4665-4be5-a869-856c45ddcf13|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 CFU|[?]|1|APL U/mL|DISCHARGE|INTRAVASCULAR ULTRASOUND|||1|4|Visit_4|65|3|WASHOUT|2020-08-12|65
e|IS|9fc393da-4665-4be5-a869-856c45ddcf13|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mkat|[?]|1|uEq|EXHALED BREATH CONDENSATE|TEST STRIP|||1|5|Visit_5|90|5|TREATMENT|2020-09-06|90
e|IS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uSiemens|[?]|1|mL/mmHg/min/L|RETICULOCYTES|BIOPSY|||1|1|Visit_1|10|7|TREATMENT|2021-01-19|10
e|IS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^3 organisms/g|[?]|1|SPRAY|INFRANATANT, PLEURAL FLUID|MALDI-TOF|Y||1|2|Visit_2|25|2|TREATMENT|2021-02-03|25
e|IS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PIXELS/cm|[?]|1|APS U|FLUID|ALCIAN BLUE STAIN|||1|3|Visit_3|40|1|FOLLOW-UP|2021-02-18|40
e|IS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Antibody Unit|[?]|1|hr/day|ARTERIAL CORD BLOOD|MUGA|||1|4|Visit_4|65|1|FOLLOW-UP|2021-03-15|65
e|IS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol/day|[?]|1|min*mg/mL|PLATELET RICH PLASMA|ELLA||Y|1|5|Visit_5|90|6|FOLLOW-UP|2021-04-09|90
e|IS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/(min*100mL)|[?]|1|IU/mL|PLEURAL TISSUE|POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|7|TREATMENT|2020-12-26|10
e|IS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/HPF|[?]|1|L/kg|ENDOTRACHEAL FLUID|WESTERGREN|||1|2|Visit_2|25|6|FOLLOW-UP|2021-01-10|25
e|IS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ks|[?]|1|10^5/L|DISCHARGE|THIN SMEAR|Y||1|3|Visit_3|40|6|WASHOUT|2021-01-25|40
e|IS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|EP U|[?]|1|U/kg/day|CARDIAC MUSCLE TISSUE|TONOMETRY|||1|4|Visit_4|65|4|WASHOUT|2021-02-19|65
e|IS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Ci/mg|[?]|1|kat|DIALYSIS FLUID, PERITONEAL|NEXT GENERATION SEQUENCING||Y|1|5|Visit_5|90|3|TREATMENT|2021-03-16|90
e|IS|fee3c810-3d76-4db4-9272-6b4e8fd14088|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kUSP|[?]|1|uCi|CELL PELLET|MRS|Y|Y|1|1|Visit_1|10|2|TREATMENT|2020-12-15|10
e|IS|fee3c810-3d76-4db4-9272-6b4e8fd14088|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/cage/wk|[?]|1|mg/dL|RETICULOCYTES|HPLC-FL|||1|2|Visit_2|25|5|TREATMENT|2020-12-30|25
e|IS|fee3c810-3d76-4db4-9272-6b4e8fd14088|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uEq/L|[?]|1|cmol|LYSATE|PATHOLOGICAL EVALUATION||Y|1|3|Visit_3|40|2|FOLLOW-UP|2021-01-14|40
e|IS|fee3c810-3d76-4db4-9272-6b4e8fd14088|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cm/min|[?]|1|kBq|EXUDATE|PHASE CONTRAST MICROSCOPY|||1|4|Visit_4|65|2|TREATMENT|2021-02-08|65
e|IS|fee3c810-3d76-4db4-9272-6b4e8fd14088|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nmol/mol|[?]|1|cm H2O|MUCUS|INCISION-INDUCED BLEEDING METHOD||Y|1|5|Visit_5|90|7|WASHOUT|2021-03-05|90
e|IS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|cd/m2|[?]|1|APL U|EMOTIONAL TEAR|KNEMOMETRY|||1|1|Visit_1|10|1|TREATMENT|2020-07-08|10
e|IS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Bq/kg|[?]|1|pkat/L|LAVAGE FLUID|CLINICAL EVALUATION|||1|2|Visit_2|25|7|FOLLOW-UP|2020-07-23|25
e|IS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|vp/mL|[?]|1|Henry|ARTERIAL BLOOD|DYNAMOMETRY|Y||1|3|Visit_3|40|5|SCREENING|2020-08-07|40
e|IS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|min/day|[?]|1|PRESSOR UNITS|CEREBROSPINAL FLUID|IMMUNO-PET SCAN|Y||1|4|Visit_4|65|2|TREATMENT|2020-09-01|65
e|IS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pptr|[?]|1|MAC50|CEREBROSPINAL FLUID|SICKLE CELL SOLUBILITY TEST|||1|5|Visit_5|90|1|SCREENING|2020-09-26|90
e|IS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|fmol/L|[?]|1|TROCHE|TRANSUDATE|CONTRAST ENHANCED PET/CT SCAN|Y||1|1|Visit_1|10|6|TREATMENT|2020-08-01|10
e|IS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Ci/uL|[?]|1|PACKAGE|EMOTIONAL TEAR|NUCLEAR RADIOLOGY||Y|1|2|Visit_2|25|2|FOLLOW-UP|2020-08-16|25
e|IS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/m2|[?]|1|AU/mL|HAIR|TRICHROME STAIN|Y|Y|1|3|Visit_3|40|5|FOLLOW-UP|2020-08-31|40
e|IS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cm|[?]|1|PIXEL|PUS|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|4|Visit_4|65|1|SCREENING|2020-09-25|65
e|IS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ugEq/L|[?]|1|mCi|SKELETAL MUSCLE TISSUE|FLUORESCENT SPOT TEST|||1|5|Visit_5|90|1|TREATMENT|2020-10-20|90
e|IS|47fad45a-9a4c-47ee-a863-089d979523b5|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Henry|[?]|1|INHALATION|CIRCULATING TUMOR CELL|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||1|1|Visit_1|10|3|SCREENING|2020-10-07|10
e|IS|47fad45a-9a4c-47ee-a863-089d979523b5|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|%/s|[?]|1|MET|BILE|HPLC/MS/MS|||1|2|Visit_2|25|7|TREATMENT|2020-10-22|25
e|IS|47fad45a-9a4c-47ee-a863-089d979523b5|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mV*min|[?]|1|keV|SUPERNATANT, PLEURAL FLUID|CT SCAN|||1|3|Visit_3|40|3|FOLLOW-UP|2020-11-06|40
e|IS|47fad45a-9a4c-47ee-a863-089d979523b5|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/mol|[?]|1|NFIU|BONE MARROW|CONTRAST ENHANCED MRI|||1|4|Visit_4|65|6|TREATMENT|2020-12-01|65
e|IS|47fad45a-9a4c-47ee-a863-089d979523b5|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 CFU/g|[?]|1|SBE/mL|AMNIOTIC FLUID|RIA||Y|1|5|Visit_5|90|5|WASHOUT|2020-12-26|90
e|IS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/animal/wk|[?]|1|ug/min|SUPERNATANT, PLEURAL FLUID|ELECTRONEUROGRAPHY|||1|1|Visit_1|10|5|WASHOUT|2020-05-23|10
e|IS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/animal/wk|[?]|1|umol/day|SMOOTH MUSCLE TISSUE|FORCED OSCILLATION TECHNIQUE|||1|2|Visit_2|25|4|TREATMENT|2020-06-07|25
e|IS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Bq/kg|[?]|1|Bq|SEBUM|CELL OF ORIGIN ASSAY||Y|1|3|Visit_3|40|3|TREATMENT|2020-06-22|40
e|IS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|breaths/min|[?]|1|mEq/uL|SMOOTH MUSCLE TISSUE|MUGA||Y|1|4|Visit_4|65|5|TREATMENT|2020-07-17|65
e|IS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|tsp|[?]|1|mg/dose|LOCHIA|PHOTOMETRIC CLOT DETECTION|||1|5|Visit_5|90|4|TREATMENT|2020-08-11|90
e|IS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|pkat|[?]|1|NFIU|HAIR FOLLICLE|INDIA INK STAIN|||1|1|Visit_1|10|3|SCREENING|2020-07-10|10
e|IS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|days/wk|[?]|1|ft3|DIALYSIS FLUID|MICROBIAL CONCENTRATION||Y|1|2|Visit_2|25|7|TREATMENT|2020-07-25|25
e|IS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|km|[?]|1|10^6 IU|VENOUS BLOOD|FLUORESCENT ENZYME IMMUNOASSAY||Y|1|3|Visit_3|40|5|TREATMENT|2020-08-09|40
e|IS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/kg/h|[?]|1|g/day|ABSCESS FLUID|SPECT/CT SCAN|Y|Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-09-03|65
e|IS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mOsm|[?]|1|MONTHS|DIALYSIS FLUID|MICROARRAY|||1|5|Visit_5|90|5|FOLLOW-UP|2020-09-28|90
e|IS|e7cee930-54f6-482e-b782-01aed0f0db06|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MBP|[?]|1|STEPS|PERITONEAL FLUID|RULER MEASUREMENT METHOD|||1|1|Visit_1|10|3|FOLLOW-UP|2021-01-07|10
e|IS|e7cee930-54f6-482e-b782-01aed0f0db06|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|SPRAY|[?]|1|mol/g|SEMINAL FLUID|COULOMETRIC TITRATION|||1|2|Visit_2|25|5|TREATMENT|2021-01-22|25
e|IS|e7cee930-54f6-482e-b782-01aed0f0db06|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cs|[?]|1|L/day|SMOOTH MUSCLE TISSUE|ELLA||Y|1|3|Visit_3|40|7|FOLLOW-UP|2021-02-06|40
e|IS|e7cee930-54f6-482e-b782-01aed0f0db06|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|amu|[?]|1|ft|MECONIUM|IN SITU HYBRIDIZATION|Y||1|4|Visit_4|65|5|TREATMENT|2021-03-03|65
e|IS|e7cee930-54f6-482e-b782-01aed0f0db06|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|steps/min|[?]|1|Ci/kg|SPUTUM|IMMUNOCHEMILUMINOMETRIC ASSAY|Y|Y|1|5|Visit_5|90|5|WASHOUT|2021-03-28|90
e|IS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|dL|[?]|1|mCi/L|URINE SEDIMENT|CARDIAC THERMODILUTION|||1|1|Visit_1|10|5|WASHOUT|2021-01-21|10
e|IS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|BAU|[?]|1|IU/day|LYSATE|GC/MS-CI|||1|2|Visit_2|25|5|TREATMENT|2021-02-05|25
e|IS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cycle/min|[?]|1|Bq/mL|PERIPHERAL BLOOD MONONUCLEAR CELL|OLIGO ACGH|||1|3|Visit_3|40|2|SCREENING|2021-02-20|40
e|IS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/L DDU|[?]|1|U/10^12 RBC|MONOCYTE|ACCELERATOR MASS SPECTROMETRY||Y|1|4|Visit_4|65|3|TREATMENT|2021-03-17|65
e|IS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nkat/L|[?]|1|ELISA unit/mL|SERUM|FREEZING POINT DEPRESSION||Y|1|5|Visit_5|90|1|TREATMENT|2021-04-11|90
e|IS|f754ae7d-0776-41c0-988c-8cf2879d85da|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/animal/day|[?]|1|/4.0 mL|SWABBED MATERIAL|REFLECTANCE SPECTROSCOPY||Y|1|1|Visit_1|10|3|TREATMENT|2020-09-17|10
e|IS|f754ae7d-0776-41c0-988c-8cf2879d85da|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6 CFU/mL|[?]|1|mg/mol|MUSCLE TISSUE|AGAR PROPORTION|||1|2|Visit_2|25|7|FOLLOW-UP|2020-10-02|25
e|IS|f754ae7d-0776-41c0-988c-8cf2879d85da|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mm/sec|[?]|1|cL|NAIL|ALCIAN BLUE STAIN|Y||1|3|Visit_3|40|7|TREATMENT|2020-10-17|40
e|IS|f754ae7d-0776-41c0-988c-8cf2879d85da|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm|[?]|1|U/m2/h|RETICULOCYTES|REVERSE TRANSCRIPTASE PCR|Y||1|4|Visit_4|65|6|FOLLOW-UP|2020-11-11|65
e|IS|f754ae7d-0776-41c0-988c-8cf2879d85da|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pt_br|[?]|1|ug/L FEU|SUPERNATANT, CEREBROSPINAL FLUID|IMMUNOFIXATION ELECTROPHORESIS|||1|5|Visit_5|90|4|SCREENING|2020-12-06|90
e|IS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|g/mol|[?]|1|ppm|MUCUS|BETA LACTAMASE|Y|Y|1|1|Visit_1|10|2|TREATMENT|2020-06-25|10
e|IS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|%/s|[?]|1|cmH2O*s2/mL|BLOOD|SPECT/CT SCAN|||1|2|Visit_2|25|7|TREATMENT|2020-07-10|25
e|IS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ng/L|[?]|1|mkat|ERYTHROCYTES|IMMUNOBLOT|Y||1|3|Visit_3|40|7|TREATMENT|2020-07-25|40
e|IS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mmol/day|[?]|1|psec|NAIL|AURAMINE STAIN|||1|4|Visit_4|65|5|FOLLOW-UP|2020-08-19|65
e|IS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 TCID 50/mL|[?]|1|MONTHS|AMNIOTIC FLUID|DOPPLER ULTRASOUND|||1|5|Visit_5|90|5|TREATMENT|2020-09-13|90
e|IS|482e40c9-2908-4269-b93c-61c311e9fde3|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|amp|[?]|1|nm|BILE|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y||1|1|Visit_1|10|4|TREATMENT|2020-07-16|10
e|IS|482e40c9-2908-4269-b93c-61c311e9fde3|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|COAT|[?]|1|psec|CALCULUS|ACID FAST STAIN|||1|2|Visit_2|25|5|TREATMENT|2020-07-31|25
e|IS|482e40c9-2908-4269-b93c-61c311e9fde3|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Rad|[?]|1|HOURS|STRIATED MUSCLE TISSUE|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||1|3|Visit_3|40|1|WASHOUT|2020-08-15|40
e|IS|482e40c9-2908-4269-b93c-61c311e9fde3|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|copies/uL|[?]|1|nL|CALCULUS|SPIRAL CT||Y|1|4|Visit_4|65|2|SCREENING|2020-09-09|65
e|IS|482e40c9-2908-4269-b93c-61c311e9fde3|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Tesla|[?]|1|nCi|HAIR|MICROPARTICLE ENZYME IMMUNOASSAY||Y|1|5|Visit_5|90|6|WASHOUT|2020-10-04|90
e|IS|f7cfb281-0556-4316-9373-65edf63c4b23|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|gMFI|[?]|1|cs|PUS|RAJI CELL RIA|||1|1|Visit_1|10|7|FOLLOW-UP|2020-06-29|10
e|IS|f7cfb281-0556-4316-9373-65edf63c4b23|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmol/L|[?]|1|ug/mol|SWABBED MATERIAL|SNELLEN EYE CHART|||1|2|Visit_2|25|6|FOLLOW-UP|2020-07-14|25
e|IS|f7cfb281-0556-4316-9373-65edf63c4b23|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|GLOBULE|[?]|1|BOTTLE|INFRANATANT, PLASMA|OLIGO ACGH||Y|1|3|Visit_3|40|3|TREATMENT|2020-07-29|40
e|IS|f7cfb281-0556-4316-9373-65edf63c4b23|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|copies/mL|[?]|1|mL/breath|VENOUS PLASMA|LC/MS/MS|||1|4|Visit_4|65|7|TREATMENT|2020-08-23|65
e|IS|f7cfb281-0556-4316-9373-65edf63c4b23|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|FFU|[?]|1|Gauss|VENOUS BLOOD|ANALYTICAL ULTRACENTRIFUGATION|Y||1|5|Visit_5|90|5|FOLLOW-UP|2020-09-17|90
e|IS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mV|[?]|1|g/g/day|BLOOD|PHOTOGRAPHY|||1|1|Visit_1|10|1|FOLLOW-UP|2021-01-10|10
e|IS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|LOZENGE|[?]|1|umol/L/h|BILE|CT SCAN||Y|1|2|Visit_2|25|3|TREATMENT|2021-01-25|25
e|IS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6 copies/mL|[?]|1|Log10 ELISA unit/dose|GASTRIC CONTENTS|CENTRIFUGATION|||1|3|Visit_3|40|1|TREATMENT|2021-02-09|40
e|IS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|log10 CFU/g|[?]|1|ug/m2|EPIDERMAL TISSUE|FARR ASSAY|||1|4|Visit_4|65|5|TREATMENT|2021-03-06|65
e|IS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|INHALATION|[?]|1|mol/mL|VENOUS CORD BLOOD|LIQUID SCINTILLATION COUNTING||Y|1|5|Visit_5|90|3|TREATMENT|2021-03-31|90
e|IS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|rpm|[?]|1|mg/mol|SEMEN|ACCELERATOR MASS SPECTROMETRY||Y|1|1|Visit_1|10|3|SCREENING|2020-09-02|10
e|IS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^9 organisms/g|[?]|1|10^6 organisms/mg|EXHALED BREATH CONDENSATE|MICROBIAL CULTURE|||1|2|Visit_2|25|1|TREATMENT|2020-09-17|25
e|IS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 IU/mL|[?]|1|umol/L/h|LEUKOCYTE|SMEAR|||1|3|Visit_3|40|7|WASHOUT|2020-10-02|40
e|IS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mm/h|[?]|1|U/mL|SUPERNATANT, SERUM|DIGITAL PCR ARRAY||Y|1|4|Visit_4|65|1|WASHOUT|2020-10-27|65
e|IS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/dose|[?]|1|cGy|BONE MARROW|FLUORESCEIN STAIN||Y|1|5|Visit_5|90|5|FOLLOW-UP|2020-11-21|90
e|IS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cm2|[?]|1|days/wk|PLEURAL FLUID|EPSILOMETER|Y||1|1|Visit_1|10|5|TREATMENT|2020-10-18|10
e|IS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mmHg*min/L|[?]|1|mEq/ug|SUPERNATANT, PLASMA|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y|Y|1|2|Visit_2|25|7|TREATMENT|2020-11-02|25
e|IS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|vg/kg|[?]|1|PIXEL|SALIVA|ISHIHARA COLOR PLATES|||1|3|Visit_3|40|7|TREATMENT|2020-11-17|40
e|IS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Weber|[?]|1|U/mmol|ADIPOSE TISSUE|ELECTRONEUROGRAPHY||Y|1|4|Visit_4|65|1|WASHOUT|2020-12-12|65
e|IS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|INHALATION|[?]|1|log10 TCID 50/dose|BLOOD|SINGLE-MOLECULE ARRAY||Y|1|5|Visit_5|90|5|TREATMENT|2021-01-06|90
e|IS|7e56eb43-62a6-45ac-9476-1d0655595a04|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^9/L|[?]|1|mg|ALVEOLAR AIR|SINGLE-SLICE SPIRAL CT||Y|1|1|Visit_1|10|2|TREATMENT|2021-01-24|10
e|IS|7e56eb43-62a6-45ac-9476-1d0655595a04|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Ejaculate U|[?]|1|HOURS|SERUM OR PLASMA OR BLOOD|MICROBIAL CULTURE, SOLID|||1|2|Visit_2|25|1|WASHOUT|2021-02-08|25
e|IS|7e56eb43-62a6-45ac-9476-1d0655595a04|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 copies/mL|[?]|1|mmHg/L/min|ALVEOLAR AIR|VENTILATION PERFUSION LUNG SCAN|||1|3|Visit_3|40|3|FOLLOW-UP|2021-02-23|40
e|IS|7e56eb43-62a6-45ac-9476-1d0655595a04|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mmol|[?]|1|g|SYNOVIAL FLUID|FARR ASSAY|Y||1|4|Visit_4|65|2|TREATMENT|2021-03-20|65
e|IS|7e56eb43-62a6-45ac-9476-1d0655595a04|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^9 organisms|[?]|1|mmol|STRIATED MUSCLE TISSUE|ICC||Y|1|5|Visit_5|90|3|SCREENING|2021-04-14|90
e|IS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cd|[?]|1|100 IU/mL|VENOUS CORD BLOOD|IMMUNOCHROMATOGRAPHY|||1|1|Visit_1|10|1|WASHOUT|2020-06-29|10
e|IS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|um2|[?]|1|Hz/s|CELL PELLET|BETA LACTAMASE|Y||1|2|Visit_2|25|6|FOLLOW-UP|2020-07-14|25
e|IS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Absorbance U|[?]|1|days/month|LYMPH|DYNAMIC LIGHT SCATTERING|Y||1|3|Visit_3|40|5|TREATMENT|2020-07-29|40
e|IS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|um/day|[?]|1|10^12/L|MUCUS|ANALYTICAL ULTRACENTRIFUGATION||Y|1|4|Visit_4|65|7|WASHOUT|2020-08-23|65
e|IS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mV|[?]|1|OD Unit|EMESIS|SPECULAR MICROSCOPY|Y|Y|1|5|Visit_5|90|5|WASHOUT|2020-09-17|90
e|IS|84f74359-c79b-4f1c-8119-a4993b071973|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|fL|[?]|1|Bq/uL|EMESIS|NUCLEAR RADIOLOGY|Y|Y|1|1|Visit_1|10|6|TREATMENT|2020-05-12|10
e|IS|84f74359-c79b-4f1c-8119-a4993b071973|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|aMFI|[?]|1|POUCH|SERUM OR PLASMA|POLYMERASE CHAIN REACTION|||1|2|Visit_2|25|6|TREATMENT|2020-05-27|25
e|IS|84f74359-c79b-4f1c-8119-a4993b071973|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|AMPULE|[?]|1|uL|PLEURAL TISSUE|SCINTIGRAPHY|||1|3|Visit_3|40|1|WASHOUT|2020-06-11|40
e|IS|84f74359-c79b-4f1c-8119-a4993b071973|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|%/min|[?]|1|ug/L/h|CARDIAC MUSCLE TISSUE|ATOMIC ABSORPTION SPECTROMETRY|Y||1|4|Visit_4|65|3|WASHOUT|2020-07-06|65
e|IS|84f74359-c79b-4f1c-8119-a4993b071973|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cs|[?]|1|ag|SUPERNATANT, SERUM|DARK FIELD MICROSCOPY|Y||1|5|Visit_5|90|7|FOLLOW-UP|2020-07-31|90
e|IS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/m2/h|[?]|1|mg/day|STRIATED MUSCLE TISSUE|APPLANATION TONOMETRY|||1|1|Visit_1|10|6|FOLLOW-UP|2020-11-06|10
e|IS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|m2|[?]|1|m|COLOSTRUM|NO INFORMATION||Y|1|2|Visit_2|25|6|TREATMENT|2020-11-21|25
e|IS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|APS U|[?]|1|ug/cm2|ERYTHROCYTES|PERIODIC ACID SCHIFF STAIN|||1|3|Visit_3|40|2|TREATMENT|2020-12-06|40
e|IS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|U|[?]|1|OI50|KERATINOCYTE|HEMATOXYLIN AND EOSIN STAIN|Y||1|4|Visit_4|65|2|WASHOUT|2020-12-31|65
e|IS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mEq|[?]|1|MdFI|ISOLATE|QUANTITATIVE COMPUTED TOMOGRAPHY||Y|1|5|Visit_5|90|4|TREATMENT|2021-01-25|90
e|IS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Bq/L|[?]|1|Ci/mg|SWABBED MATERIAL|MYELOPEROXIDASE STAIN|||1|1|Visit_1|10|3|TREATMENT|2020-09-09|10
e|IS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|CIGARETTE|[?]|1|sec|SUPERNATANT, PLEURAL FLUID|ACCELERATOR MASS SPECTROMETRY|||1|2|Visit_2|25|6|FOLLOW-UP|2020-09-24|25
e|IS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|OD Unit|[?]|1|10^6/hpf|DISCHARGE|MICROARRAY|||1|3|Visit_3|40|6|WASHOUT|2020-10-09|40
e|IS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mm3/mm2/year|[?]|1|U.CARR|EMESIS|NON-CONTACT SPECULAR MICROSCOPY|||1|4|Visit_4|65|1|FOLLOW-UP|2020-11-03|65
e|IS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kcal/day|[?]|1|uL/mL|MONOCYTE|POPULATION SEQUENCING|||1|5|Visit_5|90|2|TREATMENT|2020-11-28|90
e|IS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MAC50|[?]|1|mL/m2/min|HAIR FOLLICLE|CYSTOSCOPY|||1|1|Visit_1|10|1|TREATMENT|2021-01-28|10
e|IS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PATCH|[?]|1|beats/min|ABSCESS FLUID|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||1|2|Visit_2|25|7|SCREENING|2021-02-12|25
e|IS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/m2/day|[?]|1|Bq/mL|BREAST MILK|IMMUNOCHROMATOGRAPHY||Y|1|3|Visit_3|40|7|TREATMENT|2021-02-27|40
e|IS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|U/L|[?]|1|g|SYNOVIAL FLUID|FARNSWORTH-MUNSELL 100 HUE TEST|||1|4|Visit_4|65|7|TREATMENT|2021-03-24|65
e|IS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|oz eq|[?]|1|mph|URINE SEDIMENT|KLEIHAUER-BETKE|||1|5|Visit_5|90|7|TREATMENT|2021-04-18|90
e|IS|e2c20e9a-0ac5-4907-96de-472bee70bd79|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ukat|[?]|1|uCi/L|BREAST MILK|ZIEHL NEELSEN ACID FAST STAIN|||1|1|Visit_1|10|1|TREATMENT|2020-12-04|10
e|IS|e2c20e9a-0ac5-4907-96de-472bee70bd79|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cg|[?]|1|pmol/10^9 cells|CAPILLARY BLOOD|ORCHIDOMETERY||Y|1|2|Visit_2|25|3|TREATMENT|2020-12-19|25
e|IS|e2c20e9a-0ac5-4907-96de-472bee70bd79|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|100 IU/mL|[?]|1|10^6 copies/mL|SMEGMA|IRON HEMATOXYLIN STAIN|||1|3|Visit_3|40|3|FOLLOW-UP|2021-01-03|40
e|IS|e2c20e9a-0ac5-4907-96de-472bee70bd79|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BOTTLE|[?]|1|Watt|BLOOD|CELL OF ORIGIN ASSAY|Y|Y|1|4|Visit_4|65|4|FOLLOW-UP|2021-01-28|65
e|IS|e2c20e9a-0ac5-4907-96de-472bee70bd79|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol/kg/min|[?]|1|log10 CFU/g|SEMEN|GIEMSA STAIN|||1|5|Visit_5|90|4|TREATMENT|2021-02-22|90
e|IS|6064ca8c-b723-4d05-914a-bb547d86fcc5|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|um|[?]|1|oz|CAPILLARY PLASMA|MICROARRAY|||1|1|Visit_1|10|3|TREATMENT|2020-06-02|10
e|IS|6064ca8c-b723-4d05-914a-bb547d86fcc5|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BP|[?]|1|pptr|LEUKOCYTE|LANDOLT RING|Y||1|2|Visit_2|25|4|FOLLOW-UP|2020-06-17|25
e|IS|6064ca8c-b723-4d05-914a-bb547d86fcc5|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/min|[?]|1|mEq/dL|SUPERNATANT, SERUM|FARNSWORTH-MUNSELL 100 HUE TEST|||1|3|Visit_3|40|4|TREATMENT|2020-07-02|40
e|IS|6064ca8c-b723-4d05-914a-bb547d86fcc5|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|CAPSULE|[?]|1|grain|NAIL|WHOLE EXOME SEQUENCING||Y|1|4|Visit_4|65|7|SCREENING|2020-07-27|65
e|IS|6064ca8c-b723-4d05-914a-bb547d86fcc5|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Weber|[?]|1|Torr|SUPERNATANT, SERUM|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y|1|5|Visit_5|90|2|TREATMENT|2020-08-21|90
e|IS|8effbbff-acda-4718-89f1-e30a418f6bae|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MdFI|[?]|1|dL|EXHALED BREATH CONDENSATE|ERGOSPIROMETRY|Y|Y|1|1|Visit_1|10|6|SCREENING|2020-11-06|10
e|IS|8effbbff-acda-4718-89f1-e30a418f6bae|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug/kg|[?]|1|nL|EXPIRED AIR|IN VITRO GENE EXPRESSION ASSAY||Y|1|2|Visit_2|25|2|TREATMENT|2020-11-21|25
e|IS|8effbbff-acda-4718-89f1-e30a418f6bae|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|DAYS|[?]|1|mL/min/1.73m2|PROSTATIC FLUID|TRANSMISSION ELECTRON MICROSCOPY|Y||1|3|Visit_3|40|3|TREATMENT|2020-12-06|40
e|IS|8effbbff-acda-4718-89f1-e30a418f6bae|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/L DDU|[?]|1|log10 CFU/mL|PUS|CARDIAC THERMODILUTION|Y||1|4|Visit_4|65|3|TREATMENT|2020-12-31|65
e|IS|8effbbff-acda-4718-89f1-e30a418f6bae|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mm/sec|[?]|1|RFU|BLOOD|THIN SMEAR|||1|5|Visit_5|90|4|FOLLOW-UP|2021-01-25|90
e|IS|859b16a5-f6a2-40cc-8e01-18c112b1969e|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/wk|[?]|1|Absorbance U|INTERSTITIAL FLUID|RAJI CELL RIA|||1|1|Visit_1|10|6|TREATMENT|2020-08-18|10
e|IS|859b16a5-f6a2-40cc-8e01-18c112b1969e|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kBq|[?]|1|mL/min|SMOOTH MUSCLE TISSUE|ELECTROGASTROGRAPHY|Y||1|2|Visit_2|25|1|TREATMENT|2020-09-02|25
e|IS|859b16a5-f6a2-40cc-8e01-18c112b1969e|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/m2|[?]|1|pg/dL|VENOUS BLOOD|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y|1|3|Visit_3|40|5|TREATMENT|2020-09-17|40
e|IS|859b16a5-f6a2-40cc-8e01-18c112b1969e|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|breaths/30s|[?]|1|%/s|MUCUS|TOTAL BODY RADIOGRAPHY||Y|1|4|Visit_4|65|7|SCREENING|2020-10-12|65
e|IS|859b16a5-f6a2-40cc-8e01-18c112b1969e|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|cL|[?]|1|MAC50|SERUM|SPECTROPHOTOMETRY||Y|1|5|Visit_5|90|1|SCREENING|2020-11-06|90
e|IS|36b457ef-4cf6-4043-a836-49368ebf3f1c|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 IU|[?]|1|cpm|BLOOD|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||1|1|Visit_1|10|2|SCREENING|2020-08-16|10
e|IS|36b457ef-4cf6-4043-a836-49368ebf3f1c|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|umol/L|[?]|1|pmol/dL|SUPERNATANT, PLASMA|MANUAL COUNT||Y|1|2|Visit_2|25|2|WASHOUT|2020-08-31|25
e|IS|36b457ef-4cf6-4043-a836-49368ebf3f1c|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cal|[?]|1|foz_br|TUMOR TISSUE|FUNDUS PHOTOGRAPHY|Y|Y|1|3|Visit_3|40|6|SCREENING|2020-09-15|40
e|IS|36b457ef-4cf6-4043-a836-49368ebf3f1c|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Sv|[?]|1|Ci/ug|SEMEN|HPLC/MS/MS|||1|4|Visit_4|65|6|TREATMENT|2020-10-10|65
e|IS|36b457ef-4cf6-4043-a836-49368ebf3f1c|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|VOXEL|[?]|1|mmHg*min/L|URINE SEDIMENT|IODINE STAIN|||1|5|Visit_5|90|3|TREATMENT|2020-11-04|90
e|IS|31f33e38-bba6-4c8a-b563-14afaabae5d7|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|U/g/day|[?]|1|Enzyme U/g Hb|SALIVA|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||Y|1|1|Visit_1|10|3|TREATMENT|2020-07-01|10
e|IS|31f33e38-bba6-4c8a-b563-14afaabae5d7|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/10^3|[?]|1|10^10/L|SUPERNATANT, PLEURAL FLUID|ATOMIC ABSORPTION SPECTROMETRY|||1|2|Visit_2|25|1|TREATMENT|2020-07-16|25
e|IS|31f33e38-bba6-4c8a-b563-14afaabae5d7|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mmol/mol|[?]|1|steps/min|TRANSUDATE|FLUORESCENT SPOT TEST|||1|3|Visit_3|40|3|TREATMENT|2020-07-31|40
e|IS|31f33e38-bba6-4c8a-b563-14afaabae5d7|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g|[?]|1|atm|ADIPOSE TISSUE|PUPILLOMETRY|||1|4|Visit_4|65|3|FOLLOW-UP|2020-08-25|65
e|IS|31f33e38-bba6-4c8a-b563-14afaabae5d7|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|APS U|[?]|1|mm3/mm2/year|SYNOVIAL FLUID|EEG|||1|5|Visit_5|90|3|TREATMENT|2020-09-19|90
e|IS|6794dffe-333b-425b-8883-26f6e5ba0797|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nmol/kg/day|[?]|1|/7.5 mL|SUPERNATANT, SERUM OR PLASMA|IMMUNE REPERTOIRE DEEP SEQUENCING||Y|1|1|Visit_1|10|6|FOLLOW-UP|2020-07-09|10
e|IS|6794dffe-333b-425b-8883-26f6e5ba0797|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|min/day|[?]|1|LB|ENDOTRACHEAL FLUID|ELECTROPHORESIS||Y|1|2|Visit_2|25|4|TREATMENT|2020-07-24|25
e|IS|6794dffe-333b-425b-8883-26f6e5ba0797|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U.CARR|[?]|1|INHALATION|PROSTATIC FLUID|HPLC/IEX|||1|3|Visit_3|40|5|TREATMENT|2020-08-08|40
e|IS|6794dffe-333b-425b-8883-26f6e5ba0797|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/min/kPa|[?]|1|kN/cm2|MUCUS|CONTRAST ENHANCED PET SCAN|||1|4|Visit_4|65|4|SCREENING|2020-09-02|65
e|IS|6794dffe-333b-425b-8883-26f6e5ba0797|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/m2|[?]|1|fmol/L|EXPIRED AIR|TARGETED GENOME SEQUENCING|Y||1|5|Visit_5|90|7|TREATMENT|2020-09-27|90
e|IS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mol/mg|[?]|1|10^6 copies/mL|CIRCULATING TUMOR CELL|LIGHT SCATTERING SPECTROSCOPY|Y||1|1|Visit_1|10|1|TREATMENT|2020-06-07|10
e|IS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|genEq|[?]|1|Gauss|CARDIAC MUSCLE TISSUE|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y||1|2|Visit_2|25|7|FOLLOW-UP|2020-06-22|25
e|IS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kBq/uL|[?]|1|DNA copies/ug|BONE MARROW MONONUCLEAR CELL|HPLC|Y||1|3|Visit_3|40|7|FOLLOW-UP|2020-07-07|40
e|IS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|pmol/day|[?]|1|mg/cm2|SUPERNATANT, PLEURAL FLUID|INDIRECT IMMUNOFLUORESCENCE|Y|Y|1|4|Visit_4|65|2|FOLLOW-UP|2020-08-01|65
e|IS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/min|[?]|1|10^6 IU/mL|EMOTIONAL TEAR|CLOT DETECTION|||1|5|Visit_5|90|2|SCREENING|2020-08-26|90
e|IS|45897452-8f5a-458d-9a43-13237460ba48|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|TABLET|[?]|1|kN/cm2|SPERMATOZOON|APPLANATION TONOMETRY|Y||1|1|Visit_1|10|3|WASHOUT|2020-11-11|10
e|IS|45897452-8f5a-458d-9a43-13237460ba48|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|cmHg|GASTRIC FLUID|IMMUNOASSAY|||1|2|Visit_2|25|3|WASHOUT|2020-11-26|25
e|IS|45897452-8f5a-458d-9a43-13237460ba48|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|IMPLANT|[?]|1|pg/L|SUPERNATANT, SERUM|HILLMEN COLOR CHART||Y|1|3|Visit_3|40|5|TREATMENT|2020-12-11|40
e|IS|45897452-8f5a-458d-9a43-13237460ba48|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|nmol/mol|[?]|1|PELLET|PLATELET|FLUORIMETRY|||1|4|Visit_4|65|1|WASHOUT|2021-01-05|65
e|IS|45897452-8f5a-458d-9a43-13237460ba48|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/g|[?]|1|GPL U|SWABBED MATERIAL|EIA|||1|5|Visit_5|90|7|WASHOUT|2021-01-30|90
e|IS|16eb981f-2118-4658-a83f-93d925c410c9|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 organisms/g|[?]|1|EP U|SEMEN|PATHOLOGICAL EVALUATION|||1|1|Visit_1|10|3|SCREENING|2020-12-16|10
e|IS|16eb981f-2118-4658-a83f-93d925c410c9|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|BE/mL|[?]|1|ug/m2/day|MUCUS|LC-FL|||1|2|Visit_2|25|2|TREATMENT|2020-12-31|25
e|IS|16eb981f-2118-4658-a83f-93d925c410c9|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ng/L|[?]|1|nsec|STRIATED MUSCLE TISSUE|PAP STAIN|||1|3|Visit_3|40|5|TREATMENT|2021-01-15|40
e|IS|16eb981f-2118-4658-a83f-93d925c410c9|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ELISA unit|[?]|1|log10 CCID 50/dose|GASTRIC CONTENTS|OPTICAL DENSITY MEASUREMENT|||1|4|Visit_4|65|7|TREATMENT|2021-02-09|65
e|IS|16eb981f-2118-4658-a83f-93d925c410c9|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|MPL U/mL|[?]|1|hr/day|LYMPH|TWO-COLOR MICROARRAY|||1|5|Visit_5|90|6|TREATMENT|2021-03-06|90
e|IS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|BOWL|[?]|1|10^3 organisms/g|DISCHARGE|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||1|1|Visit_1|10|2|WASHOUT|2021-01-11|10
e|IS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|TRACE|[?]|1|cm|AMNIOTIC FLUID|U-HPLC/MS/MS||Y|1|2|Visit_2|25|5|FOLLOW-UP|2021-01-26|25
e|IS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cm H2O|[?]|1|ug/L|PERSPIRATION|ELECTRONEUROGRAPHY|||1|3|Visit_3|40|4|FOLLOW-UP|2021-02-10|40
e|IS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cpm|[?]|1|10^3 organisms/mL|SUPERNATANT, SERUM OR PLASMA|MAMMOGRAPHY||Y|1|4|Visit_4|65|4|WASHOUT|2021-03-07|65
e|IS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^4 CFU/mL|[?]|1|kIU|SMOOTH MUSCLE TISSUE|PULMONARY ANGIOGRAPHY|Y||1|5|Visit_5|90|6|WASHOUT|2021-04-01|90
e|IS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|kPa/L/sec|[?]|1|U/cL|SUPERNATANT, PLASMA|ZIEHL NEELSEN ACID FAST STAIN||Y|1|1|Visit_1|10|5|TREATMENT|2021-01-29|10
e|IS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Farad|[?]|1|IU/mg|EPIDERMAL TISSUE|BRDU CELLULAR PROLIFERATION ASSAY||Y|1|2|Visit_2|25|3|SCREENING|2021-02-13|25
e|IS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 DNA copies/mL|[?]|1|anti-Xa IU/mL|CEREBROSPINAL FLUID|OPTICAL COHERENCE TOMOGRAPHY|||1|3|Visit_3|40|1|FOLLOW-UP|2021-02-28|40
e|IS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|JDF Unit|[?]|1|pptr|CEREBROSPINAL FLUID|EPSILOMETER|||1|4|Visit_4|65|4|TREATMENT|2021-03-25|65
e|IS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/animal|[?]|1|MPS U|GASTRIC FLUID|IMMUNORADIOMETRIC ASSAY|||1|5|Visit_5|90|3|SCREENING|2021-04-19|90
e|IS|874f491c-5d55-4738-86b7-b1200b16d106|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 TCID 50/dose|[?]|1|mL/kg/h|SPERMATOZOON|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y|1|1|Visit_1|10|2|TREATMENT|2021-01-08|10
e|IS|874f491c-5d55-4738-86b7-b1200b16d106|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/animal|[?]|1|mL/cm H2O|PUS|DROPLET DIGITAL PCR|Y||1|2|Visit_2|25|7|FOLLOW-UP|2021-01-23|25
e|IS|874f491c-5d55-4738-86b7-b1200b16d106|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|foz_us|[?]|1|Ci/ug|SKIN TISSUE|HANSEL STAIN|||1|3|Visit_3|40|2|FOLLOW-UP|2021-02-07|40
e|IS|874f491c-5d55-4738-86b7-b1200b16d106|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/LSQN|[?]|1|COAT|GASTRIC FLUID|ELASTOGRAPHY|||1|4|Visit_4|65|4|TREATMENT|2021-03-04|65
e|IS|874f491c-5d55-4738-86b7-b1200b16d106|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/10^3|[?]|1|/day|BONE|ULTRASOUND|||1|5|Visit_5|90|4|FOLLOW-UP|2021-03-29|90
e|IS|281ccdef-794c-49ad-9616-6f6f68dd4543|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mJoule/cm2|[?]|1|mL*cmH2O|PLASMA ULTRAFILTRATE|RADIAL IMMUNODIFFUSION|Y||1|1|Visit_1|10|2|FOLLOW-UP|2020-06-04|10
e|IS|281ccdef-794c-49ad-9616-6f6f68dd4543|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|dB|[?]|1|IMPLANT|EXHALED BREATH CONDENSATE|LAPAROSCOPY||Y|1|2|Visit_2|25|2|TREATMENT|2020-06-19|25
e|IS|281ccdef-794c-49ad-9616-6f6f68dd4543|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|genEq/mL|[?]|1|10^3 organisms/mL|DIALYSIS FLUID, PERITONEAL|OPHTHALMOSCOPY|||1|3|Visit_3|40|7|TREATMENT|2020-07-04|40
e|IS|281ccdef-794c-49ad-9616-6f6f68dd4543|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|U/cL|[?]|1|vp/dose|LOCHIA|HILLMEN COLOR CHART|Y||1|4|Visit_4|65|1|TREATMENT|2020-07-29|65
e|IS|281ccdef-794c-49ad-9616-6f6f68dd4543|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/L|[?]|1|PACK|ARTERIAL CORD BLOOD|KINYOUN STAIN|||1|5|Visit_5|90|5|TREATMENT|2020-08-23|90
e|IS|b1179e10-e8fe-472c-a511-d6d460571857|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|INHALATION|[?]|1|APL U/mL|SALIVA|DC SHEATH FLOW|||1|1|Visit_1|10|4|WASHOUT|2020-08-02|10
e|IS|b1179e10-e8fe-472c-a511-d6d460571857|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|deg2|[?]|1|g/animal/day|SEMEN|DXA SCAN|||1|2|Visit_2|25|1|SCREENING|2020-08-17|25
e|IS|b1179e10-e8fe-472c-a511-d6d460571857|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|umol/L/min|[?]|1|mg/L FEU|SERUM|CLINICAL EVALUATION|||1|3|Visit_3|40|3|FOLLOW-UP|2020-09-01|40
e|IS|b1179e10-e8fe-472c-a511-d6d460571857|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kat|[?]|1|10^4 CFU/mL|PROSTATIC FLUID|HPLC/IEX||Y|1|4|Visit_4|65|3|WASHOUT|2020-09-26|65
e|IS|b1179e10-e8fe-472c-a511-d6d460571857|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|10^9/L|BASAL TEAR|NEURAMINIDASE INHIBITION ASSAY||Y|1|5|Visit_5|90|5|SCREENING|2020-10-21|90
e|IS|6362cf42-f286-4151-bdf7-38fcc5639eed|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|BEAM BREAKS|[?]|1|BOWL|EPIDERMAL TISSUE|FLAME PHOTOMETRY|||1|1|Visit_1|10|5|FOLLOW-UP|2020-09-07|10
e|IS|6362cf42-f286-4151-bdf7-38fcc5639eed|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|fmol/g|[?]|1|cmol|BILE|TRIPLE-PHASE MRI SCAN|||1|2|Visit_2|25|1|TREATMENT|2020-09-22|25
e|IS|6362cf42-f286-4151-bdf7-38fcc5639eed|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|scm|[?]|1|km|SUPERNATANT, CEREBROSPINAL FLUID|ETDRS EYE CHART|||1|3|Visit_3|40|2|SCREENING|2020-10-07|40
e|IS|6362cf42-f286-4151-bdf7-38fcc5639eed|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/s|[?]|1|ng/L|BILE|FLUORESCENT SPOT TEST|||1|4|Visit_4|65|1|TREATMENT|2020-11-01|65
e|IS|6362cf42-f286-4151-bdf7-38fcc5639eed|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/mL/h|[?]|1|/10^3|EMOTIONAL TEAR|CONTACT SPECULAR MICROSCOPY|||1|5|Visit_5|90|6|TREATMENT|2020-11-26|90
e|IS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|log10 IU/mL|[?]|1|U/mL|CELL PELLET|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|1|FOLLOW-UP|2020-11-30|10
e|IS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pg/L|[?]|1|SPRAY|RETICULOCYTES|SLOAN LETTER EYE CHART 100%|Y||1|2|Visit_2|25|4|SCREENING|2020-12-15|25
e|IS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^9 CFU|[?]|1|U/dL|NAIL|KINYOUN STAIN|||1|3|Visit_3|40|5|TREATMENT|2020-12-30|40
e|IS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|Siemens|MENSTRUAL BLOOD|MICROSCOPY|||1|4|Visit_4|65|7|WASHOUT|2021-01-24|65
e|IS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|BAU|[?]|1|Pa|AQUEOUS HUMOR|ELLA|Y||1|5|Visit_5|90|5|TREATMENT|2021-02-18|90
e|IS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/uL|[?]|1|Gy/h|INFRANATANT, SERUM|ELECTRICAL IMPEDANCE MYOGRAPHY|Y||1|1|Visit_1|10|5|SCREENING|2020-06-27|10
e|IS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|HOMEOPATHIC DILUTION|[?]|1|EVENTS|MECONIUM|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y|Y|1|2|Visit_2|25|1|TREATMENT|2020-07-12|25
e|IS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PLUG|[?]|1|NEBULE|ADIPOSE TISSUE|RAJI CELL RIA|||1|3|Visit_3|40|4|SCREENING|2020-07-27|40
e|IS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cpm|[?]|1|mm/h|TISSUE|TRANSMISSION ELECTRON MICROSCOPY|||1|4|Visit_4|65|3|TREATMENT|2020-08-21|65
e|IS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|RING|[?]|1|ng/dL|CALCULUS|FLUORESCENT MICROSCOPY|||1|5|Visit_5|90|4|SCREENING|2020-09-15|90
e|IS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|s*kPa|[?]|1|mg/dose|CERUMEN|PHOTOMETRIC CLOT DETECTION|Y||1|1|Visit_1|10|7|FOLLOW-UP|2020-06-22|10
e|IS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mmHg*min/L|[?]|1|um2|CORD BLOOD|OBSERVATION|||1|2|Visit_2|25|3|SCREENING|2020-07-07|25
e|IS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|rpm|[?]|1|mL*cmH2O|TISSUE|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y||1|3|Visit_3|40|1|SCREENING|2020-07-22|40
e|IS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|IU/mg|[?]|1|mEq/day|EMESIS|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||1|4|Visit_4|65|6|WASHOUT|2020-08-16|65
e|IS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/cm3/min|[?]|1|ukat/L|MONOCYTE|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|Y|1|5|Visit_5|90|1|TREATMENT|2020-09-10|90
e|IS|43880587-c397-402d-886b-9b666e3fe455|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 CFU/mL|[?]|1|tsp eq|SUPERNATANT, SERUM|DIRECT SEQUENCING|||1|1|Visit_1|10|1|TREATMENT|2020-07-21|10
e|IS|43880587-c397-402d-886b-9b666e3fe455|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm/h|[?]|1|PNU/mL|INFRANATANT, PLASMA|PANENDOSCOPY|Y||1|2|Visit_2|25|4|SCREENING|2020-08-05|25
e|IS|43880587-c397-402d-886b-9b666e3fe455|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|APL U/mL|[?]|1|nmol/mol|CERUMEN|INCISION-INDUCED BLEEDING METHOD|||1|3|Visit_3|40|3|TREATMENT|2020-08-20|40
e|IS|43880587-c397-402d-886b-9b666e3fe455|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/m2|[?]|1|mL/min/mmHg|INTERSTITIAL FLUID|DROPLET DIGITAL PCR|||1|4|Visit_4|65|5|WASHOUT|2020-09-14|65
e|IS|43880587-c397-402d-886b-9b666e3fe455|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MnFI|[?]|1|g/animal/day|PROSTATIC FLUID|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|5|Visit_5|90|3|TREATMENT|2020-10-09|90
e|IS|807f83d2-9364-4ee4-855d-304f3e252555|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|cd/m2|[?]|1|uCi/kg|LEUKOCYTE|TURBIDIMETRY|Y||1|1|Visit_1|10|7|TREATMENT|2020-05-14|10
e|IS|807f83d2-9364-4ee4-855d-304f3e252555|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ppth|[?]|1|ug/mol|GASTRIC CONTENTS|HIGH RESOLUTION CT|||1|2|Visit_2|25|4|SCREENING|2020-05-29|25
e|IS|807f83d2-9364-4ee4-855d-304f3e252555|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^9 CFU|[?]|1|cP|EXUDATE|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||1|3|Visit_3|40|6|FOLLOW-UP|2020-06-13|40
e|IS|807f83d2-9364-4ee4-855d-304f3e252555|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MnFI|[?]|1|g/mol|MIXED VENOUS BLOOD|MS/MS|||1|4|Visit_4|65|4|TREATMENT|2020-07-08|65
e|IS|807f83d2-9364-4ee4-855d-304f3e252555|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|um/day|[?]|1|copies/ug|PLEURAL TISSUE|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||1|5|Visit_5|90|1|TREATMENT|2020-08-02|90
e|IS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ms2|[?]|1|mmol2/L2|TUMOR TISSUE|OSCILLOMETRY|||1|1|Visit_1|10|7|TREATMENT|2020-12-09|10
e|IS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mU/g|[?]|1|PACK|MECONIUM|BALLPOINT PEN TECHNIQUE||Y|1|2|Visit_2|25|5|FOLLOW-UP|2020-12-24|25
e|IS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|KALLIKREIN INHIBITOR UNIT|[?]|1|Rad|PLASMA ULTRAFILTRATE|SICKLE CELL SOLUBILITY TEST|||1|3|Visit_3|40|5|TREATMENT|2021-01-08|40
e|IS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol|[?]|1|U/g/min|ATHEROSCLEROTIC PLAQUE|FLOW CYTOMETRY|||1|4|Visit_4|65|1|WASHOUT|2021-02-02|65
e|IS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uL/mL|[?]|1|nmol|PERIPHERAL BLOOD MONONUCLEAR CELL|HPLC||Y|1|5|Visit_5|90|5|TREATMENT|2021-02-27|90
e|IS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/m2|[?]|1|ug/g/h|REFLEX TEAR|CONTRAST ENHANCED PET/CT SCAN|||1|1|Visit_1|10|5|WASHOUT|2020-08-15|10
e|IS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|psec|[?]|1|ug|SALIVA|CONTRAST ENHANCED PET/CT SCAN|Y||1|2|Visit_2|25|3|TREATMENT|2020-08-30|25
e|IS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cP|[?]|1|GBq/ug|SEMINAL FLUID|TRIPLE-PHASE MRI SCAN|Y|Y|1|3|Visit_3|40|2|WASHOUT|2020-09-14|40
e|IS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cm/min|[?]|1|kg/cm2|HAIR FOLLICLE|NUCLEIC ACID HYBRIDIZATION|Y||1|4|Visit_4|65|4|TREATMENT|2020-10-09|65
e|IS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|mmol/day|PERSPIRATION|PUPILLOMETRY|||1|5|Visit_5|90|4|SCREENING|2020-11-03|90
e|IS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Ci/mL|[?]|1|cd|TISSUE|HPLC/MS|||1|1|Visit_1|10|1|TREATMENT|2020-08-01|10
e|IS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|dmol|[?]|1|cmol|SERUM OR PLASMA|PELLI-ROBSON EYE CHART|||1|2|Visit_2|25|3|FOLLOW-UP|2020-08-16|25
e|IS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PACKET|[?]|1|umol/L/sec|EPIDERMAL TISSUE|MOUSE PROTECTION ASSAY||Y|1|3|Visit_3|40|6|TREATMENT|2020-08-31|40
e|IS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/L|[?]|1|cGy|ARTERIAL CORD BLOOD|CYSTOSCOPY|Y|Y|1|4|Visit_4|65|1|TREATMENT|2020-09-25|65
e|IS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^8 PFU|[?]|1|mmol/s|VITREOUS HUMOR|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||1|5|Visit_5|90|2|SCREENING|2020-10-20|90
e|IS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|LB|[?]|1|log10 TCID 50/uL|PLASMA ULTRAFILTRATE|DXA SCAN||Y|1|1|Visit_1|10|5|SCREENING|2020-09-01|10
e|IS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PATCH|[?]|1|MBP|COLOSTRUM|INDIA INK STAIN|||1|2|Visit_2|25|6|FOLLOW-UP|2020-09-16|25
e|IS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|POUCH|[?]|1|mg/L FEU|LOCHIA|PET/CT SCAN|||1|3|Visit_3|40|7|TREATMENT|2020-10-01|40
e|IS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/500 WBC|[?]|1|/LPF|CERVICOVAGINAL SECRETION|FLOCCULATION|||1|4|Visit_4|65|7|TREATMENT|2020-10-26|65
e|IS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Antibody Unit|[?]|1|mL/breath|INFRANATANT, PLASMA|DNA MICROARRAY|Y||1|5|Visit_5|90|6|FOLLOW-UP|2020-11-20|90
e|IS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|lm|[?]|1|umol/dL|VENOUS CORD BLOOD|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||1|1|Visit_1|10|1|TREATMENT|2021-01-27|10
e|IS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|s*kPa|[?]|1|PIXELS/in|SPUTUM|IMMUNO-PET SCAN|Y|Y|1|2|Visit_2|25|1|TREATMENT|2021-02-11|25
e|IS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|bel|[?]|1|LENS|EXUDATE|MALDI-TOF|Y|Y|1|3|Visit_3|40|6|SCREENING|2021-02-26|40
e|IS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|PIXELS/cm|[?]|1|uOsm|SUPERNATANT, PLEURAL FLUID|CONTRAST ENHANCED X-RAY|Y|Y|1|4|Visit_4|65|4|TREATMENT|2021-03-23|65
e|IS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ELISA unit|[?]|1|mL/beat|SMEGMA|MICROBIAL CULTURE||Y|1|5|Visit_5|90|7|FOLLOW-UP|2021-04-17|90
e|IS|21740641-69bb-49a9-a86d-2444914f6d12|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|um/day|[?]|1|mL/mmHg|URINE|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|Y|1|1|Visit_1|10|6|TREATMENT|2020-05-17|10
e|IS|21740641-69bb-49a9-a86d-2444914f6d12|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|RNA copies/mL|[?]|1|titer|SWABBED MATERIAL|MICRODENSITOMETRY|Y|Y|1|2|Visit_2|25|6|TREATMENT|2020-06-01|25
e|IS|21740641-69bb-49a9-a86d-2444914f6d12|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kcal/day|[?]|1|/VF|INTERSTITIAL FLUID|PANENDOSCOPY|||1|3|Visit_3|40|3|TREATMENT|2020-06-16|40
e|IS|21740641-69bb-49a9-a86d-2444914f6d12|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|gtt|[?]|1|ft3|PUS|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||1|4|Visit_4|65|7|TREATMENT|2020-07-11|65
e|IS|21740641-69bb-49a9-a86d-2444914f6d12|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmAL|[?]|1|mg/min|GASTRIC CONTENTS|IMMUNOBLOT|||1|5|Visit_5|90|1|FOLLOW-UP|2020-08-05|90
e|IS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^12/L|[?]|1|TUBE|CELL PELLET|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|1|Visit_1|10|1|TREATMENT|2020-06-18|10
e|IS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/m2/day|[?]|1|ug/mL/h|PERIPHERAL BLOOD MONONUCLEAR CELL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|2|Visit_2|25|7|WASHOUT|2020-07-03|25
e|IS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/h|[?]|1|cpm|STOOL|MICROBIAL CULTURE||Y|1|3|Visit_3|40|5|TREATMENT|2020-07-18|40
e|IS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/cage/wk|[?]|1|U/m2/h|URINE|IMMUNOBLOT|||1|4|Visit_4|65|3|WASHOUT|2020-08-12|65
e|IS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|copies/ug|[?]|1|%/min|BUFFY COAT|MANUAL COUNT|Y||1|5|Visit_5|90|1|WASHOUT|2020-09-06|90
e|IS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/kg|[?]|1|MBq/uL|CERVICOVAGINAL SECRETION|PHASE CONTRAST MICROSCOPY||Y|1|1|Visit_1|10|5|TREATMENT|2021-01-21|10
e|IS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug/L DDU|[?]|1|ug/L DDU|BONE MARROW MONONUCLEAR CELL|WRIGHT-GIEMSA STAIN||Y|1|2|Visit_2|25|7|WASHOUT|2021-02-05|25
e|IS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nmol BCE/mmol|[?]|1|Anson U|ALVEOLAR AIR|IODINE STAIN|Y||1|3|Visit_3|40|7|TREATMENT|2021-02-20|40
e|IS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U.CARR|[?]|1|dpm/mg|INFRANATANT, PLEURAL FLUID|QUANTITATIVE ULTRASOUND|Y||1|4|Visit_4|65|4|TREATMENT|2021-03-17|65
e|IS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/m2/day|[?]|1|PIXELS/in|ARTERIALIZED CAPILLARY BLOOD|MICROARRAY|||1|5|Visit_5|90|4|TREATMENT|2021-04-11|90
e|IS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/g/day|[?]|1|cL|VENOUS PLASMA|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y|1|1|Visit_1|10|2|TREATMENT|2020-07-24|10
e|IS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/kg/day|[?]|1|mg/m2/day|ABSCESS FLUID|AGAR DILUTION|||1|2|Visit_2|25|4|WASHOUT|2020-08-08|25
e|IS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|fraction of 1|[?]|1|mN|EPIDERMAL TISSUE|TEST STRIP|||1|3|Visit_3|40|5|TREATMENT|2020-08-23|40
e|IS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6/L|[?]|1|vg/mL|SPUTUM|WHOLE TRANSCRIPTOME SEQUENCING|||1|4|Visit_4|65|4|FOLLOW-UP|2020-09-17|65
e|IS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/mg|[?]|1|nmol/mol|KERATINOCYTE|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|5|Visit_5|90|6|FOLLOW-UP|2020-10-12|90
e|IS|5e383a9d-dc97-4352-8add-d55a1a566b9f|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|%/s|[?]|1|10^5/L|SUPERNATANT, PLASMA|AUSCULTATION|||1|1|Visit_1|10|4|TREATMENT|2020-09-27|10
e|IS|5e383a9d-dc97-4352-8add-d55a1a566b9f|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Bq/uL|[?]|1|MPS U|EPIDERMAL TISSUE|SINGLE-SLICE SPIRAL CT|||1|2|Visit_2|25|2|TREATMENT|2020-10-12|25
e|IS|5e383a9d-dc97-4352-8add-d55a1a566b9f|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|LENS|[?]|1|mg/m2/day|SPERMATOZOON|DUKE INCISION METHOD||Y|1|3|Visit_3|40|2|FOLLOW-UP|2020-10-27|40
e|IS|5e383a9d-dc97-4352-8add-d55a1a566b9f|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|breaths/min|[?]|1|steps/min|AMNIOTIC FLUID|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||1|4|Visit_4|65|1|WASHOUT|2020-11-21|65
e|IS|5e383a9d-dc97-4352-8add-d55a1a566b9f|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/m2/min|[?]|1|PACKAGE|VENOUS CORD BLOOD|PYROSEQUENCING|Y||1|5|Visit_5|90|2|FOLLOW-UP|2020-12-16|90
e|IS|3eda746b-fb97-4950-a528-1d4ae5d3653a|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ng/mol|[?]|1|kN/cm2|SERUM OR PLASMA|THICK SMEAR|||1|1|Visit_1|10|4|FOLLOW-UP|2020-06-13|10
e|IS|3eda746b-fb97-4950-a528-1d4ae5d3653a|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|lx|[?]|1|10^5/L|SPUTUM|CHROMOGENIC ASSAY|Y||1|2|Visit_2|25|5|SCREENING|2020-06-28|25
e|IS|3eda746b-fb97-4950-a528-1d4ae5d3653a|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|CAPSULE|[?]|1|/month|RETICULOCYTES|SPECT/CT SCAN|||1|3|Visit_3|40|1|SCREENING|2020-07-13|40
e|IS|3eda746b-fb97-4950-a528-1d4ae5d3653a|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/m2/h|[?]|1|Log10 ELISA unit|PLEURAL FLUID|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||1|4|Visit_4|65|4|TREATMENT|2020-08-07|65
e|IS|3eda746b-fb97-4950-a528-1d4ae5d3653a|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|PIXELS/in|[?]|1|uEq/L|ENDOTRACHEAL FLUID|TRIPLE-PHASE SPIRAL CT SCAN|Y||1|5|Visit_5|90|1|TREATMENT|2020-09-01|90
e|IS|a3b72841-3401-4dcc-9d06-75438b408d0b|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mV/sec|[?]|1|uCi/L|PLATELET|SNP ARRAY|Y|Y|1|1|Visit_1|10|2|TREATMENT|2020-11-05|10
e|IS|a3b72841-3401-4dcc-9d06-75438b408d0b|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|STEPS|[?]|1|YEARS|SPUTUM|DNA MICROARRAY|||1|2|Visit_2|25|7|SCREENING|2020-11-20|25
e|IS|a3b72841-3401-4dcc-9d06-75438b408d0b|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|m/sec2|[?]|1|EVENTS|DIALYSIS FLUID|CHROMATOGRAPHY|||1|3|Visit_3|40|5|WASHOUT|2020-12-05|40
e|IS|a3b72841-3401-4dcc-9d06-75438b408d0b|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^6 organisms/g|[?]|1|uEq/L|GASTRIC FLUID|FLOW MICROSCOPY||Y|1|4|Visit_4|65|1|TREATMENT|2020-12-30|65
e|IS|a3b72841-3401-4dcc-9d06-75438b408d0b|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|km|[?]|1|MPL U|SMOOTH MUSCLE TISSUE|IMPULSE OSCILLOMETRY|||1|5|Visit_5|90|4|TREATMENT|2021-01-24|90
e|IS|4393406e-bda5-42e4-a752-a8121004b7ef|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kg/mol|[?]|1|mg/dL|MENSTRUAL BLOOD|ALCIAN BLUE STAIN|||1|1|Visit_1|10|6|TREATMENT|2020-10-28|10
e|IS|4393406e-bda5-42e4-a752-a8121004b7ef|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/dose|[?]|1|L/s|SKELETAL MUSCLE TISSUE|OPTICAL DENSITY MEASUREMENT|||1|2|Visit_2|25|2|TREATMENT|2020-11-12|25
e|IS|4393406e-bda5-42e4-a752-a8121004b7ef|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GLOBULE|[?]|1|ELISA unit/dose|VENOUS CORD BLOOD|DIRECT SEQUENCING||Y|1|3|Visit_3|40|6|WASHOUT|2020-11-27|40
e|IS|4393406e-bda5-42e4-a752-a8121004b7ef|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cm/min|[?]|1|Gauss|MONOCYTE|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y|Y|1|4|Visit_4|65|3|SCREENING|2020-12-22|65
e|IS|4393406e-bda5-42e4-a752-a8121004b7ef|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/kg/day|[?]|1|GPL U|ATHEROSCLEROTIC PLAQUE|DIFFUSION TENSOR MRI|||1|5|Visit_5|90|1|TREATMENT|2021-01-16|90
e|IS|d70f5903-3d94-422b-8f69-212f015b54c9|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ppb|[?]|1|GBq/g|LEUKOCYTE|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|1|Visit_1|10|6|WASHOUT|2020-05-19|10
e|IS|d70f5903-3d94-422b-8f69-212f015b54c9|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/h|[?]|1|log10 TCID 50/uL|INTERSTITIAL FLUID|CELL BASED BIOASSAY|||1|2|Visit_2|25|3|SCREENING|2020-06-03|25
e|IS|d70f5903-3d94-422b-8f69-212f015b54c9|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|SCOOPFUL|[?]|1|log10 CCID 50/dose|CAPILLARY PLASMA|INFRARED SPECTROMETRY|||1|3|Visit_3|40|5|FOLLOW-UP|2020-06-18|40
e|IS|d70f5903-3d94-422b-8f69-212f015b54c9|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|titer|[?]|1|Absorbance U/min|INFRANATANT, SERUM|MUGA|||1|4|Visit_4|65|3|TREATMENT|2020-07-13|65
e|IS|d70f5903-3d94-422b-8f69-212f015b54c9|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MdFI|[?]|1|cL|URINE SEDIMENT|STRESS ECHOCARDIOGRAPHY|||1|5|Visit_5|90|3|TREATMENT|2020-08-07|90
e|IS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|TRANSDUCING UNIT|[?]|1|beats/min|ADIPOSE TISSUE|MICROBIAL CONCENTRATION|||1|1|Visit_1|10|7|SCREENING|2021-01-06|10
e|IS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|tuberculin unit/mL|[?]|1|nmol/day|SWABBED MATERIAL|MICRO BROTH DILUTION|Y||1|2|Visit_2|25|5|WASHOUT|2021-01-21|25
e|IS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/kg|[?]|1|PHERESIS UNIT|INTERSTITIAL FLUID|SPECTROPHOTOMETRY|||1|3|Visit_3|40|7|TREATMENT|2021-02-05|40
e|IS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MET*min|[?]|1|min*mg/mL|DISCHARGE|OSCILLOMETRY|||1|4|Visit_4|65|4|TREATMENT|2021-03-02|65
e|IS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/kg|[?]|1|DIP|MUCUS|HPLC/MS||Y|1|5|Visit_5|90|7|TREATMENT|2021-03-27|90
e|IS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mol/mL|[?]|1|mm3/mm2/year|MUSCLE TISSUE|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y||1|1|Visit_1|10|3|WASHOUT|2020-07-14|10
e|IS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/g/day|[?]|1|U/kg/min|BILE|INDIRECT IMMUNOFLUORESCENCE|Y||1|2|Visit_2|25|1|TREATMENT|2020-07-29|25
e|IS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|cm|[?]|1|10^3 CFU/mL|LYSATE|GC/FID|||1|3|Visit_3|40|3|WASHOUT|2020-08-13|40
e|IS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/g/h|[?]|1|mL/dL|CARDIAC MUSCLE TISSUE|ENDOSCOPY|||1|4|Visit_4|65|6|SCREENING|2020-09-07|65
e|IS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uL/mL|[?]|1|mIU/L|ARTERIAL CORD BLOOD|REFRACTOMETRY|||1|5|Visit_5|90|7|TREATMENT|2020-10-02|90
e|IS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^3 CFU|[?]|1|g/animal/day|BONE MARROW|PYROSEQUENCING|||1|1|Visit_1|10|2|WASHOUT|2020-11-29|10
e|IS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|kg/cm2|[?]|1|L/h|ARTERIAL BLOOD|PULMONARY ANGIOGRAPHY|Y||1|2|Visit_2|25|5|TREATMENT|2020-12-14|25
e|IS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|DPM|[?]|1|PFU/animal|SMOOTH MUSCLE TISSUE|PATHOLOGICAL EVALUATION|||1|3|Visit_3|40|3|TREATMENT|2020-12-29|40
e|IS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL*cmH2O|[?]|1|DAgU|SEMINAL FLUID|SPECT/CT SCAN|||1|4|Visit_4|65|2|TREATMENT|2021-01-23|65
e|IS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|lx|[?]|1|log10 CFU/mL|AMNIOTIC FLUID|AUTOREFRACTION|||1|5|Visit_5|90|7|FOLLOW-UP|2021-02-17|90
e|IS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|OI50|[?]|1|SPRAY|CELL PELLET|TRANSTHORACIC ECHOCARDIOGRAPHY|Y||1|1|Visit_1|10|7|TREATMENT|2021-01-02|10
e|IS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/g/h|[?]|1|g/animal|BASAL TEAR|SNELLEN EYE CHART|Y||1|2|Visit_2|25|6|TREATMENT|2021-01-17|25
e|IS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cd*s/m2|[?]|1|mg/kg/day|PERSPIRATION|TOLUIDINE BLUE STAIN|Y||1|3|Visit_3|40|4|WASHOUT|2021-02-01|40
e|IS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|fraction of 1|[?]|1|10^9 CFU/g|ABSCESS FLUID|IMMUNOFLUORESCENT STAIN|||1|4|Visit_4|65|4|TREATMENT|2021-02-26|65
e|IS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|nmol/day|CALCULUS|IMMUNOPRECIPITATION||Y|1|5|Visit_5|90|7|SCREENING|2021-03-23|90
e|IS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|HEP|[?]|1|10^6 IU/mL|SERUM|PALM METHOD|||1|1|Visit_1|10|6|TREATMENT|2021-01-16|10
e|IS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|damol/L|[?]|1|/min|LEUKOCYTE|MAGNETIC RESONANCE ELASTOGRAPHY|||1|2|Visit_2|25|1|TREATMENT|2021-01-31|25
e|IS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Enzyme U|[?]|1|log10 IU/mL|SEMEN|SINGLE-MOLECULE ARRAY|||1|3|Visit_3|40|3|WASHOUT|2021-02-15|40
e|IS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|NEBULE|[?]|1|mg/kg/h|ENDOMETRIAL TISSUE|HEMAGGLUTINATION ASSAY|Y||1|4|Visit_4|65|1|FOLLOW-UP|2021-03-12|65
e|IS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|deg/s|[?]|1|10^8/L|LYMPH|OPTICAL DENSITY MEASUREMENT|||1|5|Visit_5|90|5|TREATMENT|2021-04-06|90
e|IS|296f8314-5a07-47b5-8796-31afe709b379|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|gtt|[?]|1|10^3 CFU/g|SUPERNATANT, PLASMA|FLUORESCENT SPOT TEST|Y||1|1|Visit_1|10|3|TREATMENT|2020-07-08|10
e|IS|296f8314-5a07-47b5-8796-31afe709b379|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^12/L|[?]|1|mmol/s|PERITONEAL FLUID|PERCUSSION|Y|Y|1|2|Visit_2|25|7|TREATMENT|2020-07-23|25
e|IS|296f8314-5a07-47b5-8796-31afe709b379|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ohm|[?]|1|VIRTUAL PIXEL|MUCUS|LISSAMINE GREEN STAIN||Y|1|3|Visit_3|40|1|TREATMENT|2020-08-07|40
e|IS|296f8314-5a07-47b5-8796-31afe709b379|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|DDU|[?]|1|U/10^12 RBC|PLATELET RICH PLASMA|CONTRAST ENHANCED X-RAY|Y||1|4|Visit_4|65|7|SCREENING|2020-09-01|65
e|IS|296f8314-5a07-47b5-8796-31afe709b379|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ECL unit|[?]|1|Shock Wave|AQUEOUS HUMOR|NUCLEIC ACID AMPLIFICATION TEST||Y|1|5|Visit_5|90|4|SCREENING|2020-09-26|90
e|IS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|BAR|[?]|1|L/s|URINE|DARK FIELD MICROSCOPY||Y|1|1|Visit_1|10|6|WASHOUT|2020-12-13|10
e|IS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/animal|[?]|1|pmol/dL|BONE MARROW|INCISION-INDUCED BLEEDING METHOD|Y||1|2|Visit_2|25|7|TREATMENT|2020-12-28|25
e|IS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|keV|[?]|1|in2|CERVICOVAGINAL SECRETION|RULER MEASUREMENT METHOD|Y|Y|1|3|Visit_3|40|5|WASHOUT|2021-01-12|40
e|IS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/kg/h|[?]|1|umol/h/mmol|CORD SERUM|MAMMOGRAPHY|||1|4|Visit_4|65|3|TREATMENT|2021-02-06|65
e|IS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uV|[?]|1|%/min|REFLEX TEAR|TOLUIDINE BLUE STAIN|||1|5|Visit_5|90|1|TREATMENT|2021-03-03|90
e|IS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|MET*min|[?]|1|mg/dL|HAIR|PERIPHERAL ANGIOGRAPHY|||1|1|Visit_1|10|5|WASHOUT|2021-01-25|10
e|IS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|h/wk|[?]|1|Shock Wave|EMOTIONAL TEAR|EPSILOMETER|||1|2|Visit_2|25|5|TREATMENT|2021-02-09|25
e|IS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/min|[?]|1|cup eq|EMOTIONAL TEAR|TEMPLATE INCISION METHOD|Y||1|3|Visit_3|40|5|TREATMENT|2021-02-24|40
e|IS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ppth|[?]|1|Tbsp|GASTRIC FLUID|CLAUSS METHOD|||1|4|Visit_4|65|6|FOLLOW-UP|2021-03-21|65
e|IS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|TROCHE|[?]|1|nCi|SKIN TISSUE|DUCTOGRAPHY|||1|5|Visit_5|90|7|WASHOUT|2021-04-15|90
e|IS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|lm|[?]|1|gMFI|VENOUS PLASMA|ALCIAN BLUE STAIN||Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-11-07|10
e|IS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/cm|[?]|1|/5x10^4 WBC|MIXED VENOUS BLOOD|X-RAY|||1|2|Visit_2|25|1|TREATMENT|2020-11-22|25
e|IS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cGy|[?]|1|Enzyme U/L|PLASMA ULTRAFILTRATE|ELECTROGASTROGRAPHY|||1|3|Visit_3|40|4|TREATMENT|2020-12-07|40
e|IS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/10^5|[?]|1|mMU/mL|VENOUS BLOOD|WESTERN BLOT|Y||1|4|Visit_4|65|5|FOLLOW-UP|2021-01-01|65
e|IS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|dram|[?]|1|amu|ISOLATE|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||1|5|Visit_5|90|1|WASHOUT|2021-01-26|90
e|IS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Gy|[?]|1|um/day|ADIPOSE TISSUE|COULOMETRIC TITRATION|Y||1|1|Visit_1|10|5|TREATMENT|2020-07-13|10
e|IS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|days/wk|[?]|1|APL U/mL|SKELETAL MUSCLE TISSUE|SXA SCAN|||1|2|Visit_2|25|3|TREATMENT|2020-07-28|25
e|IS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|cL|[?]|1|mL/h|COLOSTRUM|IMMUNOASSAY|||1|3|Visit_3|40|6|TREATMENT|2020-08-12|40
e|IS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^8 PFU|[?]|1|GBq/mg|SERUM|ANGIOGRAPHY|Y|Y|1|4|Visit_4|65|2|TREATMENT|2020-09-06|65
e|IS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/mmol|[?]|1|IU/kg/h|KERATINOCYTE|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y||1|5|Visit_5|90|7|WASHOUT|2020-10-01|90
e|IS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|vg/dose|PLEURAL FLUID|WHOLE TRANSCRIPTOME SEQUENCING|Y||1|1|Visit_1|10|6|FOLLOW-UP|2021-01-14|10
e|IS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmHg*min/L|[?]|1|nmol/L|EXPIRED AIR|CRYOSCOPY|||1|2|Visit_2|25|7|TREATMENT|2021-01-29|25
e|IS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/g/day|[?]|1|ug/kg|SERUM|MULTIPLE BREATH WASHOUT|Y|Y|1|3|Visit_3|40|2|TREATMENT|2021-02-13|40
e|IS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|m|[?]|1|deg|WHITE MATTER TISSUE|MICROBIAL CULTURE, LIQUID|||1|4|Visit_4|65|5|FOLLOW-UP|2021-03-10|65
e|IS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|IU|[?]|1|NEEDLE GAUGE|CEREBROSPINAL FLUID|NUCLEIC ACID BASED METHOD|||1|5|Visit_5|90|6|TREATMENT|2021-04-04|90
e|IS|b1215705-4c22-43bd-aa65-58bd8745f081|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mOsm|[?]|1|U/g Hb|EMOTIONAL TEAR|FLUORESCENT ENZYME IMMUNOASSAY|||1|1|Visit_1|10|3|FOLLOW-UP|2020-07-15|10
e|IS|b1215705-4c22-43bd-aa65-58bd8745f081|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|umol/min|[?]|1|ng/mol|BONE MARROW|IMMUNOPRECIPITATION||Y|1|2|Visit_2|25|6|SCREENING|2020-07-30|25
e|IS|b1215705-4c22-43bd-aa65-58bd8745f081|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cg|[?]|1|POUCH|SUPERNATANT, SERUM OR PLASMA|GIEMSA STAIN||Y|1|3|Visit_3|40|5|TREATMENT|2020-08-14|40
e|IS|b1215705-4c22-43bd-aa65-58bd8745f081|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ukat|[?]|1|PATCH|COLOSTRUM|ENDPOINT DILUTION ASSAY||Y|1|4|Visit_4|65|7|WASHOUT|2020-09-08|65
e|IS|b1215705-4c22-43bd-aa65-58bd8745f081|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/mL/min|[?]|1|10^3 CFU/mL|PERITONEAL FLUID|KLEIHAUER-BETKE|||1|5|Visit_5|90|3|TREATMENT|2020-10-03|90
e|IS|b99c6528-af4e-42f5-8d2d-18943b57d55a|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^4 CFU|[?]|1|F|CELL PELLET|ACID FAST STAIN|||1|1|Visit_1|10|2|TREATMENT|2020-10-25|10
e|IS|b99c6528-af4e-42f5-8d2d-18943b57d55a|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Bq/uL|[?]|1|10^9 CFU/mL|EXUDATE|PLETHYSMOGRAPHY|||1|2|Visit_2|25|4|TREATMENT|2020-11-09|25
e|IS|b99c6528-af4e-42f5-8d2d-18943b57d55a|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|KALLIKREIN INHIBITOR UNIT|[?]|1|Absorbance U/min|ISOLATE|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||1|3|Visit_3|40|1|TREATMENT|2020-11-24|40
e|IS|b99c6528-af4e-42f5-8d2d-18943b57d55a|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/min|[?]|1|CAN|SYNOVIAL FLUID|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|4|Visit_4|65|6|TREATMENT|2020-12-19|65
e|IS|b99c6528-af4e-42f5-8d2d-18943b57d55a|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|PNU/mL|[?]|1|days/month|SMEGMA|CISH|Y||1|5|Visit_5|90|2|SCREENING|2021-01-13|90
e|IS|6848e438-51ca-4a7d-8f81-26c375969a64|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/m2/day|[?]|1|TRANSDUCING UNIT|HAIR|SLIT LAMP|Y|Y|1|1|Visit_1|10|5|SCREENING|2020-11-12|10
e|IS|6848e438-51ca-4a7d-8f81-26c375969a64|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^8/L|[?]|1|YEARS|MUCUS|ACRIDINE ORANGE STAIN|||1|2|Visit_2|25|3|WASHOUT|2020-11-27|25
e|IS|6848e438-51ca-4a7d-8f81-26c375969a64|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|RATIO|[?]|1|V/sec|ENDOMETRIAL TISSUE|MAGNETIC RESONANCE ELASTOGRAPHY|||1|3|Visit_3|40|1|FOLLOW-UP|2020-12-12|40
e|IS|6848e438-51ca-4a7d-8f81-26c375969a64|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cg|[?]|1|titer|MUSCLE TISSUE|TARGETED TRANSCRIPTOME SEQUENCING|||1|4|Visit_4|65|2|SCREENING|2021-01-06|65
e|IS|6848e438-51ca-4a7d-8f81-26c375969a64|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ft|[?]|1|Tbsp|SMEGMA|DNA MICROARRAY|||1|5|Visit_5|90|2|TREATMENT|2021-01-31|90
e|IS|a6e11c33-7905-42d2-bda9-671d756d4c51|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|nkat/g Hb|[?]|1|10^4/L|SPUTUM|PHOROPTER|||1|1|Visit_1|10|2|WASHOUT|2020-08-06|10
e|IS|a6e11c33-7905-42d2-bda9-671d756d4c51|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mm/sec|[?]|1|10^6 IU/mL|SMEGMA|DYNAMIC LIGHT SCATTERING||Y|1|2|Visit_2|25|5|WASHOUT|2020-08-21|25
e|IS|a6e11c33-7905-42d2-bda9-671d756d4c51|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Sv|[?]|1|nmol/L/h|MIXED VENOUS BLOOD|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y||1|3|Visit_3|40|1|TREATMENT|2020-09-05|40
e|IS|a6e11c33-7905-42d2-bda9-671d756d4c51|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/LPF|[?]|1|APL U|SERUM|MAMMOGRAPHY|||1|4|Visit_4|65|6|TREATMENT|2020-09-30|65
e|IS|a6e11c33-7905-42d2-bda9-671d756d4c51|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|pg/cell|[?]|1|AFU|LYMPH|NUCLEAR RADIOLOGY|Y||1|5|Visit_5|90|1|FOLLOW-UP|2020-10-25|90
e|IS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uCi/kg|[?]|1|ug/L|VENOUS BLOOD|SISH|||1|1|Visit_1|10|5|TREATMENT|2020-11-12|10
e|IS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/(min*100mL)|[?]|1|RNA copies/mL|ENDOMETRIAL TISSUE|REBOUND TONOMETRY|||1|2|Visit_2|25|1|TREATMENT|2020-11-27|25
e|IS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^3 organisms/g|[?]|1|gtt|ARTERIAL BLOOD|NUCLEAR RADIOLOGY||Y|1|3|Visit_3|40|6|TREATMENT|2020-12-12|40
e|IS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/m2/h|[?]|1|uCi/L|SEMINAL FLUID|OPHTHALMOSCOPY|||1|4|Visit_4|65|3|FOLLOW-UP|2021-01-06|65
e|IS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nsec|[?]|1|kBq|NAIL|LYMPHANGIOGRAPHY|Y|Y|1|5|Visit_5|90|2|WASHOUT|2021-01-31|90
e|IS|8ef37b54-b463-43a4-879f-3ad653c4fef4|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uV2|[?]|1|10^8 PFU|PLASMA ULTRAFILTRATE|LAPAROSCOPY|Y||1|1|Visit_1|10|4|WASHOUT|2020-09-11|10
e|IS|8ef37b54-b463-43a4-879f-3ad653c4fef4|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uSiemens|[?]|1|log10 TCID 50/mL|SUPERNATANT, SERUM|IVY INCISION METHOD|Y||1|2|Visit_2|25|2|WASHOUT|2020-09-26|25
e|IS|8ef37b54-b463-43a4-879f-3ad653c4fef4|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|nkat|[?]|1|mL/kg/day|RETICULOCYTES|IHC|||1|3|Visit_3|40|2|TREATMENT|2020-10-11|40
e|IS|8ef37b54-b463-43a4-879f-3ad653c4fef4|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/dL|[?]|1|ug|REFLEX TEAR|MICROBIAL CULTURE, SOLID|Y||1|4|Visit_4|65|1|TREATMENT|2020-11-05|65
e|IS|8ef37b54-b463-43a4-879f-3ad653c4fef4|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mEq|[?]|1|ug/cm2|INFRANATANT, PLEURAL FLUID|LIGHT SCATTERING SPECTROSCOPY|Y|Y|1|5|Visit_5|90|3|SCREENING|2020-11-30|90
e|IS|cf10035c-4d44-4512-810b-c267d1c8821b|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/cage/wk|[?]|1|g|HAIR|PYROSEQUENCING|||1|1|Visit_1|10|2|WASHOUT|2020-05-27|10
e|IS|cf10035c-4d44-4512-810b-c267d1c8821b|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|OI50|[?]|1|/100 WBC|HAIR FOLLICLE|CALIPER MEASUREMENT METHOD||Y|1|2|Visit_2|25|4|TREATMENT|2020-06-11|25
e|IS|cf10035c-4d44-4512-810b-c267d1c8821b|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PNU/mL|[?]|1|mg/m2/min|MUCUS|ISHIHARA COLOR PLATES|||1|3|Visit_3|40|1|TREATMENT|2020-06-26|40
e|IS|cf10035c-4d44-4512-810b-c267d1c8821b|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CUP|[?]|1|tuberculin unit|PLASMA ULTRAFILTRATE|SPECT/CT SCAN||Y|1|4|Visit_4|65|2|WASHOUT|2020-07-21|65
e|IS|cf10035c-4d44-4512-810b-c267d1c8821b|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|FFU|[?]|1|WEEKS|CORD BLOOD|FORCED OSCILLATION TECHNIQUE|||1|5|Visit_5|90|4|WASHOUT|2020-08-15|90
e|IS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cL|[?]|1|ugEq/L|DISCHARGE|CALCOFLUOR WHITE STAIN|Y||1|1|Visit_1|10|1|TREATMENT|2020-08-01|10
e|IS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|umol/L|[?]|1|pmol/L|ADIPOSE TISSUE|VENTILATION PERFUSION LUNG SCAN|Y||1|2|Visit_2|25|5|TREATMENT|2020-08-16|25
e|IS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mg/day|[?]|1|SFC/10^6 PBMC|SEMINAL FLUID|SPIROMETRY|||1|3|Visit_3|40|5|SCREENING|2020-08-31|40
e|IS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/cage/wk|[?]|1|NEEDLE GAUGE|AQUEOUS HUMOR|INTRAVASCULAR ULTRASOUND|Y||1|4|Visit_4|65|1|TREATMENT|2020-09-25|65
e|IS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mCi|[?]|1|mEq/day|SALIVA|PHASE-CONTRAST MRI|||1|5|Visit_5|90|7|FOLLOW-UP|2020-10-20|90
e|IS|a1e0035a-3328-4966-8664-82e53a44eb59|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/dose|[?]|1|log EID 50/dose|MONOCYTE|DNA MICROARRAY||Y|1|1|Visit_1|10|4|FOLLOW-UP|2020-08-10|10
e|IS|a1e0035a-3328-4966-8664-82e53a44eb59|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/g|[?]|1|mV*min|SALIVA|RIA||Y|1|2|Visit_2|25|4|TREATMENT|2020-08-25|25
e|IS|a1e0035a-3328-4966-8664-82e53a44eb59|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/L|[?]|1|ug/day|LAVAGE FLUID|BAC ACGH|Y||1|3|Visit_3|40|4|TREATMENT|2020-09-09|40
e|IS|a1e0035a-3328-4966-8664-82e53a44eb59|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|DDU|[?]|1|msec|INFRANATANT, PLASMA|RADIATION DOSIMETRY|||1|4|Visit_4|65|7|TREATMENT|2020-10-04|65
e|IS|a1e0035a-3328-4966-8664-82e53a44eb59|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mol/mol|[?]|1|MAC50|PUS|CENTRIFUGATION|Y||1|5|Visit_5|90|2|TREATMENT|2020-10-29|90
e|IS|771377fd-724f-4056-b2ea-84e1adab1f47|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/animal|[?]|1|mL/kg/min|SYNOVIAL FLUID|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|1|Visit_1|10|6|WASHOUT|2020-11-08|10
e|IS|771377fd-724f-4056-b2ea-84e1adab1f47|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ng/day|[?]|1|CAPFUL|DISCHARGE|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y||1|2|Visit_2|25|7|WASHOUT|2020-11-23|25
e|IS|771377fd-724f-4056-b2ea-84e1adab1f47|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/cm3/min|[?]|1|mm3/mm2/year|INFRANATANT, PLASMA|ATOMIC ABSORPTION SPECTROMETRY||Y|1|3|Visit_3|40|7|FOLLOW-UP|2020-12-08|40
e|IS|771377fd-724f-4056-b2ea-84e1adab1f47|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/kg/week|[?]|1|mmol/kg|INTERSTITIAL FLUID|POLYSOMNOGRAPHY|Y||1|4|Visit_4|65|5|FOLLOW-UP|2021-01-02|65
e|IS|771377fd-724f-4056-b2ea-84e1adab1f47|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/g/day|[?]|1|ug/dose|SKIN TISSUE|MIGET|||1|5|Visit_5|90|3|WASHOUT|2021-01-27|90
e|IS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/7.5 mL|[?]|1|U|KERATINOCYTE|PLETHYSMOGRAPHY||Y|1|1|Visit_1|10|7|TREATMENT|2020-08-23|10
e|IS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6 U|[?]|1|amu|TISSUE|MICROBIAL CULTURE, LIQUID|||1|2|Visit_2|25|4|TREATMENT|2020-09-07|25
e|IS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Ci/L|[?]|1|mL/cage|EMESIS|PH METER MEASUREMENT METHOD|||1|3|Visit_3|40|1|SCREENING|2020-09-22|40
e|IS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/breath|[?]|1|U/g/min|SPUTUM|TEST STRIP|||1|4|Visit_4|65|1|FOLLOW-UP|2020-10-17|65
e|IS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^10/L|[?]|1|pg|LYSATE|SPIRAL CT SCAN WITHOUT CONTRAST|||1|5|Visit_5|90|1|WASHOUT|2020-11-11|90
e|IS|3aea0861-8f67-4717-93ce-c1e322f151d9|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mAnson U/mL|[?]|1|DISK|EPITHELIAL CELL|DOPPLER ULTRASOUND|||1|1|Visit_1|10|2|TREATMENT|2020-08-14|10
e|IS|3aea0861-8f67-4717-93ce-c1e322f151d9|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mV|[?]|1|mL/m2/day|ENDOMETRIAL TISSUE|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y|1|2|Visit_2|25|3|SCREENING|2020-08-29|25
e|IS|3aea0861-8f67-4717-93ce-c1e322f151d9|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|v/v|[?]|1|Ci/mg|MONOCYTE|BETA LACTAMASE||Y|1|3|Visit_3|40|1|TREATMENT|2020-09-13|40
e|IS|3aea0861-8f67-4717-93ce-c1e322f151d9|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|h/wk|[?]|1|IMPLANT|AMNIOTIC FLUID|CT SCAN|||1|4|Visit_4|65|1|TREATMENT|2020-10-08|65
e|IS|3aea0861-8f67-4717-93ce-c1e322f151d9|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/day|[?]|1|U/mmol|DIALYSIS FLUID, PERITONEAL|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y|1|5|Visit_5|90|5|TREATMENT|2020-11-02|90
e|IS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ngEq/L|[?]|1|mL|MECONIUM|IN SITU HYBRIDIZATION|||1|1|Visit_1|10|7|TREATMENT|2020-10-05|10
e|IS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|breaths/min|[?]|1|mg/kg/min|FLUID|FLUORESCENT MICROSCOPY|||1|2|Visit_2|25|4|TREATMENT|2020-10-20|25
e|IS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mEq/ug|[?]|1|FIU|BONE MARROW|SLOAN LETTER EYE CHART 1.25%||Y|1|3|Visit_3|40|3|SCREENING|2020-11-04|40
e|IS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mEq/day|[?]|1|g/animal/wk|BILE|ANGIOGRAPHY|Y||1|4|Visit_4|65|6|TREATMENT|2020-11-29|65
e|IS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/m2/day|[?]|1|mol/L|SALIVA|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|5|Visit_5|90|1|TREATMENT|2020-12-24|90
e|IS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cP|[?]|1|IU/g Hb|SPERMATOZOON|PALPATION||Y|1|1|Visit_1|10|3|FOLLOW-UP|2020-12-30|10
e|IS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|yd|[?]|1|mg/kg/dose|LUNG SURFACTANT|IRON HEMATOXYLIN STAIN|||1|2|Visit_2|25|2|TREATMENT|2021-01-14|25
e|IS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|deg|[?]|1|g/cage/day|SERUM OR PLASMA|LIGHT MICROSCOPY|||1|3|Visit_3|40|3|TREATMENT|2021-01-29|40
e|IS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cGy|[?]|1|mL/kg/min|CARDIAC MUSCLE TISSUE|TRIPLE-PHASE SPIRAL CT SCAN|||1|4|Visit_4|65|4|FOLLOW-UP|2021-02-23|65
e|IS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|RNA copies/mL|[?]|1|Bq/ug|COLOSTRUM|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||1|5|Visit_5|90|7|WASHOUT|2021-03-20|90
e|IS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol/kg/min|[?]|1|VOXEL|CAPILLARY BLOOD|MASS SPECTROMETRY||Y|1|1|Visit_1|10|4|TREATMENT|2020-09-19|10
e|IS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|L/L|[?]|1|Bq/kg|ADIPOSE TISSUE|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|2|Visit_2|25|5|TREATMENT|2020-10-04|25
e|IS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|psec|[?]|1|STEPS|SEBUM|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|3|Visit_3|40|7|FOLLOW-UP|2020-10-19|40
e|IS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ukat/10^12 RBC|[?]|1|LENS|CAPILLARY PLASMA|LANDOLT RING||Y|1|4|Visit_4|65|7|TREATMENT|2020-11-13|65
e|IS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|deg2|[?]|1|uCi/L|BONE MARROW MONONUCLEAR CELL|MICRO BROTH DILUTION|||1|5|Visit_5|90|6|TREATMENT|2020-12-08|90
e|IS|80565a22-8cec-46a2-abd7-91daf0767035|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Weber|[?]|1|mU/L|SPUTUM|CLAUSS METHOD||Y|1|1|Visit_1|10|5|TREATMENT|2021-01-28|10
e|IS|80565a22-8cec-46a2-abd7-91daf0767035|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/m2|[?]|1|BOTTLE|PLEURAL TISSUE|PULMONARY ANGIOGRAPHY||Y|1|2|Visit_2|25|5|TREATMENT|2021-02-12|25
e|IS|80565a22-8cec-46a2-abd7-91daf0767035|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|Bq|EPITHELIAL CELL|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|3|Visit_3|40|5|FOLLOW-UP|2021-02-27|40
e|IS|80565a22-8cec-46a2-abd7-91daf0767035|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|DAgU|[?]|1|/100 HPFs|BREAST MILK|TOTAL BODY RADIOGRAPHY||Y|1|4|Visit_4|65|5|TREATMENT|2021-03-24|65
e|IS|80565a22-8cec-46a2-abd7-91daf0767035|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|pL|[?]|1|Bq/kg|INTERSTITIAL FLUID|MS/MS|||1|5|Visit_5|90|7|TREATMENT|2021-04-18|90
e|IS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Tesla|[?]|1|mm/h|EPITHELIAL CELL|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|1|Visit_1|10|5|TREATMENT|2020-10-19|10
e|IS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Enzyme U|[?]|1|beats/min|SPUTUM|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y||1|2|Visit_2|25|1|FOLLOW-UP|2020-11-03|25
e|IS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/mg|[?]|1|MnFI|SERUM OR PLASMA OR BLOOD|WHOLE EXOME SEQUENCING||Y|1|3|Visit_3|40|5|WASHOUT|2020-11-18|40
e|IS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/min|[?]|1|SFC/10^6 PBMC|AMNIOTIC FLUID|RADIOGRAPHY|||1|4|Visit_4|65|2|SCREENING|2020-12-13|65
e|IS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ng/dL|[?]|1|kPa/L/sec|SUPERNATANT, PLASMA|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|5|Visit_5|90|2|SCREENING|2021-01-07|90
e|IS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ngEq/L|[?]|1|IU/mg|HAIR FOLLICLE|NEURAMINIDASE INHIBITION ASSAY|||1|1|Visit_1|10|5|SCREENING|2020-09-09|10
e|IS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^3/L|[?]|1|s*kPa|MUCUS|AGAR PROPORTION||Y|1|2|Visit_2|25|7|FOLLOW-UP|2020-09-24|25
e|IS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|IU/L|[?]|1|kcal/day|ALVEOLAR AIR|SLOAN LETTER EYE CHART 2.5%|||1|3|Visit_3|40|1|TREATMENT|2020-10-09|40
e|IS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL*cmH2O|[?]|1|tuberculin unit|SERUM OR PLASMA|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y||1|4|Visit_4|65|5|TREATMENT|2020-11-03|65
e|IS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|CAPSULE|[?]|1|breaths/min|SEMEN|RADIOGRAPHY|Y||1|5|Visit_5|90|5|SCREENING|2020-11-28|90
e|IS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|DIP|[?]|1|U/mg|SKELETAL MUSCLE TISSUE|RYAN BLUE STAIN||Y|1|1|Visit_1|10|4|TREATMENT|2020-06-16|10
e|IS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|VIRTUAL PIXEL|[?]|1|BAG|SKIN TISSUE|RADIOGRAPHY||Y|1|2|Visit_2|25|6|FOLLOW-UP|2020-07-01|25
e|IS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|/day|[?]|1|10^4/hpf|SERUM|PELLI-ROBSON EYE CHART|Y|Y|1|3|Visit_3|40|2|TREATMENT|2020-07-16|40
e|IS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^7 TCID 50/dose|[?]|1|log10 TCID 50/uL|ENDOTRACHEAL FLUID|CISH||Y|1|4|Visit_4|65|1|WASHOUT|2020-08-10|65
e|IS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|psi|[?]|1|mg/kg/day|ARTERIALIZED CAPILLARY BLOOD|EIA|Y|Y|1|5|Visit_5|90|1|SCREENING|2020-09-04|90
e|IS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|BP|[?]|1|oz eq|LOCHIA|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|1|Visit_1|10|4|SCREENING|2020-06-07|10
e|IS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Sv|[?]|1|IU/kg|BONE MARROW MONONUCLEAR CELL|ELECTROPHORESIS|||1|2|Visit_2|25|6|WASHOUT|2020-06-22|25
e|IS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BAG|[?]|1|rpm|PLASMA|CONTRAST ENHANCED PET SCAN||Y|1|3|Visit_3|40|6|SCREENING|2020-07-07|40
e|IS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 CFU/mL|[?]|1|mL/dose|LYSATE|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||1|4|Visit_4|65|5|FOLLOW-UP|2020-08-01|65
e|IS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PNU/mL|[?]|1|Ci/g|PLEURAL TISSUE|HANSEL STAIN||Y|1|5|Visit_5|90|1|FOLLOW-UP|2020-08-26|90
e|IS|bfc19b4b-51bb-4056-9195-8bd2db53a497|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|m/sec2|[?]|1|uEq/L|LYSATE|ICC|||1|1|Visit_1|10|3|TREATMENT|2020-07-26|10
e|IS|bfc19b4b-51bb-4056-9195-8bd2db53a497|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Bq/uL|[?]|1|SBE/mL|ARTERIAL BLOOD|GRADIENT DIFFUSION||Y|1|2|Visit_2|25|4|TREATMENT|2020-08-10|25
e|IS|bfc19b4b-51bb-4056-9195-8bd2db53a497|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|GBq|[?]|1|steps/min|CEREBROSPINAL FLUID|PET SCAN|||1|3|Visit_3|40|2|WASHOUT|2020-08-25|40
e|IS|bfc19b4b-51bb-4056-9195-8bd2db53a497|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|%(w/v)|[?]|1|ug/g/h|BILE|IMMUNOBLOT||Y|1|4|Visit_4|65|5|TREATMENT|2020-09-19|65
e|IS|bfc19b4b-51bb-4056-9195-8bd2db53a497|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm/sec|[?]|1|g/cage/day|SKIN TISSUE|HANSEL STAIN||Y|1|5|Visit_5|90|5|FOLLOW-UP|2020-10-14|90
e|IS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|grain|[?]|1|g/dL|EXUDATE|PHASE CONTRAST MICROSCOPY|||1|1|Visit_1|10|6|TREATMENT|2020-09-21|10
e|IS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|gpELISA unit/mL|[?]|1|IU/g Hb|STOOL|VENTILATION PERFUSION LUNG SCAN|||1|2|Visit_2|25|7|WASHOUT|2020-10-06|25
e|IS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^12/L|[?]|1|/10^4|SOFT TISSUE|TRICHROME STAIN|Y|Y|1|3|Visit_3|40|1|TREATMENT|2020-10-21|40
e|IS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|log10 PFU/mL|[?]|1|KALLIKREIN INHIBITOR UNIT|URINE|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|Y|1|4|Visit_4|65|6|TREATMENT|2020-11-15|65
e|IS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pmol/dL|[?]|1|Sv|SPUTUM|FORCED OSCILLATION TECHNIQUE|||1|5|Visit_5|90|2|FOLLOW-UP|2020-12-10|90
e|IS|64a70103-14bf-42f4-808b-fbdecec8bd4f|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mU/L|[?]|1|dL|DIALYSIS FLUID|POLYMERASE CHAIN REACTION||Y|1|1|Visit_1|10|4|WASHOUT|2020-09-09|10
e|IS|64a70103-14bf-42f4-808b-fbdecec8bd4f|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ng/L|[?]|1|DAgU|LOCHIA|CELLULOSE TAPE|||1|2|Visit_2|25|4|SCREENING|2020-09-24|25
e|IS|64a70103-14bf-42f4-808b-fbdecec8bd4f|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^3 CFU|[?]|1|pmol/L/h|MIXED VENOUS BLOOD|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|3|Visit_3|40|4|SCREENING|2020-10-09|40
e|IS|64a70103-14bf-42f4-808b-fbdecec8bd4f|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|LB|[?]|1|CAPLET|CAPILLARY BLOOD|X-RAY FLUORESCENCE SPECTROMETRY|||1|4|Visit_4|65|3|TREATMENT|2020-11-03|65
e|IS|64a70103-14bf-42f4-808b-fbdecec8bd4f|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|deg/mm|[?]|1|EIA unit|CIRCULATING TUMOR CELL|ELISPOT|||1|5|Visit_5|90|4|TREATMENT|2020-11-28|90
e|IS|00f3949b-b14a-47c5-942c-2ab71e03e40f|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PATCH|[?]|1|vp/mL|LYSATE|SICKLE CELL SOLUBILITY TEST|Y||1|1|Visit_1|10|7|WASHOUT|2021-01-19|10
e|IS|00f3949b-b14a-47c5-942c-2ab71e03e40f|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^3 CFU|[?]|1|grain|PLEURAL TISSUE|HPLC-UV|||1|2|Visit_2|25|3|TREATMENT|2021-02-03|25
e|IS|00f3949b-b14a-47c5-942c-2ab71e03e40f|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|g/cage|[?]|1|POUCH|SPERMATOZOON|MAGNETIC RESONANCE ELASTOGRAPHY|||1|3|Visit_3|40|2|WASHOUT|2021-02-18|40
e|IS|00f3949b-b14a-47c5-942c-2ab71e03e40f|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mU/g|[?]|1|ms/mmHg|CORD SERUM|HPLC-UV|Y||1|4|Visit_4|65|3|WASHOUT|2021-03-15|65
e|IS|00f3949b-b14a-47c5-942c-2ab71e03e40f|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|aMFI|[?]|1|uU/L|SEMEN|FLUORESCENT SPOT TEST|||1|5|Visit_5|90|5|WASHOUT|2021-04-09|90
e|IS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|TCID 50/dose|[?]|1|mg/day|ENDOMETRIAL TISSUE|ELLA|||1|1|Visit_1|10|6|WASHOUT|2020-12-27|10
e|IS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MET|[?]|1|umol/min|URINE|TARGETED GENOME SEQUENCING|||1|2|Visit_2|25|5|TREATMENT|2021-01-11|25
e|IS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|lx|[?]|1|mg/day|SPERMATOZOON|MULTI-SLICE SPIRAL CT||Y|1|3|Visit_3|40|1|TREATMENT|2021-01-26|40
e|IS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Gy/h|[?]|1|mL/min/1.73m2|ENDOTRACHEAL FLUID|HEMAGGLUTINATION ASSAY|||1|4|Visit_4|65|6|FOLLOW-UP|2021-02-20|65
e|IS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Osm|[?]|1|gMFI|SMOOTH MUSCLE TISSUE|MICROARRAY|||1|5|Visit_5|90|2|WASHOUT|2021-03-17|90
e|IS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mEq/g|[?]|1|ks|SMEGMA|RIA|||1|1|Visit_1|10|6|TREATMENT|2020-07-19|10
e|IS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DISK|[?]|1|mg/kg/dose|CORD SERUM|LISSAMINE GREEN STAIN|||1|2|Visit_2|25|3|SCREENING|2020-08-03|25
e|IS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PIXELS/in|[?]|1|in2|SUPERNATANT, CEREBROSPINAL FLUID|FREEZING POINT DEPRESSION|Y|Y|1|3|Visit_3|40|4|TREATMENT|2020-08-18|40
e|IS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^9 organisms|[?]|1|DAgU/mL|MENSTRUAL BLOOD|FLUORESCEIN STAIN|||1|4|Visit_4|65|2|TREATMENT|2020-09-12|65
e|IS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|days/wk|[?]|1|log10 TCID 50/uL|PERSPIRATION|EPSILOMETER|||1|5|Visit_5|90|4|FOLLOW-UP|2020-10-07|90
e|IS|44ca1fe6-76d2-4a94-9854-1ddbde638803|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|APPLICATION|[?]|1|deg|CARDIAC MUSCLE TISSUE|CORONARY ANGIOGRAPHY|||1|1|Visit_1|10|6|TREATMENT|2020-07-19|10
e|IS|44ca1fe6-76d2-4a94-9854-1ddbde638803|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/200 HPFs|[?]|1|Frames/s|GASTRIC FLUID|ELECTROGASTROGRAPHY|Y||1|2|Visit_2|25|6|TREATMENT|2020-08-03|25
e|IS|44ca1fe6-76d2-4a94-9854-1ddbde638803|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/min|[?]|1|log10 CCID 50/dose|SMEGMA|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||Y|1|3|Visit_3|40|5|SCREENING|2020-08-18|40
e|IS|44ca1fe6-76d2-4a94-9854-1ddbde638803|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/500 WBC|[?]|1|mEq/mmol|MECONIUM|SINGLE-SLICE SPIRAL CT||Y|1|4|Visit_4|65|3|TREATMENT|2020-09-12|65
e|IS|44ca1fe6-76d2-4a94-9854-1ddbde638803|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|m|[?]|1|kg|SEMINAL FLUID|CELLULAR PROLIFERATION ASSAY||Y|1|5|Visit_5|90|4|TREATMENT|2020-10-07|90
e|IS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cd/m2|[?]|1|GBq|PLATELET POOR PLASMA|WESTERN BLOT|||1|1|Visit_1|10|2|TREATMENT|2020-12-04|10
e|IS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pmol/10^10 cells|[?]|1|IU/kg|CEREBROSPINAL FLUID|DUCTOGRAPHY|||1|2|Visit_2|25|1|TREATMENT|2020-12-19|25
e|IS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pkat/L|[?]|1|mg/animal|GASTRIC CONTENTS|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|Y||1|3|Visit_3|40|3|FOLLOW-UP|2021-01-03|40
e|IS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|dpm/100mg|[?]|1|CFU/g|SUPERNATANT, PLASMA|SXA SCAN|||1|4|Visit_4|65|3|FOLLOW-UP|2021-01-28|65
e|IS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cycle/min|[?]|1|DNA copies/ug|PLASMA|ANTIBIOTIC AGAR SCREEN|Y|Y|1|5|Visit_5|90|2|SCREENING|2021-02-22|90
e|IS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^4 CFU/mL|[?]|1|atm|ARTERIALIZED CAPILLARY BLOOD|MULTIPLE BREATH WASHOUT|Y||1|1|Visit_1|10|1|TREATMENT|2020-06-08|10
e|IS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MdFI|[?]|1|U/g/min|BILE|HILLMEN COLOR CHART|||1|2|Visit_2|25|6|TREATMENT|2020-06-23|25
e|IS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/g/min|[?]|1|10^7 TCID 50/dose|SERUM OR PLASMA|IMMUNOFIXATION ELECTROPHORESIS|||1|3|Visit_3|40|4|SCREENING|2020-07-08|40
e|IS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/cage|[?]|1|Bq/mL|AMNIOTIC FLUID|HANSEL STAIN||Y|1|4|Visit_4|65|2|FOLLOW-UP|2020-08-02|65
e|IS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/100 WBC|[?]|1|10^6/L|INFRANATANT, PLASMA|ACRIDINE ORANGE STAIN|||1|5|Visit_5|90|4|WASHOUT|2020-08-27|90
e|IS|5a56874f-10e4-4cd0-842f-19552a04d1bd|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/kg/min|[?]|1|ug/L DDU|LYMPH|MANUAL COUNT||Y|1|1|Visit_1|10|3|TREATMENT|2020-06-20|10
e|IS|5a56874f-10e4-4cd0-842f-19552a04d1bd|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|IU/mL|[?]|1|VIAL|EXHALED BREATH CONDENSATE|MECHANICAL CLOT DETECTION|||1|2|Visit_2|25|6|WASHOUT|2020-07-05|25
e|IS|5a56874f-10e4-4cd0-842f-19552a04d1bd|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/MBP|[?]|1|ug/kg/h|ARTERIALIZED CAPILLARY BLOOD|HPLC/IEX|Y|Y|1|3|Visit_3|40|4|WASHOUT|2020-07-20|40
e|IS|5a56874f-10e4-4cd0-842f-19552a04d1bd|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/animal/day|[?]|1|mL/s|MIXED VENOUS BLOOD|PANENDOSCOPY|||1|4|Visit_4|65|1|FOLLOW-UP|2020-08-14|65
e|IS|5a56874f-10e4-4cd0-842f-19552a04d1bd|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mMU/mL|[?]|1|MdFI|COLOSTRUM|STATIC PERIMETRY|||1|5|Visit_5|90|7|TREATMENT|2020-09-08|90
e|IS|f1d4ebe5-fc72-447b-8872-67e971ff471b|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|uL/mL|[?]|1|MONTHS|GASTRIC FLUID|BIOPSY|||1|1|Visit_1|10|6|WASHOUT|2020-11-08|10
e|IS|f1d4ebe5-fc72-447b-8872-67e971ff471b|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mmol/L|[?]|1|/kg|CORD BLOOD|ULTRASOUND|||1|2|Visit_2|25|7|SCREENING|2020-11-23|25
e|IS|f1d4ebe5-fc72-447b-8872-67e971ff471b|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^9 organisms/g|[?]|1|/2500 WBC|MIXED VENOUS BLOOD|ANALYTICAL ULTRACENTRIFUGATION|||1|3|Visit_3|40|7|TREATMENT|2020-12-08|40
e|IS|f1d4ebe5-fc72-447b-8872-67e971ff471b|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/day|[?]|1|nkat/g Hb|SPERMATOZOON|FLUORESCENT IMMUNOASSAY|Y||1|4|Visit_4|65|7|SCREENING|2021-01-02|65
e|IS|f1d4ebe5-fc72-447b-8872-67e971ff471b|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^8 PFU|[?]|1|mEq/L|URINE SEDIMENT|CALIPER MEASUREMENT METHOD|||1|5|Visit_5|90|3|TREATMENT|2021-01-27|90
e|IS|2a141b73-e336-4701-9067-8d51d532596b|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|LENS|[?]|1|cg|REFLEX TEAR|ELECTRICAL IMPEDANCE MYOGRAPHY||Y|1|1|Visit_1|10|6|TREATMENT|2020-06-12|10
e|IS|2a141b73-e336-4701-9067-8d51d532596b|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/min/m2|[?]|1|U/mmol|TRANSUDATE|TWO-COLOR MICROARRAY|||1|2|Visit_2|25|6|WASHOUT|2020-06-27|25
e|IS|2a141b73-e336-4701-9067-8d51d532596b|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|/sec|MENSTRUAL BLOOD|IMMUNOPRECIPITATION|||1|3|Visit_3|40|2|TREATMENT|2020-07-12|40
e|IS|2a141b73-e336-4701-9067-8d51d532596b|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|APPLICATION|[?]|1|grain|URINE|HPLC/MS/MS|||1|4|Visit_4|65|6|TREATMENT|2020-08-06|65
e|IS|2a141b73-e336-4701-9067-8d51d532596b|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MONTHS|[?]|1|mgEq|EPIDERMAL TISSUE|WHOLE GENOME SEQUENCING|||1|5|Visit_5|90|5|WASHOUT|2020-08-31|90
e|IS|4adf9a2c-3c43-4289-8156-1a109791580c|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|in|[?]|1|/7.5 mL|URINE|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||1|1|Visit_1|10|2|SCREENING|2020-11-22|10
e|IS|4adf9a2c-3c43-4289-8156-1a109791580c|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|IU/kg/h|[?]|1|Bq/uL|SUPERNATANT, PLEURAL FLUID|MICRONEUTRALIZATION ASSAY|||1|2|Visit_2|25|1|TREATMENT|2020-12-07|25
e|IS|4adf9a2c-3c43-4289-8156-1a109791580c|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|GBq|[?]|1|TCID 50/dose|SUPERNATANT, PLEURAL FLUID|PERCUSSION|||1|3|Visit_3|40|4|WASHOUT|2020-12-22|40
e|IS|4adf9a2c-3c43-4289-8156-1a109791580c|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|h/wk|[?]|1|atm|ENDOTRACHEAL FLUID|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|4|Visit_4|65|6|WASHOUT|2021-01-16|65
e|IS|4adf9a2c-3c43-4289-8156-1a109791580c|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol2/L2|[?]|1|%(v/v)|SUPERNATANT, PLEURAL FLUID|SPECT/CT SCAN|Y||1|5|Visit_5|90|4|SCREENING|2021-02-10|90
e|IS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|dpm/100mg|[?]|1|MPL U/mL|MONOCYTE|TONOMETRY|Y||1|1|Visit_1|10|2|WASHOUT|2020-05-23|10
e|IS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6/g|[?]|1|/5x10^4 WBC|SERUM|CONFOCAL MICROSCOPY|||1|2|Visit_2|25|1|TREATMENT|2020-06-07|25
e|IS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^3 CFU|[?]|1|titer|SMOOTH MUSCLE TISSUE|MICROBIAL CULTURE, SOLID||Y|1|3|Visit_3|40|1|WASHOUT|2020-06-22|40
e|IS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6 IU/mL|[?]|1|U/mmol|MIXED VENOUS BLOOD|IVY INCISION METHOD|||1|4|Visit_4|65|6|TREATMENT|2020-07-17|65
e|IS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U/g/h|[?]|1|10^6 organisms/mg|SEBUM|MICRODENSITOMETRY|Y||1|5|Visit_5|90|4|FOLLOW-UP|2020-08-11|90
e|IS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|WAFER|[?]|1|dpm/mL|SERUM OR PLASMA OR BLOOD|LASER CAPTURE MICRODISSECTION|Y||1|1|Visit_1|10|4|TREATMENT|2020-05-19|10
e|IS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cs|[?]|1|mg/mL/min|ALVEOLAR AIR|ICC|||1|2|Visit_2|25|1|SCREENING|2020-06-03|25
e|IS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|aMFI|MIXED VENOUS BLOOD|CELL BASED BIOASSAY|Y||1|3|Visit_3|40|3|TREATMENT|2020-06-18|40
e|IS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/g/min|[?]|1|mAnson U/mL|SMOOTH MUSCLE TISSUE|CALIPER MEASUREMENT METHOD|||1|4|Visit_4|65|7|TREATMENT|2020-07-13|65
e|IS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uEq|[?]|1|U/10^12 RBC|REFLEX TEAR|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|5|Visit_5|90|6|TREATMENT|2020-08-07|90
e|IS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|IU/day|[?]|1|mm|ARTERIAL BLOOD|FLUORESCENT SPOT TEST|||1|1|Visit_1|10|2|FOLLOW-UP|2020-05-26|10
e|IS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mol/day|[?]|1|V|ARTERIAL BLOOD|AUTOREFRACTION|Y||1|2|Visit_2|25|2|TREATMENT|2020-06-10|25
e|IS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|POUCH|[?]|1|L/kg|VENOUS BLOOD|FLUORESCENT SPOT TEST||Y|1|3|Visit_3|40|3|FOLLOW-UP|2020-06-25|40
e|IS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|%(w/v)|[?]|1|L/kg|MECONIUM|ANTIMICROBIAL COMBINATION TESTING|||1|4|Visit_4|65|4|SCREENING|2020-07-20|65
e|IS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/LPF|[?]|1|uU/L|AMNIOTIC FLUID|GC/FID|Y||1|5|Visit_5|90|1|TREATMENT|2020-08-14|90
e|IS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nkat|[?]|1|MET|LYSATE|PH METER MEASUREMENT METHOD|Y||1|1|Visit_1|10|7|TREATMENT|2020-05-29|10
e|IS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|POINT|[?]|1|Hz|CORD SERUM|CONTRAST ENHANCED PET SCAN|||1|2|Visit_2|25|2|TREATMENT|2020-06-13|25
e|IS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6/g|[?]|1|CIGARETTE|LOCHIA|ELECTROGASTROGRAPHY|||1|3|Visit_3|40|2|WASHOUT|2020-06-28|40
e|IS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|nU/cL|[?]|1|/VF|PLASMA|PH METER MEASUREMENT METHOD|||1|4|Visit_4|65|3|TREATMENT|2020-07-23|65
e|IS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug/kg|[?]|1|L/day|DIALYSIS FLUID|NUCLEIC ACID SEQUENCING|Y||1|5|Visit_5|90|1|FOLLOW-UP|2020-08-17|90
e|IS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL*cmH2O|[?]|1|pmol/10^9 cells|MONOCYTE|AUDIOMETRY||Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-12-03|10
e|IS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/L|[?]|1|vp/mL|PERITONEAL FLUID|CLIP|||1|2|Visit_2|25|4|FOLLOW-UP|2020-12-18|25
e|IS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|umol/L/h|[?]|1|steps/min|STOOL|TRIPLE-PHASE MRI SCAN|||1|3|Visit_3|40|5|TREATMENT|2021-01-02|40
e|IS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|%/s|[?]|1|g/L|EXPIRED AIR|REFRACTOMETRY|||1|4|Visit_4|65|2|TREATMENT|2021-01-27|65
e|IS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uEq/L|[?]|1|ms2|INTERSTITIAL FLUID|POLYMERASE CHAIN REACTION|||1|5|Visit_5|90|3|SCREENING|2021-02-21|90
e|IS|08e4310f-f868-4858-a321-f33a21a771e8|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|m/sec2|[?]|1|PA|INFRANATANT, SERUM|NON-INVASIVE DIELECTRIC SENSING|||1|1|Visit_1|10|7|TREATMENT|2020-05-15|10
e|IS|08e4310f-f868-4858-a321-f33a21a771e8|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Ci/mg|[?]|1|TAMPON|VENOUS PLASMA|INTERRUPTER TECHNIQUE|||1|2|Visit_2|25|5|FOLLOW-UP|2020-05-30|25
e|IS|08e4310f-f868-4858-a321-f33a21a771e8|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|IU/mmol|[?]|1|h*%|REFLEX TEAR|CRYOSCOPY|||1|3|Visit_3|40|1|TREATMENT|2020-06-14|40
e|IS|08e4310f-f868-4858-a321-f33a21a771e8|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|SQU/mL|[?]|1|PELLET|MENSTRUAL BLOOD|IMMUNO-PET SCAN||Y|1|4|Visit_4|65|5|FOLLOW-UP|2020-07-09|65
e|IS|08e4310f-f868-4858-a321-f33a21a771e8|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/day|[?]|1|Ejaculate U|VENOUS PLASMA|PET SCAN|||1|5|Visit_5|90|6|TREATMENT|2020-08-03|90
e|IS|29edf133-8b5b-46d5-bf7a-f75af4658417|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg|[?]|1|mg/m2|AQUEOUS HUMOR|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|1|1|Visit_1|10|1|TREATMENT|2020-08-22|10
e|IS|29edf133-8b5b-46d5-bf7a-f75af4658417|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ppth|[?]|1|mL|PLATELET RICH PLASMA|CT SCAN|||1|2|Visit_2|25|3|FOLLOW-UP|2020-09-06|25
e|IS|29edf133-8b5b-46d5-bf7a-f75af4658417|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mV|[?]|1|fmol/g|CIRCULATING TUMOR CELL|CHROMATOGRAPHY|Y||1|3|Visit_3|40|2|TREATMENT|2020-09-21|40
e|IS|29edf133-8b5b-46d5-bf7a-f75af4658417|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|hr/day|[?]|1|L/h/m2|SEBUM|FLOCCULATION, CHARCOAL ENHANCED||Y|1|4|Visit_4|65|7|TREATMENT|2020-10-16|65
e|IS|29edf133-8b5b-46d5-bf7a-f75af4658417|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L|[?]|1|Bq/mL|PLATELET POOR PLASMA|BALLPOINT PEN TECHNIQUE|||1|5|Visit_5|90|4|TREATMENT|2020-11-10|90
e|IS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^9/L|[?]|1|gpELISA unit/mL|SERUM OR PLASMA|ERGOSPIROMETRY|Y|Y|1|1|Visit_1|10|3|WASHOUT|2020-08-09|10
e|IS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/L|[?]|1|%(v/v)|ISOLATE|GRAM STAIN|||1|2|Visit_2|25|3|TREATMENT|2020-08-24|25
e|IS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|dpm/mL|[?]|1|10^6 CFU/g|PLATELET POOR PLASMA|MICROBIAL CULTURE, SOLID|||1|3|Visit_3|40|6|FOLLOW-UP|2020-09-08|40
e|IS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|P|[?]|1|mL/sec/1.73m2|PLATELET|CORONARY ANGIOGRAPHY|||1|4|Visit_4|65|5|SCREENING|2020-10-03|65
e|IS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm|[?]|1|g/L|LYMPH|PULMONARY ANGIOGRAPHY||Y|1|5|Visit_5|90|4|WASHOUT|2020-10-28|90
e|IS|7a046104-7215-4708-9d85-66683ceb8fe8|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/200 HPFs|[?]|1|mol/mL|TISSUE|TRANSMISSION ELECTRON MICROSCOPY|||1|1|Visit_1|10|3|TREATMENT|2020-10-16|10
e|IS|7a046104-7215-4708-9d85-66683ceb8fe8|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/month|[?]|1|mol/mol|TRANSUDATE|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||1|2|Visit_2|25|7|WASHOUT|2020-10-31|25
e|IS|7a046104-7215-4708-9d85-66683ceb8fe8|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|KALLIKREIN INHIBITOR UNIT|[?]|1|in|SALIVA|IMMUNO-PET SCAN|Y||1|3|Visit_3|40|6|FOLLOW-UP|2020-11-15|40
e|IS|7a046104-7215-4708-9d85-66683ceb8fe8|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Osm|[?]|1|mOsm/kg|SUPERNATANT, PLASMA|RADIOGRAPHY||Y|1|4|Visit_4|65|6|TREATMENT|2020-12-10|65
e|IS|7a046104-7215-4708-9d85-66683ceb8fe8|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mol/day|[?]|1|umol/day|DERMAL TISSUE|CINEANGIOGRAPHY|||1|5|Visit_5|90|7|FOLLOW-UP|2021-01-04|90
e|IS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/g/min|[?]|1|cm|SERUM|RADIOIMMUNOPRECIPITATION ASSAY|Y|Y|1|1|Visit_1|10|5|WASHOUT|2021-01-26|10
e|IS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/mm|[?]|1|s*kPa|AMNIOTIC FLUID|ETDRS EYE CHART|Y||1|2|Visit_2|25|5|FOLLOW-UP|2021-02-10|25
e|IS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/day|[?]|1|g/mol|PERSPIRATION|LC-FL|||1|3|Visit_3|40|5|FOLLOW-UP|2021-02-25|40
e|IS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/animal/day|[?]|1|SACHET|MONOCYTE|FLOW CYTOMETRY|Y||1|4|Visit_4|65|6|TREATMENT|2021-03-22|65
e|IS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mmol/min/kPa|[?]|1|uOsm|PLATELET RICH PLASMA|SANGER SEQUENCING|||1|5|Visit_5|90|4|TREATMENT|2021-04-16|90
e|IS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/LPF|[?]|1|10^5/hpf|HAIR FOLLICLE|MAPH|||1|1|Visit_1|10|6|TREATMENT|2020-05-25|10
e|IS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/day|[?]|1|CIGAR|STRIATED MUSCLE TISSUE|PHYSICAL EXAMINATION|||1|2|Visit_2|25|2|TREATMENT|2020-06-09|25
e|IS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CCID 50/mL|[?]|1|Bq/mg|URINE|MAGNETIC RESONANCE ELASTOGRAPHY|||1|3|Visit_3|40|3|SCREENING|2020-06-24|40
e|IS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|AFU|[?]|1|genEq|ISOLATE|SCINTIGRAPHY|||1|4|Visit_4|65|7|TREATMENT|2020-07-19|65
e|IS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|fraction of 1|[?]|1|mL/dose|INTERSTITIAL FLUID|SIZE EXCLUSION CHROMATOGRAPHY|||1|5|Visit_5|90|5|WASHOUT|2020-08-13|90
e|IS|2550ba24-7bcf-41e2-9eae-536e13d4b345|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|nmol/L/h|[?]|1|MET*h|CIRCULATING TUMOR CELL|FLUORESCEIN STAIN|Y||1|1|Visit_1|10|2|TREATMENT|2021-01-20|10
e|IS|2550ba24-7bcf-41e2-9eae-536e13d4b345|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|PIXELS/in|[?]|1|10^6/g|SUPERNATANT, SERUM OR PLASMA|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||1|2|Visit_2|25|4|FOLLOW-UP|2021-02-04|25
e|IS|2550ba24-7bcf-41e2-9eae-536e13d4b345|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|FIU|[?]|1|Absorbance U/mL|SUPERNATANT, SERUM OR PLASMA|POLYGRAPHY|Y||1|3|Visit_3|40|6|TREATMENT|2021-02-19|40
e|IS|2550ba24-7bcf-41e2-9eae-536e13d4b345|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/MBP|[?]|1|Bq/L|SWABBED MATERIAL|MICRONEUTRALIZATION ASSAY|||1|4|Visit_4|65|4|TREATMENT|2021-03-16|65
e|IS|2550ba24-7bcf-41e2-9eae-536e13d4b345|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/kg/min|[?]|1|km|CARDIAC MUSCLE TISSUE|LASER CAPTURE MICRODISSECTION||Y|1|5|Visit_5|90|1|TREATMENT|2021-04-10|90
e|IS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|L/min|PLATELET POOR PLASMA|THERMAL IONIZATION MASS SPECTROMETRY|||1|1|Visit_1|10|2|TREATMENT|2020-08-14|10
e|IS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|CFU/g|[?]|1|g/dL|SUPERNATANT, SERUM|CYSTOSCOPY|||1|2|Visit_2|25|5|TREATMENT|2020-08-29|25
e|IS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|aMFI|[?]|1|Hounsfield Unit|BILE|ATOMIC ABSORPTION SPECTROMETRY|||1|3|Visit_3|40|4|TREATMENT|2020-09-13|40
e|IS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|g/g|[?]|1|Bq|SERUM OR PLASMA OR BLOOD|KINYOUN STAIN||Y|1|4|Visit_4|65|6|SCREENING|2020-10-08|65
e|IS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/kg/day|[?]|1|AU/mL|INTERSTITIAL FLUID|REBOUND TONOMETRY|||1|5|Visit_5|90|2|TREATMENT|2020-11-02|90
e|IS|6ec23671-252e-4dc9-b919-88254fce68a5|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PIXELS/in|[?]|1|FFU|BREAST MILK|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|1|Visit_1|10|1|TREATMENT|2020-07-28|10
e|IS|6ec23671-252e-4dc9-b919-88254fce68a5|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ppth|[?]|1|mU/g|BONE MARROW|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||1|2|Visit_2|25|7|TREATMENT|2020-08-12|25
e|IS|6ec23671-252e-4dc9-b919-88254fce68a5|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/LSQN|[?]|1|U/animal|SUPERNATANT, CEREBROSPINAL FLUID|MICROPARTICLE ENZYME IMMUNOASSAY|||1|3|Visit_3|40|3|TREATMENT|2020-08-27|40
e|IS|6ec23671-252e-4dc9-b919-88254fce68a5|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL*cmH2O|[?]|1|uV2|CAPILLARY BLOOD|SMEAR|Y||1|4|Visit_4|65|4|FOLLOW-UP|2020-09-21|65
e|IS|6ec23671-252e-4dc9-b919-88254fce68a5|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|GPL U/mL|[?]|1|GLOBULE|SUPERNATANT, SERUM|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||1|5|Visit_5|90|1|TREATMENT|2020-10-16|90
e|IS|db59e5e1-ccda-480b-8955-da5157e16c4a|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/10^4|[?]|1|ppb|EMOTIONAL TEAR|SMEAR|||1|1|Visit_1|10|2|WASHOUT|2020-05-14|10
e|IS|db59e5e1-ccda-480b-8955-da5157e16c4a|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/min|[?]|1|10^7 CFU|SUPERNATANT, PLEURAL FLUID|MODIFIED ACID FAST STAIN|||1|2|Visit_2|25|5|FOLLOW-UP|2020-05-29|25
e|IS|db59e5e1-ccda-480b-8955-da5157e16c4a|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|PLUG|[?]|1|mCi/kg|EMOTIONAL TEAR|MAPH|||1|3|Visit_3|40|1|WASHOUT|2020-06-13|40
e|IS|db59e5e1-ccda-480b-8955-da5157e16c4a|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|s^-1(%O2)^-1|[?]|1|Watt|ALVEOLAR AIR|CISH||Y|1|4|Visit_4|65|6|TREATMENT|2020-07-08|65
e|IS|db59e5e1-ccda-480b-8955-da5157e16c4a|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/VF|[?]|1|m/sec2|MENSTRUAL BLOOD|ELISA|Y||1|5|Visit_5|90|5|FOLLOW-UP|2020-08-02|90
e|IS|1dce856e-b7cb-4899-b27f-87ab8d918df4|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|RNA copies/mL|[?]|1|pmol/dL|HAIR FOLLICLE|ACRIDINE ORANGE STAIN|Y||1|1|Visit_1|10|7|WASHOUT|2020-09-12|10
e|IS|1dce856e-b7cb-4899-b27f-87ab8d918df4|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|POINT|[?]|1|mm/min|SERUM OR PLASMA OR BLOOD|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||1|2|Visit_2|25|2|SCREENING|2020-09-27|25
e|IS|1dce856e-b7cb-4899-b27f-87ab8d918df4|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kPa/L/sec|[?]|1|/500 WBC|LYMPH|LAPAROSCOPY|||1|3|Visit_3|40|2|TREATMENT|2020-10-12|40
e|IS|1dce856e-b7cb-4899-b27f-87ab8d918df4|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 CCID 50/dose|[?]|1|EID 50/mL|INFRANATANT, SERUM|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||1|4|Visit_4|65|5|WASHOUT|2020-11-06|65
e|IS|1dce856e-b7cb-4899-b27f-87ab8d918df4|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Roentgen|[?]|1|uV*sec|EXUDATE|KNEMOMETRY|||1|5|Visit_5|90|1|TREATMENT|2020-12-01|90
e|IS|7449180b-e226-4e97-a059-8760f6523f77|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Linear ft*LB|[?]|1|rpm|EMOTIONAL TEAR|TOTAL BODY RADIOGRAPHY|Y||1|1|Visit_1|10|4|WASHOUT|2020-07-04|10
e|IS|7449180b-e226-4e97-a059-8760f6523f77|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|%(v/v)|[?]|1|PIXELS/cm|BONE MARROW|DROPLET DIGITAL PCR|||1|2|Visit_2|25|7|SCREENING|2020-07-19|25
e|IS|7449180b-e226-4e97-a059-8760f6523f77|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|mol|PERSPIRATION|IMPEDANCE CONDUCTIVITY|Y|Y|1|3|Visit_3|40|3|WASHOUT|2020-08-03|40
e|IS|7449180b-e226-4e97-a059-8760f6523f77|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug/animal|[?]|1|nmol BCE/mmol|GASTRIC FLUID|HPLC/IEX||Y|1|4|Visit_4|65|4|WASHOUT|2020-08-28|65
e|IS|7449180b-e226-4e97-a059-8760f6523f77|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SBE/mL|[?]|1|mph|PLASMA|QUANTITATIVE CORONARY ANGIOGRAPHY||Y|1|5|Visit_5|90|1|FOLLOW-UP|2020-09-22|90
e|IS|f077c497-b0f0-4a20-b448-608b0cc6ab36|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|pmol|[?]|1|/mm2|EMESIS|POPULATION SEQUENCING||Y|1|1|Visit_1|10|5|FOLLOW-UP|2020-06-08|10
e|IS|f077c497-b0f0-4a20-b448-608b0cc6ab36|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|pmol/L/h|[?]|1|ug/L/h|AQUEOUS HUMOR|MICRO BROTH DILUTION|||1|2|Visit_2|25|5|SCREENING|2020-06-23|25
e|IS|f077c497-b0f0-4a20-b448-608b0cc6ab36|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Bq/g|[?]|1|nm|EXPIRED AIR|X-RAY FLUORESCENCE SPECTROMETRY|||1|3|Visit_3|40|6|WASHOUT|2020-07-08|40
e|IS|f077c497-b0f0-4a20-b448-608b0cc6ab36|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/m2/min|[?]|1|mL/animal/day|LYMPH|MUGA|||1|4|Visit_4|65|7|SCREENING|2020-08-02|65
e|IS|f077c497-b0f0-4a20-b448-608b0cc6ab36|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|nmol BCE/mmol|[?]|1|HOMEOPATHIC DILUTION|EXPIRED AIR|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||1|5|Visit_5|90|7|TREATMENT|2020-08-27|90
e|IS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/kg|[?]|1|fraction of 1|FLUID|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y|Y|1|1|Visit_1|10|6|FOLLOW-UP|2020-06-12|10
e|IS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Rad|[?]|1|BISCUIT|INTERSTITIAL FLUID|DUCTOGRAPHY|||1|2|Visit_2|25|6|FOLLOW-UP|2020-06-27|25
e|IS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|AgU/mL|[?]|1|g/day|STRIATED MUSCLE TISSUE|PLETHYSMOGRAPHY|||1|3|Visit_3|40|1|WASHOUT|2020-07-12|40
e|IS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 CFU|[?]|1|nmol BCE/mmol|EXPIRED AIR|X-RAY FLUORESCENCE SPECTROMETRY|||1|4|Visit_4|65|7|TREATMENT|2020-08-06|65
e|IS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/200 HPFs|[?]|1|/10^3|AMNIOTIC FLUID|MEDIASTINOSCOPY|Y||1|5|Visit_5|90|5|SCREENING|2020-08-31|90
e|IS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug|[?]|1|NFIU|CALCULUS|DNA MICROARRAY|Y|Y|1|1|Visit_1|10|7|FOLLOW-UP|2021-01-11|10
e|IS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|kPa|[?]|1|BOWL|FLUID|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y||1|2|Visit_2|25|3|FOLLOW-UP|2021-01-26|25
e|IS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|foz_us|[?]|1|aMFI|LUNG SURFACTANT|DIGITAL PCR|||1|3|Visit_3|40|6|SCREENING|2021-02-10|40
e|IS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/kg/min|[?]|1|mCi|SUPERNATANT, PLASMA|NEXT GENERATION TARGETED SEQUENCING|Y||1|4|Visit_4|65|7|WASHOUT|2021-03-07|65
e|IS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|APS U|[?]|1|U/kg/day|ARTERIAL CORD BLOOD|IMMUNOBLOT|||1|5|Visit_5|90|6|FOLLOW-UP|2021-04-01|90
e|IS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mEq/kg|[?]|1|10^7 CFU/mL|URINE|GC/MS-EI|||1|1|Visit_1|10|7|SCREENING|2020-09-22|10
e|IS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|L/L|[?]|1|uCi/kg|LYMPH|RADIATION DOSIMETRY|||1|2|Visit_2|25|4|WASHOUT|2020-10-07|25
e|IS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|IU/mmol|[?]|1|deg|MUCUS|JAFFE REACTION|||1|3|Visit_3|40|4|TREATMENT|2020-10-22|40
e|IS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6 U|[?]|1|mg/kg/day|PUS|ANGIOGRAPHY|||1|4|Visit_4|65|3|TREATMENT|2020-11-16|65
e|IS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|MESF|SUPERNATANT, PLEURAL FLUID|COLORIMETRY|Y||1|5|Visit_5|90|2|TREATMENT|2020-12-11|90
e|IS|7b201f93-bd8c-4507-a7b7-27a02e364647|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/g|[?]|1|mg/animal|MUSCLE TISSUE|HPLC-UV|||1|1|Visit_1|10|3|WASHOUT|2020-12-23|10
e|IS|7b201f93-bd8c-4507-a7b7-27a02e364647|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PFU/animal|[?]|1|Gy|BREAST MILK|FREEZING POINT DEPRESSION||Y|1|2|Visit_2|25|7|FOLLOW-UP|2021-01-07|25
e|IS|7b201f93-bd8c-4507-a7b7-27a02e364647|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/g/min|[?]|1|SPRAY|REFLEX TEAR|SCANNING ELECTRON MICROSCOPY|Y||1|3|Visit_3|40|5|SCREENING|2021-01-22|40
e|IS|7b201f93-bd8c-4507-a7b7-27a02e364647|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mmol|[?]|1|mL/animal|SEBUM|ENZYMATIC ULTRACENTRIFUGATION||Y|1|4|Visit_4|65|6|SCREENING|2021-02-16|65
e|IS|7b201f93-bd8c-4507-a7b7-27a02e364647|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Tesla|[?]|1|TABLET|PROSTATIC FLUID|INDIA INK STAIN|||1|5|Visit_5|90|1|TREATMENT|2021-03-13|90
e|IS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/day|[?]|1|mm|MENSTRUAL BLOOD|GC/FID|||1|1|Visit_1|10|6|TREATMENT|2020-08-05|10
e|IS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/cL|[?]|1|mm/h|AMNIOTIC FLUID|AURAMINE STAIN|Y||1|2|Visit_2|25|1|FOLLOW-UP|2020-08-20|25
e|IS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/animal|[?]|1|umol|SOFT TISSUE|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||1|3|Visit_3|40|7|TREATMENT|2020-09-04|40
e|IS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/cage/wk|[?]|1|IU/day|MECONIUM|IMMUNOCHEMILUMINOMETRIC ASSAY|Y|Y|1|4|Visit_4|65|2|TREATMENT|2020-09-29|65
e|IS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uV*sec|[?]|1|DPM|SPERMATOZOON|ICP-MS||Y|1|5|Visit_5|90|2|SCREENING|2020-10-24|90
e|IS|3611b798-9b3d-4173-b23e-3017939847e0|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/h|[?]|1|mEq/mL|EMOTIONAL TEAR|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|1|1|Visit_1|10|3|TREATMENT|2020-08-03|10
e|IS|3611b798-9b3d-4173-b23e-3017939847e0|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PA|[?]|1|psec|AQUEOUS HUMOR|HEMATOXYLIN AND EOSIN STAIN|||1|2|Visit_2|25|7|FOLLOW-UP|2020-08-18|25
e|IS|3611b798-9b3d-4173-b23e-3017939847e0|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|MET*h|[?]|1|cs|MUSCLE TISSUE|ELISPOT|||1|3|Visit_3|40|1|SCREENING|2020-09-02|40
e|IS|3611b798-9b3d-4173-b23e-3017939847e0|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|OD Unit|[?]|1|10^4 CFU/mL|MUSCLE TISSUE|ATOMIC ABSORPTION SPECTROMETRY||Y|1|4|Visit_4|65|2|WASHOUT|2020-09-27|65
e|IS|3611b798-9b3d-4173-b23e-3017939847e0|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/g|[?]|1|BOLUS|ATHEROSCLEROTIC PLAQUE|ATOMIC ABSORPTION SPECTROMETRY|||1|5|Visit_5|90|7|WASHOUT|2020-10-22|90
e|IS|f651799b-9723-4c2c-88d1-de2f347e9a69|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ohm|[?]|1|PFU/dose|EMOTIONAL TEAR|CAPILLARY ELECTROPHORESIS|||1|1|Visit_1|10|1|TREATMENT|2020-06-24|10
e|IS|f651799b-9723-4c2c-88d1-de2f347e9a69|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|pmol/10^10 cells|[?]|1|mL/m2/min|URINE SEDIMENT|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||1|2|Visit_2|25|7|TREATMENT|2020-07-09|25
e|IS|f651799b-9723-4c2c-88d1-de2f347e9a69|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^6/Ejaculate U|[?]|1|STEPS|CERUMEN|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|3|Visit_3|40|7|TREATMENT|2020-07-24|40
e|IS|f651799b-9723-4c2c-88d1-de2f347e9a69|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 IU/mL|[?]|1|mL/100g/min|TUMOR TISSUE|POLYMERASE CHAIN REACTION||Y|1|4|Visit_4|65|6|WASHOUT|2020-08-18|65
e|IS|f651799b-9723-4c2c-88d1-de2f347e9a69|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|copies/uL|[?]|1|CUP|EMESIS|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y||1|5|Visit_5|90|7|TREATMENT|2020-09-12|90
e|IS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm/min|[?]|1|mg/animal|ARTERIAL BLOOD|DNA MICROARRAY|||1|1|Visit_1|10|7|TREATMENT|2020-10-19|10
e|IS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^8 PFU|[?]|1|psi|SUPERNATANT, PLASMA|MICRODENSITOMETRY|||1|2|Visit_2|25|6|FOLLOW-UP|2020-11-03|25
e|IS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 copies/mL|[?]|1|pg|ARTERIAL CORD BLOOD|MODIFIED ACID FAST STAIN||Y|1|3|Visit_3|40|5|TREATMENT|2020-11-18|40
e|IS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|CONTAINER|[?]|1|ng/day|PERSPIRATION|IRON HEMATOXYLIN STAIN|Y|Y|1|4|Visit_4|65|6|WASHOUT|2020-12-13|65
e|IS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Weber|[?]|1|10^3/hpf|SPERMATOZOON|PERIPHERAL ANGIOGRAPHY|||1|5|Visit_5|90|6|SCREENING|2021-01-07|90
e|IS|29b16c31-df0e-493c-a777-46113b904879|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|TCID 50/dose|[?]|1|mL/s/m2|PUS|IMMUNO-PET SCAN|||1|1|Visit_1|10|5|TREATMENT|2020-06-07|10
e|IS|29b16c31-df0e-493c-a777-46113b904879|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|RFU|[?]|1|10^6 CFU|INFRANATANT, PLASMA|SINGLE-SLICE SPIRAL CT|||1|2|Visit_2|25|7|FOLLOW-UP|2020-06-22|25
e|IS|29b16c31-df0e-493c-a777-46113b904879|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^8 PFU|[?]|1|BOWL|URINE SEDIMENT|FARNSWORTH-MUNSELL 100 HUE TEST|||1|3|Visit_3|40|4|WASHOUT|2020-07-07|40
e|IS|29b16c31-df0e-493c-a777-46113b904879|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cm H2O|[?]|1|ug/m2/min|PROSTATIC FLUID|TEST STRIP|||1|4|Visit_4|65|3|TREATMENT|2020-08-01|65
e|IS|29b16c31-df0e-493c-a777-46113b904879|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|log10 PFU/mL|[?]|1|GBq/ug|WHITE MATTER TISSUE|DUKE INCISION METHOD|Y|Y|1|5|Visit_5|90|3|TREATMENT|2020-08-26|90
e|IS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dpm/mL|[?]|1|DRINK|SERUM OR PLASMA|GIEMSA STAIN|||1|1|Visit_1|10|2|SCREENING|2020-07-31|10
e|IS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|cd|[?]|1|nmol/L/min|DIALYSIS FLUID, PERITONEAL|PHYSICAL EXAMINATION||Y|1|2|Visit_2|25|3|TREATMENT|2020-08-15|25
e|IS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/dL|[?]|1|kBq/uL|CEREBROSPINAL FLUID|CYSTOSCOPY|||1|3|Visit_3|40|1|TREATMENT|2020-08-30|40
e|IS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/s|[?]|1|10^7 CFU/mL|MONOCYTE|X-RAY FLUORESCENCE SPECTROMETRY|||1|4|Visit_4|65|2|TREATMENT|2020-09-24|65
e|IS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|JDF Unit|[?]|1|pL|MIXED VENOUS BLOOD|MAMMOGRAPHY|||1|5|Visit_5|90|1|TREATMENT|2020-10-19|90
e|IS|118914c8-9f6a-47c8-b427-296a99547756|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|log EID 50/dose|[?]|1|g/cm2|PLASMA ULTRAFILTRATE|ACCELERATOR MASS SPECTROMETRY|||1|1|Visit_1|10|6|TREATMENT|2020-10-25|10
e|IS|118914c8-9f6a-47c8-b427-296a99547756|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|fraction of 1|[?]|1|mL/dose|SUPERNATANT, SERUM|CALCOFLUOR WHITE STAIN||Y|1|2|Visit_2|25|4|TREATMENT|2020-11-09|25
e|IS|118914c8-9f6a-47c8-b427-296a99547756|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|BOTTLE|[?]|1|nmol/mL/min|INFRANATANT, PLASMA|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||1|3|Visit_3|40|2|TREATMENT|2020-11-24|40
e|IS|118914c8-9f6a-47c8-b427-296a99547756|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|%|[?]|1|L/L|COLOSTRUM|FLAME PHOTOMETRY|||1|4|Visit_4|65|5|WASHOUT|2020-12-19|65
e|IS|118914c8-9f6a-47c8-b427-296a99547756|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/cage/wk|[?]|1|AFU|CALCULUS|DOPPLER ULTRASOUND|||1|5|Visit_5|90|5|WASHOUT|2021-01-13|90
e|IS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/min|[?]|1|mm|BUFFY COAT|RULER MEASUREMENT METHOD|||1|1|Visit_1|10|5|TREATMENT|2020-12-09|10
e|IS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/animal/day|[?]|1|PATCH|SEMEN|REBOUND TONOMETRY|||1|2|Visit_2|25|6|TREATMENT|2020-12-24|25
e|IS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mm/h|[?]|1|HEP|SUPERNATANT, SERUM OR PLASMA|ELECTRONEUROGRAPHY|Y||1|3|Visit_3|40|2|WASHOUT|2021-01-08|40
e|IS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|CARTRIDGE|[?]|1|hPa|PLATELET RICH PLASMA|ACRIDINE ORANGE STAIN|Y|Y|1|4|Visit_4|65|1|SCREENING|2021-02-02|65
e|IS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|SPRAY|[?]|1|mg/min|TUMOR TISSUE|URANYL ACETATE STAIN||Y|1|5|Visit_5|90|1|TREATMENT|2021-02-27|90
e|IS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|nmol/L/h|[?]|1|umol/L/sec|SOFT TISSUE|CLIP|||1|1|Visit_1|10|2|TREATMENT|2021-01-08|10
e|IS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|APL U|[?]|1|uU/dL|PERSPIRATION|ELECTROPHORESIS|||1|2|Visit_2|25|5|SCREENING|2021-01-23|25
e|IS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/m2/h|[?]|1|mmol/mol|CAPILLARY PLASMA|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||1|3|Visit_3|40|5|TREATMENT|2021-02-07|40
e|IS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|uL/kg/day|[?]|1|DIOPTER|BILE|JAEGER EYE CHART||Y|1|4|Visit_4|65|4|TREATMENT|2021-03-04|65
e|IS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nmol/kg/day|[?]|1|IU/kg|SMOOTH MUSCLE TISSUE|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|5|Visit_5|90|5|TREATMENT|2021-03-29|90
e|IS|7a5ae465-03b9-4006-a29e-94822ed857aa|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|log10 TCID 50/uL|[?]|1|SQU/mL|ENDOTRACHEAL FLUID|SLIT LAMP|||1|1|Visit_1|10|2|FOLLOW-UP|2020-07-02|10
e|IS|7a5ae465-03b9-4006-a29e-94822ed857aa|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|in2|[?]|1|mCi/kg|URINE|CINEANGIOGRAPHY|||1|2|Visit_2|25|6|TREATMENT|2020-07-17|25
e|IS|7a5ae465-03b9-4006-a29e-94822ed857aa|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mV/sec|[?]|1|log10 copies/mL|MENSTRUAL BLOOD|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||Y|1|3|Visit_3|40|5|SCREENING|2020-08-01|40
e|IS|7a5ae465-03b9-4006-a29e-94822ed857aa|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PELLET|[?]|1|L|PERITONEAL FLUID|NEURAMINIDASE INHIBITION ASSAY|||1|4|Visit_4|65|6|TREATMENT|2020-08-26|65
e|IS|7a5ae465-03b9-4006-a29e-94822ed857aa|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|cm/min|[?]|1|mmol2/L2|CORD BLOOD|PHOTOMETRIC CLOT DETECTION|Y||1|5|Visit_5|90|3|WASHOUT|2020-09-20|90
e|IS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|CFU/mL|[?]|1|mgEq|ENDOTRACHEAL FLUID|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||1|1|Visit_1|10|4|WASHOUT|2020-09-22|10
e|IS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uIU/dL|[?]|1|kDa|EXUDATE|CENTRIFUGATION||Y|1|2|Visit_2|25|5|TREATMENT|2020-10-07|25
e|IS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|C|[?]|1|10^3 RNA copies/mL|PROSTATIC FLUID|FLOW MICROSCOPY|||1|3|Visit_3|40|7|SCREENING|2020-10-22|40
e|IS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/L|[?]|1|MPL U|ARTERIAL CORD BLOOD|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||Y|1|4|Visit_4|65|5|TREATMENT|2020-11-16|65
e|IS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|SPRAY|[?]|1|g/L|INFRANATANT, SERUM|DC SHEATH FLOW||Y|1|5|Visit_5|90|2|TREATMENT|2020-12-11|90
e|IS|2e4cd860-734a-40b0-bde5-ca08297415a9|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/m2/h|[?]|1|copies/mL|EPITHELIAL CELL|ANGIOGRAPHY|||1|1|Visit_1|10|6|TREATMENT|2020-11-25|10
e|IS|2e4cd860-734a-40b0-bde5-ca08297415a9|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|psi|[?]|1|kg/mol|BONE MARROW MONONUCLEAR CELL|ATOMIC ABSORPTION SPECTROMETRY|||1|2|Visit_2|25|4|TREATMENT|2020-12-10|25
e|IS|2e4cd860-734a-40b0-bde5-ca08297415a9|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mmol/kg|[?]|1|Antibody Unit|BREAST MILK|FORCED OSCILLATION TECHNIQUE|||1|3|Visit_3|40|1|WASHOUT|2020-12-25|40
e|IS|2e4cd860-734a-40b0-bde5-ca08297415a9|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/mmHg|[?]|1|Arbitrary U|HAIR|CINEANGIOGRAPHY|||1|4|Visit_4|65|3|FOLLOW-UP|2021-01-19|65
e|IS|2e4cd860-734a-40b0-bde5-ca08297415a9|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Joule|[?]|1|SPRAY|SOFT TISSUE|SPECTROPHOTOMETRY|||1|5|Visit_5|90|7|TREATMENT|2021-02-13|90
e|IS|3f1854fb-d14e-4699-888b-d5042fa9327c|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|lx|[?]|1|mL/animal/day|BONE MARROW MONONUCLEAR CELL|PAP STAIN||Y|1|1|Visit_1|10|3|TREATMENT|2020-08-04|10
e|IS|3f1854fb-d14e-4699-888b-d5042fa9327c|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|tsp|[?]|1|gtt|REFLEX TEAR|MULTI-SLICE SPIRAL CT|Y||1|2|Visit_2|25|5|TREATMENT|2020-08-19|25
e|IS|3f1854fb-d14e-4699-888b-d5042fa9327c|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|K|[?]|1|g|BONE MARROW|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||1|3|Visit_3|40|6|WASHOUT|2020-09-03|40
e|IS|3f1854fb-d14e-4699-888b-d5042fa9327c|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|deg/s|[?]|1|pg/cell|PLASMA|RULER MEASUREMENT METHOD|Y||1|4|Visit_4|65|6|SCREENING|2020-09-28|65
e|IS|3f1854fb-d14e-4699-888b-d5042fa9327c|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|umol/L/sec|[?]|1|copies/uL|LYSATE|FLUORESCENT IMMUNOASSAY|Y||1|5|Visit_5|90|5|WASHOUT|2020-10-23|90
e|IS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/min|[?]|1|mL/kg/day|EPIDERMAL TISSUE|WRIGHT STAIN|Y||1|1|Visit_1|10|4|TREATMENT|2020-12-10|10
e|IS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/kg|[?]|1|foz_br|EPITHELIAL CELL|MULTIPLE BREATH WASHOUT|||1|2|Visit_2|25|5|TREATMENT|2020-12-25|25
e|IS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|OD Unit|[?]|1|mg/day|DERMAL TISSUE|LIQUID SCINTILLATION COUNTING|Y||1|3|Visit_3|40|3|TREATMENT|2021-01-09|40
e|IS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pptr|[?]|1|log10 CFU/g|SEMEN|IMMUNOFIXATION ELECTROPHORESIS|Y|Y|1|4|Visit_4|65|2|FOLLOW-UP|2021-02-03|65
e|IS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ppth|[?]|1|SQU/mL|ENDOTRACHEAL FLUID|IVY INCISION METHOD|Y||1|5|Visit_5|90|7|FOLLOW-UP|2021-02-28|90
e|IS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug/h|[?]|1|log EID 50/dose|LYMPH|BETA LACTAMASE|Y||1|1|Visit_1|10|6|WASHOUT|2020-07-31|10
e|IS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nU/cL|[?]|1|dpm/100mg|LOCHIA|DYNAMIC LIGHT SCATTERING|||1|2|Visit_2|25|4|WASHOUT|2020-08-15|25
e|IS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|nmol/g|[?]|1|dyn|BLOOD|CT SCAN WITHOUT CONTRAST|||1|3|Visit_3|40|4|TREATMENT|2020-08-30|40
e|IS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|10^4 CFU/mL|NAIL|RADIOGRAPHY||Y|1|4|Visit_4|65|6|TREATMENT|2020-09-24|65
e|IS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/kg/day|[?]|1|m3|MENSTRUAL BLOOD|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||1|5|Visit_5|90|6|WASHOUT|2020-10-19|90
e|IS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|SBE/mL|[?]|1|GBq/g|EMESIS|PHOTOMETRIC CLOT DETECTION|Y||1|1|Visit_1|10|4|TREATMENT|2020-06-11|10
e|IS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|SQU/mL|[?]|1|FIU|SUPERNATANT, PLEURAL FLUID|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|2|Visit_2|25|3|WASHOUT|2020-06-26|25
e|IS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Absorbance U/mL|[?]|1|pt_us|LYMPH|MODIFIED ACID FAST STAIN||Y|1|3|Visit_3|40|3|FOLLOW-UP|2020-07-11|40
e|IS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/mL|[?]|1|cm/s|COLOSTRUM|CALCOFLUOR WHITE STAIN|Y|Y|1|4|Visit_4|65|1|TREATMENT|2020-08-05|65
e|IS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/m2|[?]|1|fmol|GASTRIC CONTENTS|SEQUENCING|||1|5|Visit_5|90|3|FOLLOW-UP|2020-08-30|90
e|IS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ELISA unit/mL|[?]|1|%/min|SMOOTH MUSCLE TISSUE|COMPLEMENT FIXATION||Y|1|1|Visit_1|10|5|TREATMENT|2020-06-25|10
e|IS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kPa|[?]|1|tsp eq|SUPERNATANT, PLEURAL FLUID|MULTI-SLICE SPIRAL CT|||1|2|Visit_2|25|3|TREATMENT|2020-07-10|25
e|IS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ft2|[?]|1|ms/mmHg|SWABBED MATERIAL|SPECT SCAN|||1|3|Visit_3|40|2|WASHOUT|2020-07-25|40
e|IS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/h/mmol|[?]|1|10^4/L|SUPERNATANT, SERUM|QUANTITATIVE ULTRASOUND|||1|4|Visit_4|65|2|FOLLOW-UP|2020-08-19|65
e|IS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|foz_us|[?]|1|cy/cm|SPUTUM|OPTICAL DENSITY MEASUREMENT||Y|1|5|Visit_5|90|7|FOLLOW-UP|2020-09-13|90
e|IS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mPa|[?]|1|mL/cage/wk|LYMPH|DIFFUSION WEIGHTED MRI|Y|Y|1|1|Visit_1|10|5|FOLLOW-UP|2020-10-26|10
e|IS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|amp|[?]|1|TRANSDUCING UNIT|DIALYSIS FLUID|AURAMINE STAIN|||1|2|Visit_2|25|2|WASHOUT|2020-11-10|25
e|IS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|L/min/m2|[?]|1|nsec|CELL PELLET|PERIPHERAL ANGIOGRAPHY|||1|3|Visit_3|40|5|SCREENING|2020-11-25|40
e|IS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mIU/L|[?]|1|PLUG|MONOCYTE|ORCHIDOMETERY|||1|4|Visit_4|65|7|SCREENING|2020-12-20|65
e|IS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6 organisms/mL|[?]|1|L/h/m2|DERMAL TISSUE|MEDIASTINOSCOPY|||1|5|Visit_5|90|3|SCREENING|2021-01-14|90
e|IS|2cda4297-410a-49e4-949c-deb3dc4c6656|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|VIAL|[?]|1|fg|AQUEOUS HUMOR|NO INFORMATION|||1|1|Visit_1|10|7|WASHOUT|2020-06-20|10
e|IS|2cda4297-410a-49e4-949c-deb3dc4c6656|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|%(v/v)|[?]|1|U/mmol|STRIATED MUSCLE TISSUE|DIRECT SEQUENCING||Y|1|2|Visit_2|25|3|TREATMENT|2020-07-05|25
e|IS|2cda4297-410a-49e4-949c-deb3dc4c6656|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|EID 50/dose|[?]|1|hr/day|TISSUE|HIGH RESOLUTION CT|||1|3|Visit_3|40|4|SCREENING|2020-07-20|40
e|IS|2cda4297-410a-49e4-949c-deb3dc4c6656|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^4/hpf|[?]|1|dpm/100mg|MIXED VENOUS BLOOD|CLOT DETECTION|Y|Y|1|4|Visit_4|65|5|TREATMENT|2020-08-14|65
e|IS|2cda4297-410a-49e4-949c-deb3dc4c6656|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|MET*h|[?]|1|/min|SERUM OR PLASMA|FORCED OSCILLATION TECHNIQUE|||1|5|Visit_5|90|2|TREATMENT|2020-09-08|90
e|IS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^9 organisms/mL|[?]|1|10^3 CFU/mL|SERUM OR PLASMA OR BLOOD|PERIPHERAL ANGIOGRAPHY|||1|1|Visit_1|10|2|SCREENING|2021-01-29|10
e|IS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 organisms|[?]|1|mL/cm|PERIPHERAL BLOOD MONONUCLEAR CELL|OPHTHALMOSCOPY|||1|2|Visit_2|25|4|SCREENING|2021-02-13|25
e|IS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cmH2O/mL|[?]|1|10^3 organisms/mL|INFRANATANT, PLASMA|AURAMINE STAIN|||1|3|Visit_3|40|1|TREATMENT|2021-02-28|40
e|IS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|pt_br|[?]|1|Joule|SEBUM|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y||1|4|Visit_4|65|2|FOLLOW-UP|2021-03-25|65
e|IS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|BE/mL|[?]|1|Coulomb|AMNIOTIC FLUID|OPHTHALMOSCOPY|Y|Y|1|5|Visit_5|90|7|WASHOUT|2021-04-19|90
e|IS|9e82141b-e2b9-42c7-b813-b79bda2bd216|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^12 IU/L|[?]|1|mm3/mm2/year|SEBUM|LC-FL||Y|1|1|Visit_1|10|5|TREATMENT|2020-05-31|10
e|IS|9e82141b-e2b9-42c7-b813-b79bda2bd216|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CAN|[?]|1|mg/g/h|SERUM|CONFOCAL MICROSCOPY|||1|2|Visit_2|25|1|FOLLOW-UP|2020-06-15|25
e|IS|9e82141b-e2b9-42c7-b813-b79bda2bd216|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/g|[?]|1|MdFI|LYSATE|CLIP SEQUENCING|||1|3|Visit_3|40|3|FOLLOW-UP|2020-06-30|40
e|IS|9e82141b-e2b9-42c7-b813-b79bda2bd216|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|K|[?]|1|10^6 RNA copies/mL|REFLEX TEAR|ENZYMATIC ULTRACENTRIFUGATION|Y||1|4|Visit_4|65|1|TREATMENT|2020-07-25|65
e|IS|9e82141b-e2b9-42c7-b813-b79bda2bd216|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|L/s/kPa|[?]|1|Coulomb|SPERMATOZOON|HEMATOXYLIN AND EOSIN STAIN||Y|1|5|Visit_5|90|2|TREATMENT|2020-08-19|90
e|IS|4b432c61-c620-4c5e-8aad-411facc0f4db|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm|[?]|1|mL/beat|PLEURAL FLUID|SNP ARRAY|||1|1|Visit_1|10|2|WASHOUT|2020-09-14|10
e|IS|4b432c61-c620-4c5e-8aad-411facc0f4db|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Pa|[?]|1|pptr|LOCHIA|BALLPOINT PEN TECHNIQUE|Y|Y|1|2|Visit_2|25|1|FOLLOW-UP|2020-09-29|25
e|IS|4b432c61-c620-4c5e-8aad-411facc0f4db|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Bq/L|[?]|1|HOURS|GASTRIC FLUID|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y|Y|1|3|Visit_3|40|5|TREATMENT|2020-10-14|40
e|IS|4b432c61-c620-4c5e-8aad-411facc0f4db|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Log10 ELISA unit|[?]|1|10^3/L|WHITE MATTER TISSUE|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y|1|4|Visit_4|65|3|TREATMENT|2020-11-08|65
e|IS|4b432c61-c620-4c5e-8aad-411facc0f4db|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|uV*sec|[?]|1|ug/L FEU|ARTERIALIZED CAPILLARY BLOOD|CLAUSS METHOD|Y||1|5|Visit_5|90|4|TREATMENT|2020-12-03|90
e|IS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|deg/mm|[?]|1|APPLICATION|HAIR|PH METER MEASUREMENT METHOD|||1|1|Visit_1|10|5|TREATMENT|2020-12-26|10
e|IS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|km|[?]|1|log10 CFU/mL|URINE|TRICHROME STAIN|Y||1|2|Visit_2|25|4|WASHOUT|2021-01-10|25
e|IS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cd|[?]|1|g/cage/wk|SUPERNATANT, SERUM|MALDI-TOF|||1|3|Visit_3|40|5|TREATMENT|2021-01-25|40
e|IS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PELLET|[?]|1|ng/dL|HAIR FOLLICLE|NON-INVASIVE DIELECTRIC SENSING|||1|4|Visit_4|65|4|FOLLOW-UP|2021-02-19|65
e|IS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/kg|[?]|1|log EID 50/dose|TISSUE|NUCLEIC ACID SEQUENCING|||1|5|Visit_5|90|3|WASHOUT|2021-03-16|90
e|IS|8c8053d1-adae-4d45-870e-cf4ad2475c74|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ng/day|[?]|1|mL|COLOSTRUM|MAMMOGRAPHY||Y|1|1|Visit_1|10|7|TREATMENT|2020-05-11|10
e|IS|8c8053d1-adae-4d45-870e-cf4ad2475c74|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mEq/mmol|[?]|1|mL/s|MENSTRUAL BLOOD|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|2|Visit_2|25|7|TREATMENT|2020-05-26|25
e|IS|8c8053d1-adae-4d45-870e-cf4ad2475c74|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/mL/min|[?]|1|U/g/h|ARTERIALIZED CAPILLARY BLOOD|PELLI-ROBSON EYE CHART|||1|3|Visit_3|40|1|TREATMENT|2020-06-10|40
e|IS|8c8053d1-adae-4d45-870e-cf4ad2475c74|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol/L|[?]|1|GPL U/mL|CORD BLOOD|MANUAL CLOT DETECTION|Y||1|4|Visit_4|65|6|SCREENING|2020-07-05|65
e|IS|8c8053d1-adae-4d45-870e-cf4ad2475c74|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/L|[?]|1|Rad|DERMAL TISSUE|FLAME PHOTOMETRY|Y||1|5|Visit_5|90|3|SCREENING|2020-07-30|90
e|IS|c3b911a8-116e-4940-80a2-7128db004f4a|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ppth|[?]|1|U/mL|LYSATE|REVERSE TRANSCRIPTASE PCR|||1|1|Visit_1|10|6|WASHOUT|2020-11-19|10
e|IS|c3b911a8-116e-4940-80a2-7128db004f4a|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|umol/h/mmol|SOFT TISSUE|HPLC/MS|||1|2|Visit_2|25|5|TREATMENT|2020-12-04|25
e|IS|c3b911a8-116e-4940-80a2-7128db004f4a|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BLOCKS|[?]|1|RATIO|CEREBROSPINAL FLUID|DIGITAL PCR ARRAY|||1|3|Visit_3|40|7|TREATMENT|2020-12-19|40
e|IS|c3b911a8-116e-4940-80a2-7128db004f4a|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|titer|[?]|1|pL|BREAST MILK|KNEMOMETRY|||1|4|Visit_4|65|1|FOLLOW-UP|2021-01-13|65
e|IS|c3b911a8-116e-4940-80a2-7128db004f4a|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Ci/L|[?]|1|mol/day|BLOOD|MAMMOGRAPHY|||1|5|Visit_5|90|3|TREATMENT|2021-02-07|90
e|IS|401d66ba-bc00-4495-ba5d-796068dd1fd6|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/animal|[?]|1|SQU/mL|DIALYSIS FLUID, PERITONEAL|SPIRAL CT SCAN WITHOUT CONTRAST|Y|Y|1|1|Visit_1|10|2|TREATMENT|2020-06-11|10
e|IS|401d66ba-bc00-4495-ba5d-796068dd1fd6|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|NFIU|[?]|1|10^7/L|DISCHARGE|THICK SMEAR|||1|2|Visit_2|25|7|TREATMENT|2020-06-26|25
e|IS|401d66ba-bc00-4495-ba5d-796068dd1fd6|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|copies/ug|[?]|1|10^6/g|EPIDERMAL TISSUE|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|3|Visit_3|40|6|WASHOUT|2020-07-11|40
e|IS|401d66ba-bc00-4495-ba5d-796068dd1fd6|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL*cmH2O|[?]|1|/MBP|CORD BLOOD|NEPHELOMETRY||Y|1|4|Visit_4|65|4|SCREENING|2020-08-05|65
e|IS|401d66ba-bc00-4495-ba5d-796068dd1fd6|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cmHg|[?]|1|U/kg/min|SERUM|CALCULATION|||1|5|Visit_5|90|1|TREATMENT|2020-08-30|90
e|IS|f8113725-4deb-48a1-876a-ba168a6d2cee|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CCID 50/dose|[?]|1|U.CARR|LAVAGE FLUID|OLIGO ACGH|||1|1|Visit_1|10|1|FOLLOW-UP|2021-01-22|10
e|IS|f8113725-4deb-48a1-876a-ba168a6d2cee|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|DIP|[?]|1|/h|BREAST MILK|CYSTOSCOPY|Y||1|2|Visit_2|25|1|TREATMENT|2021-02-06|25
e|IS|f8113725-4deb-48a1-876a-ba168a6d2cee|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/kg|[?]|1|/HPF|ENDOTRACHEAL FLUID|ENDOSCOPY|Y||1|3|Visit_3|40|5|FOLLOW-UP|2021-02-21|40
e|IS|f8113725-4deb-48a1-876a-ba168a6d2cee|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/animal/wk|[?]|1|scm|SKIN TISSUE|CONTRAST ENHANCED X-RAY||Y|1|4|Visit_4|65|4|SCREENING|2021-03-18|65
e|IS|f8113725-4deb-48a1-876a-ba168a6d2cee|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol/L/min|[?]|1|cd*s/m2|INFRANATANT, PLEURAL FLUID|IRON HEMATOXYLIN STAIN|||1|5|Visit_5|90|3|TREATMENT|2021-04-12|90
e|IS|f056c174-b6da-4df6-bf95-2e31911939fb|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uL/kg/day|[?]|1|PACKET|RETICULOCYTES|PHASE-CONTRAST MRI||Y|1|1|Visit_1|10|1|TREATMENT|2020-12-16|10
e|IS|f056c174-b6da-4df6-bf95-2e31911939fb|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|DNA copies/mL|[?]|1|FEU|ADIPOSE TISSUE|MICROBIAL CULTURE||Y|1|2|Visit_2|25|4|SCREENING|2020-12-31|25
e|IS|f056c174-b6da-4df6-bf95-2e31911939fb|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/h|[?]|1|ug/L/h|EXPIRED AIR|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||1|3|Visit_3|40|5|WASHOUT|2021-01-15|40
e|IS|f056c174-b6da-4df6-bf95-2e31911939fb|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Sv|[?]|1|pg|SYNOVIAL FLUID|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||Y|1|4|Visit_4|65|7|FOLLOW-UP|2021-02-09|65
e|IS|f056c174-b6da-4df6-bf95-2e31911939fb|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|fraction of 1|[?]|1|nsec|INFRANATANT, SERUM|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|5|Visit_5|90|5|FOLLOW-UP|2021-03-06|90
e|IS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^3 copies/mL|[?]|1|uL/kg/day|WHITE MATTER TISSUE|NEXT GENERATION SEQUENCING|||1|1|Visit_1|10|3|FOLLOW-UP|2020-09-16|10
e|IS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cmHg|[?]|1|%|SUPERNATANT, PLASMA|MYELOPEROXIDASE STAIN|||1|2|Visit_2|25|1|TREATMENT|2020-10-01|25
e|IS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MPL U/mL|[?]|1|mU/L|MUSCLE TISSUE|IMMUNORADIOMETRIC ASSAY|Y|Y|1|3|Visit_3|40|2|WASHOUT|2020-10-16|40
e|IS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mN|[?]|1|mEq/ug|CAPILLARY BLOOD|RAJI CELL EIA|||1|4|Visit_4|65|7|TREATMENT|2020-11-10|65
e|IS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Log10 ELISA unit/dose|[?]|1|mmHg/sec|CERUMEN|GC/FID||Y|1|5|Visit_5|90|2|TREATMENT|2020-12-05|90
e|IS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mph|[?]|1|U/kg/h|ARTERIAL CORD BLOOD|DOPPLER ULTRASOUND|Y||1|1|Visit_1|10|4|TREATMENT|2021-01-18|10
e|IS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|10^6 organisms/g|CAPILLARY BLOOD|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y|1|2|Visit_2|25|6|WASHOUT|2021-02-02|25
e|IS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmAL|[?]|1|ug/L|PLASMA|SPIRAL CT||Y|1|3|Visit_3|40|2|TREATMENT|2021-02-17|40
e|IS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/cm2|[?]|1|mm2|BONE MARROW MONONUCLEAR CELL|EIA|Y||1|4|Visit_4|65|7|FOLLOW-UP|2021-03-14|65
e|IS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|K|[?]|1|Tesla|LUNG SURFACTANT|TRANSVAGINAL ULTRASOUND|Y||1|5|Visit_5|90|2|TREATMENT|2021-04-08|90
e|IS|02d9a74a-abc8-4b47-a4d4-a196d339f621|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|PELLET|[?]|1|vp/mL|PROSTATIC FLUID|PHOTOMETRIC CLOT DETECTION|Y|Y|1|1|Visit_1|10|5|WASHOUT|2020-09-14|10
e|IS|02d9a74a-abc8-4b47-a4d4-a196d339f621|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|L/L|[?]|1|uL/kg/day|ARTERIAL CORD BLOOD|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||1|2|Visit_2|25|4|TREATMENT|2020-09-29|25
e|IS|02d9a74a-abc8-4b47-a4d4-a196d339f621|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/mL/min|[?]|1|mV/sec|ATHEROSCLEROTIC PLAQUE|AUTOMATED COUNT|||1|3|Visit_3|40|5|TREATMENT|2020-10-14|40
e|IS|02d9a74a-abc8-4b47-a4d4-a196d339f621|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 CFU/mL|[?]|1|10^9 CFU|TRANSUDATE|OBSERVATION|||1|4|Visit_4|65|3|SCREENING|2020-11-08|65
e|IS|02d9a74a-abc8-4b47-a4d4-a196d339f621|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|USP U|[?]|1|deg|SMOOTH MUSCLE TISSUE|FARR ASSAY|||1|5|Visit_5|90|5|SCREENING|2020-12-03|90
e|IS|81480f83-206f-40c0-a5a4-f75b31cda363|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^3 CFU|[?]|1|mg/kg/h|VITREOUS HUMOR|PH METER MEASUREMENT METHOD|||1|1|Visit_1|10|7|TREATMENT|2020-11-22|10
e|IS|81480f83-206f-40c0-a5a4-f75b31cda363|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|anti-Xa IU|[?]|1|scm|PERITONEAL FLUID|ROMANOWSKY STAIN|||1|2|Visit_2|25|2|TREATMENT|2020-12-07|25
e|IS|81480f83-206f-40c0-a5a4-f75b31cda363|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|nCi|[?]|1|APS U|ATHEROSCLEROTIC PLAQUE|INDIA INK STAIN|||1|3|Visit_3|40|1|SCREENING|2020-12-22|40
e|IS|81480f83-206f-40c0-a5a4-f75b31cda363|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|GPL U/mL|[?]|1|g/cage/day|LEUKOCYTE|TRANSVAGINAL ULTRASOUND|Y||1|4|Visit_4|65|3|WASHOUT|2021-01-16|65
e|IS|81480f83-206f-40c0-a5a4-f75b31cda363|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ngEq/L|[?]|1|gtt|PLEURAL FLUID|DIGITAL PCR|||1|5|Visit_5|90|7|TREATMENT|2021-02-10|90
e|IS|2b183b69-3ed8-4356-b9e2-0988128de3f2|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|%/min|[?]|1|APL U|CEREBROSPINAL FLUID|WHOLE TRANSCRIPTOME SEQUENCING||Y|1|1|Visit_1|10|2|TREATMENT|2020-10-16|10
e|IS|2b183b69-3ed8-4356-b9e2-0988128de3f2|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|CUP|[?]|1|10^6/L|URINE|APPLANATION TONOMETRY|Y|Y|1|2|Visit_2|25|6|SCREENING|2020-10-31|25
e|IS|2b183b69-3ed8-4356-b9e2-0988128de3f2|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/VF|[?]|1|uU/L|REFLEX TEAR|OPTICAL MAPPING|||1|3|Visit_3|40|7|SCREENING|2020-11-15|40
e|IS|2b183b69-3ed8-4356-b9e2-0988128de3f2|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|cm|[?]|1|ukat|REFLEX TEAR|IMMUNO-PET SCAN|Y|Y|1|4|Visit_4|65|7|TREATMENT|2020-12-10|65
e|IS|2b183b69-3ed8-4356-b9e2-0988128de3f2|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|oz|[?]|1|um/s|PERSPIRATION|TRYPAN BLUE STAIN||Y|1|5|Visit_5|90|4|TREATMENT|2021-01-04|90
e|IS|6ed8a749-81c0-4998-817d-efc86cfaa091|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mV/sec|[?]|1|/h|ENDOTRACHEAL FLUID|PET SCAN||Y|1|1|Visit_1|10|1|SCREENING|2020-06-05|10
e|IS|6ed8a749-81c0-4998-817d-efc86cfaa091|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|IU/dL|[?]|1|uEq|INTERSTITIAL FLUID|GRAM STAIN|||1|2|Visit_2|25|1|TREATMENT|2020-06-20|25
e|IS|6ed8a749-81c0-4998-817d-efc86cfaa091|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|deg/mm|[?]|1|IU/mL|PROSTATIC FLUID|CYSTOMETRY|Y|Y|1|3|Visit_3|40|7|TREATMENT|2020-07-05|40
e|IS|6ed8a749-81c0-4998-817d-efc86cfaa091|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mV/sec|[?]|1|mmHg|PLASMA ULTRAFILTRATE|ULTRASONOGRAPHIC ELASTOGRAPHY|Y||1|4|Visit_4|65|3|TREATMENT|2020-07-30|65
e|IS|6ed8a749-81c0-4998-817d-efc86cfaa091|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|BOLUS|[?]|1|nkat/L|MUSCLE TISSUE|CONTRAST ENHANCED PET/CT SCAN|Y||1|5|Visit_5|90|4|TREATMENT|2020-08-24|90
e|IS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Siemens|[?]|1|mg/kg/min|ATHEROSCLEROTIC PLAQUE|URANYL ACETATE STAIN|||1|1|Visit_1|10|2|SCREENING|2021-01-18|10
e|IS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol/L|[?]|1|V|PLATELET POOR PLASMA|PERIPHERAL ANGIOGRAPHY|||1|2|Visit_2|25|2|FOLLOW-UP|2021-02-02|25
e|IS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/mol|[?]|1|amp|WHITE MATTER TISSUE|IVY INCISION METHOD|||1|3|Visit_3|40|3|WASHOUT|2021-02-17|40
e|IS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|BU/mL|[?]|1|steps/min|ENDOMETRIAL TISSUE|POTENTIOMETRY|||1|4|Visit_4|65|2|FOLLOW-UP|2021-03-14|65
e|IS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|IU/mg|[?]|1|cL|LEUKOCYTE|MICROBIAL BIOCHEMICAL IDENTIFICATION|||1|5|Visit_5|90|1|FOLLOW-UP|2021-04-08|90
e|IS|e6162980-e240-4924-a13a-dde28b2345cd|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|MdFI|[?]|1|cg|CORD SERUM|NEXT GENERATION TARGETED SEQUENCING|||1|1|Visit_1|10|6|FOLLOW-UP|2020-08-11|10
e|IS|e6162980-e240-4924-a13a-dde28b2345cd|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 CFU/g|[?]|1|K|SERUM|CONTRAST ENHANCED X-RAY||Y|1|2|Visit_2|25|5|TREATMENT|2020-08-26|25
e|IS|e6162980-e240-4924-a13a-dde28b2345cd|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Enzyme U/m2|[?]|1|AgU/mL|SEMINAL FLUID|MAGNETIC RESONANCE ENTEROGRAPHY|Y||1|3|Visit_3|40|3|WASHOUT|2020-09-10|40
e|IS|e6162980-e240-4924-a13a-dde28b2345cd|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Siemens|[?]|1|mU/g|SUPERNATANT, PLASMA|POLYMERASE CHAIN REACTION|||1|4|Visit_4|65|4|SCREENING|2020-10-05|65
e|IS|e6162980-e240-4924-a13a-dde28b2345cd|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol|[?]|1|BAU|SWABBED MATERIAL|MULTI-SLICE SPIRAL CT|||1|5|Visit_5|90|1|WASHOUT|2020-10-30|90
e|IS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MASK|[?]|1|COAT|SMOOTH MUSCLE TISSUE|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|1|1|Visit_1|10|5|TREATMENT|2020-06-13|10
e|IS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|APPLICATION|[?]|1|mL/min/1.73m2|EPIDERMAL TISSUE|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||1|2|Visit_2|25|2|WASHOUT|2020-06-28|25
e|IS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/2000 RBC|[?]|1|PIXELS/in|SUPERNATANT, SERUM OR PLASMA|MAGNETIC RESONANCE ANGIOGRAPHY|Y||1|3|Visit_3|40|6|TREATMENT|2020-07-13|40
e|IS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BU/mL|[?]|1|TRANSDUCING UNIT|LEUKOCYTE|LC/MS|||1|4|Visit_4|65|1|SCREENING|2020-08-07|65
e|IS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|APS U|[?]|1|%(w/w)|CELL PELLET|U-HPLC/MS/MS|||1|5|Visit_5|90|7|TREATMENT|2020-09-01|90
e|IS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Ci/kg|[?]|1|mJoule/cm2|SALIVA|RYAN BLUE STAIN|||1|1|Visit_1|10|3|SCREENING|2021-01-23|10
e|IS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol/L/h|[?]|1|BOWL|CERUMEN|MANUAL CLOT DETECTION|Y||1|2|Visit_2|25|1|TREATMENT|2021-02-07|25
e|IS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MHz|[?]|1|10^6 RNA copies/mL|BONE MARROW|HIGH RESOLUTION MELT ANALYSIS|||1|3|Visit_3|40|5|TREATMENT|2021-02-22|40
e|IS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|TAMPON|[?]|1|IU/mg|DERMAL TISSUE|KINETIC CHROMOGENIC ASSAY|Y||1|4|Visit_4|65|1|FOLLOW-UP|2021-03-19|65
e|IS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|U/g Hb|[?]|1|10^3 CFU|PLATELET|RADIATION DOSIMETRY|||1|5|Visit_5|90|7|SCREENING|2021-04-13|90
e|IS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/kg/min|[?]|1|uV|DISCHARGE|COMPLEMENT FIXATION|||1|1|Visit_1|10|3|TREATMENT|2020-11-19|10
e|IS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|L/min|[?]|1|mol/mol|SMOOTH MUSCLE TISSUE|ENDOSCOPY|Y||1|2|Visit_2|25|2|FOLLOW-UP|2020-12-04|25
e|IS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|log10 PFU|[?]|1|10^9 organisms|CAPILLARY BLOOD|NEXT GENERATION SEQUENCING|||1|3|Visit_3|40|3|TREATMENT|2020-12-19|40
e|IS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|BE/mL|[?]|1|g/g/day|SEMEN|RADIOIMMUNOPRECIPITATION ASSAY|Y|Y|1|4|Visit_4|65|1|FOLLOW-UP|2021-01-13|65
e|IS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PIXELS/in|[?]|1|IMPLANT|SUPERNATANT, SERUM|PAP STAIN|||1|5|Visit_5|90|5|TREATMENT|2021-02-07|90
e|IS|2738b933-c71d-4239-a093-6b4aa7cc41df|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PHERESIS UNIT|[?]|1|AFU|TISSUE|NO INFORMATION|||1|1|Visit_1|10|2|SCREENING|2020-05-28|10
e|IS|2738b933-c71d-4239-a093-6b4aa7cc41df|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mJoule/cm2|[?]|1|BAG|SUPERNATANT, PLEURAL FLUID|ETDRS EYE CHART|||1|2|Visit_2|25|1|TREATMENT|2020-06-12|25
e|IS|2738b933-c71d-4239-a093-6b4aa7cc41df|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PA|[?]|1|mg/h|CORD SERUM|SNP ARRAY|Y||1|3|Visit_3|40|2|TREATMENT|2020-06-27|40
e|IS|2738b933-c71d-4239-a093-6b4aa7cc41df|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|gpELISA unit/mL|[?]|1|/LSQN|BREAST MILK|HEMOCYTOMETRY||Y|1|4|Visit_4|65|1|TREATMENT|2020-07-22|65
e|IS|2738b933-c71d-4239-a093-6b4aa7cc41df|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|DISK|[?]|1|m/sec|PERITONEAL FLUID|MOUSE PROTECTION ASSAY|Y|Y|1|5|Visit_5|90|3|FOLLOW-UP|2020-08-16|90
e|IS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|m3|[?]|1|TAMPON|CORD BLOOD|SPECT/CT SCAN||Y|1|1|Visit_1|10|4|TREATMENT|2021-01-08|10
e|IS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|JAR|[?]|1|aMFI|EXPIRED AIR|SPECULAR MICROSCOPY|||1|2|Visit_2|25|7|TREATMENT|2021-01-23|25
e|IS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|kg/cm2|[?]|1|cmH2O*s/mL|SMOOTH MUSCLE TISSUE|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|3|Visit_3|40|4|TREATMENT|2021-02-07|40
e|IS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 PFU|[?]|1|uL/dose|ABSCESS FLUID|REFRACTOMETRY|||1|4|Visit_4|65|1|TREATMENT|2021-03-04|65
e|IS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug/m2|[?]|1|pmol/10^10 cells|CAPILLARY BLOOD|GC/MS|||1|5|Visit_5|90|1|WASHOUT|2021-03-29|90
e|IS|0f0ec179-5100-4a3d-9f93-54140aca7d30|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|uIU/dL|[?]|1|U/kg/min|HAIR FOLLICLE|NON-INVASIVE DIELECTRIC SENSING|Y||1|1|Visit_1|10|4|TREATMENT|2020-08-25|10
e|IS|0f0ec179-5100-4a3d-9f93-54140aca7d30|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DISK|[?]|1|log10 TCID 50/mL|LUNG SURFACTANT|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y||1|2|Visit_2|25|3|TREATMENT|2020-09-09|25
e|IS|0f0ec179-5100-4a3d-9f93-54140aca7d30|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MPL U|[?]|1|nmol/L/min|BONE MARROW|NUCLEIC ACID AMPLIFICATION TEST|||1|3|Visit_3|40|1|TREATMENT|2020-09-24|40
e|IS|0f0ec179-5100-4a3d-9f93-54140aca7d30|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^12 IU/L|[?]|1|/sec|VENOUS PLASMA|ULTRASONOGRAPHIC ELASTOGRAPHY|||1|4|Visit_4|65|6|TREATMENT|2020-10-19|65
e|IS|0f0ec179-5100-4a3d-9f93-54140aca7d30|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|s^-1(%O2)^-1|[?]|1|/mm2|TISSUE|SNELLEN EYE CHART||Y|1|5|Visit_5|90|5|FOLLOW-UP|2020-11-13|90
e|IS|6affe43d-e455-40af-8478-dc38019e89e1|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^11/L|[?]|1|kN/cm2|STOOL|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||1|1|Visit_1|10|5|TREATMENT|2020-06-17|10
e|IS|6affe43d-e455-40af-8478-dc38019e89e1|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|ug|ATHEROSCLEROTIC PLAQUE|LINE PROBE ASSAY|Y||1|2|Visit_2|25|1|FOLLOW-UP|2020-07-02|25
e|IS|6affe43d-e455-40af-8478-dc38019e89e1|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|vg/mL|[?]|1|kg/m2|EXUDATE|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|3|Visit_3|40|3|WASHOUT|2020-07-17|40
e|IS|6affe43d-e455-40af-8478-dc38019e89e1|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|%/s|[?]|1|ms/mmHg|MUCUS|WEBER GREEN STAIN|||1|4|Visit_4|65|4|TREATMENT|2020-08-11|65
e|IS|6affe43d-e455-40af-8478-dc38019e89e1|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mIU/L|[?]|1|mEq/mmol|SUPERNATANT, SERUM OR PLASMA|CYSTOSCOPY||Y|1|5|Visit_5|90|4|SCREENING|2020-09-05|90
e|IS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/g/h|[?]|1|U/kg/day|SPERMATOZOON|CLIP SEQUENCING||Y|1|1|Visit_1|10|1|SCREENING|2020-06-07|10
e|IS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug/day|[?]|1|U/g/h|HAIR|IVY INCISION METHOD|||1|2|Visit_2|25|4|TREATMENT|2020-06-22|25
e|IS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 IU|[?]|1|10^9 CFU/mL|VITREOUS HUMOR|URANYL ACETATE STAIN|||1|3|Visit_3|40|1|TREATMENT|2020-07-07|40
e|IS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|BLOCKS|[?]|1|DRUM|SUPERNATANT, PLEURAL FLUID|CT SCAN WITHOUT CONTRAST|||1|4|Visit_4|65|3|TREATMENT|2020-08-01|65
e|IS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/dose|[?]|1|MESF|KERATINOCYTE|NEXT GENERATION SEQUENCING||Y|1|5|Visit_5|90|2|WASHOUT|2020-08-26|90
e|IS|e0258c95-7bcc-4b54-895c-f290a1364b5c|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|CCID 50/dose|[?]|1|BISCUIT|SMOOTH MUSCLE TISSUE|ERGOSPIROMETRY||Y|1|1|Visit_1|10|3|TREATMENT|2020-12-27|10
e|IS|e0258c95-7bcc-4b54-895c-f290a1364b5c|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Arbitrary U|[?]|1|MBP|SPERMATOZOON|LIGHT SCATTERING SPECTROSCOPY|||1|2|Visit_2|25|3|WASHOUT|2021-01-11|25
e|IS|e0258c95-7bcc-4b54-895c-f290a1364b5c|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|TRANSDUCING UNIT/mL|[?]|1|kPa/L/sec|MECONIUM|CYSTOSCOPY|||1|3|Visit_3|40|6|TREATMENT|2021-01-26|40
e|IS|e0258c95-7bcc-4b54-895c-f290a1364b5c|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Ci/L|[?]|1|ka_u/dL|PLATELET POOR PLASMA|PH METER MEASUREMENT METHOD|||1|4|Visit_4|65|4|WASHOUT|2021-02-20|65
e|IS|e0258c95-7bcc-4b54-895c-f290a1364b5c|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|kg|[?]|1|PACKAGE|URINE SEDIMENT|FLUORESCENT ENZYME IMMUNOASSAY|Y|Y|1|5|Visit_5|90|5|SCREENING|2021-03-17|90
e|IS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|oz|[?]|1|anti-Xa IU|INFRANATANT, SERUM|IMMUNOCHEMILUMINOMETRIC ASSAY|||1|1|Visit_1|10|5|WASHOUT|2021-01-13|10
e|IS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|IMPLANT|[?]|1|ukat/10^12 RBC|SMEGMA|MICRO BROTH DILUTION|||1|2|Visit_2|25|4|SCREENING|2021-01-28|25
e|IS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/beat|[?]|1|vp/mL|CERVICOVAGINAL SECRETION|PULMONARY ANGIOGRAPHY|||1|3|Visit_3|40|3|TREATMENT|2021-02-12|40
e|IS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/kg|[?]|1|copies/ug|SKELETAL MUSCLE TISSUE|GRAM STAIN||Y|1|4|Visit_4|65|4|TREATMENT|2021-03-09|65
e|IS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U.CARR|[?]|1|mL/100g/min|PUS|ZIEHL NEELSEN ACID FAST STAIN|||1|5|Visit_5|90|1|WASHOUT|2021-04-03|90
e|IS|f8c938ff-21c8-4d0b-9335-08d2865543ab|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ft2|[?]|1|nmol/kg/day|LEUKOCYTE|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||1|1|Visit_1|10|3|WASHOUT|2020-05-11|10
e|IS|f8c938ff-21c8-4d0b-9335-08d2865543ab|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|TABLET|[?]|1|V/sec|BONE MARROW MONONUCLEAR CELL|POLYGRAPHY|Y||1|2|Visit_2|25|5|TREATMENT|2020-05-26|25
e|IS|f8c938ff-21c8-4d0b-9335-08d2865543ab|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|VIRTUAL PIXEL|[?]|1|10^5/L|PLEURAL TISSUE|IODINE STAIN|||1|3|Visit_3|40|6|TREATMENT|2020-06-10|40
e|IS|f8c938ff-21c8-4d0b-9335-08d2865543ab|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|AMPULE|[?]|1|log10 PFU|ARTERIAL BLOOD|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|1|4|Visit_4|65|5|TREATMENT|2020-07-05|65
e|IS|f8c938ff-21c8-4d0b-9335-08d2865543ab|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol|[?]|1|mol/mL|TRANSUDATE|MAGNETIC RESONANCE ANGIOGRAPHY|Y|Y|1|5|Visit_5|90|7|SCREENING|2020-07-30|90
e|IS|7176f852-7392-4636-800f-3aad48e93065|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|g/animal|[?]|1|PUFF|MENSTRUAL BLOOD|ICP-MS|||1|1|Visit_1|10|1|WASHOUT|2021-01-16|10
e|IS|7176f852-7392-4636-800f-3aad48e93065|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cal|[?]|1|ug/kg|SUPERNATANT, PLEURAL FLUID|MUGA|||1|2|Visit_2|25|1|TREATMENT|2021-01-31|25
e|IS|7176f852-7392-4636-800f-3aad48e93065|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/LPF|[?]|1|PFU/animal|EPITHELIAL CELL|SANGER SEQUENCING|Y||1|3|Visit_3|40|7|SCREENING|2021-02-15|40
e|IS|7176f852-7392-4636-800f-3aad48e93065|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|g/cage/day|[?]|1|mEq/g|SUPERNATANT, SERUM OR PLASMA|CELLULOSE TAPE|Y|Y|1|4|Visit_4|65|5|TREATMENT|2021-03-12|65
e|IS|7176f852-7392-4636-800f-3aad48e93065|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|breaths/30s|[?]|1|/mm2|MONOCYTE|CONTACT SPECULAR MICROSCOPY|Y||1|5|Visit_5|90|4|TREATMENT|2021-04-06|90
e|IS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mm/h|[?]|1|DIP|LYSATE|KINYOUN STAIN|||1|1|Visit_1|10|2|TREATMENT|2020-10-08|10
e|IS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uCi|[?]|1|uEq/L|SERUM OR PLASMA|OSCILLOMETRY|||1|2|Visit_2|25|7|SCREENING|2020-10-23|25
e|IS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mol/g|[?]|1|mgEq|URINE|MALDI|||1|3|Visit_3|40|3|TREATMENT|2020-11-07|40
e|IS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|%/s|[?]|1|Gauss|SMEGMA|LC/MS|||1|4|Visit_4|65|3|TREATMENT|2020-12-02|65
e|IS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|fg|[?]|1|mL/m2/h|SPUTUM|MULTIPLE BREATH WASHOUT|||1|5|Visit_5|90|3|TREATMENT|2020-12-27|90
e|IS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mmHg|[?]|1|pmol/10^9 cells|SEBUM|PHYSICAL EXAMINATION|||1|1|Visit_1|10|1|TREATMENT|2020-10-28|10
e|IS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Torr|[?]|1|U/g Hb|MUCUS|FUNCTIONAL MRI||Y|1|2|Visit_2|25|1|TREATMENT|2020-11-12|25
e|IS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Roentgen|[?]|1|/10^3|PLATELET RICH PLASMA|TRANSMISSION ELECTRON MICROSCOPY|Y||1|3|Visit_3|40|1|SCREENING|2020-11-27|40
e|IS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^6 CFU/mL|[?]|1|ug/g/day|STRIATED MUSCLE TISSUE|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|1|4|Visit_4|65|5|FOLLOW-UP|2020-12-22|65
e|IS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mV/sec|[?]|1|copies/mL|SALIVA|MICROBIAL CULTURE|||1|5|Visit_5|90|4|TREATMENT|2021-01-16|90
e|IS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|hr/day|[?]|1|ugEq|LOCHIA|WHOLE GENOME SEQUENCING|||1|1|Visit_1|10|7|SCREENING|2020-11-23|10
e|IS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^3 copies/mL|[?]|1|dpm/100mg|MIXED VENOUS BLOOD|PERFUSION MRI||Y|1|2|Visit_2|25|5|TREATMENT|2020-12-08|25
e|IS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Hz|[?]|1|log10 CCID 50/dose|SPERMATOZOON|ACRIDINE ORANGE STAIN|Y|Y|1|3|Visit_3|40|1|TREATMENT|2020-12-23|40
e|IS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|SUPPOSITORY|[?]|1|mL/kg/day|CEREBROSPINAL FLUID|CYSTOSCOPY|||1|4|Visit_4|65|7|SCREENING|2021-01-17|65
e|IS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6 organisms|[?]|1|mL/min|INFRANATANT, PLEURAL FLUID|LYMPHANGIOGRAPHY|||1|5|Visit_5|90|5|FOLLOW-UP|2021-02-11|90
e|IS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^11/L|[?]|1|IU/kg/h|REFLEX TEAR|AUDIOMETRY|||1|1|Visit_1|10|1|TREATMENT|2020-09-26|10
e|IS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^8 PFU|[?]|1|EID 50/dose|ARTERIAL CORD BLOOD|RADIATION DOSIMETRY|||1|2|Visit_2|25|2|TREATMENT|2020-10-11|25
e|IS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mm/sec|[?]|1|Bq/mL|AMNIOTIC FLUID|TRANSMISSION ELECTRON MICROSCOPY||Y|1|3|Visit_3|40|5|TREATMENT|2020-10-26|40
e|IS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MHz|[?]|1|pt_br|BONE MARROW MONONUCLEAR CELL|JAEGER EYE CHART|||1|4|Visit_4|65|2|TREATMENT|2020-11-20|65
e|IS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|INHALATION|[?]|1|SACHET|EMOTIONAL TEAR|CYSTOSCOPY|Y||1|5|Visit_5|90|7|FOLLOW-UP|2020-12-15|90
e|IS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|KIT|[?]|1|IU/L|MUSCLE TISSUE|SPECT SCAN||Y|1|1|Visit_1|10|5|TREATMENT|2021-01-01|10
e|IS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kg/L|[?]|1|DAYS|PLEURAL FLUID|SNP ARRAY|||1|2|Visit_2|25|5|TREATMENT|2021-01-16|25
e|IS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|m|[?]|1|pkat|INFRANATANT, PLEURAL FLUID|SXA SCAN||Y|1|3|Visit_3|40|5|TREATMENT|2021-01-31|40
e|IS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Log10 ELISA unit|[?]|1|10^4/L|DERMAL TISSUE|AUTOREFRACTION||Y|1|4|Visit_4|65|6|TREATMENT|2021-02-25|65
e|IS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SBE/mL|[?]|1|m3|SEBUM|CYSTOMETRY|Y||1|5|Visit_5|90|2|SCREENING|2021-03-22|90
e|IS|dd518f55-0280-445d-a29f-10f09b21fd53|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/wk|[?]|1|Pack Year|PLATELET|TWO-COLOR MICROARRAY|Y||1|1|Visit_1|10|4|TREATMENT|2020-05-18|10
e|IS|dd518f55-0280-445d-a29f-10f09b21fd53|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/day|[?]|1|mmol|CAPILLARY BLOOD|INCISION-INDUCED BLEEDING METHOD|||1|2|Visit_2|25|3|TREATMENT|2020-06-02|25
e|IS|dd518f55-0280-445d-a29f-10f09b21fd53|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 organisms/g|[?]|1|DAYS|EXPIRED AIR|FLUORESCENT IMMUNOASSAY|Y||1|3|Visit_3|40|6|TREATMENT|2020-06-17|40
e|IS|dd518f55-0280-445d-a29f-10f09b21fd53|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GBq|[?]|1|ug/m2|URINE|HANSEL STAIN|Y|Y|1|4|Visit_4|65|2|SCREENING|2020-07-12|65
e|IS|dd518f55-0280-445d-a29f-10f09b21fd53|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|U.CARR|[?]|1|SPRAY|MONOCYTE|SIZE EXCLUSION CHROMATOGRAPHY||Y|1|5|Visit_5|90|6|WASHOUT|2020-08-06|90
e|IS|49a972da-dfad-438e-b5bc-26ee6b955a59|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PUFF|[?]|1|atm|GASTRIC CONTENTS|GIEMSA STAIN|||1|1|Visit_1|10|3|TREATMENT|2020-06-24|10
e|IS|49a972da-dfad-438e-b5bc-26ee6b955a59|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|vg/mL|[?]|1|ag|INTERSTITIAL FLUID|AURAMINE STAIN|||1|2|Visit_2|25|6|TREATMENT|2020-07-09|25
e|IS|49a972da-dfad-438e-b5bc-26ee6b955a59|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 CFU/g|[?]|1|kPa/L/sec|FLUID|SCANNING ELECTRON MICROSCOPY|Y||1|3|Visit_3|40|7|WASHOUT|2020-07-24|40
e|IS|49a972da-dfad-438e-b5bc-26ee6b955a59|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PLUG|[?]|1|mL/breath|HAIR FOLLICLE|LIGHT SCATTERING SPECTROSCOPY|||1|4|Visit_4|65|6|TREATMENT|2020-08-18|65
e|IS|49a972da-dfad-438e-b5bc-26ee6b955a59|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|log10 CCID 50/dose|[?]|1|/2500 WBC|TISSUE|IHC||Y|1|5|Visit_5|90|1|FOLLOW-UP|2020-09-12|90
e|IS|502a42a7-2ed6-46b9-9b10-728f849334b6|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|APL U|[?]|1|kg|INFRANATANT, SERUM|MICRONEUTRALIZATION ASSAY|||1|1|Visit_1|10|4|TREATMENT|2020-11-21|10
e|IS|502a42a7-2ed6-46b9-9b10-728f849334b6|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/mg|[?]|1|U/mmol|SPUTUM|RADIATION DOSIMETRY|||1|2|Visit_2|25|1|TREATMENT|2020-12-06|25
e|IS|502a42a7-2ed6-46b9-9b10-728f849334b6|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol/g|[?]|1|VIRTUAL PIXEL|EMOTIONAL TEAR|SLOAN LETTER EYE CHART 100%||Y|1|3|Visit_3|40|6|WASHOUT|2020-12-21|40
e|IS|502a42a7-2ed6-46b9-9b10-728f849334b6|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|pmol/10^10 cells|[?]|1|mEq/L|MUCUS|FLUORESCENT ENZYME IMMUNOASSAY|Y||1|4|Visit_4|65|6|TREATMENT|2021-01-15|65
e|IS|502a42a7-2ed6-46b9-9b10-728f849334b6|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Enzyme U|[?]|1|mEq/mL|EPIDERMAL TISSUE|DIFFUSION TENSOR MRI|||1|5|Visit_5|90|5|SCREENING|2021-02-09|90
e|IS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol/g|[?]|1|cm/s|LYMPH|ANTIMICROBIAL COMBINATION TESTING|||1|1|Visit_1|10|1|TREATMENT|2020-10-26|10
e|IS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kHz|[?]|1|/HPF|LEUKOCYTE|LASER CAPTURE MICRODISSECTION|Y||1|2|Visit_2|25|7|TREATMENT|2020-11-10|25
e|IS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|APL U|[?]|1|ug/g/day|BILE|PET/SPECT SCAN||Y|1|3|Visit_3|40|5|FOLLOW-UP|2020-11-25|40
e|IS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|g|[?]|1|/200 HPFs|INTERSTITIAL FLUID|CT SCAN WITHOUT CONTRAST|||1|4|Visit_4|65|1|FOLLOW-UP|2020-12-20|65
e|IS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|deg/s|[?]|1|umol/kg/min|BONE MARROW MONONUCLEAR CELL|CONTRAST ENHANCED MRI|||1|5|Visit_5|90|7|TREATMENT|2021-01-14|90
e|IS|40c048ea-d637-426b-8afe-2da3a6961528|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/mL/h|[?]|1|IU/kg/h|CORD SERUM|ANTIBIOTIC AGAR SCREEN|||1|1|Visit_1|10|5|TREATMENT|2020-07-13|10
e|IS|40c048ea-d637-426b-8afe-2da3a6961528|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mmHg/sec|[?]|1|mg/mL/min|BONE|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y||1|2|Visit_2|25|7|FOLLOW-UP|2020-07-28|25
e|IS|40c048ea-d637-426b-8afe-2da3a6961528|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uV|[?]|1|mg/m2/day|EXUDATE|MAGNETIC RESONANCE ENTEROGRAPHY||Y|1|3|Visit_3|40|5|SCREENING|2020-08-12|40
e|IS|40c048ea-d637-426b-8afe-2da3a6961528|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mEq/day|[?]|1|SPRAY|EXPIRED AIR|CONGO RED STAIN||Y|1|4|Visit_4|65|1|WASHOUT|2020-09-06|65
e|IS|40c048ea-d637-426b-8afe-2da3a6961528|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|TAMPON|[?]|1|mL/min|SUPERNATANT, PLASMA|HIGH RESOLUTION CT|||1|5|Visit_5|90|5|WASHOUT|2020-10-01|90
e|IS|4d03b209-bd53-47f5-8251-f9fb2074bc38|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^4 CFU|[?]|1|10^11/L|BUFFY COAT|IRON HEMATOXYLIN STAIN||Y|1|1|Visit_1|10|5|FOLLOW-UP|2021-01-02|10
e|IS|4d03b209-bd53-47f5-8251-f9fb2074bc38|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mV|[?]|1|10^3 CFU/mL|INFRANATANT, SERUM|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||1|2|Visit_2|25|5|TREATMENT|2021-01-17|25
e|IS|4d03b209-bd53-47f5-8251-f9fb2074bc38|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|DNA copies/mL|[?]|1|PFU|EPITHELIAL CELL|CELLULAR PROLIFERATION ASSAY||Y|1|3|Visit_3|40|1|WASHOUT|2021-02-01|40
e|IS|4d03b209-bd53-47f5-8251-f9fb2074bc38|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/cage|[?]|1|nkat/L|MIXED VENOUS BLOOD|MUGA|Y||1|4|Visit_4|65|6|TREATMENT|2021-02-26|65
e|IS|4d03b209-bd53-47f5-8251-f9fb2074bc38|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PLUG|[?]|1|GBq|CAPILLARY PLASMA|FLUORESCENCE ANGIOGRAPHY||Y|1|5|Visit_5|90|5|WASHOUT|2021-03-23|90
e|IS|35f01eda-1acb-4700-8285-c8cd4b69b524|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|F|[?]|1|mU/g|MECONIUM|ELECTRICAL IMPEDANCE MYOGRAPHY||Y|1|1|Visit_1|10|6|SCREENING|2020-09-30|10
e|IS|35f01eda-1acb-4700-8285-c8cd4b69b524|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|umol/min|[?]|1|g/mol|PERITONEAL FLUID|PET/MRI SCAN|||1|2|Visit_2|25|7|TREATMENT|2020-10-15|25
e|IS|35f01eda-1acb-4700-8285-c8cd4b69b524|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Hounsfield Unit|[?]|1|HEP|LUNG SURFACTANT|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|3|Visit_3|40|5|SCREENING|2020-10-30|40
e|IS|35f01eda-1acb-4700-8285-c8cd4b69b524|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/m2/day|[?]|1|/7.5 mL|LAVAGE FLUID|ELLA|||1|4|Visit_4|65|3|TREATMENT|2020-11-24|65
e|IS|35f01eda-1acb-4700-8285-c8cd4b69b524|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^9 CFU/mL|[?]|1|fmol|SERUM OR PLASMA|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||1|5|Visit_5|90|7|FOLLOW-UP|2020-12-19|90
e|IS|9df97277-7d07-4020-bae0-dfa982f21c8d|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|deg2|[?]|1|cy/cm|STOOL|CLOT DETECTION||Y|1|1|Visit_1|10|4|FOLLOW-UP|2020-11-02|10
e|IS|9df97277-7d07-4020-bae0-dfa982f21c8d|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kg/L|[?]|1|IU|SUPERNATANT, SERUM|APPLANATION TONOMETRY||Y|1|2|Visit_2|25|1|TREATMENT|2020-11-17|25
e|IS|9df97277-7d07-4020-bae0-dfa982f21c8d|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^4/L|[?]|1|10^6 IU|CERUMEN|PHOTOGRAPHY|||1|3|Visit_3|40|7|WASHOUT|2020-12-02|40
e|IS|9df97277-7d07-4020-bae0-dfa982f21c8d|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mEq/dL|[?]|1|ng|ADIPOSE TISSUE|RAJI CELL RIA|||1|4|Visit_4|65|2|TREATMENT|2020-12-27|65
e|IS|9df97277-7d07-4020-bae0-dfa982f21c8d|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|hPa|[?]|1|mU/L|PLATELET RICH PLASMA|MAGNETIC RESONANCE ELASTOGRAPHY|||1|5|Visit_5|90|3|FOLLOW-UP|2021-01-21|90
e|IS|d1b522d5-557a-4361-a9da-292aa601fbc3|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/2000 RBC|[?]|1|10^4/L|BONE|TEMPLATE INCISION METHOD|||1|1|Visit_1|10|2|TREATMENT|2020-10-09|10
e|IS|d1b522d5-557a-4361-a9da-292aa601fbc3|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|U/g Hb|[?]|1|g|ATHEROSCLEROTIC PLAQUE|APPLANATION TONOMETRY||Y|1|2|Visit_2|25|2|SCREENING|2020-10-24|25
e|IS|d1b522d5-557a-4361-a9da-292aa601fbc3|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/mmHg|[?]|1|mAnson U/mL|DIALYSIS FLUID, PERITONEAL|RAJI CELL EIA|||1|3|Visit_3|40|3|WASHOUT|2020-11-08|40
e|IS|d1b522d5-557a-4361-a9da-292aa601fbc3|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Log10 ELISA unit/dose|[?]|1|cpm|SYNOVIAL FLUID|WESTERN BLOT|||1|4|Visit_4|65|6|FOLLOW-UP|2020-12-03|65
e|IS|d1b522d5-557a-4361-a9da-292aa601fbc3|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kcal|[?]|1|nmol BCE/mmol|INFRANATANT, SERUM|THICK SMEAR|Y||1|5|Visit_5|90|5|WASHOUT|2020-12-28|90
e|IS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/kg/week|[?]|1|/40 HPFs|SKELETAL MUSCLE TISSUE|FISH|||1|1|Visit_1|10|3|TREATMENT|2020-07-27|10
e|IS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MBP|[?]|1|ug/h|LUNG SURFACTANT|IRON HEMATOXYLIN STAIN|||1|2|Visit_2|25|7|TREATMENT|2020-08-11|25
e|IS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Osm|[?]|1|ug|LUNG SURFACTANT|SNELLEN EYE CHART|Y|Y|1|3|Visit_3|40|2|TREATMENT|2020-08-26|40
e|IS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/g/day|[?]|1|ppm|CAPILLARY PLASMA|IMPULSE OSCILLOMETRY|Y||1|4|Visit_4|65|4|TREATMENT|2020-09-20|65
e|IS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ppb|[?]|1|CFU/g|CAPILLARY BLOOD|FARNSWORTH-MUNSELL 100 HUE TEST|||1|5|Visit_5|90|5|TREATMENT|2020-10-15|90
e|IS|da2d0844-3608-4927-9103-cb7c52dd2c96|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/cage|[?]|1|BOWL|MUSCLE TISSUE|COLORIMETRY|Y||1|1|Visit_1|10|3|WASHOUT|2021-01-26|10
e|IS|da2d0844-3608-4927-9103-cb7c52dd2c96|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ngEq/L|[?]|1|ng/mol|SMOOTH MUSCLE TISSUE|FARNSWORTH-MUNSELL 100 HUE TEST|||1|2|Visit_2|25|2|FOLLOW-UP|2021-02-10|25
e|IS|da2d0844-3608-4927-9103-cb7c52dd2c96|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|WEEKS|[?]|1|F|VITREOUS HUMOR|ISHIHARA COLOR PLATES|||1|3|Visit_3|40|2|WASHOUT|2021-02-25|40
e|IS|da2d0844-3608-4927-9103-cb7c52dd2c96|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mph|[?]|1|umol/L/sec|PERSPIRATION|SEQUENCING||Y|1|4|Visit_4|65|2|TREATMENT|2021-03-22|65
e|IS|da2d0844-3608-4927-9103-cb7c52dd2c96|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|fmol|[?]|1|ug/dL|LAVAGE FLUID|MICROPARTICLE ENZYME IMMUNOASSAY|||1|5|Visit_5|90|3|TREATMENT|2021-04-16|90
e|IS|30b6f8a7-4512-462d-a162-45c3dad853e5|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Gy|[?]|1|MBq/uL|TRANSUDATE|ECHOCARDIOGRAPHY|||1|1|Visit_1|10|1|WASHOUT|2020-12-02|10
e|IS|30b6f8a7-4512-462d-a162-45c3dad853e5|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|pptr|[?]|1|dB|MONOCYTE|AUTOMATED COUNT|Y||1|2|Visit_2|25|5|WASHOUT|2020-12-17|25
e|IS|30b6f8a7-4512-462d-a162-45c3dad853e5|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ugEq/L|[?]|1|PIPE|ALVEOLAR AIR|GC/MS/MS|||1|3|Visit_3|40|3|TREATMENT|2021-01-01|40
e|IS|30b6f8a7-4512-462d-a162-45c3dad853e5|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|damol/L|[?]|1|ks|CERVICOVAGINAL SECRETION|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||1|4|Visit_4|65|1|TREATMENT|2021-01-26|65
e|IS|30b6f8a7-4512-462d-a162-45c3dad853e5|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/mmHg|[?]|1|g/g/day|STOOL|GRAM STAIN|||1|5|Visit_5|90|3|SCREENING|2021-02-20|90
e|IS|1a3808b9-6004-4133-8f59-49905d04655e|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol/10^10 cells|[?]|1|mV2/Hz|COLOSTRUM|CAPILLARY ELECTROPHORESIS|||1|1|Visit_1|10|5|SCREENING|2020-11-07|10
e|IS|1a3808b9-6004-4133-8f59-49905d04655e|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uSiemens|[?]|1|uIU/dL|DISCHARGE|MICROBIAL CULTURE, LIQUID||Y|1|2|Visit_2|25|5|FOLLOW-UP|2020-11-22|25
e|IS|1a3808b9-6004-4133-8f59-49905d04655e|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/g/day|[?]|1|cmH2O*s/mL|GASTRIC FLUID|CELL BASED BIOASSAY||Y|1|3|Visit_3|40|2|TREATMENT|2020-12-07|40
e|IS|1a3808b9-6004-4133-8f59-49905d04655e|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/HPF|[?]|1|kat|PERSPIRATION|LC/MS/MS|||1|4|Visit_4|65|3|TREATMENT|2021-01-01|65
e|IS|1a3808b9-6004-4133-8f59-49905d04655e|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Log10 ELISA unit|[?]|1|uIU/dL|ALVEOLAR AIR|GC/MS-CI||Y|1|5|Visit_5|90|4|TREATMENT|2021-01-26|90
e|IS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/day|[?]|1|DAgU|EPIDERMAL TISSUE|WHOLE TRANSCRIPTOME SEQUENCING|||1|1|Visit_1|10|1|TREATMENT|2021-01-19|10
e|IS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^5/hpf|[?]|1|Sv|SERUM|TARGETED GENOME SEQUENCING|Y||1|2|Visit_2|25|6|TREATMENT|2021-02-03|25
e|IS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/kg/week|[?]|1|v/v|VENOUS PLASMA|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||1|3|Visit_3|40|3|SCREENING|2021-02-18|40
e|IS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^9 CFU/g|[?]|1|um|GASTRIC CONTENTS|SLOAN LETTER EYE CHART 100%|||1|4|Visit_4|65|6|FOLLOW-UP|2021-03-15|65
e|IS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cm|[?]|1|mEq/mmol|PLATELET|MULTIPLE BREATH WASHOUT|||1|5|Visit_5|90|2|FOLLOW-UP|2021-04-09|90
e|IS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|RATIO|[?]|1|mg/L|EMOTIONAL TEAR|DUCTOGRAPHY|||1|1|Visit_1|10|1|WASHOUT|2020-07-15|10
e|IS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PACKET|[?]|1|OI50|MONOCYTE|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||1|2|Visit_2|25|1|FOLLOW-UP|2020-07-30|25
e|IS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug|[?]|1|10^9 organisms|CELL PELLET|AMSLER GRID|||1|3|Visit_3|40|1|SCREENING|2020-08-14|40
e|IS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmol/L|[?]|1|mL/100g/min|LUNG SURFACTANT|SXA SCAN|||1|4|Visit_4|65|3|FOLLOW-UP|2020-09-08|65
e|IS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|%|[?]|1|nmol BCE/L|EMESIS|FLUORIMETRY|||1|5|Visit_5|90|6|TREATMENT|2020-10-03|90
e|IS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|U/m2/day|[?]|1|mg/kg/min|LYSATE|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|1|1|Visit_1|10|2|TREATMENT|2020-09-15|10
e|IS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|eq|[?]|1|10^8 PFU|MUCUS|RIA|Y|Y|1|2|Visit_2|25|3|TREATMENT|2020-09-30|25
e|IS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Bq/L|[?]|1|BOLUS|SEMINAL FLUID|SPIROMETRY|||1|3|Visit_3|40|3|TREATMENT|2020-10-15|40
e|IS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|kBq|[?]|1|SUPPOSITORY|SUPERNATANT, SERUM OR PLASMA|DOPPLER ULTRASOUND|||1|4|Visit_4|65|3|FOLLOW-UP|2020-11-09|65
e|IS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/dose|[?]|1|uCi|LEUKOCYTE|INDIA INK STAIN|||1|5|Visit_5|90|7|TREATMENT|2020-12-04|90
e|IS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|%/min|[?]|1|APPLICATION|MUSCLE TISSUE|HIGH RESOLUTION MELT ANALYSIS|||1|1|Visit_1|10|2|TREATMENT|2020-06-10|10
e|IS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/dL|[?]|1|U/animal|CALCULUS|OPTICAL DENSITY MEASUREMENT|Y||1|2|Visit_2|25|7|TREATMENT|2020-06-25|25
e|IS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Farad|[?]|1|PFU/dose|WHITE MATTER TISSUE|PERCUSSION|Y||1|3|Visit_3|40|7|TREATMENT|2020-07-10|40
e|IS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|PNU/mL|[?]|1|ug/kg|ARTERIAL CORD BLOOD|ZIEHL NEELSEN ACID FAST STAIN|||1|4|Visit_4|65|5|TREATMENT|2020-08-04|65
e|IS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/m2/day|[?]|1|mL/m2/min|TISSUE|QUANTITATIVE ULTRASOUND|||1|5|Visit_5|90|6|TREATMENT|2020-08-29|90
e|IS|37610314-f803-4ffa-a584-ebfe09267a0d|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MET|[?]|1|BAU|SKELETAL MUSCLE TISSUE|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|1|Visit_1|10|1|TREATMENT|2020-06-30|10
e|IS|37610314-f803-4ffa-a584-ebfe09267a0d|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/breath|[?]|1|VOXEL|SMOOTH MUSCLE TISSUE|CLAUSS METHOD|||1|2|Visit_2|25|5|TREATMENT|2020-07-15|25
e|IS|37610314-f803-4ffa-a584-ebfe09267a0d|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mEq/kg|[?]|1|mV/sec|VENOUS CORD BLOOD|CINEANGIOGRAPHY|||1|3|Visit_3|40|2|TREATMENT|2020-07-30|40
e|IS|37610314-f803-4ffa-a584-ebfe09267a0d|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/kg/min|[?]|1|mg2/dL2|SYNOVIAL FLUID|AURAMINE STAIN|||1|4|Visit_4|65|2|WASHOUT|2020-08-24|65
e|IS|37610314-f803-4ffa-a584-ebfe09267a0d|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|lx|[?]|1|GBq/ug|CELL PELLET|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||1|5|Visit_5|90|5|SCREENING|2020-09-18|90
e|IS|760ec5ce-3ae7-4268-9f76-b83085ad3754|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 PFU|[?]|1|ft|EMOTIONAL TEAR|REFLECTANCE SPECTROSCOPY|Y||1|1|Visit_1|10|1|TREATMENT|2020-09-24|10
e|IS|760ec5ce-3ae7-4268-9f76-b83085ad3754|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|nkat/g Hb|[?]|1|PACKAGE|URINE|BIOPSY|Y|Y|1|2|Visit_2|25|1|TREATMENT|2020-10-09|25
e|IS|760ec5ce-3ae7-4268-9f76-b83085ad3754|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 CFU/g|[?]|1|ukat/L|PUS|MALDI||Y|1|3|Visit_3|40|4|FOLLOW-UP|2020-10-24|40
e|IS|760ec5ce-3ae7-4268-9f76-b83085ad3754|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|SQU/mL|[?]|1|U/10^12 RBC|SEMINAL FLUID|REFLECTANCE SPECTROSCOPY|||1|4|Visit_4|65|7|FOLLOW-UP|2020-11-18|65
e|IS|760ec5ce-3ae7-4268-9f76-b83085ad3754|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kcal/day|[?]|1|FINGERTIP UNIT|DERMAL TISSUE|MICRODENSITOMETRY|||1|5|Visit_5|90|4|WASHOUT|2020-12-13|90
e|IS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mEq|[?]|1|nmol/kg/day|BONE MARROW|IMMUNOFLUORESCENT STAIN|||1|1|Visit_1|10|5|WASHOUT|2020-06-15|10
e|IS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IMPLANT|[?]|1|CAN|FLUID|ICP-MS|||1|2|Visit_2|25|4|WASHOUT|2020-06-30|25
e|IS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mPa|[?]|1|10^6 organisms/mL|CERVICOVAGINAL SECRETION|RAJI CELL EIA|||1|3|Visit_3|40|7|SCREENING|2020-07-15|40
e|IS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nmol/L/min|[?]|1|10^6 CFU/g|MUSCLE TISSUE|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|4|Visit_4|65|1|TREATMENT|2020-08-09|65
e|IS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|breaths/min|[?]|1|CAPLET|CALCULUS|AURAMINE STAIN|||1|5|Visit_5|90|6|TREATMENT|2020-09-03|90
e|IS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|MPL U/mL|[?]|1|IU/kg|INFRANATANT, PLASMA|CONGO RED STAIN|||1|1|Visit_1|10|7|WASHOUT|2021-01-24|10
e|IS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pg/cell|[?]|1|dram|BUFFY COAT|WHOLE GENOME SEQUENCING|||1|2|Visit_2|25|6|TREATMENT|2021-02-08|25
e|IS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmol|[?]|1|g/day|PLASMA ULTRAFILTRATE|ANTIMICROBIAL COMBINATION TESTING|Y||1|3|Visit_3|40|4|SCREENING|2021-02-23|40
e|IS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^4/L|[?]|1|mL/(min*100mL)|SEMEN|OSCILLOMETRY|Y||1|4|Visit_4|65|3|TREATMENT|2021-03-20|65
e|IS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|%(w/w)|[?]|1|m|MENSTRUAL BLOOD|CLIP|Y|Y|1|5|Visit_5|90|4|TREATMENT|2021-04-14|90
e|IS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|log10 PFU|[?]|1|/10^3|PLASMA|HANSEL STAIN|||1|1|Visit_1|10|1|FOLLOW-UP|2020-11-13|10
e|IS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|gMFI|[?]|1|log10 TCID 50/uL|BILE|HPLC-UV|||1|2|Visit_2|25|4|WASHOUT|2020-11-28|25
e|IS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PIXELS/in|[?]|1|MBq|EXUDATE|PEAK FLOWMETRY|||1|3|Visit_3|40|2|TREATMENT|2020-12-13|40
e|IS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|CONTAINER|[?]|1|Shock Wave|SKELETAL MUSCLE TISSUE|NEPHELOMETRY|Y||1|4|Visit_4|65|6|TREATMENT|2021-01-07|65
e|IS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|IU/mg|[?]|1|oz|TUMOR TISSUE|FLUORESCENT MICROSCOPY|||1|5|Visit_5|90|2|TREATMENT|2021-02-01|90
e|IS|d7b41e15-6725-4433-8a35-72629e342b47|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ukat/10^12 RBC|[?]|1|Gy/h|PUS|MICRONEUTRALIZATION ASSAY|Y||1|1|Visit_1|10|2|FOLLOW-UP|2020-09-14|10
e|IS|d7b41e15-6725-4433-8a35-72629e342b47|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Arbitrary U|[?]|1|um|SMOOTH MUSCLE TISSUE|NEXT GENERATION SEQUENCING|Y||1|2|Visit_2|25|3|FOLLOW-UP|2020-09-29|25
e|IS|d7b41e15-6725-4433-8a35-72629e342b47|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|deg/s|SERUM|RYAN BLUE STAIN||Y|1|3|Visit_3|40|2|WASHOUT|2020-10-14|40
e|IS|d7b41e15-6725-4433-8a35-72629e342b47|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ng/dL|[?]|1|DNA copies/mL|CARDIAC MUSCLE TISSUE|FLOCCULATION|||1|4|Visit_4|65|1|SCREENING|2020-11-08|65
e|IS|d7b41e15-6725-4433-8a35-72629e342b47|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/mL/h|[?]|1|mL/kg/day|SKELETAL MUSCLE TISSUE|CELL OF ORIGIN ASSAY|||1|5|Visit_5|90|7|TREATMENT|2020-12-03|90
e|IS|aeddc1ed-545c-405e-b1f7-08131961f5ff|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/m2/day|[?]|1|IU/mg|LAVAGE FLUID|JAEGER EYE CHART|||1|1|Visit_1|10|6|FOLLOW-UP|2020-10-15|10
e|IS|aeddc1ed-545c-405e-b1f7-08131961f5ff|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^7 PFU|[?]|1|L/h/m2|CORD BLOOD|CELLULAR PROLIFERATION ASSAY|||1|2|Visit_2|25|3|TREATMENT|2020-10-30|25
e|IS|aeddc1ed-545c-405e-b1f7-08131961f5ff|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|sec|[?]|1|vg/kg|CERUMEN|IMMUNOFIXATION ELECTROPHORESIS|||1|3|Visit_3|40|2|SCREENING|2020-11-14|40
e|IS|aeddc1ed-545c-405e-b1f7-08131961f5ff|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ugEq/L|[?]|1|mg/dose|PLEURAL FLUID|MEDIASTINOSCOPY|Y||1|4|Visit_4|65|1|TREATMENT|2020-12-09|65
e|IS|aeddc1ed-545c-405e-b1f7-08131961f5ff|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|L/min|[?]|1|umol/day|STOOL|LASER CAPTURE MICRODISSECTION|||1|5|Visit_5|90|7|SCREENING|2021-01-03|90
e|IS|3effe272-6a68-4163-a4f3-bd269af6061c|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/L/min|[?]|1|pg/dL|BONE|IMMUNOFIXATION ELECTROPHORESIS|||1|1|Visit_1|10|5|FOLLOW-UP|2021-01-15|10
e|IS|3effe272-6a68-4163-a4f3-bd269af6061c|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|log10 PFU/mL|[?]|1|10^3 organisms/mL|ISOLATE|DXA SCAN|||1|2|Visit_2|25|1|TREATMENT|2021-01-30|25
e|IS|3effe272-6a68-4163-a4f3-bd269af6061c|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|dL|[?]|1|Bq/uL|SUPERNATANT, PLEURAL FLUID|PHASE-CONTRAST MRI|||1|3|Visit_3|40|2|SCREENING|2021-02-14|40
e|IS|3effe272-6a68-4163-a4f3-bd269af6061c|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mEq/mmol|[?]|1|vg/mL|MONOCYTE|ANTIMICROBIAL COMBINATION TESTING|||1|4|Visit_4|65|1|TREATMENT|2021-03-11|65
e|IS|3effe272-6a68-4163-a4f3-bd269af6061c|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|fmol|[?]|1|Ci/kg|PERSPIRATION|PATHOLOGICAL EVALUATION|||1|5|Visit_5|90|7|SCREENING|2021-04-05|90
e|IS|8153c765-a92a-4b0f-9ef3-6ca925337f54|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|tuberculin unit|[?]|1|umol/day|SYNOVIAL FLUID|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||1|1|Visit_1|10|7|SCREENING|2020-09-29|10
e|IS|8153c765-a92a-4b0f-9ef3-6ca925337f54|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|uEq|[?]|1|ms2|ATHEROSCLEROTIC PLAQUE|SANGER SEQUENCING|||1|2|Visit_2|25|2|TREATMENT|2020-10-14|25
e|IS|8153c765-a92a-4b0f-9ef3-6ca925337f54|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mkat|[?]|1|Hz/s|CARDIAC MUSCLE TISSUE|REFRACTOMETRY|||1|3|Visit_3|40|1|TREATMENT|2020-10-29|40
e|IS|8153c765-a92a-4b0f-9ef3-6ca925337f54|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|deg|[?]|1|MET*min|SUPERNATANT, CEREBROSPINAL FLUID|INDIRECT IMMUNOFLUORESCENCE|Y||1|4|Visit_4|65|2|TREATMENT|2020-11-23|65
e|IS|8153c765-a92a-4b0f-9ef3-6ca925337f54|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|POINT|[?]|1|MASK|BREAST MILK|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||1|5|Visit_5|90|1|TREATMENT|2020-12-18|90
e|IS|8d27cdcf-768e-4630-95b5-da554f6f3b56|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|L/kg|[?]|1|uU/dL|BASAL TEAR|FLOCCULATION, CHARCOAL ENHANCED|Y|Y|1|1|Visit_1|10|6|FOLLOW-UP|2020-10-30|10
e|IS|8d27cdcf-768e-4630-95b5-da554f6f3b56|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|log10 PFU|[?]|1|uV|SKIN TISSUE|OPHTHALMOSCOPY||Y|1|2|Visit_2|25|5|TREATMENT|2020-11-14|25
e|IS|8d27cdcf-768e-4630-95b5-da554f6f3b56|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/kg|[?]|1|deg|BONE MARROW|MRI||Y|1|3|Visit_3|40|2|SCREENING|2020-11-29|40
e|IS|8d27cdcf-768e-4630-95b5-da554f6f3b56|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^4/hpf|[?]|1|SCOOPFUL|SEBUM|WHOLE TRANSCRIPTOME SEQUENCING|||1|4|Visit_4|65|1|TREATMENT|2020-12-24|65
e|IS|8d27cdcf-768e-4630-95b5-da554f6f3b56|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/mL/min|[?]|1|mph|SKIN TISSUE|OLIGO ACGH|||1|5|Visit_5|90|3|SCREENING|2021-01-18|90
e|IS|5c2791ff-aaf6-413f-9827-6e97e2273388|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|FEU|[?]|1|mmol|MENSTRUAL BLOOD|RADIOIMMUNOPRECIPITATION ASSAY|||1|1|Visit_1|10|5|SCREENING|2020-09-06|10
e|IS|5c2791ff-aaf6-413f-9827-6e97e2273388|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|IU/mmol|[?]|1|10^3 CFU|PERIPHERAL BLOOD MONONUCLEAR CELL|ULTRASOUND|||1|2|Visit_2|25|5|TREATMENT|2020-09-21|25
e|IS|5c2791ff-aaf6-413f-9827-6e97e2273388|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/g/day|[?]|1|mm|STOOL|ETDRS EYE CHART|Y||1|3|Visit_3|40|4|WASHOUT|2020-10-06|40
e|IS|5c2791ff-aaf6-413f-9827-6e97e2273388|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|%(v/v)|CAPILLARY PLASMA|MAGNETIC RESONANCE ANGIOGRAPHY|||1|4|Visit_4|65|3|SCREENING|2020-10-31|65
e|IS|5c2791ff-aaf6-413f-9827-6e97e2273388|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^3/L|[?]|1|10^3 RNA copies/mL|CAPILLARY PLASMA|CELL BASED BIOASSAY|||1|5|Visit_5|90|3|SCREENING|2020-11-25|90
e|IS|b336d8c2-7bca-404e-aea3-5148d559ea99|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mAnson U/mL|[?]|1|Absorbance U/mL|SMOOTH MUSCLE TISSUE|SCINTIGRAPHY|Y||1|1|Visit_1|10|1|SCREENING|2020-09-19|10
e|IS|b336d8c2-7bca-404e-aea3-5148d559ea99|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Bq|[?]|1|Ci/L|SEBUM|WRIGHT-GIEMSA STAIN|||1|2|Visit_2|25|3|WASHOUT|2020-10-04|25
e|IS|b336d8c2-7bca-404e-aea3-5148d559ea99|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL|[?]|1|g/cm2|PERSPIRATION|PANENDOSCOPY|Y||1|3|Visit_3|40|4|SCREENING|2020-10-19|40
e|IS|b336d8c2-7bca-404e-aea3-5148d559ea99|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PFU|[?]|1|mg/L FEU|SUPERNATANT, PLEURAL FLUID|IMMUNOPRECIPITATION|||1|4|Visit_4|65|3|TREATMENT|2020-11-13|65
e|IS|b336d8c2-7bca-404e-aea3-5148d559ea99|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|psec|[?]|1|mOsm/kg|MECONIUM|REBOUND TONOMETRY|||1|5|Visit_5|90|2|TREATMENT|2020-12-08|90
e|IS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|DAgU|[?]|1|POUCH|SMEGMA|MAGNETIC RESONANCE ELASTOGRAPHY|Y|Y|1|1|Visit_1|10|3|TREATMENT|2020-06-17|10
e|IS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mm/2h|[?]|1|mm|SMEGMA|MUGA|||1|2|Visit_2|25|4|TREATMENT|2020-07-02|25
e|IS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^12 IU/L|[?]|1|ng/dL|PERSPIRATION|ISHIHARA COLOR PLATES||Y|1|3|Visit_3|40|1|FOLLOW-UP|2020-07-17|40
e|IS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/m2/min|[?]|1|kg/m2|SPUTUM|FUNDUS PHOTOGRAPHY|||1|4|Visit_4|65|5|TREATMENT|2020-08-11|65
e|IS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|DIOPTER|[?]|1|cycle/min|BASAL TEAR|VIRUS PLAQUE ASSAY|||1|5|Visit_5|90|4|TREATMENT|2020-09-05|90
e|IS|1261eee1-f073-4419-b0b7-28abd0ec1513|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kg/mol|[?]|1|mCi/kg|MUSCLE TISSUE|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y|1|1|Visit_1|10|5|FOLLOW-UP|2020-10-01|10
e|IS|1261eee1-f073-4419-b0b7-28abd0ec1513|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ng/L|[?]|1|log10 CCID 50/dose|KERATINOCYTE|AUTOREFRACTION|||1|2|Visit_2|25|5|WASHOUT|2020-10-16|25
e|IS|1261eee1-f073-4419-b0b7-28abd0ec1513|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cmol|[?]|1|cg|SOFT TISSUE|ALCIAN BLUE STAIN|Y||1|3|Visit_3|40|5|SCREENING|2020-10-31|40
e|IS|1261eee1-f073-4419-b0b7-28abd0ec1513|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|kN/cm2|[?]|1|dB|PLASMA ULTRAFILTRATE|CONTRAST ENHANCED SPIRAL CT SCAN|||1|4|Visit_4|65|4|TREATMENT|2020-11-25|65
e|IS|1261eee1-f073-4419-b0b7-28abd0ec1513|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/kg|[?]|1|L/h/m2|VENOUS BLOOD|SLIT LAMP||Y|1|5|Visit_5|90|4|TREATMENT|2020-12-20|90
e|IS|46eefdf3-c314-4e61-963c-ce7f48c636e5|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ukat/10^12 RBC|[?]|1|uU/dL|MUSCLE TISSUE|SPECT/CT SCAN|||1|1|Visit_1|10|1|TREATMENT|2020-12-29|10
e|IS|46eefdf3-c314-4e61-963c-ce7f48c636e5|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nmol/g|[?]|1|PACKET|CAPILLARY PLASMA|DIFFUSION WEIGHTED MRI|||1|2|Visit_2|25|7|WASHOUT|2021-01-13|25
e|IS|46eefdf3-c314-4e61-963c-ce7f48c636e5|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/10^3|[?]|1|10^3 DNA copies/mL|CEREBROSPINAL FLUID|WEBER GREEN STAIN|||1|3|Visit_3|40|4|TREATMENT|2021-01-28|40
e|IS|46eefdf3-c314-4e61-963c-ce7f48c636e5|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^9 CFU|[?]|1|mL/kg/min|VENOUS PLASMA|RADIOGRAPHY||Y|1|4|Visit_4|65|5|TREATMENT|2021-02-22|65
e|IS|46eefdf3-c314-4e61-963c-ce7f48c636e5|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|BAU/mL|[?]|1|OD Unit|SUPERNATANT, PLASMA|WRIGHT-GIEMSA STAIN|Y||1|5|Visit_5|90|1|TREATMENT|2021-03-19|90
e|IS|f632159b-8c91-4f0d-81cb-e5b9195588c9|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MBP|[?]|1|mCi|URINE|FLUOROSCOPY|Y||1|1|Visit_1|10|1|TREATMENT|2021-01-12|10
e|IS|f632159b-8c91-4f0d-81cb-e5b9195588c9|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|NEBULE|[?]|1|tuberculin unit/mL|GASTRIC CONTENTS|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||1|2|Visit_2|25|3|FOLLOW-UP|2021-01-27|25
e|IS|f632159b-8c91-4f0d-81cb-e5b9195588c9|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/month|[?]|1|vg/dose|ARTERIAL BLOOD|ELECTRONEUROGRAPHY|||1|3|Visit_3|40|6|TREATMENT|2021-02-11|40
e|IS|f632159b-8c91-4f0d-81cb-e5b9195588c9|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mOsm/L|[?]|1|mg/min|INFRANATANT, SERUM|CONTACT SPECULAR MICROSCOPY||Y|1|4|Visit_4|65|3|TREATMENT|2021-03-08|65
e|IS|f632159b-8c91-4f0d-81cb-e5b9195588c9|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kBq/uL|[?]|1|ng|BUFFY COAT|IMMUNOBLOT||Y|1|5|Visit_5|90|2|FOLLOW-UP|2021-04-02|90
e|IS|898a9d2f-338b-41bf-8ac0-c4a025481349|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SFC/10^6 PBMC|[?]|1|uU/L|SOFT TISSUE|HEMAGGLUTINATION INHIBITION ASSAY|||1|1|Visit_1|10|4|TREATMENT|2020-05-24|10
e|IS|898a9d2f-338b-41bf-8ac0-c4a025481349|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/dL|[?]|1|dpm/mg|VENOUS BLOOD|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|1|2|Visit_2|25|5|TREATMENT|2020-06-08|25
e|IS|898a9d2f-338b-41bf-8ac0-c4a025481349|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|CAPFUL|[?]|1|10^6 IU/mL|EXUDATE|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|Y|1|3|Visit_3|40|3|FOLLOW-UP|2020-06-23|40
e|IS|898a9d2f-338b-41bf-8ac0-c4a025481349|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mol/mol|[?]|1|U/m2/h|CIRCULATING TUMOR CELL|MAGNETIC RESONANCE ENTEROGRAPHY|Y||1|4|Visit_4|65|3|TREATMENT|2020-07-18|65
e|IS|898a9d2f-338b-41bf-8ac0-c4a025481349|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/L/h|[?]|1|ug/g/h|DIALYSIS FLUID|TELLER ACUITY CARDS|||1|5|Visit_5|90|2|TREATMENT|2020-08-12|90
e|IS|db3824aa-375d-4e40-a14b-af0e4460914e|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|hr/day|[?]|1|kg/L|ADIPOSE TISSUE|FLUORESCENCE ANGIOGRAPHY|||1|1|Visit_1|10|3|TREATMENT|2020-05-20|10
e|IS|db3824aa-375d-4e40-a14b-af0e4460914e|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MPL U/mL|[?]|1|ug/L|BLOOD|PALM METHOD|Y||1|2|Visit_2|25|6|TREATMENT|2020-06-04|25
e|IS|db3824aa-375d-4e40-a14b-af0e4460914e|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|uL/dose|[?]|1|umol|CARDIAC MUSCLE TISSUE|IMMUNORADIOMETRIC ASSAY|||1|3|Visit_3|40|4|TREATMENT|2020-06-19|40
e|IS|db3824aa-375d-4e40-a14b-af0e4460914e|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|EVENTS|[?]|1|EIA unit|FLUID|IMMUNORADIOMETRIC ASSAY|||1|4|Visit_4|65|3|TREATMENT|2020-07-14|65
e|IS|db3824aa-375d-4e40-a14b-af0e4460914e|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^6 DNA copies/mL|[?]|1|BISCUIT|BLOOD|KNEMOMETRY|Y||1|5|Visit_5|90|6|WASHOUT|2020-08-08|90
e|IS|0ea6be64-32f8-4e10-b993-687ea200e4e9|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U|[?]|1|PACKAGE|DIALYSIS FLUID, PERITONEAL|QUANTITATIVE ULTRASOUND|||1|1|Visit_1|10|1|WASHOUT|2021-01-28|10
e|IS|0ea6be64-32f8-4e10-b993-687ea200e4e9|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol/L/min|[?]|1|mol/L|INFRANATANT, SERUM|THIN SMEAR||Y|1|2|Visit_2|25|7|TREATMENT|2021-02-12|25
e|IS|0ea6be64-32f8-4e10-b993-687ea200e4e9|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^9 organisms|[?]|1|/mm2|SPUTUM|IHC|||1|3|Visit_3|40|6|TREATMENT|2021-02-27|40
e|IS|0ea6be64-32f8-4e10-b993-687ea200e4e9|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|100 IU/mL|[?]|1|mCi/kg|DERMAL TISSUE|ELECTROPHORESIS|Y||1|4|Visit_4|65|3|WASHOUT|2021-03-24|65
e|IS|0ea6be64-32f8-4e10-b993-687ea200e4e9|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|CIGARETTE|[?]|1|DNA copies/mL|STOOL|CONGO RED STAIN||Y|1|5|Visit_5|90|5|SCREENING|2021-04-18|90
e|IS|18504c4e-41c8-4c1a-a479-d179ccd318e3|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Farad|[?]|1|um2|SMEGMA|TEMPLATE INCISION METHOD|Y||1|1|Visit_1|10|4|SCREENING|2020-06-22|10
e|IS|18504c4e-41c8-4c1a-a479-d179ccd318e3|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/g/min|[?]|1|/min|STRIATED MUSCLE TISSUE|MECHANICAL CLOT DETECTION|||1|2|Visit_2|25|1|WASHOUT|2020-07-07|25
e|IS|18504c4e-41c8-4c1a-a479-d179ccd318e3|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/mL|[?]|1|pg/dL|GASTRIC CONTENTS|MICROARRAY|||1|3|Visit_3|40|1|SCREENING|2020-07-22|40
e|IS|18504c4e-41c8-4c1a-a479-d179ccd318e3|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/200 HPFs|[?]|1|LB|PUS|CALIPER MEASUREMENT METHOD||Y|1|4|Visit_4|65|4|TREATMENT|2020-08-16|65
e|IS|18504c4e-41c8-4c1a-a479-d179ccd318e3|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg|[?]|1|ECL unit|DIALYSIS FLUID, PERITONEAL|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||1|5|Visit_5|90|3|WASHOUT|2020-09-10|90
e|IS|7f211d8a-7478-4082-8d95-4ace9ceee919|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|KIT|[?]|1|U/g/h|SERUM OR PLASMA|NUCLEIC ACID SEQUENCING|||1|1|Visit_1|10|6|TREATMENT|2020-08-19|10
e|IS|7f211d8a-7478-4082-8d95-4ace9ceee919|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nmol/L/h|[?]|1|log10 IU/mL|INFRANATANT, PLASMA|CRYOSCOPY|||1|2|Visit_2|25|7|TREATMENT|2020-09-03|25
e|IS|7f211d8a-7478-4082-8d95-4ace9ceee919|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|GPS U|[?]|1|pmol/g|MENSTRUAL BLOOD|LYMPHANGIOGRAPHY|Y||1|3|Visit_3|40|1|FOLLOW-UP|2020-09-18|40
e|IS|7f211d8a-7478-4082-8d95-4ace9ceee919|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cup eq|[?]|1|mmAL|ERYTHROCYTES|PERFUSION MRI|||1|4|Visit_4|65|7|TREATMENT|2020-10-13|65
e|IS|7f211d8a-7478-4082-8d95-4ace9ceee919|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|%/min|[?]|1|RING|BONE|GC/FID|Y|Y|1|5|Visit_5|90|4|SCREENING|2020-11-07|90
e|IS|0739e140-bcac-4df9-9629-bd0748d1fdd6|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg|[?]|1|ug/L/h|SUPERNATANT, PLASMA|WESTERN BLOT|||1|1|Visit_1|10|3|WASHOUT|2020-10-09|10
e|IS|0739e140-bcac-4df9-9629-bd0748d1fdd6|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cg|[?]|1|ug/h|INTERSTITIAL FLUID|VIRUS PLAQUE ASSAY||Y|1|2|Visit_2|25|7|WASHOUT|2020-10-24|25
e|IS|0739e140-bcac-4df9-9629-bd0748d1fdd6|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|genEq|[?]|1|uU/dL|ARTERIALIZED CAPILLARY BLOOD|LIQUID SCINTILLATION COUNTING||Y|1|3|Visit_3|40|7|FOLLOW-UP|2020-11-08|40
e|IS|0739e140-bcac-4df9-9629-bd0748d1fdd6|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Siemens|[?]|1|U/kg/h|GASTRIC CONTENTS|QUANTITATIVE COMPUTED TOMOGRAPHY|Y||1|4|Visit_4|65|2|TREATMENT|2020-12-03|65
e|IS|0739e140-bcac-4df9-9629-bd0748d1fdd6|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|EIA unit|[?]|1|steps/min|INFRANATANT, SERUM|STRESS ECHOCARDIOGRAPHY|Y||1|5|Visit_5|90|5|WASHOUT|2020-12-28|90
e|IS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|STRIP|[?]|1|breaths/min|RETICULOCYTES|ENDPOINT DILUTION ASSAY|||1|1|Visit_1|10|4|TREATMENT|2020-12-21|10
e|IS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PRESSOR UNITS|[?]|1|deg/mm|URINE SEDIMENT|PET SCAN|Y|Y|1|2|Visit_2|25|2|FOLLOW-UP|2021-01-05|25
e|IS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pL|[?]|1|%(w/w)|TISSUE|LANDOLT RING|||1|3|Visit_3|40|7|SCREENING|2021-01-20|40
e|IS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|BEAM BREAKS|[?]|1|U/kg/min|INTERSTITIAL FLUID|ELISA||Y|1|4|Visit_4|65|1|SCREENING|2021-02-14|65
e|IS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9/g|[?]|1|log10 TCID 50/mL|SALIVA|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||1|5|Visit_5|90|2|TREATMENT|2021-03-11|90
e|IS|f24b931a-2cdd-4432-a1dd-69c7286f4690|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ukat|[?]|1|mEq/dL|WHITE MATTER TISSUE|KNEMOMETRY|||1|1|Visit_1|10|3|TREATMENT|2020-05-15|10
e|IS|f24b931a-2cdd-4432-a1dd-69c7286f4690|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kIU|[?]|1|PACKET|MONOCYTE|FLUORESCENCE ANGIOGRAPHY|||1|2|Visit_2|25|3|TREATMENT|2020-05-30|25
e|IS|f24b931a-2cdd-4432-a1dd-69c7286f4690|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|g/m2|[?]|1|dmol|EMOTIONAL TEAR|NEPHELOMETRY|||1|3|Visit_3|40|2|WASHOUT|2020-06-14|40
e|IS|f24b931a-2cdd-4432-a1dd-69c7286f4690|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|%|[?]|1|%(v/v)|CALCULUS|RYAN BLUE STAIN|||1|4|Visit_4|65|4|FOLLOW-UP|2020-07-09|65
e|IS|f24b931a-2cdd-4432-a1dd-69c7286f4690|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Weber|[?]|1|umol|TISSUE|SCANNING ELECTRON MICROSCOPY|||1|5|Visit_5|90|4|SCREENING|2020-08-03|90
e|IS|d394120d-7630-4fcf-a336-482599d88296|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|pmol/g|[?]|1|10^9/g|HAIR|ELISA||Y|1|1|Visit_1|10|5|TREATMENT|2021-01-22|10
e|IS|d394120d-7630-4fcf-a336-482599d88296|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cd|[?]|1|lm|EXUDATE|CONTRAST ENHANCED X-RAY|||1|2|Visit_2|25|6|TREATMENT|2021-02-06|25
e|IS|d394120d-7630-4fcf-a336-482599d88296|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/L|[?]|1|SYRINGE|LYMPH|IN SITU HYBRIDIZATION||Y|1|3|Visit_3|40|5|WASHOUT|2021-02-21|40
e|IS|d394120d-7630-4fcf-a336-482599d88296|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ng/dL|[?]|1|Bq/kg|STRIATED MUSCLE TISSUE|RULER MEASUREMENT METHOD|||1|4|Visit_4|65|3|SCREENING|2021-03-18|65
e|IS|d394120d-7630-4fcf-a336-482599d88296|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Absorbance U/min|[?]|1|WEEKS|CARDIAC MUSCLE TISSUE|TARGETED TRANSCRIPTOME SEQUENCING|Y|Y|1|5|Visit_5|90|1|FOLLOW-UP|2021-04-12|90
e|IS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/kg/day|[?]|1|HEP|STOOL|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y||1|1|Visit_1|10|1|FOLLOW-UP|2020-10-21|10
e|IS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mol/mol|[?]|1|/500 WBC|SUPERNATANT, PLASMA|AUTOREFRACTION|Y||1|2|Visit_2|25|5|TREATMENT|2020-11-05|25
e|IS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/g/h|[?]|1|mL/min/mmHg|VENOUS BLOOD|IMMUNOPRECIPITATION|||1|3|Visit_3|40|1|TREATMENT|2020-11-20|40
e|IS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DRUM|[?]|1|U/10^12 RBC|BUFFY COAT|SCANNING ELECTRON MICROSCOPY|||1|4|Visit_4|65|5|TREATMENT|2020-12-15|65
e|IS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|PNU/mL|[?]|1|U|GASTRIC FLUID|RADIOIMMUNOPRECIPITATION ASSAY|||1|5|Visit_5|90|4|TREATMENT|2021-01-09|90
e|IS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MBq/uL|[?]|1|GBq/mg|SUPERNATANT, PLASMA|MEDIASTINOSCOPY|||1|1|Visit_1|10|6|SCREENING|2020-08-15|10
e|IS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|GLOBULE|[?]|1|log10 copies/mL|SALIVA|TWO-COLOR MICROARRAY|||1|2|Visit_2|25|7|WASHOUT|2020-08-30|25
e|IS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mU|[?]|1|L/s|INFRANATANT, PLASMA|X-RAY|||1|3|Visit_3|40|2|SCREENING|2020-09-14|40
e|IS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/kg/day|[?]|1|mL/m2|DIALYSIS FLUID|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|1|4|Visit_4|65|5|FOLLOW-UP|2020-10-09|65
e|IS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|nmol/L/min|[?]|1|P|SKIN TISSUE|LINE PROBE ASSAY|||1|5|Visit_5|90|5|WASHOUT|2020-11-03|90
e|IS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|g/U|[?]|1|damol/L|ALVEOLAR AIR|PALPATION|||1|1|Visit_1|10|7|FOLLOW-UP|2020-12-21|10
e|IS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kg/L|[?]|1|mL/s/m2|LYSATE|INDIRECT IMMUNOFLUORESCENCE|||1|2|Visit_2|25|3|TREATMENT|2021-01-05|25
e|IS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|COAT|[?]|1|Ci/mL|INTERSTITIAL FLUID|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y||1|3|Visit_3|40|6|TREATMENT|2021-01-20|40
e|IS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|h*%|[?]|1|DAYS|SEBUM|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|4|Visit_4|65|4|TREATMENT|2021-02-14|65
e|IS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|IU/mmol|[?]|1|10^6 RNA copies/mL|ARTERIALIZED CAPILLARY BLOOD|PHYSICAL EXAMINATION||Y|1|5|Visit_5|90|6|TREATMENT|2021-03-11|90
e|IS|59b0fee3-2294-448e-9837-38bd6b5c794b|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|AgU/mL|[?]|1|log10 TCID 50/dose|ARTERIALIZED CAPILLARY BLOOD|CYSTOMETRY|||1|1|Visit_1|10|1|FOLLOW-UP|2021-01-01|10
e|IS|59b0fee3-2294-448e-9837-38bd6b5c794b|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Bq/ug|[?]|1|tuberculin unit/mL|PERIPHERAL BLOOD MONONUCLEAR CELL|PERCUSSION|Y|Y|1|2|Visit_2|25|5|TREATMENT|2021-01-16|25
e|IS|59b0fee3-2294-448e-9837-38bd6b5c794b|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|kg|BILE|THICK SMEAR|||1|3|Visit_3|40|3|TREATMENT|2021-01-31|40
e|IS|59b0fee3-2294-448e-9837-38bd6b5c794b|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/g/h|[?]|1|pmol/L|SEMEN|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||Y|1|4|Visit_4|65|4|TREATMENT|2021-02-25|65
e|IS|59b0fee3-2294-448e-9837-38bd6b5c794b|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^9 organisms/mL|[?]|1|cm H2O|SUPERNATANT, SERUM OR PLASMA|RAJI CELL EIA||Y|1|5|Visit_5|90|1|TREATMENT|2021-03-22|90
e|IS|d9bdb1e3-4630-423f-be01-4873bce30422|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/animal/day|[?]|1|g|PERSPIRATION|SLOAN LETTER EYE CHART 2.5%|||1|1|Visit_1|10|3|TREATMENT|2020-12-22|10
e|IS|d9bdb1e3-4630-423f-be01-4873bce30422|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/animal/day|[?]|1|ft3|SALIVA|CHROMOGENIC ASSAY||Y|1|2|Visit_2|25|3|FOLLOW-UP|2021-01-06|25
e|IS|d9bdb1e3-4630-423f-be01-4873bce30422|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PUFF|[?]|1|nkat|PLATELET|AGAR DILUTION|||1|3|Visit_3|40|6|SCREENING|2021-01-21|40
e|IS|d9bdb1e3-4630-423f-be01-4873bce30422|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 RNA copies/mL|[?]|1|10^4/L|SOFT TISSUE|AURAMINE STAIN|||1|4|Visit_4|65|1|FOLLOW-UP|2021-02-15|65
e|IS|d9bdb1e3-4630-423f-be01-4873bce30422|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/m2|[?]|1|cmH2O*s2/mL|STOOL|LC/MS|||1|5|Visit_5|90|4|TREATMENT|2021-03-12|90
e|IS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|COAT|[?]|1|GBq/mg|EXHALED BREATH CONDENSATE|ICC|||1|1|Visit_1|10|1|TREATMENT|2020-06-25|10
e|IS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mV|[?]|1|uIU/L|SUPERNATANT, PLEURAL FLUID|MASS SPECTROMETRY|||1|2|Visit_2|25|7|TREATMENT|2020-07-10|25
e|IS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/kg|[?]|1|BOWL|SERUM OR PLASMA|MICROBIAL CULTURE||Y|1|3|Visit_3|40|2|FOLLOW-UP|2020-07-25|40
e|IS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|CFU/g|[?]|1|NEEDLE GAUGE|INFRANATANT, PLEURAL FLUID|IMMUNOCHEMILUMINOMETRIC ASSAY||Y|1|4|Visit_4|65|1|TREATMENT|2020-08-19|65
e|IS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|beats/min|[?]|1|/sec|EXUDATE|RADIOGRAPHY|||1|5|Visit_5|90|3|SCREENING|2020-09-13|90
e|IS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U/g Hb|[?]|1|nU/cL|SEMEN|CLAUSS METHOD|Y||1|1|Visit_1|10|5|TREATMENT|2020-08-04|10
e|IS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|uV2|[?]|1|mg/day|ERYTHROCYTES|CONGO RED STAIN|||1|2|Visit_2|25|7|FOLLOW-UP|2020-08-19|25
e|IS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|beats/min|[?]|1|L/kg|LUNG SURFACTANT|RADIOGRAPHY|||1|3|Visit_3|40|3|FOLLOW-UP|2020-09-03|40
e|IS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mkat|[?]|1|mL/mmHg|SEBUM|ELISPOT|Y||1|4|Visit_4|65|6|SCREENING|2020-09-28|65
e|IS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|log10 IU/mL|[?]|1|mL/mmHg/min/L|BREAST MILK|ELASTOGRAPHY|Y||1|5|Visit_5|90|4|WASHOUT|2020-10-23|90
e|IS|933c3a61-59a0-4cfb-ae17-45bc48229323|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DPM|[?]|1|Watt|VENOUS PLASMA|GC/MS|||1|1|Visit_1|10|2|TREATMENT|2020-09-09|10
e|IS|933c3a61-59a0-4cfb-ae17-45bc48229323|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BOTTLE|[?]|1|DAYS|SUPERNATANT, SERUM|FUNCTIONAL MRI|||1|2|Visit_2|25|6|WASHOUT|2020-09-24|25
e|IS|933c3a61-59a0-4cfb-ae17-45bc48229323|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|s*kPa|[?]|1|HEP|BLOOD|MAGNETIC RESONANCE ENTEROGRAPHY|||1|3|Visit_3|40|3|FOLLOW-UP|2020-10-09|40
e|IS|933c3a61-59a0-4cfb-ae17-45bc48229323|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL*cmH2O|[?]|1|Enzyme U/L|LAVAGE FLUID|MICROPARTICLE ENZYME IMMUNOASSAY|Y||1|4|Visit_4|65|2|TREATMENT|2020-11-03|65
e|IS|933c3a61-59a0-4cfb-ae17-45bc48229323|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uIU/L|[?]|1|deg|EPIDERMAL TISSUE|EPSILOMETER|Y||1|5|Visit_5|90|2|TREATMENT|2020-11-28|90
e|IS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MnFI|[?]|1|Log10 ELISA unit/dose|REFLEX TEAR|CLIP SEQUENCING|||1|1|Visit_1|10|5|FOLLOW-UP|2020-10-26|10
e|IS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/m2/h|[?]|1|PFU/mL|PLASMA ULTRAFILTRATE|ROMANOWSKY STAIN||Y|1|2|Visit_2|25|4|TREATMENT|2020-11-10|25
e|IS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nkat|[?]|1|Bq/ug|SYNOVIAL FLUID|MUGA|||1|3|Visit_3|40|1|TREATMENT|2020-11-25|40
e|IS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U.CARR|[?]|1|g/animal/wk|PLATELET POOR PLASMA|FLOW CYTOMETRY|||1|4|Visit_4|65|5|TREATMENT|2020-12-20|65
e|IS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nsec|[?]|1|uV*sec|COLOSTRUM|BETA LACTAMASE|||1|5|Visit_5|90|1|TREATMENT|2021-01-14|90
e|IS|ac66129e-3244-4cd8-a235-43b4bfb7dace|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^9 organisms/g|[?]|1|deg2|SEMINAL FLUID|QUANTITATIVE COMPUTED TOMOGRAPHY|||1|1|Visit_1|10|4|WASHOUT|2020-10-29|10
e|IS|ac66129e-3244-4cd8-a235-43b4bfb7dace|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|fL|[?]|1|v/v|PLEURAL FLUID|STRESS ECHOCARDIOGRAPHY|||1|2|Visit_2|25|7|TREATMENT|2020-11-13|25
e|IS|ac66129e-3244-4cd8-a235-43b4bfb7dace|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|g/animal/wk|[?]|1|uV*sec|SUPERNATANT, SERUM|CONTRAST ENHANCED PET SCAN|||1|3|Visit_3|40|4|SCREENING|2020-11-28|40
e|IS|ac66129e-3244-4cd8-a235-43b4bfb7dace|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uCi|[?]|1|10^6 U|INFRANATANT, PLASMA|PATHOLOGICAL EVALUATION|||1|4|Visit_4|65|5|SCREENING|2020-12-23|65
e|IS|ac66129e-3244-4cd8-a235-43b4bfb7dace|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|in|[?]|1|BOX|TUMOR TISSUE|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y|Y|1|5|Visit_5|90|3|WASHOUT|2021-01-17|90
e|IS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6 RNA copies/mL|[?]|1|PHERESIS UNIT|HAIR|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|7|TREATMENT|2020-09-02|10
e|IS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^9/L|[?]|1|BOWL|NAIL|TRIPLE-PHASE MRI SCAN|||1|2|Visit_2|25|3|FOLLOW-UP|2020-09-17|25
e|IS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|foz_us|[?]|1|mL/kg/min|SMEGMA|ICC|||1|3|Visit_3|40|1|TREATMENT|2020-10-02|40
e|IS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pg/L|[?]|1|FINGERTIP UNIT|ISOLATE|MACRO BROTH DILUTION|Y||1|4|Visit_4|65|6|SCREENING|2020-10-27|65
e|IS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|TABLET|[?]|1|mol/L|DERMAL TISSUE|INTRAVASCULAR ULTRASOUND||Y|1|5|Visit_5|90|1|FOLLOW-UP|2020-11-21|90
e|IS|3d59a754-10bb-4847-93ea-433b43265a2f|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^6 CFU/g|[?]|1|CIGARETTE|SMOOTH MUSCLE TISSUE|HPLC/MS||Y|1|1|Visit_1|10|6|TREATMENT|2020-10-24|10
e|IS|3d59a754-10bb-4847-93ea-433b43265a2f|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/breath|[?]|1|mg/L|BREAST MILK|SNELLEN EYE CHART||Y|1|2|Visit_2|25|1|FOLLOW-UP|2020-11-08|25
e|IS|3d59a754-10bb-4847-93ea-433b43265a2f|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 PFU|[?]|1|Absorbance U|BASAL TEAR|MALDI-TOF|||1|3|Visit_3|40|6|TREATMENT|2020-11-23|40
e|IS|3d59a754-10bb-4847-93ea-433b43265a2f|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Ci|[?]|1|ug/h|SEMEN|GRADIENT DIFFUSION|||1|4|Visit_4|65|7|TREATMENT|2020-12-18|65
e|IS|3d59a754-10bb-4847-93ea-433b43265a2f|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Torr|[?]|1|PIXELS/in|URINE|TOLUIDINE BLUE STAIN|Y|Y|1|5|Visit_5|90|7|WASHOUT|2021-01-12|90
e|IS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|WAFER|[?]|1|NEEDLE GAUGE|URINE SEDIMENT|VIRUS PLAQUE ASSAY|||1|1|Visit_1|10|4|SCREENING|2021-01-20|10
e|IS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/day|[?]|1|mMU/mL|PUS|MICROPARTICLE ENZYME IMMUNOASSAY|||1|2|Visit_2|25|5|TREATMENT|2021-02-04|25
e|IS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/m2/day|[?]|1|log10 CFU/g|PERIPHERAL BLOOD MONONUCLEAR CELL|FLOCCULATION|Y||1|3|Visit_3|40|5|FOLLOW-UP|2021-02-19|40
e|IS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/kg|[?]|1|TABLET|TUMOR TISSUE|DOUBLE IMMUNODIFFUSION|Y|Y|1|4|Visit_4|65|4|SCREENING|2021-03-16|65
e|IS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Log10 ELISA unit/dose|[?]|1|mg/cm2|BUFFY COAT|NUCLEIC ACID BASED METHOD|||1|5|Visit_5|90|1|SCREENING|2021-04-10|90
e|IS|89209495-c485-4eb7-b858-8dc5490d2b64|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ng/mol|[?]|1|fmol/L/sec|BONE MARROW MONONUCLEAR CELL|PHOTOMETRIC CLOT DETECTION|Y||1|1|Visit_1|10|2|FOLLOW-UP|2020-09-07|10
e|IS|89209495-c485-4eb7-b858-8dc5490d2b64|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/L/h|[?]|1|umol/mg/min|SERUM|MICROBIAL CULTURE, SOLID||Y|1|2|Visit_2|25|6|TREATMENT|2020-09-22|25
e|IS|89209495-c485-4eb7-b858-8dc5490d2b64|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uIU/dL|[?]|1|GBq/g|ATHEROSCLEROTIC PLAQUE|PULMONARY ANGIOGRAPHY||Y|1|3|Visit_3|40|5|SCREENING|2020-10-07|40
e|IS|89209495-c485-4eb7-b858-8dc5490d2b64|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MESF|[?]|1|fmol/L|CEREBROSPINAL FLUID|ELECTROCHEMILUMINESCENCE||Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-11-01|65
e|IS|89209495-c485-4eb7-b858-8dc5490d2b64|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/kg/h|[?]|1|U/g|BILE|MODIFIED ACID FAST STAIN|Y||1|5|Visit_5|90|1|WASHOUT|2020-11-26|90
e|IS|d80522bb-f146-4270-a6e1-326fde50d9ca|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cmH2O/mL|[?]|1|CUP|HAIR|FREEZING POINT DEPRESSION|Y||1|1|Visit_1|10|1|WASHOUT|2020-12-31|10
e|IS|d80522bb-f146-4270-a6e1-326fde50d9ca|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/(min*100mL)|[?]|1|g/cm2|INFRANATANT, SERUM|PUPILLOMETRY|||1|2|Visit_2|25|6|SCREENING|2021-01-15|25
e|IS|d80522bb-f146-4270-a6e1-326fde50d9ca|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IU/kg|[?]|1|Watt|SERUM OR PLASMA OR BLOOD|MASS SPECTROMETRY|||1|3|Visit_3|40|7|SCREENING|2021-01-30|40
e|IS|d80522bb-f146-4270-a6e1-326fde50d9ca|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mJoule/cm2|[?]|1|LB|SERUM|ANGIOGRAPHY|Y||1|4|Visit_4|65|7|FOLLOW-UP|2021-02-24|65
e|IS|d80522bb-f146-4270-a6e1-326fde50d9ca|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug/m2/h|[?]|1|INHALATION|BLOOD|TRIPLE-PHASE MRI SCAN|||1|5|Visit_5|90|7|TREATMENT|2021-03-21|90
e|IS|3982a462-95f6-4e71-93e5-9df777770067|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mJoule/cm2|[?]|1|U/g/day|CAPILLARY BLOOD|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||1|1|Visit_1|10|2|SCREENING|2020-12-25|10
e|IS|3982a462-95f6-4e71-93e5-9df777770067|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BISCUIT|[?]|1|vg/kg|SALIVA|COULOMETRIC TITRATION|||1|2|Visit_2|25|5|SCREENING|2021-01-09|25
e|IS|3982a462-95f6-4e71-93e5-9df777770067|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|IU/kg|[?]|1|mg/animal|EPITHELIAL CELL|MALDI|||1|3|Visit_3|40|2|WASHOUT|2021-01-24|40
e|IS|3982a462-95f6-4e71-93e5-9df777770067|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/h|[?]|1|Ci/g|MUSCLE TISSUE|SPECT/CT SCAN|||1|4|Visit_4|65|3|WASHOUT|2021-02-18|65
e|IS|3982a462-95f6-4e71-93e5-9df777770067|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^3 organisms/g|[?]|1|ug/animal|GASTRIC CONTENTS|ELLA|||1|5|Visit_5|90|3|TREATMENT|2021-03-15|90
e|IS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/kg/dose|[?]|1|IU/mL|PLEURAL TISSUE|MANUAL CLOT DETECTION||Y|1|1|Visit_1|10|5|TREATMENT|2020-11-09|10
e|IS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|C|[?]|1|TABLET|HAIR FOLLICLE|NON-CONTACT SPECULAR MICROSCOPY|Y||1|2|Visit_2|25|3|SCREENING|2020-11-24|25
e|IS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|pt_us|[?]|1|mV*min|PROSTATIC FLUID|PHOTOGRAPHY||Y|1|3|Visit_3|40|6|TREATMENT|2020-12-09|40
e|IS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|IU/day|[?]|1|IU|HAIR FOLLICLE|SNP ARRAY|Y||1|4|Visit_4|65|7|TREATMENT|2021-01-03|65
e|IS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Bq/uL|[?]|1|MnFI|DIALYSIS FLUID|MICRODENSITOMETRY|Y||1|5|Visit_5|90|5|TREATMENT|2021-01-28|90
e|IS|175cfd82-a6fe-463b-81e5-07ae9e1253db|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|fraction of 1|[?]|1|mol/g|INFRANATANT, PLEURAL FLUID|OPTICAL COHERENCE TOMOGRAPHY||Y|1|1|Visit_1|10|2|WASHOUT|2020-05-26|10
e|IS|175cfd82-a6fe-463b-81e5-07ae9e1253db|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|RATIO|[?]|1|g/cage/day|URINE SEDIMENT|IVY INCISION METHOD|||1|2|Visit_2|25|5|TREATMENT|2020-06-10|25
e|IS|175cfd82-a6fe-463b-81e5-07ae9e1253db|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|in|[?]|1|mOsm/L|EXHALED BREATH CONDENSATE|ULTRASOUND|||1|3|Visit_3|40|4|TREATMENT|2020-06-25|40
e|IS|175cfd82-a6fe-463b-81e5-07ae9e1253db|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|APL U/mL|[?]|1|ug/m2/min|SEBUM|EPSILOMETER|||1|4|Visit_4|65|4|TREATMENT|2020-07-20|65
e|IS|175cfd82-a6fe-463b-81e5-07ae9e1253db|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|in|[?]|1|/LSQN|PROSTATIC FLUID|SURFACE PLASMON RESONANCE|||1|5|Visit_5|90|1|WASHOUT|2020-08-14|90
e|IS|e19b469c-40d5-4506-8233-a86bebde880d|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|CIGAR|[?]|1|VOXEL|DERMAL TISSUE|SPECT/CT SCAN|||1|1|Visit_1|10|6|SCREENING|2021-01-22|10
e|IS|e19b469c-40d5-4506-8233-a86bebde880d|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|U/mL|[?]|1|GBq|PERIPHERAL BLOOD MONONUCLEAR CELL|ENDPOINT DILUTION ASSAY|Y||1|2|Visit_2|25|5|WASHOUT|2021-02-06|25
e|IS|e19b469c-40d5-4506-8233-a86bebde880d|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cal|[?]|1|Absorbance U/min|CAPILLARY BLOOD|AUTOMATED COUNT||Y|1|3|Visit_3|40|7|SCREENING|2021-02-21|40
e|IS|e19b469c-40d5-4506-8233-a86bebde880d|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug/g/day|[?]|1|vp/dose|LYSATE|SISH|||1|4|Visit_4|65|2|TREATMENT|2021-03-18|65
e|IS|e19b469c-40d5-4506-8233-a86bebde880d|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|days/month|[?]|1|PRESSOR UNITS|DISCHARGE|KLEIHAUER-BETKE|||1|5|Visit_5|90|6|TREATMENT|2021-04-12|90
e|IS|f280a4a5-9826-4d77-adf1-992284cb3314|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kcal/day|[?]|1|Gy/min|SYNOVIAL FLUID|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||1|1|Visit_1|10|6|SCREENING|2020-12-19|10
e|IS|f280a4a5-9826-4d77-adf1-992284cb3314|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cm|[?]|1|MONTHS|BLOOD|MICROPARTICLE ENZYME IMMUNOASSAY|||1|2|Visit_2|25|5|WASHOUT|2021-01-03|25
e|IS|f280a4a5-9826-4d77-adf1-992284cb3314|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/100 HPFs|[?]|1|/200 HPFs|BONE|AUDIOMETRY|Y||1|3|Visit_3|40|3|SCREENING|2021-01-18|40
e|IS|f280a4a5-9826-4d77-adf1-992284cb3314|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|HOURS|[?]|1|CCID 50/mL|CAPILLARY PLASMA|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y||1|4|Visit_4|65|5|WASHOUT|2021-02-12|65
e|IS|f280a4a5-9826-4d77-adf1-992284cb3314|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 CFU|[?]|1|mL/m2/h|SMEGMA|HPLC-FL||Y|1|5|Visit_5|90|5|SCREENING|2021-03-09|90
e|IS|82840929-7800-4254-b60a-8af4786664f6|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Ejaculate U|[?]|1|nsec|LYSATE|CALIPER MEASUREMENT METHOD|Y||1|1|Visit_1|10|2|FOLLOW-UP|2020-06-04|10
e|IS|82840929-7800-4254-b60a-8af4786664f6|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|in|[?]|1|log10 CFU/mL|LYMPH|WHOLE EXOME SEQUENCING|||1|2|Visit_2|25|5|FOLLOW-UP|2020-06-19|25
e|IS|82840929-7800-4254-b60a-8af4786664f6|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/kg|[?]|1|IU/mg|MUSCLE TISSUE|GC/MS-CI|||1|3|Visit_3|40|2|WASHOUT|2020-07-04|40
e|IS|82840929-7800-4254-b60a-8af4786664f6|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|PNU/mL|[?]|1|Ci/uL|PLEURAL FLUID|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||1|4|Visit_4|65|4|SCREENING|2020-07-29|65
e|IS|82840929-7800-4254-b60a-8af4786664f6|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol2/L2|[?]|1|dpm/mL|MUCUS|IMMUNO-PET SCAN|Y||1|5|Visit_5|90|1|TREATMENT|2020-08-23|90
e|IS|dae25bdb-38fd-4852-9a9a-7627368e9497|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/m2/day|[?]|1|mgEq|CIRCULATING TUMOR CELL|BIOPSY|||1|1|Visit_1|10|1|SCREENING|2020-09-02|10
e|IS|dae25bdb-38fd-4852-9a9a-7627368e9497|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|dL|[?]|1|mL/mmHg/min/L|KERATINOCYTE|OPTICAL MAPPING|||1|2|Visit_2|25|7|TREATMENT|2020-09-17|25
e|IS|dae25bdb-38fd-4852-9a9a-7627368e9497|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 organisms|[?]|1|IU/mmol|SUPERNATANT, SERUM OR PLASMA|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||1|3|Visit_3|40|7|TREATMENT|2020-10-02|40
e|IS|dae25bdb-38fd-4852-9a9a-7627368e9497|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CUP|[?]|1|g/cage|URINE SEDIMENT|IMPULSE OSCILLOMETRY|||1|4|Visit_4|65|1|TREATMENT|2020-10-27|65
e|IS|dae25bdb-38fd-4852-9a9a-7627368e9497|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|CONTAINER|[?]|1|mL/m2|PLATELET|EIA|Y||1|5|Visit_5|90|1|TREATMENT|2020-11-21|90
e|IS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BLOCKS|[?]|1|mEq/g|VITREOUS HUMOR|PHASE-CONTRAST MRI|Y||1|1|Visit_1|10|7|FOLLOW-UP|2020-10-05|10
e|IS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ms/mmHg|[?]|1|10^3 copies/mL|MUSCLE TISSUE|HEMAGGLUTINATION ASSAY|Y||1|2|Visit_2|25|6|SCREENING|2020-10-20|25
e|IS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cmH2O*s/mL|[?]|1|mg/animal|PERITONEAL FLUID|LC-FL|||1|3|Visit_3|40|7|TREATMENT|2020-11-04|40
e|IS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/sec|[?]|1|U.CARR|SPUTUM|RYAN BLUE STAIN|||1|4|Visit_4|65|2|SCREENING|2020-11-29|65
e|IS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|m/sec2|[?]|1|uEq/L|CAPILLARY BLOOD|SPIROMETRY|Y||1|5|Visit_5|90|2|SCREENING|2020-12-24|90
e|IS|e7468d01-71b3-47c4-9715-62fe143364cb|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 IU/mL|[?]|1|mL/100g/min|CERVICOVAGINAL SECRETION|GIEMSA STAIN||Y|1|1|Visit_1|10|1|TREATMENT|2020-10-15|10
e|IS|e7468d01-71b3-47c4-9715-62fe143364cb|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|TUBE|[?]|1|mg/kg/h|PLATELET RICH PLASMA|DNA MICROARRAY||Y|1|2|Visit_2|25|3|TREATMENT|2020-10-30|25
e|IS|e7468d01-71b3-47c4-9715-62fe143364cb|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmHg/L/min|[?]|1|vp/mL|EXUDATE|CRYOSCOPY|||1|3|Visit_3|40|5|TREATMENT|2020-11-14|40
e|IS|e7468d01-71b3-47c4-9715-62fe143364cb|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|%(v/v)|[?]|1|nmol/L|PLASMA ULTRAFILTRATE|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||1|4|Visit_4|65|2|TREATMENT|2020-12-09|65
e|IS|e7468d01-71b3-47c4-9715-62fe143364cb|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U|[?]|1|/MBP|EPIDERMAL TISSUE|MOUSE PROTECTION ASSAY||Y|1|5|Visit_5|90|6|TREATMENT|2021-01-03|90
e|IS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|PIXEL|[?]|1|mol/mL|SALIVA|WEBER GREEN STAIN|||1|1|Visit_1|10|7|FOLLOW-UP|2020-05-18|10
e|IS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mEq/mmol|[?]|1|CAPFUL|EXUDATE|ENZYMATIC ULTRACENTRIFUGATION|||1|2|Visit_2|25|1|TREATMENT|2020-06-02|25
e|IS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/L/h|[?]|1|pmol/g|PLASMA ULTRAFILTRATE|KNEMOMETRY|Y||1|3|Visit_3|40|6|TREATMENT|2020-06-17|40
e|IS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|IU/g|[?]|1|Joule|LAVAGE FLUID|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|1|4|Visit_4|65|2|SCREENING|2020-07-12|65
e|IS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/g|[?]|1|umol/mg/min|KERATINOCYTE|NEXT GENERATION TARGETED SEQUENCING|||1|5|Visit_5|90|3|SCREENING|2020-08-06|90
e|IS|eb409ec5-4c02-41c8-a11f-03d990818c2a|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|foz_us|[?]|1|mL/cm|SEBUM|X-RAY||Y|1|1|Visit_1|10|3|WASHOUT|2020-12-09|10
e|IS|eb409ec5-4c02-41c8-a11f-03d990818c2a|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nkat/g Hb|[?]|1|mg/L|GASTRIC FLUID|DYNAMIC CONTRAST ENHANCED MRI||Y|1|2|Visit_2|25|4|TREATMENT|2020-12-24|25
e|IS|eb409ec5-4c02-41c8-a11f-03d990818c2a|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log EID 50/dose|[?]|1|DISK|VENOUS PLASMA|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y|1|3|Visit_3|40|3|SCREENING|2021-01-08|40
e|IS|eb409ec5-4c02-41c8-a11f-03d990818c2a|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|eq|[?]|1|10^3 CFU/g|CERUMEN|MIGET|||1|4|Visit_4|65|2|TREATMENT|2021-02-02|65
e|IS|eb409ec5-4c02-41c8-a11f-03d990818c2a|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U/mL|[?]|1|min/day|BASAL TEAR|FLUORESCENT IMMUNOASSAY||Y|1|5|Visit_5|90|2|SCREENING|2021-02-27|90
e|IS|2178f542-809d-4306-84e4-26d3b3b370b0|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^7 CFU|[?]|1|GBq/ug|SUPERNATANT, SERUM OR PLASMA|POLYGRAPHY|||1|1|Visit_1|10|1|TREATMENT|2020-11-06|10
e|IS|2178f542-809d-4306-84e4-26d3b3b370b0|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/cL|[?]|1|Gravitational Unit|CARDIAC MUSCLE TISSUE|SPIROMETRY|||1|2|Visit_2|25|1|TREATMENT|2020-11-21|25
e|IS|2178f542-809d-4306-84e4-26d3b3b370b0|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|uL/dose|[?]|1|g/animal/day|CORD BLOOD|ANALYTICAL ULTRACENTRIFUGATION|||1|3|Visit_3|40|6|TREATMENT|2020-12-06|40
e|IS|2178f542-809d-4306-84e4-26d3b3b370b0|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mmol/L|[?]|1|cd*s/m2|PUS|DUCTOGRAPHY|||1|4|Visit_4|65|6|SCREENING|2020-12-31|65
e|IS|2178f542-809d-4306-84e4-26d3b3b370b0|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ugEq|[?]|1|GLOBULE|URINE|PERFUSION MRI|||1|5|Visit_5|90|5|WASHOUT|2021-01-25|90
e|IS|da7423fb-461e-43a6-bcb9-aa87051bda0a|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uU/L|[?]|1|TUBE|MONOCYTE|HIGH RESOLUTION CT|Y||1|1|Visit_1|10|5|WASHOUT|2020-10-04|10
e|IS|da7423fb-461e-43a6-bcb9-aa87051bda0a|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/h|[?]|1|CYLINDER|SEBUM|CONGO RED STAIN|||1|2|Visit_2|25|2|TREATMENT|2020-10-19|25
e|IS|da7423fb-461e-43a6-bcb9-aa87051bda0a|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/L|[?]|1|TUBE|SKELETAL MUSCLE TISSUE|EPSILOMETER|||1|3|Visit_3|40|3|SCREENING|2020-11-03|40
e|IS|da7423fb-461e-43a6-bcb9-aa87051bda0a|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uEq/L|[?]|1|Ci/ug|PERITONEAL FLUID|FLUORESCENT MICROSCOPY|||1|4|Visit_4|65|4|FOLLOW-UP|2020-11-28|65
e|IS|da7423fb-461e-43a6-bcb9-aa87051bda0a|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/200 HPFs|[?]|1|mL/kg/day|SMOOTH MUSCLE TISSUE|MACRO BROTH DILUTION|||1|5|Visit_5|90|3|SCREENING|2020-12-23|90
e|IS|40e4c69f-6115-4f0e-8555-45b12b222801|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|SPRAY|[?]|1|tsp eq|ENDOMETRIAL TISSUE|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|1|1|Visit_1|10|3|FOLLOW-UP|2021-01-30|10
e|IS|40e4c69f-6115-4f0e-8555-45b12b222801|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/week|[?]|1|/ms|ENDOMETRIAL TISSUE|ENDPOINT DILUTION ASSAY|||1|2|Visit_2|25|1|FOLLOW-UP|2021-02-14|25
e|IS|40e4c69f-6115-4f0e-8555-45b12b222801|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Bq/uL|[?]|1|10^7 TCID 50/dose|SKIN TISSUE|TEMPLATE INCISION METHOD|||1|3|Visit_3|40|1|SCREENING|2021-03-01|40
e|IS|40e4c69f-6115-4f0e-8555-45b12b222801|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mmol/min/kPa/L|[?]|1|mN|VITREOUS HUMOR|PHASE-CONTRAST MRI|||1|4|Visit_4|65|4|TREATMENT|2021-03-26|65
e|IS|40e4c69f-6115-4f0e-8555-45b12b222801|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/m2/min|[?]|1|mL/g/day|GASTRIC FLUID|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y|Y|1|5|Visit_5|90|5|FOLLOW-UP|2021-04-20|90
e|IS|1307d7f6-acb6-4096-a907-08345548a82b|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|tuberculin unit|[?]|1|umol/mol|SUPERNATANT, SERUM OR PLASMA|HILLMEN COLOR CHART|Y|Y|1|1|Visit_1|10|4|SCREENING|2020-05-28|10
e|IS|1307d7f6-acb6-4096-a907-08345548a82b|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/kg|[?]|1|umol/mol|LEUKOCYTE|VIRUS PLAQUE ASSAY|||1|2|Visit_2|25|2|TREATMENT|2020-06-12|25
e|IS|1307d7f6-acb6-4096-a907-08345548a82b|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ELISA unit/mL|[?]|1|U/kg|URINE SEDIMENT|EPSILOMETER||Y|1|3|Visit_3|40|1|SCREENING|2020-06-27|40
e|IS|1307d7f6-acb6-4096-a907-08345548a82b|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cpm|[?]|1|U/kg/day|SYNOVIAL FLUID|FORCED OSCILLATION TECHNIQUE|||1|4|Visit_4|65|5|TREATMENT|2020-07-22|65
e|IS|1307d7f6-acb6-4096-a907-08345548a82b|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|FFU|[?]|1|10^9 organisms/mL|MECONIUM|ANALYTICAL ULTRACENTRIFUGATION|Y||1|5|Visit_5|90|4|TREATMENT|2020-08-16|90
e|IS|bac23835-1120-43b2-9d99-694bef97f44b|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^8 PFU|[?]|1|mg/m2|INFRANATANT, PLASMA|CONTRAST ENHANCED PET/CT SCAN|||1|1|Visit_1|10|6|WASHOUT|2020-05-21|10
e|IS|bac23835-1120-43b2-9d99-694bef97f44b|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/h|[?]|1|g/m2/day|RETICULOCYTES|RAJI CELL EIA|||1|2|Visit_2|25|3|SCREENING|2020-06-05|25
e|IS|bac23835-1120-43b2-9d99-694bef97f44b|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL|[?]|1|ELISA unit/dose|PERIPHERAL BLOOD MONONUCLEAR CELL|CRYOSCOPY||Y|1|3|Visit_3|40|5|WASHOUT|2020-06-20|40
e|IS|bac23835-1120-43b2-9d99-694bef97f44b|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/g|[?]|1|GBq/ug|SKELETAL MUSCLE TISSUE|SINGLE-SLICE SPIRAL CT|||1|4|Visit_4|65|5|TREATMENT|2020-07-15|65
e|IS|bac23835-1120-43b2-9d99-694bef97f44b|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^12 IU/L|[?]|1|dmol|SPUTUM|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||1|5|Visit_5|90|3|WASHOUT|2020-08-09|90
e|IS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PATCH|[?]|1|g/m2/day|REFLEX TEAR|NON-INVASIVE DIELECTRIC SENSING|||1|1|Visit_1|10|4|TREATMENT|2020-09-24|10
e|IS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Gy|[?]|1|yd|BILE|PHOTOMETRIC CLOT DETECTION|||1|2|Visit_2|25|6|TREATMENT|2020-10-09|25
e|IS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/kg/min|[?]|1|MET*min|SUPERNATANT, PLEURAL FLUID|KLEIHAUER-BETKE|||1|3|Visit_3|40|7|TREATMENT|2020-10-24|40
e|IS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|CFU/mL|[?]|1|Ci/mL|AMNIOTIC FLUID|ENDPOINT DILUTION ASSAY||Y|1|4|Visit_4|65|2|TREATMENT|2020-11-18|65
e|IS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|m3|[?]|1|ug/h|INFRANATANT, PLEURAL FLUID|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||1|5|Visit_5|90|1|TREATMENT|2020-12-13|90
e|IS|14cd64f5-f3c8-47a4-b40e-9c5090890870|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/h/mmol|[?]|1|%(w/v)|NAIL|SLIT LAMP PHOTOGRAPHY|||1|1|Visit_1|10|6|TREATMENT|2020-09-24|10
e|IS|14cd64f5-f3c8-47a4-b40e-9c5090890870|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|cP|[?]|1|mg/dose|CAPILLARY PLASMA|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||1|2|Visit_2|25|1|FOLLOW-UP|2020-10-09|25
e|IS|14cd64f5-f3c8-47a4-b40e-9c5090890870|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|ppth|INFRANATANT, PLASMA|TRYPAN BLUE STAIN|Y||1|3|Visit_3|40|4|TREATMENT|2020-10-24|40
e|IS|14cd64f5-f3c8-47a4-b40e-9c5090890870|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/m2|[?]|1|msec|SKIN TISSUE|MASS SPECTROMETRY|||1|4|Visit_4|65|1|SCREENING|2020-11-18|65
e|IS|14cd64f5-f3c8-47a4-b40e-9c5090890870|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/s/m2|[?]|1|%/min|SKIN TISSUE|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|5|Visit_5|90|3|TREATMENT|2020-12-13|90
e|IS|ca4a06be-5e6a-4220-9854-e5fe02b384af|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/cm H2O|[?]|1|mL/h|TISSUE|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|Y|1|1|Visit_1|10|5|TREATMENT|2020-10-03|10
e|IS|ca4a06be-5e6a-4220-9854-e5fe02b384af|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|log10 IU/mL|[?]|1|Siemens|BONE|CONFOCAL MICROSCOPY|||1|2|Visit_2|25|6|TREATMENT|2020-10-18|25
e|IS|ca4a06be-5e6a-4220-9854-e5fe02b384af|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|fmol/L|[?]|1|GPL U/mL|SMEGMA|PERIODIC ACID SCHIFF STAIN|||1|3|Visit_3|40|2|TREATMENT|2020-11-02|40
e|IS|ca4a06be-5e6a-4220-9854-e5fe02b384af|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mV/sec|[?]|1|g/cage/wk|PROSTATIC FLUID|GC/FID||Y|1|4|Visit_4|65|5|SCREENING|2020-11-27|65
e|IS|ca4a06be-5e6a-4220-9854-e5fe02b384af|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Henry|[?]|1|mg/animal|SALIVA|SLOAN LETTER EYE CHART 1.25%|||1|5|Visit_5|90|2|TREATMENT|2020-12-22|90
e|IS|55504c69-a659-402b-a0cb-95ab4e08c086|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/mol|[?]|1|10^7 CFU/mL|SYNOVIAL FLUID|HIGH RESOLUTION MELT ANALYSIS|||1|1|Visit_1|10|6|TREATMENT|2021-01-14|10
e|IS|55504c69-a659-402b-a0cb-95ab4e08c086|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|STEPS|[?]|1|KIT|TUMOR TISSUE|FLUORESCENCE ANGIOGRAPHY|||1|2|Visit_2|25|3|SCREENING|2021-01-29|25
e|IS|55504c69-a659-402b-a0cb-95ab4e08c086|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|10^9/g|LYMPH|PEAK FLOWMETRY|Y||1|3|Visit_3|40|3|TREATMENT|2021-02-13|40
e|IS|55504c69-a659-402b-a0cb-95ab4e08c086|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U|[?]|1|s/h|REFLEX TEAR|PEAK FLOWMETRY|||1|4|Visit_4|65|1|SCREENING|2021-03-10|65
e|IS|55504c69-a659-402b-a0cb-95ab4e08c086|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mmol/min/kPa/L|[?]|1|nmol BCE/L|SYNOVIAL FLUID|SPIRAL CT SCAN WITHOUT CONTRAST||Y|1|5|Visit_5|90|3|TREATMENT|2021-04-04|90
e|IS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|km/h|[?]|1|pmol/g|SMEGMA|TOTAL BODY RADIOGRAPHY|||1|1|Visit_1|10|5|TREATMENT|2020-11-30|10
e|IS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Tbsp|[?]|1|10^9/L|SERUM|ELISA|Y||1|2|Visit_2|25|6|FOLLOW-UP|2020-12-15|25
e|IS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|gMFI|[?]|1|mgEq|LYMPH|LC/MS|||1|3|Visit_3|40|2|TREATMENT|2020-12-30|40
e|IS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pmol/day|[?]|1|um2|HAIR|HPLC|Y||1|4|Visit_4|65|3|WASHOUT|2021-01-24|65
e|IS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|SUPPOSITORY|[?]|1|ug/kg/h|BREAST MILK|MACRO BROTH DILUTION|Y||1|5|Visit_5|90|2|FOLLOW-UP|2021-02-18|90
e|IS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|CCID 50/mL|[?]|1|IMPLANT|BLOOD|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-12-11|10
e|IS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/L|[?]|1|lm|ALVEOLAR AIR|NUCLEIC ACID AMPLIFICATION TEST|||1|2|Visit_2|25|5|FOLLOW-UP|2020-12-26|25
e|IS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nCi|[?]|1|g/cage|EXPIRED AIR|ELECTROMYOGRAPHY|Y||1|3|Visit_3|40|4|WASHOUT|2021-01-10|40
e|IS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PFU/mL|[?]|1|nCi|SMEGMA|COULOMETRIC TITRATION|||1|4|Visit_4|65|6|SCREENING|2021-02-04|65
e|IS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/kg/day|[?]|1|IU/dL|CORD SERUM|INTERRUPTER TECHNIQUE|||1|5|Visit_5|90|4|TREATMENT|2021-03-01|90
e|IS|12c24fff-080b-4889-a455-ff55d5c0536c|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mPa|[?]|1|mg/g/min|STOOL|LASER CAPTURE MICRODISSECTION|||1|1|Visit_1|10|3|TREATMENT|2021-01-27|10
e|IS|12c24fff-080b-4889-a455-ff55d5c0536c|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|sec|[?]|1|keV|CAPILLARY BLOOD|ULTRASONOGRAPHIC ELASTOGRAPHY|||1|2|Visit_2|25|2|SCREENING|2021-02-11|25
e|IS|12c24fff-080b-4889-a455-ff55d5c0536c|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|vp/dose|[?]|1|kN/cm2|EXHALED BREATH CONDENSATE|NEURAMINIDASE INHIBITION ASSAY|||1|3|Visit_3|40|3|TREATMENT|2021-02-26|40
e|IS|12c24fff-080b-4889-a455-ff55d5c0536c|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|amp|[?]|1|log10 PFU|ATHEROSCLEROTIC PLAQUE|INFRARED SPECTROMETRY|||1|4|Visit_4|65|3|WASHOUT|2021-03-23|65
e|IS|12c24fff-080b-4889-a455-ff55d5c0536c|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^3/hpf|[?]|1|U/m2|GASTRIC FLUID|IMMUNOFIXATION ELECTROPHORESIS||Y|1|5|Visit_5|90|3|TREATMENT|2021-04-17|90
e|IS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/L DDU|[?]|1|AMPULE|GASTRIC FLUID|PLETHYSMOGRAPHY|||1|1|Visit_1|10|6|SCREENING|2021-01-21|10
e|IS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CIGARETTE|[?]|1|% INHIBITION|PLATELET RICH PLASMA|CONTRAST ENHANCED PET/CT SCAN|||1|2|Visit_2|25|1|TREATMENT|2021-02-05|25
e|IS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/10^12 RBC|[?]|1|/LSQN|VENOUS CORD BLOOD|FLUORESCENT IMMUNOASSAY|||1|3|Visit_3|40|5|TREATMENT|2021-02-20|40
e|IS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|BE/mL|[?]|1|K|SMEGMA|HPLC/MS|||1|4|Visit_4|65|6|TREATMENT|2021-03-17|65
e|IS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Henry|[?]|1|log10 PFU/mL|URINE|PET/MRI SCAN||Y|1|5|Visit_5|90|5|TREATMENT|2021-04-11|90
e|IS|05a142dc-a779-44cb-ab2e-f961676a3940|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|L/h|[?]|1|m3|PLASMA ULTRAFILTRATE|SLIT LAMP PHOTOGRAPHY|Y||1|1|Visit_1|10|4|TREATMENT|2020-11-18|10
e|IS|05a142dc-a779-44cb-ab2e-f961676a3940|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Ci/g|[?]|1|RNA copies/mL|VENOUS PLASMA|HPLC||Y|1|2|Visit_2|25|6|TREATMENT|2020-12-03|25
e|IS|05a142dc-a779-44cb-ab2e-f961676a3940|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/kg|[?]|1|BAU/mL|SWABBED MATERIAL|LAPAROSCOPY|Y||1|3|Visit_3|40|7|TREATMENT|2020-12-18|40
e|IS|05a142dc-a779-44cb-ab2e-f961676a3940|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|fmol|[?]|1|dpm/100mg|TISSUE|MALDI-TOF|Y||1|4|Visit_4|65|2|WASHOUT|2021-01-12|65
e|IS|05a142dc-a779-44cb-ab2e-f961676a3940|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/L|[?]|1|10^9 organisms|PLEURAL TISSUE|ETDRS EYE CHART||Y|1|5|Visit_5|90|4|SCREENING|2021-02-06|90
e|IS|498524c5-08c4-41a4-af81-876ab2452f64|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|nmol/L|[?]|1|mg/h|CORD BLOOD|PHASE CONTRAST MICROSCOPY||Y|1|1|Visit_1|10|5|TREATMENT|2020-12-09|10
e|IS|498524c5-08c4-41a4-af81-876ab2452f64|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|EU|[?]|1|CAPSULE|ALVEOLAR AIR|HIGH RESOLUTION MELT ANALYSIS|Y||1|2|Visit_2|25|3|WASHOUT|2020-12-24|25
e|IS|498524c5-08c4-41a4-af81-876ab2452f64|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/g/day|[?]|1|POUCH|SEMEN|PULSE OXIMETRY|Y||1|3|Visit_3|40|5|TREATMENT|2021-01-08|40
e|IS|498524c5-08c4-41a4-af81-876ab2452f64|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|L/s|[?]|1|mL/cage|CELL PELLET|PERFUSION MRI||Y|1|4|Visit_4|65|7|SCREENING|2021-02-02|65
e|IS|498524c5-08c4-41a4-af81-876ab2452f64|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PIXELS/in|[?]|1|QUANTITY SUFFICIENT|HAIR|TRIPLE-PHASE MRI SCAN|||1|5|Visit_5|90|6|TREATMENT|2021-02-27|90
e|IS|93490930-01cd-470e-81a3-bcd7a140ccc1|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mPa|[?]|1|U/kg/min|MIXED VENOUS BLOOD|EEG|||1|1|Visit_1|10|6|TREATMENT|2020-11-17|10
e|IS|93490930-01cd-470e-81a3-bcd7a140ccc1|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|NEBULE|[?]|1|CAN|ATHEROSCLEROTIC PLAQUE|QUANTITATIVE CORONARY ANGIOGRAPHY||Y|1|2|Visit_2|25|2|WASHOUT|2020-12-02|25
e|IS|93490930-01cd-470e-81a3-bcd7a140ccc1|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mEq|[?]|1|min*mg/mL|SUPERNATANT, SERUM OR PLASMA|QUANTITATIVE COMPUTED TOMOGRAPHY|Y|Y|1|3|Visit_3|40|6|TREATMENT|2020-12-17|40
e|IS|93490930-01cd-470e-81a3-bcd7a140ccc1|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 U|[?]|1|pg/L|DISCHARGE|WEBER GREEN STAIN|Y||1|4|Visit_4|65|5|WASHOUT|2021-01-11|65
e|IS|93490930-01cd-470e-81a3-bcd7a140ccc1|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SQU/mL|[?]|1|EVENTS|EMOTIONAL TEAR|IMMUNE REPERTOIRE DEEP SEQUENCING|Y||1|5|Visit_5|90|4|WASHOUT|2021-02-05|90
e|IS|fd588c97-c57f-432f-81a0-a116a017c5dd|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mol|[?]|1|pt_br|SUPERNATANT, PLASMA|PHOTOMETRIC CLOT DETECTION|||1|1|Visit_1|10|1|WASHOUT|2020-06-03|10
e|IS|fd588c97-c57f-432f-81a0-a116a017c5dd|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MnFI|[?]|1|g/day|CERUMEN|SIZE EXCLUSION CHROMATOGRAPHY|Y|Y|1|2|Visit_2|25|4|WASHOUT|2020-06-18|25
e|IS|fd588c97-c57f-432f-81a0-a116a017c5dd|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|SQU/mL|[?]|1|PACK|CARDIAC MUSCLE TISSUE|X-RAY FLUORESCENCE SPECTROMETRY|||1|3|Visit_3|40|6|SCREENING|2020-07-03|40
e|IS|fd588c97-c57f-432f-81a0-a116a017c5dd|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cm H2O|[?]|1|tsp|SERUM OR PLASMA|ROMANOWSKY STAIN|||1|4|Visit_4|65|7|WASHOUT|2020-07-28|65
e|IS|fd588c97-c57f-432f-81a0-a116a017c5dd|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm2|[?]|1|DAgU|DIALYSIS FLUID|HPLC-FL|||1|5|Visit_5|90|4|SCREENING|2020-08-22|90
e|IS|18028efc-33b9-4741-a47a-8fdac0a90e6e|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9/L|[?]|1|mL/day|ARTERIAL BLOOD|RADIOIMMUNOPRECIPITATION ASSAY|||1|1|Visit_1|10|4|WASHOUT|2020-12-22|10
e|IS|18028efc-33b9-4741-a47a-8fdac0a90e6e|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mol/mL|[?]|1|mg/day|MIXED VENOUS BLOOD|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|2|Visit_2|25|4|FOLLOW-UP|2021-01-06|25
e|IS|18028efc-33b9-4741-a47a-8fdac0a90e6e|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/m2/min|[?]|1|mCi/kg|PLASMA|MIGET||Y|1|3|Visit_3|40|4|WASHOUT|2021-01-21|40
e|IS|18028efc-33b9-4741-a47a-8fdac0a90e6e|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|beats/min|[?]|1|kUSP|CEREBROSPINAL FLUID|DARK FIELD MICROSCOPY|||1|4|Visit_4|65|3|FOLLOW-UP|2021-02-15|65
e|IS|18028efc-33b9-4741-a47a-8fdac0a90e6e|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/m2/min|[?]|1|mEq|INFRANATANT, PLEURAL FLUID|ORCHIDOMETERY|||1|5|Visit_5|90|6|FOLLOW-UP|2021-03-12|90
e|IS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/animal/wk|[?]|1|umol/L/sec|SEMINAL FLUID|MANUAL CLOT DETECTION|Y||1|1|Visit_1|10|5|FOLLOW-UP|2020-06-04|10
e|IS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ka_u/dL|[?]|1|uL/mL|LYSATE|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|2|Visit_2|25|6|TREATMENT|2020-06-19|25
e|IS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^7 TCID 50/dose|[?]|1|10^3 RNA copies/mL|ALVEOLAR AIR|IRON HEMATOXYLIN STAIN|Y||1|3|Visit_3|40|7|TREATMENT|2020-07-04|40
e|IS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|JDF Unit|[?]|1|nmol/mL/min|SUPERNATANT, SERUM|KINYOUN STAIN|Y||1|4|Visit_4|65|2|FOLLOW-UP|2020-07-29|65
e|IS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|WEEKS|LOCHIA|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|1|5|Visit_5|90|1|WASHOUT|2020-08-23|90
e|IS|08fccce4-64bf-431e-81b0-a96566e77df6|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DAgU|[?]|1|mL/min|MUSCLE TISSUE|GRADIENT DIFFUSION|||1|1|Visit_1|10|7|WASHOUT|2021-01-20|10
e|IS|08fccce4-64bf-431e-81b0-a96566e77df6|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/m2/min|[?]|1|kg/cm2|SUPERNATANT, SERUM OR PLASMA|ELECTROCHEMILUMINESCENCE|||1|2|Visit_2|25|6|WASHOUT|2021-02-04|25
e|IS|08fccce4-64bf-431e-81b0-a96566e77df6|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|tuberculin unit|[?]|1|10^6 IU/mL|ABSCESS FLUID|DXA SCAN|||1|3|Visit_3|40|4|TREATMENT|2021-02-19|40
e|IS|08fccce4-64bf-431e-81b0-a96566e77df6|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/cm H2O|[?]|1|fmol/L/sec|SUPERNATANT, PLEURAL FLUID|CLAUSS METHOD|||1|4|Visit_4|65|5|SCREENING|2021-03-16|65
e|IS|08fccce4-64bf-431e-81b0-a96566e77df6|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|dL|[?]|1|nmol BCE/mmol|MIXED VENOUS BLOOD|FLOCCULATION, CHARCOAL ENHANCED|||1|5|Visit_5|90|4|TREATMENT|2021-04-10|90
e|IS|0354fab5-5636-4504-8345-af060ad4c90c|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|SQU/mL|[?]|1|L/day|VENOUS BLOOD|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|1|Visit_1|10|5|TREATMENT|2021-01-23|10
e|IS|0354fab5-5636-4504-8345-af060ad4c90c|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6 RNA copies/mL|[?]|1|IU/L|SKELETAL MUSCLE TISSUE|PEAK FLOWMETRY|Y|Y|1|2|Visit_2|25|5|TREATMENT|2021-02-07|25
e|IS|0354fab5-5636-4504-8345-af060ad4c90c|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|atm|[?]|1|g/L|LEUKOCYTE|PLETHYSMOGRAPHY|||1|3|Visit_3|40|6|FOLLOW-UP|2021-02-22|40
e|IS|0354fab5-5636-4504-8345-af060ad4c90c|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mU|[?]|1|g/mol|SWABBED MATERIAL|HIGH RESOLUTION MELT ANALYSIS|||1|4|Visit_4|65|7|TREATMENT|2021-03-19|65
e|IS|0354fab5-5636-4504-8345-af060ad4c90c|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|F|[?]|1|LB|BUFFY COAT|GC/MS-EI|||1|5|Visit_5|90|1|TREATMENT|2021-04-13|90
e|IS|f4f1a53a-d621-4f75-b44e-96b959aed03d|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|gMFI|[?]|1|mL/(min*100mL)|PUS|WEBER GREEN STAIN|||1|1|Visit_1|10|7|TREATMENT|2021-01-09|10
e|IS|f4f1a53a-d621-4f75-b44e-96b959aed03d|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Torr|[?]|1|mL/m2|MONOCYTE|ANTIBIOTIC AGAR SCREEN|Y|Y|1|2|Visit_2|25|7|TREATMENT|2021-01-24|25
e|IS|f4f1a53a-d621-4f75-b44e-96b959aed03d|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uCi|[?]|1|ugEq|DERMAL TISSUE|ELECTROMYOGRAPHY|||1|3|Visit_3|40|4|SCREENING|2021-02-08|40
e|IS|f4f1a53a-d621-4f75-b44e-96b959aed03d|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|NEBULE|[?]|1|genEq|BILE|MACRO BROTH DILUTION|Y||1|4|Visit_4|65|3|TREATMENT|2021-03-05|65
e|IS|f4f1a53a-d621-4f75-b44e-96b959aed03d|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/m2/h|[?]|1|umol/min|BASAL TEAR|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|5|Visit_5|90|1|TREATMENT|2021-03-30|90
e|IS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|EU|[?]|1|mL/animal|MUCUS|DXA SCAN|||1|1|Visit_1|10|4|TREATMENT|2020-10-01|10
e|IS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mmAL|[?]|1|CONTAINER|SMEGMA|IMMUNOASSAY|Y||1|2|Visit_2|25|3|FOLLOW-UP|2020-10-16|25
e|IS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mEq/mL|[?]|1|IU/mmol|SWABBED MATERIAL|DIFFUSION TENSOR MRI|Y||1|3|Visit_3|40|2|WASHOUT|2020-10-31|40
e|IS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ft3|[?]|1|titer|SWABBED MATERIAL|CONTRAST ENHANCED PET SCAN||Y|1|4|Visit_4|65|5|TREATMENT|2020-11-25|65
e|IS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/L|[?]|1|fmol|ARTERIAL BLOOD|GC/FID||Y|1|5|Visit_5|90|1|TREATMENT|2020-12-20|90
e|IS|679423a4-92cf-4a93-8277-282f9b43f2ed|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|L/s|[?]|1|pkat|CALCULUS|OLIGO ACGH|||1|1|Visit_1|10|6|TREATMENT|2020-08-03|10
e|IS|679423a4-92cf-4a93-8277-282f9b43f2ed|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|%(w/v)|[?]|1|MASK|REFLEX TEAR|PERIPHERAL ANGIOGRAPHY|||1|2|Visit_2|25|5|WASHOUT|2020-08-18|25
e|IS|679423a4-92cf-4a93-8277-282f9b43f2ed|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Pa|[?]|1|/min|EXUDATE|ROMANOWSKY STAIN|||1|3|Visit_3|40|3|WASHOUT|2020-09-02|40
e|IS|679423a4-92cf-4a93-8277-282f9b43f2ed|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mmol/L|[?]|1|PIXELS/cm|CALCULUS|ETDRS EYE CHART||Y|1|4|Visit_4|65|5|WASHOUT|2020-09-27|65
e|IS|679423a4-92cf-4a93-8277-282f9b43f2ed|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PIPE|[?]|1|uCi/L|MONOCYTE|MICROSCOPY|||1|5|Visit_5|90|3|TREATMENT|2020-10-22|90
e|IS|fb686cda-337b-46aa-b67b-790414201d9a|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DAgU|[?]|1|GBq/g|GASTRIC CONTENTS|KNEMOMETRY||Y|1|1|Visit_1|10|1|TREATMENT|2020-05-26|10
e|IS|fb686cda-337b-46aa-b67b-790414201d9a|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|POUCH|[?]|1|tuberculin unit|COLOSTRUM|SPECT SCAN|Y|Y|1|2|Visit_2|25|6|TREATMENT|2020-06-10|25
e|IS|fb686cda-337b-46aa-b67b-790414201d9a|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|L/day|[?]|1|Arbitrary U|PLATELET RICH PLASMA|DOUBLE IMMUNODIFFUSION|||1|3|Visit_3|40|4|WASHOUT|2020-06-25|40
e|IS|fb686cda-337b-46aa-b67b-790414201d9a|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U|[?]|1|ug/mL/h|LYSATE|INFRARED SPECTROMETRY|||1|4|Visit_4|65|5|TREATMENT|2020-07-20|65
e|IS|fb686cda-337b-46aa-b67b-790414201d9a|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|m3|[?]|1|ng/day|SMOOTH MUSCLE TISSUE|FISH|||1|5|Visit_5|90|6|TREATMENT|2020-08-14|90
e|IS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/wk|[?]|1|cmH2O/mL|VITREOUS HUMOR|MICROBIAL CULTURE, SOLID|Y||1|1|Visit_1|10|2|WASHOUT|2020-10-05|10
e|IS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nmol/mL/min|[?]|1|ug/h|ENDOMETRIAL TISSUE|CALIPER MEASUREMENT METHOD|||1|2|Visit_2|25|3|SCREENING|2020-10-20|25
e|IS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|titer|[?]|1|U/m2|KERATINOCYTE|HEMAGGLUTINATION INHIBITION ASSAY|Y||1|3|Visit_3|40|6|SCREENING|2020-11-04|40
e|IS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|days/month|[?]|1|mg/m2/day|PERIPHERAL BLOOD MONONUCLEAR CELL|PET/CT SCAN||Y|1|4|Visit_4|65|2|TREATMENT|2020-11-29|65
e|IS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|steps/min|[?]|1|kUSP|EMESIS|NUCLEIC ACID HYBRIDIZATION|||1|5|Visit_5|90|2|TREATMENT|2020-12-24|90
e|IS|92d7a180-9353-41f8-93e2-ebcee32a1c63|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|%(w/w)|[?]|1|10^9 organisms|SERUM OR PLASMA OR BLOOD|TRIPLE-PHASE MRI SCAN|||1|1|Visit_1|10|7|FOLLOW-UP|2020-12-06|10
e|IS|92d7a180-9353-41f8-93e2-ebcee32a1c63|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kg/cm|[?]|1|log10 PFU/mL|TRANSUDATE|TRICHROME STAIN|||1|2|Visit_2|25|6|SCREENING|2020-12-21|25
e|IS|92d7a180-9353-41f8-93e2-ebcee32a1c63|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|OD Unit|[?]|1|10^6 CFU/g|LUNG SURFACTANT|HEMOCYTOMETRY|||1|3|Visit_3|40|7|TREATMENT|2021-01-05|40
e|IS|92d7a180-9353-41f8-93e2-ebcee32a1c63|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|deg2|[?]|1|ms2|LOCHIA|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|4|Visit_4|65|4|TREATMENT|2021-01-30|65
e|IS|92d7a180-9353-41f8-93e2-ebcee32a1c63|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|psec|[?]|1|uOsm|SERUM|TEST STRIP||Y|1|5|Visit_5|90|1|FOLLOW-UP|2021-02-24|90
e|IS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/animal|[?]|1|tuberculin unit/mL|SUPERNATANT, CEREBROSPINAL FLUID|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y||1|1|Visit_1|10|6|SCREENING|2020-10-17|10
e|IS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^10/L|[?]|1|CIGARETTE|INFRANATANT, PLEURAL FLUID|HPLC-FL|||1|2|Visit_2|25|3|TREATMENT|2020-11-01|25
e|IS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mEq/mL|[?]|1|cd/m2|SUPERNATANT, SERUM OR PLASMA|CALCOFLUOR WHITE STAIN|||1|3|Visit_3|40|2|TREATMENT|2020-11-16|40
e|IS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mol/L|[?]|1|10^9 CFU|HAIR|SLIT LAMP|Y||1|4|Visit_4|65|7|TREATMENT|2020-12-11|65
e|IS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|kcal|[?]|1|TRANSDUCING UNIT|ARTERIALIZED CAPILLARY BLOOD|DARK FIELD MICROSCOPY|||1|5|Visit_5|90|6|TREATMENT|2021-01-05|90
e|IS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|nmol/mL/min|[?]|1|ohm|SERUM OR PLASMA OR BLOOD|SCANNING ELECTRON MICROSCOPY|Y||1|1|Visit_1|10|2|TREATMENT|2020-11-21|10
e|IS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/m2/min|[?]|1|nmol/mol|AQUEOUS HUMOR|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y|1|2|Visit_2|25|4|FOLLOW-UP|2020-12-06|25
e|IS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IU/g Hb|[?]|1|CIGAR|URINE|BAC ACGH||Y|1|3|Visit_3|40|1|TREATMENT|2020-12-21|40
e|IS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Watt|[?]|1|MPS U|DIALYSIS FLUID, PERITONEAL|MANUAL COUNT|Y||1|4|Visit_4|65|7|FOLLOW-UP|2021-01-15|65
e|IS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/kg/day|[?]|1|ft2|EXPIRED AIR|PATHOLOGICAL EVALUATION||Y|1|5|Visit_5|90|3|TREATMENT|2021-02-09|90
e|IS|4a195822-d646-4b22-a3b9-f6642442474d|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kBq|[?]|1|EU|SPERMATOZOON|CINEANGIOGRAPHY|Y||1|1|Visit_1|10|2|TREATMENT|2020-07-25|10
e|IS|4a195822-d646-4b22-a3b9-f6642442474d|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ka_u/dL|[?]|1|umol/L/h|BONE MARROW MONONUCLEAR CELL|DYNAMIC CONTRAST ENHANCED MRI|||1|2|Visit_2|25|2|SCREENING|2020-08-09|25
e|IS|4a195822-d646-4b22-a3b9-f6642442474d|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|NFIU|[?]|1|mL/kg/day|LUNG SURFACTANT|SLIT LAMP|Y|Y|1|3|Visit_3|40|6|FOLLOW-UP|2020-08-24|40
e|IS|4a195822-d646-4b22-a3b9-f6642442474d|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|BP|[?]|1|mAnson U/mL|PLATELET POOR PLASMA|CONTRAST ENHANCED MRI||Y|1|4|Visit_4|65|1|TREATMENT|2020-09-18|65
e|IS|4a195822-d646-4b22-a3b9-f6642442474d|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|g/mol|[?]|1|uIU/dL|SALIVA|FARNSWORTH-MUNSELL 100 HUE TEST|||1|5|Visit_5|90|5|SCREENING|2020-10-13|90
e|IS|515808c1-fda7-43bb-91dc-28e2d4e308cd|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|uV|[?]|1|dpm/0.5 mL|LYSATE|FLOW MICROSCOPY|||1|1|Visit_1|10|6|SCREENING|2020-09-07|10
e|IS|515808c1-fda7-43bb-91dc-28e2d4e308cd|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/LSQN|[?]|1|mL/cage/wk|DIALYSIS FLUID|RADIATION DOSIMETRY|||1|2|Visit_2|25|2|TREATMENT|2020-09-22|25
e|IS|515808c1-fda7-43bb-91dc-28e2d4e308cd|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|v/v|[?]|1|mCi/kg|BUFFY COAT|FLOCCULATION, CHARCOAL ENHANCED|Y||1|3|Visit_3|40|6|WASHOUT|2020-10-07|40
e|IS|515808c1-fda7-43bb-91dc-28e2d4e308cd|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|dpm/100mg|[?]|1|mg/h|SALIVA|NUCLEIC ACID SEQUENCING|||1|4|Visit_4|65|6|TREATMENT|2020-11-01|65
e|IS|515808c1-fda7-43bb-91dc-28e2d4e308cd|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cGy|[?]|1|days/wk|SOFT TISSUE|THIN SMEAR||Y|1|5|Visit_5|90|1|WASHOUT|2020-11-26|90
e|IS|18461665-388d-403b-90e4-2b42fcb4a01a|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|anti-Xa IU/mL|[?]|1|FINGERTIP UNIT|COLOSTRUM|NEXT GENERATION SEQUENCING||Y|1|1|Visit_1|10|1|TREATMENT|2020-10-03|10
e|IS|18461665-388d-403b-90e4-2b42fcb4a01a|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PFU/animal|[?]|1|cL|ADIPOSE TISSUE|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||1|2|Visit_2|25|3|FOLLOW-UP|2020-10-18|25
e|IS|18461665-388d-403b-90e4-2b42fcb4a01a|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug|[?]|1|Joule|PERITONEAL FLUID|SPIROMETRY|||1|3|Visit_3|40|2|TREATMENT|2020-11-02|40
e|IS|18461665-388d-403b-90e4-2b42fcb4a01a|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|in|[?]|1|IU/day|URINE SEDIMENT|PHOROPTER|Y||1|4|Visit_4|65|4|WASHOUT|2020-11-27|65
e|IS|18461665-388d-403b-90e4-2b42fcb4a01a|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|L/s|[?]|1|mL/g/min|SOFT TISSUE|PET/MRI SCAN|||1|5|Visit_5|90|1|TREATMENT|2020-12-22|90
e|IS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BAG|[?]|1|ug/m2/day|INFRANATANT, PLASMA|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|1|1|Visit_1|10|1|FOLLOW-UP|2020-08-14|10
e|IS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/10^5|[?]|1|mV|SPUTUM|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||Y|1|2|Visit_2|25|6|TREATMENT|2020-08-29|25
e|IS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^12 IU/L|[?]|1|BAG|DERMAL TISSUE|LIGHT SCATTERING SPECTROSCOPY|||1|3|Visit_3|40|1|WASHOUT|2020-09-13|40
e|IS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Linear ft*LB|[?]|1|Roentgen|URINE|REFRACTOMETRY|||1|4|Visit_4|65|5|FOLLOW-UP|2020-10-08|65
e|IS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Tesla|[?]|1|umol/mg/min|SUPERNATANT, PLASMA|POLYMERASE CHAIN REACTION|Y||1|5|Visit_5|90|2|TREATMENT|2020-11-02|90
e|IS|e3ce1661-1b72-4835-88d1-5a6d3655b674|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ugEq|[?]|1|kat|HAIR FOLLICLE|LINE PROBE ASSAY|Y|Y|1|1|Visit_1|10|7|TREATMENT|2020-08-12|10
e|IS|e3ce1661-1b72-4835-88d1-5a6d3655b674|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|um2|[?]|1|g|REFLEX TEAR|NON-INVASIVE DIELECTRIC SENSING|||1|2|Visit_2|25|5|WASHOUT|2020-08-27|25
e|IS|e3ce1661-1b72-4835-88d1-5a6d3655b674|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BOLUS|[?]|1|PFU/dose|MUSCLE TISSUE|DIFFUSION WEIGHTED MRI|||1|3|Visit_3|40|6|TREATMENT|2020-09-11|40
e|IS|e3ce1661-1b72-4835-88d1-5a6d3655b674|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|GBq/ug|[?]|1|/HPF|PLEURAL FLUID|FARNSWORTH-MUNSELL 100 HUE TEST|||1|4|Visit_4|65|5|FOLLOW-UP|2020-10-06|65
e|IS|e3ce1661-1b72-4835-88d1-5a6d3655b674|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ng/mol|[?]|1|IU|LYMPH|ACCELERATOR MASS SPECTROMETRY||Y|1|5|Visit_5|90|2|TREATMENT|2020-10-31|90
e|IS|240844e9-3dda-438e-81b2-8f6aa4e0427e|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mg/kg|[?]|1|pt_br|CARDIAC MUSCLE TISSUE|IMMUNOPRECIPITATION|Y|Y|1|1|Visit_1|10|5|TREATMENT|2020-12-09|10
e|IS|240844e9-3dda-438e-81b2-8f6aa4e0427e|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|GLOBULE|BONE|HANSEL STAIN||Y|1|2|Visit_2|25|6|SCREENING|2020-12-24|25
e|IS|240844e9-3dda-438e-81b2-8f6aa4e0427e|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mV2/Hz|[?]|1|ELISA unit|SKELETAL MUSCLE TISSUE|PH METER MEASUREMENT METHOD||Y|1|3|Visit_3|40|5|TREATMENT|2021-01-08|40
e|IS|240844e9-3dda-438e-81b2-8f6aa4e0427e|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|P|[?]|1|mmHg|BONE MARROW|QUANTITATIVE ULTRASOUND||Y|1|4|Visit_4|65|5|TREATMENT|2021-02-02|65
e|IS|240844e9-3dda-438e-81b2-8f6aa4e0427e|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/dL|[?]|1|s^-1(%O2)^-1|CAPILLARY BLOOD|GRAM STAIN|||1|5|Visit_5|90|4|TREATMENT|2021-02-27|90
e|IS|fccf5c5d-deb6-4f13-a485-afcda3556578|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mol/day|[?]|1|mL/kg|BUFFY COAT|GC/MS/MS|Y|Y|1|1|Visit_1|10|5|WASHOUT|2020-08-04|10
e|IS|fccf5c5d-deb6-4f13-a485-afcda3556578|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cd*s/m2|[?]|1|CAPFUL|SMEGMA|FARR ASSAY|||1|2|Visit_2|25|6|TREATMENT|2020-08-19|25
e|IS|fccf5c5d-deb6-4f13-a485-afcda3556578|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cpm|[?]|1|mL/min|EXUDATE|IRON HEMATOXYLIN STAIN|Y||1|3|Visit_3|40|4|SCREENING|2020-09-03|40
e|IS|fccf5c5d-deb6-4f13-a485-afcda3556578|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CCID 50/mL|[?]|1|JAR|SYNOVIAL FLUID|ANALYTICAL ULTRACENTRIFUGATION||Y|1|4|Visit_4|65|1|SCREENING|2020-09-28|65
e|IS|fccf5c5d-deb6-4f13-a485-afcda3556578|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol/L/h|[?]|1|min|SOFT TISSUE|PHASE-CONTRAST MRI|||1|5|Visit_5|90|3|SCREENING|2020-10-23|90
e|IS|94620ed0-1ae8-4fa5-a629-9210860b0be9|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/wk|[?]|1|U/kg|BILE|PALM METHOD|||1|1|Visit_1|10|2|FOLLOW-UP|2020-08-04|10
e|IS|94620ed0-1ae8-4fa5-a629-9210860b0be9|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|sec|[?]|1|CIGARETTE|BILE|MAPH|||1|2|Visit_2|25|1|FOLLOW-UP|2020-08-19|25
e|IS|94620ed0-1ae8-4fa5-a629-9210860b0be9|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|APPLICATION|[?]|1|mU|HAIR FOLLICLE|CRYOSCOPY|Y||1|3|Visit_3|40|2|TREATMENT|2020-09-03|40
e|IS|94620ed0-1ae8-4fa5-a629-9210860b0be9|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mmol/L|[?]|1|uIU/L|LYMPH|FREEZING POINT DEPRESSION|Y||1|4|Visit_4|65|1|TREATMENT|2020-09-28|65
e|IS|94620ed0-1ae8-4fa5-a629-9210860b0be9|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|oz eq|[?]|1|CUP|DERMAL TISSUE|CENTRIFUGATION|||1|5|Visit_5|90|6|SCREENING|2020-10-23|90
e|IS|9c3b6912-19be-435c-87fc-781a08efb847|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|breaths/min|[?]|1|mg/kg/day|SPUTUM|IMMUNOCHEMILUMINOMETRIC ASSAY|||1|1|Visit_1|10|1|TREATMENT|2021-01-22|10
e|IS|9c3b6912-19be-435c-87fc-781a08efb847|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^3 CFU|[?]|1|fraction of 1|EMOTIONAL TEAR|IMPEDANCE CONDUCTIVITY|||1|2|Visit_2|25|7|SCREENING|2021-02-06|25
e|IS|9c3b6912-19be-435c-87fc-781a08efb847|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|U/kg|[?]|1|/2500 WBC|ENDOMETRIAL TISSUE|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||Y|1|3|Visit_3|40|2|TREATMENT|2021-02-21|40
e|IS|9c3b6912-19be-435c-87fc-781a08efb847|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/L|[?]|1|RING|RETICULOCYTES|DIRECT SEQUENCING|Y|Y|1|4|Visit_4|65|6|TREATMENT|2021-03-18|65
e|IS|9c3b6912-19be-435c-87fc-781a08efb847|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|g/L|[?]|1|steps/min|CAPILLARY PLASMA|PUPILLOMETRY|Y||1|5|Visit_5|90|4|TREATMENT|2021-04-12|90
e|IS|171a6d85-ba2e-45da-b31b-01651b26e890|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|umol/L/sec|[?]|1|U/mL|VENOUS CORD BLOOD|TRANSTHORACIC ECHOCARDIOGRAPHY|Y|Y|1|1|Visit_1|10|5|TREATMENT|2020-08-02|10
e|IS|171a6d85-ba2e-45da-b31b-01651b26e890|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|CYLINDER|[?]|1|mL/kg|SUPERNATANT, PLEURAL FLUID|NON-INVASIVE DIELECTRIC SENSING|||1|2|Visit_2|25|3|WASHOUT|2020-08-17|25
e|IS|171a6d85-ba2e-45da-b31b-01651b26e890|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mEq/kg|[?]|1|copies/mL|SUPERNATANT, PLASMA|COMPLEMENT FIXATION|Y||1|3|Visit_3|40|1|FOLLOW-UP|2020-09-01|40
e|IS|171a6d85-ba2e-45da-b31b-01651b26e890|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/day|[?]|1|BOLUS|CEREBROSPINAL FLUID|ELECTROGASTROGRAPHY|||1|4|Visit_4|65|7|FOLLOW-UP|2020-09-26|65
e|IS|171a6d85-ba2e-45da-b31b-01651b26e890|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|km/h|[?]|1|10^7 CFU|AQUEOUS HUMOR|SPECT SCAN|||1|5|Visit_5|90|6|TREATMENT|2020-10-21|90
e|IS|a8338164-1bb5-4474-9432-4d5a81ab30d8|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cm2|[?]|1|mEq/uL|ISOLATE|WHOLE EXOME SEQUENCING||Y|1|1|Visit_1|10|7|SCREENING|2020-12-10|10
e|IS|a8338164-1bb5-4474-9432-4d5a81ab30d8|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|uL/mL|[?]|1|kg/cm|DERMAL TISSUE|NUCLEIC ACID AMPLIFICATION TEST|||1|2|Visit_2|25|7|TREATMENT|2020-12-25|25
e|IS|a8338164-1bb5-4474-9432-4d5a81ab30d8|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|kg|[?]|1|dram|CARDIAC MUSCLE TISSUE|CLINICAL EVALUATION||Y|1|3|Visit_3|40|7|SCREENING|2021-01-09|40
e|IS|a8338164-1bb5-4474-9432-4d5a81ab30d8|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cmH2O/mL|[?]|1|cup eq|EXHALED BREATH CONDENSATE|COULOMETRIC TITRATION|||1|4|Visit_4|65|5|TREATMENT|2021-02-03|65
e|IS|a8338164-1bb5-4474-9432-4d5a81ab30d8|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mU/L|[?]|1|anti-Xa IU|PLEURAL FLUID|ANTIBIOTIC AGAR SCREEN|||1|5|Visit_5|90|2|TREATMENT|2021-02-28|90
e|IS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log EID 50/dose|[?]|1|cd*s/m2|COLOSTRUM|CLIP SEQUENCING|Y|Y|1|1|Visit_1|10|5|WASHOUT|2020-06-17|10
e|IS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|dpm/mL|[?]|1|IU/day|ARTERIAL BLOOD|FLUORESCENT SPOT TEST|Y||1|2|Visit_2|25|7|WASHOUT|2020-07-02|25
e|IS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/min|[?]|1|/kg|MIXED VENOUS BLOOD|MAGNETIC RESONANCE ENTEROGRAPHY|||1|3|Visit_3|40|4|SCREENING|2020-07-17|40
e|IS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Siemens|[?]|1|CCID 50/dose|PLATELET POOR PLASMA|CALIPER MEASUREMENT METHOD||Y|1|4|Visit_4|65|5|SCREENING|2020-08-11|65
e|IS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/L|[?]|1|uL/mL|CERVICOVAGINAL SECRETION|SURFACE PLASMON RESONANCE|||1|5|Visit_5|90|5|SCREENING|2020-09-05|90
e|IS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mEq/g|[?]|1|SPRAY|BUFFY COAT|IRON HEMATOXYLIN STAIN||Y|1|1|Visit_1|10|4|TREATMENT|2020-12-25|10
e|IS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mEq|[?]|1|PFU/animal|URINE SEDIMENT|HPLC/MS/MS|||1|2|Visit_2|25|7|SCREENING|2021-01-09|25
e|IS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|kN/cm2|[?]|1|Ci|SMEGMA|NO INFORMATION||Y|1|3|Visit_3|40|6|TREATMENT|2021-01-24|40
e|IS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mEq/L|[?]|1|/kg|PERITONEAL FLUID|COMPLEMENT FIXATION|||1|4|Visit_4|65|3|TREATMENT|2021-02-18|65
e|IS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^3 RNA copies/mL|[?]|1|Shock Wave|BONE MARROW MONONUCLEAR CELL|STATIC PERIMETRY|||1|5|Visit_5|90|2|WASHOUT|2021-03-15|90
e|IS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|CONTAINER|[?]|1|gMFI|TISSUE|THERMAL IONIZATION MASS SPECTROMETRY||Y|1|1|Visit_1|10|3|WASHOUT|2020-08-14|10
e|IS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|CAPSULE|[?]|1|cGy|ARTERIAL CORD BLOOD|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y||1|2|Visit_2|25|6|FOLLOW-UP|2020-08-29|25
e|IS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|genEq|[?]|1|nmol/mol|ABSCESS FLUID|CONTRAST ENHANCED CT SCAN|||1|3|Visit_3|40|1|TREATMENT|2020-09-13|40
e|IS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|um/day|[?]|1|mm/min|ADIPOSE TISSUE|MAPH|||1|4|Visit_4|65|2|SCREENING|2020-10-08|65
e|IS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Tbsp|[?]|1|um/s|ERYTHROCYTES|GRAM STAIN|Y||1|5|Visit_5|90|6|TREATMENT|2020-11-02|90
e|IS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|copies/mL|[?]|1|umol/L/h|SWABBED MATERIAL|SPIROMETRY|||1|1|Visit_1|10|2|TREATMENT|2021-01-09|10
e|IS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|dL|[?]|1|keV|CEREBROSPINAL FLUID|CLOT DETECTION||Y|1|2|Visit_2|25|5|FOLLOW-UP|2021-01-24|25
e|IS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 CFU/mL|[?]|1|mOsm/L|CEREBROSPINAL FLUID|X-RAY FLUORESCENCE SPECTROMETRY|||1|3|Visit_3|40|4|TREATMENT|2021-02-08|40
e|IS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/MBP|[?]|1|AMPULE|VENOUS BLOOD|GC/MS||Y|1|4|Visit_4|65|7|FOLLOW-UP|2021-03-05|65
e|IS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|HEP|[?]|1|kg/cm|SERUM|SINGLE-MOLECULE ARRAY|||1|5|Visit_5|90|6|WASHOUT|2021-03-30|90
e|IS|87998e13-813a-464d-935c-d5513cd0db5e|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg|[?]|1|SACHET|EPIDERMAL TISSUE|SINGLE-SLICE SPIRAL CT|||1|1|Visit_1|10|7|FOLLOW-UP|2020-08-31|10
e|IS|87998e13-813a-464d-935c-d5513cd0db5e|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|cd*s/m2|[?]|1|mg|TISSUE|MICRODENSITOMETRY|Y||1|2|Visit_2|25|7|SCREENING|2020-09-15|25
e|IS|87998e13-813a-464d-935c-d5513cd0db5e|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/g/day|[?]|1|U/mL|HAIR|POLYSOMNOGRAPHY|||1|3|Visit_3|40|5|TREATMENT|2020-09-30|40
e|IS|87998e13-813a-464d-935c-d5513cd0db5e|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|rpm|[?]|1|OD Unit|SUPERNATANT, SERUM OR PLASMA|HIGH RESOLUTION MELT ANALYSIS|||1|4|Visit_4|65|6|FOLLOW-UP|2020-10-25|65
e|IS|87998e13-813a-464d-935c-d5513cd0db5e|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PIXELS/in|[?]|1|mAnson U/mL|STOOL|HANSEL STAIN||Y|1|5|Visit_5|90|1|TREATMENT|2020-11-19|90
e|IS|7812e96e-ea53-4eb0-8160-d4118c567c9d|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6 IU/mL|[?]|1|umol/mol|ALVEOLAR AIR|SANGER SEQUENCING||Y|1|1|Visit_1|10|7|TREATMENT|2021-01-27|10
e|IS|7812e96e-ea53-4eb0-8160-d4118c567c9d|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|DRUM|SMEGMA|BAC ACGH|Y||1|2|Visit_2|25|4|TREATMENT|2021-02-11|25
e|IS|7812e96e-ea53-4eb0-8160-d4118c567c9d|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uCi|[?]|1|mEq/mL|VENOUS CORD BLOOD|RADIAL IMMUNODIFFUSION|||1|3|Visit_3|40|1|FOLLOW-UP|2021-02-26|40
e|IS|7812e96e-ea53-4eb0-8160-d4118c567c9d|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|U/kg|[?]|1|cg|URINE|RAJI CELL RIA|Y||1|4|Visit_4|65|6|TREATMENT|2021-03-23|65
e|IS|7812e96e-ea53-4eb0-8160-d4118c567c9d|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Enzyme U/L|[?]|1|fg|INFRANATANT, PLASMA|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||1|5|Visit_5|90|1|WASHOUT|2021-04-17|90
e|IS|f9c6c448-0e3d-421f-a63f-be4aeb965256|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|hPa|[?]|1|mL/s/m2|CERUMEN|WHOLE TRANSCRIPTOME SEQUENCING||Y|1|1|Visit_1|10|4|WASHOUT|2020-11-08|10
e|IS|f9c6c448-0e3d-421f-a63f-be4aeb965256|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|TROCHE|[?]|1|uCi|SERUM OR PLASMA|NON-INVASIVE DIELECTRIC SENSING|||1|2|Visit_2|25|1|WASHOUT|2020-11-23|25
e|IS|f9c6c448-0e3d-421f-a63f-be4aeb965256|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|CAPFUL|[?]|1|cm H2O|CORD BLOOD|BRDU CELLULAR PROLIFERATION ASSAY|Y||1|3|Visit_3|40|5|FOLLOW-UP|2020-12-08|40
e|IS|f9c6c448-0e3d-421f-a63f-be4aeb965256|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|USP U|[?]|1|log EID 50/dose|SPERMATOZOON|IMMUNOFLUORESCENT STAIN|||1|4|Visit_4|65|6|WASHOUT|2021-01-02|65
e|IS|f9c6c448-0e3d-421f-a63f-be4aeb965256|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ug/kg/day|[?]|1|10^7 TCID 50/dose|ENDOTRACHEAL FLUID|JAEGER EYE CHART|||1|5|Visit_5|90|7|TREATMENT|2021-01-27|90
e|IS|e8da815a-b53c-46f4-a546-e8553152719f|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mol/mg|[?]|1|CUP|STOOL|MIGET|Y||1|1|Visit_1|10|1|SCREENING|2020-12-27|10
e|IS|e8da815a-b53c-46f4-a546-e8553152719f|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^10/L|[?]|1|U/g Hb|EXUDATE|SPECT SCAN||Y|1|2|Visit_2|25|6|WASHOUT|2021-01-11|25
e|IS|e8da815a-b53c-46f4-a546-e8553152719f|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|DNA copies/ug|[?]|1|PA|SPUTUM|WHOLE TRANSCRIPTOME SEQUENCING|||1|3|Visit_3|40|3|TREATMENT|2021-01-26|40
e|IS|e8da815a-b53c-46f4-a546-e8553152719f|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|LB|[?]|1|mIU/L|BONE MARROW|DYNAMOMETRY|||1|4|Visit_4|65|1|TREATMENT|2021-02-20|65
e|IS|e8da815a-b53c-46f4-a546-e8553152719f|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^9 organisms|[?]|1|mL/beat|ATHEROSCLEROTIC PLAQUE|TOLUIDINE BLUE STAIN|||1|5|Visit_5|90|7|SCREENING|2021-03-17|90
e|IS|701d794b-07b4-4394-a2a4-d31a9f5b743a|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mV|[?]|1|10^7 TCID 50/dose|LEUKOCYTE|ZIEHL NEELSEN ACID FAST STAIN|||1|1|Visit_1|10|6|TREATMENT|2021-01-29|10
e|IS|701d794b-07b4-4394-a2a4-d31a9f5b743a|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|CAPLET|[?]|1|Absorbance U/mL|ARTERIAL CORD BLOOD|CELL OF ORIGIN ASSAY|||1|2|Visit_2|25|2|SCREENING|2021-02-13|25
e|IS|701d794b-07b4-4394-a2a4-d31a9f5b743a|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cm H2O|[?]|1|mm3/mm2/year|SPERMATOZOON|MALDI-TOF|||1|3|Visit_3|40|2|TREATMENT|2021-02-28|40
e|IS|701d794b-07b4-4394-a2a4-d31a9f5b743a|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^3 organisms/g|[?]|1|kat|SEMEN|KINETIC MICROPARTICLE IMMUNOASSAY|||1|4|Visit_4|65|7|WASHOUT|2021-03-25|65
e|IS|701d794b-07b4-4394-a2a4-d31a9f5b743a|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MET*min|[?]|1|mOsm/L|CELL PELLET|CELL BASED BIOASSAY|||1|5|Visit_5|90|5|WASHOUT|2021-04-19|90
e|IS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/m2|[?]|1|U/mL|SERUM OR PLASMA OR BLOOD|WHOLE EXOME SEQUENCING|||1|1|Visit_1|10|3|FOLLOW-UP|2020-12-25|10
e|IS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kV|[?]|1|10^6 U|RETICULOCYTES|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||1|2|Visit_2|25|2|TREATMENT|2021-01-09|25
e|IS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mol/mL|[?]|1|POUCH|GASTRIC CONTENTS|CELL OF ORIGIN ASSAY|||1|3|Visit_3|40|4|TREATMENT|2021-01-24|40
e|IS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|g/cage/wk|[?]|1|cmol/L|EPITHELIAL CELL|CONTRAST ENHANCED PET/CT SCAN|||1|4|Visit_4|65|5|TREATMENT|2021-02-18|65
e|IS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|APL U|[?]|1|kg/cm2|SPUTUM|HEMAGGLUTINATION ASSAY|||1|5|Visit_5|90|6|FOLLOW-UP|2021-03-15|90
e|IS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|foz_br|[?]|1|10^3 CFU/g|DIALYSIS FLUID, PERITONEAL|MAGNETIC RESONANCE ANGIOGRAPHY|||1|1|Visit_1|10|7|TREATMENT|2020-08-10|10
e|IS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mN|[?]|1|DRINK|SMOOTH MUSCLE TISSUE|SPECT SCAN|Y|Y|1|2|Visit_2|25|3|TREATMENT|2020-08-25|25
e|IS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/g/day|[?]|1|pt_br|PLASMA|BAC ACGH|Y||1|3|Visit_3|40|5|TREATMENT|2020-09-09|40
e|IS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|% INHIBITION|[?]|1|RFU|HAIR|OLIGO ACGH|||1|4|Visit_4|65|4|SCREENING|2020-10-04|65
e|IS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^3 CFU|[?]|1|Gy/min|MIXED VENOUS BLOOD|FUNCTIONAL MRI||Y|1|5|Visit_5|90|2|SCREENING|2020-10-29|90
e|IS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/m2/day|[?]|1|/HPF|EPITHELIAL CELL|ELECTROCHEMILUMINESCENCE|||1|1|Visit_1|10|1|FOLLOW-UP|2021-01-02|10
e|IS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|L/kg|[?]|1|10^3 CFU/mL|DERMAL TISSUE|CRYOSCOPY||Y|1|2|Visit_2|25|7|TREATMENT|2021-01-17|25
e|IS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|mg/h|TISSUE|IMMUNORADIOMETRIC ASSAY|||1|3|Visit_3|40|6|SCREENING|2021-02-01|40
e|IS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cm/s|[?]|1|10^9 organisms/mg|INFRANATANT, SERUM|IMMUNOPRECIPITATION|Y||1|4|Visit_4|65|7|TREATMENT|2021-02-26|65
e|IS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mmHg/sec|[?]|1|USP U|ATHEROSCLEROTIC PLAQUE|IMPULSE OSCILLOMETRY|Y||1|5|Visit_5|90|7|TREATMENT|2021-03-23|90
e|IS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|gtt|[?]|1|GPL U/mL|INTERSTITIAL FLUID|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||1|1|Visit_1|10|3|TREATMENT|2020-11-29|10
e|IS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|TRACE|[?]|1|CAN|SEMINAL FLUID|HPLC-UV||Y|1|2|Visit_2|25|5|FOLLOW-UP|2020-12-14|25
e|IS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/day|[?]|1|PELLET|BONE MARROW|SICKLE CELL SOLUBILITY TEST||Y|1|3|Visit_3|40|6|TREATMENT|2020-12-29|40
e|IS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ag|[?]|1|U/mmol|BREAST MILK|SPIRAL CT SCAN WITHOUT CONTRAST|Y||1|4|Visit_4|65|2|SCREENING|2021-01-23|65
e|IS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ft|[?]|1|10^7 TCID 50/dose|ENDOTRACHEAL FLUID|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||1|5|Visit_5|90|2|TREATMENT|2021-02-17|90
e|IS|2661da18-b539-49d8-ac80-9da03c127d21|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|mmHg|SUPERNATANT, PLASMA|X-RAY|||1|1|Visit_1|10|2|SCREENING|2020-07-26|10
e|IS|2661da18-b539-49d8-ac80-9da03c127d21|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/m2|[?]|1|pm|DIALYSIS FLUID|JAEGER EYE CHART||Y|1|2|Visit_2|25|2|SCREENING|2020-08-10|25
e|IS|2661da18-b539-49d8-ac80-9da03c127d21|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/animal|[?]|1|Torr|SOFT TISSUE|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y||1|3|Visit_3|40|6|WASHOUT|2020-08-25|40
e|IS|2661da18-b539-49d8-ac80-9da03c127d21|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/kg/dose|[?]|1|Bq/uL|SWABBED MATERIAL|ACRIDINE ORANGE STAIN|||1|4|Visit_4|65|2|TREATMENT|2020-09-19|65
e|IS|2661da18-b539-49d8-ac80-9da03c127d21|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mol/mL|[?]|1|mV*min|VITREOUS HUMOR|OPHTHALMOSCOPY||Y|1|5|Visit_5|90|7|WASHOUT|2020-10-14|90
e|IS|f1835786-c567-4235-9bd1-f7ffcec12741|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^12/L|[?]|1|uIU/L|DIALYSIS FLUID, PERITONEAL|ISHIHARA COLOR PLATES|||1|1|Visit_1|10|5|WASHOUT|2020-08-06|10
e|IS|f1835786-c567-4235-9bd1-f7ffcec12741|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|uEq/L|[?]|1|U/g Hb|SKELETAL MUSCLE TISSUE|CAPILLARY ELECTROPHORESIS||Y|1|2|Visit_2|25|6|SCREENING|2020-08-21|25
e|IS|f1835786-c567-4235-9bd1-f7ffcec12741|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/min|[?]|1|IU/L|TRANSUDATE|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|3|Visit_3|40|7|TREATMENT|2020-09-05|40
e|IS|f1835786-c567-4235-9bd1-f7ffcec12741|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Ci/g|[?]|1|breaths/min|SOFT TISSUE|ANTIBIOTIC AGAR SCREEN||Y|1|4|Visit_4|65|6|TREATMENT|2020-09-30|65
e|IS|f1835786-c567-4235-9bd1-f7ffcec12741|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nkat|[?]|1|U/m2/h|BREAST MILK|HPLC/MS/MS|Y||1|5|Visit_5|90|4|TREATMENT|2020-10-25|90
e|IS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/cmH2O|[?]|1|Sv|SWABBED MATERIAL|ULTRASOUND|||1|1|Visit_1|10|2|SCREENING|2020-07-10|10
e|IS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cmHg|[?]|1|10^8/L|MUSCLE TISSUE|CELLULOSE TAPE||Y|1|2|Visit_2|25|1|TREATMENT|2020-07-25|25
e|IS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PIPE|[?]|1|g/animal/day|CAPILLARY BLOOD|RADIAL IMMUNODIFFUSION|||1|3|Visit_3|40|3|TREATMENT|2020-08-09|40
e|IS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|%(w/w)|[?]|1|mol/g|SKELETAL MUSCLE TISSUE|MANUAL CLOT DETECTION||Y|1|4|Visit_4|65|3|FOLLOW-UP|2020-09-03|65
e|IS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Ci/mL|[?]|1|uOsm|VENOUS BLOOD|CYSTOSCOPY|Y|Y|1|5|Visit_5|90|4|FOLLOW-UP|2020-09-28|90
e|IS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/L/h|[?]|1|uL/mL|VENOUS PLASMA|SMEAR|Y|Y|1|1|Visit_1|10|4|SCREENING|2020-07-23|10
e|IS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|PNU/mL|[?]|1|pmol|URINE|STATIC PERIMETRY|||1|2|Visit_2|25|2|TREATMENT|2020-08-07|25
e|IS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mol/mL|[?]|1|PFU|CORD SERUM|FLUORESCENT ENZYME IMMUNOASSAY||Y|1|3|Visit_3|40|3|WASHOUT|2020-08-22|40
e|IS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/s/m2|[?]|1|PRESSOR UNITS|VITREOUS HUMOR|PULMONARY ANGIOGRAPHY|||1|4|Visit_4|65|2|TREATMENT|2020-09-16|65
e|IS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|g/mol|[?]|1|mmol/L|PERITONEAL FLUID|CALCOFLUOR WHITE STAIN|||1|5|Visit_5|90|7|SCREENING|2020-10-11|90
e|IS|65c439f8-9658-4ac5-9eae-0837182a90fd|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MdFI|[?]|1|RING|HAIR|MICROBIAL CONCENTRATION|||1|1|Visit_1|10|1|TREATMENT|2020-06-04|10
e|IS|65c439f8-9658-4ac5-9eae-0837182a90fd|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ag|[?]|1|Bq/mg|CERVICOVAGINAL SECRETION|FLOCCULATION|Y||1|2|Visit_2|25|3|TREATMENT|2020-06-19|25
e|IS|65c439f8-9658-4ac5-9eae-0837182a90fd|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ugEq|[?]|1|/10^3|SKIN TISSUE|ELISA|||1|3|Visit_3|40|1|WASHOUT|2020-07-04|40
e|IS|65c439f8-9658-4ac5-9eae-0837182a90fd|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|s*kPa|[?]|1|MET*min|MIXED VENOUS BLOOD|TARGETED GENOME SEQUENCING||Y|1|4|Visit_4|65|3|TREATMENT|2020-07-29|65
e|IS|65c439f8-9658-4ac5-9eae-0837182a90fd|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/cmH2O|[?]|1|PLUG|BONE MARROW MONONUCLEAR CELL|RADIATION DOSIMETRY|||1|5|Visit_5|90|4|FOLLOW-UP|2020-08-23|90
e|IS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MBq/uL|[?]|1|MBP|EPIDERMAL TISSUE|FARR ASSAY|||1|1|Visit_1|10|1|WASHOUT|2020-06-12|10
e|IS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CARTRIDGE|[?]|1|kBq/uL|BONE MARROW MONONUCLEAR CELL|TRIPLE-PHASE SPIRAL CT SCAN|||1|2|Visit_2|25|2|TREATMENT|2020-06-27|25
e|IS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mol/L|[?]|1|DAgU|BONE|INDIRECT IMMUNOFLUORESCENCE|||1|3|Visit_3|40|6|TREATMENT|2020-07-12|40
e|IS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|pmol/g|[?]|1|AMPULE|LEUKOCYTE|FLOCCULATION, CHARCOAL ENHANCED|Y||1|4|Visit_4|65|6|TREATMENT|2020-08-06|65
e|IS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Rad|[?]|1|10^3 CFU/g|VENOUS CORD BLOOD|HPLC/IEX||Y|1|5|Visit_5|90|1|TREATMENT|2020-08-31|90
e|IS|16dcaefa-701c-4863-b010-8ac640aeb55a|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kg/cm|[?]|1|g/mol|VENOUS PLASMA|WHOLE GENOME SEQUENCING|||1|1|Visit_1|10|7|TREATMENT|2020-06-17|10
e|IS|16dcaefa-701c-4863-b010-8ac640aeb55a|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|BU/mL|[?]|1|Gauss|CAPILLARY BLOOD|SPECTROPHOTOMETRY|||1|2|Visit_2|25|3|TREATMENT|2020-07-02|25
e|IS|16dcaefa-701c-4863-b010-8ac640aeb55a|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|vg/mL|[?]|1|U/m2/day|LOCHIA|WHOLE TRANSCRIPTOME SEQUENCING|||1|3|Visit_3|40|2|TREATMENT|2020-07-17|40
e|IS|16dcaefa-701c-4863-b010-8ac640aeb55a|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|BOLUS|[?]|1|min/day|CAPILLARY PLASMA|SPIRAL CT|||1|4|Visit_4|65|1|FOLLOW-UP|2020-08-11|65
e|IS|16dcaefa-701c-4863-b010-8ac640aeb55a|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pm|[?]|1|bel|DIALYSIS FLUID|TARGETED GENOME SEQUENCING|||1|5|Visit_5|90|6|TREATMENT|2020-09-05|90
e|IS|4c19e870-9195-41d8-9c8a-8a54bb428732|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CYLINDER|[?]|1|DIOPTER|SUPERNATANT, SERUM OR PLASMA|INFRARED SPECTROMETRY|||1|1|Visit_1|10|4|TREATMENT|2020-08-03|10
e|IS|4c19e870-9195-41d8-9c8a-8a54bb428732|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nCi|[?]|1|Coulomb|SERUM OR PLASMA|U-HPLC/MS/MS|||1|2|Visit_2|25|2|TREATMENT|2020-08-18|25
e|IS|4c19e870-9195-41d8-9c8a-8a54bb428732|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cmol|[?]|1|mL/animal/wk|SEMEN|POPULATION SEQUENCING|||1|3|Visit_3|40|6|TREATMENT|2020-09-02|40
e|IS|4c19e870-9195-41d8-9c8a-8a54bb428732|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kPa|[?]|1|mL/kg/min|DISCHARGE|DISK DIFFUSION|||1|4|Visit_4|65|5|FOLLOW-UP|2020-09-27|65
e|IS|4c19e870-9195-41d8-9c8a-8a54bb428732|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|EVENTS|[?]|1|uCi/kg|SEMEN|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||1|5|Visit_5|90|4|WASHOUT|2020-10-22|90
e|IS|7682184f-0801-4315-9c5f-116f7321a2b0|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/s/m2|[?]|1|AgU/mL|SUPERNATANT, PLEURAL FLUID|SNP ARRAY|||1|1|Visit_1|10|5|TREATMENT|2020-12-22|10
e|IS|7682184f-0801-4315-9c5f-116f7321a2b0|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|kg/cm2|[?]|1|POUCH|BLOOD|INFRARED SPECTROMETRY|||1|2|Visit_2|25|6|FOLLOW-UP|2021-01-06|25
e|IS|7682184f-0801-4315-9c5f-116f7321a2b0|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cmol/L|[?]|1|/10^3|CIRCULATING TUMOR CELL|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||1|3|Visit_3|40|6|SCREENING|2021-01-21|40
e|IS|7682184f-0801-4315-9c5f-116f7321a2b0|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|TRACE|[?]|1|mL/day|HAIR|FLUORESCENT ENZYME IMMUNOASSAY|||1|4|Visit_4|65|5|TREATMENT|2021-02-15|65
e|IS|7682184f-0801-4315-9c5f-116f7321a2b0|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/500 WBC|[?]|1|mol/mL|CALCULUS|MICROARRAY|Y||1|5|Visit_5|90|6|TREATMENT|2021-03-12|90
e|IS|c40f9cb3-b597-4614-8ba5-d40849030ff9|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6 IU|[?]|1|mg/min|EXUDATE|DYNAMIC LIGHT SCATTERING|||1|1|Visit_1|10|1|WASHOUT|2020-12-12|10
e|IS|c40f9cb3-b597-4614-8ba5-d40849030ff9|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cg|[?]|1|lx|LAVAGE FLUID|DIFFUSION TENSOR MRI|||1|2|Visit_2|25|5|FOLLOW-UP|2020-12-27|25
e|IS|c40f9cb3-b597-4614-8ba5-d40849030ff9|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Gy/h|[?]|1|mg/kg/dose|PLEURAL FLUID|HPLC/MS/MS|||1|3|Visit_3|40|4|WASHOUT|2021-01-11|40
e|IS|c40f9cb3-b597-4614-8ba5-d40849030ff9|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mmol/min/kPa/L|[?]|1|10^7 PFU|CARDIAC MUSCLE TISSUE|ANALYTICAL ULTRACENTRIFUGATION||Y|1|4|Visit_4|65|7|FOLLOW-UP|2021-02-05|65
e|IS|c40f9cb3-b597-4614-8ba5-d40849030ff9|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/ug|[?]|1|uV2|FLUID|WRIGHT STAIN|||1|5|Visit_5|90|1|WASHOUT|2021-03-02|90
e|IS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|Absorbance U|SPUTUM|ELECTROGASTROGRAPHY||Y|1|1|Visit_1|10|2|TREATMENT|2020-09-09|10
e|IS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|TRACE|[?]|1|CIGAR|EMESIS|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|2|Visit_2|25|2|FOLLOW-UP|2020-09-24|25
e|IS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|tsp eq|[?]|1|g/kg|CERVICOVAGINAL SECRETION|IN VITRO GENE EXPRESSION ASSAY|Y|Y|1|3|Visit_3|40|4|TREATMENT|2020-10-09|40
e|IS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kUSP|[?]|1|scm|TUMOR TISSUE|MICROBIAL CULTURE|Y||1|4|Visit_4|65|6|TREATMENT|2020-11-03|65
e|IS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nm|[?]|1|nmol/L/min|INTERSTITIAL FLUID|HPLC-FL|||1|5|Visit_5|90|4|TREATMENT|2020-11-28|90
e|IS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Ci/mL|[?]|1|mL/m2/min|INFRANATANT, PLEURAL FLUID|MICROBIAL CULTURE|Y|Y|1|1|Visit_1|10|6|FOLLOW-UP|2020-11-07|10
e|IS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|cpm|EMOTIONAL TEAR|PH METER MEASUREMENT METHOD|Y||1|2|Visit_2|25|5|FOLLOW-UP|2020-11-22|25
e|IS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ag|[?]|1|DIP|BILE|RULER MEASUREMENT METHOD|||1|3|Visit_3|40|7|TREATMENT|2020-12-07|40
e|IS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kUSP|[?]|1|umol/mg/min|EPITHELIAL CELL|HEMAGGLUTINATION ASSAY||Y|1|4|Visit_4|65|6|SCREENING|2021-01-01|65
e|IS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|pmol/dL|[?]|1|/VF|ATHEROSCLEROTIC PLAQUE|IHC|||1|5|Visit_5|90|5|TREATMENT|2021-01-26|90
e|IS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|AFU|[?]|1|yd|SKIN TISSUE|IN VITRO GENE EXPRESSION ASSAY|||1|1|Visit_1|10|3|SCREENING|2020-08-22|10
e|IS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6/L|[?]|1|g/cage|DERMAL TISSUE|DISK DIFFUSION|||1|2|Visit_2|25|4|WASHOUT|2020-09-06|25
e|IS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|V/sec|[?]|1|PIPE|LOCHIA|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|3|Visit_3|40|3|TREATMENT|2020-09-21|40
e|IS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|TABLET|[?]|1|10^6 IU/mL|BONE MARROW|SPIROMETRY|||1|4|Visit_4|65|3|WASHOUT|2020-10-16|65
e|IS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|log10 TCID 50/dose|[?]|1|DAYS|GASTRIC FLUID|ELISPOT|||1|5|Visit_5|90|7|SCREENING|2020-11-10|90
e|IS|3da865e8-9680-4112-b6d3-1f5763cfdaae|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Shock Wave|[?]|1|mg/mL/min|SYNOVIAL FLUID|MASS SPECTROMETRY|||1|1|Visit_1|10|3|SCREENING|2021-01-20|10
e|IS|3da865e8-9680-4112-b6d3-1f5763cfdaae|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|L/h/m2|[?]|1|psi|PERIPHERAL BLOOD MONONUCLEAR CELL|LINE PROBE ASSAY|||1|2|Visit_2|25|6|TREATMENT|2021-02-04|25
e|IS|3da865e8-9680-4112-b6d3-1f5763cfdaae|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/m2/h|[?]|1|s^-1(%O2)^-1|SUPERNATANT, CEREBROSPINAL FLUID|OLIGO ACGH|||1|3|Visit_3|40|7|TREATMENT|2021-02-19|40
e|IS|3da865e8-9680-4112-b6d3-1f5763cfdaae|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^6 CFU/mL|[?]|1|Rad|EPIDERMAL TISSUE|NUCLEIC ACID AMPLIFICATION TEST||Y|1|4|Visit_4|65|2|SCREENING|2021-03-16|65
e|IS|3da865e8-9680-4112-b6d3-1f5763cfdaae|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|RNA copies/mL|BREAST MILK|LEAD CITRATE STAIN||Y|1|5|Visit_5|90|2|WASHOUT|2021-04-10|90
e|IS|60afc3a3-56b7-4988-9006-e12f3bc1097c|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log10 CFU/mL|[?]|1|rpm|PUS|REBOUND TONOMETRY|||1|1|Visit_1|10|4|TREATMENT|2020-08-16|10
e|IS|60afc3a3-56b7-4988-9006-e12f3bc1097c|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Absorbance U/min|[?]|1|mL/cm H2O|SEBUM|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|||1|2|Visit_2|25|7|TREATMENT|2020-08-31|25
e|IS|60afc3a3-56b7-4988-9006-e12f3bc1097c|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mmol2/L2|[?]|1|ft|BONE MARROW|SCANNING ELECTRON MICROSCOPY|||1|3|Visit_3|40|5|TREATMENT|2020-09-15|40
e|IS|60afc3a3-56b7-4988-9006-e12f3bc1097c|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|AgU/mL|[?]|1|%(v/v)|CIRCULATING TUMOR CELL|PHOTOMETRY|||1|4|Visit_4|65|3|FOLLOW-UP|2020-10-10|65
e|IS|60afc3a3-56b7-4988-9006-e12f3bc1097c|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|% INHIBITION|[?]|1|cy/cm|TUMOR TISSUE|CYSTOMETRY||Y|1|5|Visit_5|90|2|FOLLOW-UP|2020-11-04|90
e|IS|440119fb-ad46-4348-b236-8e2979c7bf2e|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ELISA unit/mL|[?]|1|Henry|ENDOMETRIAL TISSUE|MODIFIED ACID FAST STAIN||Y|1|1|Visit_1|10|3|TREATMENT|2020-12-16|10
e|IS|440119fb-ad46-4348-b236-8e2979c7bf2e|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|SFC/10^6 PBMC|[?]|1|Antibody Unit|NAIL|PERFUSION MRI|||1|2|Visit_2|25|5|TREATMENT|2020-12-31|25
e|IS|440119fb-ad46-4348-b236-8e2979c7bf2e|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uL/dose|[?]|1|ng/L|BUFFY COAT|PHOTOMETRY|||1|3|Visit_3|40|4|FOLLOW-UP|2021-01-15|40
e|IS|440119fb-ad46-4348-b236-8e2979c7bf2e|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|%/min|[?]|1|Log10 ELISA unit/dose|SALIVA|INTRAVASCULAR ULTRASOUND|||1|4|Visit_4|65|7|SCREENING|2021-02-09|65
e|IS|440119fb-ad46-4348-b236-8e2979c7bf2e|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^9 CFU|[?]|1|10^10/L|CORD SERUM|ENDPOINT DILUTION ASSAY||Y|1|5|Visit_5|90|7|WASHOUT|2021-03-06|90
e|IS|af45a9de-c8aa-4602-8e3b-d16998740ebd|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 PFU|[?]|1|days/month|EPIDERMAL TISSUE|PYROSEQUENCING|Y||1|1|Visit_1|10|5|FOLLOW-UP|2020-06-15|10
e|IS|af45a9de-c8aa-4602-8e3b-d16998740ebd|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^9/dose|[?]|1|mm2|PLEURAL TISSUE|RADIAL IMMUNODIFFUSION|||1|2|Visit_2|25|2|TREATMENT|2020-06-30|25
e|IS|af45a9de-c8aa-4602-8e3b-d16998740ebd|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|STEPS|[?]|1|Gauss|TRANSUDATE|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|3|Visit_3|40|5|TREATMENT|2020-07-15|40
e|IS|af45a9de-c8aa-4602-8e3b-d16998740ebd|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nmol/mL/min|[?]|1|/VF|HAIR|MICRONEUTRALIZATION ASSAY||Y|1|4|Visit_4|65|5|FOLLOW-UP|2020-08-09|65
e|IS|af45a9de-c8aa-4602-8e3b-d16998740ebd|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|copies/ug|[?]|1|IMPLANT|PROSTATIC FLUID|NUCLEIC ACID SEQUENCING|||1|5|Visit_5|90|7|TREATMENT|2020-09-03|90
e|IS|23306866-3fcb-418d-861b-de3bd779260d|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MESF|[?]|1|tsp eq|CORD BLOOD|AUTOMATED COUNT|||1|1|Visit_1|10|1|WASHOUT|2020-07-25|10
e|IS|23306866-3fcb-418d-861b-de3bd779260d|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/cm2|[?]|1|%|SKIN TISSUE|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|2|Visit_2|25|6|TREATMENT|2020-08-09|25
e|IS|23306866-3fcb-418d-861b-de3bd779260d|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MBq/uL|[?]|1|dpm/mg|SUPERNATANT, SERUM|IHC|||1|3|Visit_3|40|6|FOLLOW-UP|2020-08-24|40
e|IS|23306866-3fcb-418d-861b-de3bd779260d|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PIXELS/cm|[?]|1|mol/mol|PERSPIRATION|SANGER SEQUENCING||Y|1|4|Visit_4|65|6|TREATMENT|2020-09-18|65
e|IS|23306866-3fcb-418d-861b-de3bd779260d|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/g/min|[?]|1|ukat|SOFT TISSUE|MICROSCOPY|Y||1|5|Visit_5|90|3|TREATMENT|2020-10-13|90
e|IS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/g/min|[?]|1|mg/mL/day|SMOOTH MUSCLE TISSUE|PH METER MEASUREMENT METHOD|||1|1|Visit_1|10|5|TREATMENT|2020-08-04|10
e|IS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|NEEDLE GAUGE|[?]|1|mCi|INFRANATANT, PLEURAL FLUID|ISHIHARA COLOR PLATES|Y||1|2|Visit_2|25|4|WASHOUT|2020-08-19|25
e|IS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|DAYS|[?]|1|vg/mL|ARTERIAL CORD BLOOD|AUTOREFRACTION|||1|3|Visit_3|40|3|FOLLOW-UP|2020-09-03|40
e|IS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/day|[?]|1|Log10 ELISA unit/dose|TRANSUDATE|DIGITAL PCR ARRAY||Y|1|4|Visit_4|65|6|FOLLOW-UP|2020-09-28|65
e|IS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kg/cm|[?]|1|ug/kg/day|STOOL|IMPULSE OSCILLOMETRY|Y||1|5|Visit_5|90|3|TREATMENT|2020-10-23|90
e|IS|92855d33-eee6-449f-a9e6-c06a1532571f|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U/kg/h|[?]|1|PELLET|SERUM|MICROPARTICLE ENZYME IMMUNOASSAY|||1|1|Visit_1|10|6|WASHOUT|2020-11-29|10
e|IS|92855d33-eee6-449f-a9e6-c06a1532571f|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SFC/10^6 PBMC|[?]|1|EIA unit|SUPERNATANT, PLEURAL FLUID|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||1|2|Visit_2|25|7|TREATMENT|2020-12-14|25
e|IS|92855d33-eee6-449f-a9e6-c06a1532571f|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/month|[?]|1|MET*min|LYMPH|PANENDOSCOPY||Y|1|3|Visit_3|40|6|WASHOUT|2020-12-29|40
e|IS|92855d33-eee6-449f-a9e6-c06a1532571f|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|AMPULE|[?]|1|msec|MENSTRUAL BLOOD|RAJI CELL RIA|Y||1|4|Visit_4|65|4|FOLLOW-UP|2021-01-23|65
e|IS|92855d33-eee6-449f-a9e6-c06a1532571f|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/min|[?]|1|mmAL|RETICULOCYTES|RAJI CELL EIA|Y||1|5|Visit_5|90|2|SCREENING|2021-02-17|90
e|IS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cal|[?]|1|U/g|ERYTHROCYTES|IMMUNOCHEMILUMINOMETRIC ASSAY||Y|1|1|Visit_1|10|5|SCREENING|2021-01-29|10
e|IS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/day|[?]|1|MPS U|DISCHARGE|RAJI CELL RIA|||1|2|Visit_2|25|6|TREATMENT|2021-02-13|25
e|IS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|1/(s*kPa)|[?]|1|anti-Xa IU/mL|STRIATED MUSCLE TISSUE|CELL OF ORIGIN ASSAY|||1|3|Visit_3|40|4|WASHOUT|2021-02-28|40
e|IS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/day|[?]|1|pg/L|LYMPH|ICP-MS|||1|4|Visit_4|65|5|WASHOUT|2021-03-25|65
e|IS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|L/s/kPa|[?]|1|ug/m2/min|ABSCESS FLUID|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|Y|1|5|Visit_5|90|5|TREATMENT|2021-04-19|90
e|IS|40cb9bc3-abec-4158-bdee-becdeceba727|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Bq/mg|[?]|1|10^6 CFU|COLOSTRUM|INTRAVASCULAR ULTRASOUND||Y|1|1|Visit_1|10|2|WASHOUT|2020-10-19|10
e|IS|40cb9bc3-abec-4158-bdee-becdeceba727|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/2500 WBC|[?]|1|ks|SMEGMA|CONTRAST ENHANCED PET SCAN||Y|1|2|Visit_2|25|5|TREATMENT|2020-11-03|25
e|IS|40cb9bc3-abec-4158-bdee-becdeceba727|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|L/min|[?]|1|STRIP|LEUKOCYTE|POLYSOMNOGRAPHY||Y|1|3|Visit_3|40|7|SCREENING|2020-11-18|40
e|IS|40cb9bc3-abec-4158-bdee-becdeceba727|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^12/L|[?]|1|s^-1(%O2)^-1|GASTRIC FLUID|IN SITU HYBRIDIZATION|Y||1|4|Visit_4|65|4|WASHOUT|2020-12-13|65
e|IS|40cb9bc3-abec-4158-bdee-becdeceba727|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/kg|[?]|1|/500 WBC|BONE|U-HPLC/MS/MS||Y|1|5|Visit_5|90|1|TREATMENT|2021-01-07|90
e|IS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cs|[?]|1|CFU/mL|ARTERIAL BLOOD|FUNDUS PHOTOGRAPHY||Y|1|1|Visit_1|10|7|TREATMENT|2020-10-17|10
e|IS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|dpm/mg|[?]|1|pmol/g|CORD BLOOD|ARTERIAL SPIN LABELING FUNCTIONAL MRI||Y|1|2|Visit_2|25|1|TREATMENT|2020-11-01|25
e|IS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|gMFI|[?]|1|umol/L/min|VENOUS PLASMA|LIGHT MICROSCOPY|Y||1|3|Visit_3|40|2|SCREENING|2020-11-16|40
e|IS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BEAM BREAKS|[?]|1|dmol|SPUTUM|HILLMEN COLOR CHART|||1|4|Visit_4|65|1|TREATMENT|2020-12-11|65
e|IS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nmol BCE/L|[?]|1|ug/L DDU|SALIVA|HPLC|||1|5|Visit_5|90|7|TREATMENT|2021-01-05|90
e|IS|616b284a-3fed-4009-bafe-7da10acd537e|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ms/mmHg|[?]|1|cs|SUPERNATANT, PLASMA|FLAME PHOTOMETRY|||1|1|Visit_1|10|7|FOLLOW-UP|2020-09-03|10
e|IS|616b284a-3fed-4009-bafe-7da10acd537e|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|in|[?]|1|m/sec2|SEMINAL FLUID|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||1|2|Visit_2|25|4|FOLLOW-UP|2020-09-18|25
e|IS|616b284a-3fed-4009-bafe-7da10acd537e|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|nmol/day|[?]|1|mg/mol|VENOUS CORD BLOOD|SPECT/CT SCAN|||1|3|Visit_3|40|5|SCREENING|2020-10-03|40
e|IS|616b284a-3fed-4009-bafe-7da10acd537e|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/uL|[?]|1|genEq/mL|SYNOVIAL FLUID|CLINICAL EVALUATION|||1|4|Visit_4|65|5|FOLLOW-UP|2020-10-28|65
e|IS|616b284a-3fed-4009-bafe-7da10acd537e|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mkat|[?]|1|10^6/L|ERYTHROCYTES|FLOCCULATION, CHARCOAL ENHANCED||Y|1|5|Visit_5|90|7|SCREENING|2020-11-22|90
e|IS|d39b53da-187f-4da6-9614-2bd301e9ad05|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PIXEL|[?]|1|PIXELS/cm|INFRANATANT, SERUM|PANENDOSCOPY|||1|1|Visit_1|10|5|SCREENING|2020-10-02|10
e|IS|d39b53da-187f-4da6-9614-2bd301e9ad05|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nkat/L|[?]|1|log10 PFU/mL|CIRCULATING TUMOR CELL|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|Y|1|2|Visit_2|25|4|FOLLOW-UP|2020-10-17|25
e|IS|d39b53da-187f-4da6-9614-2bd301e9ad05|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|AU/mL|[?]|1|mU/g|ARTERIAL BLOOD|CONGO RED STAIN|||1|3|Visit_3|40|1|TREATMENT|2020-11-01|40
e|IS|d39b53da-187f-4da6-9614-2bd301e9ad05|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BAU|[?]|1|tuberculin unit|BONE MARROW|PET/MRI SCAN|||1|4|Visit_4|65|4|FOLLOW-UP|2020-11-26|65
e|IS|d39b53da-187f-4da6-9614-2bd301e9ad05|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^12 IU/L|[?]|1|L/h|SALIVA|RAJI CELL RIA|||1|5|Visit_5|90|7|SCREENING|2020-12-21|90
e|IS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nCi|[?]|1|mmol/g|INTERSTITIAL FLUID|MACRO BROTH DILUTION|||1|1|Visit_1|10|5|WASHOUT|2020-12-04|10
e|IS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/100 WBC|[?]|1|mL/cage/day|SPERMATOZOON|DYNAMIC LIGHT SCATTERING|||1|2|Visit_2|25|2|SCREENING|2020-12-19|25
e|IS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug/mL/h|[?]|1|uEq|CEREBROSPINAL FLUID|EEG|||1|3|Visit_3|40|4|SCREENING|2021-01-03|40
e|IS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|DRINK|[?]|1|ppb|GASTRIC CONTENTS|CONTRAST ENHANCED PET SCAN||Y|1|4|Visit_4|65|1|FOLLOW-UP|2021-01-28|65
e|IS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/kg/min|[?]|1|Frames/s|BASAL TEAR|SINGLE-SLICE SPIRAL CT|||1|5|Visit_5|90|2|TREATMENT|2021-02-22|90
e|IS|e51cf168-af89-44d9-9e56-14785071f6b0|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mol/g|[?]|1|Linear ft*LB|ARTERIAL BLOOD|ULTRASONOGRAPHIC ELASTOGRAPHY|||1|1|Visit_1|10|3|FOLLOW-UP|2020-11-27|10
e|IS|e51cf168-af89-44d9-9e56-14785071f6b0|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|GBq|[?]|1|BOLUS|CALCULUS|DIRECT SEQUENCING|||1|2|Visit_2|25|4|SCREENING|2020-12-12|25
e|IS|e51cf168-af89-44d9-9e56-14785071f6b0|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nmol/day|[?]|1|10^6 organisms|SYNOVIAL FLUID|WESTERN BLOT|||1|3|Visit_3|40|7|WASHOUT|2020-12-27|40
e|IS|e51cf168-af89-44d9-9e56-14785071f6b0|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mEq/day|[?]|1|mg/dL|PLEURAL TISSUE|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|4|Visit_4|65|5|TREATMENT|2021-01-21|65
e|IS|e51cf168-af89-44d9-9e56-14785071f6b0|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cm|[?]|1|USP U|STRIATED MUSCLE TISSUE|DROPLET DIGITAL PCR|Y||1|5|Visit_5|90|5|TREATMENT|2021-02-15|90
e|IS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/g/day|[?]|1|mL/cage|SKELETAL MUSCLE TISSUE|NO INFORMATION|||1|1|Visit_1|10|1|TREATMENT|2020-06-13|10
e|IS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|WAFER|[?]|1|SPRAY|EMESIS|ANALYTICAL ULTRACENTRIFUGATION|||1|2|Visit_2|25|7|SCREENING|2020-06-28|25
e|IS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/kg/h|[?]|1|EID 50/dose|SERUM OR PLASMA OR BLOOD|MICROBIAL CULTURE, SOLID|||1|3|Visit_3|40|7|FOLLOW-UP|2020-07-13|40
e|IS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|IU/day|[?]|1|PFU|WHITE MATTER TISSUE|SPECTROPHOTOMETRY|Y||1|4|Visit_4|65|3|WASHOUT|2020-08-07|65
e|IS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/h|[?]|1|MdFI|TISSUE|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|5|Visit_5|90|6|SCREENING|2020-09-01|90
e|IS|a110e924-90a1-4e84-b47a-410f800fa201|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|BAU/mL|[?]|1|Ejaculate U|PLATELET RICH PLASMA|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||1|1|Visit_1|10|7|WASHOUT|2020-10-29|10
e|IS|a110e924-90a1-4e84-b47a-410f800fa201|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/U|[?]|1|um2|HAIR FOLLICLE|CLAUSS METHOD|Y|Y|1|2|Visit_2|25|5|TREATMENT|2020-11-13|25
e|IS|a110e924-90a1-4e84-b47a-410f800fa201|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|mL/kg/h|ARTERIAL BLOOD|TEST STRIP||Y|1|3|Visit_3|40|4|SCREENING|2020-11-28|40
e|IS|a110e924-90a1-4e84-b47a-410f800fa201|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mV/sec|[?]|1|mol/day|EMESIS|DYNAMOMETRY|||1|4|Visit_4|65|6|WASHOUT|2020-12-23|65
e|IS|a110e924-90a1-4e84-b47a-410f800fa201|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/m2/day|[?]|1|ngEq/L|HAIR FOLLICLE|PERFUSION MRI|||1|5|Visit_5|90|2|TREATMENT|2021-01-17|90
e|IS|40681cb8-5d49-4e1d-b893-f5fad62a0885|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kPa|[?]|1|g/mol|SYNOVIAL FLUID|AGAR DILUTION|||1|1|Visit_1|10|3|WASHOUT|2020-08-08|10
e|IS|40681cb8-5d49-4e1d-b893-f5fad62a0885|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|JDF Unit|[?]|1|10^6 U|PLATELET|SPECT/CT SCAN|Y|Y|1|2|Visit_2|25|4|TREATMENT|2020-08-23|25
e|IS|40681cb8-5d49-4e1d-b893-f5fad62a0885|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Bq/kg|[?]|1|kBq|STRIATED MUSCLE TISSUE|TRYPAN BLUE STAIN|||1|3|Visit_3|40|7|TREATMENT|2020-09-07|40
e|IS|40681cb8-5d49-4e1d-b893-f5fad62a0885|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|titer|[?]|1|vp/mL|CAPILLARY PLASMA|BAC ACGH|||1|4|Visit_4|65|6|TREATMENT|2020-10-02|65
e|IS|40681cb8-5d49-4e1d-b893-f5fad62a0885|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/5x10^4 WBC|[?]|1|mL/cage/day|ARTERIALIZED CAPILLARY BLOOD|ECHOCARDIOGRAPHY|||1|5|Visit_5|90|1|TREATMENT|2020-10-27|90
e|IS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Mile|[?]|1|mg/kg|EMOTIONAL TEAR|GC/MS|Y||1|1|Visit_1|10|5|WASHOUT|2020-12-17|10
e|IS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 organisms/g|[?]|1|/mm2|EMOTIONAL TEAR|RYAN BLUE STAIN|||1|2|Visit_2|25|2|FOLLOW-UP|2021-01-01|25
e|IS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|HEP|[?]|1|BP|BASAL TEAR|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||1|3|Visit_3|40|5|TREATMENT|2021-01-16|40
e|IS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Bq/uL|[?]|1|dB|MUCUS|RADIATION DOSIMETRY|||1|4|Visit_4|65|2|TREATMENT|2021-02-10|65
e|IS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|USP U|[?]|1|ug/m2/min|ENDOMETRIAL TISSUE|POLYSOMNOGRAPHY|||1|5|Visit_5|90|3|FOLLOW-UP|2021-03-07|90
e|IS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Tbsp|[?]|1|foz_br|URINE|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|1|Visit_1|10|3|TREATMENT|2020-09-10|10
e|IS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cmHg|[?]|1|mN|FLUID|DC SHEATH FLOW||Y|1|2|Visit_2|25|3|TREATMENT|2020-09-25|25
e|IS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/dL|[?]|1|mL/g/day|MUCUS|DOPPLER ULTRASOUND|||1|3|Visit_3|40|5|TREATMENT|2020-10-10|40
e|IS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PUFF|[?]|1|10^9 organisms/mL|CAPILLARY BLOOD|GIEMSA STAIN|Y||1|4|Visit_4|65|3|TREATMENT|2020-11-04|65
e|IS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|fL|[?]|1|ug/m2/min|PUS|INTRAVASCULAR ULTRASOUND|Y||1|5|Visit_5|90|5|WASHOUT|2020-11-29|90
e|IS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|log10 TCID 50/dose|[?]|1|mg/m2/day|BONE MARROW MONONUCLEAR CELL|GRADIENT DIFFUSION|||1|1|Visit_1|10|3|TREATMENT|2020-07-12|10
e|IS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Absorbance U|[?]|1|ug/m2/min|PLEURAL FLUID|FISH|||1|2|Visit_2|25|7|TREATMENT|2020-07-27|25
e|IS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|anti-Xa IU|[?]|1|U/animal|COLOSTRUM|AGAR DILUTION|||1|3|Visit_3|40|6|FOLLOW-UP|2020-08-11|40
e|IS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|10^7 TCID 50/dose|CALCULUS|SPECT/CT SCAN|||1|4|Visit_4|65|5|TREATMENT|2020-09-05|65
e|IS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|fmol|[?]|1|dpm/0.5 mL|PLEURAL TISSUE|MICRODENSITOMETRY|Y||1|5|Visit_5|90|1|TREATMENT|2020-09-30|90
e|IS|f81742a2-5250-43d7-a6e2-8fcb1625a114|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Gravitational Unit|[?]|1|10^8 PFU|RETICULOCYTES|SXA SCAN||Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-05-30|10
e|IS|f81742a2-5250-43d7-a6e2-8fcb1625a114|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mIU/L|[?]|1|/min|SERUM OR PLASMA OR BLOOD|CONGO RED STAIN||Y|1|2|Visit_2|25|6|TREATMENT|2020-06-14|25
e|IS|f81742a2-5250-43d7-a6e2-8fcb1625a114|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Ejaculate U|[?]|1|kat|INFRANATANT, SERUM|DARK FIELD MICROSCOPY||Y|1|3|Visit_3|40|1|TREATMENT|2020-06-29|40
e|IS|f81742a2-5250-43d7-a6e2-8fcb1625a114|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/100 HPFs|[?]|1|HOURS|RETICULOCYTES|THIN SMEAR|Y||1|4|Visit_4|65|5|FOLLOW-UP|2020-07-24|65
e|IS|f81742a2-5250-43d7-a6e2-8fcb1625a114|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|uCi/L|[?]|1|U/kg/h|BONE MARROW|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||1|5|Visit_5|90|5|TREATMENT|2020-08-18|90
e|IS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DDU|[?]|1|nmol/day|VENOUS CORD BLOOD|NEXT GENERATION SEQUENCING||Y|1|1|Visit_1|10|1|TREATMENT|2020-06-24|10
e|IS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|V/sec|[?]|1|/mm2|VENOUS PLASMA|EEG|Y||1|2|Visit_2|25|6|TREATMENT|2020-07-09|25
e|IS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|gMFI|[?]|1|/4.0 mL|CELL PELLET|SLOAN LETTER EYE CHART 1.25%|||1|3|Visit_3|40|2|TREATMENT|2020-07-24|40
e|IS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 copies/mL|[?]|1|PIXELS/in|CORD BLOOD|FUNCTIONAL MRI|||1|4|Visit_4|65|5|FOLLOW-UP|2020-08-18|65
e|IS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mmHg/L/min|[?]|1|U.CARR|ABSCESS FLUID|TURBIDIMETRY|Y||1|5|Visit_5|90|6|SCREENING|2020-09-12|90
e|IS|84d68bcc-dc7a-4366-9630-40ce8885351d|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|v/v|[?]|1|dram|BLOOD|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y||1|1|Visit_1|10|4|FOLLOW-UP|2020-06-16|10
e|IS|84d68bcc-dc7a-4366-9630-40ce8885351d|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|EP U|[?]|1|uEq|LYSATE|FLUORESCENT SPOT TEST||Y|1|2|Visit_2|25|4|WASHOUT|2020-07-01|25
e|IS|84d68bcc-dc7a-4366-9630-40ce8885351d|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|gpELISA unit/mL|[?]|1|CFU/mL|MONOCYTE|DNA MICROARRAY|||1|3|Visit_3|40|2|WASHOUT|2020-07-16|40
e|IS|84d68bcc-dc7a-4366-9630-40ce8885351d|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|GLOBULE|[?]|1|BAR|LYSATE|TRIPLE-PHASE SPIRAL CT SCAN||Y|1|4|Visit_4|65|4|SCREENING|2020-08-10|65
e|IS|84d68bcc-dc7a-4366-9630-40ce8885351d|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^3 CFU|[?]|1|mmol/s|FLUID|FUNDUS PHOTOGRAPHY|Y|Y|1|5|Visit_5|90|6|TREATMENT|2020-09-04|90
e|IS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|m3|[?]|1|Enzyme U|INFRANATANT, PLASMA|QUANTITATIVE CORONARY ANGIOGRAPHY|Y|Y|1|1|Visit_1|10|4|TREATMENT|2021-01-08|10
e|IS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|tsp eq|[?]|1|10^5/hpf|KERATINOCYTE|TELLER ACUITY CARDS|||1|2|Visit_2|25|4|TREATMENT|2021-01-23|25
e|IS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|cup eq|CELL PELLET|HEMAGGLUTINATION ASSAY|||1|3|Visit_3|40|5|FOLLOW-UP|2021-02-07|40
e|IS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|L/s/kPa|[?]|1|Watt|SKELETAL MUSCLE TISSUE|ELLA|||1|4|Visit_4|65|1|TREATMENT|2021-03-04|65
e|IS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nmol/day|[?]|1|ELISA unit/mL|BONE|IN SITU HYBRIDIZATION|Y||1|5|Visit_5|90|5|FOLLOW-UP|2021-03-29|90
e|IS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/g/min|[?]|1|umol/kg/min|AMNIOTIC FLUID|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||1|1|Visit_1|10|2|TREATMENT|2020-12-21|10
e|IS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|psi|[?]|1|dpm/0.5 mL|EXUDATE|AGAR PROPORTION|||1|2|Visit_2|25|6|TREATMENT|2021-01-05|25
e|IS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/cage|[?]|1|mmol/min/kPa/L|INFRANATANT, SERUM|POLYMERASE CHAIN REACTION|||1|3|Visit_3|40|2|FOLLOW-UP|2021-01-20|40
e|IS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cmol|[?]|1|amu|ADIPOSE TISSUE|DYNAMOMETRY|Y||1|4|Visit_4|65|2|TREATMENT|2021-02-14|65
e|IS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mOsm/L|[?]|1|Ci|PROSTATIC FLUID|ELISPOT|||1|5|Visit_5|90|1|SCREENING|2021-03-11|90
e|IS|98737dfa-0058-4420-a515-38526f01f90d|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|CUP|[?]|1|deg/mm|ADIPOSE TISSUE|FLUORESCENT SPOT TEST||Y|1|1|Visit_1|10|7|SCREENING|2020-09-09|10
e|IS|98737dfa-0058-4420-a515-38526f01f90d|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Ci/uL|[?]|1|vg/mL|LEUKOCYTE|SPECTROPHOTOMETRY|||1|2|Visit_2|25|3|WASHOUT|2020-09-24|25
e|IS|98737dfa-0058-4420-a515-38526f01f90d|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|HOMEOPATHIC DILUTION|[?]|1|mL/m2/day|BUFFY COAT|DC SHEATH FLOW|||1|3|Visit_3|40|6|SCREENING|2020-10-09|40
e|IS|98737dfa-0058-4420-a515-38526f01f90d|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|mmAL|MONOCYTE|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y|Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-11-03|65
e|IS|98737dfa-0058-4420-a515-38526f01f90d|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uEq/L|[?]|1|mmol/day|ATHEROSCLEROTIC PLAQUE|PULSE OXIMETRY|||1|5|Visit_5|90|4|TREATMENT|2020-11-28|90
e|IS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Ejaculate U|[?]|1|MASK|PLASMA|PHYSICAL EXAMINATION|||1|1|Visit_1|10|4|FOLLOW-UP|2020-10-03|10
e|IS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|fL|[?]|1|kDa|SWABBED MATERIAL|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|2|Visit_2|25|5|TREATMENT|2020-10-18|25
e|IS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/animal|[?]|1|tsp|PLATELET|TONOMETRY||Y|1|3|Visit_3|40|2|TREATMENT|2020-11-02|40
e|IS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|umol/min|[?]|1|ug/kg|COLOSTRUM|CISH||Y|1|4|Visit_4|65|1|WASHOUT|2020-11-27|65
e|IS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|uEq|[?]|1|MPL U/mL|LEUKOCYTE|RADIOGRAPHY|Y||1|5|Visit_5|90|2|WASHOUT|2020-12-22|90
e|IS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/2500 WBC|[?]|1|mm2|SUPERNATANT, PLEURAL FLUID|PANENDOSCOPY||Y|1|1|Visit_1|10|6|FOLLOW-UP|2020-09-20|10
e|IS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/kg/min|[?]|1|dpm/mL|FLUID|MANUAL COUNT|||1|2|Visit_2|25|1|TREATMENT|2020-10-05|25
e|IS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cpm|[?]|1|RING|INFRANATANT, PLASMA|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|3|Visit_3|40|5|TREATMENT|2020-10-20|40
e|IS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PRESSOR UNITS|[?]|1|Farad|MUCUS|GC/MS-EI||Y|1|4|Visit_4|65|4|WASHOUT|2020-11-14|65
e|IS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|m2|[?]|1|MPS U|MUSCLE TISSUE|BAC ACGH|||1|5|Visit_5|90|7|WASHOUT|2020-12-09|90
e|IS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|oz eq|[?]|1|PFU/animal|SALIVA|IMMUNO-PET SCAN|||1|1|Visit_1|10|4|FOLLOW-UP|2020-12-21|10
e|IS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kcal|[?]|1|uIU/L|LYSATE|FLUORESCENCE ANGIOGRAPHY|||1|2|Visit_2|25|3|TREATMENT|2021-01-05|25
e|IS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|km|[?]|1|vp/dose|HAIR|NUCLEAR RADIOLOGY|||1|3|Visit_3|40|6|TREATMENT|2021-01-20|40
e|IS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/m2/day|[?]|1|MET|ABSCESS FLUID|PHOTOGRAPHY|||1|4|Visit_4|65|4|WASHOUT|2021-02-14|65
e|IS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|hPa|[?]|1|10^6 organisms/mL|LYMPH|FLUORESCENT ENZYME IMMUNOASSAY|||1|5|Visit_5|90|7|FOLLOW-UP|2021-03-11|90
e|IS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pmol/g|[?]|1|AMPULE|EMOTIONAL TEAR|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||1|1|Visit_1|10|7|WASHOUT|2020-06-09|10
e|IS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|log10 TCID 50/uL|[?]|1|ug/g/day|BILE|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y|1|2|Visit_2|25|3|TREATMENT|2020-06-24|25
e|IS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|/mm|[?]|1|mmol/mol|CERVICOVAGINAL SECRETION|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|3|Visit_3|40|2|TREATMENT|2020-07-09|40
e|IS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nkat/L|[?]|1|U/mg|SALIVA|PET SCAN|||1|4|Visit_4|65|6|TREATMENT|2020-08-03|65
e|IS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/L FEU|[?]|1|mOsm/L|ALVEOLAR AIR|TEST STRIP|||1|5|Visit_5|90|6|TREATMENT|2020-08-28|90
e|IS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/g|[?]|1|mmol/kg|AMNIOTIC FLUID|CISH|Y||1|1|Visit_1|10|4|WASHOUT|2020-05-28|10
e|IS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6/g|[?]|1|cal|CAPILLARY BLOOD|MULTIPLE BREATH WASHOUT||Y|1|2|Visit_2|25|4|TREATMENT|2020-06-12|25
e|IS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/mm|[?]|1|cd*s/m2|TUMOR TISSUE|CONTRAST ENHANCED MRI|||1|3|Visit_3|40|5|FOLLOW-UP|2020-06-27|40
e|IS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|AU/mL|[?]|1|Hz/s|INFRANATANT, PLEURAL FLUID|FISH||Y|1|4|Visit_4|65|5|WASHOUT|2020-07-22|65
e|IS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/100g/min|[?]|1|DROP|SALIVA|MOUSE PROTECTION ASSAY|||1|5|Visit_5|90|6|SCREENING|2020-08-16|90
e|IS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log10 IU/mL|[?]|1|/100 HPFs|EMESIS|CRYOSCOPY|||1|1|Visit_1|10|2|FOLLOW-UP|2020-11-08|10
e|IS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/m2|[?]|1|Pa|ADIPOSE TISSUE|RAJI CELL RIA|Y||1|2|Visit_2|25|3|SCREENING|2020-11-23|25
e|IS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ft2|[?]|1|AgU/mL|TISSUE|HEMOCYTOMETRY|Y||1|3|Visit_3|40|2|FOLLOW-UP|2020-12-08|40
e|IS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cm|[?]|1|log10 TCID 50/mL|REFLEX TEAR|CARDIAC THERMODILUTION|Y||1|4|Visit_4|65|5|TREATMENT|2021-01-02|65
e|IS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/mmHg|[?]|1|pL|EXUDATE|GEL ELECTROPHORESIS||Y|1|5|Visit_5|90|5|SCREENING|2021-01-27|90
e|IS|7e9f4283-f90b-4f74-939c-b42648e8373c|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^9 CFU/mL|[?]|1|mL/100g/min|KERATINOCYTE|ENDOSCOPY|||1|1|Visit_1|10|3|SCREENING|2020-12-15|10
e|IS|7e9f4283-f90b-4f74-939c-b42648e8373c|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|min|[?]|1|10^3 CFU/mL|CIRCULATING TUMOR CELL|PHYSICAL EXAMINATION|||1|2|Visit_2|25|2|TREATMENT|2020-12-30|25
e|IS|7e9f4283-f90b-4f74-939c-b42648e8373c|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DAgU|[?]|1|pmol/day|EXUDATE|OPTICAL MAPPING|||1|3|Visit_3|40|3|TREATMENT|2021-01-14|40
e|IS|7e9f4283-f90b-4f74-939c-b42648e8373c|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/g/min|[?]|1|/40 HPFs|BONE MARROW MONONUCLEAR CELL|CAPILLARY ELECTROPHORESIS|||1|4|Visit_4|65|2|TREATMENT|2021-02-08|65
e|IS|7e9f4283-f90b-4f74-939c-b42648e8373c|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/kg|[?]|1|PELLET|SPERMATOZOON|LAPAROSCOPY|||1|5|Visit_5|90|5|FOLLOW-UP|2021-03-05|90
e|IS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|IU|[?]|1|L/L|CIRCULATING TUMOR CELL|SPIRAL CT SCAN WITHOUT CONTRAST|Y||1|1|Visit_1|10|7|TREATMENT|2020-10-31|10
e|IS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uEq|[?]|1|ft3|DERMAL TISSUE|IMMUNOTURBIDIMETRY||Y|1|2|Visit_2|25|7|TREATMENT|2020-11-15|25
e|IS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MONTHS|[?]|1|ELISA unit/dose|PUS|MASS SPECTROMETRY|Y||1|3|Visit_3|40|6|SCREENING|2020-11-30|40
e|IS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|umol/mol|[?]|1|pmol/L/h|PLEURAL TISSUE|SPIROMETRY|||1|4|Visit_4|65|4|WASHOUT|2020-12-25|65
e|IS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uU/dL|[?]|1|ppb|BREAST MILK|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y||1|5|Visit_5|90|3|TREATMENT|2021-01-19|90
e|IS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|AgU/mL|[?]|1|mL/animal/wk|SEBUM|KARYOTYPING|||1|1|Visit_1|10|3|TREATMENT|2020-05-16|10
e|IS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BAU|[?]|1|genEq/mL|VENOUS PLASMA|CORONARY ANGIOGRAPHY|||1|2|Visit_2|25|4|TREATMENT|2020-05-31|25
e|IS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|vp/mL|[?]|1|Ci/kg|SALIVA|CONTRAST ENHANCED SPIRAL CT SCAN|||1|3|Visit_3|40|1|FOLLOW-UP|2020-06-15|40
e|IS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/L|[?]|1|mmol|SERUM|SANGER SEQUENCING|||1|4|Visit_4|65|3|WASHOUT|2020-07-10|65
e|IS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mm/h|[?]|1|scm|VENOUS BLOOD|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y||1|5|Visit_5|90|5|SCREENING|2020-08-04|90
e|IS|595aa95c-4378-47c1-96e9-5512d08fb653|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|CFU/g|BONE MARROW|FLUORESCEIN STAIN|||1|1|Visit_1|10|7|WASHOUT|2020-08-23|10
e|IS|595aa95c-4378-47c1-96e9-5512d08fb653|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/dL|[?]|1|mg/kg/week|SUPERNATANT, SERUM OR PLASMA|TARGETED TRANSCRIPTOME SEQUENCING|||1|2|Visit_2|25|4|WASHOUT|2020-09-07|25
e|IS|595aa95c-4378-47c1-96e9-5512d08fb653|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ks|[?]|1|ms2|NAIL|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||1|3|Visit_3|40|4|SCREENING|2020-09-22|40
e|IS|595aa95c-4378-47c1-96e9-5512d08fb653|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|umol/day|[?]|1|mm/2h|VENOUS PLASMA|THICK SMEAR|Y|Y|1|4|Visit_4|65|4|TREATMENT|2020-10-17|65
e|IS|595aa95c-4378-47c1-96e9-5512d08fb653|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mol/L|[?]|1|mV*min|ARTERIAL BLOOD|TOTAL BODY IRRADIATION|||1|5|Visit_5|90|1|TREATMENT|2020-11-11|90
e|IS|b528dc24-e791-41b1-95b3-fc0be18da47f|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Ci/mL|[?]|1|dyn|KERATINOCYTE|CLOT DETECTION||Y|1|1|Visit_1|10|4|FOLLOW-UP|2020-12-27|10
e|IS|b528dc24-e791-41b1-95b3-fc0be18da47f|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|log10 TCID 50/uL|[?]|1|dpm/0.5 mL|GASTRIC CONTENTS|NUCLEIC ACID AMPLIFICATION TEST||Y|1|2|Visit_2|25|1|TREATMENT|2021-01-11|25
e|IS|b528dc24-e791-41b1-95b3-fc0be18da47f|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|/100 WBC|[?]|1|uV|PERIPHERAL BLOOD MONONUCLEAR CELL|VENTILATION PERFUSION LUNG SCAN|||1|3|Visit_3|40|4|TREATMENT|2021-01-26|40
e|IS|b528dc24-e791-41b1-95b3-fc0be18da47f|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Gy/h|[?]|1|PFU/dose|LUNG SURFACTANT|PULMONARY ANGIOGRAPHY||Y|1|4|Visit_4|65|2|WASHOUT|2021-02-20|65
e|IS|b528dc24-e791-41b1-95b3-fc0be18da47f|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Ci/ug|[?]|1|dpm/mg|SPERMATOZOON|PERFUSION MRI|||1|5|Visit_5|90|2|FOLLOW-UP|2021-03-17|90
e|IS|7a43c892-0e7f-4f33-9130-e175e475531f|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ks|[?]|1|m|NAIL|SINGLE-MOLECULE ARRAY|||1|1|Visit_1|10|4|TREATMENT|2020-05-17|10
e|IS|7a43c892-0e7f-4f33-9130-e175e475531f|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|MET|[?]|1|mL/mmHg/min/L|EXUDATE|FLOCCULATION, CHARCOAL ENHANCED|Y||1|2|Visit_2|25|4|TREATMENT|2020-06-01|25
e|IS|7a43c892-0e7f-4f33-9130-e175e475531f|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|CCID 50/mL|[?]|1|pmol/dL|SERUM|ELLA|||1|3|Visit_3|40|4|TREATMENT|2020-06-16|40
e|IS|7a43c892-0e7f-4f33-9130-e175e475531f|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|keV|[?]|1|mEq/mL|MONOCYTE|TRANSTHORACIC ECHOCARDIOGRAPHY|||1|4|Visit_4|65|1|SCREENING|2020-07-11|65
e|IS|7a43c892-0e7f-4f33-9130-e175e475531f|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|PIXELS/cm|[?]|1|fmol|SPERMATOZOON|INCISION-INDUCED BLEEDING METHOD|||1|5|Visit_5|90|4|FOLLOW-UP|2020-08-05|90
e|IS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pm|[?]|1|IU/L|STOOL|FREEZING POINT DEPRESSION|||1|1|Visit_1|10|4|SCREENING|2020-12-10|10
e|IS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mEq/day|[?]|1|mol/mL|CAPILLARY BLOOD|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||1|2|Visit_2|25|7|FOLLOW-UP|2020-12-25|25
e|IS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/mol|[?]|1|EID 50/mL|PLEURAL FLUID|CELLULOSE TAPE||Y|1|3|Visit_3|40|1|WASHOUT|2021-01-09|40
e|IS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nCi|[?]|1|/VF|NAIL|MUGA|||1|4|Visit_4|65|3|TREATMENT|2021-02-03|65
e|IS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/animal|[?]|1|mL/100g/min|SUPERNATANT, SERUM OR PLASMA|LC-FL||Y|1|5|Visit_5|90|3|TREATMENT|2021-02-28|90
e|IS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kIU|[?]|1|/cmH2O|URINE|PULMONARY ANGIOGRAPHY|Y||1|1|Visit_1|10|3|TREATMENT|2020-08-27|10
e|IS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mol/day|[?]|1|cGy|SUPERNATANT, PLASMA|CENTRIFUGATION|||1|2|Visit_2|25|2|TREATMENT|2020-09-11|25
e|IS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|min*mg/mL|[?]|1|BAG|SMEGMA|GRAM STAIN||Y|1|3|Visit_3|40|2|TREATMENT|2020-09-26|40
e|IS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|fraction of 1|[?]|1|C|CERVICOVAGINAL SECRETION|NO INFORMATION|||1|4|Visit_4|65|6|WASHOUT|2020-10-21|65
e|IS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol/kg|[?]|1|deg/s|REFLEX TEAR|GC/MS-CI|||1|5|Visit_5|90|4|TREATMENT|2020-11-15|90
e|IS|ea7907aa-811e-48ec-9fc6-ab8affde8913|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|min|[?]|1|dpm/mg|WHITE MATTER TISSUE|PAP STAIN|||1|1|Visit_1|10|2|TREATMENT|2020-06-28|10
e|IS|ea7907aa-811e-48ec-9fc6-ab8affde8913|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uSiemens|[?]|1|ft3|PERSPIRATION|TOLUIDINE BLUE STAIN|||1|2|Visit_2|25|7|WASHOUT|2020-07-13|25
e|IS|ea7907aa-811e-48ec-9fc6-ab8affde8913|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/kg/min|[?]|1|log10 TCID 50/mL|RETICULOCYTES|PHOTOMETRY|Y||1|3|Visit_3|40|6|TREATMENT|2020-07-28|40
e|IS|ea7907aa-811e-48ec-9fc6-ab8affde8913|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/kg/day|[?]|1|U/mmol|VENOUS PLASMA|GC/FID|||1|4|Visit_4|65|2|FOLLOW-UP|2020-08-22|65
e|IS|ea7907aa-811e-48ec-9fc6-ab8affde8913|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/MBP|[?]|1|CAPSULE|PLEURAL FLUID|PULSE OXIMETRY|||1|5|Visit_5|90|6|WASHOUT|2020-09-16|90
e|IS|3aa9935c-943d-406a-bb6e-fc067fa8a487|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mAnson U/mL|[?]|1|m/sec|CARDIAC MUSCLE TISSUE|FLUORESCEIN STAIN|||1|1|Visit_1|10|2|TREATMENT|2020-08-27|10
e|IS|3aa9935c-943d-406a-bb6e-fc067fa8a487|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/sec|[?]|1|/mm|ISOLATE|SNP ARRAY|||1|2|Visit_2|25|1|TREATMENT|2020-09-11|25
e|IS|3aa9935c-943d-406a-bb6e-fc067fa8a487|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/L FEU|[?]|1|g/mol|ENDOTRACHEAL FLUID|IN VITRO GENE EXPRESSION ASSAY|||1|3|Visit_3|40|6|FOLLOW-UP|2020-09-26|40
e|IS|3aa9935c-943d-406a-bb6e-fc067fa8a487|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|K|[?]|1|g/kg|SERUM OR PLASMA OR BLOOD|CLOT DETECTION|||1|4|Visit_4|65|2|TREATMENT|2020-10-21|65
e|IS|3aa9935c-943d-406a-bb6e-fc067fa8a487|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Gy/min|[?]|1|Absorbance U/mL|INTERSTITIAL FLUID|POLYSOMNOGRAPHY||Y|1|5|Visit_5|90|2|WASHOUT|2020-11-15|90
e|IS|0cac2007-ca12-45ba-9b1c-70f753232f05|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ppb|[?]|1|MONTHS|TUMOR TISSUE|CLOT DETECTION|||1|1|Visit_1|10|7|SCREENING|2020-12-01|10
e|IS|0cac2007-ca12-45ba-9b1c-70f753232f05|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/day|[?]|1|kg/L|ENDOTRACHEAL FLUID|MASS SPECTROMETRY||Y|1|2|Visit_2|25|4|FOLLOW-UP|2020-12-16|25
e|IS|0cac2007-ca12-45ba-9b1c-70f753232f05|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/kg/h|[?]|1|cmol|SWABBED MATERIAL|ISHIHARA COLOR PLATES|||1|3|Visit_3|40|1|TREATMENT|2020-12-31|40
e|IS|0cac2007-ca12-45ba-9b1c-70f753232f05|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/g|[?]|1|pmol/day|CORD SERUM|MUGA|||1|4|Visit_4|65|7|TREATMENT|2021-01-25|65
e|IS|0cac2007-ca12-45ba-9b1c-70f753232f05|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/mL/min|[?]|1|ug/L|PLEURAL TISSUE|KARYOTYPING|Y||1|5|Visit_5|90|3|TREATMENT|2021-02-19|90
e|IS|2339e91a-b93e-426f-9b60-3d3b6969268d|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GBq/g|[?]|1|BU|SPUTUM|SISH|||1|1|Visit_1|10|6|WASHOUT|2020-07-07|10
e|IS|2339e91a-b93e-426f-9b60-3d3b6969268d|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cmH2O*s/mL|[?]|1|pmol/day|PERSPIRATION|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||1|2|Visit_2|25|4|FOLLOW-UP|2020-07-22|25
e|IS|2339e91a-b93e-426f-9b60-3d3b6969268d|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nmol/L/h|[?]|1|DIOPTER|SYNOVIAL FLUID|LISSAMINE GREEN STAIN|||1|3|Visit_3|40|5|WASHOUT|2020-08-06|40
e|IS|2339e91a-b93e-426f-9b60-3d3b6969268d|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|lx|[?]|1|Anson U|SERUM OR PLASMA OR BLOOD|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||1|4|Visit_4|65|6|SCREENING|2020-08-31|65
e|IS|2339e91a-b93e-426f-9b60-3d3b6969268d|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ELISA unit/dose|[?]|1|10^9/g|ARTERIALIZED CAPILLARY BLOOD|SINGLE-SLICE SPIRAL CT|||1|5|Visit_5|90|1|TREATMENT|2020-09-25|90
e|IS|0d09e35b-e864-4492-a341-21c71d92b551|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|tuberculin unit/mL|[?]|1|mph|SOFT TISSUE|STATIC PERIMETRY|||1|1|Visit_1|10|3|FOLLOW-UP|2020-10-30|10
e|IS|0d09e35b-e864-4492-a341-21c71d92b551|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|umol/mg/min|[?]|1|ft|NAIL|HEMAGGLUTINATION INHIBITION ASSAY||Y|1|2|Visit_2|25|5|SCREENING|2020-11-14|25
e|IS|0d09e35b-e864-4492-a341-21c71d92b551|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PHERESIS UNIT|[?]|1|/LPF|BONE|REBOUND TONOMETRY|||1|3|Visit_3|40|3|FOLLOW-UP|2020-11-29|40
e|IS|0d09e35b-e864-4492-a341-21c71d92b551|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^7/L|[?]|1|Bq/g|PLATELET RICH PLASMA|NEXT GENERATION TARGETED SEQUENCING|||1|4|Visit_4|65|5|FOLLOW-UP|2020-12-24|65
e|IS|0d09e35b-e864-4492-a341-21c71d92b551|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|BU/mL|[?]|1|100 IU/mL|VITREOUS HUMOR|CT SCAN WITHOUT CONTRAST|Y||1|5|Visit_5|90|3|WASHOUT|2021-01-18|90
e|IS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|100 IU/mL|[?]|1|/month|CERUMEN|DIRECT SEQUENCING|||1|1|Visit_1|10|6|TREATMENT|2020-06-05|10
e|IS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/dL|[?]|1|uEq|SALIVA|PHOTOMETRIC CLOT DETECTION|||1|2|Visit_2|25|6|WASHOUT|2020-06-20|25
e|IS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mEq/mL|[?]|1|ug/m2|BONE MARROW|JAFFE REACTION|||1|3|Visit_3|40|7|SCREENING|2020-07-05|40
e|IS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/2000 RBC|[?]|1|TUBE|PERSPIRATION|LIGHT MICROSCOPY|||1|4|Visit_4|65|4|SCREENING|2020-07-30|65
e|IS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|log10 CFU/g|[?]|1|mEq/day|CERUMEN|ENZYMATIC COLORIMETRY|||1|5|Visit_5|90|7|TREATMENT|2020-08-24|90
e|IS|0a5b1036-cd00-4221-b218-ee2664e5a43e|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/g|[?]|1|mV|EXPIRED AIR|LIGHT MICROSCOPY||Y|1|1|Visit_1|10|1|TREATMENT|2021-01-02|10
e|IS|0a5b1036-cd00-4221-b218-ee2664e5a43e|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|dyn|[?]|1|10^9 organisms/g|MECONIUM|MICRODENSITOMETRY|||1|2|Visit_2|25|2|TREATMENT|2021-01-17|25
e|IS|0a5b1036-cd00-4221-b218-ee2664e5a43e|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kcal|[?]|1|cs|KERATINOCYTE|TWO-COLOR MICROARRAY|Y||1|3|Visit_3|40|7|FOLLOW-UP|2021-02-01|40
e|IS|0a5b1036-cd00-4221-b218-ee2664e5a43e|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|BAG|[?]|1|10^3 organisms|STRIATED MUSCLE TISSUE|PUPILLOMETRY|||1|4|Visit_4|65|7|TREATMENT|2021-02-26|65
e|IS|0a5b1036-cd00-4221-b218-ee2664e5a43e|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|kN/cm2|[?]|1|g/animal/wk|REFLEX TEAR|HEMOCYTOMETRY|||1|5|Visit_5|90|5|FOLLOW-UP|2021-03-23|90
e|IS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/2500 WBC|[?]|1|pmol/10^9 cells|MUCUS|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||1|1|Visit_1|10|2|TREATMENT|2020-09-30|10
e|IS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|h*%|[?]|1|Antibody Unit|STOOL|ACCELERATOR MASS SPECTROMETRY|||1|2|Visit_2|25|7|WASHOUT|2020-10-15|25
e|IS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/L|[?]|1|10^6 RNA copies/mL|EXPIRED AIR|X-RAY FLUORESCENCE SPECTROMETRY|||1|3|Visit_3|40|1|TREATMENT|2020-10-30|40
e|IS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|RFU|[?]|1|tsp eq|URINE|OPTICAL DENSITY MEASUREMENT|||1|4|Visit_4|65|4|TREATMENT|2020-11-24|65
e|IS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|umol/dL|[?]|1|10^6 DNA copies/mL|WHITE MATTER TISSUE|SIZE EXCLUSION CHROMATOGRAPHY|||1|5|Visit_5|90|6|FOLLOW-UP|2020-12-19|90
e|IS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/kg|[?]|1|lm|INFRANATANT, PLASMA|ETDRS EYE CHART|Y||1|1|Visit_1|10|3|FOLLOW-UP|2020-11-12|10
e|IS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|%(w/w)|[?]|1|OD Unit|SUPERNATANT, SERUM|RAJI CELL RIA|Y||1|2|Visit_2|25|4|TREATMENT|2020-11-27|25
e|IS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|um2|[?]|1|U/g Hb|AMNIOTIC FLUID|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|3|Visit_3|40|5|TREATMENT|2020-12-12|40
e|IS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|ka_u/dL|PLATELET POOR PLASMA|GIEMSA STAIN|Y||1|4|Visit_4|65|5|WASHOUT|2021-01-06|65
e|IS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|msec|[?]|1|mg/mL/day|ATHEROSCLEROTIC PLAQUE|PLETHYSMOGRAPHY|Y||1|5|Visit_5|90|5|FOLLOW-UP|2021-01-31|90
e|IS|e7262592-01e8-4cb3-b967-ec1037505e81|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/500 WBC|[?]|1|mph|LAVAGE FLUID|ETDRS EYE CHART|||1|1|Visit_1|10|6|WASHOUT|2020-09-12|10
e|IS|e7262592-01e8-4cb3-b967-ec1037505e81|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pmol/L|[?]|1|log10 TCID 50/mL|URINE|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||1|2|Visit_2|25|6|TREATMENT|2020-09-27|25
e|IS|e7262592-01e8-4cb3-b967-ec1037505e81|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mPa|[?]|1|USP U|BASAL TEAR|NEPHELOMETRY|||1|3|Visit_3|40|1|TREATMENT|2020-10-12|40
e|IS|e7262592-01e8-4cb3-b967-ec1037505e81|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/L|[?]|1|pt_br|LEUKOCYTE|DC SHEATH FLOW|Y||1|4|Visit_4|65|1|SCREENING|2020-11-06|65
e|IS|e7262592-01e8-4cb3-b967-ec1037505e81|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log EID 50/dose|[?]|1|EID 50/dose|PERSPIRATION|DYNAMIC CONTRAST ENHANCED MRI|Y||1|5|Visit_5|90|3|FOLLOW-UP|2020-12-01|90
e|IS|bf150829-1b25-418a-9bc6-61716984387c|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Ci/mg|[?]|1|Henry|GASTRIC CONTENTS|INCISION-INDUCED BLEEDING METHOD|Y||1|1|Visit_1|10|7|WASHOUT|2020-06-15|10
e|IS|bf150829-1b25-418a-9bc6-61716984387c|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug/kg/min|[?]|1|QUANTITY SUFFICIENT|LYSATE|MS/MS|||1|2|Visit_2|25|7|TREATMENT|2020-06-30|25
e|IS|bf150829-1b25-418a-9bc6-61716984387c|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mV*min|[?]|1|m|VENOUS PLASMA|MICROBIAL CULTURE, LIQUID|||1|3|Visit_3|40|1|SCREENING|2020-07-15|40
e|IS|bf150829-1b25-418a-9bc6-61716984387c|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/mL/day|[?]|1|JAR|PERIPHERAL BLOOD MONONUCLEAR CELL|SINGLE-SLICE SPIRAL CT||Y|1|4|Visit_4|65|6|WASHOUT|2020-08-09|65
e|IS|bf150829-1b25-418a-9bc6-61716984387c|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|FEU|[?]|1|titer|EPITHELIAL CELL|URANYL ACETATE STAIN|||1|5|Visit_5|90|7|SCREENING|2020-09-03|90
e|IS|5c1cc260-97a0-493c-bc11-57f31ffd7455|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Frames/s|[?]|1|deg/s|HAIR|QUANTITATIVE CORONARY ANGIOGRAPHY||Y|1|1|Visit_1|10|6|FOLLOW-UP|2020-09-06|10
e|IS|5c1cc260-97a0-493c-bc11-57f31ffd7455|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^9/g|[?]|1|cpm|NAIL|CONTRAST ENHANCED PET/CT SCAN|Y||1|2|Visit_2|25|5|SCREENING|2020-09-21|25
e|IS|5c1cc260-97a0-493c-bc11-57f31ffd7455|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|cmHg|[?]|1|mg/cm2|SPUTUM|AUTOREFRACTION|||1|3|Visit_3|40|3|SCREENING|2020-10-06|40
e|IS|5c1cc260-97a0-493c-bc11-57f31ffd7455|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MHz|[?]|1|U/mL|MUSCLE TISSUE|FLOCCULATION|||1|4|Visit_4|65|5|FOLLOW-UP|2020-10-31|65
e|IS|5c1cc260-97a0-493c-bc11-57f31ffd7455|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|h*%|[?]|1|10^4/L|ERYTHROCYTES|QUANTITATIVE CORONARY ANGIOGRAPHY|||1|5|Visit_5|90|6|FOLLOW-UP|2020-11-25|90
e|IS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pmol/L|[?]|1|JDF Unit|CERUMEN|NUCLEIC ACID HYBRIDIZATION|||1|1|Visit_1|10|3|WASHOUT|2020-07-19|10
e|IS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mmHg|[?]|1|CONTAINER|SMOOTH MUSCLE TISSUE|REVERSE TRANSCRIPTASE PCR|Y||1|2|Visit_2|25|4|SCREENING|2020-08-03|25
e|IS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dyn|[?]|1|mJoule/cm2|PLATELET RICH PLASMA|ELISA|Y|Y|1|3|Visit_3|40|5|WASHOUT|2020-08-18|40
e|IS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uOsm|[?]|1|Siemens|STRIATED MUSCLE TISSUE|AURAMINE STAIN|||1|4|Visit_4|65|5|TREATMENT|2020-09-12|65
e|IS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uOsm|[?]|1|BOLUS|MONOCYTE|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y|1|5|Visit_5|90|1|SCREENING|2020-10-07|90
e|IS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6 CFU|[?]|1|g/animal/wk|SPERMATOZOON|MIGET||Y|1|1|Visit_1|10|2|WASHOUT|2020-10-07|10
e|IS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|SQU/mL|[?]|1|10^5/L|ENDOMETRIAL TISSUE|PERIODIC ACID SCHIFF STAIN|Y||1|2|Visit_2|25|7|WASHOUT|2020-10-22|25
e|IS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/2500 WBC|[?]|1|ug/g/day|PERSPIRATION|MICRODENSITOMETRY|Y||1|3|Visit_3|40|6|TREATMENT|2020-11-06|40
e|IS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/VF|[?]|1|/200 HPFs|CORD BLOOD|COULOMETRIC TITRATION||Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-12-01|65
e|IS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|GBq/mg|[?]|1|uCi/kg|SUPERNATANT, PLEURAL FLUID|CONTRAST ENHANCED X-RAY|||1|5|Visit_5|90|2|TREATMENT|2020-12-26|90
e|IS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|PLUG|EPITHELIAL CELL|MIGET|Y|Y|1|1|Visit_1|10|1|SCREENING|2020-05-15|10
e|IS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Gauss|[?]|1|TRANSDUCING UNIT/mL|CARDIAC MUSCLE TISSUE|MOUSE PROTECTION ASSAY||Y|1|2|Visit_2|25|7|TREATMENT|2020-05-30|25
e|IS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^9 organisms/mg|[?]|1|mL/h|ENDOMETRIAL TISSUE|ACID FAST STAIN|||1|3|Visit_3|40|1|SCREENING|2020-06-14|40
e|IS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MASK|[?]|1|breaths/min|DIALYSIS FLUID, PERITONEAL|IMMUNOFLUORESCENT STAIN|||1|4|Visit_4|65|6|FOLLOW-UP|2020-07-09|65
e|IS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 IU/mL|[?]|1|IU/g|CAPILLARY BLOOD|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y|1|5|Visit_5|90|5|TREATMENT|2020-08-03|90
e|IS|09238251-feaf-45a9-b295-dfed9a75fbb2|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|APL U/mL|[?]|1|L/min/m2|DISCHARGE|RADIATION DOSIMETRY|||1|1|Visit_1|10|3|FOLLOW-UP|2020-06-26|10
e|IS|09238251-feaf-45a9-b295-dfed9a75fbb2|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|BU/mL|[?]|1|/ms|MECONIUM|WHOLE GENOME SEQUENCING|||1|2|Visit_2|25|1|TREATMENT|2020-07-11|25
e|IS|09238251-feaf-45a9-b295-dfed9a75fbb2|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|GPL U/mL|[?]|1|BISCUIT|SPERMATOZOON|SPIRAL CT SCAN WITHOUT CONTRAST|Y|Y|1|3|Visit_3|40|4|FOLLOW-UP|2020-07-26|40
e|IS|09238251-feaf-45a9-b295-dfed9a75fbb2|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|pg|[?]|1|EU|CAPILLARY BLOOD|SPECTROPHOTOMETRY|||1|4|Visit_4|65|7|WASHOUT|2020-08-20|65
e|IS|09238251-feaf-45a9-b295-dfed9a75fbb2|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|mL/h|SERUM OR PLASMA|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||1|5|Visit_5|90|1|WASHOUT|2020-09-14|90
e|IS|3e896568-85dc-4a14-ba41-eb3575940a9d|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mol/mg|[?]|1|U/dL|STOOL|MALDI-TOF||Y|1|1|Visit_1|10|6|FOLLOW-UP|2021-01-26|10
e|IS|3e896568-85dc-4a14-ba41-eb3575940a9d|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|g/U|[?]|1|MET*min|EMESIS|PHYSICAL EXAMINATION||Y|1|2|Visit_2|25|4|TREATMENT|2021-02-10|25
e|IS|3e896568-85dc-4a14-ba41-eb3575940a9d|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^4 CFU/mL|[?]|1|mm/min|URINE|HEMOCYTOMETRY|||1|3|Visit_3|40|2|TREATMENT|2021-02-25|40
e|IS|3e896568-85dc-4a14-ba41-eb3575940a9d|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|IU/g|[?]|1|mg/g/min|PLASMA ULTRAFILTRATE|SNELLEN EYE CHART|||1|4|Visit_4|65|1|SCREENING|2021-03-22|65
e|IS|3e896568-85dc-4a14-ba41-eb3575940a9d|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|um2|[?]|1|10^9 organisms|CERVICOVAGINAL SECRETION|THERMAL IONIZATION MASS SPECTROMETRY|||1|5|Visit_5|90|6|FOLLOW-UP|2021-04-16|90
e|IS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|TRANSDUCING UNIT/mL|[?]|1|U/kg/day|ATHEROSCLEROTIC PLAQUE|LIGHT MICROSCOPY|||1|1|Visit_1|10|5|TREATMENT|2020-10-22|10
e|IS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|dpm/0.5 mL|[?]|1|deg|SMEGMA|CHROMATOGRAPHY|||1|2|Visit_2|25|6|TREATMENT|2020-11-06|25
e|IS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Absorbance U/mL|[?]|1|dpm/100mg|BASAL TEAR|WESTERGREN|||1|3|Visit_3|40|1|TREATMENT|2020-11-21|40
e|IS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|JAR|[?]|1|PNU/mL|CEREBROSPINAL FLUID|MICROBIAL BIOCHEMICAL IDENTIFICATION|||1|4|Visit_4|65|3|FOLLOW-UP|2020-12-16|65
e|IS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 CFU|[?]|1|Ci/kg|CAPILLARY BLOOD|MAPH|Y||1|5|Visit_5|90|7|TREATMENT|2021-01-10|90
e|IS|725c5a91-72b0-4b2c-a51a-d1006303373e|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|OD Unit|[?]|1|IU/day|TRANSUDATE|SXA SCAN|||1|1|Visit_1|10|5|TREATMENT|2020-11-23|10
e|IS|725c5a91-72b0-4b2c-a51a-d1006303373e|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Hounsfield Unit|[?]|1|steps/min|ENDOTRACHEAL FLUID|ALCIAN BLUE STAIN|||1|2|Visit_2|25|6|TREATMENT|2020-12-08|25
e|IS|725c5a91-72b0-4b2c-a51a-d1006303373e|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|DRINK|[?]|1|10^5/hpf|SKIN TISSUE|CONTRAST ENHANCED MRI|Y||1|3|Visit_3|40|2|TREATMENT|2020-12-23|40
e|IS|725c5a91-72b0-4b2c-a51a-d1006303373e|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/m2|[?]|1|copies/ug|SWABBED MATERIAL|HEMAGGLUTINATION INHIBITION ASSAY|||1|4|Visit_4|65|6|TREATMENT|2021-01-17|65
e|IS|725c5a91-72b0-4b2c-a51a-d1006303373e|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|nm|[?]|1|kV|MUSCLE TISSUE|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y||1|5|Visit_5|90|4|FOLLOW-UP|2021-02-11|90
e|IS|5bf5b31d-a59d-46b7-8f8f-97919d449565|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/cage/wk|[?]|1|P|INFRANATANT, PLASMA|LANDOLT RING|Y|Y|1|1|Visit_1|10|1|SCREENING|2021-01-01|10
e|IS|5bf5b31d-a59d-46b7-8f8f-97919d449565|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/ms|[?]|1|Frames/s|COLOSTRUM|NUCLEIC ACID SEQUENCING|||1|2|Visit_2|25|4|SCREENING|2021-01-16|25
e|IS|5bf5b31d-a59d-46b7-8f8f-97919d449565|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mm/min|[?]|1|cGy|SUPERNATANT, PLEURAL FLUID|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|3|Visit_3|40|5|TREATMENT|2021-01-31|40
e|IS|5bf5b31d-a59d-46b7-8f8f-97919d449565|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Absorbance U/mL|[?]|1|/mm|FLUID|KINETIC CHROMOGENIC ASSAY|||1|4|Visit_4|65|7|TREATMENT|2021-02-25|65
e|IS|5bf5b31d-a59d-46b7-8f8f-97919d449565|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|umol/L/h|[?]|1|dB|SMEGMA|TRICHROME STAIN||Y|1|5|Visit_5|90|4|FOLLOW-UP|2021-03-22|90
e|IS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mm2|[?]|1|uL|ATHEROSCLEROTIC PLAQUE|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y|1|1|Visit_1|10|1|WASHOUT|2020-05-26|10
e|IS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nmol/L/h|[?]|1|deg/mm|CARDIAC MUSCLE TISSUE|ELECTROGASTROGRAPHY|||1|2|Visit_2|25|6|SCREENING|2020-06-10|25
e|IS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/animal|[?]|1|anti-Xa IU/mL|CERUMEN|DIGITAL PCR|Y||1|3|Visit_3|40|3|SCREENING|2020-06-25|40
e|IS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|pt_us|[?]|1|g/m2/day|PLATELET POOR PLASMA|ANTIBIOTIC AGAR SCREEN|||1|4|Visit_4|65|3|SCREENING|2020-07-20|65
e|IS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^5/hpf|[?]|1|10^6/g|EXHALED BREATH CONDENSATE|SIZE EXCLUSION CHROMATOGRAPHY|||1|5|Visit_5|90|1|TREATMENT|2020-08-14|90
e|IS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|%/min|[?]|1|nsec|PLEURAL TISSUE|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y||1|1|Visit_1|10|5|WASHOUT|2020-10-14|10
e|IS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^3/hpf|[?]|1|10^9/L|VENOUS CORD BLOOD|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y||1|2|Visit_2|25|4|TREATMENT|2020-10-29|25
e|IS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^4/hpf|[?]|1|ukat|SKELETAL MUSCLE TISSUE|MICROSCOPY|||1|3|Visit_3|40|5|TREATMENT|2020-11-13|40
e|IS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|oz|KERATINOCYTE|INFRARED SPECTROMETRY|||1|4|Visit_4|65|4|SCREENING|2020-12-08|65
e|IS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Bq/g|[?]|1|kUSP|VENOUS PLASMA|DYNAMOMETRY|Y||1|5|Visit_5|90|2|FOLLOW-UP|2021-01-02|90
e|IS|f8878ffd-67af-414c-b346-596dbec640cf|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|msec|[?]|1|pg|VENOUS BLOOD|SCANNING ELECTRON MICROSCOPY|Y||1|1|Visit_1|10|4|TREATMENT|2021-01-04|10
e|IS|f8878ffd-67af-414c-b346-596dbec640cf|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|GLOBULE|[?]|1|keV|ERYTHROCYTES|TRYPAN BLUE STAIN|Y||1|2|Visit_2|25|2|TREATMENT|2021-01-19|25
e|IS|f8878ffd-67af-414c-b346-596dbec640cf|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 organisms/g|[?]|1|PIXEL|SEMEN|REVERSE TRANSCRIPTASE PCR|||1|3|Visit_3|40|7|SCREENING|2021-02-03|40
e|IS|f8878ffd-67af-414c-b346-596dbec640cf|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|pmol/L|WHITE MATTER TISSUE|NEURAMINIDASE INHIBITION ASSAY|||1|4|Visit_4|65|6|FOLLOW-UP|2021-02-28|65
e|IS|f8878ffd-67af-414c-b346-596dbec640cf|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|sec|[?]|1|BAU|LEUKOCYTE|ELISPOT|||1|5|Visit_5|90|6|WASHOUT|2021-03-25|90
e|IS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/day|[?]|1|U/g Hb|AQUEOUS HUMOR|IMMUNOPRECIPITATION|Y||1|1|Visit_1|10|5|SCREENING|2020-05-11|10
e|IS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kcal|[?]|1|kg/cm2|ADIPOSE TISSUE|PERIPHERAL ANGIOGRAPHY|Y||1|2|Visit_2|25|7|SCREENING|2020-05-26|25
e|IS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|U/kg/h|[?]|1|cmol/L|INFRANATANT, PLEURAL FLUID|ACID FAST STAIN|||1|3|Visit_3|40|3|TREATMENT|2020-06-10|40
e|IS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|IU/g Hb|[?]|1|Mile|INTERSTITIAL FLUID|DIFFUSION TENSOR MRI|||1|4|Visit_4|65|1|SCREENING|2020-07-05|65
e|IS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ft2|[?]|1|cs|CERVICOVAGINAL SECRETION|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||1|5|Visit_5|90|5|WASHOUT|2020-07-30|90
e|IS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/kg/day|[?]|1|TUBE|STRIATED MUSCLE TISSUE|GIEMSA STAIN|Y||1|1|Visit_1|10|4|TREATMENT|2020-07-02|10
e|IS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|L/L|[?]|1|mAnson U/mL|ENDOTRACHEAL FLUID|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|1|2|Visit_2|25|7|FOLLOW-UP|2020-07-17|25
e|IS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|g/day|[?]|1|nmol/L|PLEURAL FLUID|IMPULSE OSCILLOMETRY|||1|3|Visit_3|40|2|FOLLOW-UP|2020-08-01|40
e|IS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CIGAR|[?]|1|cm|CORD SERUM|ICP-MS|||1|4|Visit_4|65|2|WASHOUT|2020-08-26|65
e|IS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|IU/L|[?]|1|mg/m2/h|SWABBED MATERIAL|SLOAN LETTER EYE CHART 100%||Y|1|5|Visit_5|90|4|WASHOUT|2020-09-20|90
e|IS|b832144e-88c4-4ad6-b173-abac7802a36c|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|um/day|[?]|1|kHz|SUPERNATANT, SERUM|MEDIASTINOSCOPY|||1|1|Visit_1|10|3|SCREENING|2021-01-14|10
e|IS|b832144e-88c4-4ad6-b173-abac7802a36c|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|GPL U/mL|[?]|1|Anson U|PERITONEAL FLUID|WRIGHT-GIEMSA STAIN|||1|2|Visit_2|25|6|WASHOUT|2021-01-29|25
e|IS|b832144e-88c4-4ad6-b173-abac7802a36c|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|HOURS|[?]|1|h/wk|INFRANATANT, SERUM|PYROSEQUENCING|||1|3|Visit_3|40|2|FOLLOW-UP|2021-02-13|40
e|IS|b832144e-88c4-4ad6-b173-abac7802a36c|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|GPL U|[?]|1|pmol/dL|EXUDATE|PHYSICAL EXAMINATION|||1|4|Visit_4|65|6|TREATMENT|2021-03-10|65
e|IS|b832144e-88c4-4ad6-b173-abac7802a36c|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 TCID 50/mL|[?]|1|CCID 50/mL|URINE|WEBER GREEN STAIN|||1|5|Visit_5|90|1|FOLLOW-UP|2021-04-04|90
e|IS|6acacd87-c487-401c-8888-76ccf97b640d|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mPa|[?]|1|ug/g/day|DISCHARGE|LISSAMINE GREEN STAIN|||1|1|Visit_1|10|6|TREATMENT|2020-05-25|10
e|IS|6acacd87-c487-401c-8888-76ccf97b640d|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BU|[?]|1|g/cage/wk|BREAST MILK|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y||1|2|Visit_2|25|7|TREATMENT|2020-06-09|25
e|IS|6acacd87-c487-401c-8888-76ccf97b640d|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|umol/L/min|[?]|1|cL|SALIVA|SPECT/CT SCAN||Y|1|3|Visit_3|40|4|WASHOUT|2020-06-24|40
e|IS|6acacd87-c487-401c-8888-76ccf97b640d|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/kg/min|[?]|1|km|SALIVA|WRIGHT STAIN|||1|4|Visit_4|65|7|WASHOUT|2020-07-19|65
e|IS|6acacd87-c487-401c-8888-76ccf97b640d|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|anti-Xa IU|[?]|1|mm|PUS|HANSEL STAIN|||1|5|Visit_5|90|6|SCREENING|2020-08-13|90
e|IS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|m2|[?]|1|MHz|PLATELET POOR PLASMA|IN VITRO GENE EXPRESSION ASSAY|||1|1|Visit_1|10|3|SCREENING|2020-07-16|10
e|IS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uL|[?]|1|L/L|BONE MARROW MONONUCLEAR CELL|MAGNETIC RESONANCE ELASTOGRAPHY|||1|2|Visit_2|25|4|TREATMENT|2020-07-31|25
e|IS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|APPLICATION|[?]|1|FINGERTIP UNIT|PERSPIRATION|PERCUSSION|||1|3|Visit_3|40|4|SCREENING|2020-08-15|40
e|IS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 RNA copies/mL|[?]|1|mmol/g|SUPERNATANT, SERUM|FLOCCULATION, CHARCOAL ENHANCED|||1|4|Visit_4|65|3|FOLLOW-UP|2020-09-09|65
e|IS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|pmol/L/h|[?]|1|SQU/mL|SUPERNATANT, SERUM|HPLC-FL|||1|5|Visit_5|90|5|WASHOUT|2020-10-04|90
e|IS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|foz_us|[?]|1|mL/g/h|BONE|RADIOIMMUNOPRECIPITATION ASSAY|Y||1|1|Visit_1|10|1|TREATMENT|2021-01-03|10
e|IS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|RNA copies/mL|[?]|1|nCi|TRANSUDATE|HEMAGGLUTINATION INHIBITION ASSAY|||1|2|Visit_2|25|4|SCREENING|2021-01-18|25
e|IS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pmol/10^9 cells|[?]|1|10^6 CFU|CAPILLARY PLASMA|PEAK FLOWMETRY|||1|3|Visit_3|40|1|WASHOUT|2021-02-02|40
e|IS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uV2|[?]|1|in|INFRANATANT, PLEURAL FLUID|KLEIHAUER-BETKE|||1|4|Visit_4|65|2|TREATMENT|2021-02-27|65
e|IS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|hr/day|[?]|1|log10 PFU|ALVEOLAR AIR|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|1|5|Visit_5|90|5|WASHOUT|2021-03-24|90
e|IS|0670f6a3-18c9-4027-91c1-56f5555589a8|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ag|[?]|1|U/kg/h|SPUTUM|KLEIHAUER-BETKE|||1|1|Visit_1|10|7|TREATMENT|2020-05-13|10
e|IS|0670f6a3-18c9-4027-91c1-56f5555589a8|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|PATCH|[?]|1|/h|PERIPHERAL BLOOD MONONUCLEAR CELL|IMMUNOPRECIPITATION||Y|1|2|Visit_2|25|5|TREATMENT|2020-05-28|25
e|IS|0670f6a3-18c9-4027-91c1-56f5555589a8|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^12 IU/L|[?]|1|um|BREAST MILK|WRIGHT-GIEMSA STAIN|||1|3|Visit_3|40|2|SCREENING|2020-06-12|40
e|IS|0670f6a3-18c9-4027-91c1-56f5555589a8|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Log10 ELISA unit|[?]|1|uL|LAVAGE FLUID|DUCTOGRAPHY|||1|4|Visit_4|65|3|TREATMENT|2020-07-07|65
e|IS|0670f6a3-18c9-4027-91c1-56f5555589a8|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|AU/mL|[?]|1|mL/min|ALVEOLAR AIR|TEMPLATE INCISION METHOD|||1|5|Visit_5|90|7|WASHOUT|2020-08-01|90
e|IS|59179734-8784-4a88-aa6b-51b6082ffc1b|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|DNA copies/ug|[?]|1|kUSP|PLATELET|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|1|Visit_1|10|7|WASHOUT|2020-08-11|10
e|IS|59179734-8784-4a88-aa6b-51b6082ffc1b|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/mmHg|[?]|1|10^3/hpf|LUNG SURFACTANT|FLUORESCENT ENZYME IMMUNOASSAY|||1|2|Visit_2|25|1|TREATMENT|2020-08-26|25
e|IS|59179734-8784-4a88-aa6b-51b6082ffc1b|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|g/kg/day|[?]|1|/day|VENOUS CORD BLOOD|BIOPSY|Y||1|3|Visit_3|40|7|SCREENING|2020-09-10|40
e|IS|59179734-8784-4a88-aa6b-51b6082ffc1b|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|MET|[?]|1|U/animal|CALCULUS|CORONARY ANGIOGRAPHY|||1|4|Visit_4|65|7|TREATMENT|2020-10-05|65
e|IS|59179734-8784-4a88-aa6b-51b6082ffc1b|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/2500 WBC|[?]|1|dram|PLEURAL TISSUE|LIGHT SCATTERING SPECTROSCOPY|||1|5|Visit_5|90|3|TREATMENT|2020-10-30|90
e|IS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|foz_br|[?]|1|Ci|SERUM OR PLASMA|SINGLE-MOLECULE ARRAY|||1|1|Visit_1|10|7|WASHOUT|2020-08-22|10
e|IS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cmH2O*s/mL|[?]|1|AgU/mL|BONE|PHOTOMETRY||Y|1|2|Visit_2|25|5|WASHOUT|2020-09-06|25
e|IS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/g/min|[?]|1|log10 PFU|ARTERIAL BLOOD|MICRONEUTRALIZATION ASSAY|||1|3|Visit_3|40|1|FOLLOW-UP|2020-09-21|40
e|IS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/min/mmHg|[?]|1|uCi/L|ARTERIAL CORD BLOOD|SPIRAL CT SCAN WITHOUT CONTRAST|||1|4|Visit_4|65|6|WASHOUT|2020-10-16|65
e|IS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/4.0 mL|[?]|1|mOsm|SEBUM|KINETIC MICROPARTICLE IMMUNOASSAY|||1|5|Visit_5|90|3|TREATMENT|2020-11-10|90
e|IS|01c642f8-48ef-4375-aa2b-d0940b74e580|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Enzyme U|[?]|1|PACK|ARTERIALIZED CAPILLARY BLOOD|THERMAL IONIZATION MASS SPECTROMETRY|||1|1|Visit_1|10|6|WASHOUT|2020-09-19|10
e|IS|01c642f8-48ef-4375-aa2b-d0940b74e580|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|pptr|[?]|1|mL/kg|SERUM OR PLASMA|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||1|2|Visit_2|25|4|TREATMENT|2020-10-04|25
e|IS|01c642f8-48ef-4375-aa2b-d0940b74e580|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Watt|[?]|1|10^6 DNA copies/mL|HAIR|SPECULAR MICROSCOPY|||1|3|Visit_3|40|5|TREATMENT|2020-10-19|40
e|IS|01c642f8-48ef-4375-aa2b-d0940b74e580|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Bq/ug|[?]|1|uV2|EMESIS|ELASTOGRAPHY|Y||1|4|Visit_4|65|4|TREATMENT|2020-11-13|65
e|IS|01c642f8-48ef-4375-aa2b-d0940b74e580|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mm3/mm2/year|[?]|1|nL|VITREOUS HUMOR|MICROPARTICLE ENZYME IMMUNOASSAY|Y||1|5|Visit_5|90|5|SCREENING|2020-12-08|90
e|IS|c0e7028c-6f5c-410a-afde-e56af2177983|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|USP U|[?]|1|fmol/g|PERITONEAL FLUID|ENZYMATIC COLORIMETRY||Y|1|1|Visit_1|10|3|TREATMENT|2020-07-06|10
e|IS|c0e7028c-6f5c-410a-afde-e56af2177983|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dyn|[?]|1|KALLIKREIN INHIBITOR UNIT|LYMPH|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|1|2|Visit_2|25|1|FOLLOW-UP|2020-07-21|25
e|IS|c0e7028c-6f5c-410a-afde-e56af2177983|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|amu|[?]|1|mol/mg|SOFT TISSUE|PET/CT SCAN|||1|3|Visit_3|40|3|SCREENING|2020-08-05|40
e|IS|c0e7028c-6f5c-410a-afde-e56af2177983|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|U/kg/min|[?]|1|KIT|VENOUS PLASMA|FLUORESCENT MICROSCOPY|Y||1|4|Visit_4|65|5|FOLLOW-UP|2020-08-30|65
e|IS|c0e7028c-6f5c-410a-afde-e56af2177983|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/kg/week|[?]|1|um/day|ISOLATE|MICRODENSITOMETRY|||1|5|Visit_5|90|3|FOLLOW-UP|2020-09-24|90
e|IS|eba928ed-9434-4e75-b49d-169298f966e1|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DIOPTER|[?]|1|U/kg/day|GASTRIC CONTENTS|CT SCAN|Y||1|1|Visit_1|10|4|FOLLOW-UP|2020-08-12|10
e|IS|eba928ed-9434-4e75-b49d-169298f966e1|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Pack Year|[?]|1|mmHg|SKIN TISSUE|PHOTOMETRY||Y|1|2|Visit_2|25|3|WASHOUT|2020-08-27|25
e|IS|eba928ed-9434-4e75-b49d-169298f966e1|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|tsp eq|[?]|1|U.CARR|GASTRIC FLUID|FLUORESCENT MICROSCOPY|Y|Y|1|3|Visit_3|40|6|TREATMENT|2020-09-11|40
e|IS|eba928ed-9434-4e75-b49d-169298f966e1|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|damol/L|[?]|1|atm|PLATELET|GEL ELECTROPHORESIS|||1|4|Visit_4|65|1|TREATMENT|2020-10-06|65
e|IS|eba928ed-9434-4e75-b49d-169298f966e1|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/L|[?]|1|ug/m2/h|BONE|RADIOIMMUNOPRECIPITATION ASSAY|||1|5|Visit_5|90|7|SCREENING|2020-10-31|90
e|IS|4772aa80-2097-4867-a549-b6f9b140f141|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|nmol/mL/min|[?]|1|cmH2O*s/mL|DIALYSIS FLUID, PERITONEAL|WHOLE GENOME SEQUENCING|||1|1|Visit_1|10|3|TREATMENT|2020-07-12|10
e|IS|4772aa80-2097-4867-a549-b6f9b140f141|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|EU|[?]|1|U/m2|SEMINAL FLUID|FARNSWORTH-MUNSELL 100 HUE TEST|||1|2|Visit_2|25|6|SCREENING|2020-07-27|25
e|IS|4772aa80-2097-4867-a549-b6f9b140f141|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|keV|[?]|1|Shock Wave|SUPERNATANT, SERUM|MAMMOGRAPHY|||1|3|Visit_3|40|4|TREATMENT|2020-08-11|40
e|IS|4772aa80-2097-4867-a549-b6f9b140f141|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/m2/day|[?]|1|DIP|PLATELET POOR PLASMA|ULTRASONOGRAPHIC ELASTOGRAPHY|Y||1|4|Visit_4|65|5|SCREENING|2020-09-05|65
e|IS|4772aa80-2097-4867-a549-b6f9b140f141|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|USP U|[?]|1|PIXEL|SERUM OR PLASMA OR BLOOD|X-RAY FLUORESCENCE SPECTROMETRY||Y|1|5|Visit_5|90|3|WASHOUT|2020-09-30|90
e|IS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ng|[?]|1|CFU/g|BREAST MILK|HEMAGGLUTINATION ASSAY|Y||1|1|Visit_1|10|1|TREATMENT|2020-06-07|10
e|IS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/ms|[?]|1|cd*s/m2|CALCULUS|VENTILATION PERFUSION LUNG SCAN|||1|2|Visit_2|25|2|FOLLOW-UP|2020-06-22|25
e|IS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MESF|[?]|1|mL/g/min|VITREOUS HUMOR|IMMUNOTURBIDIMETRY|||1|3|Visit_3|40|2|FOLLOW-UP|2020-07-07|40
e|IS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 CFU|[?]|1|mEq/mmol|LYMPH|COLORIMETRY|Y||1|4|Visit_4|65|1|WASHOUT|2020-08-01|65
e|IS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/mL/day|[?]|1|L/s/kPa|CARDIAC MUSCLE TISSUE|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y|1|5|Visit_5|90|1|TREATMENT|2020-08-26|90
e|IS|4d8dd0d0-407d-4374-8345-c11f30603273|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|DDU|[?]|1|Coulomb|CAPILLARY PLASMA|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|1|Visit_1|10|5|FOLLOW-UP|2021-01-01|10
e|IS|4d8dd0d0-407d-4374-8345-c11f30603273|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|RING|[?]|1|kg/L|CALCULUS|MICRONEUTRALIZATION ASSAY|Y|Y|1|2|Visit_2|25|4|TREATMENT|2021-01-16|25
e|IS|4d8dd0d0-407d-4374-8345-c11f30603273|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U/animal|[?]|1|GBq/mg|BREAST MILK|AGAR DILUTION|||1|3|Visit_3|40|7|TREATMENT|2021-01-31|40
e|IS|4d8dd0d0-407d-4374-8345-c11f30603273|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/g/min|[?]|1|mCi/kg|SUPERNATANT, SERUM OR PLASMA|PAP STAIN|||1|4|Visit_4|65|6|TREATMENT|2021-02-25|65
e|IS|4d8dd0d0-407d-4374-8345-c11f30603273|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/min|[?]|1|Enzyme U/L|INFRANATANT, PLEURAL FLUID|SLOAN LETTER EYE CHART 1.25%|||1|5|Visit_5|90|6|FOLLOW-UP|2021-03-22|90
e|IS|6996077b-556a-47b9-bbff-20c1b4df35ea|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|deg/s|[?]|1|mm|ARTERIALIZED CAPILLARY BLOOD|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-06-08|10
e|IS|6996077b-556a-47b9-bbff-20c1b4df35ea|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/cm H2O|[?]|1|NEBULE|KERATINOCYTE|TELLER ACUITY CARDS||Y|1|2|Visit_2|25|4|TREATMENT|2020-06-23|25
e|IS|6996077b-556a-47b9-bbff-20c1b4df35ea|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/L|[?]|1|CFU/g|MONOCYTE|DXA SCAN|||1|3|Visit_3|40|2|TREATMENT|2020-07-08|40
e|IS|6996077b-556a-47b9-bbff-20c1b4df35ea|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mol/g|[?]|1|mEq/mL|BASAL TEAR|TURBIDIMETRY|Y||1|4|Visit_4|65|7|SCREENING|2020-08-02|65
e|IS|6996077b-556a-47b9-bbff-20c1b4df35ea|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cd/m2|[?]|1|CAN|PLATELET|LC/MS|Y||1|5|Visit_5|90|1|WASHOUT|2020-08-27|90
e|IS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/kg|[?]|1|Ci/mg|URINE|GIEMSA STAIN|Y||1|1|Visit_1|10|2|WASHOUT|2020-10-23|10
e|IS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ppb|[?]|1|sec|AMNIOTIC FLUID|MIGET|||1|2|Visit_2|25|1|WASHOUT|2020-11-07|25
e|IS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cm|[?]|1|/2500 WBC|LEUKOCYTE|PH METER MEASUREMENT METHOD||Y|1|3|Visit_3|40|6|SCREENING|2020-11-22|40
e|IS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BAU|[?]|1|10^3 organisms/mL|VENOUS PLASMA|IMMUNOCHROMATOGRAPHY|||1|4|Visit_4|65|6|WASHOUT|2020-12-17|65
e|IS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mEq/day|[?]|1|cL|CAPILLARY BLOOD|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||1|5|Visit_5|90|7|TREATMENT|2021-01-11|90
e|IS|738d539e-a810-4207-8904-fc6a5d055424|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|oz|[?]|1|umol/h/mmol|WHITE MATTER TISSUE|PERIODIC ACID SCHIFF STAIN||Y|1|1|Visit_1|10|4|SCREENING|2021-01-08|10
e|IS|738d539e-a810-4207-8904-fc6a5d055424|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|TCID 50/dose|[?]|1|dpm/mL|ERYTHROCYTES|PULMONARY ANGIOGRAPHY|||1|2|Visit_2|25|3|SCREENING|2021-01-23|25
e|IS|738d539e-a810-4207-8904-fc6a5d055424|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cpm|[?]|1|IU/day|MIXED VENOUS BLOOD|THICK SMEAR|||1|3|Visit_3|40|2|FOLLOW-UP|2021-02-07|40
e|IS|738d539e-a810-4207-8904-fc6a5d055424|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|CAPSULE|[?]|1|10^6 organisms/g|INTERSTITIAL FLUID|ELECTROCHEMILUMINESCENCE|||1|4|Visit_4|65|3|TREATMENT|2021-03-04|65
e|IS|738d539e-a810-4207-8904-fc6a5d055424|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MdFI|[?]|1|%(v/v)|HAIR|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||1|5|Visit_5|90|5|TREATMENT|2021-03-29|90
e|IS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|C|[?]|1|g/animal/day|ARTERIAL CORD BLOOD|WRIGHT-GIEMSA STAIN||Y|1|1|Visit_1|10|4|TREATMENT|2020-08-11|10
e|IS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|%/min|[?]|1|mPa|VITREOUS HUMOR|FORCED OSCILLATION TECHNIQUE||Y|1|2|Visit_2|25|2|TREATMENT|2020-08-26|25
e|IS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|fg|[?]|1|umol/day|PLASMA ULTRAFILTRATE|PEAK FLOWMETRY|||1|3|Visit_3|40|6|SCREENING|2020-09-10|40
e|IS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Ci/mL|[?]|1|Osm|SERUM OR PLASMA|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||Y|1|4|Visit_4|65|5|TREATMENT|2020-10-05|65
e|IS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MBq/uL|[?]|1|10^4/L|SERUM|ROMANOWSKY STAIN|Y||1|5|Visit_5|90|2|SCREENING|2020-10-30|90
e|IS|20841d37-0444-4d1d-b934-1e805cdacdaf|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^3 RNA copies/mL|[?]|1|ECL unit|AQUEOUS HUMOR|SEQUENCING|||1|1|Visit_1|10|1|SCREENING|2020-11-22|10
e|IS|20841d37-0444-4d1d-b934-1e805cdacdaf|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U/m2/min|[?]|1|%(v/v)|INFRANATANT, SERUM|ELECTROPHORESIS|||1|2|Visit_2|25|1|TREATMENT|2020-12-07|25
e|IS|20841d37-0444-4d1d-b934-1e805cdacdaf|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|pL|[?]|1|BEAM BREAKS|HAIR FOLLICLE|PET/MRI SCAN|||1|3|Visit_3|40|5|TREATMENT|2020-12-22|40
e|IS|20841d37-0444-4d1d-b934-1e805cdacdaf|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|VIRTUAL PIXEL|[?]|1|Frames/s|BLOOD|X-RAY|||1|4|Visit_4|65|7|TREATMENT|2021-01-16|65
e|IS|20841d37-0444-4d1d-b934-1e805cdacdaf|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/h|[?]|1|%/min|SUPERNATANT, PLASMA|MACRO BROTH DILUTION||Y|1|5|Visit_5|90|3|FOLLOW-UP|2021-02-10|90
e|IS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ms/mmHg|[?]|1|/100 HPFs|ENDOMETRIAL TISSUE|ULTRASOUND|||1|1|Visit_1|10|7|TREATMENT|2020-11-01|10
e|IS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^11/L|[?]|1|ug/g/min|HAIR|CONTRAST ENHANCED PET/CT SCAN|||1|2|Visit_2|25|5|WASHOUT|2020-11-16|25
e|IS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|fraction of 1|[?]|1|g/kg/day|EPIDERMAL TISSUE|ENZYMATIC SPECTROPHOTOMETRY|||1|3|Visit_3|40|2|TREATMENT|2020-12-01|40
e|IS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|usec|[?]|1|mL/100g/min|WHITE MATTER TISSUE|CALIPER MEASUREMENT METHOD||Y|1|4|Visit_4|65|2|TREATMENT|2020-12-26|65
e|IS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|BEAM BREAKS|[?]|1|mL/100g/min|PLATELET POOR PLASMA|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|5|Visit_5|90|6|WASHOUT|2021-01-20|90
e|IS|d74682f1-824e-449d-bdf1-db517d8fdf2e|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^7/L|[?]|1|OD Unit|SALIVA|TARGETED TRANSCRIPTOME SEQUENCING|||1|1|Visit_1|10|3|WASHOUT|2020-08-08|10
e|IS|d74682f1-824e-449d-bdf1-db517d8fdf2e|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/MBP|[?]|1|mJoule/cm2|VENOUS PLASMA|PAP STAIN|||1|2|Visit_2|25|4|FOLLOW-UP|2020-08-23|25
e|IS|d74682f1-824e-449d-bdf1-db517d8fdf2e|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|PFU/animal|[?]|1|gMFI|ERYTHROCYTES|MUGA|||1|3|Visit_3|40|6|TREATMENT|2020-09-07|40
e|IS|d74682f1-824e-449d-bdf1-db517d8fdf2e|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/m2/min|[?]|1|aMFI|SALIVA|LIGHT SCATTERING SPECTROSCOPY||Y|1|4|Visit_4|65|2|WASHOUT|2020-10-02|65
e|IS|d74682f1-824e-449d-bdf1-db517d8fdf2e|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SBE/mL|[?]|1|mg/m2/h|DISCHARGE|OPHTHALMOSCOPY|||1|5|Visit_5|90|7|SCREENING|2020-10-27|90
e|IS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|BEAM BREAKS|[?]|1|/10^5|LYMPH|SCANNING ELECTRON MICROSCOPY|||1|1|Visit_1|10|5|SCREENING|2020-12-07|10
e|IS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|VIRTUAL PIXEL|[?]|1|mL/g/h|MECONIUM|INFRARED SPECTROMETRY|||1|2|Visit_2|25|7|WASHOUT|2020-12-22|25
e|IS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/mmol|[?]|1|BU/mL|CARDIAC MUSCLE TISSUE|NO INFORMATION||Y|1|3|Visit_3|40|3|FOLLOW-UP|2021-01-06|40
e|IS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/m2|[?]|1|mOsm|CAPILLARY BLOOD|DOPPLER ULTRASOUND|||1|4|Visit_4|65|1|TREATMENT|2021-01-31|65
e|IS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|log10 TCID 50/dose|[?]|1|/cmH2O|PLASMA ULTRAFILTRATE|IMMUNORADIOMETRIC ASSAY|Y||1|5|Visit_5|90|3|TREATMENT|2021-02-25|90
e|IS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|um2|[?]|1|BOWL|ARTERIAL BLOOD|CT SCAN WITHOUT CONTRAST|||1|1|Visit_1|10|1|TREATMENT|2020-07-02|10
e|IS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Gy/h|[?]|1|atm|ERYTHROCYTES|TRIPLE-PHASE MRI SCAN|||1|2|Visit_2|25|5|FOLLOW-UP|2020-07-17|25
e|IS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^8 PFU|[?]|1|AFU|ARTERIAL CORD BLOOD|RADIATION DOSIMETRY|||1|3|Visit_3|40|7|SCREENING|2020-08-01|40
e|IS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 organisms|[?]|1|Torr|HAIR|ZIEHL NEELSEN ACID FAST STAIN|||1|4|Visit_4|65|7|SCREENING|2020-08-26|65
e|IS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Bq/g|[?]|1|10^4 CFU/mL|BLOOD|PERCUSSION|Y|Y|1|5|Visit_5|90|3|WASHOUT|2020-09-20|90
e|IS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/g/h|[?]|1|mmHg*min/L|PERITONEAL FLUID|APPLANATION TONOMETRY||Y|1|1|Visit_1|10|1|SCREENING|2020-11-17|10
e|IS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Bq/kg|[?]|1|ug/cm2|VITREOUS HUMOR|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y||1|2|Visit_2|25|3|FOLLOW-UP|2020-12-02|25
e|IS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|L/s|[?]|1|cmH2O*s2/mL|SERUM OR PLASMA OR BLOOD|IMMUNOCHROMATOGRAPHY|||1|3|Visit_3|40|7|TREATMENT|2020-12-17|40
e|IS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uL/mL|[?]|1|ug/m2|MONOCYTE|KARYOTYPING|||1|4|Visit_4|65|3|SCREENING|2021-01-11|65
e|IS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|RATIO|[?]|1|hr/day|LYSATE|MALDI-TOF|||1|5|Visit_5|90|4|TREATMENT|2021-02-05|90
e|IS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kg/cm|[?]|1|cmol|SEMEN|SLOAN LETTER EYE CHART 2.5%|Y|Y|1|1|Visit_1|10|6|SCREENING|2020-10-27|10
e|IS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|pmol/dL|[?]|1|U/m2/min|MIXED VENOUS BLOOD|DROPLET DIGITAL PCR|||1|2|Visit_2|25|5|TREATMENT|2020-11-11|25
e|IS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mCi/kg|[?]|1|WAFER|LYSATE|HPLC-UV|||1|3|Visit_3|40|2|TREATMENT|2020-11-26|40
e|IS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|anti-Xa IU|[?]|1|umol/L|DISCHARGE|INDIA INK STAIN|||1|4|Visit_4|65|2|FOLLOW-UP|2020-12-21|65
e|IS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|WAFER|[?]|1|g/cage/wk|LYSATE|GC/MS|Y||1|5|Visit_5|90|4|TREATMENT|2021-01-15|90
e|IS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Absorbance U|[?]|1|U/mmol|DISCHARGE|INDIA INK STAIN|||1|1|Visit_1|10|3|TREATMENT|2020-12-24|10
e|IS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/min|[?]|1|mEq/dL|PLATELET RICH PLASMA|SCANNING ELECTRON MICROSCOPY|||1|2|Visit_2|25|4|TREATMENT|2021-01-08|25
e|IS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|gtt|[?]|1|nkat|SOFT TISSUE|ULTRASONOGRAPHIC ELASTOGRAPHY|||1|3|Visit_3|40|7|WASHOUT|2021-01-23|40
e|IS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|nmol/mol|[?]|1|mEq/L|EPITHELIAL CELL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||1|4|Visit_4|65|3|SCREENING|2021-02-17|65
e|IS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/kg|[?]|1|mN|COLOSTRUM|TARGETED GENOME SEQUENCING||Y|1|5|Visit_5|90|1|FOLLOW-UP|2021-03-14|90
e|IS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MONTHS|[?]|1|mU/L|PERITONEAL FLUID|STRESS ECHOCARDIOGRAPHY|Y||1|1|Visit_1|10|3|TREATMENT|2020-05-16|10
e|IS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^4 CFU/mL|[?]|1|TAMPON|SERUM OR PLASMA|HPLC||Y|1|2|Visit_2|25|5|WASHOUT|2020-05-31|25
e|IS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DRUM|[?]|1|MET|INFRANATANT, PLEURAL FLUID|HPLC|||1|3|Visit_3|40|5|TREATMENT|2020-06-15|40
e|IS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ng/dL|[?]|1|lm|CARDIAC MUSCLE TISSUE|SNP ARRAY|||1|4|Visit_4|65|3|SCREENING|2020-07-10|65
e|IS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|U/m2/day|[?]|1|/month|BONE|IMPEDANCE CONDUCTIVITY|||1|5|Visit_5|90|2|TREATMENT|2020-08-04|90
e|IS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|umol/mg/min|ADIPOSE TISSUE|MODIFIED ACID FAST STAIN|||1|1|Visit_1|10|2|TREATMENT|2020-11-29|10
e|IS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^9 organisms/mL|[?]|1|tuberculin unit/mL|CAPILLARY PLASMA|SPECTROPHOTOMETRY|||1|2|Visit_2|25|2|TREATMENT|2020-12-14|25
e|IS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Ci/L|[?]|1|nmol|COLOSTRUM|POLYSOMNOGRAPHY|||1|3|Visit_3|40|2|FOLLOW-UP|2020-12-29|40
e|IS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|foz_us|[?]|1|nmol BCE/L|URINE|ELECTROPHORESIS|||1|4|Visit_4|65|5|TREATMENT|2021-01-23|65
e|IS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug/kg|[?]|1|kBq/uL|MONOCYTE|AMSLER GRID|||1|5|Visit_5|90|5|SCREENING|2021-02-17|90
e|IS|1e1de453-920a-4132-b2f7-6335ee81ec83|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|foz_br|[?]|1|vg/kg|SOFT TISSUE|X-RAY FLUORESCENCE SPECTROMETRY|||1|1|Visit_1|10|4|WASHOUT|2020-10-22|10
e|IS|1e1de453-920a-4132-b2f7-6335ee81ec83|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cy/cm|[?]|1|V|EPITHELIAL CELL|ANALYTICAL ULTRACENTRIFUGATION|Y||1|2|Visit_2|25|5|WASHOUT|2020-11-06|25
e|IS|1e1de453-920a-4132-b2f7-6335ee81ec83|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U/cL|[?]|1|msec|URINE SEDIMENT|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||1|3|Visit_3|40|6|TREATMENT|2020-11-21|40
e|IS|1e1de453-920a-4132-b2f7-6335ee81ec83|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|kPa|[?]|1|ELISA unit/dose|PLEURAL FLUID|ECHOCARDIOGRAPHY||Y|1|4|Visit_4|65|1|FOLLOW-UP|2020-12-16|65
e|IS|1e1de453-920a-4132-b2f7-6335ee81ec83|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mEq|[?]|1|Newton|ARTERIAL CORD BLOOD|IMMUNOFLUORESCENT STAIN|||1|5|Visit_5|90|3|SCREENING|2021-01-10|90
e|IS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Coulomb|[?]|1|PFU/dose|CERUMEN|POLYGRAPHY|||1|1|Visit_1|10|7|TREATMENT|2020-06-29|10
e|IS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 IU/mL|[?]|1|mmHg/L/min|BONE MARROW|PERIODIC ACID SCHIFF STAIN|Y|Y|1|2|Visit_2|25|7|SCREENING|2020-07-14|25
e|IS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mol/g|[?]|1|rpm|EMOTIONAL TEAR|IMMUNOFIXATION ELECTROPHORESIS|||1|3|Visit_3|40|3|WASHOUT|2020-07-29|40
e|IS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/min|[?]|1|ug/m2/min|CELL PELLET|JAEGER EYE CHART|||1|4|Visit_4|65|2|FOLLOW-UP|2020-08-23|65
e|IS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MET|[?]|1|TABLET|PLEURAL FLUID|CISH|||1|5|Visit_5|90|4|TREATMENT|2020-09-17|90
e|IS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DAgU|[?]|1|mL/kg|TUMOR TISSUE|RAJI CELL EIA|||1|1|Visit_1|10|1|SCREENING|2020-12-16|10
e|IS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|umol/L/h|ENDOMETRIAL TISSUE|PHASE-CONTRAST MRI|||1|2|Visit_2|25|6|TREATMENT|2020-12-31|25
e|IS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mEq/L|[?]|1|vg/dose|CERVICOVAGINAL SECRETION|TEST STRIP|||1|3|Visit_3|40|7|TREATMENT|2021-01-15|40
e|IS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|s^-1(%O2)^-1|[?]|1|fraction of 1|LEUKOCYTE|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||1|4|Visit_4|65|3|WASHOUT|2021-02-09|65
e|IS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|pkat|[?]|1|MPL U/mL|SERUM OR PLASMA OR BLOOD|IMMUNOTURBIDIMETRY|||1|5|Visit_5|90|4|WASHOUT|2021-03-06|90
e|IS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cP|[?]|1|mmAL|SUPERNATANT, PLEURAL FLUID|SLOAN LETTER EYE CHART 1.25%|||1|1|Visit_1|10|6|TREATMENT|2020-06-09|10
e|IS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/h|[?]|1|MBq/uL|RETICULOCYTES|POLYGRAPHY||Y|1|2|Visit_2|25|2|TREATMENT|2020-06-24|25
e|IS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|SCOOPFUL|[?]|1|LENS|CAPILLARY BLOOD|MODIFIED ACID FAST STAIN||Y|1|3|Visit_3|40|3|TREATMENT|2020-07-09|40
e|IS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/L|[?]|1|pmol/g|ERYTHROCYTES|IVY INCISION METHOD|Y||1|4|Visit_4|65|5|TREATMENT|2020-08-03|65
e|IS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|PACKAGE|[?]|1|L/h/m2|BASAL TEAR|TRANSTHORACIC ECHOCARDIOGRAPHY|Y||1|5|Visit_5|90|1|FOLLOW-UP|2020-08-28|90
e|IS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|sec|[?]|1|10^7 PFU|MONOCYTE|FORCED OSCILLATION TECHNIQUE|||1|1|Visit_1|10|3|TREATMENT|2020-10-29|10
e|IS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|K|[?]|1|10^9 CFU/g|CEREBROSPINAL FLUID|MICROBIAL CULTURE, SOLID|Y||1|2|Visit_2|25|1|SCREENING|2020-11-13|25
e|IS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mmol/g|[?]|1|BAG|BILE|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y|1|3|Visit_3|40|7|TREATMENT|2020-11-28|40
e|IS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Bq/mL|[?]|1|mg/m2/day|STOOL|IMMUNOFLUORESCENT STAIN|||1|4|Visit_4|65|3|FOLLOW-UP|2020-12-23|65
e|IS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/mol|[?]|1|10^6 organisms/mL|PROSTATIC FLUID|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|5|Visit_5|90|5|WASHOUT|2021-01-17|90
e|IS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|in2|[?]|1|lm|FLUID|IRON HEMATOXYLIN STAIN|Y||1|1|Visit_1|10|6|TREATMENT|2020-12-24|10
e|IS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^9/L|[?]|1|U/mg|SPERMATOZOON|SLIT LAMP||Y|1|2|Visit_2|25|3|WASHOUT|2021-01-08|25
e|IS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6/Ejaculate U|[?]|1|DROP|BONE MARROW MONONUCLEAR CELL|PET/CT SCAN WITHOUT CONTRAST|Y||1|3|Visit_3|40|6|TREATMENT|2021-01-23|40
e|IS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nkat/L|[?]|1|GPL U/mL|LUNG SURFACTANT|CONTRAST ENHANCED X-RAY|||1|4|Visit_4|65|6|TREATMENT|2021-02-17|65
e|IS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|foz_br|[?]|1|kIU|PERIPHERAL BLOOD MONONUCLEAR CELL|DOUBLE IMMUNODIFFUSION|||1|5|Visit_5|90|3|WASHOUT|2021-03-14|90
e|IS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|pg/cell|[?]|1|QUANTITY SUFFICIENT|PERSPIRATION|RIA|Y|Y|1|1|Visit_1|10|2|TREATMENT|2020-10-17|10
e|IS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uEq|[?]|1|mEq/mmol|DERMAL TISSUE|CLOT DETECTION|Y||1|2|Visit_2|25|1|FOLLOW-UP|2020-11-01|25
e|IS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cmH2O/mL|[?]|1|rpm|HAIR FOLLICLE|OPTICAL MAPPING|Y||1|3|Visit_3|40|2|FOLLOW-UP|2020-11-16|40
e|IS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Ci/g|[?]|1|nkat/g Hb|BREAST MILK|IMMUNO-PET SCAN|||1|4|Visit_4|65|5|WASHOUT|2020-12-11|65
e|IS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/cm2|[?]|1|log10 PFU/mL|BONE MARROW MONONUCLEAR CELL|OPTICAL MAPPING|||1|5|Visit_5|90|7|TREATMENT|2021-01-05|90
e|IS|a1d203ef-7ee1-4373-988a-370532bae2b1|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|dpm/mL|[?]|1|min/day|SWABBED MATERIAL|PET/CT SCAN|||1|1|Visit_1|10|7|FOLLOW-UP|2021-01-28|10
e|IS|a1d203ef-7ee1-4373-988a-370532bae2b1|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kcal|[?]|1|uU/dL|BASAL TEAR|ALCIAN BLUE STAIN|Y|Y|1|2|Visit_2|25|2|SCREENING|2021-02-12|25
e|IS|a1d203ef-7ee1-4373-988a-370532bae2b1|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|GBq|[?]|1|GPS U|EXHALED BREATH CONDENSATE|GC/MS-CI|||1|3|Visit_3|40|7|TREATMENT|2021-02-27|40
e|IS|a1d203ef-7ee1-4373-988a-370532bae2b1|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/L|[?]|1|ag|MENSTRUAL BLOOD|LC/MS/MS|Y||1|4|Visit_4|65|2|FOLLOW-UP|2021-03-24|65
e|IS|a1d203ef-7ee1-4373-988a-370532bae2b1|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ks|[?]|1|ug/dose|ATHEROSCLEROTIC PLAQUE|MULTIPLE BREATH WASHOUT||Y|1|5|Visit_5|90|4|TREATMENT|2021-04-18|90
e|IS|4389d158-cb51-4779-b19a-f38dbef0806a|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 PFU/mL|[?]|1|Linear ft*LB|VITREOUS HUMOR|AGAR PROPORTION|||1|1|Visit_1|10|4|TREATMENT|2020-06-22|10
e|IS|4389d158-cb51-4779-b19a-f38dbef0806a|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|U/mg|[?]|1|mL/beat|LUNG SURFACTANT|IN SITU HYBRIDIZATION|Y||1|2|Visit_2|25|6|SCREENING|2020-07-07|25
e|IS|4389d158-cb51-4779-b19a-f38dbef0806a|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pkat|[?]|1|mg/mL/day|TUMOR TISSUE|SIZE EXCLUSION CHROMATOGRAPHY|Y||1|3|Visit_3|40|6|FOLLOW-UP|2020-07-22|40
e|IS|4389d158-cb51-4779-b19a-f38dbef0806a|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|fg|[?]|1|IU/mmol|SUPERNATANT, PLASMA|ROMANOWSKY STAIN|||1|4|Visit_4|65|7|WASHOUT|2020-08-16|65
e|IS|4389d158-cb51-4779-b19a-f38dbef0806a|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uL/kg/day|[?]|1|uL/mL|DERMAL TISSUE|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||1|5|Visit_5|90|4|TREATMENT|2020-09-10|90
e|IS|3a973b7a-3583-4383-b59e-3dab51b511bd|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Gy|[?]|1|CAPSULE|BUFFY COAT|MICRONEUTRALIZATION ASSAY|||1|1|Visit_1|10|2|TREATMENT|2021-01-19|10
e|IS|3a973b7a-3583-4383-b59e-3dab51b511bd|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/2000 RBC|[?]|1|tsp eq|PERITONEAL FLUID|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y||1|2|Visit_2|25|1|FOLLOW-UP|2021-02-03|25
e|IS|3a973b7a-3583-4383-b59e-3dab51b511bd|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|hr/day|[?]|1|damol/L|SUPERNATANT, PLASMA|GC/MS/MS|||1|3|Visit_3|40|3|FOLLOW-UP|2021-02-18|40
e|IS|3a973b7a-3583-4383-b59e-3dab51b511bd|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MONTHS|[?]|1|U/10^12 RBC|LAVAGE FLUID|CARDIAC THERMODILUTION|||1|4|Visit_4|65|5|TREATMENT|2021-03-15|65
e|IS|3a973b7a-3583-4383-b59e-3dab51b511bd|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 organisms/mL|[?]|1|MdFI|SEBUM|NUCLEIC ACID BASED METHOD|||1|5|Visit_5|90|4|SCREENING|2021-04-09|90
e|IS|d283591c-2085-459e-94f2-d3eb6b81aea7|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|amu|[?]|1|mEq/uL|SKIN TISSUE|ERGOSPIROMETRY|Y||1|1|Visit_1|10|1|TREATMENT|2020-09-28|10
e|IS|d283591c-2085-459e-94f2-d3eb6b81aea7|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/m2/min|[?]|1|10^4/hpf|EPITHELIAL CELL|LYMPHANGIOGRAPHY|||1|2|Visit_2|25|1|WASHOUT|2020-10-13|25
e|IS|d283591c-2085-459e-94f2-d3eb6b81aea7|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|CAPFUL|[?]|1|APL U|SOFT TISSUE|TRANSTHORACIC ECHOCARDIOGRAPHY|||1|3|Visit_3|40|3|WASHOUT|2020-10-28|40
e|IS|d283591c-2085-459e-94f2-d3eb6b81aea7|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^11/L|[?]|1|10^3 CFU/g|PLATELET POOR PLASMA|RADIOGRAPHY|||1|4|Visit_4|65|5|TREATMENT|2020-11-22|65
e|IS|d283591c-2085-459e-94f2-d3eb6b81aea7|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Coulomb|[?]|1|g/animal/day|CEREBROSPINAL FLUID|DYNAMOMETRY|||1|5|Visit_5|90|6|TREATMENT|2020-12-17|90
e|IS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|lm|[?]|1|10^6 CFU|PLASMA ULTRAFILTRATE|PAP STAIN||Y|1|1|Visit_1|10|4|TREATMENT|2020-10-01|10
e|IS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PACK|[?]|1|Log10 ELISA unit|ARTERIAL BLOOD|HEMOCYTOMETRY|Y|Y|1|2|Visit_2|25|6|TREATMENT|2020-10-16|25
e|IS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uSiemens|[?]|1|km|PLATELET POOR PLASMA|ELLA|||1|3|Visit_3|40|1|TREATMENT|2020-10-31|40
e|IS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 CFU|[?]|1|AFU|PROSTATIC FLUID|IN VITRO GENE EXPRESSION ASSAY|||1|4|Visit_4|65|5|TREATMENT|2020-11-25|65
e|IS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|dpm/mL|[?]|1|vg/mL|STRIATED MUSCLE TISSUE|ELECTRONEUROGRAPHY|||1|5|Visit_5|90|2|SCREENING|2020-12-20|90
e|IS|4cd63e56-3d93-403a-8011-3b4fcf26e445|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|psi|[?]|1|msec|SUPERNATANT, PLASMA|GC/FID|||1|1|Visit_1|10|1|TREATMENT|2020-12-27|10
e|IS|4cd63e56-3d93-403a-8011-3b4fcf26e445|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|dL|[?]|1|U/m2|PLEURAL FLUID|LC/MS|||1|2|Visit_2|25|7|SCREENING|2021-01-11|25
e|IS|4cd63e56-3d93-403a-8011-3b4fcf26e445|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uOsm|[?]|1|um2|SMOOTH MUSCLE TISSUE|CELL BASED BIOASSAY|||1|3|Visit_3|40|3|TREATMENT|2021-01-26|40
e|IS|4cd63e56-3d93-403a-8011-3b4fcf26e445|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/uL|[?]|1|uEq/L|SYNOVIAL FLUID|HPLC/MS/MS|||1|4|Visit_4|65|3|TREATMENT|2021-02-20|65
e|IS|4cd63e56-3d93-403a-8011-3b4fcf26e445|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|g/cm2|[?]|1|PACK|SMOOTH MUSCLE TISSUE|CONGO RED STAIN|Y||1|5|Visit_5|90|1|SCREENING|2021-03-17|90
e|IS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MPL U/mL|[?]|1|mAnson U/mL|SUPERNATANT, SERUM|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|1|Visit_1|10|2|TREATMENT|2020-05-23|10
e|IS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/animal|[?]|1|gpELISA unit/mL|ATHEROSCLEROTIC PLAQUE|TRANSTHORACIC ECHOCARDIOGRAPHY|||1|2|Visit_2|25|6|FOLLOW-UP|2020-06-07|25
e|IS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|CAN|[?]|1|Siemens|LAVAGE FLUID|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||1|3|Visit_3|40|5|TREATMENT|2020-06-22|40
e|IS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/kg/day|[?]|1|EID 50/mL|ISOLATE|GC/MS/MS|||1|4|Visit_4|65|2|SCREENING|2020-07-17|65
e|IS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/VF|[?]|1|JAR|PLEURAL FLUID|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y||1|5|Visit_5|90|7|WASHOUT|2020-08-11|90
e|IS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kg/m2|[?]|1|dpm/0.5 mL|SEBUM|THIN SMEAR|Y||1|1|Visit_1|10|7|SCREENING|2020-08-09|10
e|IS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|DNA copies/mL|[?]|1|cmH2O*s/mL|CERUMEN|CONGO RED STAIN|||1|2|Visit_2|25|5|TREATMENT|2020-08-24|25
e|IS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|DAYS|[?]|1|mL/cage|URINE SEDIMENT|FLUORESCENT SPOT TEST|||1|3|Visit_3|40|1|TREATMENT|2020-09-08|40
e|IS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|copies/ug|[?]|1|umol/mg/min|ATHEROSCLEROTIC PLAQUE|MICROARRAY|||1|4|Visit_4|65|6|FOLLOW-UP|2020-10-03|65
e|IS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/MBP|[?]|1|YEARS|STOOL|CELL BASED BIOASSAY|Y||1|5|Visit_5|90|3|TREATMENT|2020-10-28|90
e|IS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|U/cL|[?]|1|U/animal|URINE SEDIMENT|RADIOGRAPHY|||1|1|Visit_1|10|1|TREATMENT|2020-06-28|10
e|IS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug/g/h|[?]|1|U/g/min|ENDOTRACHEAL FLUID|INDIRECT IMMUNOFLUORESCENCE|||1|2|Visit_2|25|1|TREATMENT|2020-07-13|25
e|IS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|CONTAINER|[?]|1|BEAM BREAKS|DERMAL TISSUE|ELECTROCHEMILUMINESCENCE|Y||1|3|Visit_3|40|7|SCREENING|2020-07-28|40
e|IS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/m2/min|[?]|1|Ci/L|SUPERNATANT, PLEURAL FLUID|MAGNETIC RESONANCE ANGIOGRAPHY|Y||1|4|Visit_4|65|5|TREATMENT|2020-08-22|65
e|IS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|vg/kg|[?]|1|min*mg/mL|HAIR FOLLICLE|GC/MS||Y|1|5|Visit_5|90|7|WASHOUT|2020-09-16|90
e|IS|9bdf9856-3b2a-43db-b369-3e13868ef413|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|beats/min|[?]|1|/40 HPFs|MUSCLE TISSUE|CONGO RED STAIN||Y|1|1|Visit_1|10|5|SCREENING|2021-01-23|10
e|IS|9bdf9856-3b2a-43db-b369-3e13868ef413|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Bq/g|[?]|1|fmol|AQUEOUS HUMOR|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y|1|2|Visit_2|25|1|FOLLOW-UP|2021-02-07|25
e|IS|9bdf9856-3b2a-43db-b369-3e13868ef413|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|LENS|[?]|1|breaths/min|PROSTATIC FLUID|AUSCULTATION|||1|3|Visit_3|40|6|FOLLOW-UP|2021-02-22|40
e|IS|9bdf9856-3b2a-43db-b369-3e13868ef413|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ng/dL|[?]|1|kUSP|PLEURAL TISSUE|LC/MS||Y|1|4|Visit_4|65|4|FOLLOW-UP|2021-03-19|65
e|IS|9bdf9856-3b2a-43db-b369-3e13868ef413|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|EIA unit|[?]|1|L|VENOUS BLOOD|TEMPLATE INCISION METHOD|||1|5|Visit_5|90|1|SCREENING|2021-04-13|90
e|IS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 organisms|[?]|1|MBq/uL|INFRANATANT, PLEURAL FLUID|ISHIHARA COLOR PLATES|||1|1|Visit_1|10|5|FOLLOW-UP|2020-12-28|10
e|IS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|psi|[?]|1|CYLINDER|AMNIOTIC FLUID|MANUAL COUNT|||1|2|Visit_2|25|7|TREATMENT|2021-01-12|25
e|IS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|L/min/m2|[?]|1|Bq/ug|CORD SERUM|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||1|3|Visit_3|40|1|FOLLOW-UP|2021-01-27|40
e|IS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mmol/s|[?]|1|HOMEOPATHIC DILUTION|STOOL|SXA SCAN|||1|4|Visit_4|65|3|TREATMENT|2021-02-21|65
e|IS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug|[?]|1|USP U|HAIR FOLLICLE|AGAR DILUTION|||1|5|Visit_5|90|1|TREATMENT|2021-03-18|90
e|IS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 PFU|[?]|1|EP U|RETICULOCYTES|HPLC/MS|Y||1|1|Visit_1|10|3|FOLLOW-UP|2020-12-29|10
e|IS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|bel|[?]|1|mmol/mol|AQUEOUS HUMOR|MASS SPECTROMETRY|||1|2|Visit_2|25|5|WASHOUT|2021-01-13|25
e|IS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Shock Wave|[?]|1|nmol/L|WHITE MATTER TISSUE|ROMANOWSKY STAIN|Y||1|3|Visit_3|40|5|SCREENING|2021-01-28|40
e|IS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/animal/day|[?]|1|Newton|NAIL|MICROBIAL CONCENTRATION|||1|4|Visit_4|65|1|WASHOUT|2021-02-22|65
e|IS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/animal/wk|[?]|1|U/kg/min|ISOLATE|NUCLEIC ACID HYBRIDIZATION|||1|5|Visit_5|90|7|SCREENING|2021-03-19|90
e|IS|066281d3-27b8-439f-8340-f59115f646ef|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug/m2/day|[?]|1|ft2|EXUDATE|MYELOPEROXIDASE STAIN||Y|1|1|Visit_1|10|4|TREATMENT|2020-10-21|10
e|IS|066281d3-27b8-439f-8340-f59115f646ef|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ft2|[?]|1|PELLET|ARTERIALIZED CAPILLARY BLOOD|ELLA|||1|2|Visit_2|25|7|SCREENING|2020-11-05|25
e|IS|066281d3-27b8-439f-8340-f59115f646ef|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ELISA unit/mL|[?]|1|/h|TUMOR TISSUE|PHASE CONTRAST MICROSCOPY|||1|3|Visit_3|40|3|TREATMENT|2020-11-20|40
e|IS|066281d3-27b8-439f-8340-f59115f646ef|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MESF|[?]|1|10^6 CFU/g|PLATELET RICH PLASMA|CHROMOGENIC ASSAY|||1|4|Visit_4|65|6|SCREENING|2020-12-15|65
e|IS|066281d3-27b8-439f-8340-f59115f646ef|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Tesla|[?]|1|nkat|EXPIRED AIR|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||1|5|Visit_5|90|7|TREATMENT|2021-01-09|90
e|IS|d23cc47e-da96-4042-a69f-60097beaef0e|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BAU|[?]|1|Gauss|DISCHARGE|RADIOGRAPHY||Y|1|1|Visit_1|10|6|TREATMENT|2021-01-21|10
e|IS|d23cc47e-da96-4042-a69f-60097beaef0e|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|pmol/10^10 cells|[?]|1|kN/cm2|STRIATED MUSCLE TISSUE|NEURAMINIDASE INHIBITION ASSAY||Y|1|2|Visit_2|25|3|TREATMENT|2021-02-05|25
e|IS|d23cc47e-da96-4042-a69f-60097beaef0e|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Ci/mg|[?]|1|10^12 IU/L|TUMOR TISSUE|WHOLE TRANSCRIPTOME SEQUENCING|||1|3|Visit_3|40|1|TREATMENT|2021-02-20|40
e|IS|d23cc47e-da96-4042-a69f-60097beaef0e|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|cP|[?]|1|mmAL|PLATELET|DYNAMIC LIGHT SCATTERING|Y||1|4|Visit_4|65|1|TREATMENT|2021-03-17|65
e|IS|d23cc47e-da96-4042-a69f-60097beaef0e|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|IU/kg|[?]|1|MPL U/mL|VENOUS CORD BLOOD|SANGER SEQUENCING|||1|5|Visit_5|90|6|TREATMENT|2021-04-11|90
e|IS|b896c679-87d0-4e29-ad27-3944cf09b3ec|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Bq/uL|[?]|1|log10 copies/mL|URINE SEDIMENT|ICC||Y|1|1|Visit_1|10|1|TREATMENT|2021-01-02|10
e|IS|b896c679-87d0-4e29-ad27-3944cf09b3ec|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|m/sec|[?]|1|U/g/min|MUCUS|FLUOROSCOPY|||1|2|Visit_2|25|2|SCREENING|2021-01-17|25
e|IS|b896c679-87d0-4e29-ad27-3944cf09b3ec|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmol/day|[?]|1|10^4 CFU/mL|AMNIOTIC FLUID|DISK DIFFUSION|||1|3|Visit_3|40|5|TREATMENT|2021-02-01|40
e|IS|b896c679-87d0-4e29-ad27-3944cf09b3ec|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Enzyme U/L|[?]|1|dram|BUFFY COAT|RULER MEASUREMENT METHOD|Y|Y|1|4|Visit_4|65|6|WASHOUT|2021-02-26|65
e|IS|b896c679-87d0-4e29-ad27-3944cf09b3ec|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/(min*100mL)|[?]|1|10^3 CFU|REFLEX TEAR|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|Y|1|5|Visit_5|90|4|FOLLOW-UP|2021-03-23|90
e|IS|6d0ec221-6eb6-4fed-806e-2bc700968333|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/7.5 mL|[?]|1|min*mg/mL|INFRANATANT, SERUM|CAPILLARY ELECTROPHORESIS|||1|1|Visit_1|10|1|TREATMENT|2020-07-27|10
e|IS|6d0ec221-6eb6-4fed-806e-2bc700968333|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|keV|[?]|1|mU|AMNIOTIC FLUID|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y|Y|1|2|Visit_2|25|2|TREATMENT|2020-08-11|25
e|IS|6d0ec221-6eb6-4fed-806e-2bc700968333|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|1/(s*kPa)|[?]|1|/day|ARTERIAL CORD BLOOD|SCINTIGRAPHY|Y||1|3|Visit_3|40|4|TREATMENT|2020-08-26|40
e|IS|6d0ec221-6eb6-4fed-806e-2bc700968333|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|log10 CFU/mL|[?]|1|Torr|DIALYSIS FLUID, PERITONEAL|FARR ASSAY||Y|1|4|Visit_4|65|7|WASHOUT|2020-09-20|65
e|IS|6d0ec221-6eb6-4fed-806e-2bc700968333|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^3/L|[?]|1|/wk|VITREOUS HUMOR|PATHOLOGICAL EVALUATION|||1|5|Visit_5|90|7|TREATMENT|2020-10-15|90
e|IS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/cage/day|[?]|1|kg/L|EPIDERMAL TISSUE|ICP-MS|||1|1|Visit_1|10|1|TREATMENT|2020-10-03|10
e|IS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^6 CFU/mL|[?]|1|/LSQN|PLATELET RICH PLASMA|IMMUNOCHROMATOGRAPHY|||1|2|Visit_2|25|1|FOLLOW-UP|2020-10-18|25
e|IS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|g/cage|[?]|1|ng/dL|SKIN TISSUE|ELECTROGASTROGRAPHY|||1|3|Visit_3|40|2|TREATMENT|2020-11-02|40
e|IS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/dL|[?]|1|HOURS|EPITHELIAL CELL|FLUORESCENCE ANGIOGRAPHY|||1|4|Visit_4|65|3|TREATMENT|2020-11-27|65
e|IS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|IU/dL|[?]|1|mL/dL|BONE MARROW|PULSE OXIMETRY|||1|5|Visit_5|90|1|TREATMENT|2020-12-22|90
e|IS|15e5e7ca-b832-450c-a20c-b21585086328|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|100 IU/mL|[?]|1|10^8/L|SOFT TISSUE|AUTOMATED COUNT|Y||1|1|Visit_1|10|3|TREATMENT|2021-01-05|10
e|IS|15e5e7ca-b832-450c-a20c-b21585086328|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/m2/day|[?]|1|in2|ARTERIAL CORD BLOOD|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y|1|2|Visit_2|25|2|TREATMENT|2021-01-20|25
e|IS|15e5e7ca-b832-450c-a20c-b21585086328|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Log10 ELISA unit/dose|[?]|1|mmAL|CORD SERUM|SNELLEN EYE CHART||Y|1|3|Visit_3|40|2|FOLLOW-UP|2021-02-04|40
e|IS|15e5e7ca-b832-450c-a20c-b21585086328|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/uL|[?]|1|mL/dL|ARTERIAL CORD BLOOD|COLORIMETRY|||1|4|Visit_4|65|3|SCREENING|2021-03-01|65
e|IS|15e5e7ca-b832-450c-a20c-b21585086328|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Bq/g|[?]|1|Gravitational Unit|SUPERNATANT, PLASMA|CONGO RED STAIN|Y|Y|1|5|Visit_5|90|3|FOLLOW-UP|2021-03-26|90
e|IS|b46ff3a2-f257-4803-8064-e29bd1114bfc|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Gy/h|[?]|1|PFU/animal|SPERMATOZOON|IMPEDANCE CONDUCTIVITY||Y|1|1|Visit_1|10|1|TREATMENT|2020-10-13|10
e|IS|b46ff3a2-f257-4803-8064-e29bd1114bfc|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|TABLET|[?]|1|10^9 organisms/mg|SUPERNATANT, PLASMA|IHC|||1|2|Visit_2|25|3|TREATMENT|2020-10-28|25
e|IS|b46ff3a2-f257-4803-8064-e29bd1114bfc|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Bq/uL|[?]|1|vp/mL|BONE MARROW|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|Y|1|3|Visit_3|40|4|TREATMENT|2020-11-12|40
e|IS|b46ff3a2-f257-4803-8064-e29bd1114bfc|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|days/wk|[?]|1|pt_us|HAIR|DOUBLE IMMUNODIFFUSION|||1|4|Visit_4|65|1|WASHOUT|2020-12-07|65
e|IS|b46ff3a2-f257-4803-8064-e29bd1114bfc|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Roentgen|[?]|1|AU/mL|ADIPOSE TISSUE|POLYSOMNOGRAPHY|||1|5|Visit_5|90|5|TREATMENT|2021-01-01|90
e|IS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|MET*h|[?]|1|um|BASAL TEAR|IODINE STAIN|||1|1|Visit_1|10|3|TREATMENT|2020-12-06|10
e|IS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nkat|[?]|1|ug/L/h|ALVEOLAR AIR|INFRARED SPECTROMETRY|||1|2|Visit_2|25|6|SCREENING|2020-12-21|25
e|IS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/dose|[?]|1|keV|BREAST MILK|CORONARY ANGIOGRAPHY|||1|3|Visit_3|40|2|FOLLOW-UP|2021-01-05|40
e|IS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/g/h|[?]|1|pkat/L|BLOOD|PET/CT SCAN WITHOUT CONTRAST||Y|1|4|Visit_4|65|1|TREATMENT|2021-01-30|65
e|IS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/m2/h|[?]|1|10^9 organisms/mL|AQUEOUS HUMOR|HANSEL STAIN|||1|5|Visit_5|90|2|TREATMENT|2021-02-24|90
e|IS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|%/s|[?]|1|anti-Xa IU|EPIDERMAL TISSUE|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||1|1|Visit_1|10|3|TREATMENT|2020-10-06|10
e|IS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BEAM BREAKS|[?]|1|mL*cmH2O|ARTERIAL BLOOD|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||1|2|Visit_2|25|2|SCREENING|2020-10-21|25
e|IS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mmol/min/kPa|[?]|1|mph|SPUTUM|CLIP|||1|3|Visit_3|40|6|TREATMENT|2020-11-05|40
e|IS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/week|[?]|1|cmol|SKELETAL MUSCLE TISSUE|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|4|Visit_4|65|1|TREATMENT|2020-11-30|65
e|IS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/min|[?]|1|DNA copies/mL|BILE|VIRUS PLAQUE ASSAY||Y|1|5|Visit_5|90|3|WASHOUT|2020-12-25|90
e|IS|944a2627-13f1-4ecf-9545-8819a1327138|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|genEq/mL|[?]|1|mol/day|TISSUE|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y|Y|1|1|Visit_1|10|6|WASHOUT|2021-01-17|10
e|IS|944a2627-13f1-4ecf-9545-8819a1327138|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|USP U|[?]|1|MPL U|MECONIUM|AUTOREFRACTION|||1|2|Visit_2|25|1|TREATMENT|2021-02-01|25
e|IS|944a2627-13f1-4ecf-9545-8819a1327138|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mCi|[?]|1|Enzyme U/m2|SOFT TISSUE|HEMAGGLUTINATION INHIBITION ASSAY|||1|3|Visit_3|40|3|TREATMENT|2021-02-16|40
e|IS|944a2627-13f1-4ecf-9545-8819a1327138|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ELISA unit/mL|[?]|1|steps/min|SEBUM|SPIROMETRY||Y|1|4|Visit_4|65|2|FOLLOW-UP|2021-03-13|65
e|IS|944a2627-13f1-4ecf-9545-8819a1327138|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/g/h|[?]|1|Tbsp|CERUMEN|CONTRAST ENHANCED X-RAY|||1|5|Visit_5|90|7|WASHOUT|2021-04-07|90
e|IS|7902955a-6336-45e5-a15d-7c368a28ac4f|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|amp|[?]|1|%/s|BLOOD|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||1|1|Visit_1|10|3|TREATMENT|2020-06-01|10
e|IS|7902955a-6336-45e5-a15d-7c368a28ac4f|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^7/L|[?]|1|m|SMOOTH MUSCLE TISSUE|GRAM STAIN|||1|2|Visit_2|25|1|TREATMENT|2020-06-16|25
e|IS|7902955a-6336-45e5-a15d-7c368a28ac4f|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cmH2O*s2/mL|[?]|1|mg/mol|TISSUE|RADIATION DOSIMETRY|||1|3|Visit_3|40|6|FOLLOW-UP|2020-07-01|40
e|IS|7902955a-6336-45e5-a15d-7c368a28ac4f|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|CFU/mL|[?]|1|AFU|MENSTRUAL BLOOD|SIZE EXCLUSION CHROMATOGRAPHY|Y|Y|1|4|Visit_4|65|3|SCREENING|2020-07-26|65
e|IS|7902955a-6336-45e5-a15d-7c368a28ac4f|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Gy/min|[?]|1|ng/mol|MONOCYTE|ETDRS EYE CHART|Y||1|5|Visit_5|90|4|TREATMENT|2020-08-20|90
e|IS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/g/min|[?]|1|mmol/min/kPa|CALCULUS|MAGNETIC RESONANCE ENTEROGRAPHY|||1|1|Visit_1|10|3|TREATMENT|2020-12-20|10
e|IS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|atm|[?]|1|DIOPTER|TISSUE|IMMUNE REPERTOIRE DEEP SEQUENCING|Y||1|2|Visit_2|25|6|FOLLOW-UP|2021-01-04|25
e|IS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Absorbance U/mL|[?]|1|Bq/kg|SUPERNATANT, PLEURAL FLUID|KINETIC CHROMOGENIC ASSAY||Y|1|3|Visit_3|40|6|TREATMENT|2021-01-19|40
e|IS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ppm|[?]|1|DNA copies/mL|PLASMA|CARDIAC THERMODILUTION|||1|4|Visit_4|65|4|SCREENING|2021-02-13|65
e|IS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uCi|[?]|1|/LSQN|BONE MARROW|CT SCAN WITHOUT CONTRAST||Y|1|5|Visit_5|90|1|TREATMENT|2021-03-10|90
e|IS|6071d81f-2f38-414f-90ca-4ad80c971054|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Henry|[?]|1|COAT|ARTERIALIZED CAPILLARY BLOOD|RIA|||1|1|Visit_1|10|1|SCREENING|2020-09-07|10
e|IS|6071d81f-2f38-414f-90ca-4ad80c971054|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|MET*h|[?]|1|deg/s|ARTERIALIZED CAPILLARY BLOOD|INDIRECT IMMUNOFLUORESCENCE|||1|2|Visit_2|25|3|TREATMENT|2020-09-22|25
e|IS|6071d81f-2f38-414f-90ca-4ad80c971054|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|nkat/L|[?]|1|IU/mL|STOOL|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||Y|1|3|Visit_3|40|3|WASHOUT|2020-10-07|40
e|IS|6071d81f-2f38-414f-90ca-4ad80c971054|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Bq/uL|[?]|1|10^9/g|SUPERNATANT, CEREBROSPINAL FLUID|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||1|4|Visit_4|65|2|WASHOUT|2020-11-01|65
e|IS|6071d81f-2f38-414f-90ca-4ad80c971054|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|umol/L/h|[?]|1|mol/g|PERIPHERAL BLOOD MONONUCLEAR CELL|NUCLEIC ACID HYBRIDIZATION|Y||1|5|Visit_5|90|4|SCREENING|2020-11-26|90
e|IS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|dmol|[?]|1|log EID 50/dose|MENSTRUAL BLOOD|ENZYMATIC ULTRACENTRIFUGATION|Y|Y|1|1|Visit_1|10|3|WASHOUT|2020-09-28|10
e|IS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|%|[?]|1|kHz|EXUDATE|PATHOLOGICAL EVALUATION|||1|2|Visit_2|25|4|TREATMENT|2020-10-13|25
e|IS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm2|[?]|1|copies/ug|PLEURAL FLUID|ANTIMICROBIAL COMBINATION TESTING|Y||1|3|Visit_3|40|7|TREATMENT|2020-10-28|40
e|IS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/mL/day|[?]|1|IU/g Hb|INFRANATANT, PLASMA|STATIC PERIMETRY||Y|1|4|Visit_4|65|3|TREATMENT|2020-11-22|65
e|IS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/L|[?]|1|amp|VITREOUS HUMOR|MALDI|||1|5|Visit_5|90|2|FOLLOW-UP|2020-12-17|90
e|IS|a046d48d-b1fa-4d46-902e-3984aed00ec7|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/mm2|[?]|1|fL|PLEURAL FLUID|FLOCCULATION, CHARCOAL ENHANCED|||1|1|Visit_1|10|7|SCREENING|2020-08-01|10
e|IS|a046d48d-b1fa-4d46-902e-3984aed00ec7|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg2/dL2|[?]|1|g/g/day|CERVICOVAGINAL SECRETION|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||1|2|Visit_2|25|3|FOLLOW-UP|2020-08-16|25
e|IS|a046d48d-b1fa-4d46-902e-3984aed00ec7|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|fg|[?]|1|BLOCKS|PUS|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||1|3|Visit_3|40|4|SCREENING|2020-08-31|40
e|IS|a046d48d-b1fa-4d46-902e-3984aed00ec7|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uCi/L|[?]|1|CCID 50/mL|SPUTUM|MICROBIAL CONCENTRATION|Y||1|4|Visit_4|65|6|WASHOUT|2020-09-25|65
e|IS|a046d48d-b1fa-4d46-902e-3984aed00ec7|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/day|[?]|1|um|MECONIUM|CARDIAC THERMODILUTION||Y|1|5|Visit_5|90|6|FOLLOW-UP|2020-10-20|90
e|IS|8b60e1b0-2cd9-419d-b345-9006af042932|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^6/hpf|[?]|1|ngEq/L|EMESIS|MASS SPECTROMETRY|||1|1|Visit_1|10|7|FOLLOW-UP|2020-12-16|10
e|IS|8b60e1b0-2cd9-419d-b345-9006af042932|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|PIXELS/in|[?]|1|ppth|CALCULUS|PHOTOMETRIC CLOT DETECTION||Y|1|2|Visit_2|25|4|SCREENING|2020-12-31|25
e|IS|8b60e1b0-2cd9-419d-b345-9006af042932|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Bq/mg|[?]|1|Gy/min|SALIVA|INDIRECT IMMUNOFLUORESCENCE|Y||1|3|Visit_3|40|3|FOLLOW-UP|2021-01-15|40
e|IS|8b60e1b0-2cd9-419d-b345-9006af042932|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|WAFER|[?]|1|dmol|BONE MARROW|BRDU CELLULAR PROLIFERATION ASSAY|||1|4|Visit_4|65|5|FOLLOW-UP|2021-02-09|65
e|IS|8b60e1b0-2cd9-419d-b345-9006af042932|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/s|[?]|1|nm|EPITHELIAL CELL|MECHANICAL CLOT DETECTION|||1|5|Visit_5|90|5|FOLLOW-UP|2021-03-06|90
e|IS|712029bc-471a-4e3d-9123-e38b3c38bc6c|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|psec|[?]|1|MET*h|ARTERIAL BLOOD|PHOROPTER|||1|1|Visit_1|10|6|TREATMENT|2021-01-24|10
e|IS|712029bc-471a-4e3d-9123-e38b3c38bc6c|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PACKAGE|[?]|1|uCi/kg|STOOL|INTERRUPTER TECHNIQUE||Y|1|2|Visit_2|25|3|SCREENING|2021-02-08|25
e|IS|712029bc-471a-4e3d-9123-e38b3c38bc6c|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|tuberculin unit|[?]|1|mm/2h|CELL PELLET|LIQUID SCINTILLATION COUNTING||Y|1|3|Visit_3|40|3|TREATMENT|2021-02-23|40
e|IS|712029bc-471a-4e3d-9123-e38b3c38bc6c|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cg|[?]|1|10^9/dose|SALIVA|RIA|||1|4|Visit_4|65|4|TREATMENT|2021-03-20|65
e|IS|712029bc-471a-4e3d-9123-e38b3c38bc6c|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|U/g/day|[?]|1|/4.0 mL|VENOUS CORD BLOOD|FLUORESCENCE ANGIOGRAPHY||Y|1|5|Visit_5|90|3|TREATMENT|2021-04-14|90
e|IS|92c0183d-5704-45ad-9aec-e24bc5777b80|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PIXEL|[?]|1|dyn|SWABBED MATERIAL|PELLI-ROBSON EYE CHART|||1|1|Visit_1|10|3|WASHOUT|2021-01-20|10
e|IS|92c0183d-5704-45ad-9aec-e24bc5777b80|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/m2|[?]|1|h/wk|ARTERIAL BLOOD|SCANNING ELECTRON MICROSCOPY||Y|1|2|Visit_2|25|1|WASHOUT|2021-02-04|25
e|IS|92c0183d-5704-45ad-9aec-e24bc5777b80|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 DNA copies/mL|[?]|1|pptr|ABSCESS FLUID|FISH|||1|3|Visit_3|40|3|TREATMENT|2021-02-19|40
e|IS|92c0183d-5704-45ad-9aec-e24bc5777b80|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|APS U|[?]|1|mEq/uL|TISSUE|MICROARRAY|||1|4|Visit_4|65|5|SCREENING|2021-03-16|65
e|IS|92c0183d-5704-45ad-9aec-e24bc5777b80|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ng/day|[?]|1|DDU|ISOLATE|SISH|||1|5|Visit_5|90|1|SCREENING|2021-04-10|90
e|IS|52ce3b1f-9500-4323-861d-73c8b96f59de|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|usec|[?]|1|PACK|CERUMEN|IN SITU HYBRIDIZATION|Y|Y|1|1|Visit_1|10|7|TREATMENT|2020-10-26|10
e|IS|52ce3b1f-9500-4323-861d-73c8b96f59de|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|pmol/10^10 cells|[?]|1|1/(s*kPa)|LYSATE|ORCHIDOMETERY||Y|1|2|Visit_2|25|7|WASHOUT|2020-11-10|25
e|IS|52ce3b1f-9500-4323-861d-73c8b96f59de|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|EID 50/mL|[?]|1|mL/h|REFLEX TEAR|FUNDUS PHOTOGRAPHY|Y||1|3|Visit_3|40|1|FOLLOW-UP|2020-11-25|40
e|IS|52ce3b1f-9500-4323-861d-73c8b96f59de|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mAnson U/mL|[?]|1|mm/2h|PLASMA|IMPULSE OSCILLOMETRY|||1|4|Visit_4|65|2|TREATMENT|2020-12-20|65
e|IS|52ce3b1f-9500-4323-861d-73c8b96f59de|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/dL|[?]|1|CAN|DIALYSIS FLUID|ENDOSCOPY|||1|5|Visit_5|90|5|TREATMENT|2021-01-14|90
e|IS|3655d198-2e7e-419e-8337-d7eea7d795ca|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|APL U/mL|[?]|1|mm/2h|SKELETAL MUSCLE TISSUE|MANUAL COUNT||Y|1|1|Visit_1|10|4|FOLLOW-UP|2020-11-23|10
e|IS|3655d198-2e7e-419e-8337-d7eea7d795ca|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|deg2|[?]|1|U/mL|FLUID|TELLER ACUITY CARDS|||1|2|Visit_2|25|7|FOLLOW-UP|2020-12-08|25
e|IS|3655d198-2e7e-419e-8337-d7eea7d795ca|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|tsp eq|[?]|1|U/g/day|CAPILLARY BLOOD|FORCED OSCILLATION TECHNIQUE||Y|1|3|Visit_3|40|2|TREATMENT|2020-12-23|40
e|IS|3655d198-2e7e-419e-8337-d7eea7d795ca|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|TRACE|[?]|1|mL/cage/day|AQUEOUS HUMOR|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||Y|1|4|Visit_4|65|5|SCREENING|2021-01-17|65
e|IS|3655d198-2e7e-419e-8337-d7eea7d795ca|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^6 U|[?]|1|mV*min|SUPERNATANT, PLASMA|PHYSICAL EXAMINATION|||1|5|Visit_5|90|4|FOLLOW-UP|2021-02-11|90
e|IS|d47da6bf-8abf-4b62-8bb8-797155981158|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/40 HPFs|[?]|1|10^3 DNA copies/mL|SMOOTH MUSCLE TISSUE|IMPULSE OSCILLOMETRY|||1|1|Visit_1|10|7|TREATMENT|2020-09-10|10
e|IS|d47da6bf-8abf-4b62-8bb8-797155981158|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|msec|[?]|1|10^7/L|AMNIOTIC FLUID|ICP-MS|Y||1|2|Visit_2|25|5|TREATMENT|2020-09-25|25
e|IS|d47da6bf-8abf-4b62-8bb8-797155981158|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ks|[?]|1|Gy|ENDOTRACHEAL FLUID|TRANSVAGINAL ULTRASOUND|||1|3|Visit_3|40|6|SCREENING|2020-10-10|40
e|IS|d47da6bf-8abf-4b62-8bb8-797155981158|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ng/L|[?]|1|Torr|PLATELET POOR PLASMA|PULMONARY ANGIOGRAPHY|||1|4|Visit_4|65|3|TREATMENT|2020-11-04|65
e|IS|d47da6bf-8abf-4b62-8bb8-797155981158|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|BISCUIT|[?]|1|OD Unit|SERUM OR PLASMA OR BLOOD|CONTRAST ENHANCED PET SCAN||Y|1|5|Visit_5|90|5|SCREENING|2020-11-29|90
e|IS|25e81c81-8c23-4c9e-be79-35247384dd1f|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/kg/min|[?]|1|10^3 CFU/g|PLATELET|ELECTROGASTROGRAPHY|||1|1|Visit_1|10|5|TREATMENT|2020-08-08|10
e|IS|25e81c81-8c23-4c9e-be79-35247384dd1f|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/2000 RBC|[?]|1|fL|EPIDERMAL TISSUE|CLOT DETECTION|||1|2|Visit_2|25|4|SCREENING|2020-08-23|25
e|IS|25e81c81-8c23-4c9e-be79-35247384dd1f|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|g/cage/day|[?]|1|/500 WBC|BREAST MILK|JAEGER EYE CHART||Y|1|3|Visit_3|40|1|TREATMENT|2020-09-07|40
e|IS|25e81c81-8c23-4c9e-be79-35247384dd1f|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|CFU/g|[?]|1|um/s|BONE|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||1|4|Visit_4|65|2|TREATMENT|2020-10-02|65
e|IS|25e81c81-8c23-4c9e-be79-35247384dd1f|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|uCi|[?]|1|TAMPON|SMOOTH MUSCLE TISSUE|MULTI-SLICE SPIRAL CT|Y||1|5|Visit_5|90|4|TREATMENT|2020-10-27|90
e|IS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|FFU|[?]|1|g/kg/day|GASTRIC CONTENTS|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|Y|1|1|Visit_1|10|3|TREATMENT|2020-07-27|10
e|IS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mIU/L|[?]|1|mL/kg/h|SUPERNATANT, PLASMA|NUCLEAR RADIOLOGY|Y||1|2|Visit_2|25|5|WASHOUT|2020-08-11|25
e|IS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/g|[?]|1|ms2|SPERMATOZOON|IMMUNODIFFUSION|||1|3|Visit_3|40|4|WASHOUT|2020-08-26|40
e|IS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/7.5 mL|[?]|1|vg/mL|AMNIOTIC FLUID|ENDPOINT DILUTION ASSAY||Y|1|4|Visit_4|65|4|SCREENING|2020-09-20|65
e|IS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/g/min|[?]|1|g/cage/wk|SUPERNATANT, PLEURAL FLUID|SPIRAL CT||Y|1|5|Visit_5|90|4|SCREENING|2020-10-15|90
e|IS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mkat|[?]|1|/HPF|ENDOMETRIAL TISSUE|NUCLEIC ACID BASED METHOD|Y||1|1|Visit_1|10|5|TREATMENT|2020-11-12|10
e|IS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 DNA copies/mL|[?]|1|NEBULE|SALIVA|FLUORESCENT ENZYME IMMUNOASSAY|||1|2|Visit_2|25|7|TREATMENT|2020-11-27|25
e|IS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|DISK|[?]|1|BOWL|DIALYSIS FLUID|U-HPLC/MS/MS|||1|3|Visit_3|40|1|WASHOUT|2020-12-12|40
e|IS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|lx|[?]|1|mL/mmHg/min/L|SEMEN|IODINE STAIN|Y||1|4|Visit_4|65|3|WASHOUT|2021-01-06|65
e|IS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mm|[?]|1|mm/sec|SUPERNATANT, PLASMA|TOTAL BODY IRRADIATION|||1|5|Visit_5|90|1|SCREENING|2021-01-31|90
e|IS|5ba70148-c29b-47af-9280-10d1a942380a|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dpm/mg|[?]|1|ka_u/dL|EMOTIONAL TEAR|CT SCAN WITHOUT CONTRAST|||1|1|Visit_1|10|2|TREATMENT|2020-11-28|10
e|IS|5ba70148-c29b-47af-9280-10d1a942380a|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|IU/kg|[?]|1|/5x10^4 WBC|CARDIAC MUSCLE TISSUE|MACRO BROTH DILUTION|Y||1|2|Visit_2|25|4|TREATMENT|2020-12-13|25
e|IS|5ba70148-c29b-47af-9280-10d1a942380a|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mm2|[?]|1|eq|NAIL|NON-INVASIVE DIELECTRIC SENSING|||1|3|Visit_3|40|5|SCREENING|2020-12-28|40
e|IS|5ba70148-c29b-47af-9280-10d1a942380a|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|log10 CFU/mL|[?]|1|10^6 CFU/g|SERUM OR PLASMA|MANUAL CLOT DETECTION||Y|1|4|Visit_4|65|3|WASHOUT|2021-01-22|65
e|IS|5ba70148-c29b-47af-9280-10d1a942380a|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^9/g|[?]|1|LENS|LYSATE|MICROBIAL CONCENTRATION|||1|5|Visit_5|90|3|TREATMENT|2021-02-16|90
e|IS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/cage/wk|[?]|1|Antibody Unit|URINE SEDIMENT|TOTAL BODY RADIOGRAPHY|||1|1|Visit_1|10|1|SCREENING|2020-05-27|10
e|IS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Ci/kg|[?]|1|mL/cage/day|BONE MARROW MONONUCLEAR CELL|PET/CT SCAN|Y||1|2|Visit_2|25|4|SCREENING|2020-06-11|25
e|IS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ng/mol|[?]|1|cd|BONE MARROW MONONUCLEAR CELL|ISHIHARA COLOR PLATES|||1|3|Visit_3|40|5|TREATMENT|2020-06-26|40
e|IS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/cm H2O|[?]|1|ug/L FEU|INTERSTITIAL FLUID|IHC|||1|4|Visit_4|65|4|FOLLOW-UP|2020-07-21|65
e|IS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|L/L|[?]|1|kBq/uL|MECONIUM|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y||1|5|Visit_5|90|5|SCREENING|2020-08-15|90
e|IS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kPa/L/sec|[?]|1|s^-1(%O2)^-1|SWABBED MATERIAL|TELLER ACUITY CARDS|Y||1|1|Visit_1|10|5|FOLLOW-UP|2020-06-19|10
e|IS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uEq|[?]|1|mL/g/day|DERMAL TISSUE|TONOMETRY|||1|2|Visit_2|25|6|TREATMENT|2020-07-04|25
e|IS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Osm|[?]|1|DNA copies/ug|CALCULUS|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y|1|3|Visit_3|40|6|WASHOUT|2020-07-19|40
e|IS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mV|[?]|1|ugEq/L|CIRCULATING TUMOR CELL|BETA LACTAMASE||Y|1|4|Visit_4|65|6|TREATMENT|2020-08-13|65
e|IS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Shock Wave|[?]|1|10^6 DNA copies/mL|BASAL TEAR|TEMPLATE INCISION METHOD|Y||1|5|Visit_5|90|7|TREATMENT|2020-09-07|90
e|IS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MdFI|[?]|1|umol|SUPERNATANT, SERUM OR PLASMA|ELISA|Y|Y|1|1|Visit_1|10|4|TREATMENT|2020-08-20|10
e|IS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|IU/mL|[?]|1|DAgU/mL|MUSCLE TISSUE|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|2|Visit_2|25|3|SCREENING|2020-09-04|25
e|IS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|APL U|[?]|1|FFU|BASAL TEAR|ANTIMICROBIAL COMBINATION TESTING|||1|3|Visit_3|40|1|TREATMENT|2020-09-19|40
e|IS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/kg/h|[?]|1|U/kg/h|HAIR FOLLICLE|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y||1|4|Visit_4|65|4|WASHOUT|2020-10-14|65
e|IS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|fmol|[?]|1|mm2|TISSUE|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y|1|5|Visit_5|90|3|TREATMENT|2020-11-08|90
e|IS|a73142e4-e34b-4144-b95f-7a5562574c1b|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/g/day|[?]|1|fmol/L|EPITHELIAL CELL|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||1|1|Visit_1|10|2|TREATMENT|2020-08-08|10
e|IS|a73142e4-e34b-4144-b95f-7a5562574c1b|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|vg/kg|[?]|1|deg|LUNG SURFACTANT|REFLECTANCE SPECTROSCOPY|||1|2|Visit_2|25|3|TREATMENT|2020-08-23|25
e|IS|a73142e4-e34b-4144-b95f-7a5562574c1b|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PIPE|[?]|1|10^6 CFU/mL|SMOOTH MUSCLE TISSUE|DISK DIFFUSION|||1|3|Visit_3|40|7|TREATMENT|2020-09-07|40
e|IS|a73142e4-e34b-4144-b95f-7a5562574c1b|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/dL|[?]|1|mL/s/m2|ENDOMETRIAL TISSUE|NEPHELOMETRY|||1|4|Visit_4|65|7|TREATMENT|2020-10-02|65
e|IS|a73142e4-e34b-4144-b95f-7a5562574c1b|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|POUCH|[?]|1|mL/cage/wk|HAIR|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|5|Visit_5|90|6|SCREENING|2020-10-27|90
e|IS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|NEBULE|[?]|1|mEq/L|CORD BLOOD|HPLC-FL|||1|1|Visit_1|10|2|WASHOUT|2020-06-03|10
e|IS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^9 CFU/mL|[?]|1|umol|PLEURAL TISSUE|MAMMOGRAPHY|||1|2|Visit_2|25|7|TREATMENT|2020-06-18|25
e|IS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kDa|[?]|1|mL/g/h|TRANSUDATE|SLOAN LETTER EYE CHART 1.25%|Y||1|3|Visit_3|40|6|WASHOUT|2020-07-03|40
e|IS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/m2/min|[?]|1|nmol/day|INTERSTITIAL FLUID|NON-CONTACT SPECULAR MICROSCOPY|Y||1|4|Visit_4|65|1|WASHOUT|2020-07-28|65
e|IS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|IU/mL|[?]|1|EU|SMEGMA|IMPEDANCE CONDUCTIVITY|Y||1|5|Visit_5|90|7|SCREENING|2020-08-22|90
e|IS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/mm|[?]|1|fmol/L/sec|PLATELET RICH PLASMA|IMPEDANCE CONDUCTIVITY|||1|1|Visit_1|10|6|WASHOUT|2020-05-29|10
e|IS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kcal|[?]|1|AFU|PERSPIRATION|CONTRAST ENHANCED PET SCAN|||1|2|Visit_2|25|7|SCREENING|2020-06-13|25
e|IS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mU/L|[?]|1|PACKET|SUPERNATANT, PLEURAL FLUID|GRADIENT DIFFUSION|||1|3|Visit_3|40|7|WASHOUT|2020-06-28|40
e|IS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|umol/dL|[?]|1|nkat/L|KERATINOCYTE|LIGHT SCATTERING SPECTROSCOPY|Y||1|4|Visit_4|65|6|TREATMENT|2020-07-23|65
e|IS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kg/mol|[?]|1|CAPSULE|SYNOVIAL FLUID|ANGIOGRAPHY|Y||1|5|Visit_5|90|4|FOLLOW-UP|2020-08-17|90
e|IS|1d8aba56-f62e-4116-b447-899dedd3d4df|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Coulomb|[?]|1|mm/sec|ENDOTRACHEAL FLUID|ELISA|||1|1|Visit_1|10|7|FOLLOW-UP|2020-09-29|10
e|IS|1d8aba56-f62e-4116-b447-899dedd3d4df|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mOsm|[?]|1|10^9 CFU/g|LAVAGE FLUID|CONTRAST ENHANCED CT SCAN|Y|Y|1|2|Visit_2|25|5|TREATMENT|2020-10-14|25
e|IS|1d8aba56-f62e-4116-b447-899dedd3d4df|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kDa|[?]|1|L/h/m2|SUPERNATANT, PLEURAL FLUID|MAPH|Y||1|3|Visit_3|40|1|WASHOUT|2020-10-29|40
e|IS|1d8aba56-f62e-4116-b447-899dedd3d4df|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Rad|[?]|1|pm|PERIPHERAL BLOOD MONONUCLEAR CELL|AUTOMATED COUNT|||1|4|Visit_4|65|6|SCREENING|2020-11-23|65
e|IS|1d8aba56-f62e-4116-b447-899dedd3d4df|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ft3|[?]|1|mmHg*min/L|PLASMA ULTRAFILTRATE|TEST STRIP||Y|1|5|Visit_5|90|7|TREATMENT|2020-12-18|90
e|IS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|IU/day|[?]|1|log10 CFU/mL|EXHALED BREATH CONDENSATE|PUPILLOMETRY||Y|1|1|Visit_1|10|4|TREATMENT|2020-08-14|10
e|IS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|nkat/L|[?]|1|L/s|SKIN TISSUE|EPSILOMETER||Y|1|2|Visit_2|25|4|TREATMENT|2020-08-29|25
e|IS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/kg/min|[?]|1|mL/cage/wk|AQUEOUS HUMOR|REFRACTOMETRY|||1|3|Visit_3|40|1|TREATMENT|2020-09-13|40
e|IS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^7 TCID 50/dose|[?]|1|pkat/L|GASTRIC CONTENTS|SPECT SCAN|Y|Y|1|4|Visit_4|65|7|TREATMENT|2020-10-08|65
e|IS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/h|[?]|1|APL U|SPUTUM|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y|1|5|Visit_5|90|2|SCREENING|2020-11-02|90
e|IS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/L|[?]|1|mCi|PERSPIRATION|WESTERN BLOT||Y|1|1|Visit_1|10|1|TREATMENT|2020-06-07|10
e|IS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nmol/mL/min|[?]|1|mL/animal|TRANSUDATE|WHOLE GENOME SEQUENCING|||1|2|Visit_2|25|3|TREATMENT|2020-06-22|25
e|IS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|SUPPOSITORY|[?]|1|MPL U|LAVAGE FLUID|URANYL ACETATE STAIN|||1|3|Visit_3|40|2|TREATMENT|2020-07-07|40
e|IS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 IU/mL|[?]|1|mol/mL|BONE MARROW MONONUCLEAR CELL|MRI WITHOUT CONTRAST||Y|1|4|Visit_4|65|6|TREATMENT|2020-08-01|65
e|IS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^8/L|[?]|1|WAFER|SUPERNATANT, SERUM|LYMPHANGIOGRAPHY|||1|5|Visit_5|90|2|WASHOUT|2020-08-26|90
e|IS|b4f81b74-fee9-4544-9404-206d931ed8e5|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pt_us|[?]|1|Gravitational Unit|PLATELET POOR PLASMA|MECHANICAL CLOT DETECTION|||1|1|Visit_1|10|6|FOLLOW-UP|2020-10-18|10
e|IS|b4f81b74-fee9-4544-9404-206d931ed8e5|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|umol/kg/min|[?]|1|uL|SUPERNATANT, PLEURAL FLUID|LC-FL|||1|2|Visit_2|25|4|SCREENING|2020-11-02|25
e|IS|b4f81b74-fee9-4544-9404-206d931ed8e5|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mph|[?]|1|deg/mm|LAVAGE FLUID|MAPH|||1|3|Visit_3|40|6|WASHOUT|2020-11-17|40
e|IS|b4f81b74-fee9-4544-9404-206d931ed8e5|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|TROCHE|[?]|1|cmHg|SUPERNATANT, PLEURAL FLUID|PALPATION|||1|4|Visit_4|65|2|SCREENING|2020-12-12|65
e|IS|b4f81b74-fee9-4544-9404-206d931ed8e5|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|AU/mL|[?]|1|mL/cm3/min|GASTRIC CONTENTS|MICROPARTICLE ENZYME IMMUNOASSAY|||1|5|Visit_5|90|2|SCREENING|2021-01-06|90
e|IS|9e69b457-20db-45e5-a535-0cd8ac102fea|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol|[?]|1|Bq/mg|MONOCYTE|HILLMEN COLOR CHART|||1|1|Visit_1|10|6|WASHOUT|2020-06-07|10
e|IS|9e69b457-20db-45e5-a535-0cd8ac102fea|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^7 TCID 50/dose|[?]|1|LB|PLASMA ULTRAFILTRATE|CALCULATION|||1|2|Visit_2|25|1|WASHOUT|2020-06-22|25
e|IS|9e69b457-20db-45e5-a535-0cd8ac102fea|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|EP U|[?]|1|YEARS|VENOUS CORD BLOOD|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y||1|3|Visit_3|40|2|FOLLOW-UP|2020-07-07|40
e|IS|9e69b457-20db-45e5-a535-0cd8ac102fea|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Hz/s|[?]|1|CIGAR|HAIR FOLLICLE|IODINE STAIN|Y||1|4|Visit_4|65|7|TREATMENT|2020-08-01|65
e|IS|9e69b457-20db-45e5-a535-0cd8ac102fea|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|nL|[?]|1|pmol/L/h|PLEURAL FLUID|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|5|Visit_5|90|3|TREATMENT|2020-08-26|90
e|IS|14211798-ddf6-47c8-bd9d-056d95bad8ff|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nmol|[?]|1|ug/m2|GASTRIC CONTENTS|SXA SCAN||Y|1|1|Visit_1|10|5|TREATMENT|2020-09-26|10
e|IS|14211798-ddf6-47c8-bd9d-056d95bad8ff|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|log10 PFU|[?]|1|vp/dose|AMNIOTIC FLUID|ENZYMATIC ULTRACENTRIFUGATION|||1|2|Visit_2|25|4|WASHOUT|2020-10-11|25
e|IS|14211798-ddf6-47c8-bd9d-056d95bad8ff|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/mmHg|[?]|1|mEq/L|EMOTIONAL TEAR|CISH|||1|3|Visit_3|40|2|TREATMENT|2020-10-26|40
e|IS|14211798-ddf6-47c8-bd9d-056d95bad8ff|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|MHz|[?]|1|/500 WBC|BLOOD|MECHANICAL CLOT DETECTION|||1|4|Visit_4|65|6|TREATMENT|2020-11-20|65
e|IS|14211798-ddf6-47c8-bd9d-056d95bad8ff|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|CFU/mL|[?]|1|mg/g/h|VITREOUS HUMOR|X-RAY||Y|1|5|Visit_5|90|3|FOLLOW-UP|2020-12-15|90
e|IS|63f3194e-9b88-491a-9a68-19109ed86e2b|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|log EID 50/dose|[?]|1|DPM|BREAST MILK|MICROBIAL CULTURE|Y||1|1|Visit_1|10|6|WASHOUT|2020-06-10|10
e|IS|63f3194e-9b88-491a-9a68-19109ed86e2b|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/kg/day|[?]|1|uIU/dL|ISOLATE|NUCLEIC ACID AMPLIFICATION TEST|||1|2|Visit_2|25|6|TREATMENT|2020-06-25|25
e|IS|63f3194e-9b88-491a-9a68-19109ed86e2b|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|TROCHE|[?]|1|MnFI|BILE|ELISPOT|Y|Y|1|3|Visit_3|40|6|TREATMENT|2020-07-10|40
e|IS|63f3194e-9b88-491a-9a68-19109ed86e2b|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ng/dL|[?]|1|mm/2h|ARTERIALIZED CAPILLARY BLOOD|LC/MS|||1|4|Visit_4|65|5|TREATMENT|2020-08-04|65
e|IS|63f3194e-9b88-491a-9a68-19109ed86e2b|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uCi/L|[?]|1|log10 TCID 50/dose|PLEURAL TISSUE|ANTIMICROBIAL COMBINATION TESTING|||1|5|Visit_5|90|6|TREATMENT|2020-08-29|90
e|IS|b6208258-d7c2-4dde-addf-4677946ab165|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/min|[?]|1|cmHg|SKELETAL MUSCLE TISSUE|CELLULAR PROLIFERATION ASSAY|||1|1|Visit_1|10|2|TREATMENT|2020-09-20|10
e|IS|b6208258-d7c2-4dde-addf-4677946ab165|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/L|[?]|1|dpm/mg|CARDIAC MUSCLE TISSUE|CORONARY ANGIOGRAPHY|Y||1|2|Visit_2|25|1|TREATMENT|2020-10-05|25
e|IS|b6208258-d7c2-4dde-addf-4677946ab165|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pmol|[?]|1|mL/min|TISSUE|KARYOTYPING|Y|Y|1|3|Visit_3|40|1|SCREENING|2020-10-20|40
e|IS|b6208258-d7c2-4dde-addf-4677946ab165|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|L/min|[?]|1|anti-Xa IU|RETICULOCYTES|AGAR PROPORTION||Y|1|4|Visit_4|65|5|SCREENING|2020-11-14|65
e|IS|b6208258-d7c2-4dde-addf-4677946ab165|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|CARTRIDGE|[?]|1|pkat/L|ARTERIAL BLOOD|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||Y|1|5|Visit_5|90|4|TREATMENT|2020-12-09|90
e|IS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nmol/L/h|[?]|1|10^9 organisms/mL|GASTRIC FLUID|SURFACE PLASMON RESONANCE||Y|1|1|Visit_1|10|4|TREATMENT|2021-01-26|10
e|IS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|min|[?]|1|/ms|MIXED VENOUS BLOOD|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||1|2|Visit_2|25|6|FOLLOW-UP|2021-02-10|25
e|IS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IU/kg/h|[?]|1|log10 TCID 50/mL|DIALYSIS FLUID|CHROMOGENIC ASSAY|||1|3|Visit_3|40|1|SCREENING|2021-02-25|40
e|IS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/g|[?]|1|Gy/h|PLEURAL TISSUE|PHASE CONTRAST MICROSCOPY|||1|4|Visit_4|65|1|SCREENING|2021-03-22|65
e|IS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|copies/mL|[?]|1|cycle/min|LYSATE|PYROSEQUENCING|Y|Y|1|5|Visit_5|90|1|TREATMENT|2021-04-16|90
e|IS|e148c13d-ee41-4503-a7e5-397dd6155f04|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GBq|[?]|1|10^3 organisms/g|VENOUS CORD BLOOD|IMMUNOASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-07-18|10
e|IS|e148c13d-ee41-4503-a7e5-397dd6155f04|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/g/min|[?]|1|BAU/mL|CORD BLOOD|CELL OF ORIGIN ASSAY|||1|2|Visit_2|25|3|TREATMENT|2020-08-02|25
e|IS|e148c13d-ee41-4503-a7e5-397dd6155f04|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|INHALATION|[?]|1|FFU|MECONIUM|TEMPLATE INCISION METHOD|||1|3|Visit_3|40|2|TREATMENT|2020-08-17|40
e|IS|e148c13d-ee41-4503-a7e5-397dd6155f04|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|APS U|[?]|1|uEq|SEMEN|LINE PROBE ASSAY|||1|4|Visit_4|65|2|FOLLOW-UP|2020-09-11|65
e|IS|e148c13d-ee41-4503-a7e5-397dd6155f04|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/sec|[?]|1|L/s/kPa|PLATELET|CISH|||1|5|Visit_5|90|1|FOLLOW-UP|2020-10-06|90
e|IS|815de94a-f259-41ee-8951-8df150184a25|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/dL|[?]|1|FEU|NAIL|FISH|||1|1|Visit_1|10|2|TREATMENT|2020-07-07|10
e|IS|815de94a-f259-41ee-8951-8df150184a25|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|kg/cm|[?]|1|EID 50/mL|PLEURAL TISSUE|HPLC-FL|Y||1|2|Visit_2|25|7|SCREENING|2020-07-22|25
e|IS|815de94a-f259-41ee-8951-8df150184a25|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mU|[?]|1|mmol/L|SPERMATOZOON|ATOMIC ABSORPTION SPECTROMETRY|Y||1|3|Visit_3|40|4|FOLLOW-UP|2020-08-06|40
e|IS|815de94a-f259-41ee-8951-8df150184a25|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|min/day|[?]|1|ug/mol|INTERSTITIAL FLUID|CHROMATOGRAPHY|||1|4|Visit_4|65|6|WASHOUT|2020-08-31|65
e|IS|815de94a-f259-41ee-8951-8df150184a25|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CCID 50/mL|[?]|1|DAgU|SKELETAL MUSCLE TISSUE|IODINE STAIN|||1|5|Visit_5|90|3|TREATMENT|2020-09-25|90
e|IS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|h*%|[?]|1|ug/dL|ABSCESS FLUID|GRADIENT DIFFUSION|||1|1|Visit_1|10|2|SCREENING|2020-05-16|10
e|IS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|DNA copies/mL|[?]|1|copies/ug|SEBUM|ERGOSPIROMETRY||Y|1|2|Visit_2|25|5|FOLLOW-UP|2020-05-31|25
e|IS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/min|[?]|1|GLOBULE|SALIVA|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|1|3|Visit_3|40|1|FOLLOW-UP|2020-06-15|40
e|IS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mol/mg|[?]|1|cal|BILE|SEQUENCING|||1|4|Visit_4|65|7|TREATMENT|2020-07-10|65
e|IS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mIU/L|[?]|1|Enzyme U/m2|PLATELET POOR PLASMA|SMEAR|Y||1|5|Visit_5|90|5|SCREENING|2020-08-04|90
e|IS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Coulomb|[?]|1|DAgU/mL|LEUKOCYTE|DYNAMIC LIGHT SCATTERING||Y|1|1|Visit_1|10|7|TREATMENT|2021-01-25|10
e|IS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|beats/min|[?]|1|/10^3|CORD BLOOD|PERIODIC ACID SCHIFF STAIN|Y|Y|1|2|Visit_2|25|1|FOLLOW-UP|2021-02-09|25
e|IS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mEq/mmol|[?]|1|uL/dose|CARDIAC MUSCLE TISSUE|SLIT LAMP PHOTOGRAPHY|Y||1|3|Visit_3|40|4|TREATMENT|2021-02-24|40
e|IS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|um/s|[?]|1|DIP|URINE SEDIMENT|HPLC/MS|Y||1|4|Visit_4|65|4|TREATMENT|2021-03-21|65
e|IS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|min/day|[?]|1|mL*cmH2O|LOCHIA|OBSERVATION|||1|5|Visit_5|90|3|WASHOUT|2021-04-15|90
e|IS|a616ef00-05d6-459a-8474-06ab3eb493b1|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nmol BCE/mmol|[?]|1|U/animal|CAPILLARY BLOOD|TOTAL BODY IRRADIATION|Y||1|1|Visit_1|10|3|TREATMENT|2020-09-25|10
e|IS|a616ef00-05d6-459a-8474-06ab3eb493b1|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|min/day|EMOTIONAL TEAR|CT SCAN WITHOUT CONTRAST|Y|Y|1|2|Visit_2|25|6|FOLLOW-UP|2020-10-10|25
e|IS|a616ef00-05d6-459a-8474-06ab3eb493b1|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/kg/day|[?]|1|U/g/min|CIRCULATING TUMOR CELL|ANALYTICAL ULTRACENTRIFUGATION|Y||1|3|Visit_3|40|7|TREATMENT|2020-10-25|40
e|IS|a616ef00-05d6-459a-8474-06ab3eb493b1|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pptr|[?]|1|10^6 copies/mL|STRIATED MUSCLE TISSUE|HIGH RESOLUTION MELT ANALYSIS||Y|1|4|Visit_4|65|6|TREATMENT|2020-11-19|65
e|IS|a616ef00-05d6-459a-8474-06ab3eb493b1|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|dpm/100mg|[?]|1|HOURS|ADIPOSE TISSUE|SISH|||1|5|Visit_5|90|6|FOLLOW-UP|2020-12-14|90
e|IS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Newton|[?]|1|umol|BONE MARROW|LINE PROBE ASSAY|||1|1|Visit_1|10|5|TREATMENT|2020-08-20|10
e|IS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cm2|[?]|1|DAgU/mL|LOCHIA|BRDU CELLULAR PROLIFERATION ASSAY|Y||1|2|Visit_2|25|5|TREATMENT|2020-09-04|25
e|IS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pg/L|[?]|1|Ci/kg|EXHALED BREATH CONDENSATE|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y|1|3|Visit_3|40|6|WASHOUT|2020-09-19|40
e|IS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BOX|[?]|1|kPa|SMEGMA|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|4|Visit_4|65|3|WASHOUT|2020-10-14|65
e|IS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|psec|[?]|1|mAmp|BONE|ROMANOWSKY STAIN|Y|Y|1|5|Visit_5|90|3|TREATMENT|2020-11-08|90
e|IS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U/g/h|[?]|1|USP U|CORD BLOOD|CENTRIFUGATION|Y|Y|1|1|Visit_1|10|3|FOLLOW-UP|2020-10-21|10
e|IS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|nmol/L/h|[?]|1|mEq/day|DIALYSIS FLUID, PERITONEAL|THICK SMEAR|Y||1|2|Visit_2|25|4|TREATMENT|2020-11-05|25
e|IS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|INHALATION|[?]|1|umol/L/h|CARDIAC MUSCLE TISSUE|PERIODIC ACID SCHIFF STAIN||Y|1|3|Visit_3|40|4|SCREENING|2020-11-20|40
e|IS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|BEAM BREAKS|[?]|1|mkat|PERIPHERAL BLOOD MONONUCLEAR CELL|POLYSOMNOGRAPHY|||1|4|Visit_4|65|3|WASHOUT|2020-12-15|65
e|IS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cy/cm|[?]|1|ug/g/day|ADIPOSE TISSUE|BALLPOINT PEN TECHNIQUE||Y|1|5|Visit_5|90|1|FOLLOW-UP|2021-01-09|90
e|IS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|APPLICATION|[?]|1|cP|CAPILLARY BLOOD|DYNAMIC CONTRAST ENHANCED MRI||Y|1|1|Visit_1|10|5|TREATMENT|2020-07-04|10
e|IS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mmol/s|[?]|1|kg/cm|RETICULOCYTES|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||1|2|Visit_2|25|1|TREATMENT|2020-07-19|25
e|IS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dpm/0.5 mL|[?]|1|mkat|BONE MARROW|POPULATION SEQUENCING|Y||1|3|Visit_3|40|3|TREATMENT|2020-08-03|40
e|IS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/g/min|[?]|1|ug/kg/h|SUPERNATANT, SERUM|PANENDOSCOPY|Y||1|4|Visit_4|65|7|TREATMENT|2020-08-28|65
e|IS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MHz|[?]|1|ECL unit|KERATINOCYTE|IMPEDANCE CONDUCTIVITY|||1|5|Visit_5|90|1|FOLLOW-UP|2020-09-22|90
e|IS|2014bcd0-1430-4096-87f5-650a01dae626|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|WAFER|[?]|1|GLOBULE|LUNG SURFACTANT|TRIPLE-PHASE MRI SCAN||Y|1|1|Visit_1|10|6|TREATMENT|2020-05-31|10
e|IS|2014bcd0-1430-4096-87f5-650a01dae626|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|vp/dose|[?]|1|mol/mg|CEREBROSPINAL FLUID|LANDOLT RING||Y|1|2|Visit_2|25|7|TREATMENT|2020-06-15|25
e|IS|2014bcd0-1430-4096-87f5-650a01dae626|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/s|[?]|1|ug/dL|SKELETAL MUSCLE TISSUE|ROMANOWSKY STAIN|||1|3|Visit_3|40|4|TREATMENT|2020-06-30|40
e|IS|2014bcd0-1430-4096-87f5-650a01dae626|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kg|[?]|1|mL/min|SKIN TISSUE|TRANSMISSION ELECTRON MICROSCOPY|||1|4|Visit_4|65|1|SCREENING|2020-07-25|65
e|IS|2014bcd0-1430-4096-87f5-650a01dae626|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|APPLICATION|[?]|1|log10 PFU/mL|ATHEROSCLEROTIC PLAQUE|INTRAVASCULAR ULTRASOUND|||1|5|Visit_5|90|6|SCREENING|2020-08-19|90
e|IS|e043f1b3-6b65-45c0-bdae-eb783406c263|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|L|[?]|1|Tesla|BLOOD|MICROARRAY||Y|1|1|Visit_1|10|6|FOLLOW-UP|2020-11-11|10
e|IS|e043f1b3-6b65-45c0-bdae-eb783406c263|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/10^4|[?]|1|mMU/mL|SKIN TISSUE|GC/MS|Y|Y|1|2|Visit_2|25|3|TREATMENT|2020-11-26|25
e|IS|e043f1b3-6b65-45c0-bdae-eb783406c263|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 CFU/mL|[?]|1|10^10/L|EXPIRED AIR|STATIC PERIMETRY|||1|3|Visit_3|40|1|TREATMENT|2020-12-11|40
e|IS|e043f1b3-6b65-45c0-bdae-eb783406c263|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|100 IU/mL|[?]|1|mg/h|SERUM OR PLASMA|ELECTROMYOGRAPHY||Y|1|4|Visit_4|65|4|WASHOUT|2021-01-05|65
e|IS|e043f1b3-6b65-45c0-bdae-eb783406c263|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pmol/10^9 cells|[?]|1|10^5/hpf|ISOLATE|IMMUNOFIXATION ELECTROPHORESIS|Y||1|5|Visit_5|90|4|TREATMENT|2021-01-30|90
e|IS|45623c39-86de-4b2f-bf2d-998d0e941e92|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|GBq/g|[?]|1|mmol/s|SMEGMA|CALIPER MEASUREMENT METHOD|||1|1|Visit_1|10|6|TREATMENT|2020-07-22|10
e|IS|45623c39-86de-4b2f-bf2d-998d0e941e92|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|CIGARETTE|[?]|1|/200 HPFs|EPIDERMAL TISSUE|LANDOLT RING||Y|1|2|Visit_2|25|1|TREATMENT|2020-08-06|25
e|IS|45623c39-86de-4b2f-bf2d-998d0e941e92|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|JAR|[?]|1|pmol/L|DIALYSIS FLUID, PERITONEAL|ARTERIAL SPIN LABELING FUNCTIONAL MRI||Y|1|3|Visit_3|40|5|SCREENING|2020-08-21|40
e|IS|45623c39-86de-4b2f-bf2d-998d0e941e92|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|vp/mL|[?]|1|mL|LOCHIA|AUTOMATED COUNT|Y||1|4|Visit_4|65|2|WASHOUT|2020-09-15|65
e|IS|45623c39-86de-4b2f-bf2d-998d0e941e92|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nkat/g Hb|[?]|1|U/animal|STOOL|THIN SMEAR|||1|5|Visit_5|90|1|TREATMENT|2020-10-10|90
e|IS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mol|[?]|1|cm H2O|SEMINAL FLUID|TRYPAN BLUE STAIN|||1|1|Visit_1|10|1|FOLLOW-UP|2020-10-18|10
e|IS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/cm H2O|[?]|1|pmol/L|DERMAL TISSUE|AMSLER GRID|||1|2|Visit_2|25|6|WASHOUT|2020-11-02|25
e|IS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Enzyme U/L|[?]|1|10^3/L|CERVICOVAGINAL SECRETION|PHOTOMETRIC CLOT DETECTION|||1|3|Visit_3|40|2|TREATMENT|2020-11-17|40
e|IS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Ci/uL|[?]|1|TAMPON|MECONIUM|ELISA||Y|1|4|Visit_4|65|7|TREATMENT|2020-12-12|65
e|IS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|APL U/mL|[?]|1|mL/m2/min|SMOOTH MUSCLE TISSUE|ELLA|Y||1|5|Visit_5|90|4|SCREENING|2021-01-06|90
e|IS|e5a105f7-38ac-4f19-aace-4149ed9b1100|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|oz eq|[?]|1|mm/2h|ENDOMETRIAL TISSUE|FORCED OSCILLATION TECHNIQUE||Y|1|1|Visit_1|10|7|FOLLOW-UP|2020-09-03|10
e|IS|e5a105f7-38ac-4f19-aace-4149ed9b1100|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|s*kPa|[?]|1|ug/mol|ADIPOSE TISSUE|MAMMOGRAPHY|||1|2|Visit_2|25|6|TREATMENT|2020-09-18|25
e|IS|e5a105f7-38ac-4f19-aace-4149ed9b1100|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmol/min/kPa/L|[?]|1|tsp eq|EMOTIONAL TEAR|INTRAVASCULAR ULTRASOUND|||1|3|Visit_3|40|3|FOLLOW-UP|2020-10-03|40
e|IS|e5a105f7-38ac-4f19-aace-4149ed9b1100|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uOsm|[?]|1|ug/L/h|SEMINAL FLUID|PH METER MEASUREMENT METHOD|||1|4|Visit_4|65|6|SCREENING|2020-10-28|65
e|IS|e5a105f7-38ac-4f19-aace-4149ed9b1100|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PLUG|[?]|1|10^3 CFU|PLATELET|CYSTOMETRY|||1|5|Visit_5|90|7|TREATMENT|2020-11-22|90
e|IS|c568ab93-8e7f-4e4e-9685-f0c13f293606|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9/L|[?]|1|10^3/L|SKELETAL MUSCLE TISSUE|DARK FIELD MICROSCOPY|Y||1|1|Visit_1|10|6|SCREENING|2021-01-14|10
e|IS|c568ab93-8e7f-4e4e-9685-f0c13f293606|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mm/h|[?]|1|10^6 DNA copies/mL|ADIPOSE TISSUE|REFLECTANCE SPECTROSCOPY|Y||1|2|Visit_2|25|6|TREATMENT|2021-01-29|25
e|IS|c568ab93-8e7f-4e4e-9685-f0c13f293606|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^7 TCID 50/dose|[?]|1|pmol|BONE|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y||1|3|Visit_3|40|7|TREATMENT|2021-02-13|40
e|IS|c568ab93-8e7f-4e4e-9685-f0c13f293606|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|DAgU/mL|[?]|1|DIOPTER|ARTERIAL BLOOD|PHOTOMETRY|||1|4|Visit_4|65|1|TREATMENT|2021-03-10|65
e|IS|c568ab93-8e7f-4e4e-9685-f0c13f293606|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ugEq/L|[?]|1|umol/kg/min|SUPERNATANT, PLEURAL FLUID|CALCULATION|||1|5|Visit_5|90|5|FOLLOW-UP|2021-04-04|90
e|IS|bccd8af0-2ecf-4091-92e4-681597b57ca4|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|pmol/dL|[?]|1|Gy|INFRANATANT, SERUM|TRANSVAGINAL ULTRASOUND|||1|1|Visit_1|10|5|TREATMENT|2020-09-30|10
e|IS|bccd8af0-2ecf-4091-92e4-681597b57ca4|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ms/mmHg|[?]|1|Ci/kg|BASAL TEAR|LC/MS/MS||Y|1|2|Visit_2|25|2|SCREENING|2020-10-15|25
e|IS|bccd8af0-2ecf-4091-92e4-681597b57ca4|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|msec|[?]|1|CAPLET|KERATINOCYTE|DNA MICROARRAY||Y|1|3|Visit_3|40|6|TREATMENT|2020-10-30|40
e|IS|bccd8af0-2ecf-4091-92e4-681597b57ca4|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pmol|[?]|1|gpELISA unit/mL|SERUM OR PLASMA OR BLOOD|ELISPOT||Y|1|4|Visit_4|65|5|FOLLOW-UP|2020-11-24|65
e|IS|bccd8af0-2ecf-4091-92e4-681597b57ca4|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6 RNA copies/mL|[?]|1|hPa|PLEURAL FLUID|FLUORESCENT MICROSCOPY|Y||1|5|Visit_5|90|3|TREATMENT|2020-12-19|90
e|IS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/mol|[?]|1|mL/cm3/min|PLASMA ULTRAFILTRATE|MAGNETIC RESONANCE ELASTOGRAPHY|||1|1|Visit_1|10|6|TREATMENT|2020-08-06|10
e|IS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/animal/wk|[?]|1|amol|PERITONEAL FLUID|HPLC/IEX|Y||1|2|Visit_2|25|4|WASHOUT|2020-08-21|25
e|IS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/dose|[?]|1|mL|CIRCULATING TUMOR CELL|FORCED OSCILLATION TECHNIQUE|||1|3|Visit_3|40|4|TREATMENT|2020-09-05|40
e|IS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Arbitrary U|[?]|1|FIU|BREAST MILK|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|4|Visit_4|65|7|WASHOUT|2020-09-30|65
e|IS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nm|[?]|1|ukat/L|CALCULUS|BETA LACTAMASE||Y|1|5|Visit_5|90|3|TREATMENT|2020-10-25|90
e|IS|c40fc52b-2668-4fab-b051-5b258da72f2c|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uV2|[?]|1|NEBULE|SKELETAL MUSCLE TISSUE|DYNAMIC LIGHT SCATTERING|||1|1|Visit_1|10|7|SCREENING|2020-10-11|10
e|IS|c40fc52b-2668-4fab-b051-5b258da72f2c|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/kg|[?]|1|gtt|WHITE MATTER TISSUE|MAGNETIC RESONANCE ELASTOGRAPHY|||1|2|Visit_2|25|7|TREATMENT|2020-10-26|25
e|IS|c40fc52b-2668-4fab-b051-5b258da72f2c|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 U|[?]|1|Hz|LYSATE|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||1|3|Visit_3|40|4|TREATMENT|2020-11-10|40
e|IS|c40fc52b-2668-4fab-b051-5b258da72f2c|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|RING|[?]|1|CFU/g|ALVEOLAR AIR|FLUORESCENT MICROSCOPY|Y||1|4|Visit_4|65|7|WASHOUT|2020-12-05|65
e|IS|c40fc52b-2668-4fab-b051-5b258da72f2c|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|genEq/mL|[?]|1|log10 copies/mL|PLATELET RICH PLASMA|ULTRASONOGRAPHIC ELASTOGRAPHY||Y|1|5|Visit_5|90|6|TREATMENT|2020-12-30|90
e|IS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ng/mol|[?]|1|JDF Unit|ARTERIALIZED CAPILLARY BLOOD|PHASE-CONTRAST MRI|||1|1|Visit_1|10|7|TREATMENT|2020-07-28|10
e|IS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mEq|[?]|1|pm|INTERSTITIAL FLUID|DIGITAL PCR|||1|2|Visit_2|25|5|FOLLOW-UP|2020-08-12|25
e|IS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log10 PFU|[?]|1|mg/mL/min|ARTERIAL CORD BLOOD|SNELLEN EYE CHART|||1|3|Visit_3|40|5|WASHOUT|2020-08-27|40
e|IS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug/g/min|[?]|1|mph|AQUEOUS HUMOR|INDIA INK STAIN|||1|4|Visit_4|65|1|SCREENING|2020-09-21|65
e|IS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|DAYS|[?]|1|mL/cage/day|LUNG SURFACTANT|CONGO RED STAIN|||1|5|Visit_5|90|4|SCREENING|2020-10-16|90
e|IS|f7773659-f207-4b29-8389-3aa766a6337a|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mm3/mm2/year|[?]|1|mmHg*min/L|EMOTIONAL TEAR|CLAUSS METHOD|||1|1|Visit_1|10|3|TREATMENT|2020-10-19|10
e|IS|f7773659-f207-4b29-8389-3aa766a6337a|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mm/min|[?]|1|dmol|PLATELET|FLUORESCEIN STAIN||Y|1|2|Visit_2|25|4|TREATMENT|2020-11-03|25
e|IS|f7773659-f207-4b29-8389-3aa766a6337a|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|breaths/min|[?]|1|mEq/mL|INTERSTITIAL FLUID|AMSLER GRID|||1|3|Visit_3|40|2|TREATMENT|2020-11-18|40
e|IS|f7773659-f207-4b29-8389-3aa766a6337a|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/kg/day|[?]|1|K|CALCULUS|CARDIAC THERMODILUTION|||1|4|Visit_4|65|3|WASHOUT|2020-12-13|65
e|IS|f7773659-f207-4b29-8389-3aa766a6337a|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|log10 CFU/g|[?]|1|mg/g/h|EPITHELIAL CELL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y||1|5|Visit_5|90|6|WASHOUT|2021-01-07|90
e|IS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ug/kg/day|[?]|1|mEq/dL|PLEURAL FLUID|MULTI-SLICE SPIRAL CT|Y||1|1|Visit_1|10|6|FOLLOW-UP|2021-01-07|10
e|IS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|vg/dose|[?]|1|mmol/day|BREAST MILK|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|2|Visit_2|25|5|TREATMENT|2021-01-22|25
e|IS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7/L|[?]|1|L|GASTRIC CONTENTS|MRI WITHOUT CONTRAST|||1|3|Visit_3|40|3|WASHOUT|2021-02-06|40
e|IS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/kg|[?]|1|mmHg/L/min|LYMPH|LASER CAPTURE MICRODISSECTION|Y||1|4|Visit_4|65|2|SCREENING|2021-03-03|65
e|IS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SUPPOSITORY|[?]|1|ug|MUSCLE TISSUE|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||1|5|Visit_5|90|3|WASHOUT|2021-03-28|90
e|IS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mEq/g|[?]|1|g/U|VITREOUS HUMOR|INFRARED SPECTROMETRY|||1|1|Visit_1|10|6|SCREENING|2021-01-26|10
e|IS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/mL/min|[?]|1|ppm|SUPERNATANT, CEREBROSPINAL FLUID|AGAR DILUTION|||1|2|Visit_2|25|1|WASHOUT|2021-02-10|25
e|IS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IMPLANT|[?]|1|GBq|INTERSTITIAL FLUID|BETA LACTAMASE|||1|3|Visit_3|40|6|FOLLOW-UP|2021-02-25|40
e|IS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|breaths/30s|[?]|1|pmol/10^10 cells|NAIL|SLOAN LETTER EYE CHART 1.25%|||1|4|Visit_4|65|7|TREATMENT|2021-03-22|65
e|IS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^7 PFU|[?]|1|usec|PLASMA|DIGITAL PCR ARRAY|||1|5|Visit_5|90|6|WASHOUT|2021-04-16|90
e|IS|700049a2-ef66-466b-b1d8-f0800bcfde43|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|SPRAY|[?]|1|PATCH|SERUM OR PLASMA|COMPLEMENT FIXATION||Y|1|1|Visit_1|10|1|SCREENING|2020-06-27|10
e|IS|700049a2-ef66-466b-b1d8-f0800bcfde43|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GPL U|[?]|1|mL/min|VENOUS BLOOD|IN VITRO GENE EXPRESSION ASSAY||Y|1|2|Visit_2|25|4|TREATMENT|2020-07-12|25
e|IS|700049a2-ef66-466b-b1d8-f0800bcfde43|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kIU|[?]|1|ug/cm2|GASTRIC FLUID|LINE PROBE ASSAY|||1|3|Visit_3|40|1|TREATMENT|2020-07-27|40
e|IS|700049a2-ef66-466b-b1d8-f0800bcfde43|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|umol/h/mmol|[?]|1|U/g|SUPERNATANT, SERUM OR PLASMA|IN VITRO GENE EXPRESSION ASSAY|||1|4|Visit_4|65|4|SCREENING|2020-08-21|65
e|IS|700049a2-ef66-466b-b1d8-f0800bcfde43|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MET*min|[?]|1|scm|PERITONEAL FLUID|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||1|5|Visit_5|90|5|SCREENING|2020-09-15|90
e|IS|00d906a6-2d14-4199-aff9-524388c5117f|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^3 organisms|[?]|1|mL/sec/1.73m2|INTERSTITIAL FLUID|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||1|1|Visit_1|10|5|FOLLOW-UP|2020-11-24|10
e|IS|00d906a6-2d14-4199-aff9-524388c5117f|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DIP|[?]|1|cm2|BASAL TEAR|SLOAN LETTER EYE CHART 100%|||1|2|Visit_2|25|4|TREATMENT|2020-12-09|25
e|IS|00d906a6-2d14-4199-aff9-524388c5117f|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|VOXEL|[?]|1|10^9 CFU/g|SUPERNATANT, CEREBROSPINAL FLUID|EEG||Y|1|3|Visit_3|40|7|TREATMENT|2020-12-24|40
e|IS|00d906a6-2d14-4199-aff9-524388c5117f|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|%/s|[?]|1|umol/L|EXHALED BREATH CONDENSATE|SCINTIGRAPHY|||1|4|Visit_4|65|5|SCREENING|2021-01-18|65
e|IS|00d906a6-2d14-4199-aff9-524388c5117f|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cL|[?]|1|U/dL|SERUM OR PLASMA|CELL OF ORIGIN ASSAY|||1|5|Visit_5|90|4|TREATMENT|2021-02-12|90
e|IS|2fcc5910-bce0-4510-b17e-3925850d6d32|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/100 HPFs|[?]|1|usec|INTERSTITIAL FLUID|RADIATION DOSIMETRY|||1|1|Visit_1|10|7|FOLLOW-UP|2020-12-16|10
e|IS|2fcc5910-bce0-4510-b17e-3925850d6d32|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|gtt|[?]|1|nmol/kg/day|SERUM OR PLASMA|ELISPOT|||1|2|Visit_2|25|7|FOLLOW-UP|2020-12-31|25
e|IS|2fcc5910-bce0-4510-b17e-3925850d6d32|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|% INHIBITION|[?]|1|Tbsp|RETICULOCYTES|IMPULSE OSCILLOMETRY||Y|1|3|Visit_3|40|5|WASHOUT|2021-01-15|40
e|IS|2fcc5910-bce0-4510-b17e-3925850d6d32|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kUSP|[?]|1|mg/m2/day|ISOLATE|STRESS ECHOCARDIOGRAPHY|||1|4|Visit_4|65|5|SCREENING|2021-02-09|65
e|IS|2fcc5910-bce0-4510-b17e-3925850d6d32|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|IU/kg/h|[?]|1|L/h|LYMPH|HPLC|||1|5|Visit_5|90|4|SCREENING|2021-03-06|90
e|IS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/cm H2O|[?]|1|10^7 CFU/mL|HAIR|OPTICAL DENSITY MEASUREMENT|||1|1|Visit_1|10|7|TREATMENT|2020-08-31|10
e|IS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/min/mmHg|[?]|1|IU/mmol|PLATELET POOR PLASMA|X-RAY|||1|2|Visit_2|25|2|TREATMENT|2020-09-15|25
e|IS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/2000 RBC|[?]|1|BOTTLE|DISCHARGE|DISK DIFFUSION|Y||1|3|Visit_3|40|4|TREATMENT|2020-09-30|40
e|IS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|L/day|[?]|1|deg2|ALVEOLAR AIR|CHROMATOGRAPHY|||1|4|Visit_4|65|2|TREATMENT|2020-10-25|65
e|IS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/dL|[?]|1|CFU/g|SKIN TISSUE|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||1|5|Visit_5|90|7|FOLLOW-UP|2020-11-19|90
e|IS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/sec|[?]|1|mg/dL|BONE|TARGETED GENOME SEQUENCING|||1|1|Visit_1|10|2|TREATMENT|2020-07-26|10
e|IS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|L/L|PLEURAL FLUID|REFRACTOMETRY|Y|Y|1|2|Visit_2|25|4|TREATMENT|2020-08-10|25
e|IS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^9/L|[?]|1|10^6 CFU/mL|LEUKOCYTE|ULTRASONOGRAPHIC ELASTOGRAPHY|||1|3|Visit_3|40|6|SCREENING|2020-08-25|40
e|IS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg2/dL2|[?]|1|Watt|SALIVA|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||1|4|Visit_4|65|2|TREATMENT|2020-09-19|65
e|IS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kg/m2|[?]|1|10^9 organisms/g|MUSCLE TISSUE|BALLPOINT PEN TECHNIQUE|Y||1|5|Visit_5|90|2|TREATMENT|2020-10-14|90
e|IS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|EP U|[?]|1|Rad|BONE MARROW MONONUCLEAR CELL|APPLANATION TONOMETRY|||1|1|Visit_1|10|2|TREATMENT|2020-10-28|10
e|IS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BE/mL|[?]|1|nU/cL|SUPERNATANT, PLEURAL FLUID|ZIEHL NEELSEN ACID FAST STAIN|||1|2|Visit_2|25|7|TREATMENT|2020-11-12|25
e|IS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|h/wk|[?]|1|MPL U|VENOUS CORD BLOOD|AUSCULTATION||Y|1|3|Visit_3|40|5|TREATMENT|2020-11-27|40
e|IS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|SQU/mL|[?]|1|Gy|BASAL TEAR|MANUAL CLOT DETECTION|||1|4|Visit_4|65|3|TREATMENT|2020-12-22|65
e|IS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|copies/mL|[?]|1|10^6 CFU|AQUEOUS HUMOR|PLETHYSMOGRAPHY|Y||1|5|Visit_5|90|4|FOLLOW-UP|2021-01-16|90
e|IS|ff163542-abec-4260-b257-f15a11e580ee|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/cage|[?]|1|DAYS|SALIVA|VIRUS PLAQUE ASSAY|Y||1|1|Visit_1|10|5|TREATMENT|2020-08-16|10
e|IS|ff163542-abec-4260-b257-f15a11e580ee|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/m2/day|[?]|1|fL|VENOUS PLASMA|QUANTITATIVE COMPUTED TOMOGRAPHY|||1|2|Visit_2|25|3|TREATMENT|2020-08-31|25
e|IS|ff163542-abec-4260-b257-f15a11e580ee|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^8 PFU|[?]|1|10^6/L|CARDIAC MUSCLE TISSUE|ELISA|||1|3|Visit_3|40|7|WASHOUT|2020-09-15|40
e|IS|ff163542-abec-4260-b257-f15a11e580ee|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|U/mg|[?]|1|kg/cm|ERYTHROCYTES|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y||1|4|Visit_4|65|6|TREATMENT|2020-10-10|65
e|IS|ff163542-abec-4260-b257-f15a11e580ee|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Absorbance U/min|[?]|1|VIRTUAL PIXEL|SERUM|DISK DIFFUSION|||1|5|Visit_5|90|4|WASHOUT|2020-11-04|90
e|IS|bb73f732-a52f-4013-9ae6-60ff23b9c224|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6 CFU/g|[?]|1|Anson U|INFRANATANT, PLEURAL FLUID|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y||1|1|Visit_1|10|2|TREATMENT|2020-08-05|10
e|IS|bb73f732-a52f-4013-9ae6-60ff23b9c224|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|TRANSDUCING UNIT/mL|[?]|1|10^8 PFU|MECONIUM|TRICHROME STAIN||Y|1|2|Visit_2|25|3|FOLLOW-UP|2020-08-20|25
e|IS|bb73f732-a52f-4013-9ae6-60ff23b9c224|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^8/L|[?]|1|INHALATION|WHITE MATTER TISSUE|ENZYMATIC ULTRACENTRIFUGATION|||1|3|Visit_3|40|2|WASHOUT|2020-09-04|40
e|IS|bb73f732-a52f-4013-9ae6-60ff23b9c224|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ELISA unit/dose|[?]|1|h/wk|BONE MARROW MONONUCLEAR CELL|SICKLE CELL SOLUBILITY TEST|||1|4|Visit_4|65|4|TREATMENT|2020-09-29|65
e|IS|bb73f732-a52f-4013-9ae6-60ff23b9c224|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/day|[?]|1|mL/sec/1.73m2|CERUMEN|CALCULATION|||1|5|Visit_5|90|1|TREATMENT|2020-10-24|90
e|IS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U/kg|[?]|1|cmHg|PERIPHERAL BLOOD MONONUCLEAR CELL|POLYSOMNOGRAPHY|Y||1|1|Visit_1|10|1|FOLLOW-UP|2020-07-21|10
e|IS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/sec|[?]|1|mg/kg/week|CAPILLARY BLOOD|ICC|||1|2|Visit_2|25|3|TREATMENT|2020-08-05|25
e|IS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|L/min/m2|[?]|1|IU/kg/h|LAVAGE FLUID|SEQUENCING|Y|Y|1|3|Visit_3|40|7|WASHOUT|2020-08-20|40
e|IS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PRESSOR UNITS|[?]|1|TRACE|EXHALED BREATH CONDENSATE|ELECTROPHORESIS||Y|1|4|Visit_4|65|3|WASHOUT|2020-09-14|65
e|IS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|U/L|[?]|1|min/day|PLATELET|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||1|5|Visit_5|90|1|TREATMENT|2020-10-09|90
e|IS|8e056558-ffd2-4c43-bbfa-40914b38af34|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/2000 RBC|[?]|1|km|SPUTUM|IODINE STAIN|||1|1|Visit_1|10|1|TREATMENT|2021-01-29|10
e|IS|8e056558-ffd2-4c43-bbfa-40914b38af34|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|nmol/L/min|SPUTUM|CLINICAL EVALUATION||Y|1|2|Visit_2|25|3|FOLLOW-UP|2021-02-13|25
e|IS|8e056558-ffd2-4c43-bbfa-40914b38af34|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|STRIP|[?]|1|mV2/Hz|TRANSUDATE|CONTRAST ENHANCED PET SCAN|||1|3|Visit_3|40|2|TREATMENT|2021-02-28|40
e|IS|8e056558-ffd2-4c43-bbfa-40914b38af34|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cm/s|[?]|1|nCi|SOFT TISSUE|PERCUSSION|||1|4|Visit_4|65|2|TREATMENT|2021-03-25|65
e|IS|8e056558-ffd2-4c43-bbfa-40914b38af34|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|amol|[?]|1|TAMPON|ARTERIAL BLOOD|POLYMERASE CHAIN REACTION|||1|5|Visit_5|90|1|TREATMENT|2021-04-19|90
e|IS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|dyn|[?]|1|Tbsp|EXUDATE|SICKLE CELL SOLUBILITY TEST||Y|1|1|Visit_1|10|4|TREATMENT|2020-05-29|10
e|IS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|LENS|[?]|1|FFU|CERVICOVAGINAL SECRETION|WESTERGREN|Y|Y|1|2|Visit_2|25|3|TREATMENT|2020-06-13|25
e|IS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uU/dL|[?]|1|ag|PLATELET|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y||1|3|Visit_3|40|5|TREATMENT|2020-06-28|40
e|IS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cm|[?]|1|mN|CARDIAC MUSCLE TISSUE|X-RAY|||1|4|Visit_4|65|6|WASHOUT|2020-07-23|65
e|IS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|vp/dose|[?]|1|ug/mol|SKIN TISSUE|OPHTHALMOSCOPY|||1|5|Visit_5|90|7|TREATMENT|2020-08-17|90
e|IS|624c1353-347a-417d-9aab-7f1e7077ba7f|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/min|[?]|1|g/cage|BREAST MILK|GC/MS-CI|||1|1|Visit_1|10|1|WASHOUT|2020-08-28|10
e|IS|624c1353-347a-417d-9aab-7f1e7077ba7f|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|SPRAY|[?]|1|OD Unit|GASTRIC FLUID|PATHOLOGICAL EVALUATION||Y|1|2|Visit_2|25|7|WASHOUT|2020-09-12|25
e|IS|624c1353-347a-417d-9aab-7f1e7077ba7f|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|pmol/dL|[?]|1|ng/mol|LUNG SURFACTANT|SINGLE-SLICE SPIRAL CT|||1|3|Visit_3|40|5|WASHOUT|2020-09-27|40
e|IS|624c1353-347a-417d-9aab-7f1e7077ba7f|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|GPL U/mL|[?]|1|ms/mmHg|BREAST MILK|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|4|Visit_4|65|2|TREATMENT|2020-10-22|65
e|IS|624c1353-347a-417d-9aab-7f1e7077ba7f|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|pmol/dL|BONE|SANGER SEQUENCING|||1|5|Visit_5|90|2|TREATMENT|2020-11-16|90
e|IS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/L FEU|[?]|1|nU/cL|MECONIUM|MALDI-TOF|||1|1|Visit_1|10|2|TREATMENT|2020-08-02|10
e|IS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mOsm/L|[?]|1|MPL U/mL|CAPILLARY PLASMA|FLUORESCENCE ANGIOGRAPHY|Y||1|2|Visit_2|25|7|TREATMENT|2020-08-17|25
e|IS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|L|[?]|1|10^3 organisms/mL|PLASMA|FLOW MICROSCOPY|||1|3|Visit_3|40|3|FOLLOW-UP|2020-09-01|40
e|IS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|P|[?]|1|mg/g/min|EMESIS|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||1|4|Visit_4|65|4|SCREENING|2020-09-26|65
e|IS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|vp/mL|[?]|1|RNA copies/mL|BREAST MILK|THERMAL IONIZATION MASS SPECTROMETRY||Y|1|5|Visit_5|90|3|WASHOUT|2020-10-21|90
e|IS|da6294b5-de91-4bf7-b160-55d22fefcb07|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|deg2|[?]|1|tsp eq|LYMPH|QUANTITATIVE COMPUTED TOMOGRAPHY|||1|1|Visit_1|10|3|WASHOUT|2020-06-28|10
e|IS|da6294b5-de91-4bf7-b160-55d22fefcb07|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6/L|[?]|1|mg/m2/min|EMESIS|TURBIDIMETRY|||1|2|Visit_2|25|7|WASHOUT|2020-07-13|25
e|IS|da6294b5-de91-4bf7-b160-55d22fefcb07|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ukat/L|[?]|1|/5x10^4 WBC|ENDOTRACHEAL FLUID|FORCED OSCILLATION TECHNIQUE||Y|1|3|Visit_3|40|7|WASHOUT|2020-07-28|40
e|IS|da6294b5-de91-4bf7-b160-55d22fefcb07|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/L|[?]|1|U/m2/h|SKIN TISSUE|INTERRUPTER TECHNIQUE|||1|4|Visit_4|65|5|TREATMENT|2020-08-22|65
e|IS|da6294b5-de91-4bf7-b160-55d22fefcb07|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|kV|[?]|1|/VF|PLATELET RICH PLASMA|PHYSICAL EXAMINATION||Y|1|5|Visit_5|90|4|TREATMENT|2020-09-16|90
e|IS|c01c16d4-7a37-421d-9191-1874eba6a1e3|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mV/sec|[?]|1|bel|MIXED VENOUS BLOOD|FUNDUS PHOTOGRAPHY||Y|1|1|Visit_1|10|2|SCREENING|2020-10-09|10
e|IS|c01c16d4-7a37-421d-9191-1874eba6a1e3|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mmol/L|[?]|1|keV|SEMEN|TOTAL BODY IRRADIATION|||1|2|Visit_2|25|7|FOLLOW-UP|2020-10-24|25
e|IS|c01c16d4-7a37-421d-9191-1874eba6a1e3|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|100 IU/mL|[?]|1|Hz/s|SOFT TISSUE|REBOUND TONOMETRY|||1|3|Visit_3|40|6|TREATMENT|2020-11-08|40
e|IS|c01c16d4-7a37-421d-9191-1874eba6a1e3|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|g/L|[?]|1|mL/kg|EXHALED BREATH CONDENSATE|POLYMERASE CHAIN REACTION|Y||1|4|Visit_4|65|5|TREATMENT|2020-12-03|65
e|IS|c01c16d4-7a37-421d-9191-1874eba6a1e3|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/min|[?]|1|nmol/L/h|CALCULUS|KINETIC CHROMOGENIC ASSAY|||1|5|Visit_5|90|1|TREATMENT|2020-12-28|90
e|IS|6036407d-5ac8-400d-91f7-afd63f3cab88|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nmol/L/h|[?]|1|MESF|SALIVA|HILLMEN COLOR CHART|||1|1|Visit_1|10|2|FOLLOW-UP|2020-06-22|10
e|IS|6036407d-5ac8-400d-91f7-afd63f3cab88|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ELISA unit|[?]|1|HEP|PUS|CLOT DETECTION|||1|2|Visit_2|25|5|TREATMENT|2020-07-07|25
e|IS|6036407d-5ac8-400d-91f7-afd63f3cab88|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/mol|[?]|1|10^8 PFU|EXPIRED AIR|ANGIOGRAPHY|Y||1|3|Visit_3|40|7|WASHOUT|2020-07-22|40
e|IS|6036407d-5ac8-400d-91f7-afd63f3cab88|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|BLOCKS|[?]|1|Osm|ARTERIALIZED CAPILLARY BLOOD|SEQUENCING|Y||1|4|Visit_4|65|2|FOLLOW-UP|2020-08-16|65
e|IS|6036407d-5ac8-400d-91f7-afd63f3cab88|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|steps/min|[?]|1|psi|LOCHIA|FLOW CYTOMETRY|||1|5|Visit_5|90|3|WASHOUT|2020-09-10|90
e|IS|69cf0c4b-13f6-4955-8046-72a333059d6e|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6/hpf|[?]|1|mmol/kg|URINE|PHOTOMETRY|||1|1|Visit_1|10|5|SCREENING|2020-12-16|10
e|IS|69cf0c4b-13f6-4955-8046-72a333059d6e|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/m2/day|[?]|1|hPa|PLEURAL TISSUE|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y||1|2|Visit_2|25|5|TREATMENT|2020-12-31|25
e|IS|69cf0c4b-13f6-4955-8046-72a333059d6e|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/7.5 mL|[?]|1|JAR|PERIPHERAL BLOOD MONONUCLEAR CELL|CINEANGIOGRAPHY|Y||1|3|Visit_3|40|2|TREATMENT|2021-01-15|40
e|IS|69cf0c4b-13f6-4955-8046-72a333059d6e|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|MdFI|SPERMATOZOON|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|4|Visit_4|65|6|TREATMENT|2021-02-09|65
e|IS|69cf0c4b-13f6-4955-8046-72a333059d6e|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Ci/g|[?]|1|POUCH|EXUDATE|MAMMOGRAPHY|Y||1|5|Visit_5|90|2|WASHOUT|2021-03-06|90
e|IS|19829028-595c-4811-90e3-0ca696a04ba3|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|U/kg/h|[?]|1|umol/dL|DISCHARGE|IMMUNOBLOT||Y|1|1|Visit_1|10|3|TREATMENT|2020-07-15|10
e|IS|19829028-595c-4811-90e3-0ca696a04ba3|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Newton|[?]|1|10^9 CFU/mL|PERSPIRATION|WHOLE TRANSCRIPTOME SEQUENCING|Y|Y|1|2|Visit_2|25|1|TREATMENT|2020-07-30|25
e|IS|19829028-595c-4811-90e3-0ca696a04ba3|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U/g/day|[?]|1|g/U|ADIPOSE TISSUE|OLIGO ACGH|||1|3|Visit_3|40|3|TREATMENT|2020-08-14|40
e|IS|19829028-595c-4811-90e3-0ca696a04ba3|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|uL/mL|[?]|1|%(w/v)|SEMINAL FLUID|POPULATION SEQUENCING|||1|4|Visit_4|65|2|WASHOUT|2020-09-08|65
e|IS|19829028-595c-4811-90e3-0ca696a04ba3|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/animal|[?]|1|10^6/L|URINE SEDIMENT|LC/MS|||1|5|Visit_5|90|6|FOLLOW-UP|2020-10-03|90
e|IS|562a8182-8e9b-4a68-9b95-bc52df58ed46|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|log10 IU/mL|[?]|1|TRANSDUCING UNIT|PERIPHERAL BLOOD MONONUCLEAR CELL|WRIGHT-GIEMSA STAIN|||1|1|Visit_1|10|6|TREATMENT|2020-09-05|10
e|IS|562a8182-8e9b-4a68-9b95-bc52df58ed46|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/m2|[?]|1|uL/kg/day|EMOTIONAL TEAR|HEMOCYTOMETRY|||1|2|Visit_2|25|4|TREATMENT|2020-09-20|25
e|IS|562a8182-8e9b-4a68-9b95-bc52df58ed46|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|uIU/L|[?]|1|ng|LOCHIA|KLEIHAUER-BETKE|||1|3|Visit_3|40|5|FOLLOW-UP|2020-10-05|40
e|IS|562a8182-8e9b-4a68-9b95-bc52df58ed46|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|cm/s|[?]|1|BOTTLE|EMESIS|X-RAY|Y||1|4|Visit_4|65|2|SCREENING|2020-10-30|65
e|IS|562a8182-8e9b-4a68-9b95-bc52df58ed46|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/m2/h|[?]|1|BAU/mL|DERMAL TISSUE|TRANSMISSION ELECTRON MICROSCOPY||Y|1|5|Visit_5|90|6|TREATMENT|2020-11-24|90
e|IS|b29e6912-42f4-471b-ad90-1ec446f89ac0|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug|[?]|1|10^6 RNA copies/mL|LOCHIA|WHOLE GENOME SEQUENCING||Y|1|1|Visit_1|10|6|TREATMENT|2021-01-19|10
e|IS|b29e6912-42f4-471b-ad90-1ec446f89ac0|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|pL|[?]|1|uCi/kg|DIALYSIS FLUID, PERITONEAL|MICROARRAY|Y||1|2|Visit_2|25|3|WASHOUT|2021-02-03|25
e|IS|b29e6912-42f4-471b-ad90-1ec446f89ac0|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CCID 50/mL|[?]|1|mkat|SALIVA|ANALYTICAL ULTRACENTRIFUGATION|Y||1|3|Visit_3|40|1|SCREENING|2021-02-18|40
e|IS|b29e6912-42f4-471b-ad90-1ec446f89ac0|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Gauss|[?]|1|nmol/kg/day|BREAST MILK|MS/MS||Y|1|4|Visit_4|65|2|SCREENING|2021-03-15|65
e|IS|b29e6912-42f4-471b-ad90-1ec446f89ac0|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^5/hpf|[?]|1|pmol/day|PLASMA ULTRAFILTRATE|GC/FID|Y||1|5|Visit_5|90|1|TREATMENT|2021-04-09|90
e|IS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mm/2h|[?]|1|mm2|PLEURAL TISSUE|GEL ELECTROPHORESIS|||1|1|Visit_1|10|4|SCREENING|2020-06-09|10
e|IS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|g/dL|[?]|1|Gy|PERSPIRATION|IMMUNOPRECIPITATION|||1|2|Visit_2|25|1|SCREENING|2020-06-24|25
e|IS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|L/min/m2|[?]|1|ng/mol|SUPERNATANT, SERUM OR PLASMA|LIGHT SCATTERING SPECTROSCOPY|Y|Y|1|3|Visit_3|40|3|FOLLOW-UP|2020-07-09|40
e|IS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|U/kg/day|[?]|1|mol/L|EMOTIONAL TEAR|PAP STAIN|Y||1|4|Visit_4|65|2|FOLLOW-UP|2020-08-03|65
e|IS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|deg2|[?]|1|L/s|LEUKOCYTE|TRANSVAGINAL ULTRASOUND|||1|5|Visit_5|90|6|TREATMENT|2020-08-28|90
e|IS|396295ba-9f4c-4689-88c2-f80cb28b567a|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Antibody Unit|[?]|1|TRACE|HAIR|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||1|1|Visit_1|10|3|FOLLOW-UP|2020-12-31|10
e|IS|396295ba-9f4c-4689-88c2-f80cb28b567a|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/dL|[?]|1|nmol BCE/mmol|ADIPOSE TISSUE|LIQUID SCINTILLATION COUNTING|||1|2|Visit_2|25|1|SCREENING|2021-01-15|25
e|IS|396295ba-9f4c-4689-88c2-f80cb28b567a|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mol/mL|[?]|1|U/L|CIRCULATING TUMOR CELL|STATIC PERIMETRY|||1|3|Visit_3|40|1|TREATMENT|2021-01-30|40
e|IS|396295ba-9f4c-4689-88c2-f80cb28b567a|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/kg|[?]|1|K|MUSCLE TISSUE|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y|Y|1|4|Visit_4|65|6|TREATMENT|2021-02-24|65
e|IS|396295ba-9f4c-4689-88c2-f80cb28b567a|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|HOMEOPATHIC DILUTION|[?]|1|TROCHE|PLATELET|SCANNING ELECTRON MICROSCOPY||Y|1|5|Visit_5|90|5|TREATMENT|2021-03-21|90
e|IS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/cage/day|[?]|1|pt_br|MUCUS|ELECTROPHORESIS|||1|1|Visit_1|10|3|TREATMENT|2020-08-26|10
e|IS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|IU/day|[?]|1|IU/g|SERUM OR PLASMA|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y||1|2|Visit_2|25|7|SCREENING|2020-09-10|25
e|IS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|pL|[?]|1|mL/sec/1.73m2|EXHALED BREATH CONDENSATE|CYSTOMETRY|Y||1|3|Visit_3|40|2|WASHOUT|2020-09-25|40
e|IS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/L/sec|[?]|1|uOsm|MIXED VENOUS BLOOD|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||1|4|Visit_4|65|1|TREATMENT|2020-10-20|65
e|IS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/m2|[?]|1|ug/g/min|ABSCESS FLUID|CHROMOGENIC ASSAY||Y|1|5|Visit_5|90|7|FOLLOW-UP|2020-11-14|90
e|IS|55b23180-01f2-498e-a0af-cb9cd7d81750|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/mm2|[?]|1|CAPLET|LYMPH|DYNAMIC LIGHT SCATTERING||Y|1|1|Visit_1|10|7|TREATMENT|2020-07-01|10
e|IS|55b23180-01f2-498e-a0af-cb9cd7d81750|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 organisms/mg|[?]|1|kg/mol|DERMAL TISSUE|FLUORESCENT SPOT TEST|||1|2|Visit_2|25|2|SCREENING|2020-07-16|25
e|IS|55b23180-01f2-498e-a0af-cb9cd7d81750|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|IU/g Hb|[?]|1|HOURS|SUPERNATANT, PLASMA|HEMAGGLUTINATION ASSAY|||1|3|Visit_3|40|2|TREATMENT|2020-07-31|40
e|IS|55b23180-01f2-498e-a0af-cb9cd7d81750|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mU|[?]|1|beats/min|MUSCLE TISSUE|MICRO BROTH DILUTION|Y||1|4|Visit_4|65|1|TREATMENT|2020-08-25|65
e|IS|55b23180-01f2-498e-a0af-cb9cd7d81750|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ms/mmHg|[?]|1|oz|SMEGMA|MUGA||Y|1|5|Visit_5|90|3|FOLLOW-UP|2020-09-19|90
e|IS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PIPE|[?]|1|CYLINDER|SERUM|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|5|TREATMENT|2020-11-09|10
e|IS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Ci|[?]|1|log10 IU/mL|CORD SERUM|CALCULATION|Y||1|2|Visit_2|25|2|TREATMENT|2020-11-24|25
e|IS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL*cmH2O|[?]|1|ug/dL|TUMOR TISSUE|JAFFE REACTION|||1|3|Visit_3|40|4|TREATMENT|2020-12-09|40
e|IS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mU/L|[?]|1|mL/animal/day|CEREBROSPINAL FLUID|OLIGO ACGH|||1|4|Visit_4|65|6|TREATMENT|2021-01-03|65
e|IS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmol/L|[?]|1|/ms|SEMINAL FLUID|CONTACT SPECULAR MICROSCOPY|||1|5|Visit_5|90|6|FOLLOW-UP|2021-01-28|90
e|IS|940e4aef-5648-46b3-9c3e-7c40f7930030|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^12/L|[?]|1|mEq/uL|SKIN TISSUE|ORCHIDOMETERY|Y||1|1|Visit_1|10|2|WASHOUT|2020-11-15|10
e|IS|940e4aef-5648-46b3-9c3e-7c40f7930030|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/month|[?]|1|DPM|CORD BLOOD|DROPLET DIGITAL PCR||Y|1|2|Visit_2|25|7|WASHOUT|2020-11-30|25
e|IS|940e4aef-5648-46b3-9c3e-7c40f7930030|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|gtt|[?]|1|/10^5|VENOUS PLASMA|PAP STAIN|||1|3|Visit_3|40|1|TREATMENT|2020-12-15|40
e|IS|940e4aef-5648-46b3-9c3e-7c40f7930030|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mm|[?]|1|ug/dL|GASTRIC FLUID|ELECTRONEUROGRAPHY|Y||1|4|Visit_4|65|4|TREATMENT|2021-01-09|65
e|IS|940e4aef-5648-46b3-9c3e-7c40f7930030|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nmol/L/h|[?]|1|nmol/day|CORD BLOOD|QUANTITATIVE ULTRASOUND||Y|1|5|Visit_5|90|4|SCREENING|2021-02-03|90
e|IS|e4bece1e-6672-4b55-824f-56aa923e60f9|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/g/day|[?]|1|ppm|PERSPIRATION|FLUORESCENCE ANGIOGRAPHY||Y|1|1|Visit_1|10|5|TREATMENT|2020-06-22|10
e|IS|e4bece1e-6672-4b55-824f-56aa923e60f9|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uIU/dL|[?]|1|mAnson U/mL|BLOOD|TONOMETRY|Y||1|2|Visit_2|25|2|TREATMENT|2020-07-07|25
e|IS|e4bece1e-6672-4b55-824f-56aa923e60f9|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|msec|[?]|1|10^6 organisms/g|SPERMATOZOON|DARK FIELD MICROSCOPY|||1|3|Visit_3|40|4|TREATMENT|2020-07-22|40
e|IS|e4bece1e-6672-4b55-824f-56aa923e60f9|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MASK|[?]|1|BOX|CELL PELLET|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|4|Visit_4|65|7|SCREENING|2020-08-16|65
e|IS|e4bece1e-6672-4b55-824f-56aa923e60f9|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|mmol2/L2|EMESIS|WHOLE GENOME SEQUENCING||Y|1|5|Visit_5|90|5|SCREENING|2020-09-10|90
e|IS|12e607da-f53c-4078-9742-23a111db6f54|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|psec|[?]|1|mg/kg/day|PERITONEAL FLUID|MICROBIAL CONCENTRATION|||1|1|Visit_1|10|4|TREATMENT|2020-10-03|10
e|IS|12e607da-f53c-4078-9742-23a111db6f54|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/animal|[?]|1|10^6/hpf|PLEURAL FLUID|PATHOLOGICAL EVALUATION|||1|2|Visit_2|25|2|TREATMENT|2020-10-18|25
e|IS|12e607da-f53c-4078-9742-23a111db6f54|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/day|[?]|1|IU|TISSUE|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|3|Visit_3|40|2|TREATMENT|2020-11-02|40
e|IS|12e607da-f53c-4078-9742-23a111db6f54|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/mm2|[?]|1|IU/kg|CALCULUS|HIGH RESOLUTION CT||Y|1|4|Visit_4|65|7|TREATMENT|2020-11-27|65
e|IS|12e607da-f53c-4078-9742-23a111db6f54|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol/g|[?]|1|Log10 ELISA unit|LUNG SURFACTANT|ELECTROCHEMILUMINESCENCE|||1|5|Visit_5|90|6|SCREENING|2020-12-22|90
e|IS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PRESSOR UNITS|[?]|1|mg/mL/min|TRANSUDATE|MICROARRAY||Y|1|1|Visit_1|10|4|SCREENING|2021-01-26|10
e|IS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|v/v|[?]|1|Hz|PLASMA|CYSTOSCOPY|Y||1|2|Visit_2|25|6|SCREENING|2021-02-10|25
e|IS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|L/s/kPa|[?]|1|Ci|LAVAGE FLUID|KINETIC CHROMOGENIC ASSAY|Y||1|3|Visit_3|40|4|SCREENING|2021-02-25|40
e|IS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ka_u/dL|[?]|1|pmol/L|CERUMEN|KARYOTYPING|||1|4|Visit_4|65|7|WASHOUT|2021-03-22|65
e|IS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|dpm/mg|[?]|1|mJoule/cm2|BUFFY COAT|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|5|Visit_5|90|4|WASHOUT|2021-04-16|90
e|IS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Log10 ELISA unit/dose|[?]|1|mL/sec/1.73m2|VENOUS CORD BLOOD|FLUORESCENT SPOT TEST||Y|1|1|Visit_1|10|1|SCREENING|2020-07-16|10
e|IS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|PRESSOR UNITS|[?]|1|mEq/dL|PLASMA ULTRAFILTRATE|HEMATOXYLIN AND EOSIN STAIN|||1|2|Visit_2|25|3|TREATMENT|2020-07-31|25
e|IS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|vp/mL|[?]|1|mg/h|PERIPHERAL BLOOD MONONUCLEAR CELL|OPTICAL DENSITY MEASUREMENT||Y|1|3|Visit_3|40|3|TREATMENT|2020-08-15|40
e|IS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^9 CFU/g|[?]|1|mL/animal|CAPILLARY BLOOD|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||1|4|Visit_4|65|2|SCREENING|2020-09-09|65
e|IS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/LPF|[?]|1|nmol/kg/day|ARTERIAL BLOOD|TELLER ACUITY CARDS|Y|Y|1|5|Visit_5|90|6|TREATMENT|2020-10-04|90
e|IS|3260122d-3bf4-45ff-a026-2379158721d0|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/day|[?]|1|/MBP|CARDIAC MUSCLE TISSUE|NEPHELOMETRY|||1|1|Visit_1|10|1|TREATMENT|2020-06-04|10
e|IS|3260122d-3bf4-45ff-a026-2379158721d0|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|sec|[?]|1|Absorbance U/mL|SUPERNATANT, SERUM OR PLASMA|CONTACT SPECULAR MICROSCOPY||Y|1|2|Visit_2|25|3|SCREENING|2020-06-19|25
e|IS|3260122d-3bf4-45ff-a026-2379158721d0|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|m/sec2|[?]|1|Bq/mg|CAPILLARY BLOOD|DC SHEATH FLOW|||1|3|Visit_3|40|1|WASHOUT|2020-07-04|40
e|IS|3260122d-3bf4-45ff-a026-2379158721d0|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|DNA copies/ug|[?]|1|cmol|SYNOVIAL FLUID|CALCULATION|||1|4|Visit_4|65|5|TREATMENT|2020-07-29|65
e|IS|3260122d-3bf4-45ff-a026-2379158721d0|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kV|[?]|1|/VF|ADIPOSE TISSUE|ELECTROPHORESIS|||1|5|Visit_5|90|6|TREATMENT|2020-08-23|90
e|IS|05eb4e29-887e-4cdb-8854-49939a8a13d1|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Rad|[?]|1|kg/cm|PERIPHERAL BLOOD MONONUCLEAR CELL|HILLMEN COLOR CHART|||1|1|Visit_1|10|5|FOLLOW-UP|2020-11-05|10
e|IS|05eb4e29-887e-4cdb-8854-49939a8a13d1|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/mL/min|[?]|1|Ci/ug|INFRANATANT, PLASMA|KLEIHAUER-BETKE|||1|2|Visit_2|25|4|TREATMENT|2020-11-20|25
e|IS|05eb4e29-887e-4cdb-8854-49939a8a13d1|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/10^12 RBC|[?]|1|GLOBULE|ADIPOSE TISSUE|TARGETED TRANSCRIPTOME SEQUENCING|Y||1|3|Visit_3|40|1|TREATMENT|2020-12-05|40
e|IS|05eb4e29-887e-4cdb-8854-49939a8a13d1|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MdFI|[?]|1|ug/L/h|BONE MARROW|U-HPLC/MS/MS||Y|1|4|Visit_4|65|6|SCREENING|2020-12-30|65
e|IS|05eb4e29-887e-4cdb-8854-49939a8a13d1|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|vp/dose|[?]|1|log10 CCID 50/dose|ALVEOLAR AIR|REBOUND TONOMETRY|||1|5|Visit_5|90|6|FOLLOW-UP|2021-01-24|90
e|IS|c8390c70-766d-4252-9356-39591651bcdf|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ngEq/L|[?]|1|MESF|STRIATED MUSCLE TISSUE|DIGITAL PCR|||1|1|Visit_1|10|6|SCREENING|2020-08-11|10
e|IS|c8390c70-766d-4252-9356-39591651bcdf|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mmol/mol|[?]|1|mmAL|ARTERIALIZED CAPILLARY BLOOD|THERMAL IONIZATION MASS SPECTROMETRY|Y||1|2|Visit_2|25|2|TREATMENT|2020-08-26|25
e|IS|c8390c70-766d-4252-9356-39591651bcdf|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|/day|[?]|1|DAgU/mL|REFLEX TEAR|TOTAL BODY IRRADIATION||Y|1|3|Visit_3|40|7|WASHOUT|2020-09-10|40
e|IS|c8390c70-766d-4252-9356-39591651bcdf|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|V|[?]|1|mL/m2/day|ARTERIAL BLOOD|FARNSWORTH-MUNSELL 100 HUE TEST|||1|4|Visit_4|65|4|WASHOUT|2020-10-05|65
e|IS|c8390c70-766d-4252-9356-39591651bcdf|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|genEq/mL|[?]|1|um/day|ERYTHROCYTES|URANYL ACETATE STAIN|||1|5|Visit_5|90|2|TREATMENT|2020-10-30|90
e|IS|a40bf877-c070-40b3-89df-d566b942246e|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^3 RNA copies/mL|[?]|1|tuberculin unit/mL|SUPERNATANT, CEREBROSPINAL FLUID|CONTRAST ENHANCED CT SCAN|||1|1|Visit_1|10|7|FOLLOW-UP|2020-06-16|10
e|IS|a40bf877-c070-40b3-89df-d566b942246e|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/g/day|[?]|1|10^9 organisms|PERSPIRATION|SPECTROPHOTOMETRY||Y|1|2|Visit_2|25|1|WASHOUT|2020-07-01|25
e|IS|a40bf877-c070-40b3-89df-d566b942246e|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6/g|[?]|1|10^6 IU/mL|PLEURAL FLUID|FUNCTIONAL MRI|Y||1|3|Visit_3|40|2|TREATMENT|2020-07-16|40
e|IS|a40bf877-c070-40b3-89df-d566b942246e|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|AgU/mL|[?]|1|fmol/L|VENOUS BLOOD|WEBER GREEN STAIN|||1|4|Visit_4|65|7|FOLLOW-UP|2020-08-10|65
e|IS|a40bf877-c070-40b3-89df-d566b942246e|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/m2|[?]|1|AU/mL|TRANSUDATE|ECHOCARDIOGRAPHY|||1|5|Visit_5|90|7|TREATMENT|2020-09-04|90
e|IS|e9633621-3d08-4b47-b394-5bd3fa47c07f|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|g/mol|[?]|1|kV|INTERSTITIAL FLUID|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||1|1|Visit_1|10|7|WASHOUT|2021-01-16|10
e|IS|e9633621-3d08-4b47-b394-5bd3fa47c07f|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/min/mmHg|[?]|1|10^6/hpf|SMEGMA|DIFFUSION TENSOR MRI|Y|Y|1|2|Visit_2|25|4|TREATMENT|2021-01-31|25
e|IS|e9633621-3d08-4b47-b394-5bd3fa47c07f|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uL/dose|[?]|1|mg/day|PLASMA|IN SITU HYBRIDIZATION|||1|3|Visit_3|40|5|TREATMENT|2021-02-15|40
e|IS|e9633621-3d08-4b47-b394-5bd3fa47c07f|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^9/L|[?]|1|psi|PERIPHERAL BLOOD MONONUCLEAR CELL|FLUORESCENT ENZYME IMMUNOASSAY||Y|1|4|Visit_4|65|3|TREATMENT|2021-03-12|65
e|IS|e9633621-3d08-4b47-b394-5bd3fa47c07f|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kg/mol|[?]|1|BU/mL|TRANSUDATE|PELLI-ROBSON EYE CHART|Y|Y|1|5|Visit_5|90|4|TREATMENT|2021-04-06|90
e|IS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kIU|[?]|1|mL/cm H2O|CORD SERUM|CORONARY ANGIOGRAPHY||Y|1|1|Visit_1|10|7|TREATMENT|2020-06-08|10
e|IS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmol/min/kPa|[?]|1|CUP|PLEURAL FLUID|CHROMOGENIC ASSAY|||1|2|Visit_2|25|7|SCREENING|2020-06-23|25
e|IS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Ci|[?]|1|kDa|PROSTATIC FLUID|POLYSOMNOGRAPHY|Y||1|3|Visit_3|40|2|SCREENING|2020-07-08|40
e|IS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|L/day|[?]|1|cm2|PUS|IODINE STAIN|||1|4|Visit_4|65|3|WASHOUT|2020-08-02|65
e|IS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|KIT|[?]|1|Bq|ARTERIAL BLOOD|HPLC-UV|||1|5|Visit_5|90|6|TREATMENT|2020-08-27|90
e|IS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mmHg*min/L|[?]|1|log10 TCID 50/dose|BUFFY COAT|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-07-16|10
e|IS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PLUG|[?]|1|U/mL|CERUMEN|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||1|2|Visit_2|25|5|SCREENING|2020-07-31|25
e|IS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mm/2h|[?]|1|CCID 50/dose|DISCHARGE|VENTILATION PERFUSION LUNG SCAN|||1|3|Visit_3|40|1|SCREENING|2020-08-15|40
e|IS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|fmol/L|[?]|1|beats/min|EXHALED BREATH CONDENSATE|MICROSCOPY|||1|4|Visit_4|65|6|FOLLOW-UP|2020-09-09|65
e|IS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cm|[?]|1|U/g|PERIPHERAL BLOOD MONONUCLEAR CELL|IVY INCISION METHOD|||1|5|Visit_5|90|4|TREATMENT|2020-10-04|90
e|IS|63f43990-e56e-440c-a445-76e7d114cf26|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Joule|[?]|1|10^9 organisms/mL|CAPILLARY PLASMA|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|1|1|Visit_1|10|7|WASHOUT|2020-10-02|10
e|IS|63f43990-e56e-440c-a445-76e7d114cf26|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mCi/kg|[?]|1|mL/beat|RETICULOCYTES|CELLULAR PROLIFERATION ASSAY||Y|1|2|Visit_2|25|5|TREATMENT|2020-10-17|25
e|IS|63f43990-e56e-440c-a445-76e7d114cf26|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|tsp eq|[?]|1|10^6 organisms|TRANSUDATE|MICRODENSITOMETRY|Y||1|3|Visit_3|40|1|WASHOUT|2020-11-01|40
e|IS|63f43990-e56e-440c-a445-76e7d114cf26|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|EID 50/mL|[?]|1|anti-Xa IU/mL|CIRCULATING TUMOR CELL|RADIAL IMMUNODIFFUSION|||1|4|Visit_4|65|1|FOLLOW-UP|2020-11-26|65
e|IS|63f43990-e56e-440c-a445-76e7d114cf26|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ms/mmHg|[?]|1|mV*min|ARTERIAL CORD BLOOD|GIEMSA STAIN|Y||1|5|Visit_5|90|6|TREATMENT|2020-12-21|90
e|IS|380c89f4-2650-4a54-92f5-5e1278b9a91e|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|deg/mm|[?]|1|mm/sec|STRIATED MUSCLE TISSUE|IMPULSE OSCILLOMETRY||Y|1|1|Visit_1|10|6|SCREENING|2020-10-22|10
e|IS|380c89f4-2650-4a54-92f5-5e1278b9a91e|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 organisms/g|[?]|1|/mm|CERUMEN|CLINICAL EVALUATION|||1|2|Visit_2|25|2|TREATMENT|2020-11-06|25
e|IS|380c89f4-2650-4a54-92f5-5e1278b9a91e|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg|[?]|1|IU/g Hb|PUS|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y|Y|1|3|Visit_3|40|5|FOLLOW-UP|2020-11-21|40
e|IS|380c89f4-2650-4a54-92f5-5e1278b9a91e|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/mol|[?]|1|lx|EMESIS|INTERRUPTER TECHNIQUE|||1|4|Visit_4|65|6|TREATMENT|2020-12-16|65
e|IS|380c89f4-2650-4a54-92f5-5e1278b9a91e|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mEq/g|[?]|1|IU|BUFFY COAT|CLOT DETECTION||Y|1|5|Visit_5|90|6|SCREENING|2021-01-10|90
e|IS|84c1f5f4-6415-49d8-b854-22e7529d65b6|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|g/animal|[?]|1|Gy|INFRANATANT, SERUM|CELLULOSE TAPE||Y|1|1|Visit_1|10|3|SCREENING|2020-12-05|10
e|IS|84c1f5f4-6415-49d8-b854-22e7529d65b6|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 copies/mL|[?]|1|kBq/uL|EPITHELIAL CELL|OPTICAL DENSITY MEASUREMENT|Y||1|2|Visit_2|25|3|TREATMENT|2020-12-20|25
e|IS|84c1f5f4-6415-49d8-b854-22e7529d65b6|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mmAL|[?]|1|log10 IU/mL|CORD BLOOD|POTENTIOMETRY|||1|3|Visit_3|40|4|FOLLOW-UP|2021-01-04|40
e|IS|84c1f5f4-6415-49d8-b854-22e7529d65b6|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|GPL U/mL|[?]|1|uL|SEBUM|ISHIHARA COLOR PLATES|||1|4|Visit_4|65|4|TREATMENT|2021-01-29|65
e|IS|84c1f5f4-6415-49d8-b854-22e7529d65b6|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^3/L|[?]|1|10^6/hpf|MENSTRUAL BLOOD|BALLPOINT PEN TECHNIQUE|||1|5|Visit_5|90|7|TREATMENT|2021-02-23|90
e|IS|77c26a0c-0c84-44d7-8351-a50f3236e59a|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 copies/mL|[?]|1|uEq/L|BASAL TEAR|MIGET|Y||1|1|Visit_1|10|7|TREATMENT|2020-05-14|10
e|IS|77c26a0c-0c84-44d7-8351-a50f3236e59a|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|TRANSDUCING UNIT|[?]|1|LENS|TRANSUDATE|X-RAY FLUORESCENCE SPECTROMETRY|||1|2|Visit_2|25|3|WASHOUT|2020-05-29|25
e|IS|77c26a0c-0c84-44d7-8351-a50f3236e59a|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/min|[?]|1|CCID 50/mL|CERVICOVAGINAL SECRETION|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||1|3|Visit_3|40|7|FOLLOW-UP|2020-06-13|40
e|IS|77c26a0c-0c84-44d7-8351-a50f3236e59a|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|oz|[?]|1|mL/kg/day|PLATELET|HPLC/MS/MS|||1|4|Visit_4|65|7|FOLLOW-UP|2020-07-08|65
e|IS|77c26a0c-0c84-44d7-8351-a50f3236e59a|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mV2/Hz|[?]|1|ug/g/day|DERMAL TISSUE|MRS|Y||1|5|Visit_5|90|1|TREATMENT|2020-08-02|90
e|IS|a201c78a-e826-4f42-a997-7c6a019e2c91|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Ci/uL|[?]|1|mEq/day|INTERSTITIAL FLUID|DXA SCAN||Y|1|1|Visit_1|10|2|WASHOUT|2020-08-03|10
e|IS|a201c78a-e826-4f42-a997-7c6a019e2c91|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mol/mol|[?]|1|/100 HPFs|PERSPIRATION|THIN SMEAR|||1|2|Visit_2|25|1|WASHOUT|2020-08-18|25
e|IS|a201c78a-e826-4f42-a997-7c6a019e2c91|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/cm2|[?]|1|MBP|CERUMEN|ENZYMATIC COLORIMETRY|Y|Y|1|3|Visit_3|40|7|WASHOUT|2020-09-02|40
e|IS|a201c78a-e826-4f42-a997-7c6a019e2c91|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmHg/L/min|[?]|1|SCOOPFUL|LEUKOCYTE|RADIOIMMUNOPRECIPITATION ASSAY|||1|4|Visit_4|65|2|TREATMENT|2020-09-27|65
e|IS|a201c78a-e826-4f42-a997-7c6a019e2c91|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/g/min|[?]|1|IU/dL|ABSCESS FLUID|CONTRAST ENHANCED SPIRAL CT SCAN|||1|5|Visit_5|90|2|TREATMENT|2020-10-22|90
e|IS|c41880bd-1e29-4961-b74d-bb0d979ab00f|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log10 CFU/g|[?]|1|Absorbance U/mL|LEUKOCYTE|ACID FAST STAIN|||1|1|Visit_1|10|4|TREATMENT|2020-09-11|10
e|IS|c41880bd-1e29-4961-b74d-bb0d979ab00f|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kPa|[?]|1|pm|SMOOTH MUSCLE TISSUE|CONTRAST ENHANCED CT SCAN|Y||1|2|Visit_2|25|7|SCREENING|2020-09-26|25
e|IS|c41880bd-1e29-4961-b74d-bb0d979ab00f|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol/kg/min|[?]|1|mg/m2/min|COLOSTRUM|AUTOREFRACTION||Y|1|3|Visit_3|40|7|TREATMENT|2020-10-11|40
e|IS|c41880bd-1e29-4961-b74d-bb0d979ab00f|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|RNA copies/mL|[?]|1|mL/breath|SKIN TISSUE|KINYOUN STAIN|Y||1|4|Visit_4|65|5|FOLLOW-UP|2020-11-05|65
e|IS|c41880bd-1e29-4961-b74d-bb0d979ab00f|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cP|[?]|1|OI50|AMNIOTIC FLUID|MAMMOGRAPHY|||1|5|Visit_5|90|3|TREATMENT|2020-11-30|90
e|IS|7de60015-fa9d-4a39-bd19-51c718a624e6|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|lm|[?]|1|%/min|CERUMEN|HIGH RESOLUTION MELT ANALYSIS|||1|1|Visit_1|10|1|TREATMENT|2020-10-24|10
e|IS|7de60015-fa9d-4a39-bd19-51c718a624e6|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DNA copies/ug|[?]|1|kg/L|SUPERNATANT, SERUM|REFRACTOMETRY|||1|2|Visit_2|25|6|TREATMENT|2020-11-08|25
e|IS|7de60015-fa9d-4a39-bd19-51c718a624e6|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|g/cage/day|[?]|1|ug/mol|SYNOVIAL FLUID|PERCUSSION|Y||1|3|Visit_3|40|7|WASHOUT|2020-11-23|40
e|IS|7de60015-fa9d-4a39-bd19-51c718a624e6|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mmol/g|[?]|1|OD Unit|BONE MARROW|CT SCAN|Y||1|4|Visit_4|65|4|WASHOUT|2020-12-18|65
e|IS|7de60015-fa9d-4a39-bd19-51c718a624e6|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mmol/day|[?]|1|TUBE|VENOUS PLASMA|SANGER SEQUENCING|Y||1|5|Visit_5|90|3|TREATMENT|2021-01-12|90
e|IS|34d03f58-155a-4908-bba3-aa979be84610|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mm/min|[?]|1|VOXEL|INFRANATANT, PLEURAL FLUID|PELLI-ROBSON EYE CHART||Y|1|1|Visit_1|10|5|SCREENING|2020-06-29|10
e|IS|34d03f58-155a-4908-bba3-aa979be84610|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CUP|[?]|1|g/animal/wk|CORD SERUM|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||1|2|Visit_2|25|3|TREATMENT|2020-07-14|25
e|IS|34d03f58-155a-4908-bba3-aa979be84610|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|L|[?]|1|umol/h/mmol|MECONIUM|TOTAL BODY RADIOGRAPHY|||1|3|Visit_3|40|1|TREATMENT|2020-07-29|40
e|IS|34d03f58-155a-4908-bba3-aa979be84610|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/100 HPFs|[?]|1|g/cm2|SUPERNATANT, SERUM|DOPPLER ULTRASOUND|Y||1|4|Visit_4|65|7|TREATMENT|2020-08-23|65
e|IS|34d03f58-155a-4908-bba3-aa979be84610|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6 U|[?]|1|Ejaculate U|SEMINAL FLUID|MANUAL CLOT DETECTION||Y|1|5|Visit_5|90|2|TREATMENT|2020-09-17|90
e|IS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mEq/mmol|[?]|1|mL/g/min|BILE|TRANSTHORACIC ECHOCARDIOGRAPHY|||1|1|Visit_1|10|2|TREATMENT|2020-08-23|10
e|IS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/m2/h|[?]|1|10^6 organisms|SUPERNATANT, SERUM OR PLASMA|CELL OF ORIGIN ASSAY||Y|1|2|Visit_2|25|1|TREATMENT|2020-09-07|25
e|IS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/5x10^4 WBC|[?]|1|10^8 PFU|VENOUS BLOOD|WESTERGREN|||1|3|Visit_3|40|5|TREATMENT|2020-09-22|40
e|IS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Shock Wave|[?]|1|CCID 50/mL|SEBUM|SMEAR|||1|4|Visit_4|65|7|WASHOUT|2020-10-17|65
e|IS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kg/cm2|[?]|1|uIU/dL|PERITONEAL FLUID|HEMAGGLUTINATION INHIBITION ASSAY|||1|5|Visit_5|90|1|TREATMENT|2020-11-11|90
e|IS|4191788e-b2dc-4885-87d8-da9feb6deea5|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|kPa|[?]|1|Farad|CELL PELLET|SPIRAL CT|||1|1|Visit_1|10|6|TREATMENT|2020-09-11|10
e|IS|4191788e-b2dc-4885-87d8-da9feb6deea5|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SACHET|[?]|1|/2500 WBC|BREAST MILK|COLORIMETRY|||1|2|Visit_2|25|5|WASHOUT|2020-09-26|25
e|IS|4191788e-b2dc-4885-87d8-da9feb6deea5|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DISK|[?]|1|titer|MECONIUM|MICROPARTICLE ENZYME IMMUNOASSAY|||1|3|Visit_3|40|2|SCREENING|2020-10-11|40
e|IS|4191788e-b2dc-4885-87d8-da9feb6deea5|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ELISA unit|[?]|1|BU|BONE MARROW|TARGETED TRANSCRIPTOME SEQUENCING||Y|1|4|Visit_4|65|4|TREATMENT|2020-11-05|65
e|IS|4191788e-b2dc-4885-87d8-da9feb6deea5|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|STRIP|[?]|1|mEq/day|CALCULUS|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||1|5|Visit_5|90|7|TREATMENT|2020-11-30|90
e|IS|8572a9c4-eb87-4745-81b9-8316bc8de69e|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ag|[?]|1|ug/mol|DERMAL TISSUE|HEMAGGLUTINATION INHIBITION ASSAY|||1|1|Visit_1|10|3|TREATMENT|2020-12-24|10
e|IS|8572a9c4-eb87-4745-81b9-8316bc8de69e|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|g/L|[?]|1|CUP|PERSPIRATION|WHOLE EXOME SEQUENCING|Y||1|2|Visit_2|25|5|TREATMENT|2021-01-08|25
e|IS|8572a9c4-eb87-4745-81b9-8316bc8de69e|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cmHg|[?]|1|10^6 CFU/g|SUPERNATANT, PLASMA|WRIGHT-GIEMSA STAIN|||1|3|Visit_3|40|3|TREATMENT|2021-01-23|40
e|IS|8572a9c4-eb87-4745-81b9-8316bc8de69e|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ng|[?]|1|mmol/kg|VENOUS CORD BLOOD|THERMAL IONIZATION MASS SPECTROMETRY||Y|1|4|Visit_4|65|3|WASHOUT|2021-02-17|65
e|IS|8572a9c4-eb87-4745-81b9-8316bc8de69e|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Absorbance U|[?]|1|U/10^12 RBC|SUPERNATANT, SERUM OR PLASMA|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|5|Visit_5|90|2|FOLLOW-UP|2021-03-14|90
e|IS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uV|[?]|1|BU/mL|BONE|BAC ACGH|||1|1|Visit_1|10|2|TREATMENT|2020-11-26|10
e|IS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|GBq/g|[?]|1|L/s|DIALYSIS FLUID|PET/CT SCAN WITHOUT CONTRAST|||1|2|Visit_2|25|1|TREATMENT|2020-12-11|25
e|IS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uEq|[?]|1|nmol/g|CORD BLOOD|CALCULATION|Y||1|3|Visit_3|40|4|TREATMENT|2020-12-26|40
e|IS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 CFU/g|[?]|1|kUSP|MUCUS|FLAME PHOTOMETRY|||1|4|Visit_4|65|1|TREATMENT|2021-01-20|65
e|IS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Ci/kg|[?]|1|EVENTS|VITREOUS HUMOR|PANENDOSCOPY|Y|Y|1|5|Visit_5|90|6|FOLLOW-UP|2021-02-14|90
e|IS|3eceae61-a4a0-49fd-964b-9f142e0da067|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kcal/day|[?]|1|ug/mol|MUSCLE TISSUE|PET SCAN|||1|1|Visit_1|10|7|WASHOUT|2020-08-28|10
e|IS|3eceae61-a4a0-49fd-964b-9f142e0da067|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nkat|[?]|1|mEq/ug|ENDOTRACHEAL FLUID|COLORIMETRY|||1|2|Visit_2|25|5|WASHOUT|2020-09-12|25
e|IS|3eceae61-a4a0-49fd-964b-9f142e0da067|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ECL unit|[?]|1|/sec|WHITE MATTER TISSUE|PERFUSION MRI|Y||1|3|Visit_3|40|7|SCREENING|2020-09-27|40
e|IS|3eceae61-a4a0-49fd-964b-9f142e0da067|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dB|[?]|1|10^7 CFU|URINE SEDIMENT|FORCED OSCILLATION TECHNIQUE|||1|4|Visit_4|65|2|TREATMENT|2020-10-22|65
e|IS|3eceae61-a4a0-49fd-964b-9f142e0da067|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mmol/min/kPa/L|[?]|1|damol/L|LYMPH|MALDI|Y||1|5|Visit_5|90|5|FOLLOW-UP|2020-11-16|90
e|IS|fe7ad71c-601d-4909-b56a-401c9a10f00c|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/m2/min|[?]|1|ug/animal|SOFT TISSUE|CALCULATION|||1|1|Visit_1|10|3|TREATMENT|2020-05-21|10
e|IS|fe7ad71c-601d-4909-b56a-401c9a10f00c|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|GBq|[?]|1|nmol|EPIDERMAL TISSUE|PEAK FLOWMETRY|||1|2|Visit_2|25|4|WASHOUT|2020-06-05|25
e|IS|fe7ad71c-601d-4909-b56a-401c9a10f00c|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmAL|[?]|1|mg/dose|ARTERIAL BLOOD|HIGH RESOLUTION CT|||1|3|Visit_3|40|1|FOLLOW-UP|2020-06-20|40
e|IS|fe7ad71c-601d-4909-b56a-401c9a10f00c|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|K|[?]|1|mEq/mmol|EXUDATE|GRAM STAIN|||1|4|Visit_4|65|3|WASHOUT|2020-07-15|65
e|IS|fe7ad71c-601d-4909-b56a-401c9a10f00c|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|kPa|[?]|1|MdFI|ARTERIALIZED CAPILLARY BLOOD|GC/FID|||1|5|Visit_5|90|5|SCREENING|2020-08-09|90
e|IS|cc52d895-5819-46c0-b8e6-b948f1cd2408|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Log10 ELISA unit|[?]|1|Bq/ug|LUNG SURFACTANT|SMEAR|||1|1|Visit_1|10|3|TREATMENT|2020-07-06|10
e|IS|cc52d895-5819-46c0-b8e6-b948f1cd2408|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/kg|[?]|1|Gy/min|BONE MARROW|TEST STRIP|||1|2|Visit_2|25|6|SCREENING|2020-07-21|25
e|IS|cc52d895-5819-46c0-b8e6-b948f1cd2408|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|EID 50/mL|[?]|1|ug/dose|CERUMEN|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|Y|1|3|Visit_3|40|3|SCREENING|2020-08-05|40
e|IS|cc52d895-5819-46c0-b8e6-b948f1cd2408|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|kg/cm2|ARTERIAL BLOOD|BETA LACTAMASE||Y|1|4|Visit_4|65|3|TREATMENT|2020-08-30|65
e|IS|cc52d895-5819-46c0-b8e6-b948f1cd2408|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Linear ft*LB|[?]|1|CAPFUL|NAIL|CELLULOSE TAPE|||1|5|Visit_5|90|6|SCREENING|2020-09-24|90
e|IS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Pa|[?]|1|mL/cage/day|EXHALED BREATH CONDENSATE|DOUBLE IMMUNODIFFUSION|Y||1|1|Visit_1|10|3|TREATMENT|2021-01-29|10
e|IS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|uV*sec|[?]|1|VIAL|EMOTIONAL TEAR|COULOMETRIC TITRATION|Y|Y|1|2|Visit_2|25|2|SCREENING|2021-02-13|25
e|IS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|deg/s|[?]|1|Bq|AQUEOUS HUMOR|HPLC|||1|3|Visit_3|40|6|TREATMENT|2021-02-28|40
e|IS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PIXELS/in|[?]|1|mL/g/day|SMOOTH MUSCLE TISSUE|FLAME PHOTOMETRY||Y|1|4|Visit_4|65|6|TREATMENT|2021-03-25|65
e|IS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ka_u/dL|[?]|1|ft3|SPERMATOZOON|ELECTROCHEMILUMINESCENCE|Y||1|5|Visit_5|90|6|TREATMENT|2021-04-19|90
e|IS|1409edea-a372-4938-889b-df6ee93b8543|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|breaths/30s|[?]|1|umol/mol|SPERMATOZOON|CINEANGIOGRAPHY|Y||1|1|Visit_1|10|6|TREATMENT|2020-08-27|10
e|IS|1409edea-a372-4938-889b-df6ee93b8543|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|km/h|[?]|1|CFU/g|CERVICOVAGINAL SECRETION|QUANTITATIVE COMPUTED TOMOGRAPHY|||1|2|Visit_2|25|6|TREATMENT|2020-09-11|25
e|IS|1409edea-a372-4938-889b-df6ee93b8543|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kV|[?]|1|mL/beat|PLATELET|TOTAL BODY RADIOGRAPHY|||1|3|Visit_3|40|3|TREATMENT|2020-09-26|40
e|IS|1409edea-a372-4938-889b-df6ee93b8543|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^5/L|[?]|1|lm|EXHALED BREATH CONDENSATE|TOTAL BODY RADIOGRAPHY|||1|4|Visit_4|65|2|WASHOUT|2020-10-21|65
e|IS|1409edea-a372-4938-889b-df6ee93b8543|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|s*kPa|[?]|1|SQU/mL|BLOOD|IMMUNOTURBIDIMETRY|Y|Y|1|5|Visit_5|90|5|TREATMENT|2020-11-15|90
e|IS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/g Hb|[?]|1|ppb|DIALYSIS FLUID, PERITONEAL|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|1|Visit_1|10|5|WASHOUT|2020-09-04|10
e|IS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6 RNA copies/mL|[?]|1|VOXEL|MENSTRUAL BLOOD|DYNAMIC CONTRAST ENHANCED MRI||Y|1|2|Visit_2|25|2|SCREENING|2020-09-19|25
e|IS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|anti-Xa IU/mL|[?]|1|STRIP|AMNIOTIC FLUID|ENZYMATIC COLORIMETRY|||1|3|Visit_3|40|3|SCREENING|2020-10-04|40
e|IS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ng/L|[?]|1|log10 TCID 50/uL|SERUM OR PLASMA|THICK SMEAR|||1|4|Visit_4|65|7|WASHOUT|2020-10-29|65
e|IS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|fmol/L/sec|[?]|1|mm/min|PLATELET RICH PLASMA|REFRACTOMETRY|||1|5|Visit_5|90|2|WASHOUT|2020-11-23|90
e|IS|7c244128-0508-422f-88ba-ecce68cec054|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|CFU/g|[?]|1|nmol/mL/min|ENDOMETRIAL TISSUE|OBSERVATION|Y||1|1|Visit_1|10|6|TREATMENT|2020-08-05|10
e|IS|7c244128-0508-422f-88ba-ecce68cec054|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/200 HPFs|[?]|1|10^6 DNA copies/mL|MENSTRUAL BLOOD|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||1|2|Visit_2|25|1|TREATMENT|2020-08-20|25
e|IS|7c244128-0508-422f-88ba-ecce68cec054|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|C|[?]|1|10^9 organisms/mL|ALVEOLAR AIR|HPLC/MS||Y|1|3|Visit_3|40|2|TREATMENT|2020-09-04|40
e|IS|7c244128-0508-422f-88ba-ecce68cec054|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|titer|[?]|1|uL|LYMPH|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||1|4|Visit_4|65|2|TREATMENT|2020-09-29|65
e|IS|7c244128-0508-422f-88ba-ecce68cec054|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|CIGAR|[?]|1|POUCH|EXHALED BREATH CONDENSATE|POLYSOMNOGRAPHY||Y|1|5|Visit_5|90|4|TREATMENT|2020-10-24|90
e|IS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uL/kg/day|[?]|1|LOZENGE|INFRANATANT, PLASMA|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|1|Visit_1|10|6|TREATMENT|2020-12-16|10
e|IS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/U|[?]|1|L/h/m2|TRANSUDATE|DROPLET DIGITAL PCR|Y||1|2|Visit_2|25|4|FOLLOW-UP|2020-12-31|25
e|IS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug/mol|[?]|1|Enzyme U/g Hb|BONE MARROW MONONUCLEAR CELL|HEMATOXYLIN AND EOSIN STAIN||Y|1|3|Visit_3|40|5|TREATMENT|2021-01-15|40
e|IS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|g/day|[?]|1|mmol/min/kPa|STOOL|SPIRAL CT|Y||1|4|Visit_4|65|2|SCREENING|2021-02-09|65
e|IS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^9/dose|[?]|1|dyn|SOFT TISSUE|ELISPOT|||1|5|Visit_5|90|7|TREATMENT|2021-03-06|90
e|IS|e870fe2f-b08c-41d9-a672-07da09fe2b99|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^3 DNA copies/mL|[?]|1|g/mol|ARTERIAL CORD BLOOD|ACCELERATOR MASS SPECTROMETRY|||1|1|Visit_1|10|6|TREATMENT|2020-08-12|10
e|IS|e870fe2f-b08c-41d9-a672-07da09fe2b99|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CCID 50/dose|[?]|1|um|CAPILLARY BLOOD|OBSERVATION|||1|2|Visit_2|25|1|TREATMENT|2020-08-27|25
e|IS|e870fe2f-b08c-41d9-a672-07da09fe2b99|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/day|[?]|1|cg|SMOOTH MUSCLE TISSUE|OPTICAL MAPPING|||1|3|Visit_3|40|4|WASHOUT|2020-09-11|40
e|IS|e870fe2f-b08c-41d9-a672-07da09fe2b99|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|log10 CFU/mL|[?]|1|mL/animal/day|EMESIS|FREEZING POINT DEPRESSION||Y|1|4|Visit_4|65|6|SCREENING|2020-10-06|65
e|IS|e870fe2f-b08c-41d9-a672-07da09fe2b99|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ug/L/h|[?]|1|DNA copies/ug|AMNIOTIC FLUID|X-RAY FLUORESCENCE SPECTROMETRY|||1|5|Visit_5|90|2|TREATMENT|2020-10-31|90
e|IS|32979638-fb88-4cbb-a110-a4d2016e9bc5|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|NEEDLE GAUGE|[?]|1|mg/g/min|LYMPH|TRYPAN BLUE STAIN||Y|1|1|Visit_1|10|2|WASHOUT|2020-07-15|10
e|IS|32979638-fb88-4cbb-a110-a4d2016e9bc5|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Bq|[?]|1|HOURS|EXPIRED AIR|FLOW CYTOMETRY|||1|2|Visit_2|25|4|SCREENING|2020-07-30|25
e|IS|32979638-fb88-4cbb-a110-a4d2016e9bc5|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CAN|[?]|1|atm|PLEURAL FLUID|PET/CT SCAN WITHOUT CONTRAST|||1|3|Visit_3|40|3|TREATMENT|2020-08-14|40
e|IS|32979638-fb88-4cbb-a110-a4d2016e9bc5|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|in2|[?]|1|/4.0 mL|LAVAGE FLUID|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|4|Visit_4|65|5|TREATMENT|2020-09-08|65
e|IS|32979638-fb88-4cbb-a110-a4d2016e9bc5|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ELISA unit/dose|[?]|1|nmol/g|GASTRIC FLUID|ELECTROMYOGRAPHY|||1|5|Visit_5|90|7|TREATMENT|2020-10-03|90
e|IS|39b8db88-810b-4402-9ca3-c2bab1939c1c|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^12 IU/L|[?]|1|mU|PLATELET POOR PLASMA|CALCOFLUOR WHITE STAIN||Y|1|1|Visit_1|10|7|SCREENING|2020-11-15|10
e|IS|39b8db88-810b-4402-9ca3-c2bab1939c1c|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/10^4|[?]|1|pmol/dL|SYNOVIAL FLUID|ELECTROCHEMILUMINESCENCE|Y||1|2|Visit_2|25|5|SCREENING|2020-11-30|25
e|IS|39b8db88-810b-4402-9ca3-c2bab1939c1c|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U/cL|[?]|1|AgU/mL|ENDOTRACHEAL FLUID|HIGH RESOLUTION CT|||1|3|Visit_3|40|3|SCREENING|2020-12-15|40
e|IS|39b8db88-810b-4402-9ca3-c2bab1939c1c|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmHg*min/L|[?]|1|km|LUNG SURFACTANT|DIGITAL PCR|||1|4|Visit_4|65|2|SCREENING|2021-01-09|65
e|IS|39b8db88-810b-4402-9ca3-c2bab1939c1c|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CYLINDER|[?]|1|/LSQN|PLATELET|SPECT SCAN|||1|5|Visit_5|90|6|TREATMENT|2021-02-03|90
e|IS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|tuberculin unit/mL|[?]|1|Pack Year|SKIN TISSUE|IN SITU HYBRIDIZATION|||1|1|Visit_1|10|4|TREATMENT|2020-07-27|10
e|IS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mm|[?]|1|Hounsfield Unit|BONE MARROW|CONTACT SPECULAR MICROSCOPY|||1|2|Visit_2|25|5|WASHOUT|2020-08-11|25
e|IS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uL|[?]|1|IU/g Hb|PLEURAL FLUID|INTRAVASCULAR ULTRASOUND|||1|3|Visit_3|40|1|TREATMENT|2020-08-26|40
e|IS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/day|[?]|1|ug/kg|GASTRIC CONTENTS|WHOLE GENOME SEQUENCING|Y||1|4|Visit_4|65|4|WASHOUT|2020-09-20|65
e|IS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/min/kPa|[?]|1|log10 CFU/mL|EXHALED BREATH CONDENSATE|IMMUNOFLUORESCENT STAIN|||1|5|Visit_5|90|3|TREATMENT|2020-10-15|90
e|IS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/(min*100mL)|[?]|1|vg/dose|DERMAL TISSUE|TRIPLE-PHASE SPIRAL CT SCAN|||1|1|Visit_1|10|5|TREATMENT|2020-11-03|10
e|IS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol|[?]|1|pmol/10^9 cells|AMNIOTIC FLUID|SXA SCAN|Y||1|2|Visit_2|25|7|TREATMENT|2020-11-18|25
e|IS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmH2O/mL|[?]|1|L/min|PLATELET RICH PLASMA|BIOPSY||Y|1|3|Visit_3|40|7|WASHOUT|2020-12-03|40
e|IS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/kg/day|[?]|1|10^12/L|SALIVA|ETDRS EYE CHART||Y|1|4|Visit_4|65|6|SCREENING|2020-12-28|65
e|IS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|eq|[?]|1|MET*min|ERYTHROCYTES|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y||1|5|Visit_5|90|7|TREATMENT|2021-01-22|90
e|IS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|anti-Xa IU/mL|[?]|1|U/mL|GASTRIC FLUID|OLIGO ACGH|Y||1|1|Visit_1|10|6|TREATMENT|2020-05-24|10
e|IS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 CFU/g|[?]|1|h/wk|MIXED VENOUS BLOOD|FLUORESCENT SPOT TEST|Y||1|2|Visit_2|25|5|TREATMENT|2020-06-08|25
e|IS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|genEq/mL|[?]|1|F|ABSCESS FLUID|IMMUNODIFFUSION|||1|3|Visit_3|40|7|TREATMENT|2020-06-23|40
e|IS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nU/cL|[?]|1|g/L|EMESIS|QUANTITATIVE ULTRASOUND|||1|4|Visit_4|65|1|TREATMENT|2020-07-18|65
e|IS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|um|[?]|1|g/day|CEREBROSPINAL FLUID|DOPPLER ULTRASOUND|||1|5|Visit_5|90|7|WASHOUT|2020-08-12|90
e|IS|6edb7414-d8f4-44da-8483-504b93a7e705|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kg/cm|[?]|1|mL/min|DISCHARGE|MRI WITHOUT CONTRAST|Y||1|1|Visit_1|10|2|WASHOUT|2020-06-07|10
e|IS|6edb7414-d8f4-44da-8483-504b93a7e705|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|BU|[?]|1|SBE/mL|MONOCYTE|CYSTOMETRY||Y|1|2|Visit_2|25|3|FOLLOW-UP|2020-06-22|25
e|IS|6edb7414-d8f4-44da-8483-504b93a7e705|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Henry|[?]|1|MdFI|TUMOR TISSUE|HIGH RESOLUTION CT|||1|3|Visit_3|40|2|SCREENING|2020-07-07|40
e|IS|6edb7414-d8f4-44da-8483-504b93a7e705|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/kg|[?]|1|cup eq|CERVICOVAGINAL SECRETION|PUPILLOMETRY|||1|4|Visit_4|65|3|SCREENING|2020-08-01|65
e|IS|6edb7414-d8f4-44da-8483-504b93a7e705|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/m2/day|[?]|1|Hz/s|LEUKOCYTE|MICROPARTICLE ENZYME IMMUNOASSAY||Y|1|5|Visit_5|90|3|TREATMENT|2020-08-26|90
e|IS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|days/month|[?]|1|aMFI|TUMOR TISSUE|HIGH RESOLUTION MELT ANALYSIS|||1|1|Visit_1|10|7|WASHOUT|2020-05-16|10
e|IS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/wk|[?]|1|cmHg|CELL PELLET|CONTRAST ENHANCED PET/CT SCAN||Y|1|2|Visit_2|25|5|WASHOUT|2020-05-31|25
e|IS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|v/v|[?]|1|Pa|CORD BLOOD|ULTRASOUND||Y|1|3|Visit_3|40|5|TREATMENT|2020-06-15|40
e|IS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ft|[?]|1|mN|DIALYSIS FLUID, PERITONEAL|SPECT SCAN|Y||1|4|Visit_4|65|1|WASHOUT|2020-07-10|65
e|IS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|VOXEL|[?]|1|Shock Wave|ENDOMETRIAL TISSUE|ACID FAST STAIN|||1|5|Visit_5|90|3|SCREENING|2020-08-04|90
e|IS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/cm2|[?]|1|YEARS|PERITONEAL FLUID|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||1|1|Visit_1|10|3|TREATMENT|2020-05-18|10
e|IS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|CCID 50/mL|[?]|1|kPa|PLATELET RICH PLASMA|POPULATION SEQUENCING|Y||1|2|Visit_2|25|4|TREATMENT|2020-06-02|25
e|IS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|log10 IU/mL|[?]|1|mmol/min/kPa/L|TISSUE|PATHOLOGICAL EVALUATION||Y|1|3|Visit_3|40|5|TREATMENT|2020-06-17|40
e|IS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|DAgU|[?]|1|U/g Hb|PLATELET RICH PLASMA|HIGH RESOLUTION CT||Y|1|4|Visit_4|65|5|WASHOUT|2020-07-12|65
e|IS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mEq/mL|[?]|1|ug/day|SPUTUM|DOPPLER ULTRASOUND|Y|Y|1|5|Visit_5|90|2|TREATMENT|2020-08-06|90
e|IS|47d55e87-e559-424d-a6ad-d533a0d77f39|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^4 CFU/mL|[?]|1|SACHET|STRIATED MUSCLE TISSUE|TRANSVAGINAL ULTRASOUND|Y|Y|1|1|Visit_1|10|3|TREATMENT|2021-01-12|10
e|IS|47d55e87-e559-424d-a6ad-d533a0d77f39|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL|[?]|1|ppb|CALCULUS|CYSTOMETRY||Y|1|2|Visit_2|25|5|TREATMENT|2021-01-27|25
e|IS|47d55e87-e559-424d-a6ad-d533a0d77f39|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/L|[?]|1|DIOPTER|DISCHARGE|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||Y|1|3|Visit_3|40|6|FOLLOW-UP|2021-02-11|40
e|IS|47d55e87-e559-424d-a6ad-d533a0d77f39|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/g Hb|[?]|1|PFU/mL|EXHALED BREATH CONDENSATE|CHROMOGENIC ASSAY||Y|1|4|Visit_4|65|7|SCREENING|2021-03-08|65
e|IS|47d55e87-e559-424d-a6ad-d533a0d77f39|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/mol|[?]|1|10^3 organisms/g|LAVAGE FLUID|PERIPHERAL ANGIOGRAPHY|||1|5|Visit_5|90|2|TREATMENT|2021-04-02|90
e|IS|f89c08df-2e24-4c97-a451-1980cecebf14|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 DNA copies/mL|[?]|1|mL/kg/min|MUSCLE TISSUE|ENZYMATIC SPECTROPHOTOMETRY|||1|1|Visit_1|10|6|WASHOUT|2020-12-18|10
e|IS|f89c08df-2e24-4c97-a451-1980cecebf14|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|titer|[?]|1|log10 copies/mL|INTERSTITIAL FLUID|PET/CT SCAN|||1|2|Visit_2|25|6|FOLLOW-UP|2021-01-02|25
e|IS|f89c08df-2e24-4c97-a451-1980cecebf14|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/s|[?]|1|ELISA unit/dose|CERUMEN|ANTIMICROBIAL COMBINATION TESTING||Y|1|3|Visit_3|40|4|TREATMENT|2021-01-17|40
e|IS|f89c08df-2e24-4c97-a451-1980cecebf14|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mEq/L|[?]|1|TRANSDUCING UNIT/mL|PERIPHERAL BLOOD MONONUCLEAR CELL|GRAM STAIN|||1|4|Visit_4|65|5|TREATMENT|2021-02-11|65
e|IS|f89c08df-2e24-4c97-a451-1980cecebf14|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|CAPLET|[?]|1|cs|PLEURAL TISSUE|FARR ASSAY||Y|1|5|Visit_5|90|4|TREATMENT|2021-03-08|90
e|IS|dbb225ed-e322-4946-a60a-0fafd7e22953|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|PFU/mL|[?]|1|BOLUS|MIXED VENOUS BLOOD|ROMANOWSKY STAIN||Y|1|1|Visit_1|10|5|TREATMENT|2021-01-24|10
e|IS|dbb225ed-e322-4946-a60a-0fafd7e22953|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MONTHS|[?]|1|10^9 organisms/mL|AMNIOTIC FLUID|FUNCTIONAL MRI|||1|2|Visit_2|25|1|WASHOUT|2021-02-08|25
e|IS|dbb225ed-e322-4946-a60a-0fafd7e22953|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|100 IU/mL|[?]|1|ng|CORD SERUM|DIFFUSION TENSOR MRI||Y|1|3|Visit_3|40|1|TREATMENT|2021-02-23|40
e|IS|dbb225ed-e322-4946-a60a-0fafd7e22953|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|GLOBULE|[?]|1|CAN|BLOOD|RADIOIMMUNOPRECIPITATION ASSAY|Y|Y|1|4|Visit_4|65|1|FOLLOW-UP|2021-03-20|65
e|IS|dbb225ed-e322-4946-a60a-0fafd7e22953|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|fmol/L/sec|ADIPOSE TISSUE|ENDPOINT DILUTION ASSAY||Y|1|5|Visit_5|90|6|FOLLOW-UP|2021-04-14|90
e|IS|95e61698-43f7-4cc5-aafa-06dac7870743|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|g/animal/wk|[?]|1|10^4/L|PLASMA|COULOMETRIC TITRATION|Y||1|1|Visit_1|10|2|SCREENING|2020-12-25|10
e|IS|95e61698-43f7-4cc5-aafa-06dac7870743|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mCi|[?]|1|um/s|INFRANATANT, PLASMA|FUNDUS PHOTOGRAPHY|Y||1|2|Visit_2|25|5|FOLLOW-UP|2021-01-09|25
e|IS|95e61698-43f7-4cc5-aafa-06dac7870743|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BOX|[?]|1|g/dL|CERUMEN|SLIT LAMP PHOTOGRAPHY|Y||1|3|Visit_3|40|1|TREATMENT|2021-01-24|40
e|IS|95e61698-43f7-4cc5-aafa-06dac7870743|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|DAgU/mL|[?]|1|uCi/kg|DIALYSIS FLUID, PERITONEAL|LC/MS|Y||1|4|Visit_4|65|3|TREATMENT|2021-02-18|65
e|IS|95e61698-43f7-4cc5-aafa-06dac7870743|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/cm|[?]|1|Enzyme U|ARTERIAL CORD BLOOD|OPTICAL DENSITY MEASUREMENT|||1|5|Visit_5|90|6|TREATMENT|2021-03-15|90
e|IS|151308c7-03aa-4a0b-b13f-9838edb218ef|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/mg|[?]|1|BOLUS|INFRANATANT, PLEURAL FLUID|STATIC PERIMETRY|||1|1|Visit_1|10|4|TREATMENT|2020-09-13|10
e|IS|151308c7-03aa-4a0b-b13f-9838edb218ef|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ukat/10^12 RBC|[?]|1|ng/dL|DIALYSIS FLUID, PERITONEAL|AGAR DILUTION|||1|2|Visit_2|25|6|TREATMENT|2020-09-28|25
e|IS|151308c7-03aa-4a0b-b13f-9838edb218ef|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|10^8/L|CAPILLARY PLASMA|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y|1|3|Visit_3|40|5|WASHOUT|2020-10-13|40
e|IS|151308c7-03aa-4a0b-b13f-9838edb218ef|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^8 PFU|[?]|1|mL/cm H2O|ADIPOSE TISSUE|ENZYMATIC SPECTROPHOTOMETRY|||1|4|Visit_4|65|4|FOLLOW-UP|2020-11-07|65
e|IS|151308c7-03aa-4a0b-b13f-9838edb218ef|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kPa/L/sec|[?]|1|mL/animal/wk|BONE MARROW MONONUCLEAR CELL|CONTRAST ENHANCED CT SCAN||Y|1|5|Visit_5|90|3|WASHOUT|2020-12-02|90
e|IS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|gMFI|[?]|1|ug/m2/min|SEMINAL FLUID|MIGET||Y|1|1|Visit_1|10|1|TREATMENT|2020-06-15|10
e|IS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|pg/dL|[?]|1|vg/dose|ADIPOSE TISSUE|AUTOREFRACTION|||1|2|Visit_2|25|7|SCREENING|2020-06-30|25
e|IS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|OD Unit|[?]|1|IU/mL|VITREOUS HUMOR|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||Y|1|3|Visit_3|40|1|WASHOUT|2020-07-15|40
e|IS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|psec|[?]|1|10^6/L|CIRCULATING TUMOR CELL|WHOLE EXOME SEQUENCING|Y||1|4|Visit_4|65|1|TREATMENT|2020-08-09|65
e|IS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|KIT|[?]|1|nmol BCE/L|NAIL|LIGHT MICROSCOPY|Y||1|5|Visit_5|90|3|WASHOUT|2020-09-03|90
e|IS|23605586-1b30-4f05-bb15-417dd3a79994|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U/g|[?]|1|CCID 50/mL|BLOOD|DYNAMIC CONTRAST ENHANCED MRI|||1|1|Visit_1|10|1|SCREENING|2020-10-31|10
e|IS|23605586-1b30-4f05-bb15-417dd3a79994|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|BOLUS|[?]|1|dram|PLEURAL TISSUE|SANGER SEQUENCING||Y|1|2|Visit_2|25|2|WASHOUT|2020-11-15|25
e|IS|23605586-1b30-4f05-bb15-417dd3a79994|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|fmol/L/sec|[?]|1|STRIP|ENDOTRACHEAL FLUID|PAP STAIN|||1|3|Visit_3|40|2|WASHOUT|2020-11-30|40
e|IS|23605586-1b30-4f05-bb15-417dd3a79994|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|uIU/dL|[?]|1|m|SYNOVIAL FLUID|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|Y|1|4|Visit_4|65|1|TREATMENT|2020-12-25|65
e|IS|23605586-1b30-4f05-bb15-417dd3a79994|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|MASK|[?]|1|U/g|SEBUM|IMPULSE OSCILLOMETRY|||1|5|Visit_5|90|4|TREATMENT|2021-01-19|90
e|IS|57d15ac0-06a6-40e0-9201-4d947651c9b0|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nmol/day|[?]|1|umol/mg/min|PERIPHERAL BLOOD MONONUCLEAR CELL|SICKLE CELL SOLUBILITY TEST|Y|Y|1|1|Visit_1|10|4|TREATMENT|2020-08-28|10
e|IS|57d15ac0-06a6-40e0-9201-4d947651c9b0|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|GBq/mg|[?]|1|BAG|SERUM|GRAM STAIN|||1|2|Visit_2|25|4|TREATMENT|2020-09-12|25
e|IS|57d15ac0-06a6-40e0-9201-4d947651c9b0|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ng/day|[?]|1|g/animal|STOOL|RADIOGRAPHY|||1|3|Visit_3|40|5|SCREENING|2020-09-27|40
e|IS|57d15ac0-06a6-40e0-9201-4d947651c9b0|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mkat|[?]|1|mol|TISSUE|CAPILLARY ELECTROPHORESIS||Y|1|4|Visit_4|65|3|SCREENING|2020-10-22|65
e|IS|57d15ac0-06a6-40e0-9201-4d947651c9b0|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Ci/uL|[?]|1|mL/mmHg/min/L|SUPERNATANT, SERUM|FISH|||1|5|Visit_5|90|5|WASHOUT|2020-11-16|90
e|IS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uIU/L|[?]|1|Newton|DIALYSIS FLUID, PERITONEAL|DNA MICROARRAY|||1|1|Visit_1|10|3|TREATMENT|2020-08-12|10
e|IS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mCi/kg|[?]|1|PACKET|PROSTATIC FLUID|PET/CT SCAN|Y||1|2|Visit_2|25|6|FOLLOW-UP|2020-08-27|25
e|IS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|PUFF|[?]|1|MdFI|AQUEOUS HUMOR|DIGITAL PCR ARRAY|||1|3|Visit_3|40|6|TREATMENT|2020-09-11|40
e|IS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dyn|[?]|1|U/m2/day|PROSTATIC FLUID|DYNAMIC CONTRAST ENHANCED MRI|||1|4|Visit_4|65|1|WASHOUT|2020-10-06|65
e|IS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/10^3|[?]|1|uU/dL|PLASMA ULTRAFILTRATE|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||1|5|Visit_5|90|3|TREATMENT|2020-10-31|90
e|IS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/mol|[?]|1|PFU/dose|VENOUS PLASMA|MULTIPLE BREATH WASHOUT|||1|1|Visit_1|10|3|TREATMENT|2020-08-31|10
e|IS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/cm2|[?]|1|10^6/Ejaculate U|MONOCYTE|NUCLEAR RADIOLOGY|||1|2|Visit_2|25|2|FOLLOW-UP|2020-09-15|25
e|IS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|LOZENGE|[?]|1|pg/L|KERATINOCYTE|PHOTOGRAPHY|Y||1|3|Visit_3|40|6|TREATMENT|2020-09-30|40
e|IS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cd*s/m2|[?]|1|SCOOPFUL|CORD SERUM|SPECULAR MICROSCOPY|||1|4|Visit_4|65|5|TREATMENT|2020-10-25|65
e|IS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|log10 PFU|[?]|1|Mile|URINE SEDIMENT|IMMUNOCHEMILUMINOMETRIC ASSAY|Y|Y|1|5|Visit_5|90|2|WASHOUT|2020-11-19|90
e|IS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mol/mL|[?]|1|BAG|EXPIRED AIR|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||1|1|Visit_1|10|3|TREATMENT|2020-12-24|10
e|IS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Ci|[?]|1|cd*s/m2|MENSTRUAL BLOOD|DYNAMOMETRY|||1|2|Visit_2|25|4|TREATMENT|2021-01-08|25
e|IS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|ug/h|LYSATE|ENZYMATIC ULTRACENTRIFUGATION|Y||1|3|Visit_3|40|2|TREATMENT|2021-01-23|40
e|IS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/min/mmHg|[?]|1|Ci|PERITONEAL FLUID|WESTERGREN|Y||1|4|Visit_4|65|1|TREATMENT|2021-02-17|65
e|IS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MBq|[?]|1|umol/day|TISSUE|MOUSE PROTECTION ASSAY|||1|5|Visit_5|90|5|TREATMENT|2021-03-14|90
e|IS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug/m2/h|[?]|1|U/mL|SUPERNATANT, SERUM OR PLASMA|CONTRAST ENHANCED X-RAY||Y|1|1|Visit_1|10|2|TREATMENT|2020-07-02|10
e|IS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|fmol/L|[?]|1|nkat|BONE MARROW|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|2|Visit_2|25|1|TREATMENT|2020-07-17|25
e|IS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/kg|[?]|1|L/s/kPa|SPUTUM|ELLA|||1|3|Visit_3|40|2|SCREENING|2020-08-01|40
e|IS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/g/h|[?]|1|g/animal/day|LEUKOCYTE|MALDI-TOF|||1|4|Visit_4|65|4|WASHOUT|2020-08-26|65
e|IS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PFU/dose|[?]|1|nL|TISSUE|HPLC/IEX|||1|5|Visit_5|90|4|TREATMENT|2020-09-20|90
e|IS|81f62132-123e-4888-abbe-8e289599e965|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mCi/L|[?]|1|Siemens|DIALYSIS FLUID, PERITONEAL|FLOCCULATION, CHARCOAL ENHANCED|Y||1|1|Visit_1|10|1|WASHOUT|2020-12-04|10
e|IS|81f62132-123e-4888-abbe-8e289599e965|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|/wk|[?]|1|ng/dL|SYNOVIAL FLUID|INFRARED SPECTROMETRY||Y|1|2|Visit_2|25|1|WASHOUT|2020-12-19|25
e|IS|81f62132-123e-4888-abbe-8e289599e965|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ks|[?]|1|ppth|SUPERNATANT, SERUM|ATOMIC ABSORPTION SPECTROMETRY||Y|1|3|Visit_3|40|1|SCREENING|2021-01-03|40
e|IS|81f62132-123e-4888-abbe-8e289599e965|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 IU/mL|[?]|1|pptr|CAPILLARY PLASMA|LC/MS|Y||1|4|Visit_4|65|5|TREATMENT|2021-01-28|65
e|IS|81f62132-123e-4888-abbe-8e289599e965|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Bq/L|[?]|1|g/animal/wk|STRIATED MUSCLE TISSUE|GEL ELECTROPHORESIS||Y|1|5|Visit_5|90|4|TREATMENT|2021-02-22|90
e|IS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^6 U|[?]|1|Mile|ISOLATE|FISH||Y|1|1|Visit_1|10|1|SCREENING|2020-05-16|10
e|IS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|deg2|[?]|1|Watt|INFRANATANT, SERUM|DROPLET DIGITAL PCR|||1|2|Visit_2|25|1|TREATMENT|2020-05-31|25
e|IS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|fL|[?]|1|mL/100g/min|ARTERIAL CORD BLOOD|CARDIAC THERMODILUTION|||1|3|Visit_3|40|1|TREATMENT|2020-06-15|40
e|IS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|amp|[?]|1|VOXEL|ARTERIAL CORD BLOOD|MIGET|Y||1|4|Visit_4|65|5|WASHOUT|2020-07-10|65
e|IS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mol/mL|[?]|1|Bq/uL|EPIDERMAL TISSUE|MS/MS|Y||1|5|Visit_5|90|4|TREATMENT|2020-08-04|90
e|IS|49282406-97ec-4108-adf9-e01c18ce59c6|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|g/animal|[?]|1|tuberculin unit|EXHALED BREATH CONDENSATE|LYMPHANGIOGRAPHY|||1|1|Visit_1|10|5|TREATMENT|2020-05-17|10
e|IS|49282406-97ec-4108-adf9-e01c18ce59c6|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kV|[?]|1|/min|LYMPH|CINEANGIOGRAPHY|Y||1|2|Visit_2|25|1|FOLLOW-UP|2020-06-01|25
e|IS|49282406-97ec-4108-adf9-e01c18ce59c6|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/10^3|[?]|1|fmol/g|ATHEROSCLEROTIC PLAQUE|MALDI-TOF|||1|3|Visit_3|40|2|SCREENING|2020-06-16|40
e|IS|49282406-97ec-4108-adf9-e01c18ce59c6|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Ci/uL|[?]|1|mL/sec/1.73m2|AQUEOUS HUMOR|MRS|||1|4|Visit_4|65|1|SCREENING|2020-07-11|65
e|IS|49282406-97ec-4108-adf9-e01c18ce59c6|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mol/mg|[?]|1|mmol/L|PERSPIRATION|DIRECT SEQUENCING|||1|5|Visit_5|90|5|WASHOUT|2020-08-05|90
e|IS|310936c8-7d24-4eea-9892-1cd8bb675421|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/mg/min|[?]|1|Enzyme U/g Hb|MONOCYTE|DYNAMIC CONTRAST ENHANCED MRI||Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-07-06|10
e|IS|310936c8-7d24-4eea-9892-1cd8bb675421|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/kg/day|[?]|1|HOMEOPATHIC DILUTION|SMEGMA|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|2|Visit_2|25|6|SCREENING|2020-07-21|25
e|IS|310936c8-7d24-4eea-9892-1cd8bb675421|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/mm2|[?]|1|cup eq|EXUDATE|HPLC/MS/MS|Y||1|3|Visit_3|40|3|TREATMENT|2020-08-05|40
e|IS|310936c8-7d24-4eea-9892-1cd8bb675421|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|mL/h|AQUEOUS HUMOR|IN SITU HYBRIDIZATION||Y|1|4|Visit_4|65|3|SCREENING|2020-08-30|65
e|IS|310936c8-7d24-4eea-9892-1cd8bb675421|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|CONTAINER|[?]|1|cm/s|SOFT TISSUE|SCANNING ELECTRON MICROSCOPY|Y||1|5|Visit_5|90|1|FOLLOW-UP|2020-09-24|90
e|IS|034e303b-5675-4188-bcea-fc2e53b155d6|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|GPL U/mL|[?]|1|ug/m2|VITREOUS HUMOR|PUPILLOMETRY|||1|1|Visit_1|10|6|WASHOUT|2020-06-01|10
e|IS|034e303b-5675-4188-bcea-fc2e53b155d6|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|%|[?]|1|10^3 CFU|SPERMATOZOON|MS/MS|||1|2|Visit_2|25|3|SCREENING|2020-06-16|25
e|IS|034e303b-5675-4188-bcea-fc2e53b155d6|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|BP|[?]|1|Shock Wave|COLOSTRUM|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||1|3|Visit_3|40|7|TREATMENT|2020-07-01|40
e|IS|034e303b-5675-4188-bcea-fc2e53b155d6|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|copies/uL|[?]|1|AgU/mL|SUPERNATANT, PLASMA|MODIFIED ACID FAST STAIN|||1|4|Visit_4|65|2|SCREENING|2020-07-26|65
e|IS|034e303b-5675-4188-bcea-fc2e53b155d6|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CIGAR|[?]|1|mmHg/sec|VENOUS PLASMA|CORONARY ANGIOGRAPHY|||1|5|Visit_5|90|6|WASHOUT|2020-08-20|90
e|IS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|copies/mL|[?]|1|fL|TRANSUDATE|PHOTOMETRY|||1|1|Visit_1|10|6|WASHOUT|2020-07-07|10
e|IS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|vp/mL|[?]|1|ohm|CARDIAC MUSCLE TISSUE|SPECULAR MICROSCOPY|Y||1|2|Visit_2|25|6|TREATMENT|2020-07-22|25
e|IS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Enzyme U/m2|[?]|1|BOX|SERUM|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|3|Visit_3|40|5|TREATMENT|2020-08-06|40
e|IS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mU/g|[?]|1|g/m2/day|BREAST MILK|PET/MRI SCAN|||1|4|Visit_4|65|5|TREATMENT|2020-08-31|65
e|IS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|g/day|[?]|1|mV/sec|BONE|MICRONEUTRALIZATION ASSAY|||1|5|Visit_5|90|3|WASHOUT|2020-09-25|90
e|IS|c912affb-cbc2-4919-81b4-ecaa03908261|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/10^3|[?]|1|10^6 CFU/g|HAIR|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||1|1|Visit_1|10|2|WASHOUT|2020-07-12|10
e|IS|c912affb-cbc2-4919-81b4-ecaa03908261|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kBq/uL|[?]|1|m/sec|HAIR FOLLICLE|CONFOCAL MICROSCOPY||Y|1|2|Visit_2|25|2|TREATMENT|2020-07-27|25
e|IS|c912affb-cbc2-4919-81b4-ecaa03908261|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/h|[?]|1|mL/cage/day|VENOUS BLOOD|SLOAN LETTER EYE CHART 1.25%|||1|3|Visit_3|40|3|SCREENING|2020-08-11|40
e|IS|c912affb-cbc2-4919-81b4-ecaa03908261|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|NEBULE|[?]|1|nmol/L|PERITONEAL FLUID|STATIC PERIMETRY|||1|4|Visit_4|65|6|TREATMENT|2020-09-05|65
e|IS|c912affb-cbc2-4919-81b4-ecaa03908261|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/cm2|[?]|1|nmol/mL/min|PERSPIRATION|BIOIMPEDANCE SPECTROSCOPY||Y|1|5|Visit_5|90|3|TREATMENT|2020-09-30|90
e|IS|5af817f0-5dfb-4046-ac7c-4bae16a90036|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/h|[?]|1|ug/L/h|BONE MARROW|HPLC/MS/MS|||1|1|Visit_1|10|3|SCREENING|2020-07-06|10
e|IS|5af817f0-5dfb-4046-ac7c-4bae16a90036|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|C|[?]|1|PELLET|BONE MARROW MONONUCLEAR CELL|SISH|Y|Y|1|2|Visit_2|25|2|SCREENING|2020-07-21|25
e|IS|5af817f0-5dfb-4046-ac7c-4bae16a90036|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uV2|[?]|1|genEq/mL|VENOUS PLASMA|SLOAN LETTER EYE CHART 1.25%|||1|3|Visit_3|40|1|TREATMENT|2020-08-05|40
e|IS|5af817f0-5dfb-4046-ac7c-4bae16a90036|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cGy|[?]|1|Hz/s|CERVICOVAGINAL SECRETION|RAJI CELL RIA|||1|4|Visit_4|65|7|TREATMENT|2020-08-30|65
e|IS|5af817f0-5dfb-4046-ac7c-4bae16a90036|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/L|[?]|1|IU/L|URINE|HEMATOXYLIN AND EOSIN STAIN||Y|1|5|Visit_5|90|2|TREATMENT|2020-09-24|90
e|IS|dcefd656-a59a-4b71-9260-efcbcecd2132|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|INHALATION|[?]|1|uV2|LUNG SURFACTANT|MRS|||1|1|Visit_1|10|3|FOLLOW-UP|2020-06-04|10
e|IS|dcefd656-a59a-4b71-9260-efcbcecd2132|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PIXELS/cm|[?]|1|10^3 copies/mL|VENOUS CORD BLOOD|MACRO BROTH DILUTION||Y|1|2|Visit_2|25|3|SCREENING|2020-06-19|25
e|IS|dcefd656-a59a-4b71-9260-efcbcecd2132|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/m2|[?]|1|10^6/L|BONE MARROW|TRICHROME STAIN||Y|1|3|Visit_3|40|7|WASHOUT|2020-07-04|40
e|IS|dcefd656-a59a-4b71-9260-efcbcecd2132|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 CFU/g|[?]|1|APL U/mL|SOFT TISSUE|CAPILLARY ELECTROPHORESIS|||1|4|Visit_4|65|4|FOLLOW-UP|2020-07-29|65
e|IS|dcefd656-a59a-4b71-9260-efcbcecd2132|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|breaths/30s|[?]|1|ug/day|PROSTATIC FLUID|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y|1|5|Visit_5|90|4|TREATMENT|2020-08-23|90
e|IS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/mmHg|[?]|1|BOLUS|PLATELET POOR PLASMA|AGAR PROPORTION|||1|1|Visit_1|10|1|SCREENING|2020-12-22|10
e|IS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|oz|[?]|1|Enzyme U|CORD SERUM|DOUBLE IMMUNODIFFUSION|||1|2|Visit_2|25|5|FOLLOW-UP|2021-01-06|25
e|IS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mCi/L|[?]|1|CAPSULE|EXUDATE|CONTRAST ENHANCED PET/CT SCAN|||1|3|Visit_3|40|7|WASHOUT|2021-01-21|40
e|IS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/g/min|[?]|1|mL/s|EXPIRED AIR|IMPULSE OSCILLOMETRY|Y||1|4|Visit_4|65|5|SCREENING|2021-02-15|65
e|IS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|pmol/L/h|[?]|1|IU|EMESIS|INFRARED SPECTROMETRY|Y||1|5|Visit_5|90|1|FOLLOW-UP|2021-03-12|90
e|IS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cpm|[?]|1|nmol/mL/min|STOOL|COMPLEMENT FIXATION|||1|1|Visit_1|10|5|TREATMENT|2020-09-24|10
e|IS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/kg|[?]|1|10^4 CFU|SPERMATOZOON|SPIRAL CT SCAN WITHOUT CONTRAST||Y|1|2|Visit_2|25|1|FOLLOW-UP|2020-10-09|25
e|IS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|fmol|[?]|1|U/animal|KERATINOCYTE|SPECULAR MICROSCOPY|||1|3|Visit_3|40|7|FOLLOW-UP|2020-10-24|40
e|IS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g|[?]|1|mL|WHITE MATTER TISSUE|PALM METHOD|Y||1|4|Visit_4|65|6|FOLLOW-UP|2020-11-18|65
e|IS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ELISA unit|[?]|1|BOWL|MIXED VENOUS BLOOD|AGAR DILUTION|||1|5|Visit_5|90|7|TREATMENT|2020-12-13|90
e|IS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/kg/min|[?]|1|cycle/min|SUPERNATANT, PLEURAL FLUID|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||1|1|Visit_1|10|3|TREATMENT|2020-10-31|10
e|IS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mN|[?]|1|kHz|SEMINAL FLUID|FUNDUS PHOTOGRAPHY|||1|2|Visit_2|25|3|FOLLOW-UP|2020-11-15|25
e|IS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uOsm|[?]|1|cGy|DIALYSIS FLUID|LAPAROSCOPY||Y|1|3|Visit_3|40|5|TREATMENT|2020-11-30|40
e|IS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|amu|[?]|1|10^4/hpf|CIRCULATING TUMOR CELL|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y|1|4|Visit_4|65|4|TREATMENT|2020-12-25|65
e|IS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mOsm/L|[?]|1|BAU|LOCHIA|IMMUNORADIOMETRIC ASSAY|Y|Y|1|5|Visit_5|90|7|FOLLOW-UP|2021-01-19|90
e|IS|46304edd-0b05-4819-8fcb-35cf9c02764d|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6 organisms/mL|[?]|1|U/m2|CORD SERUM|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y||1|1|Visit_1|10|2|FOLLOW-UP|2020-12-03|10
e|IS|46304edd-0b05-4819-8fcb-35cf9c02764d|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|um/day|[?]|1|mL/g/day|CIRCULATING TUMOR CELL|CISH||Y|1|2|Visit_2|25|6|FOLLOW-UP|2020-12-18|25
e|IS|46304edd-0b05-4819-8fcb-35cf9c02764d|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ng/mol|[?]|1|10^3 CFU|SPUTUM|REVERSE TRANSCRIPTASE PCR|Y|Y|1|3|Visit_3|40|6|FOLLOW-UP|2021-01-02|40
e|IS|46304edd-0b05-4819-8fcb-35cf9c02764d|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|msec|INFRANATANT, SERUM|AGAR DILUTION|||1|4|Visit_4|65|7|SCREENING|2021-01-27|65
e|IS|46304edd-0b05-4819-8fcb-35cf9c02764d|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|U/m2/h|[?]|1|nmol/L/h|LYSATE|MICROBIAL CULTURE|Y||1|5|Visit_5|90|4|FOLLOW-UP|2021-02-21|90
e|IS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/kg/h|[?]|1|cGy|PERIPHERAL BLOOD MONONUCLEAR CELL|TRANSVAGINAL ULTRASOUND|Y||1|1|Visit_1|10|3|TREATMENT|2020-05-26|10
e|IS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Tbsp|[?]|1|/mm|PERIPHERAL BLOOD MONONUCLEAR CELL|HIGH RESOLUTION MELT ANALYSIS||Y|1|2|Visit_2|25|7|WASHOUT|2020-06-10|25
e|IS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|rpm|[?]|1|mL/cage|ATHEROSCLEROTIC PLAQUE|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||1|3|Visit_3|40|1|TREATMENT|2020-06-25|40
e|IS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SPRAY|[?]|1|uV2|BASAL TEAR|MULTIPLE BREATH WASHOUT|Y||1|4|Visit_4|65|5|SCREENING|2020-07-20|65
e|IS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|aMFI|[?]|1|uL/dose|SALIVA|LAPAROSCOPY|||1|5|Visit_5|90|1|TREATMENT|2020-08-14|90
e|IS|daa3b89e-637a-43de-86c1-d0db93f00430|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mmHg*min/L|[?]|1|%(v/v)|LAVAGE FLUID|FLUORESCENT IMMUNOASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-10-11|10
e|IS|daa3b89e-637a-43de-86c1-d0db93f00430|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|AU/mL|[?]|1|uOsm|NAIL|DUCTOGRAPHY||Y|1|2|Visit_2|25|6|TREATMENT|2020-10-26|25
e|IS|daa3b89e-637a-43de-86c1-d0db93f00430|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/m2/min|[?]|1|cGy|EXUDATE|LYMPHANGIOGRAPHY|Y||1|3|Visit_3|40|5|FOLLOW-UP|2020-11-10|40
e|IS|daa3b89e-637a-43de-86c1-d0db93f00430|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Frames/s|[?]|1|yd|INFRANATANT, SERUM|RADIOGRAPHY|Y||1|4|Visit_4|65|7|TREATMENT|2020-12-05|65
e|IS|daa3b89e-637a-43de-86c1-d0db93f00430|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|EIA unit|DIALYSIS FLUID, PERITONEAL|HPLC-FL|Y||1|5|Visit_5|90|2|FOLLOW-UP|2020-12-30|90
e|IS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/mm|[?]|1|GBq/mg|LYSATE|CLIP SEQUENCING|||1|1|Visit_1|10|5|WASHOUT|2020-07-04|10
e|IS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cy/cm|[?]|1|mol/day|SUPERNATANT, CEREBROSPINAL FLUID|MACRO BROTH DILUTION||Y|1|2|Visit_2|25|4|WASHOUT|2020-07-19|25
e|IS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Frames/s|[?]|1|mAmp|LYMPH|FLOCCULATION, CHARCOAL ENHANCED||Y|1|3|Visit_3|40|5|TREATMENT|2020-08-03|40
e|IS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uV2|[?]|1|CCID 50/dose|PLASMA|CT SCAN||Y|1|4|Visit_4|65|2|FOLLOW-UP|2020-08-28|65
e|IS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Linear ft*LB|[?]|1|10^7/L|ARTERIAL BLOOD|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y|1|5|Visit_5|90|2|FOLLOW-UP|2020-09-22|90
e|IS|c22014f2-2d7b-4897-8ad5-e46785e51837|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|STEPS|[?]|1|SPRAY|SUPERNATANT, PLEURAL FLUID|PYROSEQUENCING|Y||1|1|Visit_1|10|5|SCREENING|2020-08-13|10
e|IS|c22014f2-2d7b-4897-8ad5-e46785e51837|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BOTTLE|[?]|1|ug/min|BLOOD|CONTRAST ENHANCED PET SCAN|||1|2|Visit_2|25|1|TREATMENT|2020-08-28|25
e|IS|c22014f2-2d7b-4897-8ad5-e46785e51837|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nmol/L/h|[?]|1|fL|SWABBED MATERIAL|COLORIMETRY|||1|3|Visit_3|40|5|TREATMENT|2020-09-12|40
e|IS|c22014f2-2d7b-4897-8ad5-e46785e51837|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MPL U/mL|[?]|1|/min|SEMINAL FLUID|NO INFORMATION|||1|4|Visit_4|65|3|TREATMENT|2020-10-07|65
e|IS|c22014f2-2d7b-4897-8ad5-e46785e51837|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|IU/L|[?]|1|%/s|SMEGMA|PHOTOMETRIC CLOT DETECTION|Y|Y|1|5|Visit_5|90|4|SCREENING|2020-11-01|90
e|IS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|DNA copies/mL|[?]|1|uU/L|DIALYSIS FLUID, PERITONEAL|TRANSVAGINAL ULTRASOUND|||1|1|Visit_1|10|2|WASHOUT|2020-10-11|10
e|IS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uIU/dL|[?]|1|MBq|TRANSUDATE|PELLI-ROBSON EYE CHART|||1|2|Visit_2|25|7|SCREENING|2020-10-26|25
e|IS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mm3/mm2/year|[?]|1|mL/(min*100mL)|SUPERNATANT, PLEURAL FLUID|TELLER ACUITY CARDS||Y|1|3|Visit_3|40|4|SCREENING|2020-11-10|40
e|IS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|AU/mL|[?]|1|mEq/L|CORD SERUM|POLYSOMNOGRAPHY|||1|4|Visit_4|65|1|TREATMENT|2020-12-05|65
e|IS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^6 IU|[?]|1|MET*min|CERVICOVAGINAL SECRETION|CLINICAL EVALUATION|||1|5|Visit_5|90|4|WASHOUT|2020-12-30|90
e|IS|24ce0c77-1921-4b87-91da-3627e2afd399|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U|[?]|1|10^9 organisms/mg|ENDOTRACHEAL FLUID|CHROMATOGRAPHY|||1|1|Visit_1|10|2|TREATMENT|2021-01-29|10
e|IS|24ce0c77-1921-4b87-91da-3627e2afd399|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|CAPFUL|[?]|1|uCi/kg|GASTRIC FLUID|CHROMATOGRAPHY||Y|1|2|Visit_2|25|5|SCREENING|2021-02-13|25
e|IS|24ce0c77-1921-4b87-91da-3627e2afd399|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|atm|[?]|1|PUFF|MIXED VENOUS BLOOD|ACID FAST STAIN|||1|3|Visit_3|40|1|SCREENING|2021-02-28|40
e|IS|24ce0c77-1921-4b87-91da-3627e2afd399|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|TABLET|[?]|1|10^3 RNA copies/mL|PLATELET POOR PLASMA|HIGH RESOLUTION MELT ANALYSIS|||1|4|Visit_4|65|7|TREATMENT|2021-03-25|65
e|IS|24ce0c77-1921-4b87-91da-3627e2afd399|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cm2|[?]|1|dyn|LYSATE|MAPH|||1|5|Visit_5|90|4|WASHOUT|2021-04-19|90
e|IS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kg/cm|[?]|1|mL/m2/day|SEMEN|RAJI CELL EIA||Y|1|1|Visit_1|10|2|WASHOUT|2020-08-20|10
e|IS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mm3/mm2/year|[?]|1|Absorbance U/min|PLEURAL TISSUE|GIEMSA STAIN||Y|1|2|Visit_2|25|4|FOLLOW-UP|2020-09-04|25
e|IS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|BE/mL|[?]|1|Gauss|PLATELET POOR PLASMA|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|3|Visit_3|40|4|FOLLOW-UP|2020-09-19|40
e|IS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|dpm/0.5 mL|[?]|1|10^4/L|GASTRIC FLUID|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|1|4|Visit_4|65|3|FOLLOW-UP|2020-10-14|65
e|IS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|RNA copies/mL|[?]|1|/100 WBC|STOOL|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|5|Visit_5|90|7|TREATMENT|2020-11-08|90
e|IS|f4b83a72-7cde-4e02-8883-05e789c617a8|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/dose|[?]|1|ug/m2/day|KERATINOCYTE|ISHIHARA COLOR PLATES|Y||1|1|Visit_1|10|5|SCREENING|2020-12-25|10
e|IS|f4b83a72-7cde-4e02-8883-05e789c617a8|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|BAG|[?]|1|10^3 CFU|VENOUS BLOOD|FLOW MICROSCOPY|||1|2|Visit_2|25|4|WASHOUT|2021-01-09|25
e|IS|f4b83a72-7cde-4e02-8883-05e789c617a8|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|10^10/L|ARTERIAL CORD BLOOD|SPIROMETRY|||1|3|Visit_3|40|4|TREATMENT|2021-01-24|40
e|IS|f4b83a72-7cde-4e02-8883-05e789c617a8|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/L/h|[?]|1|umol/min|EMESIS|LC-FL|||1|4|Visit_4|65|6|TREATMENT|2021-02-18|65
e|IS|f4b83a72-7cde-4e02-8883-05e789c617a8|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|dpm/mg|[?]|1|%/min|SEMINAL FLUID|FLOW MICROSCOPY||Y|1|5|Visit_5|90|4|TREATMENT|2021-03-15|90
e|IS|c4087538-422a-4bcf-af25-ed4aab36ed4b|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|TCID 50/dose|[?]|1|/kg|SPUTUM|DXA SCAN|||1|1|Visit_1|10|4|SCREENING|2021-01-09|10
e|IS|c4087538-422a-4bcf-af25-ed4aab36ed4b|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ug/g/min|[?]|1|mL/min/1.73m2|CORD SERUM|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|2|Visit_2|25|6|WASHOUT|2021-01-24|25
e|IS|c4087538-422a-4bcf-af25-ed4aab36ed4b|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BOLUS|[?]|1|Torr|NAIL|TRANSMISSION ELECTRON MICROSCOPY|Y|Y|1|3|Visit_3|40|2|TREATMENT|2021-02-08|40
e|IS|c4087538-422a-4bcf-af25-ed4aab36ed4b|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|g/kg|[?]|1|mU/L|BONE|NUCLEIC ACID AMPLIFICATION TEST|||1|4|Visit_4|65|5|TREATMENT|2021-03-05|65
e|IS|c4087538-422a-4bcf-af25-ed4aab36ed4b|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/L FEU|[?]|1|Torr|SUPERNATANT, PLASMA|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|5|Visit_5|90|6|SCREENING|2021-03-30|90
e|IS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|CAPLET|[?]|1|mmol/min/kPa/L|TUMOR TISSUE|PALPATION|||1|1|Visit_1|10|3|FOLLOW-UP|2020-11-06|10
e|IS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|L/kg|[?]|1|U/kg/min|PLEURAL TISSUE|INCISION-INDUCED BLEEDING METHOD|Y||1|2|Visit_2|25|5|TREATMENT|2020-11-21|25
e|IS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U/m2|[?]|1|ngEq/L|CERUMEN|MICROBIAL CULTURE, SOLID|||1|3|Visit_3|40|5|TREATMENT|2020-12-06|40
e|IS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|SFC/10^6 PBMC|[?]|1|Weber|MUSCLE TISSUE|AUTOMATED COUNT|||1|4|Visit_4|65|6|WASHOUT|2020-12-31|65
e|IS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/min|[?]|1|umol/L/h|CORD BLOOD|SPECT/CT SCAN|||1|5|Visit_5|90|5|SCREENING|2021-01-25|90
e|IS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|IU/mg|[?]|1|BOWL|ABSCESS FLUID|DIRECT SEQUENCING||Y|1|1|Visit_1|10|5|WASHOUT|2020-08-11|10
e|IS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Gy/h|[?]|1|mol|MONOCYTE|INTERRUPTER TECHNIQUE|||1|2|Visit_2|25|4|FOLLOW-UP|2020-08-26|25
e|IS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|umol|[?]|1|APPLICATION|EMESIS|PHOTOMETRY|Y|Y|1|3|Visit_3|40|6|SCREENING|2020-09-10|40
e|IS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uCi/kg|[?]|1|ng|INFRANATANT, PLEURAL FLUID|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y|Y|1|4|Visit_4|65|3|WASHOUT|2020-10-05|65
e|IS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Henry|[?]|1|bel|LYSATE|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|5|Visit_5|90|4|SCREENING|2020-10-30|90
e|IS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug/g/h|[?]|1|ug/m2/day|ERYTHROCYTES|POLYSOMNOGRAPHY|||1|1|Visit_1|10|5|FOLLOW-UP|2020-10-11|10
e|IS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MPL U/mL|[?]|1|/ms|ENDOTRACHEAL FLUID|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||1|2|Visit_2|25|6|SCREENING|2020-10-26|25
e|IS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Osm|[?]|1|m/sec|STOOL|COULOMETRIC TITRATION|||1|3|Visit_3|40|2|SCREENING|2020-11-10|40
e|IS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Tesla|[?]|1|ng/day|ARTERIALIZED CAPILLARY BLOOD|NON-INVASIVE DIELECTRIC SENSING|||1|4|Visit_4|65|5|TREATMENT|2020-12-05|65
e|IS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uV2|[?]|1|m/sec2|TRANSUDATE|GRAM STAIN|Y||1|5|Visit_5|90|3|FOLLOW-UP|2020-12-30|90
e|IS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|rpm|[?]|1|IU/mL|GASTRIC FLUID|GRAM STAIN|||1|1|Visit_1|10|4|TREATMENT|2020-07-04|10
e|IS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/kg/week|[?]|1|IU/dL|SERUM|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||1|2|Visit_2|25|4|WASHOUT|2020-07-19|25
e|IS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mmol/g|[?]|1|IU/dL|BONE MARROW|BETA LACTAMASE|||1|3|Visit_3|40|1|TREATMENT|2020-08-03|40
e|IS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/100 WBC|[?]|1|PFU|ARTERIAL CORD BLOOD|NO INFORMATION|||1|4|Visit_4|65|4|TREATMENT|2020-08-28|65
e|IS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mg/mol|[?]|1|nm|DERMAL TISSUE|IMPEDANCE CONDUCTIVITY|Y|Y|1|5|Visit_5|90|1|WASHOUT|2020-09-22|90
e|IS|1e577f2d-2c45-477d-b74f-af24b81d6d20|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/day|[?]|1|ppm|MENSTRUAL BLOOD|KNEMOMETRY||Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-09-23|10
e|IS|1e577f2d-2c45-477d-b74f-af24b81d6d20|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mm/sec|[?]|1|mmol/min/kPa|PERIPHERAL BLOOD MONONUCLEAR CELL|X-RAY|||1|2|Visit_2|25|1|SCREENING|2020-10-08|25
e|IS|1e577f2d-2c45-477d-b74f-af24b81d6d20|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BOX|[?]|1|POINT|GASTRIC CONTENTS|CYSTOMETRY|||1|3|Visit_3|40|7|TREATMENT|2020-10-23|40
e|IS|1e577f2d-2c45-477d-b74f-af24b81d6d20|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9/L|[?]|1|mmol/mol|CORD BLOOD|ELECTROPHORESIS|||1|4|Visit_4|65|2|TREATMENT|2020-11-17|65
e|IS|1e577f2d-2c45-477d-b74f-af24b81d6d20|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|uIU/dL|[?]|1|/2500 WBC|PLEURAL TISSUE|CLIP|||1|5|Visit_5|90|1|FOLLOW-UP|2020-12-12|90
e|IS|f845101e-c057-4f84-94b3-6043afb42ac7|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|dL|[?]|1|GPL U|BILE|CONTRAST ENHANCED PET/CT SCAN|||1|1|Visit_1|10|2|WASHOUT|2020-10-27|10
e|IS|f845101e-c057-4f84-94b3-6043afb42ac7|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|yd|[?]|1|Enzyme U/m2|EMESIS|WESTERN BLOT|||1|2|Visit_2|25|5|TREATMENT|2020-11-11|25
e|IS|f845101e-c057-4f84-94b3-6043afb42ac7|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/g/day|[?]|1|ngEq/L|EXHALED BREATH CONDENSATE|SLOAN LETTER EYE CHART 1.25%|||1|3|Visit_3|40|2|SCREENING|2020-11-26|40
e|IS|f845101e-c057-4f84-94b3-6043afb42ac7|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|TRANSDUCING UNIT/mL|[?]|1|g/m2/day|SUPERNATANT, PLASMA|BAC ACGH|Y||1|4|Visit_4|65|6|FOLLOW-UP|2020-12-21|65
e|IS|f845101e-c057-4f84-94b3-6043afb42ac7|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/s/m2|[?]|1|copies/mL|ARTERIALIZED CAPILLARY BLOOD|PERIPHERAL ANGIOGRAPHY|||1|5|Visit_5|90|7|SCREENING|2021-01-15|90
e|IS|4ddb2076-6837-4028-81bc-3e8057475977|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/m2/day|[?]|1|mU/L|CEREBROSPINAL FLUID|WHOLE EXOME SEQUENCING|Y|Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-12-27|10
e|IS|4ddb2076-6837-4028-81bc-3e8057475977|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uIU/L|[?]|1|g/animal|SMOOTH MUSCLE TISSUE|MALDI|Y||1|2|Visit_2|25|7|TREATMENT|2021-01-11|25
e|IS|4ddb2076-6837-4028-81bc-3e8057475977|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|pkat|[?]|1|nmol/mL/min|SMOOTH MUSCLE TISSUE|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y|1|3|Visit_3|40|6|WASHOUT|2021-01-26|40
e|IS|4ddb2076-6837-4028-81bc-3e8057475977|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mm/2h|[?]|1|GBq|URINE|IVY INCISION METHOD||Y|1|4|Visit_4|65|6|TREATMENT|2021-02-20|65
e|IS|4ddb2076-6837-4028-81bc-3e8057475977|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/mol|[?]|1|10^6 IU/mL|SMOOTH MUSCLE TISSUE|MANUAL COUNT|||1|5|Visit_5|90|5|FOLLOW-UP|2021-03-17|90
e|IS|c165c69c-2ab2-495c-a190-e32d1204bc4e|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ppth|[?]|1|OD Unit|BASAL TEAR|PHOTOMETRIC CLOT DETECTION|Y||1|1|Visit_1|10|5|TREATMENT|2021-01-01|10
e|IS|c165c69c-2ab2-495c-a190-e32d1204bc4e|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BAU/mL|[?]|1|kHz|ENDOMETRIAL TISSUE|MICROPARTICLE ENZYME IMMUNOASSAY|||1|2|Visit_2|25|6|TREATMENT|2021-01-16|25
e|IS|c165c69c-2ab2-495c-a190-e32d1204bc4e|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|BOWL|[?]|1|10^9 organisms/g|INFRANATANT, PLASMA|IMMUNOCHROMATOGRAPHY|||1|3|Visit_3|40|3|TREATMENT|2021-01-31|40
e|IS|c165c69c-2ab2-495c-a190-e32d1204bc4e|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|COAT|[?]|1|mL/dose|MUCUS|DIFFUSION TENSOR MRI||Y|1|4|Visit_4|65|3|TREATMENT|2021-02-25|65
e|IS|c165c69c-2ab2-495c-a190-e32d1204bc4e|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|BOTTLE|[?]|1|Tesla|PERIPHERAL BLOOD MONONUCLEAR CELL|GEL ELECTROPHORESIS|||1|5|Visit_5|90|4|FOLLOW-UP|2021-03-22|90
e|IS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^12 IU/L|[?]|1|U/mg|REFLEX TEAR|WRIGHT-GIEMSA STAIN|||1|1|Visit_1|10|4|TREATMENT|2020-12-29|10
e|IS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^12/L|[?]|1|CIGARETTE|LEUKOCYTE|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y|1|2|Visit_2|25|4|SCREENING|2021-01-13|25
e|IS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|beats/min|[?]|1|log10 copies/mL|MENSTRUAL BLOOD|MODIFIED ACID FAST STAIN|||1|3|Visit_3|40|4|SCREENING|2021-01-28|40
e|IS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|L/s|[?]|1|/10^3|BILE|PYROSEQUENCING|||1|4|Visit_4|65|7|FOLLOW-UP|2021-02-22|65
e|IS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/kg|[?]|1|CFU/g|SEBUM|POLYGRAPHY||Y|1|5|Visit_5|90|4|WASHOUT|2021-03-19|90
e|IS|024a9f6d-4ff1-4673-8617-3790f831fce7|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|NFIU|[?]|1|mmol/min/kPa/L|STRIATED MUSCLE TISSUE|IODINE STAIN|Y||1|1|Visit_1|10|3|WASHOUT|2020-06-13|10
e|IS|024a9f6d-4ff1-4673-8617-3790f831fce7|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ugEq/L|[?]|1|mL/mmHg/min/L|SMEGMA|IMMUNOBLOT|||1|2|Visit_2|25|3|TREATMENT|2020-06-28|25
e|IS|024a9f6d-4ff1-4673-8617-3790f831fce7|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cup eq|[?]|1|TRACE|PLATELET|IODINE STAIN|Y||1|3|Visit_3|40|5|TREATMENT|2020-07-13|40
e|IS|024a9f6d-4ff1-4673-8617-3790f831fce7|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DAgU|[?]|1|10^6/hpf|CAPILLARY BLOOD|JAFFE REACTION|||1|4|Visit_4|65|4|SCREENING|2020-08-07|65
e|IS|024a9f6d-4ff1-4673-8617-3790f831fce7|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|log10 CFU/mL|[?]|1|mg/kg/week|SMEGMA|FLUORESCEIN STAIN|||1|5|Visit_5|90|1|SCREENING|2020-09-01|90
e|IS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Bq/kg|[?]|1|/ms|EXHALED BREATH CONDENSATE|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||1|1|Visit_1|10|2|SCREENING|2020-11-18|10
e|IS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Bq/L|[?]|1|cGy|PLEURAL FLUID|IMMUNORADIOMETRIC ASSAY|||1|2|Visit_2|25|7|TREATMENT|2020-12-03|25
e|IS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|EU|[?]|1|mJoule/cm2|SYNOVIAL FLUID|URANYL ACETATE STAIN|||1|3|Visit_3|40|3|TREATMENT|2020-12-18|40
e|IS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|hPa|[?]|1|Ci/mg|SKELETAL MUSCLE TISSUE|PHYSICAL EXAMINATION|||1|4|Visit_4|65|5|TREATMENT|2021-01-12|65
e|IS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/2500 WBC|[?]|1|cpm|LAVAGE FLUID|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||1|5|Visit_5|90|4|TREATMENT|2021-02-06|90
e|IS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ng|[?]|1|Shock Wave|PLEURAL TISSUE|KINETIC MICROPARTICLE IMMUNOASSAY|||1|1|Visit_1|10|6|WASHOUT|2020-11-11|10
e|IS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|HOMEOPATHIC DILUTION|[?]|1|umol|EXHALED BREATH CONDENSATE|PALPATION||Y|1|2|Visit_2|25|1|TREATMENT|2020-11-26|25
e|IS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/L DDU|[?]|1|mg/g/min|COLOSTRUM|AUTOREFRACTION|||1|3|Visit_3|40|2|SCREENING|2020-12-11|40
e|IS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^3 CFU/g|[?]|1|10^3 CFU/mL|HAIR FOLLICLE|CHROMATOGRAPHY|||1|4|Visit_4|65|5|FOLLOW-UP|2021-01-05|65
e|IS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^8 PFU|[?]|1|days/wk|MENSTRUAL BLOOD|INDIA INK STAIN|Y||1|5|Visit_5|90|1|TREATMENT|2021-01-30|90
e|IS|95c4465b-162a-433d-83c9-6d67dd729c9e|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|dram|[?]|1|/4.0 mL|ENDOMETRIAL TISSUE|PAP STAIN||Y|1|1|Visit_1|10|1|TREATMENT|2020-10-22|10
e|IS|95c4465b-162a-433d-83c9-6d67dd729c9e|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^3 CFU/mL|[?]|1|log10 PFU|PERITONEAL FLUID|INCISION-INDUCED BLEEDING METHOD|Y||1|2|Visit_2|25|1|TREATMENT|2020-11-06|25
e|IS|95c4465b-162a-433d-83c9-6d67dd729c9e|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/g/day|[?]|1|ug/kg/h|EXPIRED AIR|GC/MS/MS|||1|3|Visit_3|40|2|TREATMENT|2020-11-21|40
e|IS|95c4465b-162a-433d-83c9-6d67dd729c9e|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kDa|[?]|1|g/animal|EXUDATE|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|4|Visit_4|65|2|TREATMENT|2020-12-16|65
e|IS|95c4465b-162a-433d-83c9-6d67dd729c9e|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/500 WBC|[?]|1|F|SUPERNATANT, PLASMA|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|5|Visit_5|90|1|TREATMENT|2021-01-10|90
e|IS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Torr|[?]|1|DIP|CERVICOVAGINAL SECRETION|ANTIBIOTIC AGAR SCREEN|||1|1|Visit_1|10|2|FOLLOW-UP|2020-06-27|10
e|IS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mMU/mL|[?]|1|mAnson U/mL|ARTERIAL CORD BLOOD|INFRARED SPECTROMETRY|Y||1|2|Visit_2|25|5|SCREENING|2020-07-12|25
e|IS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^3 organisms/g|[?]|1|Arbitrary U|ALVEOLAR AIR|CELL BASED BIOASSAY|||1|3|Visit_3|40|7|SCREENING|2020-07-27|40
e|IS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|um/s|[?]|1|Enzyme U/L|VENOUS PLASMA|NO INFORMATION||Y|1|4|Visit_4|65|1|FOLLOW-UP|2020-08-21|65
e|IS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|KIT|[?]|1|SACHET|LUNG SURFACTANT|PET/MRI SCAN|||1|5|Visit_5|90|3|FOLLOW-UP|2020-09-15|90
e|IS|beb6b1ab-1264-456a-bf2b-81e28493301d|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/kg/min|[?]|1|kHz|DIALYSIS FLUID, PERITONEAL|CELL BASED BIOASSAY|||1|1|Visit_1|10|2|TREATMENT|2020-06-10|10
e|IS|beb6b1ab-1264-456a-bf2b-81e28493301d|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kg/mol|[?]|1|ug/m2/min|SPERMATOZOON|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||1|2|Visit_2|25|4|TREATMENT|2020-06-25|25
e|IS|beb6b1ab-1264-456a-bf2b-81e28493301d|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|deg/mm|[?]|1|%|URINE SEDIMENT|OBSERVATION|||1|3|Visit_3|40|7|TREATMENT|2020-07-10|40
e|IS|beb6b1ab-1264-456a-bf2b-81e28493301d|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ft|[?]|1|10^3 CFU/g|BONE MARROW|GC/MS-CI||Y|1|4|Visit_4|65|6|FOLLOW-UP|2020-08-04|65
e|IS|beb6b1ab-1264-456a-bf2b-81e28493301d|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mEq/day|[?]|1|IU/day|INFRANATANT, PLEURAL FLUID|REBOUND TONOMETRY|||1|5|Visit_5|90|1|TREATMENT|2020-08-29|90
e|IS|4292c06d-044e-4dff-aea0-830178a6e220|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mN|[?]|1|ug/g/day|SEMEN|OBSERVATION|Y||1|1|Visit_1|10|1|WASHOUT|2020-12-02|10
e|IS|4292c06d-044e-4dff-aea0-830178a6e220|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cL|[?]|1|mg/kg/dose|CERUMEN|PATHOLOGICAL EVALUATION|Y||1|2|Visit_2|25|1|WASHOUT|2020-12-17|25
e|IS|4292c06d-044e-4dff-aea0-830178a6e220|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|RNA copies/mL|[?]|1|mg/g/h|SEBUM|REVERSE TRANSCRIPTASE PCR|||1|3|Visit_3|40|6|WASHOUT|2021-01-01|40
e|IS|4292c06d-044e-4dff-aea0-830178a6e220|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|EU|[?]|1|g/U|AQUEOUS HUMOR|IHC|||1|4|Visit_4|65|3|TREATMENT|2021-01-26|65
e|IS|4292c06d-044e-4dff-aea0-830178a6e220|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DRUM|[?]|1|mmol/kg|SKIN TISSUE|IMMUNORADIOMETRIC ASSAY|Y||1|5|Visit_5|90|6|TREATMENT|2021-02-20|90
e|IS|050c12d2-cf9f-402b-9332-d6a9771ed115|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GBq/g|[?]|1|uU/L|ISOLATE|ELECTROPHORESIS|Y||1|1|Visit_1|10|2|SCREENING|2020-08-18|10
e|IS|050c12d2-cf9f-402b-9332-d6a9771ed115|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mU/g|[?]|1|mgEq|ATHEROSCLEROTIC PLAQUE|MALDI-TOF|||1|2|Visit_2|25|4|SCREENING|2020-09-02|25
e|IS|050c12d2-cf9f-402b-9332-d6a9771ed115|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Gauss|[?]|1|kcal|SMOOTH MUSCLE TISSUE|TONOMETRY|Y||1|3|Visit_3|40|6|WASHOUT|2020-09-17|40
e|IS|050c12d2-cf9f-402b-9332-d6a9771ed115|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|WAFER|[?]|1|breaths/30s|PERITONEAL FLUID|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|4|Visit_4|65|2|TREATMENT|2020-10-12|65
e|IS|050c12d2-cf9f-402b-9332-d6a9771ed115|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/L|[?]|1|tuberculin unit/mL|SERUM OR PLASMA|PEAK FLOWMETRY|Y||1|5|Visit_5|90|2|TREATMENT|2020-11-06|90
e|IS|2f1073e4-607f-423f-a5de-f531b828e2d3|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/day|[?]|1|aMFI|BASAL TEAR|LISSAMINE GREEN STAIN||Y|1|1|Visit_1|10|6|TREATMENT|2020-10-15|10
e|IS|2f1073e4-607f-423f-a5de-f531b828e2d3|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|kV|[?]|1|EP U|NAIL|CLIP SEQUENCING|||1|2|Visit_2|25|2|FOLLOW-UP|2020-10-30|25
e|IS|2f1073e4-607f-423f-a5de-f531b828e2d3|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|umol/L/sec|[?]|1|CAPFUL|PROSTATIC FLUID|REFLECTANCE SPECTROSCOPY||Y|1|3|Visit_3|40|5|TREATMENT|2020-11-14|40
e|IS|2f1073e4-607f-423f-a5de-f531b828e2d3|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/L/sec|[?]|1|ukat/L|PERITONEAL FLUID|TEST STRIP|Y||1|4|Visit_4|65|2|TREATMENT|2020-12-09|65
e|IS|2f1073e4-607f-423f-a5de-f531b828e2d3|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/L|[?]|1|pg/dL|CAPILLARY PLASMA|IMMUNOBLOT|Y||1|5|Visit_5|90|5|FOLLOW-UP|2021-01-03|90
e|IS|df466903-3212-4e73-bff0-a183447c7408|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|MONTHS|[?]|1|TRANSDUCING UNIT/mL|SPUTUM|LISSAMINE GREEN STAIN|||1|1|Visit_1|10|5|WASHOUT|2020-11-01|10
e|IS|df466903-3212-4e73-bff0-a183447c7408|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|fraction of 1|[?]|1|min/day|HAIR|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||1|2|Visit_2|25|7|TREATMENT|2020-11-16|25
e|IS|df466903-3212-4e73-bff0-a183447c7408|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/animal|[?]|1|msec|SERUM|FLUORESCENT ENZYME IMMUNOASSAY|||1|3|Visit_3|40|3|TREATMENT|2020-12-01|40
e|IS|df466903-3212-4e73-bff0-a183447c7408|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cmH2O*s2/mL|[?]|1|mg/kg|SERUM OR PLASMA|MULTI-SLICE SPIRAL CT|Y|Y|1|4|Visit_4|65|7|SCREENING|2020-12-26|65
e|IS|df466903-3212-4e73-bff0-a183447c7408|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|aMFI|[?]|1|mEq/kg|VENOUS BLOOD|JAEGER EYE CHART|||1|5|Visit_5|90|5|WASHOUT|2021-01-20|90
e|IS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nkat|[?]|1|cy/cm|MUCUS|CHROMATOGRAPHY|||1|1|Visit_1|10|5|TREATMENT|2020-07-13|10
e|IS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MESF|[?]|1|/200 HPFs|CIRCULATING TUMOR CELL|PULMONARY ANGIOGRAPHY|Y||1|2|Visit_2|25|1|TREATMENT|2020-07-28|25
e|IS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^9 CFU/mL|[?]|1|10^6 CFU/mL|SUPERNATANT, PLEURAL FLUID|BETA LACTAMASE|Y||1|3|Visit_3|40|4|TREATMENT|2020-08-12|40
e|IS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|BAU/mL|SERUM OR PLASMA|SPIROMETRY||Y|1|4|Visit_4|65|2|TREATMENT|2020-09-06|65
e|IS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/L/sec|[?]|1|10^6 organisms/mg|KERATINOCYTE|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|5|Visit_5|90|6|FOLLOW-UP|2020-10-01|90
e|IS|c37df2f6-be8a-4709-b97d-061ab9754e0d|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|m2|[?]|1|umol/L/h|ARTERIALIZED CAPILLARY BLOOD|PERCUSSION|||1|1|Visit_1|10|6|WASHOUT|2020-08-01|10
e|IS|c37df2f6-be8a-4709-b97d-061ab9754e0d|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mCi/L|[?]|1|JAR|PLASMA ULTRAFILTRATE|DUCTOGRAPHY|Y||1|2|Visit_2|25|4|WASHOUT|2020-08-16|25
e|IS|c37df2f6-be8a-4709-b97d-061ab9754e0d|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mJoule/cm2|[?]|1|nCi|EXHALED BREATH CONDENSATE|PET/CT SCAN|Y||1|3|Visit_3|40|5|WASHOUT|2020-08-31|40
e|IS|c37df2f6-be8a-4709-b97d-061ab9754e0d|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|V|[?]|1|ukat/L|CERVICOVAGINAL SECRETION|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||1|4|Visit_4|65|6|TREATMENT|2020-09-25|65
e|IS|c37df2f6-be8a-4709-b97d-061ab9754e0d|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/L FEU|[?]|1|tuberculin unit|WHITE MATTER TISSUE|IMMUNODIFFUSION|||1|5|Visit_5|90|3|TREATMENT|2020-10-20|90
e|IS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PELLET|[?]|1|PIXELS/cm|ABSCESS FLUID|IHC|||1|1|Visit_1|10|7|TREATMENT|2020-05-13|10
e|IS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/mmHg|[?]|1|BAG|LEUKOCYTE|PET/CT SCAN WITHOUT CONTRAST|||1|2|Visit_2|25|1|FOLLOW-UP|2020-05-28|25
e|IS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SACHET|[?]|1|ug/g/day|GASTRIC CONTENTS|PET SCAN|||1|3|Visit_3|40|7|SCREENING|2020-06-12|40
e|IS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|NEBULE|[?]|1|g/m2|PLASMA ULTRAFILTRATE|KINYOUN STAIN|Y|Y|1|4|Visit_4|65|7|TREATMENT|2020-07-07|65
e|IS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/beat|[?]|1|BISCUIT|BREAST MILK|IHC|||1|5|Visit_5|90|6|TREATMENT|2020-08-01|90
e|IS|cec9e0ce-4d09-470c-9c26-df661d316a69|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|days/month|[?]|1|ms/mmHg|BLOOD|HIGH RESOLUTION MELT ANALYSIS|||1|1|Visit_1|10|1|SCREENING|2021-01-05|10
e|IS|cec9e0ce-4d09-470c-9c26-df661d316a69|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/200 HPFs|[?]|1|Joule|URINE SEDIMENT|COLORIMETRY|||1|2|Visit_2|25|5|TREATMENT|2021-01-20|25
e|IS|cec9e0ce-4d09-470c-9c26-df661d316a69|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/h|[?]|1|/day|HAIR|MAGNETIC RESONANCE ENTEROGRAPHY|||1|3|Visit_3|40|5|TREATMENT|2021-02-04|40
e|IS|cec9e0ce-4d09-470c-9c26-df661d316a69|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cmHg|[?]|1|s/h|WHITE MATTER TISSUE|ATOMIC ABSORPTION SPECTROMETRY|||1|4|Visit_4|65|7|FOLLOW-UP|2021-03-01|65
e|IS|cec9e0ce-4d09-470c-9c26-df661d316a69|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ng/dL|[?]|1|nkat/g Hb|BILE|SLOAN LETTER EYE CHART 1.25%|||1|5|Visit_5|90|4|TREATMENT|2021-03-26|90
e|IS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|rpm|[?]|1|mL/cage/wk|DIALYSIS FLUID, PERITONEAL|OBSERVATION|||1|1|Visit_1|10|2|FOLLOW-UP|2021-01-17|10
e|IS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PA|[?]|1|log10 CFU/mL|LYMPH|RADIOGRAPHY|||1|2|Visit_2|25|3|TREATMENT|2021-02-01|25
e|IS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|PACK|[?]|1|mg/kg|INFRANATANT, PLASMA|ANTIMICROBIAL COMBINATION TESTING|||1|3|Visit_3|40|2|TREATMENT|2021-02-16|40
e|IS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|PATCH|[?]|1|kUSP|RETICULOCYTES|PET/CT SCAN WITHOUT CONTRAST|||1|4|Visit_4|65|7|FOLLOW-UP|2021-03-13|65
e|IS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/mL/h|[?]|1|mm3/mm2/year|GASTRIC FLUID|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||1|5|Visit_5|90|7|TREATMENT|2021-04-07|90
e|IS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ms2|[?]|1|U/m2|ERYTHROCYTES|CLINICAL EVALUATION|||1|1|Visit_1|10|1|TREATMENT|2020-07-07|10
e|IS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|beats/min|[?]|1|Farad|MIXED VENOUS BLOOD|THERMAL IONIZATION MASS SPECTROMETRY|||1|2|Visit_2|25|5|WASHOUT|2020-07-22|25
e|IS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/cage/day|[?]|1|ag|TRANSUDATE|INTRAVASCULAR ULTRASOUND|Y||1|3|Visit_3|40|5|TREATMENT|2020-08-06|40
e|IS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|km/h|[?]|1|U|ERYTHROCYTES|COLORIMETRY||Y|1|4|Visit_4|65|3|TREATMENT|2020-08-31|65
e|IS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Gy|[?]|1|/min|AMNIOTIC FLUID|DIFFUSION TENSOR MRI|||1|5|Visit_5|90|3|TREATMENT|2020-09-25|90
e|IS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mEq/uL|[?]|1|ngEq/L|LOCHIA|CONTRAST ENHANCED X-RAY|||1|1|Visit_1|10|7|TREATMENT|2020-07-12|10
e|IS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/kg/min|[?]|1|10^9/L|DISCHARGE|IHC|Y|Y|1|2|Visit_2|25|3|TREATMENT|2020-07-27|25
e|IS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/g/day|[?]|1|cy/cm|INTERSTITIAL FLUID|IODINE STAIN||Y|1|3|Visit_3|40|3|TREATMENT|2020-08-11|40
e|IS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BP|[?]|1|umol/dL|CALCULUS|PERIODIC ACID SCHIFF STAIN||Y|1|4|Visit_4|65|5|TREATMENT|2020-09-05|65
e|IS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mEq/L|[?]|1|VIRTUAL PIXEL|EPIDERMAL TISSUE|ENZYMATIC SPECTROPHOTOMETRY|||1|5|Visit_5|90|4|TREATMENT|2020-09-30|90
e|IS|7ff27a70-0472-4cc1-b057-6b161ab29568|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mkat|[?]|1|oz eq|SMEGMA|KARYOTYPING||Y|1|1|Visit_1|10|3|WASHOUT|2020-11-19|10
e|IS|7ff27a70-0472-4cc1-b057-6b161ab29568|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 U|[?]|1|CFU/g|ADIPOSE TISSUE|FLUOROSCOPY||Y|1|2|Visit_2|25|2|SCREENING|2020-12-04|25
e|IS|7ff27a70-0472-4cc1-b057-6b161ab29568|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|CCID 50/mL|[?]|1|MBP|BONE MARROW|MALDI|||1|3|Visit_3|40|3|TREATMENT|2020-12-19|40
e|IS|7ff27a70-0472-4cc1-b057-6b161ab29568|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^6 IU/mL|[?]|1|mg/m2/day|PERSPIRATION|RAJI CELL RIA|||1|4|Visit_4|65|1|SCREENING|2021-01-13|65
e|IS|7ff27a70-0472-4cc1-b057-6b161ab29568|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|deg/s|[?]|1|umol/h/mmol|HAIR FOLLICLE|DIGITAL PCR||Y|1|5|Visit_5|90|5|FOLLOW-UP|2021-02-07|90
e|IS|40529b01-9a80-4ada-a8df-96eec0e65043|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kBq/uL|[?]|1|mg/m2|CARDIAC MUSCLE TISSUE|DARK FIELD MICROSCOPY|Y||1|1|Visit_1|10|7|WASHOUT|2020-06-17|10
e|IS|40529b01-9a80-4ada-a8df-96eec0e65043|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Ci|[?]|1|/100 WBC|LOCHIA|HEMAGGLUTINATION ASSAY|||1|2|Visit_2|25|4|TREATMENT|2020-07-02|25
e|IS|40529b01-9a80-4ada-a8df-96eec0e65043|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|DPM|[?]|1|mmAL|SKELETAL MUSCLE TISSUE|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y||1|3|Visit_3|40|7|TREATMENT|2020-07-17|40
e|IS|40529b01-9a80-4ada-a8df-96eec0e65043|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|oz|[?]|1|mL/animal|SOFT TISSUE|KNEMOMETRY|||1|4|Visit_4|65|7|SCREENING|2020-08-11|65
e|IS|40529b01-9a80-4ada-a8df-96eec0e65043|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/L|[?]|1|nkat/g Hb|PLATELET POOR PLASMA|IMMUNOCHROMATOGRAPHY|||1|5|Visit_5|90|7|WASHOUT|2020-09-05|90
e|IS|f3e22efc-0948-4c6e-9173-8e284d342d33|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|m2|[?]|1|pg/L|STRIATED MUSCLE TISSUE|EIA|Y||1|1|Visit_1|10|6|SCREENING|2020-12-06|10
e|IS|f3e22efc-0948-4c6e-9173-8e284d342d33|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PFU/mL|[?]|1|10^6 IU/mL|PLASMA|DC SHEATH FLOW|||1|2|Visit_2|25|5|FOLLOW-UP|2020-12-21|25
e|IS|f3e22efc-0948-4c6e-9173-8e284d342d33|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PFU|[?]|1|MdFI|PERSPIRATION|SCANNING ELECTRON MICROSCOPY|Y||1|3|Visit_3|40|5|TREATMENT|2021-01-05|40
e|IS|f3e22efc-0948-4c6e-9173-8e284d342d33|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|um2|[?]|1|ugEq/L|VENOUS PLASMA|DIFFUSION TENSOR MRI|Y||1|4|Visit_4|65|2|TREATMENT|2021-01-30|65
e|IS|f3e22efc-0948-4c6e-9173-8e284d342d33|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|nsec|DISCHARGE|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y|1|5|Visit_5|90|1|TREATMENT|2021-02-24|90
e|IS|919eb5b4-a3df-41c6-86f7-c78501bb4335|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/g/min|[?]|1|mL/kg/day|PROSTATIC FLUID|ATOMIC ABSORPTION SPECTROMETRY|||1|1|Visit_1|10|6|TREATMENT|2020-10-01|10
e|IS|919eb5b4-a3df-41c6-86f7-c78501bb4335|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/mg|[?]|1|OD Unit|MECONIUM|KARYOTYPING|||1|2|Visit_2|25|2|TREATMENT|2020-10-16|25
e|IS|919eb5b4-a3df-41c6-86f7-c78501bb4335|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nkat/g Hb|[?]|1|U/g/day|TRANSUDATE|ELECTROMYOGRAPHY|||1|3|Visit_3|40|2|TREATMENT|2020-10-31|40
e|IS|919eb5b4-a3df-41c6-86f7-c78501bb4335|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|IU/kg/h|[?]|1|nmol/mol|ARTERIAL BLOOD|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||Y|1|4|Visit_4|65|6|SCREENING|2020-11-25|65
e|IS|919eb5b4-a3df-41c6-86f7-c78501bb4335|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PACK|[?]|1|mg/L FEU|PLASMA ULTRAFILTRATE|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y||1|5|Visit_5|90|3|TREATMENT|2020-12-20|90
e|IS|f918d6e0-6fc2-4303-b323-521c5d531773|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uCi/kg|[?]|1|SFC/10^6 PBMC|BLOOD|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||1|1|Visit_1|10|1|SCREENING|2020-07-31|10
e|IS|f918d6e0-6fc2-4303-b323-521c5d531773|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mm3/mm2/year|[?]|1|%(w/w)|VITREOUS HUMOR|PHYSICAL EXAMINATION||Y|1|2|Visit_2|25|1|FOLLOW-UP|2020-08-15|25
e|IS|f918d6e0-6fc2-4303-b323-521c5d531773|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg2/dL2|[?]|1|deg2|MIXED VENOUS BLOOD|LIGHT MICROSCOPY|||1|3|Visit_3|40|5|WASHOUT|2020-08-30|40
e|IS|f918d6e0-6fc2-4303-b323-521c5d531773|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mph|[?]|1|10^6 RNA copies/mL|SMOOTH MUSCLE TISSUE|GC/MS-CI|||1|4|Visit_4|65|5|TREATMENT|2020-09-24|65
e|IS|f918d6e0-6fc2-4303-b323-521c5d531773|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 PFU|[?]|1|ug/L|ABSCESS FLUID|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|Y|1|5|Visit_5|90|1|TREATMENT|2020-10-19|90
e|IS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cal|[?]|1|10^7 TCID 50/dose|SUPERNATANT, SERUM OR PLASMA|TEST STRIP|Y||1|1|Visit_1|10|2|SCREENING|2020-11-24|10
e|IS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U/mL|[?]|1|gpELISA unit/mL|SYNOVIAL FLUID|HEMOCYTOMETRY|Y||1|2|Visit_2|25|2|TREATMENT|2020-12-09|25
e|IS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g/animal/day|[?]|1|GPS U|INFRANATANT, PLASMA|LINE PROBE ASSAY||Y|1|3|Visit_3|40|7|TREATMENT|2020-12-24|40
e|IS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mol|[?]|1|mol/L|CIRCULATING TUMOR CELL|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||1|4|Visit_4|65|4|WASHOUT|2021-01-18|65
e|IS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|copies/ug|[?]|1|10^3 DNA copies/mL|TISSUE|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||Y|1|5|Visit_5|90|2|SCREENING|2021-02-12|90
e|IS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|days/month|[?]|1|nmol|SUPERNATANT, CEREBROSPINAL FLUID|POLYGRAPHY|Y||1|1|Visit_1|10|6|FOLLOW-UP|2020-06-21|10
e|IS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/g/min|[?]|1|mmol|MUCUS|REFRACTOMETRY|||1|2|Visit_2|25|1|TREATMENT|2020-07-06|25
e|IS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/mol|[?]|1|genEq/mL|MIXED VENOUS BLOOD|REFLECTANCE SPECTROSCOPY|Y||1|3|Visit_3|40|3|FOLLOW-UP|2020-07-21|40
e|IS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^7 TCID 50/dose|[?]|1|STEPS|PERSPIRATION|ENZYMATIC ULTRACENTRIFUGATION|||1|4|Visit_4|65|7|SCREENING|2020-08-15|65
e|IS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|%(w/v)|[?]|1|g/animal/day|BONE|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||1|5|Visit_5|90|5|WASHOUT|2020-09-09|90
e|IS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Absorbance U|[?]|1|mkat|URINE SEDIMENT|CONTRAST ENHANCED X-RAY|||1|1|Visit_1|10|6|TREATMENT|2020-07-19|10
e|IS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug/g/day|[?]|1|ohm|ENDOTRACHEAL FLUID|FLUORESCENT SPOT TEST|||1|2|Visit_2|25|2|TREATMENT|2020-08-03|25
e|IS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mU/L|[?]|1|JAR|SEBUM|GC/MS||Y|1|3|Visit_3|40|2|TREATMENT|2020-08-18|40
e|IS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ukat/10^12 RBC|[?]|1|nmol/L|ARTERIAL BLOOD|CONTRAST ENHANCED SPIRAL CT SCAN|||1|4|Visit_4|65|5|TREATMENT|2020-09-12|65
e|IS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MET*min|[?]|1|IU/g|PLASMA ULTRAFILTRATE|AUTOREFRACTION|||1|5|Visit_5|90|2|TREATMENT|2020-10-07|90
e|IS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|CARTRIDGE|[?]|1|gpELISA unit/mL|INFRANATANT, SERUM|DXA SCAN|||1|1|Visit_1|10|6|TREATMENT|2020-11-27|10
e|IS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IMPLANT|[?]|1|g/kg/day|ARTERIAL CORD BLOOD|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|2|Visit_2|25|4|SCREENING|2020-12-12|25
e|IS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|bel|[?]|1|uV*sec|BONE MARROW MONONUCLEAR CELL|RADIOIMMUNOPRECIPITATION ASSAY||Y|1|3|Visit_3|40|6|TREATMENT|2020-12-27|40
e|IS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6/L|[?]|1|dpm/0.5 mL|AQUEOUS HUMOR|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|1|4|Visit_4|65|3|TREATMENT|2021-01-21|65
e|IS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|DPM|[?]|1|ug/dose|VENOUS BLOOD|HEMOCYTOMETRY||Y|1|5|Visit_5|90|3|TREATMENT|2021-02-15|90
e|IS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mgEq|[?]|1|BISCUIT|GASTRIC CONTENTS|PERCUSSION|||1|1|Visit_1|10|4|FOLLOW-UP|2020-12-09|10
e|IS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|uL/kg/day|[?]|1|ug/L DDU|CEREBROSPINAL FLUID|NON-CONTACT SPECULAR MICROSCOPY||Y|1|2|Visit_2|25|3|WASHOUT|2020-12-24|25
e|IS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ohm|[?]|1|U/cL|BREAST MILK|FLAME PHOTOMETRY|Y|Y|1|3|Visit_3|40|2|SCREENING|2021-01-08|40
e|IS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/m2/day|[?]|1|mgEq|HAIR FOLLICLE|CELL OF ORIGIN ASSAY|||1|4|Visit_4|65|4|SCREENING|2021-02-02|65
e|IS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BAG|[?]|1|JDF Unit|PLATELET RICH PLASMA|SCANNING ELECTRON MICROSCOPY|Y||1|5|Visit_5|90|6|FOLLOW-UP|2021-02-27|90
e|IS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/g/min|[?]|1|in2|CERUMEN|U-HPLC/MS/MS|||1|1|Visit_1|10|2|TREATMENT|2020-07-06|10
e|IS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|RNA copies/mL|[?]|1|P|SKELETAL MUSCLE TISSUE|CALCOFLUOR WHITE STAIN||Y|1|2|Visit_2|25|6|TREATMENT|2020-07-21|25
e|IS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/VF|[?]|1|mg/kg/day|HAIR|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|3|Visit_3|40|5|TREATMENT|2020-08-05|40
e|IS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^7/L|[?]|1|mol|PROSTATIC FLUID|CLOT DETECTION|||1|4|Visit_4|65|4|TREATMENT|2020-08-30|65
e|IS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|tuberculin unit/mL|[?]|1|uCi/L|NAIL|SNELLEN EYE CHART|Y||1|5|Visit_5|90|4|TREATMENT|2020-09-24|90
e|IS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|vg/dose|[?]|1|gtt|SMOOTH MUSCLE TISSUE|HEMAGGLUTINATION ASSAY|||1|1|Visit_1|10|7|WASHOUT|2020-12-13|10
e|IS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/g|[?]|1|BOTTLE|SUPERNATANT, CEREBROSPINAL FLUID|ENZYMATIC COLORIMETRY||Y|1|2|Visit_2|25|3|TREATMENT|2020-12-28|25
e|IS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mg/m2/day|[?]|1|BAU/mL|REFLEX TEAR|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||1|3|Visit_3|40|7|WASHOUT|2021-01-12|40
e|IS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|v/v|[?]|1|CFU/g|LYSATE|LIGHT SCATTERING SPECTROSCOPY|Y||1|4|Visit_4|65|1|WASHOUT|2021-02-06|65
e|IS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cm H2O|[?]|1|anti-Xa IU|MENSTRUAL BLOOD|ECHOCARDIOGRAPHY|||1|5|Visit_5|90|3|FOLLOW-UP|2021-03-03|90
e|IS|324a2c67-4802-4806-aff2-04fb9c7394d4|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/mL/min|[?]|1|uCi|CERVICOVAGINAL SECRETION|LIGHT MICROSCOPY|Y||1|1|Visit_1|10|3|SCREENING|2020-05-27|10
e|IS|324a2c67-4802-4806-aff2-04fb9c7394d4|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|BAU/mL|[?]|1|CCID 50/dose|SKELETAL MUSCLE TISSUE|SANGER SEQUENCING|Y||1|2|Visit_2|25|3|FOLLOW-UP|2020-06-11|25
e|IS|324a2c67-4802-4806-aff2-04fb9c7394d4|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|psec|[?]|1|atm|SUPERNATANT, PLEURAL FLUID|GC/FID||Y|1|3|Visit_3|40|6|TREATMENT|2020-06-26|40
e|IS|324a2c67-4802-4806-aff2-04fb9c7394d4|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|bel|[?]|1|DNA copies/mL|BLOOD|IMPULSE OSCILLOMETRY|||1|4|Visit_4|65|1|SCREENING|2020-07-21|65
e|IS|324a2c67-4802-4806-aff2-04fb9c7394d4|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|KALLIKREIN INHIBITOR UNIT|[?]|1|dpm/mL|ENDOMETRIAL TISSUE|TEST STRIP|||1|5|Visit_5|90|6|TREATMENT|2020-08-15|90
e|IS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 IU/mL|[?]|1|Bq/kg|FLUID|MACRO BROTH DILUTION||Y|1|1|Visit_1|10|6|TREATMENT|2020-12-19|10
e|IS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|gtt|[?]|1|mmol/kg|GASTRIC CONTENTS|PERIPHERAL ANGIOGRAPHY|||1|2|Visit_2|25|7|FOLLOW-UP|2021-01-03|25
e|IS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 CFU|[?]|1|psi|DISCHARGE|CINEANGIOGRAPHY||Y|1|3|Visit_3|40|4|WASHOUT|2021-01-18|40
e|IS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|BU|[?]|1|DIP|SOFT TISSUE|VIRUS PLAQUE ASSAY|Y||1|4|Visit_4|65|5|TREATMENT|2021-02-12|65
e|IS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cm|[?]|1|TCID 50/dose|SEMEN|HIGH RESOLUTION MELT ANALYSIS|Y||1|5|Visit_5|90|5|TREATMENT|2021-03-09|90
e|IS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mm|[?]|1|kUSP|NAIL|RADIOIMMUNOPRECIPITATION ASSAY|Y|Y|1|1|Visit_1|10|3|TREATMENT|2020-08-24|10
e|IS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|/wk|EXPIRED AIR|MICROSCOPY|Y||1|2|Visit_2|25|5|WASHOUT|2020-09-08|25
e|IS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|L/h/m2|[?]|1|mV*min|LYMPH|GC/FID|||1|3|Visit_3|40|4|TREATMENT|2020-09-23|40
e|IS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|SBE/mL|[?]|1|mCi/L|VENOUS PLASMA|MANUAL CLOT DETECTION|||1|4|Visit_4|65|5|WASHOUT|2020-10-18|65
e|IS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|log10 TCID 50/dose|[?]|1|mEq/day|PLATELET RICH PLASMA|IMMUNOASSAY|||1|5|Visit_5|90|2|TREATMENT|2020-11-12|90
e|IS|911dc297-91cb-42b1-8a26-18f6c83c32a6|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pkat|[?]|1|cm|ERYTHROCYTES|ANTIBIOTIC AGAR SCREEN||Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-12-01|10
e|IS|911dc297-91cb-42b1-8a26-18f6c83c32a6|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/animal|[?]|1|10^6 IU/mL|PLATELET POOR PLASMA|SCANNING ELECTRON MICROSCOPY|Y||1|2|Visit_2|25|4|FOLLOW-UP|2020-12-16|25
e|IS|911dc297-91cb-42b1-8a26-18f6c83c32a6|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|oz eq|[?]|1|ugEq/L|SUPERNATANT, CEREBROSPINAL FLUID|KLEIHAUER-BETKE|||1|3|Visit_3|40|2|TREATMENT|2020-12-31|40
e|IS|911dc297-91cb-42b1-8a26-18f6c83c32a6|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|U/mL|[?]|1|DAYS|ALVEOLAR AIR|BALLPOINT PEN TECHNIQUE|Y||1|4|Visit_4|65|7|TREATMENT|2021-01-25|65
e|IS|911dc297-91cb-42b1-8a26-18f6c83c32a6|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kV|[?]|1|oz|SUPERNATANT, SERUM OR PLASMA|PLETHYSMOGRAPHY|||1|5|Visit_5|90|3|SCREENING|2021-02-19|90
e|IS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/s/m2|[?]|1|U.CARR|WHITE MATTER TISSUE|AGAR DILUTION|||1|1|Visit_1|10|7|FOLLOW-UP|2020-11-25|10
e|IS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|K|[?]|1|nmol/L/h|SMEGMA|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||1|2|Visit_2|25|4|SCREENING|2020-12-10|25
e|IS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^3 organisms/mL|[?]|1|10^6/g|FLUID|HPLC-FL|Y||1|3|Visit_3|40|1|TREATMENT|2020-12-25|40
e|IS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|BAG|PLASMA|JAEGER EYE CHART|Y||1|4|Visit_4|65|7|TREATMENT|2021-01-19|65
e|IS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|EID 50/dose|[?]|1|mL/min/mmHg|STRIATED MUSCLE TISSUE|HPLC/MS|Y||1|5|Visit_5|90|6|FOLLOW-UP|2021-02-13|90
e|IS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kV|[?]|1|grain|HAIR|LIQUID SCINTILLATION COUNTING||Y|1|1|Visit_1|10|1|WASHOUT|2020-08-15|10
e|IS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|U/g/h|[?]|1|10^7 CFU/mL|EPIDERMAL TISSUE|CONFOCAL MICROSCOPY|Y||1|2|Visit_2|25|2|TREATMENT|2020-08-30|25
e|IS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|amp|BONE MARROW MONONUCLEAR CELL|MANUAL CLOT DETECTION|||1|3|Visit_3|40|3|TREATMENT|2020-09-14|40
e|IS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/5x10^4 WBC|[?]|1|mg/kg/day|SEMEN|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y||1|4|Visit_4|65|3|TREATMENT|2020-10-09|65
e|IS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|FFU|[?]|1|uL/dose|SUPERNATANT, SERUM|LIGHT MICROSCOPY|||1|5|Visit_5|90|4|TREATMENT|2020-11-03|90
e|IS|7eb97152-173c-4923-8604-5dad3140cc25|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|umol/L/min|[?]|1|CCID 50/dose|MIXED VENOUS BLOOD|LC/MS/MS|||1|1|Visit_1|10|5|SCREENING|2020-09-05|10
e|IS|7eb97152-173c-4923-8604-5dad3140cc25|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/kg|[?]|1|mol/mol|SPERMATOZOON|LIGHT MICROSCOPY||Y|1|2|Visit_2|25|5|TREATMENT|2020-09-20|25
e|IS|7eb97152-173c-4923-8604-5dad3140cc25|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg|[?]|1|DAgU/mL|TUMOR TISSUE|CONTRAST ENHANCED SPIRAL CT SCAN|Y|Y|1|3|Visit_3|40|5|FOLLOW-UP|2020-10-05|40
e|IS|7eb97152-173c-4923-8604-5dad3140cc25|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SFC/10^6 PBMC|[?]|1|cmHg|PERIPHERAL BLOOD MONONUCLEAR CELL|PULMONARY ANGIOGRAPHY|Y||1|4|Visit_4|65|4|TREATMENT|2020-10-30|65
e|IS|7eb97152-173c-4923-8604-5dad3140cc25|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|MdFI|[?]|1|MBq/uL|URINE|DIGITAL PCR|Y||1|5|Visit_5|90|6|TREATMENT|2020-11-24|90
e|IS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|pmol/dL|[?]|1|V/sec|STRIATED MUSCLE TISSUE|LEAD CITRATE STAIN||Y|1|1|Visit_1|10|2|TREATMENT|2020-08-08|10
e|IS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|U/m2/h|[?]|1|mMU/mL|ABSCESS FLUID|MULTIPLE BREATH WASHOUT|||1|2|Visit_2|25|3|WASHOUT|2020-08-23|25
e|IS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|pmol/dL|[?]|1|HOMEOPATHIC DILUTION|SPUTUM|MRI|Y||1|3|Visit_3|40|2|TREATMENT|2020-09-07|40
e|IS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|dpm/0.5 mL|[?]|1|EIA unit|CARDIAC MUSCLE TISSUE|CELL BASED BIOASSAY|||1|4|Visit_4|65|1|SCREENING|2020-10-02|65
e|IS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|umol/mg/min|[?]|1|MAC50|PLEURAL FLUID|MEDIASTINOSCOPY||Y|1|5|Visit_5|90|7|TREATMENT|2020-10-27|90
e|IS|96f68979-6869-403b-a8bd-78c8f965f98a|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/g/day|[?]|1|CAPLET|ARTERIALIZED CAPILLARY BLOOD|LINE PROBE ASSAY||Y|1|1|Visit_1|10|7|WASHOUT|2020-05-26|10
e|IS|96f68979-6869-403b-a8bd-78c8f965f98a|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Bq/g|[?]|1|BOWL|SERUM OR PLASMA|STRESS ECHOCARDIOGRAPHY|||1|2|Visit_2|25|2|FOLLOW-UP|2020-06-10|25
e|IS|96f68979-6869-403b-a8bd-78c8f965f98a|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ng/L|[?]|1|10^9/dose|MONOCYTE|DARK FIELD MICROSCOPY||Y|1|3|Visit_3|40|1|TREATMENT|2020-06-25|40
e|IS|96f68979-6869-403b-a8bd-78c8f965f98a|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uEq/L|[?]|1|U.CARR|EMESIS|NEPHELOMETRY|Y||1|4|Visit_4|65|3|TREATMENT|2020-07-20|65
e|IS|96f68979-6869-403b-a8bd-78c8f965f98a|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Coulomb|[?]|1|COAT|EXHALED BREATH CONDENSATE|MICROBIAL CULTURE|Y||1|5|Visit_5|90|4|TREATMENT|2020-08-14|90
e|IS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|APS U|[?]|1|FFU|EMESIS|ELISPOT|||1|1|Visit_1|10|7|SCREENING|2020-10-16|10
e|IS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|NFIU|[?]|1|MET|URINE|NEXT GENERATION TARGETED SEQUENCING||Y|1|2|Visit_2|25|5|WASHOUT|2020-10-31|25
e|IS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|DPM|[?]|1|SCOOPFUL|BONE MARROW|FLUORESCENCE ANGIOGRAPHY|||1|3|Visit_3|40|5|FOLLOW-UP|2020-11-15|40
e|IS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|L/min|[?]|1|mmol/min/kPa|RETICULOCYTES|MASS SPECTROMETRY|||1|4|Visit_4|65|6|TREATMENT|2020-12-10|65
e|IS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|umol|[?]|1|nCi|PROSTATIC FLUID|SCINTIGRAPHY|||1|5|Visit_5|90|3|TREATMENT|2021-01-04|90
e|IS|d62dc655-8865-4592-af0b-744524d9a24c|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BLOCKS|[?]|1|Enzyme U/L|GASTRIC CONTENTS|CLAUSS METHOD||Y|1|1|Visit_1|10|5|TREATMENT|2020-09-29|10
e|IS|d62dc655-8865-4592-af0b-744524d9a24c|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/2500 WBC|[?]|1|Linear ft*LB|INTERSTITIAL FLUID|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y|1|2|Visit_2|25|5|TREATMENT|2020-10-14|25
e|IS|d62dc655-8865-4592-af0b-744524d9a24c|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|steps/min|[?]|1|mmAL|BONE|EPSILOMETER|||1|3|Visit_3|40|4|TREATMENT|2020-10-29|40
e|IS|d62dc655-8865-4592-af0b-744524d9a24c|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cal|[?]|1|RNA copies/mL|GASTRIC FLUID|SEQUENCING|||1|4|Visit_4|65|4|TREATMENT|2020-11-23|65
e|IS|d62dc655-8865-4592-af0b-744524d9a24c|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^3 organisms|[?]|1|cmHg|TISSUE|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||1|5|Visit_5|90|3|TREATMENT|2020-12-18|90
e|IS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|GLOBULE|[?]|1|ug/L DDU|MECONIUM|MOUSE PROTECTION ASSAY|||1|1|Visit_1|10|6|TREATMENT|2021-01-08|10
e|IS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|in2|[?]|1|10^6 IU/mL|ISOLATE|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||1|2|Visit_2|25|6|TREATMENT|2021-01-23|25
e|IS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/mmHg|[?]|1|BP|PLASMA ULTRAFILTRATE|QUANTITATIVE CORONARY ANGIOGRAPHY|Y||1|3|Visit_3|40|2|WASHOUT|2021-02-07|40
e|IS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|EP U|[?]|1|TCID 50/dose|LOCHIA|PALPATION|||1|4|Visit_4|65|5|WASHOUT|2021-03-04|65
e|IS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|%(v/v)|[?]|1|CYLINDER|ISOLATE|MICROBIAL CONCENTRATION|||1|5|Visit_5|90|6|SCREENING|2021-03-29|90
e|IS|8005bd56-3bd6-477a-a466-b9a3bd189770|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|log10 CFU/mL|[?]|1|mmol/g|EMOTIONAL TEAR|MIGET|||1|1|Visit_1|10|2|TREATMENT|2020-12-23|10
e|IS|8005bd56-3bd6-477a-a466-b9a3bd189770|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|SBE/mL|[?]|1|mkat|BONE MARROW MONONUCLEAR CELL|DYNAMIC CONTRAST ENHANCED MRI||Y|1|2|Visit_2|25|3|TREATMENT|2021-01-07|25
e|IS|8005bd56-3bd6-477a-a466-b9a3bd189770|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|PFU/mL|[?]|1|PHERESIS UNIT|ATHEROSCLEROTIC PLAQUE|ANALYTICAL ULTRACENTRIFUGATION|||1|3|Visit_3|40|5|WASHOUT|2021-01-22|40
e|IS|8005bd56-3bd6-477a-a466-b9a3bd189770|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/kg|[?]|1|/day|PLATELET POOR PLASMA|HEMATOXYLIN AND EOSIN STAIN|||1|4|Visit_4|65|5|TREATMENT|2021-02-16|65
e|IS|8005bd56-3bd6-477a-a466-b9a3bd189770|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/500 WBC|[?]|1|g/m2|DISCHARGE|FUNCTIONAL MRI|||1|5|Visit_5|90|2|SCREENING|2021-03-13|90
e|IS|078ea33d-4114-4320-9116-740b8385a94e|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mEq/kg|[?]|1|WEEKS|ALVEOLAR AIR|PERFUSION MRI|||1|1|Visit_1|10|5|SCREENING|2020-07-26|10
e|IS|078ea33d-4114-4320-9116-740b8385a94e|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|keV|[?]|1|nmol/mol|PERSPIRATION|GRAM STAIN|Y||1|2|Visit_2|25|1|SCREENING|2020-08-10|25
e|IS|078ea33d-4114-4320-9116-740b8385a94e|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|CAN|[?]|1|ft3|EPIDERMAL TISSUE|CONGO RED STAIN|Y||1|3|Visit_3|40|1|TREATMENT|2020-08-25|40
e|IS|078ea33d-4114-4320-9116-740b8385a94e|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|APL U|[?]|1|L/h/m2|ATHEROSCLEROTIC PLAQUE|SLOAN LETTER EYE CHART 100%|||1|4|Visit_4|65|4|TREATMENT|2020-09-19|65
e|IS|078ea33d-4114-4320-9116-740b8385a94e|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|pg|[?]|1|%/s|PERSPIRATION|RADIOIMMUNOPRECIPITATION ASSAY|||1|5|Visit_5|90|1|FOLLOW-UP|2020-10-14|90
e|IS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|log10 TCID 50/uL|[?]|1|mg/day|BONE MARROW MONONUCLEAR CELL|HEMATOXYLIN AND EOSIN STAIN|||1|1|Visit_1|10|7|TREATMENT|2020-06-03|10
e|IS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kIU|[?]|1|mol/mol|CALCULUS|IMPULSE OSCILLOMETRY|||1|2|Visit_2|25|5|WASHOUT|2020-06-18|25
e|IS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|nCi|[?]|1|rpm|SKIN TISSUE|CONTACT SPECULAR MICROSCOPY|||1|3|Visit_3|40|1|SCREENING|2020-07-03|40
e|IS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL|[?]|1|10^12/L|RETICULOCYTES|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y||1|4|Visit_4|65|3|TREATMENT|2020-07-28|65
e|IS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|CCID 50/dose|[?]|1|mm3/mm2/year|NAIL|PANENDOSCOPY|||1|5|Visit_5|90|4|FOLLOW-UP|2020-08-22|90
e|IS|c5f292ad-1729-402b-820f-83ecd29ba00d|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^9 organisms/mL|[?]|1|Ci/L|DIALYSIS FLUID|SLOAN LETTER EYE CHART 1.25%||Y|1|1|Visit_1|10|5|FOLLOW-UP|2020-06-08|10
e|IS|c5f292ad-1729-402b-820f-83ecd29ba00d|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/dL|[?]|1|BU|AMNIOTIC FLUID|MODIFIED ACID FAST STAIN|||1|2|Visit_2|25|1|SCREENING|2020-06-23|25
e|IS|c5f292ad-1729-402b-820f-83ecd29ba00d|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|keV|[?]|1|MONTHS|DIALYSIS FLUID|DOUBLE IMMUNODIFFUSION|||1|3|Visit_3|40|6|TREATMENT|2020-07-08|40
e|IS|c5f292ad-1729-402b-820f-83ecd29ba00d|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Hounsfield Unit|[?]|1|ug/kg/min|LYSATE|CALCOFLUOR WHITE STAIN||Y|1|4|Visit_4|65|5|SCREENING|2020-08-02|65
e|IS|c5f292ad-1729-402b-820f-83ecd29ba00d|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/L/h|[?]|1|mg/animal|ABSCESS FLUID|NON-CONTACT SPECULAR MICROSCOPY|||1|5|Visit_5|90|3|TREATMENT|2020-08-27|90
e|IS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|TRACE|[?]|1|s^-1(%O2)^-1|ADIPOSE TISSUE|ALCIAN BLUE STAIN||Y|1|1|Visit_1|10|4|TREATMENT|2020-06-27|10
e|IS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ka_u/dL|[?]|1|km/h|ARTERIAL CORD BLOOD|MRI WITHOUT CONTRAST|||1|2|Visit_2|25|6|WASHOUT|2020-07-12|25
e|IS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|BOLUS|[?]|1|mph|WHITE MATTER TISSUE|SPECULAR MICROSCOPY|||1|3|Visit_3|40|6|WASHOUT|2020-07-27|40
e|IS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 copies/mL|[?]|1|RFU|URINE|ATOMIC ABSORPTION SPECTROMETRY|||1|4|Visit_4|65|2|FOLLOW-UP|2020-08-21|65
e|IS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|dL|[?]|1|PUFF|MECONIUM|DC SHEATH FLOW|||1|5|Visit_5|90|7|WASHOUT|2020-09-15|90
e|IS|7f95b9c0-3b77-4c60-8890-ecc955f97122|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Ci/kg|[?]|1|vg/kg|CAPILLARY BLOOD|LEAD CITRATE STAIN||Y|1|1|Visit_1|10|2|WASHOUT|2020-09-25|10
e|IS|7f95b9c0-3b77-4c60-8890-ecc955f97122|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 DNA copies/mL|[?]|1|mg/h|CORD SERUM|QUANTITATIVE ULTRASOUND||Y|1|2|Visit_2|25|6|TREATMENT|2020-10-10|25
e|IS|7f95b9c0-3b77-4c60-8890-ecc955f97122|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|IU/kg|[?]|1|mm/sec|MUCUS|DXA SCAN|||1|3|Visit_3|40|1|WASHOUT|2020-10-25|40
e|IS|7f95b9c0-3b77-4c60-8890-ecc955f97122|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/cm2|[?]|1|10^6 CFU|SERUM OR PLASMA|MRI WITHOUT CONTRAST||Y|1|4|Visit_4|65|2|TREATMENT|2020-11-19|65
e|IS|7f95b9c0-3b77-4c60-8890-ecc955f97122|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mEq/dL|[?]|1|nmol/mol|REFLEX TEAR|NEURAMINIDASE INHIBITION ASSAY|||1|5|Visit_5|90|1|FOLLOW-UP|2020-12-14|90
e|IS|2be43c56-83f3-4148-9cb1-97c6d191d20e|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmH2O*s/mL|[?]|1|Ci|LAVAGE FLUID|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|2|TREATMENT|2020-10-03|10
e|IS|2be43c56-83f3-4148-9cb1-97c6d191d20e|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|keV|[?]|1|U/m2/min|PUS|ANTIMICROBIAL COMBINATION TESTING||Y|1|2|Visit_2|25|7|SCREENING|2020-10-18|25
e|IS|2be43c56-83f3-4148-9cb1-97c6d191d20e|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/kg/min|[?]|1|DROP|CERVICOVAGINAL SECRETION|MS/MS|Y||1|3|Visit_3|40|7|WASHOUT|2020-11-02|40
e|IS|2be43c56-83f3-4148-9cb1-97c6d191d20e|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|min|[?]|1|ohm|HAIR FOLLICLE|ORCHIDOMETERY|||1|4|Visit_4|65|3|SCREENING|2020-11-27|65
e|IS|2be43c56-83f3-4148-9cb1-97c6d191d20e|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ug/m2|[?]|1|mL/dL|PLEURAL TISSUE|COLORIMETRY|||1|5|Visit_5|90|3|SCREENING|2020-12-22|90
e|IS|e27e0325-5fbe-46c0-8264-982d83124203|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|fmol/L|[?]|1|ug/m2|DIALYSIS FLUID|CALCOFLUOR WHITE STAIN|||1|1|Visit_1|10|1|TREATMENT|2020-07-07|10
e|IS|e27e0325-5fbe-46c0-8264-982d83124203|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|amu|[?]|1|kPa|TUMOR TISSUE|TELLER ACUITY CARDS|Y||1|2|Visit_2|25|7|TREATMENT|2020-07-22|25
e|IS|e27e0325-5fbe-46c0-8264-982d83124203|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^12 IU/L|[?]|1|ug/L/h|MECONIUM|TRYPAN BLUE STAIN|||1|3|Visit_3|40|1|SCREENING|2020-08-06|40
e|IS|e27e0325-5fbe-46c0-8264-982d83124203|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6/Ejaculate U|[?]|1|MPL U|PERITONEAL FLUID|INCISION-INDUCED BLEEDING METHOD|||1|4|Visit_4|65|2|TREATMENT|2020-08-31|65
e|IS|e27e0325-5fbe-46c0-8264-982d83124203|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mkat|[?]|1|Farad|PLASMA|MICRODENSITOMETRY||Y|1|5|Visit_5|90|2|TREATMENT|2020-09-25|90
e|IS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|BAU/mL|[?]|1|m2|PLEURAL TISSUE|DARK FIELD MICROSCOPY|||1|1|Visit_1|10|3|TREATMENT|2020-12-19|10
e|IS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mMU/mL|[?]|1|mmHg*min/L|LYMPH|ELISA|Y||1|2|Visit_2|25|7|TREATMENT|2021-01-03|25
e|IS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PIXELS/cm|[?]|1|mL/kg|EMESIS|NEXT GENERATION TARGETED SEQUENCING|||1|3|Visit_3|40|6|SCREENING|2021-01-18|40
e|IS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg|[?]|1|keV|LYSATE|RYAN BLUE STAIN|||1|4|Visit_4|65|3|TREATMENT|2021-02-12|65
e|IS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug/L|[?]|1|Enzyme U/m2|INFRANATANT, PLASMA|ISHIHARA COLOR PLATES|||1|5|Visit_5|90|7|SCREENING|2021-03-09|90
e|IS|29e08650-9eae-461f-981e-f2a20d8d4492|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kDa|[?]|1|Bq/g|URINE|FLOCCULATION, CHARCOAL ENHANCED|Y||1|1|Visit_1|10|3|FOLLOW-UP|2020-11-17|10
e|IS|29e08650-9eae-461f-981e-f2a20d8d4492|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|DROP|[?]|1|mU/L|SMOOTH MUSCLE TISSUE|KINYOUN STAIN|Y||1|2|Visit_2|25|4|TREATMENT|2020-12-02|25
e|IS|29e08650-9eae-461f-981e-f2a20d8d4492|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IU/g Hb|[?]|1|AFU|TUMOR TISSUE|SPIROMETRY||Y|1|3|Visit_3|40|1|TREATMENT|2020-12-17|40
e|IS|29e08650-9eae-461f-981e-f2a20d8d4492|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|fg|[?]|1|PFU|SUPERNATANT, PLEURAL FLUID|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y|1|4|Visit_4|65|3|TREATMENT|2021-01-11|65
e|IS|29e08650-9eae-461f-981e-f2a20d8d4492|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/g/day|[?]|1|psec|TUMOR TISSUE|IMMUNOASSAY|||1|5|Visit_5|90|6|WASHOUT|2021-02-05|90
e|IS|2b944a62-10bc-475e-a90d-da3f07a2c4df|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|USP U|[?]|1|CARTRIDGE|LYMPH|VIRUS PLAQUE ASSAY|Y||1|1|Visit_1|10|2|FOLLOW-UP|2020-09-01|10
e|IS|2b944a62-10bc-475e-a90d-da3f07a2c4df|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Torr|[?]|1|10^9 CFU/g|DIALYSIS FLUID, PERITONEAL|TRANSTHORACIC ECHOCARDIOGRAPHY|||1|2|Visit_2|25|7|TREATMENT|2020-09-16|25
e|IS|2b944a62-10bc-475e-a90d-da3f07a2c4df|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 RNA copies/mL|[?]|1|/VF|SEBUM|POLYSOMNOGRAPHY|Y||1|3|Visit_3|40|2|TREATMENT|2020-10-01|40
e|IS|2b944a62-10bc-475e-a90d-da3f07a2c4df|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|CCID 50/dose|[?]|1|cy/cm|BILE|PANENDOSCOPY|Y||1|4|Visit_4|65|2|WASHOUT|2020-10-26|65
e|IS|2b944a62-10bc-475e-a90d-da3f07a2c4df|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/m2|[?]|1|amp|PERIPHERAL BLOOD MONONUCLEAR CELL|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||Y|1|5|Visit_5|90|2|FOLLOW-UP|2020-11-20|90
e|IS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/L/min|[?]|1|PIXEL|CERUMEN|NEXT GENERATION SEQUENCING||Y|1|1|Visit_1|10|5|SCREENING|2020-09-09|10
e|IS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|USP U|[?]|1|U/g Hb|SKELETAL MUSCLE TISSUE|CONTRAST ENHANCED PET SCAN|||1|2|Visit_2|25|4|TREATMENT|2020-09-24|25
e|IS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/mol|[?]|1|mV|SMOOTH MUSCLE TISSUE|MS/MS|||1|3|Visit_3|40|1|WASHOUT|2020-10-09|40
e|IS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Enzyme U/L|[?]|1|Roentgen|PLATELET POOR PLASMA|MICROPARTICLE ENZYME IMMUNOASSAY|||1|4|Visit_4|65|3|TREATMENT|2020-11-03|65
e|IS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kHz|[?]|1|Tesla|PERITONEAL FLUID|PUPILLOMETRY|Y||1|5|Visit_5|90|2|FOLLOW-UP|2020-11-28|90
e|IS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|oz|[?]|1|ug/kg/min|CALCULUS|WHOLE TRANSCRIPTOME SEQUENCING|||1|1|Visit_1|10|6|TREATMENT|2020-11-12|10
e|IS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|PACKAGE|[?]|1|deg/mm|INFRANATANT, PLEURAL FLUID|TARGETED TRANSCRIPTOME SEQUENCING|Y||1|2|Visit_2|25|5|TREATMENT|2020-11-27|25
e|IS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|kDa|[?]|1|km/h|BLOOD|IMMUNOCHROMATOGRAPHY||Y|1|3|Visit_3|40|6|TREATMENT|2020-12-12|40
e|IS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/animal/wk|[?]|1|ng/dL|BREAST MILK|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y|1|4|Visit_4|65|5|WASHOUT|2021-01-06|65
e|IS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^4 CFU|[?]|1|/sec|TISSUE|FLOW MICROSCOPY|Y||1|5|Visit_5|90|4|TREATMENT|2021-01-31|90
e|IS|1fce031b-680b-414f-9b74-d6383e10091d|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ng/L|[?]|1|mL/animal|ERYTHROCYTES|INFRARED SPECTROMETRY|||1|1|Visit_1|10|3|FOLLOW-UP|2020-05-31|10
e|IS|1fce031b-680b-414f-9b74-d6383e10091d|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 copies/mL|[?]|1|log EID 50/dose|SPUTUM|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y||1|2|Visit_2|25|6|SCREENING|2020-06-15|25
e|IS|1fce031b-680b-414f-9b74-d6383e10091d|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|kg/m2|[?]|1|mV2/Hz|CIRCULATING TUMOR CELL|RIA|||1|3|Visit_3|40|1|WASHOUT|2020-06-30|40
e|IS|1fce031b-680b-414f-9b74-d6383e10091d|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|IU/dL|[?]|1|mOsm/L|DISCHARGE|CLIP|||1|4|Visit_4|65|2|TREATMENT|2020-07-25|65
e|IS|1fce031b-680b-414f-9b74-d6383e10091d|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|C|[?]|1|/min|INFRANATANT, PLEURAL FLUID|STATIC PERIMETRY|Y||1|5|Visit_5|90|6|FOLLOW-UP|2020-08-19|90
e|IS|dcc67696-e91a-4cef-81dd-f2d2711363ae|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/L FEU|[?]|1|10^5/L|SWABBED MATERIAL|ETDRS EYE CHART|||1|1|Visit_1|10|4|WASHOUT|2020-12-28|10
e|IS|dcc67696-e91a-4cef-81dd-f2d2711363ae|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/L DDU|[?]|1|Farad|LEUKOCYTE|LANDOLT RING|||1|2|Visit_2|25|5|TREATMENT|2021-01-12|25
e|IS|dcc67696-e91a-4cef-81dd-f2d2711363ae|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/kg/min|[?]|1|cup eq|CERUMEN|IMMUNOTURBIDIMETRY|||1|3|Visit_3|40|6|TREATMENT|2021-01-27|40
e|IS|dcc67696-e91a-4cef-81dd-f2d2711363ae|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pL|[?]|1|lx|PLEURAL TISSUE|TWO-COLOR MICROARRAY|Y||1|4|Visit_4|65|5|TREATMENT|2021-02-21|65
e|IS|dcc67696-e91a-4cef-81dd-f2d2711363ae|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kPa/L/sec|[?]|1|Gauss|ISOLATE|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|5|Visit_5|90|3|SCREENING|2021-03-18|90
e|IS|91e83d7a-186a-4fed-8750-af796d77d356|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|IMPLANT|[?]|1|mg/kg/min|INFRANATANT, SERUM|SLIT LAMP PHOTOGRAPHY|||1|1|Visit_1|10|5|SCREENING|2020-06-02|10
e|IS|91e83d7a-186a-4fed-8750-af796d77d356|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|in|[?]|1|kat|SEMINAL FLUID|RADIATION DOSIMETRY|||1|2|Visit_2|25|7|TREATMENT|2020-06-17|25
e|IS|91e83d7a-186a-4fed-8750-af796d77d356|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ms2|[?]|1|10^4/hpf|PERIPHERAL BLOOD MONONUCLEAR CELL|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|3|Visit_3|40|6|SCREENING|2020-07-02|40
e|IS|91e83d7a-186a-4fed-8750-af796d77d356|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|1/(s*kPa)|[?]|1|SACHET|SMOOTH MUSCLE TISSUE|SISH|||1|4|Visit_4|65|1|TREATMENT|2020-07-27|65
e|IS|91e83d7a-186a-4fed-8750-af796d77d356|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|km/h|[?]|1|ka_u/dL|ARTERIAL CORD BLOOD|LC/MS|||1|5|Visit_5|90|7|WASHOUT|2020-08-21|90
e|IS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uU/L|[?]|1|JAR|PLEURAL TISSUE|SPECT/CT SCAN|||1|1|Visit_1|10|1|FOLLOW-UP|2020-05-13|10
e|IS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/LPF|[?]|1|PA|BILE|ACCELERATOR MASS SPECTROMETRY|||1|2|Visit_2|25|6|TREATMENT|2020-05-28|25
e|IS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/day|[?]|1|Ci/L|MENSTRUAL BLOOD|TRANSMISSION ELECTRON MICROSCOPY|||1|3|Visit_3|40|4|TREATMENT|2020-06-12|40
e|IS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6/g|[?]|1|DAgU|PLEURAL FLUID|MASS SPECTROMETRY||Y|1|4|Visit_4|65|7|SCREENING|2020-07-07|65
e|IS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|nmol/mol|[?]|1|psec|SOFT TISSUE|X-RAY FLUORESCENCE SPECTROMETRY|||1|5|Visit_5|90|7|WASHOUT|2020-08-01|90
e|IS|0145dfac-a107-4368-b358-bcd136e1ecb3|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MdFI|[?]|1|Absorbance U|BILE|ATOMIC ABSORPTION SPECTROMETRY|||1|1|Visit_1|10|7|TREATMENT|2021-01-08|10
e|IS|0145dfac-a107-4368-b358-bcd136e1ecb3|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Absorbance U/min|[?]|1|L/min|MECONIUM|MAGNETIC RESONANCE ELASTOGRAPHY|Y||1|2|Visit_2|25|1|WASHOUT|2021-01-23|25
e|IS|0145dfac-a107-4368-b358-bcd136e1ecb3|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|g|[?]|1|mL/s/m2|SWABBED MATERIAL|MICROSCOPY||Y|1|3|Visit_3|40|2|WASHOUT|2021-02-07|40
e|IS|0145dfac-a107-4368-b358-bcd136e1ecb3|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|fraction of 1|[?]|1|L/s|VITREOUS HUMOR|PULMONARY ANGIOGRAPHY|||1|4|Visit_4|65|2|WASHOUT|2021-03-04|65
e|IS|0145dfac-a107-4368-b358-bcd136e1ecb3|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/animal|[?]|1|MdFI|DISCHARGE|ENZYMATIC COLORIMETRY|||1|5|Visit_5|90|5|WASHOUT|2021-03-29|90
e|IS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/cmH2O|[?]|1|umol/L/sec|TRANSUDATE|CLIP SEQUENCING|||1|1|Visit_1|10|1|TREATMENT|2020-12-29|10
e|IS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|amp|[?]|1|mL/animal/wk|INFRANATANT, PLEURAL FLUID|IMMUNOTURBIDIMETRY|||1|2|Visit_2|25|4|TREATMENT|2021-01-13|25
e|IS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|log10 TCID 50/mL|[?]|1|mmHg|GASTRIC CONTENTS|FLUORIMETRY|||1|3|Visit_3|40|3|FOLLOW-UP|2021-01-28|40
e|IS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nm|[?]|1|mV/sec|SUPERNATANT, PLASMA|OPTICAL DENSITY MEASUREMENT|||1|4|Visit_4|65|1|WASHOUT|2021-02-22|65
e|IS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PIXELS/cm|[?]|1|g/L|SUPERNATANT, PLASMA|X-RAY|||1|5|Visit_5|90|3|WASHOUT|2021-03-19|90
e|IS|d4d79f6a-ba90-4503-934b-8a86286d83d3|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|s^-1(%O2)^-1|[?]|1|10^3 CFU|SWABBED MATERIAL|COMPUTERIZED CORNEAL TOPOGRAPHY|Y|Y|1|1|Visit_1|10|3|TREATMENT|2020-11-17|10
e|IS|d4d79f6a-ba90-4503-934b-8a86286d83d3|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/mg|[?]|1|cpm|BASAL TEAR|FISH||Y|1|2|Visit_2|25|6|TREATMENT|2020-12-02|25
e|IS|d4d79f6a-ba90-4503-934b-8a86286d83d3|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/(min*100mL)|[?]|1|g/cage/wk|RETICULOCYTES|GC/MS-CI|||1|3|Visit_3|40|1|TREATMENT|2020-12-17|40
e|IS|d4d79f6a-ba90-4503-934b-8a86286d83d3|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|kg/L|[?]|1|/sec|CERUMEN|HIGH RESOLUTION CT|||1|4|Visit_4|65|6|TREATMENT|2021-01-11|65
e|IS|d4d79f6a-ba90-4503-934b-8a86286d83d3|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mOsm/kg|[?]|1|ks|CORD SERUM|RADIATION DOSIMETRY|Y||1|5|Visit_5|90|6|TREATMENT|2021-02-05|90
e|IS|a329c350-49e2-415d-ba3c-e1ee929aec86|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pL|[?]|1|TUBE|FLUID|TURBIDIMETRY|||1|1|Visit_1|10|4|TREATMENT|2020-08-15|10
e|IS|a329c350-49e2-415d-ba3c-e1ee929aec86|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nkat/g Hb|[?]|1|cmH2O*s/mL|SEBUM|ENDOSCOPY|Y||1|2|Visit_2|25|6|TREATMENT|2020-08-30|25
e|IS|a329c350-49e2-415d-ba3c-e1ee929aec86|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Ci|[?]|1|U/m2/min|SPUTUM|TELLER ACUITY CARDS|Y|Y|1|3|Visit_3|40|3|SCREENING|2020-09-14|40
e|IS|a329c350-49e2-415d-ba3c-e1ee929aec86|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/LPF|[?]|1|Enzyme U/L|EPIDERMAL TISSUE|QUANTITATIVE CORONARY ANGIOGRAPHY|Y||1|4|Visit_4|65|6|TREATMENT|2020-10-09|65
e|IS|a329c350-49e2-415d-ba3c-e1ee929aec86|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|amol|[?]|1|breaths/30s|EXHALED BREATH CONDENSATE|FISH|||1|5|Visit_5|90|6|TREATMENT|2020-11-03|90
e|IS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|mol/mg|EMESIS|CONTACT SPECULAR MICROSCOPY|||1|1|Visit_1|10|5|TREATMENT|2020-10-01|10
e|IS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mmol/s|[?]|1|RFU|CORD SERUM|AGAR PROPORTION|||1|2|Visit_2|25|2|TREATMENT|2020-10-16|25
e|IS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/kg/h|[?]|1|/100 WBC|URINE SEDIMENT|PUPILLOMETRY|||1|3|Visit_3|40|3|TREATMENT|2020-10-31|40
e|IS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|log EID 50/dose|[?]|1|genEq|EPIDERMAL TISSUE|MICROBIAL CULTURE|||1|4|Visit_4|65|1|SCREENING|2020-11-25|65
e|IS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/min/mmHg|[?]|1|kg/cm|SMEGMA|OPHTHALMOSCOPY|||1|5|Visit_5|90|3|TREATMENT|2020-12-20|90
e|IS|128153ce-7bee-4f8d-bb60-fb1776370b6d|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PNU/mL|[?]|1|pmol/day|PLASMA ULTRAFILTRATE|PELLI-ROBSON EYE CHART|Y||1|1|Visit_1|10|6|SCREENING|2021-01-11|10
e|IS|128153ce-7bee-4f8d-bb60-fb1776370b6d|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|umol|[?]|1|MBq|MIXED VENOUS BLOOD|VENTILATION PERFUSION LUNG SCAN|||1|2|Visit_2|25|5|FOLLOW-UP|2021-01-26|25
e|IS|128153ce-7bee-4f8d-bb60-fb1776370b6d|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|pmol/10^9 cells|[?]|1|ug/m2/min|PLASMA|ELECTROCHEMILUMINESCENCE|||1|3|Visit_3|40|5|SCREENING|2021-02-10|40
e|IS|128153ce-7bee-4f8d-bb60-fb1776370b6d|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|umol/L/min|[?]|1|cm/min|CORD BLOOD|CELLULOSE TAPE|Y||1|4|Visit_4|65|5|WASHOUT|2021-03-07|65
e|IS|128153ce-7bee-4f8d-bb60-fb1776370b6d|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cm/min|[?]|1|ngEq/L|VENOUS BLOOD|MAMMOGRAPHY|||1|5|Visit_5|90|4|TREATMENT|2021-04-01|90
e|IS|22ee2f20-4a66-458f-a153-9d7e871e1db2|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|IU/mL|[?]|1|10^6 copies/mL|AQUEOUS HUMOR|AMSLER GRID|||1|1|Visit_1|10|6|SCREENING|2020-06-17|10
e|IS|22ee2f20-4a66-458f-a153-9d7e871e1db2|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cm|[?]|1|U/kg|MONOCYTE|HPLC/IEX|||1|2|Visit_2|25|2|FOLLOW-UP|2020-07-02|25
e|IS|22ee2f20-4a66-458f-a153-9d7e871e1db2|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|DAYS|[?]|1|pmol/day|PERSPIRATION|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y||1|3|Visit_3|40|7|WASHOUT|2020-07-17|40
e|IS|22ee2f20-4a66-458f-a153-9d7e871e1db2|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ukat/L|[?]|1|umol/L/h|SUPERNATANT, CEREBROSPINAL FLUID|AUTOREFRACTION|||1|4|Visit_4|65|2|TREATMENT|2020-08-11|65
e|IS|22ee2f20-4a66-458f-a153-9d7e871e1db2|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U|[?]|1|fL|PLATELET|IMPEDANCE CONDUCTIVITY||Y|1|5|Visit_5|90|2|SCREENING|2020-09-05|90
e|IS|b7caaa04-bcc7-4350-ad98-85670a19778f|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|HOURS|[?]|1|U.CARR|VITREOUS HUMOR|MODIFIED ACID FAST STAIN|||1|1|Visit_1|10|2|TREATMENT|2020-07-06|10
e|IS|b7caaa04-bcc7-4350-ad98-85670a19778f|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|IU/mmol|[?]|1|STEPS|VENOUS CORD BLOOD|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|2|Visit_2|25|6|WASHOUT|2020-07-21|25
e|IS|b7caaa04-bcc7-4350-ad98-85670a19778f|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|deg|[?]|1|cpm|WHITE MATTER TISSUE|KARYOTYPING||Y|1|3|Visit_3|40|5|TREATMENT|2020-08-05|40
e|IS|b7caaa04-bcc7-4350-ad98-85670a19778f|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BAG|[?]|1|Ci/mL|STOOL|IMPULSE OSCILLOMETRY|||1|4|Visit_4|65|3|SCREENING|2020-08-30|65
e|IS|b7caaa04-bcc7-4350-ad98-85670a19778f|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|GLOBULE|[?]|1|ug/day|MONOCYTE|COLORIMETRY|||1|5|Visit_5|90|5|TREATMENT|2020-09-24|90
e|IS|2b58d5fd-3ec8-415b-bb53-a252049f228a|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|EVENTS|[?]|1|U/kg/day|ARTERIALIZED CAPILLARY BLOOD|DIFFUSION TENSOR MRI|||1|1|Visit_1|10|7|WASHOUT|2020-12-17|10
e|IS|2b58d5fd-3ec8-415b-bb53-a252049f228a|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|MET*min|VENOUS BLOOD|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||1|2|Visit_2|25|5|TREATMENT|2021-01-01|25
e|IS|2b58d5fd-3ec8-415b-bb53-a252049f228a|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/kg/min|[?]|1|uU/dL|TUMOR TISSUE|COMPLEMENT FIXATION||Y|1|3|Visit_3|40|2|TREATMENT|2021-01-16|40
e|IS|2b58d5fd-3ec8-415b-bb53-a252049f228a|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|P|[?]|1|10^9 organisms|SUPERNATANT, CEREBROSPINAL FLUID|PHOTOGRAPHY|||1|4|Visit_4|65|6|WASHOUT|2021-02-10|65
e|IS|2b58d5fd-3ec8-415b-bb53-a252049f228a|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|QUANTITY SUFFICIENT|[?]|1|DAgU|TUMOR TISSUE|MS/MS|||1|5|Visit_5|90|1|TREATMENT|2021-03-07|90
e|IS|60b23345-43f6-42eb-9225-5a674456c9b9|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|DRUM|[?]|1|mAnson U/mL|CALCULUS|CLOT DETECTION|Y||1|1|Visit_1|10|6|TREATMENT|2021-01-15|10
e|IS|60b23345-43f6-42eb-9225-5a674456c9b9|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|km/h|[?]|1|pL|INFRANATANT, PLASMA|SEQUENCING||Y|1|2|Visit_2|25|4|TREATMENT|2021-01-30|25
e|IS|60b23345-43f6-42eb-9225-5a674456c9b9|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/h|[?]|1|10^6 organisms|PLEURAL FLUID|JAFFE REACTION|Y||1|3|Visit_3|40|1|FOLLOW-UP|2021-02-14|40
e|IS|60b23345-43f6-42eb-9225-5a674456c9b9|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Mile|[?]|1|ng/mol|KERATINOCYTE|IMMUNOPRECIPITATION|Y||1|4|Visit_4|65|5|TREATMENT|2021-03-11|65
e|IS|60b23345-43f6-42eb-9225-5a674456c9b9|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol2/L2|[?]|1|IU/kg/h|VENOUS CORD BLOOD|HANSEL STAIN||Y|1|5|Visit_5|90|5|FOLLOW-UP|2021-04-05|90
e|IS|7979239e-2a6b-48e3-9d11-41c97b33d229|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|steps/min|SERUM|MANUAL COUNT|Y||1|1|Visit_1|10|7|WASHOUT|2021-01-15|10
e|IS|7979239e-2a6b-48e3-9d11-41c97b33d229|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|TRANSDUCING UNIT|[?]|1|Pa|BONE MARROW MONONUCLEAR CELL|WHOLE TRANSCRIPTOME SEQUENCING|||1|2|Visit_2|25|1|TREATMENT|2021-01-30|25
e|IS|7979239e-2a6b-48e3-9d11-41c97b33d229|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IU/mL|[?]|1|ng/dL|RETICULOCYTES|TURBIDIMETRY|Y|Y|1|3|Visit_3|40|7|SCREENING|2021-02-14|40
e|IS|7979239e-2a6b-48e3-9d11-41c97b33d229|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nU/cL|[?]|1|MnFI|COLOSTRUM|MICROBIAL CULTURE|Y||1|4|Visit_4|65|2|WASHOUT|2021-03-11|65
e|IS|7979239e-2a6b-48e3-9d11-41c97b33d229|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^7 CFU|[?]|1|SQU/mL|SKIN TISSUE|NUCLEIC ACID SEQUENCING|||1|5|Visit_5|90|7|SCREENING|2021-04-05|90
e|IS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BOX|[?]|1|mg/cm2|VENOUS CORD BLOOD|IHC|Y||1|1|Visit_1|10|3|WASHOUT|2020-08-06|10
e|IS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|g/dL|[?]|1|uV|INTERSTITIAL FLUID|ANTIBIOTIC AGAR SCREEN|||1|2|Visit_2|25|2|WASHOUT|2020-08-21|25
e|IS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|uL|[?]|1|Bq/kg|ENDOTRACHEAL FLUID|MICROBIAL CULTURE, LIQUID||Y|1|3|Visit_3|40|7|SCREENING|2020-09-05|40
e|IS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|GBq|[?]|1|uU/dL|ARTERIAL CORD BLOOD|PHASE-CONTRAST MRI|||1|4|Visit_4|65|3|FOLLOW-UP|2020-09-30|65
e|IS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|L/kg|[?]|1|ELISA unit/mL|CEREBROSPINAL FLUID|SINGLE-SLICE SPIRAL CT|||1|5|Visit_5|90|2|WASHOUT|2020-10-25|90
e|IS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/h/m2|[?]|1|Linear ft*LB|FLUID|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|1|1|Visit_1|10|2|TREATMENT|2021-01-05|10
e|IS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|pt_us|[?]|1|mEq/g|PLASMA ULTRAFILTRATE|CALCULATION||Y|1|2|Visit_2|25|4|FOLLOW-UP|2021-01-20|25
e|IS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/animal|[?]|1|10^3 organisms/g|EPITHELIAL CELL|HPLC/MS|||1|3|Visit_3|40|1|TREATMENT|2021-02-04|40
e|IS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|/10^5|MUCUS|PET/CT SCAN|||1|4|Visit_4|65|6|TREATMENT|2021-03-01|65
e|IS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|nmol/L|[?]|1|mU|BREAST MILK|STRESS ECHOCARDIOGRAPHY||Y|1|5|Visit_5|90|2|FOLLOW-UP|2021-03-26|90
e|IS|da35fc01-4258-4e4d-99d9-4172e84c46e8|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mPa|[?]|1|10^9 CFU/g|INFRANATANT, SERUM|PHOTOGRAPHY|Y|Y|1|1|Visit_1|10|2|WASHOUT|2020-07-22|10
e|IS|da35fc01-4258-4e4d-99d9-4172e84c46e8|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/cage/day|[?]|1|CFU/g|CERVICOVAGINAL SECRETION|PET SCAN||Y|1|2|Visit_2|25|2|WASHOUT|2020-08-06|25
e|IS|da35fc01-4258-4e4d-99d9-4172e84c46e8|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mmol2/L2|[?]|1|mmHg*min/L|TISSUE|SNELLEN EYE CHART|||1|3|Visit_3|40|7|TREATMENT|2020-08-21|40
e|IS|da35fc01-4258-4e4d-99d9-4172e84c46e8|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/h|[?]|1|ag|SOFT TISSUE|INDIA INK STAIN|||1|4|Visit_4|65|4|SCREENING|2020-09-15|65
e|IS|da35fc01-4258-4e4d-99d9-4172e84c46e8|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/L|[?]|1|Bq/mL|BREAST MILK|MALDI|||1|5|Visit_5|90|7|TREATMENT|2020-10-10|90
e|IS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MHz|[?]|1|ug/m2|TRANSUDATE|IMMUNOTURBIDIMETRY|||1|1|Visit_1|10|3|FOLLOW-UP|2020-08-04|10
e|IS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/LSQN|[?]|1|/100 HPFs|LYSATE|IMMUNORADIOMETRIC ASSAY||Y|1|2|Visit_2|25|6|TREATMENT|2020-08-19|25
e|IS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|PATCH|[?]|1|CAN|SEBUM|THICK SMEAR|||1|3|Visit_3|40|6|TREATMENT|2020-09-03|40
e|IS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/mol|[?]|1|ng/L|PROSTATIC FLUID|STATIC PERIMETRY|||1|4|Visit_4|65|5|TREATMENT|2020-09-28|65
e|IS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cGy|[?]|1|DNA copies/ug|ARTERIAL CORD BLOOD|PET/CT SCAN WITHOUT CONTRAST|Y||1|5|Visit_5|90|7|WASHOUT|2020-10-23|90
e|IS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/kg/min|[?]|1|mL/min/mmHg|ISOLATE|HPLC/MS|||1|1|Visit_1|10|4|SCREENING|2020-12-14|10
e|IS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|V/sec|[?]|1|Ci|CIRCULATING TUMOR CELL|PULSE OXIMETRY|||1|2|Visit_2|25|2|TREATMENT|2020-12-29|25
e|IS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol/kg|[?]|1|mmol|GASTRIC FLUID|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y||1|3|Visit_3|40|3|TREATMENT|2021-01-13|40
e|IS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/g|[?]|1|in|URINE|SEQUENCING|||1|4|Visit_4|65|3|TREATMENT|2021-02-07|65
e|IS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|uU/dL|[?]|1|MET|SPERMATOZOON|TURBIDIMETRY|||1|5|Visit_5|90|5|SCREENING|2021-03-04|90
e|IS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|umol|[?]|1|SBE/mL|EMOTIONAL TEAR|MS/MS|||1|1|Visit_1|10|4|SCREENING|2020-06-09|10
e|IS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/dose|[?]|1|mPa|EMESIS|IN SITU HYBRIDIZATION|||1|2|Visit_2|25|5|WASHOUT|2020-06-24|25
e|IS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mEq/L|[?]|1|Bq/mg|ENDOMETRIAL TISSUE|EEG|Y|Y|1|3|Visit_3|40|3|WASHOUT|2020-07-09|40
e|IS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mEq/kg|[?]|1|/2500 WBC|CALCULUS|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y||1|4|Visit_4|65|5|FOLLOW-UP|2020-08-03|65
e|IS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|log10 TCID 50/dose|[?]|1|DNA copies/ug|BONE|CALCULATION|||1|5|Visit_5|90|1|TREATMENT|2020-08-28|90
e|IS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|STEPS|[?]|1|PHERESIS UNIT|MUCUS|CINEANGIOGRAPHY||Y|1|1|Visit_1|10|4|TREATMENT|2020-05-24|10
e|IS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/m2/min|[?]|1|g/animal/day|SKIN TISSUE|CALIPER MEASUREMENT METHOD|||1|2|Visit_2|25|6|WASHOUT|2020-06-08|25
e|IS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Absorbance U/mL|[?]|1|RING|FLUID|CONFOCAL MICROSCOPY|||1|3|Visit_3|40|3|FOLLOW-UP|2020-06-23|40
e|IS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ft3|[?]|1|Tesla|SMEGMA|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y||1|4|Visit_4|65|1|SCREENING|2020-07-18|65
e|IS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|deg|[?]|1|mL/beat|CELL PELLET|MAMMOGRAPHY|||1|5|Visit_5|90|3|SCREENING|2020-08-12|90
e|IS|136d59c6-9645-447a-a047-68d33dbb708e|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|fraction of 1|[?]|1|ng/mol|ENDOMETRIAL TISSUE|HANSEL STAIN||Y|1|1|Visit_1|10|3|TREATMENT|2020-09-24|10
e|IS|136d59c6-9645-447a-a047-68d33dbb708e|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|V|[?]|1|mmHg/sec|DIALYSIS FLUID|MUGA|||1|2|Visit_2|25|1|SCREENING|2020-10-09|25
e|IS|136d59c6-9645-447a-a047-68d33dbb708e|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|EIA unit|[?]|1|kg/cm2|SUPERNATANT, SERUM OR PLASMA|MOUSE PROTECTION ASSAY||Y|1|3|Visit_3|40|4|TREATMENT|2020-10-24|40
e|IS|136d59c6-9645-447a-a047-68d33dbb708e|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|CFU/mL|[?]|1|g/animal|GASTRIC CONTENTS|IMPEDANCE CONDUCTIVITY|||1|4|Visit_4|65|5|SCREENING|2020-11-18|65
e|IS|136d59c6-9645-447a-a047-68d33dbb708e|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PFU/mL|[?]|1|FINGERTIP UNIT|URINE|PULMONARY ANGIOGRAPHY|||1|5|Visit_5|90|7|WASHOUT|2020-12-13|90
e|IS|2e393b90-213c-4661-ad55-cabb2008bf14|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|CAPFUL|[?]|1|/LSQN|REFLEX TEAR|MS/MS|Y||1|1|Visit_1|10|2|FOLLOW-UP|2020-06-26|10
e|IS|2e393b90-213c-4661-ad55-cabb2008bf14|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/kg/day|[?]|1|L/h/m2|PERSPIRATION|IHC|||1|2|Visit_2|25|7|WASHOUT|2020-07-11|25
e|IS|2e393b90-213c-4661-ad55-cabb2008bf14|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|SYRINGE|[?]|1|mEq/L|VENOUS CORD BLOOD|IODINE STAIN|||1|3|Visit_3|40|2|SCREENING|2020-07-26|40
e|IS|2e393b90-213c-4661-ad55-cabb2008bf14|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol/mol|[?]|1|CONTAINER|CORD SERUM|MICROPARTICLE ENZYME IMMUNOASSAY|||1|4|Visit_4|65|6|FOLLOW-UP|2020-08-20|65
e|IS|2e393b90-213c-4661-ad55-cabb2008bf14|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cGy|[?]|1|ug/L/h|LOCHIA|VENTILATION PERFUSION LUNG SCAN|||1|5|Visit_5|90|4|TREATMENT|2020-09-14|90
e|IS|f72002d8-262b-49da-84a4-42e6011286f0|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|HOMEOPATHIC DILUTION|[?]|1|L/s/kPa|EXHALED BREATH CONDENSATE|TOTAL BODY RADIOGRAPHY|||1|1|Visit_1|10|1|FOLLOW-UP|2020-10-14|10
e|IS|f72002d8-262b-49da-84a4-42e6011286f0|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/kg|[?]|1|EU|URINE|SANGER SEQUENCING|||1|2|Visit_2|25|4|TREATMENT|2020-10-29|25
e|IS|f72002d8-262b-49da-84a4-42e6011286f0|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/kg/h|[?]|1|s^-1(%O2)^-1|SMOOTH MUSCLE TISSUE|PYROSEQUENCING|Y||1|3|Visit_3|40|7|FOLLOW-UP|2020-11-13|40
e|IS|f72002d8-262b-49da-84a4-42e6011286f0|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmH2O/mL|[?]|1|MET|CAPILLARY PLASMA|TEST STRIP|Y||1|4|Visit_4|65|1|TREATMENT|2020-12-08|65
e|IS|f72002d8-262b-49da-84a4-42e6011286f0|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kg/L|[?]|1|mg/day|GASTRIC CONTENTS|CLIP|Y|Y|1|5|Visit_5|90|7|SCREENING|2021-01-02|90
e|IS|68869dda-531d-4218-b2b0-4f5f46825569|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|pkat|[?]|1|uU/L|LYMPH|LC/MS/MS|Y|Y|1|1|Visit_1|10|2|SCREENING|2020-12-08|10
e|IS|68869dda-531d-4218-b2b0-4f5f46825569|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/kg|[?]|1|U/mmol|KERATINOCYTE|IMMUNOCHROMATOGRAPHY|||1|2|Visit_2|25|1|TREATMENT|2020-12-23|25
e|IS|68869dda-531d-4218-b2b0-4f5f46825569|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ng/mol|[?]|1|BOWL|SERUM OR PLASMA|SNP ARRAY||Y|1|3|Visit_3|40|5|TREATMENT|2021-01-07|40
e|IS|68869dda-531d-4218-b2b0-4f5f46825569|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|BAU|[?]|1|mEq/g|PLEURAL FLUID|CALCOFLUOR WHITE STAIN|Y||1|4|Visit_4|65|5|WASHOUT|2021-02-01|65
e|IS|68869dda-531d-4218-b2b0-4f5f46825569|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|umol/min|[?]|1|g/cage|GASTRIC FLUID|HANSEL STAIN||Y|1|5|Visit_5|90|2|TREATMENT|2021-02-26|90
e|IS|68888445-1819-4f4c-bd0c-a445906476fb|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmHg/sec|[?]|1|%|SYNOVIAL FLUID|SEQUENCING|Y|Y|1|1|Visit_1|10|7|WASHOUT|2021-01-14|10
e|IS|68888445-1819-4f4c-bd0c-a445906476fb|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/dose|[?]|1|gMFI|NAIL|WHOLE GENOME SEQUENCING||Y|1|2|Visit_2|25|1|TREATMENT|2021-01-29|25
e|IS|68888445-1819-4f4c-bd0c-a445906476fb|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mmol/L|[?]|1|DISK|ENDOTRACHEAL FLUID|NO INFORMATION|||1|3|Visit_3|40|2|TREATMENT|2021-02-13|40
e|IS|68888445-1819-4f4c-bd0c-a445906476fb|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/7.5 mL|[?]|1|10^6 CFU|MENSTRUAL BLOOD|GC/FID|||1|4|Visit_4|65|2|WASHOUT|2021-03-10|65
e|IS|68888445-1819-4f4c-bd0c-a445906476fb|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/g/h|[?]|1|mL/cage|CIRCULATING TUMOR CELL|AUTOREFRACTION|||1|5|Visit_5|90|4|TREATMENT|2021-04-04|90
e|IS|b2ce31a0-513a-449a-aa2c-7c9668fde275|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|copies/ug|[?]|1|cmH2O/mL|CAPILLARY BLOOD|ANTIBIOTIC AGAR SCREEN|||1|1|Visit_1|10|3|TREATMENT|2020-06-24|10
e|IS|b2ce31a0-513a-449a-aa2c-7c9668fde275|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mmol/L|[?]|1|Absorbance U/min|EPITHELIAL CELL|NEURAMINIDASE INHIBITION ASSAY||Y|1|2|Visit_2|25|6|WASHOUT|2020-07-09|25
e|IS|b2ce31a0-513a-449a-aa2c-7c9668fde275|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Ci/L|[?]|1|U/m2/day|URINE SEDIMENT|GC/MS-CI|||1|3|Visit_3|40|6|SCREENING|2020-07-24|40
e|IS|b2ce31a0-513a-449a-aa2c-7c9668fde275|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mCi/L|[?]|1|/10^4|MIXED VENOUS BLOOD|NON-INVASIVE DIELECTRIC SENSING|||1|4|Visit_4|65|6|TREATMENT|2020-08-18|65
e|IS|b2ce31a0-513a-449a-aa2c-7c9668fde275|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|sec|[?]|1|DISK|STOOL|ELECTROGASTROGRAPHY|||1|5|Visit_5|90|4|FOLLOW-UP|2020-09-12|90
e|IS|6c1d481b-985a-4be0-97ca-ecd06a81b456|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol/g|[?]|1|uL/kg/day|TISSUE|FUNCTIONAL MRI|Y||1|1|Visit_1|10|3|FOLLOW-UP|2020-10-05|10
e|IS|6c1d481b-985a-4be0-97ca-ecd06a81b456|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|BAG|[?]|1|hPa|NAIL|POLYGRAPHY|||1|2|Visit_2|25|2|WASHOUT|2020-10-20|25
e|IS|6c1d481b-985a-4be0-97ca-ecd06a81b456|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BU|[?]|1|mg2/dL2|SEMINAL FLUID|KLEIHAUER-BETKE|||1|3|Visit_3|40|3|TREATMENT|2020-11-04|40
e|IS|6c1d481b-985a-4be0-97ca-ecd06a81b456|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Anson U|[?]|1|WAFER|PLASMA|ICP-MS|||1|4|Visit_4|65|4|TREATMENT|2020-11-29|65
e|IS|6c1d481b-985a-4be0-97ca-ecd06a81b456|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|SCOOPFUL|[?]|1|g|GASTRIC CONTENTS|WESTERGREN||Y|1|5|Visit_5|90|1|TREATMENT|2020-12-24|90
e|IS|645a9247-efcb-4641-9514-58d6e28560e0|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|v/v|[?]|1|anti-Xa IU|SEMINAL FLUID|PALPATION|Y||1|1|Visit_1|10|3|TREATMENT|2020-12-21|10
e|IS|645a9247-efcb-4641-9514-58d6e28560e0|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|SPRAY|[?]|1|FINGERTIP UNIT|STRIATED MUSCLE TISSUE|IN VITRO GENE EXPRESSION ASSAY|||1|2|Visit_2|25|5|TREATMENT|2021-01-05|25
e|IS|645a9247-efcb-4641-9514-58d6e28560e0|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|GBq|[?]|1|mg/day|WHITE MATTER TISSUE|SEQUENCING|||1|3|Visit_3|40|3|TREATMENT|2021-01-20|40
e|IS|645a9247-efcb-4641-9514-58d6e28560e0|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^7 TCID 50/dose|[?]|1|mL/beat|SERUM OR PLASMA|PET/CT SCAN WITHOUT CONTRAST||Y|1|4|Visit_4|65|5|SCREENING|2021-02-14|65
e|IS|645a9247-efcb-4641-9514-58d6e28560e0|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|YEARS|[?]|1|mg/mol|SALIVA|IMMUNOTURBIDIMETRY|||1|5|Visit_5|90|5|TREATMENT|2021-03-11|90
e|IS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|gpELISA unit/mL|[?]|1|ng/dL|LYMPH|VENTILATION PERFUSION LUNG SCAN|||1|1|Visit_1|10|4|FOLLOW-UP|2020-09-15|10
e|IS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/animal|[?]|1|nkat|PERIPHERAL BLOOD MONONUCLEAR CELL|RADIAL IMMUNODIFFUSION|Y||1|2|Visit_2|25|4|SCREENING|2020-09-30|25
e|IS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/dose|[?]|1|SACHET|SMOOTH MUSCLE TISSUE|SXA SCAN|Y||1|3|Visit_3|40|1|TREATMENT|2020-10-15|40
e|IS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/L|[?]|1|ft|PLASMA ULTRAFILTRATE|HPLC/IEX|Y|Y|1|4|Visit_4|65|6|TREATMENT|2020-11-09|65
e|IS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mkat|[?]|1|mL/min|SUPERNATANT, PLASMA|CLAUSS METHOD||Y|1|5|Visit_5|90|7|FOLLOW-UP|2020-12-04|90
e|IS|05b05951-b1ba-4c51-b50f-9c842532bc4e|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|min*mg/mL|[?]|1|10^12/L|SEBUM|THERMAL IONIZATION MASS SPECTROMETRY||Y|1|1|Visit_1|10|5|SCREENING|2020-07-28|10
e|IS|05b05951-b1ba-4c51-b50f-9c842532bc4e|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm/min|[?]|1|ng|CAPILLARY BLOOD|MAGNETIC RESONANCE ANGIOGRAPHY|||1|2|Visit_2|25|3|WASHOUT|2020-08-12|25
e|IS|05b05951-b1ba-4c51-b50f-9c842532bc4e|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 CFU/mL|[?]|1|HOURS|HAIR|RADIATION DOSIMETRY|Y||1|3|Visit_3|40|7|TREATMENT|2020-08-27|40
e|IS|05b05951-b1ba-4c51-b50f-9c842532bc4e|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mmol/min/kPa/L|[?]|1|fmol/g|CORD SERUM|HPLC-FL|Y|Y|1|4|Visit_4|65|6|TREATMENT|2020-09-21|65
e|IS|05b05951-b1ba-4c51-b50f-9c842532bc4e|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/kg|[?]|1|mm/2h|CELL PELLET|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y||1|5|Visit_5|90|2|WASHOUT|2020-10-16|90
e|IS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|L/h|[?]|1|fmol/L|SKELETAL MUSCLE TISSUE|CONTRAST ENHANCED CT SCAN|||1|1|Visit_1|10|1|SCREENING|2020-10-23|10
e|IS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cmH2O*s2/mL|[?]|1|s/h|ARTERIALIZED CAPILLARY BLOOD|FLUORESCENCE ANGIOGRAPHY||Y|1|2|Visit_2|25|5|FOLLOW-UP|2020-11-07|25
e|IS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/mmol|[?]|1|dmol|STOOL|ROMANOWSKY STAIN||Y|1|3|Visit_3|40|5|FOLLOW-UP|2020-11-22|40
e|IS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|DAgU|[?]|1|LB|STOOL|ICC|||1|4|Visit_4|65|4|FOLLOW-UP|2020-12-17|65
e|IS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/h/mmol|[?]|1|mmol/mol|BUFFY COAT|CLIP|Y||1|5|Visit_5|90|5|SCREENING|2021-01-11|90
e|IS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|RING|[?]|1|OD Unit|BLOOD|STRESS ECHOCARDIOGRAPHY|||1|1|Visit_1|10|5|SCREENING|2020-08-31|10
e|IS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|IU/mL|[?]|1|CAPLET|URINE|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|2|Visit_2|25|6|WASHOUT|2020-09-15|25
e|IS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|MPL U/mL|[?]|1|ks|SERUM OR PLASMA|RADIOGRAPHY|||1|3|Visit_3|40|7|TREATMENT|2020-09-30|40
e|IS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|genEq|[?]|1|uCi/kg|ARTERIALIZED CAPILLARY BLOOD|HPLC-UV|||1|4|Visit_4|65|5|TREATMENT|2020-10-25|65
e|IS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cmHg|[?]|1|U|ADIPOSE TISSUE|DXA SCAN||Y|1|5|Visit_5|90|5|FOLLOW-UP|2020-11-19|90
e|IS|51a49847-6405-4842-b549-0e2ab99f61b2|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|L/L|[?]|1|mL/s/m2|HAIR|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|1|Visit_1|10|7|TREATMENT|2021-01-16|10
e|IS|51a49847-6405-4842-b549-0e2ab99f61b2|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ukat/L|[?]|1|mg/mol|PLATELET RICH PLASMA|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||1|2|Visit_2|25|4|TREATMENT|2021-01-31|25
e|IS|51a49847-6405-4842-b549-0e2ab99f61b2|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mIU/L|[?]|1|10^6 U|ISOLATE|POLYMERASE CHAIN REACTION|||1|3|Visit_3|40|7|WASHOUT|2021-02-15|40
e|IS|51a49847-6405-4842-b549-0e2ab99f61b2|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Ci/g|[?]|1|umol/L|SERUM|MAGNETIC RESONANCE ENTEROGRAPHY|Y||1|4|Visit_4|65|1|WASHOUT|2021-03-12|65
e|IS|51a49847-6405-4842-b549-0e2ab99f61b2|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uV|[?]|1|mkat|SUPERNATANT, SERUM OR PLASMA|HPLC|Y|Y|1|5|Visit_5|90|7|SCREENING|2021-04-06|90
e|IS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/500 WBC|[?]|1|mL/beat|BILE|BALLPOINT PEN TECHNIQUE|||1|1|Visit_1|10|6|SCREENING|2020-05-21|10
e|IS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmol/s|[?]|1|ug/kg/day|REFLEX TEAR|MICROBIAL CONCENTRATION||Y|1|2|Visit_2|25|5|TREATMENT|2020-06-05|25
e|IS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^8/L|[?]|1|mL/s/m2|EMOTIONAL TEAR|CINEANGIOGRAPHY|||1|3|Visit_3|40|2|TREATMENT|2020-06-20|40
e|IS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|fmol|[?]|1|FEU|LOCHIA|CLAUSS METHOD|||1|4|Visit_4|65|3|FOLLOW-UP|2020-07-15|65
e|IS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|pmol|[?]|1|m3|SUPERNATANT, PLEURAL FLUID|URANYL ACETATE STAIN|||1|5|Visit_5|90|1|TREATMENT|2020-08-09|90
e|IS|98166d74-caa7-4693-a817-b2cbae947ff8|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|L|[?]|1|log10 CFU/g|LUNG SURFACTANT|FLOCCULATION|||1|1|Visit_1|10|5|TREATMENT|2021-01-11|10
e|IS|98166d74-caa7-4693-a817-b2cbae947ff8|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^3 organisms/g|[?]|1|psec|LEUKOCYTE|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|2|Visit_2|25|1|TREATMENT|2021-01-26|25
e|IS|98166d74-caa7-4693-a817-b2cbae947ff8|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|log10 CFU/mL|[?]|1|mL/cage|TUMOR TISSUE|LISSAMINE GREEN STAIN|Y||1|3|Visit_3|40|2|TREATMENT|2021-02-10|40
e|IS|98166d74-caa7-4693-a817-b2cbae947ff8|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Bq/ug|[?]|1|MET*h|BLOOD|MICROSCOPY|||1|4|Visit_4|65|6|TREATMENT|2021-03-07|65
e|IS|98166d74-caa7-4693-a817-b2cbae947ff8|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/g/min|[?]|1|ag|URINE SEDIMENT|MICROBIAL CULTURE, SOLID|Y||1|5|Visit_5|90|3|SCREENING|2021-04-01|90
e|IS|cb07675a-2042-44da-a1f9-8b7783347e88|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|tsp eq|[?]|1|10^11/L|LUNG SURFACTANT|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|1|1|Visit_1|10|2|SCREENING|2020-12-05|10
e|IS|cb07675a-2042-44da-a1f9-8b7783347e88|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|LENS|[?]|1|L/s/kPa|INTERSTITIAL FLUID|POTENTIOMETRY||Y|1|2|Visit_2|25|6|SCREENING|2020-12-20|25
e|IS|cb07675a-2042-44da-a1f9-8b7783347e88|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/kg/min|[?]|1|/mm2|BONE MARROW MONONUCLEAR CELL|TRYPAN BLUE STAIN|||1|3|Visit_3|40|7|TREATMENT|2021-01-04|40
e|IS|cb07675a-2042-44da-a1f9-8b7783347e88|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ukat|[?]|1|mPa|ENDOMETRIAL TISSUE|ELECTRONEUROGRAPHY|Y||1|4|Visit_4|65|7|FOLLOW-UP|2021-01-29|65
e|IS|cb07675a-2042-44da-a1f9-8b7783347e88|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/kg|[?]|1|km|SERUM|WHOLE GENOME SEQUENCING|||1|5|Visit_5|90|1|FOLLOW-UP|2021-02-23|90
e|IS|a8a14aa1-4484-4bbc-86bf-c44257146a26|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6/hpf|[?]|1|mAnson U/mL|VITREOUS HUMOR|CT SCAN||Y|1|1|Visit_1|10|6|TREATMENT|2020-07-01|10
e|IS|a8a14aa1-4484-4bbc-86bf-c44257146a26|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Ci/ug|[?]|1|ng/day|MUCUS|CONTRAST ENHANCED CT SCAN|||1|2|Visit_2|25|6|WASHOUT|2020-07-16|25
e|IS|a8a14aa1-4484-4bbc-86bf-c44257146a26|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|FFU|[?]|1|Ejaculate U|DISCHARGE|WESTERGREN|||1|3|Visit_3|40|4|TREATMENT|2020-07-31|40
e|IS|a8a14aa1-4484-4bbc-86bf-c44257146a26|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/cm3/min|[?]|1|MPL U/mL|VENOUS PLASMA|KARYOTYPING|Y||1|4|Visit_4|65|1|WASHOUT|2020-08-25|65
e|IS|a8a14aa1-4484-4bbc-86bf-c44257146a26|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/day|[?]|1|Newton|SMOOTH MUSCLE TISSUE|KINETIC MICROPARTICLE IMMUNOASSAY|Y||1|5|Visit_5|90|3|TREATMENT|2020-09-19|90
e|IS|dfa4c661-9317-4bec-b307-a31eeadcaba6|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^5/L|[?]|1|copies/uL|CARDIAC MUSCLE TISSUE|RAJI CELL EIA|||1|1|Visit_1|10|4|TREATMENT|2020-06-04|10
e|IS|dfa4c661-9317-4bec-b307-a31eeadcaba6|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|BAU|[?]|1|uL|SUPERNATANT, SERUM|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y||1|2|Visit_2|25|4|TREATMENT|2020-06-19|25
e|IS|dfa4c661-9317-4bec-b307-a31eeadcaba6|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|log10 copies/mL|[?]|1|10^4 CFU/mL|LUNG SURFACTANT|MAMMOGRAPHY|||1|3|Visit_3|40|6|SCREENING|2020-07-04|40
e|IS|dfa4c661-9317-4bec-b307-a31eeadcaba6|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|log10 TCID 50/mL|[?]|1|breaths/min|CEREBROSPINAL FLUID|TRICHROME STAIN||Y|1|4|Visit_4|65|5|TREATMENT|2020-07-29|65
e|IS|dfa4c661-9317-4bec-b307-a31eeadcaba6|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|pmol/dL|[?]|1|10^6 U|SPUTUM|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|||1|5|Visit_5|90|2|SCREENING|2020-08-23|90
e|IS|9ed984a9-c153-4729-9dc9-3bb3d9059919|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/m2/min|[?]|1|ug/mol|WHITE MATTER TISSUE|MICROBIAL BIOCHEMICAL IDENTIFICATION|||1|1|Visit_1|10|6|TREATMENT|2020-09-01|10
e|IS|9ed984a9-c153-4729-9dc9-3bb3d9059919|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|oz|[?]|1|sec|INTERSTITIAL FLUID|PET/CT SCAN|Y|Y|1|2|Visit_2|25|6|TREATMENT|2020-09-16|25
e|IS|9ed984a9-c153-4729-9dc9-3bb3d9059919|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/mol|[?]|1|Hounsfield Unit|LOCHIA|MAGNETIC RESONANCE ENTEROGRAPHY|Y||1|3|Visit_3|40|2|SCREENING|2020-10-01|40
e|IS|9ed984a9-c153-4729-9dc9-3bb3d9059919|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/100 HPFs|[?]|1|Osm|EPITHELIAL CELL|HANSEL STAIN|||1|4|Visit_4|65|6|WASHOUT|2020-10-26|65
e|IS|9ed984a9-c153-4729-9dc9-3bb3d9059919|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|vg/dose|[?]|1|AFU|BUFFY COAT|FLOCCULATION, CHARCOAL ENHANCED|||1|5|Visit_5|90|4|TREATMENT|2020-11-20|90
e|IS|fb234b67-3c81-4d55-bc63-2389a23d67b2|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|fmol/g|[?]|1|Ci/mg|PLATELET RICH PLASMA|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y||1|1|Visit_1|10|2|TREATMENT|2021-01-11|10
e|IS|fb234b67-3c81-4d55-bc63-2389a23d67b2|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cycle/min|[?]|1|mmol/kg|BONE MARROW|FLOW MICROSCOPY|||1|2|Visit_2|25|2|SCREENING|2021-01-26|25
e|IS|fb234b67-3c81-4d55-bc63-2389a23d67b2|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|APL U|[?]|1|Ci|EPIDERMAL TISSUE|PERCUSSION|Y|Y|1|3|Visit_3|40|4|TREATMENT|2021-02-10|40
e|IS|fb234b67-3c81-4d55-bc63-2389a23d67b2|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mph|[?]|1|10^9 organisms|GASTRIC CONTENTS|SLOAN LETTER EYE CHART 2.5%||Y|1|4|Visit_4|65|2|TREATMENT|2021-03-07|65
e|IS|fb234b67-3c81-4d55-bc63-2389a23d67b2|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mol/g|[?]|1|POUCH|RETICULOCYTES|IMMUNOCHROMATOGRAPHY||Y|1|5|Visit_5|90|3|TREATMENT|2021-04-01|90
e|IS|84d7ff44-cbe2-446f-b667-5bc539de519b|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nmol BCE/L|[?]|1|10^3/hpf|ADIPOSE TISSUE|POLYMERASE CHAIN REACTION|Y||1|1|Visit_1|10|6|FOLLOW-UP|2020-07-06|10
e|IS|84d7ff44-cbe2-446f-b667-5bc539de519b|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/kg|[?]|1|10^9 CFU/g|BONE|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||1|2|Visit_2|25|1|WASHOUT|2020-07-21|25
e|IS|84d7ff44-cbe2-446f-b667-5bc539de519b|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/7.5 mL|[?]|1|DISK|BASAL TEAR|MANUAL CLOT DETECTION||Y|1|3|Visit_3|40|1|SCREENING|2020-08-05|40
e|IS|84d7ff44-cbe2-446f-b667-5bc539de519b|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|HOMEOPATHIC DILUTION|[?]|1|YEARS|CORD SERUM|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||1|4|Visit_4|65|3|TREATMENT|2020-08-30|65
e|IS|84d7ff44-cbe2-446f-b667-5bc539de519b|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uOsm|[?]|1|BU/mL|HAIR FOLLICLE|MANUAL COUNT||Y|1|5|Visit_5|90|7|WASHOUT|2020-09-24|90
e|IS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|VOXEL|[?]|1|10^7 CFU|PLATELET POOR PLASMA|ETDRS EYE CHART|||1|1|Visit_1|10|2|SCREENING|2020-09-24|10
e|IS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|pmol/g|[?]|1|mL/mmHg|ADIPOSE TISSUE|COMPLEMENT FIXATION|||1|2|Visit_2|25|5|FOLLOW-UP|2020-10-09|25
e|IS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|log10 CCID 50/dose|[?]|1|/LPF|MUSCLE TISSUE|REVERSE TRANSCRIPTASE PCR||Y|1|3|Visit_3|40|5|FOLLOW-UP|2020-10-24|40
e|IS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|m|[?]|1|mCi/kg|TUMOR TISSUE|KINETIC MICROPARTICLE IMMUNOASSAY|Y|Y|1|4|Visit_4|65|6|TREATMENT|2020-11-18|65
e|IS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/m2/day|[?]|1|BP|SWABBED MATERIAL|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y||1|5|Visit_5|90|4|FOLLOW-UP|2020-12-13|90
e|IS|955188f1-b434-40ab-94c8-0c0fb7f23e84|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|kBq|[?]|1|ug/animal|AMNIOTIC FLUID|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|1|Visit_1|10|6|TREATMENT|2020-12-14|10
e|IS|955188f1-b434-40ab-94c8-0c0fb7f23e84|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|DIOPTER|[?]|1|mol/L|LAVAGE FLUID|GC/MS-EI|||1|2|Visit_2|25|6|TREATMENT|2020-12-29|25
e|IS|955188f1-b434-40ab-94c8-0c0fb7f23e84|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^7 PFU|[?]|1|deg2|EXHALED BREATH CONDENSATE|NUCLEAR RADIOLOGY|||1|3|Visit_3|40|2|TREATMENT|2021-01-13|40
e|IS|955188f1-b434-40ab-94c8-0c0fb7f23e84|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PRESSOR UNITS|[?]|1|cd|EXHALED BREATH CONDENSATE|SISH|Y||1|4|Visit_4|65|6|FOLLOW-UP|2021-02-07|65
e|IS|955188f1-b434-40ab-94c8-0c0fb7f23e84|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|U/kg/h|[?]|1|uL/mL|URINE|U-HPLC/MS/MS|||1|5|Visit_5|90|4|SCREENING|2021-03-04|90
e|IS|5a384b5e-954c-4af9-bd60-96aadc72ca44|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uL/dose|[?]|1|ms2|SPUTUM|CLOT DETECTION|||1|1|Visit_1|10|4|TREATMENT|2020-10-09|10
e|IS|5a384b5e-954c-4af9-bd60-96aadc72ca44|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6/hpf|[?]|1|vg/dose|INTERSTITIAL FLUID|PET/SPECT SCAN|||1|2|Visit_2|25|5|TREATMENT|2020-10-24|25
e|IS|5a384b5e-954c-4af9-bd60-96aadc72ca44|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pt_br|[?]|1|MPL U/mL|PLATELET|ECHOCARDIOGRAPHY|Y||1|3|Visit_3|40|2|TREATMENT|2020-11-08|40
e|IS|5a384b5e-954c-4af9-bd60-96aadc72ca44|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BOX|[?]|1|ug/L/h|CORD SERUM|ELLA|Y||1|4|Visit_4|65|6|TREATMENT|2020-12-03|65
e|IS|5a384b5e-954c-4af9-bd60-96aadc72ca44|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MdFI|[?]|1|RFU|SERUM|ACID FAST STAIN|Y||1|5|Visit_5|90|3|TREATMENT|2020-12-28|90
e|IS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nkat/L|[?]|1|L/h/m2|BONE MARROW|ARTERIAL SPIN LABELING FUNCTIONAL MRI||Y|1|1|Visit_1|10|4|TREATMENT|2020-07-02|10
e|IS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/VF|[?]|1|mL/kg/day|MUCUS|FLOCCULATION, CHARCOAL ENHANCED|||1|2|Visit_2|25|5|TREATMENT|2020-07-17|25
e|IS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kg/m2|[?]|1|mmol2/L2|STOOL|LEAD CITRATE STAIN|||1|3|Visit_3|40|2|WASHOUT|2020-08-01|40
e|IS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|LENS|[?]|1|ugEq|MIXED VENOUS BLOOD|JAEGER EYE CHART|||1|4|Visit_4|65|6|TREATMENT|2020-08-26|65
e|IS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mmHg*min/L|[?]|1|mL/beat|STRIATED MUSCLE TISSUE|ALCIAN BLUE STAIN|Y||1|5|Visit_5|90|4|SCREENING|2020-09-20|90
e|IS|f9432d72-f7d7-4cdf-a173-2e2029258474|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/100g/min|[?]|1|mm/min|SUPERNATANT, PLASMA|POTENTIOMETRY|||1|1|Visit_1|10|6|TREATMENT|2020-11-20|10
e|IS|f9432d72-f7d7-4cdf-a173-2e2029258474|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|min|[?]|1|SPRAY|SPERMATOZOON|IMPEDANCE CONDUCTIVITY|||1|2|Visit_2|25|2|FOLLOW-UP|2020-12-05|25
e|IS|f9432d72-f7d7-4cdf-a173-2e2029258474|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|CUP|[?]|1|10^9 organisms/mg|LYMPH|INDIA INK STAIN|||1|3|Visit_3|40|4|TREATMENT|2020-12-20|40
e|IS|f9432d72-f7d7-4cdf-a173-2e2029258474|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 CFU|[?]|1|BAU/mL|CAPILLARY BLOOD|KNEMOMETRY|||1|4|Visit_4|65|7|TREATMENT|2021-01-14|65
e|IS|f9432d72-f7d7-4cdf-a173-2e2029258474|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|dmol|[?]|1|mol|SYNOVIAL FLUID|HPLC-UV|||1|5|Visit_5|90|5|TREATMENT|2021-02-08|90
e|IS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Bq/g|[?]|1|mEq/kg|ARTERIAL CORD BLOOD|POTENTIOMETRY|||1|1|Visit_1|10|5|WASHOUT|2020-12-19|10
e|IS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MESF|[?]|1|U/10^12 RBC|WHITE MATTER TISSUE|INDIRECT IMMUNOFLUORESCENCE|Y||1|2|Visit_2|25|3|SCREENING|2021-01-03|25
e|IS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|U/cL|[?]|1|eq|BREAST MILK|U-HPLC/MS/MS|Y|Y|1|3|Visit_3|40|4|WASHOUT|2021-01-18|40
e|IS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/animal|[?]|1|ELISA unit/mL|GASTRIC CONTENTS|SPECT/CT SCAN|Y||1|4|Visit_4|65|2|TREATMENT|2021-02-12|65
e|IS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ugEq|[?]|1|PFU/animal|PLASMA ULTRAFILTRATE|FLUOROSCOPY|||1|5|Visit_5|90|4|TREATMENT|2021-03-09|90
e|IS|0fc0650f-ed95-422d-b407-dcee93178780|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mN|[?]|1|Joule|ISOLATE|MICROSCOPY|||1|1|Visit_1|10|1|TREATMENT|2020-08-23|10
e|IS|0fc0650f-ed95-422d-b407-dcee93178780|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|amol|[?]|1|grain|HAIR|LISSAMINE GREEN STAIN||Y|1|2|Visit_2|25|3|WASHOUT|2020-09-07|25
e|IS|0fc0650f-ed95-422d-b407-dcee93178780|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|RNA copies/mL|[?]|1|/h|CORD SERUM|PULMONARY ANGIOGRAPHY|||1|3|Visit_3|40|1|FOLLOW-UP|2020-09-22|40
e|IS|0fc0650f-ed95-422d-b407-dcee93178780|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/kg/min|[?]|1|BE/mL|STRIATED MUSCLE TISSUE|CORONARY ANGIOGRAPHY|Y|Y|1|4|Visit_4|65|3|WASHOUT|2020-10-17|65
e|IS|0fc0650f-ed95-422d-b407-dcee93178780|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 IU/mL|[?]|1|Frames/s|EXHALED BREATH CONDENSATE|IMPULSE OSCILLOMETRY||Y|1|5|Visit_5|90|3|TREATMENT|2020-11-11|90
e|IS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mol/day|[?]|1|YEARS|HAIR|WHOLE GENOME SEQUENCING||Y|1|1|Visit_1|10|3|TREATMENT|2020-06-03|10
e|IS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|oz eq|REFLEX TEAR|FLUORESCENT MICROSCOPY|||1|2|Visit_2|25|1|TREATMENT|2020-06-18|25
e|IS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mol/g|[?]|1|HOURS|MONOCYTE|CT SCAN|Y|Y|1|3|Visit_3|40|1|TREATMENT|2020-07-03|40
e|IS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^9 CFU/g|[?]|1|Roentgen|CERVICOVAGINAL SECRETION|EIA|||1|4|Visit_4|65|7|FOLLOW-UP|2020-07-28|65
e|IS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/m2/h|[?]|1|GBq/mg|BONE|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|5|Visit_5|90|5|TREATMENT|2020-08-22|90
e|IS|a6f48290-787a-46ad-bee1-ae263ad3c121|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|g/L|[?]|1|GPS U|LEUKOCYTE|RIA|||1|1|Visit_1|10|1|WASHOUT|2021-01-19|10
e|IS|a6f48290-787a-46ad-bee1-ae263ad3c121|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug/kg/h|[?]|1|fraction of 1|LYSATE|X-RAY FLUORESCENCE SPECTROMETRY|||1|2|Visit_2|25|3|TREATMENT|2021-02-03|25
e|IS|a6f48290-787a-46ad-bee1-ae263ad3c121|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kN/cm2|[?]|1|CIGARETTE|SYNOVIAL FLUID|AGAR PROPORTION|||1|3|Visit_3|40|7|SCREENING|2021-02-18|40
e|IS|a6f48290-787a-46ad-bee1-ae263ad3c121|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mmol/L|[?]|1|Gy/min|DIALYSIS FLUID|X-RAY||Y|1|4|Visit_4|65|1|WASHOUT|2021-03-15|65
e|IS|a6f48290-787a-46ad-bee1-ae263ad3c121|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol/s|[?]|1|WAFER|MUSCLE TISSUE|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||1|5|Visit_5|90|7|TREATMENT|2021-04-09|90
e|IS|565e5c83-9c67-4718-bd54-af34be936427|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|m2|[?]|1|uEq|PERIPHERAL BLOOD MONONUCLEAR CELL|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-06-09|10
e|IS|565e5c83-9c67-4718-bd54-af34be936427|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|oz eq|[?]|1|min*mg/mL|GASTRIC CONTENTS|EEG|||1|2|Visit_2|25|3|SCREENING|2020-06-24|25
e|IS|565e5c83-9c67-4718-bd54-af34be936427|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Osm|[?]|1|ft2|BASAL TEAR|SINGLE-SLICE SPIRAL CT|Y||1|3|Visit_3|40|2|SCREENING|2020-07-09|40
e|IS|565e5c83-9c67-4718-bd54-af34be936427|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/beat|[?]|1|U.CARR|MENSTRUAL BLOOD|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|4|Visit_4|65|2|FOLLOW-UP|2020-08-03|65
e|IS|565e5c83-9c67-4718-bd54-af34be936427|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^5/hpf|[?]|1|CAPFUL|EXHALED BREATH CONDENSATE|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|5|Visit_5|90|5|WASHOUT|2020-08-28|90
e|IS|b238304c-15ef-4c6e-a32c-9cd583a233a9|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 CCID 50/dose|[?]|1|/10^3|EXUDATE|SPIRAL CT|Y||1|1|Visit_1|10|2|TREATMENT|2021-01-07|10
e|IS|b238304c-15ef-4c6e-a32c-9cd583a233a9|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol/10^10 cells|[?]|1|ms/mmHg|SALIVA|LEAD CITRATE STAIN|Y||1|2|Visit_2|25|1|WASHOUT|2021-01-22|25
e|IS|b238304c-15ef-4c6e-a32c-9cd583a233a9|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|dram|[?]|1|mm/min|VENOUS BLOOD|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|3|Visit_3|40|6|TREATMENT|2021-02-06|40
e|IS|b238304c-15ef-4c6e-a32c-9cd583a233a9|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/animal/wk|[?]|1|v/v|CEREBROSPINAL FLUID|GRADIENT DIFFUSION|||1|4|Visit_4|65|4|TREATMENT|2021-03-03|65
e|IS|b238304c-15ef-4c6e-a32c-9cd583a233a9|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/dL|[?]|1|10^10/L|SERUM OR PLASMA|SISH|||1|5|Visit_5|90|3|TREATMENT|2021-03-28|90
e|IS|c273f039-bca9-4d55-8620-5c5db32a6c4b|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uL/dose|[?]|1|10^3 CFU/mL|URINE|DROPLET DIGITAL PCR|||1|1|Visit_1|10|3|FOLLOW-UP|2020-09-23|10
e|IS|c273f039-bca9-4d55-8620-5c5db32a6c4b|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|kcal/day|[?]|1|CFU/mL|AMNIOTIC FLUID|PEAK FLOWMETRY|||1|2|Visit_2|25|7|TREATMENT|2020-10-08|25
e|IS|c273f039-bca9-4d55-8620-5c5db32a6c4b|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cmH2O/mL|[?]|1|kV|TUMOR TISSUE|PALM METHOD|||1|3|Visit_3|40|6|TREATMENT|2020-10-23|40
e|IS|c273f039-bca9-4d55-8620-5c5db32a6c4b|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mMU/mL|[?]|1|EID 50/dose|SUPERNATANT, PLEURAL FLUID|PYROSEQUENCING|Y|Y|1|4|Visit_4|65|6|FOLLOW-UP|2020-11-17|65
e|IS|c273f039-bca9-4d55-8620-5c5db32a6c4b|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|TROCHE|[?]|1|mL|SEMEN|CALCULATION||Y|1|5|Visit_5|90|6|SCREENING|2020-12-12|90
e|IS|2cdb5053-2108-4f50-8906-8afabc855a36|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^4/L|[?]|1|PLUG|STOOL|KINETIC CHROMOGENIC ASSAY|Y||1|1|Visit_1|10|1|FOLLOW-UP|2020-08-28|10
e|IS|2cdb5053-2108-4f50-8906-8afabc855a36|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|JAR|[?]|1|U/kg/h|SERUM|AURAMINE STAIN|||1|2|Visit_2|25|2|TREATMENT|2020-09-12|25
e|IS|2cdb5053-2108-4f50-8906-8afabc855a36|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/g/h|[?]|1|mmol|SMEGMA|FLUORESCENT IMMUNOASSAY|||1|3|Visit_3|40|6|TREATMENT|2020-09-27|40
e|IS|2cdb5053-2108-4f50-8906-8afabc855a36|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|EIA unit|CORD BLOOD|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||1|4|Visit_4|65|5|TREATMENT|2020-10-22|65
e|IS|2cdb5053-2108-4f50-8906-8afabc855a36|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/breath|[?]|1|MnFI|SYNOVIAL FLUID|DYNAMIC LIGHT SCATTERING|||1|5|Visit_5|90|2|TREATMENT|2020-11-16|90
e|IS|fce7149a-503e-4209-8c62-8044a2ad1c1c|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Torr|[?]|1|GPS U|ADIPOSE TISSUE|GEL ELECTROPHORESIS|||1|1|Visit_1|10|2|WASHOUT|2020-08-06|10
e|IS|fce7149a-503e-4209-8c62-8044a2ad1c1c|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ft3|[?]|1|Log10 ELISA unit/dose|CAPILLARY BLOOD|PET/CT SCAN|||1|2|Visit_2|25|5|WASHOUT|2020-08-21|25
e|IS|fce7149a-503e-4209-8c62-8044a2ad1c1c|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/cmH2O|[?]|1|Gy/min|CAPILLARY BLOOD|TOLUIDINE BLUE STAIN|Y||1|3|Visit_3|40|4|WASHOUT|2020-09-05|40
e|IS|fce7149a-503e-4209-8c62-8044a2ad1c1c|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/L/h|[?]|1|Farad|ARTERIALIZED CAPILLARY BLOOD|CONTRAST ENHANCED PET SCAN|||1|4|Visit_4|65|1|TREATMENT|2020-09-30|65
e|IS|fce7149a-503e-4209-8c62-8044a2ad1c1c|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|PUFF|[?]|1|ug/g/h|EMESIS|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|5|Visit_5|90|1|TREATMENT|2020-10-25|90
e|IS|c8aad550-11a1-4473-8b35-79b7dfb08122|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/cage|[?]|1|10^7 PFU|SEMINAL FLUID|FLOCCULATION, CHARCOAL ENHANCED|||1|1|Visit_1|10|2|TREATMENT|2020-06-09|10
e|IS|c8aad550-11a1-4473-8b35-79b7dfb08122|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|APL U|[?]|1|BOLUS|ADIPOSE TISSUE|BIOIMPEDANCE SPECTROSCOPY|||1|2|Visit_2|25|2|TREATMENT|2020-06-24|25
e|IS|c8aad550-11a1-4473-8b35-79b7dfb08122|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|vg/kg|[?]|1|GBq|SUPERNATANT, SERUM|FLUORESCEIN STAIN|||1|3|Visit_3|40|1|SCREENING|2020-07-09|40
e|IS|c8aad550-11a1-4473-8b35-79b7dfb08122|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|GBq/mg|[?]|1|IU/dL|ERYTHROCYTES|MICRONEUTRALIZATION ASSAY|Y||1|4|Visit_4|65|1|SCREENING|2020-08-03|65
e|IS|c8aad550-11a1-4473-8b35-79b7dfb08122|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mph|[?]|1|JDF Unit|PLEURAL FLUID|EIA|||1|5|Visit_5|90|5|WASHOUT|2020-08-28|90
e|IS|f1967c6e-c520-4482-be7e-01ada4380d87|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kUSP|[?]|1|BOTTLE|LEUKOCYTE|DOPPLER ULTRASOUND|Y||1|1|Visit_1|10|4|TREATMENT|2021-01-05|10
e|IS|f1967c6e-c520-4482-be7e-01ada4380d87|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mgEq|[?]|1|ug/kg/h|LYSATE|DIGITAL PCR|||1|2|Visit_2|25|2|TREATMENT|2021-01-20|25
e|IS|f1967c6e-c520-4482-be7e-01ada4380d87|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kUSP|[?]|1|gpELISA unit/mL|ENDOMETRIAL TISSUE|IMMUNOCHROMATOGRAPHY|||1|3|Visit_3|40|7|FOLLOW-UP|2021-02-04|40
e|IS|f1967c6e-c520-4482-be7e-01ada4380d87|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|pL|[?]|1|TABLET|URINE|FLUORESCENT ENZYME IMMUNOASSAY|Y||1|4|Visit_4|65|3|TREATMENT|2021-03-01|65
e|IS|f1967c6e-c520-4482-be7e-01ada4380d87|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|scm|[?]|1|mL/(min*100mL)|SKIN TISSUE|ENZYMATIC ULTRACENTRIFUGATION|||1|5|Visit_5|90|6|TREATMENT|2021-03-26|90
e|IS|2a5a1c03-f54e-47da-8dda-2104c9423e94|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^5/hpf|[?]|1|10^9 CFU/mL|SOFT TISSUE|KNEMOMETRY||Y|1|1|Visit_1|10|5|TREATMENT|2021-01-01|10
e|IS|2a5a1c03-f54e-47da-8dda-2104c9423e94|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|DAYS|[?]|1|TUBE|FLUID|SISH||Y|1|2|Visit_2|25|1|WASHOUT|2021-01-16|25
e|IS|2a5a1c03-f54e-47da-8dda-2104c9423e94|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|eq|PLASMA|ELISPOT||Y|1|3|Visit_3|40|6|TREATMENT|2021-01-31|40
e|IS|2a5a1c03-f54e-47da-8dda-2104c9423e94|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nsec|[?]|1|U/kg/min|TRANSUDATE|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y||1|4|Visit_4|65|6|TREATMENT|2021-02-25|65
e|IS|2a5a1c03-f54e-47da-8dda-2104c9423e94|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|COAT|[?]|1|g/kg/day|COLOSTRUM|REFLECTANCE SPECTROSCOPY|||1|5|Visit_5|90|5|SCREENING|2021-03-22|90
e|IS|8f98bac3-8010-4902-8ae1-783dc5fea72d|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|log10 PFU/mL|[?]|1|L/s/kPa|INFRANATANT, PLEURAL FLUID|MACRO BROTH DILUTION|||1|1|Visit_1|10|1|TREATMENT|2020-06-29|10
e|IS|8f98bac3-8010-4902-8ae1-783dc5fea72d|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ppb|[?]|1|umol/L/min|BASAL TEAR|FLUORESCENT ENZYME IMMUNOASSAY||Y|1|2|Visit_2|25|2|FOLLOW-UP|2020-07-14|25
e|IS|8f98bac3-8010-4902-8ae1-783dc5fea72d|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|g/kg/day|[?]|1|100 IU/mL|ARTERIALIZED CAPILLARY BLOOD|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y||1|3|Visit_3|40|4|WASHOUT|2020-07-29|40
e|IS|8f98bac3-8010-4902-8ae1-783dc5fea72d|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nmol|[?]|1|VIAL|HAIR FOLLICLE|PET/CT SCAN|||1|4|Visit_4|65|7|FOLLOW-UP|2020-08-23|65
e|IS|8f98bac3-8010-4902-8ae1-783dc5fea72d|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/mL/min|[?]|1|Frames/s|INTERSTITIAL FLUID|ZIEHL NEELSEN ACID FAST STAIN|||1|5|Visit_5|90|3|FOLLOW-UP|2020-09-17|90
e|IS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MESF|[?]|1|L/day|ERYTHROCYTES|AGAR DILUTION|||1|1|Visit_1|10|5|WASHOUT|2020-12-11|10
e|IS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmol2/L2|[?]|1|PIXEL|SEMINAL FLUID|MICROPARTICLE ENZYME IMMUNOASSAY|Y||1|2|Visit_2|25|2|SCREENING|2020-12-26|25
e|IS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|vg/dose|[?]|1|mg/L FEU|WHITE MATTER TISSUE|HEMAGGLUTINATION ASSAY|||1|3|Visit_3|40|1|TREATMENT|2021-01-10|40
e|IS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|amol|[?]|1|TRANSDUCING UNIT|EPIDERMAL TISSUE|PALM METHOD|Y||1|4|Visit_4|65|4|SCREENING|2021-02-04|65
e|IS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uU/dL|[?]|1|Ci/mL|VENOUS BLOOD|COLORIMETRY|||1|5|Visit_5|90|5|TREATMENT|2021-03-01|90
e|IS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/animal|[?]|1|10^9 CFU/mL|INFRANATANT, PLASMA|ANALYTICAL ULTRACENTRIFUGATION|||1|1|Visit_1|10|5|WASHOUT|2020-06-13|10
e|IS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BISCUIT|[?]|1|/h|ARTERIALIZED CAPILLARY BLOOD|SCANNING ELECTRON MICROSCOPY|||1|2|Visit_2|25|5|FOLLOW-UP|2020-06-28|25
e|IS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|log10 CCID 50/dose|[?]|1|Ci/uL|SUPERNATANT, SERUM|STATIC PERIMETRY|Y||1|3|Visit_3|40|6|TREATMENT|2020-07-13|40
e|IS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|NFIU|[?]|1|U/mmol|EXHALED BREATH CONDENSATE|ANALYTICAL ULTRACENTRIFUGATION|Y||1|4|Visit_4|65|6|TREATMENT|2020-08-07|65
e|IS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|HEP|[?]|1|mL/dL|BILE|MICRONEUTRALIZATION ASSAY||Y|1|5|Visit_5|90|6|TREATMENT|2020-09-01|90
e|IS|4be1ea69-9baf-45b4-873b-13a879544d9c|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/day|[?]|1|g/animal/wk|SERUM OR PLASMA|PHYSICAL EXAMINATION|||1|1|Visit_1|10|6|SCREENING|2021-01-26|10
e|IS|4be1ea69-9baf-45b4-873b-13a879544d9c|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mEq/mL|[?]|1|g/animal/day|CIRCULATING TUMOR CELL|NON-INVASIVE DIELECTRIC SENSING|Y||1|2|Visit_2|25|1|FOLLOW-UP|2021-02-10|25
e|IS|4be1ea69-9baf-45b4-873b-13a879544d9c|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/10^3|[?]|1|cmol|SOFT TISSUE|SPECT/CT SCAN||Y|1|3|Visit_3|40|7|TREATMENT|2021-02-25|40
e|IS|4be1ea69-9baf-45b4-873b-13a879544d9c|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CARTRIDGE|[?]|1|MPS U|ENDOTRACHEAL FLUID|LIGHT SCATTERING SPECTROSCOPY|||1|4|Visit_4|65|2|TREATMENT|2021-03-22|65
e|IS|4be1ea69-9baf-45b4-873b-13a879544d9c|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mph|[?]|1|cm/min|EPIDERMAL TISSUE|WHOLE GENOME SEQUENCING|||1|5|Visit_5|90|3|TREATMENT|2021-04-16|90
e|IS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mol/day|[?]|1|km/h|VENOUS BLOOD|LASER CAPTURE MICRODISSECTION|||1|1|Visit_1|10|4|SCREENING|2020-10-29|10
e|IS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|CCID 50/dose|[?]|1|Bq/g|ARTERIALIZED CAPILLARY BLOOD|AGAR PROPORTION|||1|2|Visit_2|25|5|TREATMENT|2020-11-13|25
e|IS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/g/h|[?]|1|mL*cmH2O|LAVAGE FLUID|ULTRASONOGRAPHIC ELASTOGRAPHY|||1|3|Visit_3|40|1|TREATMENT|2020-11-28|40
e|IS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|mEq/mL|CORD BLOOD|FLUORESCENT ENZYME IMMUNOASSAY|Y||1|4|Visit_4|65|3|FOLLOW-UP|2020-12-23|65
e|IS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^11/L|[?]|1|10^9/dose|SUPERNATANT, PLASMA|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||1|5|Visit_5|90|5|TREATMENT|2021-01-17|90
e|IS|16720f71-55b5-478f-b041-00b61ae19ac9|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/dose|[?]|1|Tesla|VENOUS BLOOD|COULOMETRIC TITRATION|||1|1|Visit_1|10|7|SCREENING|2021-01-10|10
e|IS|16720f71-55b5-478f-b041-00b61ae19ac9|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PIXEL|[?]|1|nL|ERYTHROCYTES|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|2|Visit_2|25|2|TREATMENT|2021-01-25|25
e|IS|16720f71-55b5-478f-b041-00b61ae19ac9|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|gMFI|[?]|1|TABLET|GASTRIC FLUID|PHOTOMETRY||Y|1|3|Visit_3|40|5|WASHOUT|2021-02-09|40
e|IS|16720f71-55b5-478f-b041-00b61ae19ac9|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|IU/day|[?]|1|Pa|BONE MARROW MONONUCLEAR CELL|CONTACT SPECULAR MICROSCOPY||Y|1|4|Visit_4|65|2|FOLLOW-UP|2021-03-06|65
e|IS|16720f71-55b5-478f-b041-00b61ae19ac9|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^12/L|[?]|1|mmol|BUFFY COAT|ERGOSPIROMETRY||Y|1|5|Visit_5|90|1|TREATMENT|2021-03-31|90
e|IS|4349f45e-f18b-4606-9a72-fd45e64e17dc|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|SCOOPFUL|[?]|1|fmol/L/sec|ABSCESS FLUID|CLINICAL EVALUATION|||1|1|Visit_1|10|4|TREATMENT|2021-01-11|10
e|IS|4349f45e-f18b-4606-9a72-fd45e64e17dc|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/m2/day|[?]|1|RFU|ARTERIALIZED CAPILLARY BLOOD|INTERRUPTER TECHNIQUE||Y|1|2|Visit_2|25|3|SCREENING|2021-01-26|25
e|IS|4349f45e-f18b-4606-9a72-fd45e64e17dc|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ukat/L|[?]|1|Joule|SWABBED MATERIAL|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||1|3|Visit_3|40|4|WASHOUT|2021-02-10|40
e|IS|4349f45e-f18b-4606-9a72-fd45e64e17dc|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|min/day|[?]|1|nm|FLUID|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y||1|4|Visit_4|65|1|FOLLOW-UP|2021-03-07|65
e|IS|4349f45e-f18b-4606-9a72-fd45e64e17dc|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|tuberculin unit/mL|[?]|1|cd/m2|REFLEX TEAR|ATOMIC ABSORPTION SPECTROMETRY|||1|5|Visit_5|90|5|TREATMENT|2021-04-01|90
e|IS|32e36ec1-6895-42ff-bf33-52977e72b338|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Ci/uL|[?]|1|10^4 CFU|PUS|ACCELERATOR MASS SPECTROMETRY|||1|1|Visit_1|10|3|TREATMENT|2020-09-05|10
e|IS|32e36ec1-6895-42ff-bf33-52977e72b338|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ELISA unit/dose|[?]|1|umol/day|SUPERNATANT, PLEURAL FLUID|LC/MS/MS|Y|Y|1|2|Visit_2|25|2|TREATMENT|2020-09-20|25
e|IS|32e36ec1-6895-42ff-bf33-52977e72b338|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmol/g|[?]|1|mL/s|PLASMA ULTRAFILTRATE|IMMUNOTURBIDIMETRY|||1|3|Visit_3|40|5|TREATMENT|2020-10-05|40
e|IS|32e36ec1-6895-42ff-bf33-52977e72b338|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|IU/g Hb|[?]|1|BU/mL|EMOTIONAL TEAR|WHOLE EXOME SEQUENCING|Y||1|4|Visit_4|65|4|SCREENING|2020-10-30|65
e|IS|32e36ec1-6895-42ff-bf33-52977e72b338|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mV2/Hz|[?]|1|nmol/L/h|GASTRIC FLUID|PERFUSION MRI|||1|5|Visit_5|90|6|FOLLOW-UP|2020-11-24|90
e|IS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 CFU|[?]|1|BOLUS|URINE SEDIMENT|ICP-MS||Y|1|1|Visit_1|10|7|TREATMENT|2020-10-25|10
e|IS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uL/kg/day|[?]|1|/wk|AMNIOTIC FLUID|OBSERVATION|Y||1|2|Visit_2|25|1|FOLLOW-UP|2020-11-09|25
e|IS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|v/v|[?]|1|anti-Xa IU|BASAL TEAR|FARNSWORTH-MUNSELL 100 HUE TEST|Y||1|3|Visit_3|40|1|TREATMENT|2020-11-24|40
e|IS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^4 CFU|[?]|1|U/kg/min|PERITONEAL FLUID|MEDIASTINOSCOPY|Y|Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-12-19|65
e|IS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mmol/min/kPa|[?]|1|mL/m2|ABSCESS FLUID|URANYL ACETATE STAIN|||1|5|Visit_5|90|6|SCREENING|2021-01-13|90
e|IS|0329de16-fc7a-4941-900c-b390dac637aa|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Log10 ELISA unit|[?]|1|mEq/day|PLATELET RICH PLASMA|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|1|1|Visit_1|10|1|TREATMENT|2020-09-27|10
e|IS|0329de16-fc7a-4941-900c-b390dac637aa|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3/L|[?]|1|anti-Xa IU|SMEGMA|CLAUSS METHOD|||1|2|Visit_2|25|4|FOLLOW-UP|2020-10-12|25
e|IS|0329de16-fc7a-4941-900c-b390dac637aa|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Gy|[?]|1|cmH2O*s/mL|MONOCYTE|FLUORESCENT MICROSCOPY|||1|3|Visit_3|40|7|TREATMENT|2020-10-27|40
e|IS|0329de16-fc7a-4941-900c-b390dac637aa|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BP|[?]|1|ug/mL/h|AMNIOTIC FLUID|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y||1|4|Visit_4|65|2|TREATMENT|2020-11-21|65
e|IS|0329de16-fc7a-4941-900c-b390dac637aa|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/dose|[?]|1|/mm|GASTRIC FLUID|GC/MS-EI|||1|5|Visit_5|90|4|WASHOUT|2020-12-16|90
e|IS|89d364c9-1338-472b-af0b-19280e45508b|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/m2/h|[?]|1|pmol/g|SERUM OR PLASMA|IMMUNORADIOMETRIC ASSAY|||1|1|Visit_1|10|6|WASHOUT|2020-10-15|10
e|IS|89d364c9-1338-472b-af0b-19280e45508b|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Anson U|[?]|1|PFU/mL|MENSTRUAL BLOOD|CONTRAST ENHANCED CT SCAN|||1|2|Visit_2|25|5|TREATMENT|2020-10-30|25
e|IS|89d364c9-1338-472b-af0b-19280e45508b|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mCi/L|[?]|1|U/L|PLATELET RICH PLASMA|WRIGHT STAIN|||1|3|Visit_3|40|6|FOLLOW-UP|2020-11-14|40
e|IS|89d364c9-1338-472b-af0b-19280e45508b|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Gy/min|[?]|1|PUFF|ARTERIAL BLOOD|FLUORESCENT IMMUNOASSAY|||1|4|Visit_4|65|5|WASHOUT|2020-12-09|65
e|IS|89d364c9-1338-472b-af0b-19280e45508b|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|tsp|[?]|1|nmol/mol|SEMEN|SLIT LAMP|Y||1|5|Visit_5|90|5|SCREENING|2021-01-03|90
e|IS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ug/cm2|[?]|1|CAN|HAIR FOLLICLE|ANALYTICAL ULTRACENTRIFUGATION|||1|1|Visit_1|10|2|TREATMENT|2020-05-27|10
e|IS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/L|[?]|1|oz eq|HAIR FOLLICLE|ENZYMATIC SPECTROPHOTOMETRY|||1|2|Visit_2|25|7|TREATMENT|2020-06-11|25
e|IS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|BOWL|[?]|1|nU/cL|BLOOD|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|3|Visit_3|40|6|TREATMENT|2020-06-26|40
e|IS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|uCi/L|[?]|1|mL/cage/wk|DIALYSIS FLUID, PERITONEAL|NEXT GENERATION SEQUENCING|||1|4|Visit_4|65|2|TREATMENT|2020-07-21|65
e|IS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|STRIP|[?]|1|mL/cage/day|CAPILLARY PLASMA|PHOTOMETRIC CLOT DETECTION|Y||1|5|Visit_5|90|2|TREATMENT|2020-08-15|90
e|IS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|g/dL|[?]|1|IU/mg|EMESIS|U-HPLC/MS/MS|||1|1|Visit_1|10|7|TREATMENT|2020-10-12|10
e|IS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|L/day|[?]|1|anti-Xa IU|EXPIRED AIR|FLUOROSCOPY|||1|2|Visit_2|25|6|TREATMENT|2020-10-27|25
e|IS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|DNA copies/ug|[?]|1|mL/s/m2|PLATELET POOR PLASMA|BAC ACGH|||1|3|Visit_3|40|2|WASHOUT|2020-11-11|40
e|IS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|IU/g Hb|[?]|1|10^3 CFU|SKELETAL MUSCLE TISSUE|AGAR PROPORTION|||1|4|Visit_4|65|5|SCREENING|2020-12-06|65
e|IS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|psec|[?]|1|DPM|BONE MARROW MONONUCLEAR CELL|MICROPARTICLE ENZYME IMMUNOASSAY|Y||1|5|Visit_5|90|2|TREATMENT|2020-12-31|90
e|IS|0c103005-efae-48ed-91e3-35d38fa1d359|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 IU|[?]|1|mAmp|SUPERNATANT, PLEURAL FLUID|APPLANATION TONOMETRY|Y||1|1|Visit_1|10|1|FOLLOW-UP|2020-05-28|10
e|IS|0c103005-efae-48ed-91e3-35d38fa1d359|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|log10 PFU|[?]|1|msec|SPUTUM|PERIPHERAL ANGIOGRAPHY|||1|2|Visit_2|25|3|TREATMENT|2020-06-12|25
e|IS|0c103005-efae-48ed-91e3-35d38fa1d359|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kg/cm|[?]|1|mL/sec/1.73m2|SMOOTH MUSCLE TISSUE|REFLECTANCE SPECTROSCOPY|||1|3|Visit_3|40|6|SCREENING|2020-06-27|40
e|IS|0c103005-efae-48ed-91e3-35d38fa1d359|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/kg/day|[?]|1|breaths/30s|LEUKOCYTE|PERIODIC ACID SCHIFF STAIN|||1|4|Visit_4|65|7|WASHOUT|2020-07-22|65
e|IS|0c103005-efae-48ed-91e3-35d38fa1d359|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ppth|[?]|1|mL/min/mmHg|EPITHELIAL CELL|SCINTIGRAPHY|||1|5|Visit_5|90|4|WASHOUT|2020-08-16|90
e|IS|c9808184-3432-448c-a5e5-50176715effa|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^3 CFU/mL|[?]|1|ug/m2/min|CERUMEN|IRON HEMATOXYLIN STAIN|||1|1|Visit_1|10|2|TREATMENT|2020-12-29|10
e|IS|c9808184-3432-448c-a5e5-50176715effa|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|MBq/uL|[?]|1|mOsm/kg|SERUM OR PLASMA OR BLOOD|POPULATION SEQUENCING||Y|1|2|Visit_2|25|2|TREATMENT|2021-01-13|25
e|IS|c9808184-3432-448c-a5e5-50176715effa|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^4 CFU/mL|[?]|1|Linear ft*LB|PLASMA|LYMPHANGIOGRAPHY|||1|3|Visit_3|40|3|TREATMENT|2021-01-28|40
e|IS|c9808184-3432-448c-a5e5-50176715effa|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Tbsp|[?]|1|mEq/g|VENOUS BLOOD|FLOW CYTOMETRY|||1|4|Visit_4|65|1|TREATMENT|2021-02-22|65
e|IS|c9808184-3432-448c-a5e5-50176715effa|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mmHg/L/min|[?]|1|mg/kg/min|SOFT TISSUE|AGAR DILUTION|||1|5|Visit_5|90|6|FOLLOW-UP|2021-03-19|90
e|IS|c3d7d293-975f-44de-bd35-0168eec40ac9|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|MnFI|[?]|1|BISCUIT|SUPERNATANT, PLASMA|MAGNETIC RESONANCE ELASTOGRAPHY||Y|1|1|Visit_1|10|3|FOLLOW-UP|2021-01-04|10
e|IS|c3d7d293-975f-44de-bd35-0168eec40ac9|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PUFF|[?]|1|/mm2|EPITHELIAL CELL|SEQUENCING|||1|2|Visit_2|25|3|TREATMENT|2021-01-19|25
e|IS|c3d7d293-975f-44de-bd35-0168eec40ac9|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|in|[?]|1|ukat/L|ATHEROSCLEROTIC PLAQUE|IMPULSE OSCILLOMETRY||Y|1|3|Visit_3|40|1|TREATMENT|2021-02-03|40
e|IS|c3d7d293-975f-44de-bd35-0168eec40ac9|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|deg/s|[?]|1|g/m2/day|STOOL|FLOCCULATION, CHARCOAL ENHANCED|||1|4|Visit_4|65|3|WASHOUT|2021-02-28|65
e|IS|c3d7d293-975f-44de-bd35-0168eec40ac9|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/g/min|[?]|1|mL/sec/1.73m2|KERATINOCYTE|ACRIDINE ORANGE STAIN|||1|5|Visit_5|90|2|TREATMENT|2021-03-25|90
e|IS|2db1f07d-a7db-4cc3-8943-536e24378f08|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|beats/min|[?]|1|10^7 CFU/mL|CORD BLOOD|FLUORESCENT ENZYME IMMUNOASSAY|||1|1|Visit_1|10|7|FOLLOW-UP|2020-06-12|10
e|IS|2db1f07d-a7db-4cc3-8943-536e24378f08|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MET*h|[?]|1|GPL U|INFRANATANT, PLASMA|SLOAN LETTER EYE CHART 100%|||1|2|Visit_2|25|4|TREATMENT|2020-06-27|25
e|IS|2db1f07d-a7db-4cc3-8943-536e24378f08|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uCi/kg|[?]|1|100 IU/mL|CORD BLOOD|PHOTOMETRY|Y||1|3|Visit_3|40|6|FOLLOW-UP|2020-07-12|40
e|IS|2db1f07d-a7db-4cc3-8943-536e24378f08|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|umol/kg/min|[?]|1|lm|URINE SEDIMENT|LC-FL|||1|4|Visit_4|65|3|TREATMENT|2020-08-06|65
e|IS|2db1f07d-a7db-4cc3-8943-536e24378f08|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|INHALATION|[?]|1|/7.5 mL|MENSTRUAL BLOOD|COLORIMETRY|||1|5|Visit_5|90|5|TREATMENT|2020-08-31|90
e|IS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/L|[?]|1|PFU/animal|EMOTIONAL TEAR|BIOPSY|||1|1|Visit_1|10|1|SCREENING|2020-12-15|10
e|IS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|CYLINDER|[?]|1|fraction of 1|SUPERNATANT, PLASMA|URANYL ACETATE STAIN|||1|2|Visit_2|25|5|FOLLOW-UP|2020-12-30|25
e|IS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6 CFU/mL|[?]|1|dpm/0.5 mL|LOCHIA|SEQUENCING|||1|3|Visit_3|40|4|WASHOUT|2021-01-14|40
e|IS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mg/g/min|[?]|1|10^6 RNA copies/mL|INTERSTITIAL FLUID|MAGNETIC RESONANCE ANGIOGRAPHY|||1|4|Visit_4|65|1|TREATMENT|2021-02-08|65
e|IS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|dpm/mL|[?]|1|pkat|VENOUS BLOOD|AMSLER GRID|||1|5|Visit_5|90|5|TREATMENT|2021-03-05|90
e|IS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|nm|[?]|1|mm/h|SMEGMA|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y|1|1|Visit_1|10|4|TREATMENT|2020-12-04|10
e|IS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/cage/day|[?]|1|uV|SKIN TISSUE|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|Y|1|2|Visit_2|25|6|WASHOUT|2020-12-19|25
e|IS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|in|[?]|1|dmol|ARTERIAL CORD BLOOD|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||1|3|Visit_3|40|4|FOLLOW-UP|2021-01-03|40
e|IS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/m2|[?]|1|umol/L/sec|HAIR|IMMUNOFLUORESCENT STAIN||Y|1|4|Visit_4|65|5|TREATMENT|2021-01-28|65
e|IS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|NEBULE|[?]|1|BOTTLE|PLATELET RICH PLASMA|APPLANATION TONOMETRY|||1|5|Visit_5|90|1|TREATMENT|2021-02-22|90
e|IS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|aMFI|[?]|1|Farad|RETICULOCYTES|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||1|1|Visit_1|10|6|TREATMENT|2020-07-23|10
e|IS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/day|[?]|1|m|SUPERNATANT, CEREBROSPINAL FLUID|MRI WITHOUT CONTRAST|||1|2|Visit_2|25|6|WASHOUT|2020-08-07|25
e|IS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mCi/L|[?]|1|uV2|VENOUS PLASMA|BETA LACTAMASE||Y|1|3|Visit_3|40|5|TREATMENT|2020-08-22|40
e|IS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|U/cL|[?]|1|uEq|MONOCYTE|ULTRASOUND|||1|4|Visit_4|65|5|TREATMENT|2020-09-16|65
e|IS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/g|[?]|1|nmol/L|PLEURAL TISSUE|CONTACT SPECULAR MICROSCOPY|||1|5|Visit_5|90|3|FOLLOW-UP|2020-10-11|90
e|IS|0a42f96a-49c3-492f-a272-bf9989e53e9d|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BAU/mL|[?]|1|mmol/min/kPa|REFLEX TEAR|ELLA|Y||1|1|Visit_1|10|4|FOLLOW-UP|2021-01-26|10
e|IS|0a42f96a-49c3-492f-a272-bf9989e53e9d|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|hPa|[?]|1|U/mg|LYSATE|PET/SPECT SCAN||Y|1|2|Visit_2|25|6|TREATMENT|2021-02-10|25
e|IS|0a42f96a-49c3-492f-a272-bf9989e53e9d|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PFU/animal|[?]|1|/HPF|GASTRIC FLUID|CONTRAST ENHANCED PET/CT SCAN||Y|1|3|Visit_3|40|1|TREATMENT|2021-02-25|40
e|IS|0a42f96a-49c3-492f-a272-bf9989e53e9d|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|PFU/animal|[?]|1|cup eq|EPIDERMAL TISSUE|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||1|4|Visit_4|65|3|WASHOUT|2021-03-22|65
e|IS|0a42f96a-49c3-492f-a272-bf9989e53e9d|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|kg/mol|[?]|1|in|LAVAGE FLUID|TRICHROME STAIN|||1|5|Visit_5|90|5|TREATMENT|2021-04-16|90
e|IS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/10^5|[?]|1|PACKAGE|BUFFY COAT|ELISPOT|||1|1|Visit_1|10|4|TREATMENT|2021-01-08|10
e|IS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|TRANSDUCING UNIT/mL|[?]|1|mg/kg|HAIR FOLLICLE|POLYMERASE CHAIN REACTION|||1|2|Visit_2|25|7|TREATMENT|2021-01-23|25
e|IS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|dram|[?]|1|STRIP|EXPIRED AIR|IMMUNODIFFUSION|||1|3|Visit_3|40|6|TREATMENT|2021-02-07|40
e|IS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mEq/day|[?]|1|Absorbance U/min|BLOOD|HPLC-FL||Y|1|4|Visit_4|65|4|TREATMENT|2021-03-04|65
e|IS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|m|[?]|1|IU/mL|SERUM OR PLASMA|LINE PROBE ASSAY|||1|5|Visit_5|90|6|SCREENING|2021-03-29|90
e|IS|d3651e5f-bc38-4c96-afbf-5a65873ff306|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mAnson U/mL|[?]|1|U|SUPERNATANT, SERUM OR PLASMA|AGAR DILUTION||Y|1|1|Visit_1|10|5|TREATMENT|2020-07-28|10
e|IS|d3651e5f-bc38-4c96-afbf-5a65873ff306|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dmol|[?]|1|mg/g/h|CORD BLOOD|TRANSMISSION ELECTRON MICROSCOPY|Y||1|2|Visit_2|25|4|TREATMENT|2020-08-12|25
e|IS|d3651e5f-bc38-4c96-afbf-5a65873ff306|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|DNA copies/ug|[?]|1|mol|SEMEN|KINYOUN STAIN|Y|Y|1|3|Visit_3|40|5|TREATMENT|2020-08-27|40
e|IS|d3651e5f-bc38-4c96-afbf-5a65873ff306|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|fL|[?]|1|ug/L DDU|SERUM OR PLASMA|GEL ELECTROPHORESIS|||1|4|Visit_4|65|4|TREATMENT|2020-09-21|65
e|IS|d3651e5f-bc38-4c96-afbf-5a65873ff306|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|cm/s|[?]|1|PIXELS/cm|SOFT TISSUE|PET/SPECT SCAN||Y|1|5|Visit_5|90|1|TREATMENT|2020-10-16|90
e|IS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|g/m2|SYNOVIAL FLUID|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||1|1|Visit_1|10|6|TREATMENT|2020-06-11|10
e|IS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|lx|[?]|1|deg2|ATHEROSCLEROTIC PLAQUE|SLIT LAMP||Y|1|2|Visit_2|25|2|FOLLOW-UP|2020-06-26|25
e|IS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/day|[?]|1|lx|MONOCYTE|PET/SPECT SCAN|Y||1|3|Visit_3|40|3|WASHOUT|2020-07-11|40
e|IS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Bq/uL|[?]|1|ug/g/min|AMNIOTIC FLUID|MALDI||Y|1|4|Visit_4|65|4|WASHOUT|2020-08-05|65
e|IS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|psec|[?]|1|fmol/g|TRANSUDATE|MULTI-SLICE SPIRAL CT|||1|5|Visit_5|90|6|TREATMENT|2020-08-30|90
e|IS|f50537d2-e098-4dae-8f91-16f2357d709c|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|hr/day|[?]|1|rpm|LUNG SURFACTANT|PHOTOMETRIC CLOT DETECTION|||1|1|Visit_1|10|6|TREATMENT|2020-12-07|10
e|IS|f50537d2-e098-4dae-8f91-16f2357d709c|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DAgU|[?]|1|CUP|BONE|RYAN BLUE STAIN|||1|2|Visit_2|25|5|TREATMENT|2020-12-22|25
e|IS|f50537d2-e098-4dae-8f91-16f2357d709c|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|V/sec|[?]|1|cal|EMOTIONAL TEAR|MICROBIAL CULTURE||Y|1|3|Visit_3|40|3|FOLLOW-UP|2021-01-06|40
e|IS|f50537d2-e098-4dae-8f91-16f2357d709c|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/kg/min|[?]|1|dpm/mL|CAPILLARY PLASMA|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|4|Visit_4|65|4|TREATMENT|2021-01-31|65
e|IS|f50537d2-e098-4dae-8f91-16f2357d709c|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/kg/day|[?]|1|10^12/L|INTERSTITIAL FLUID|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|5|Visit_5|90|7|TREATMENT|2021-02-25|90
e|IS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MESF|[?]|1|1/(s*kPa)|TUMOR TISSUE|WHOLE GENOME SEQUENCING|||1|1|Visit_1|10|2|SCREENING|2020-07-19|10
e|IS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|um|[?]|1|pmol/dL|SUPERNATANT, SERUM|DOUBLE IMMUNODIFFUSION|||1|2|Visit_2|25|4|WASHOUT|2020-08-03|25
e|IS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|kBq|[?]|1|%(w/v)|DIALYSIS FLUID|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y||1|3|Visit_3|40|3|TREATMENT|2020-08-18|40
e|IS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ELISA unit|[?]|1|/10^5|KERATINOCYTE|HEMAGGLUTINATION ASSAY|||1|4|Visit_4|65|7|TREATMENT|2020-09-12|65
e|IS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/day|[?]|1|Siemens|BONE MARROW|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|5|Visit_5|90|5|FOLLOW-UP|2020-10-07|90
e|IS|489870ed-9da5-4df6-a5ef-17821c449c84|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|log10 CFU/mL|[?]|1|Ci/uL|CELL PELLET|HPLC-FL|||1|1|Visit_1|10|6|TREATMENT|2020-07-30|10
e|IS|489870ed-9da5-4df6-a5ef-17821c449c84|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|IU/day|[?]|1|mg/min|SPUTUM|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y|1|2|Visit_2|25|7|SCREENING|2020-08-14|25
e|IS|489870ed-9da5-4df6-a5ef-17821c449c84|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 organisms|[?]|1|log10 TCID 50/uL|INFRANATANT, PLASMA|LIQUID SCINTILLATION COUNTING|||1|3|Visit_3|40|2|WASHOUT|2020-08-29|40
e|IS|489870ed-9da5-4df6-a5ef-17821c449c84|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BU/mL|[?]|1|BISCUIT|PLASMA ULTRAFILTRATE|JAEGER EYE CHART||Y|1|4|Visit_4|65|6|FOLLOW-UP|2020-09-23|65
e|IS|489870ed-9da5-4df6-a5ef-17821c449c84|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/ms|[?]|1|dpm/mL|VENOUS CORD BLOOD|TONOMETRY|||1|5|Visit_5|90|7|TREATMENT|2020-10-18|90
e|IS|90fe992f-5a11-4829-b3b0-1c8314f53012|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|C|[?]|1|mL/(min*100mL)|EMOTIONAL TEAR|MICROARRAY|||1|1|Visit_1|10|2|TREATMENT|2020-09-23|10
e|IS|90fe992f-5a11-4829-b3b0-1c8314f53012|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|genEq|[?]|1|beats/min|SUPERNATANT, PLASMA|MULTI-SLICE SPIRAL CT|||1|2|Visit_2|25|7|SCREENING|2020-10-08|25
e|IS|90fe992f-5a11-4829-b3b0-1c8314f53012|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmHg/sec|[?]|1|10^4 CFU/mL|LAVAGE FLUID|ELECTRONEUROGRAPHY|||1|3|Visit_3|40|7|FOLLOW-UP|2020-10-23|40
e|IS|90fe992f-5a11-4829-b3b0-1c8314f53012|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|FFU|[?]|1|mN|BILE|COMPLEMENT FIXATION|||1|4|Visit_4|65|7|TREATMENT|2020-11-17|65
e|IS|90fe992f-5a11-4829-b3b0-1c8314f53012|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/dL|[?]|1|g/m2|ENDOTRACHEAL FLUID|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||1|5|Visit_5|90|5|WASHOUT|2020-12-12|90
e|IS|74be8de0-3307-4cc3-9044-05068b60f7e0|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/LSQN|[?]|1|dpm/100mg|SKIN TISSUE|TRANSVAGINAL ULTRASOUND|||1|1|Visit_1|10|1|TREATMENT|2020-10-20|10
e|IS|74be8de0-3307-4cc3-9044-05068b60f7e0|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/kg|[?]|1|fmol/L|SERUM OR PLASMA OR BLOOD|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|2|Visit_2|25|2|WASHOUT|2020-11-04|25
e|IS|74be8de0-3307-4cc3-9044-05068b60f7e0|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|PNU/mL|[?]|1|cd|TUMOR TISSUE|WHOLE EXOME SEQUENCING|||1|3|Visit_3|40|2|TREATMENT|2020-11-19|40
e|IS|74be8de0-3307-4cc3-9044-05068b60f7e0|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mU|[?]|1|IU/mg|HAIR FOLLICLE|PET/CT SCAN WITHOUT CONTRAST|Y|Y|1|4|Visit_4|65|3|TREATMENT|2020-12-14|65
e|IS|74be8de0-3307-4cc3-9044-05068b60f7e0|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|DRUM|[?]|1|ug/h|ARTERIALIZED CAPILLARY BLOOD|PALM METHOD|||1|5|Visit_5|90|7|WASHOUT|2021-01-08|90
e|IS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/dL|[?]|1|/10^4|KERATINOCYTE|CAPILLARY ELECTROPHORESIS||Y|1|1|Visit_1|10|4|TREATMENT|2020-06-11|10
e|IS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|WEEKS|[?]|1|PELLET|ARTERIAL BLOOD|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y||1|2|Visit_2|25|7|FOLLOW-UP|2020-06-26|25
e|IS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PFU|[?]|1|ug/L FEU|PERITONEAL FLUID|KARYOTYPING|||1|3|Visit_3|40|6|TREATMENT|2020-07-11|40
e|IS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mOsm/L|[?]|1|km|PLEURAL TISSUE|KINETIC MICROPARTICLE IMMUNOASSAY|Y||1|4|Visit_4|65|1|TREATMENT|2020-08-05|65
e|IS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cy/cm|[?]|1|cg|KERATINOCYTE|GC/FID||Y|1|5|Visit_5|90|1|TREATMENT|2020-08-30|90
e|IS|8825b806-fa76-49d7-b281-d36fc42fee1e|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|NEEDLE GAUGE|[?]|1|mL/g/h|BASAL TEAR|POLYMERASE CHAIN REACTION||Y|1|1|Visit_1|10|2|WASHOUT|2020-08-29|10
e|IS|8825b806-fa76-49d7-b281-d36fc42fee1e|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|RFU|[?]|1|km|REFLEX TEAR|HEMOCYTOMETRY|Y||1|2|Visit_2|25|5|FOLLOW-UP|2020-09-13|25
e|IS|8825b806-fa76-49d7-b281-d36fc42fee1e|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PRESSOR UNITS|[?]|1|TRANSDUCING UNIT/mL|BONE MARROW|SCINTIGRAPHY|||1|3|Visit_3|40|4|TREATMENT|2020-09-28|40
e|IS|8825b806-fa76-49d7-b281-d36fc42fee1e|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|copies/ug|[?]|1|/10^3|CORD SERUM|PYROSEQUENCING|||1|4|Visit_4|65|7|FOLLOW-UP|2020-10-23|65
e|IS|8825b806-fa76-49d7-b281-d36fc42fee1e|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|L/s/kPa|[?]|1|mL/g/h|EPIDERMAL TISSUE|OPHTHALMOSCOPY||Y|1|5|Visit_5|90|4|WASHOUT|2020-11-17|90
e|IS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|nmol BCE/L|[?]|1|mL/m2/day|ENDOMETRIAL TISSUE|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||1|1|Visit_1|10|7|TREATMENT|2020-05-19|10
e|IS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ugEq|[?]|1|log10 TCID 50/dose|CALCULUS|HPLC/MS||Y|1|2|Visit_2|25|2|WASHOUT|2020-06-03|25
e|IS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mV2/Hz|[?]|1|Enzyme U/m2|SERUM|STRESS ECHOCARDIOGRAPHY||Y|1|3|Visit_3|40|6|SCREENING|2020-06-18|40
e|IS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^6 CFU/g|[?]|1|mMU/mL|VITREOUS HUMOR|WEBER GREEN STAIN|||1|4|Visit_4|65|2|TREATMENT|2020-07-13|65
e|IS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|dB|[?]|1|/7.5 mL|PLEURAL TISSUE|MAGNETIC RESONANCE ENTEROGRAPHY|||1|5|Visit_5|90|4|FOLLOW-UP|2020-08-07|90
e|IS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|log10 PFU|[?]|1|mph|ERYTHROCYTES|INTRAVASCULAR ULTRASOUND|||1|1|Visit_1|10|5|SCREENING|2021-01-14|10
e|IS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|nL|[?]|1|ugEq|EXUDATE|PHOROPTER|||1|2|Visit_2|25|3|TREATMENT|2021-01-29|25
e|IS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/g/h|[?]|1|Bq/mL|ALVEOLAR AIR|FLUOROSCOPY||Y|1|3|Visit_3|40|6|TREATMENT|2021-02-13|40
e|IS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|TRACE|PERITONEAL FLUID|HEMATOXYLIN AND EOSIN STAIN|Y||1|4|Visit_4|65|6|FOLLOW-UP|2021-03-10|65
e|IS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|OD Unit|[?]|1|10^6 organisms|BUFFY COAT|KINYOUN STAIN|Y||1|5|Visit_5|90|6|WASHOUT|2021-04-04|90
e|IS|b36220d8-c129-48bf-8c41-542a954b819a|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|%(w/w)|[?]|1|Antibody Unit|STRIATED MUSCLE TISSUE|ALCIAN BLUE STAIN|||1|1|Visit_1|10|5|SCREENING|2020-05-24|10
e|IS|b36220d8-c129-48bf-8c41-542a954b819a|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/animal/wk|[?]|1|mL/sec/1.73m2|SUPERNATANT, SERUM|FORCED OSCILLATION TECHNIQUE||Y|1|2|Visit_2|25|2|TREATMENT|2020-06-08|25
e|IS|b36220d8-c129-48bf-8c41-542a954b819a|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mm/2h|[?]|1|BAR|EXUDATE|ENDOSCOPY|Y||1|3|Visit_3|40|6|FOLLOW-UP|2020-06-23|40
e|IS|b36220d8-c129-48bf-8c41-542a954b819a|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|uV|TISSUE|RAJI CELL EIA|||1|4|Visit_4|65|3|SCREENING|2020-07-18|65
e|IS|b36220d8-c129-48bf-8c41-542a954b819a|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^5/L|[?]|1|PFU/animal|LUNG SURFACTANT|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||1|5|Visit_5|90|7|TREATMENT|2020-08-12|90
e|IS|92d3477b-7460-4ce8-b237-38ca4c55fc91|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|copies/mL|[?]|1|tsp|ABSCESS FLUID|GC/FID|||1|1|Visit_1|10|6|TREATMENT|2020-08-14|10
e|IS|92d3477b-7460-4ce8-b237-38ca4c55fc91|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|foz_us|[?]|1|ppm|SEMINAL FLUID|INFRARED SPECTROMETRY|||1|2|Visit_2|25|5|TREATMENT|2020-08-29|25
e|IS|92d3477b-7460-4ce8-b237-38ca4c55fc91|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BE/mL|[?]|1|Tesla|HAIR FOLLICLE|PAP STAIN|||1|3|Visit_3|40|6|TREATMENT|2020-09-13|40
e|IS|92d3477b-7460-4ce8-b237-38ca4c55fc91|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|IU/kg|[?]|1|um2|SKELETAL MUSCLE TISSUE|AUDIOMETRY|||1|4|Visit_4|65|1|FOLLOW-UP|2020-10-08|65
e|IS|92d3477b-7460-4ce8-b237-38ca4c55fc91|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uL/kg/day|[?]|1|mol/g|DERMAL TISSUE|CISH|||1|5|Visit_5|90|3|TREATMENT|2020-11-02|90
e|IS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mmol/min/kPa|[?]|1|mg/mL/day|DERMAL TISSUE|TONOMETRY||Y|1|1|Visit_1|10|3|TREATMENT|2020-12-16|10
e|IS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/m2|[?]|1|pg/dL|ERYTHROCYTES|PERCUSSION|||1|2|Visit_2|25|4|TREATMENT|2020-12-31|25
e|IS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/kg/min|[?]|1|g/animal|GASTRIC CONTENTS|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||1|3|Visit_3|40|6|WASHOUT|2021-01-15|40
e|IS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|TROCHE|[?]|1|CYLINDER|URINE SEDIMENT|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||1|4|Visit_4|65|1|FOLLOW-UP|2021-02-09|65
e|IS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|foz_us|[?]|1|keV|SUPERNATANT, PLASMA|ACID FAST STAIN|||1|5|Visit_5|90|4|FOLLOW-UP|2021-03-06|90
e|IS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uL/kg/day|[?]|1|copies/ug|PLATELET|IODINE STAIN||Y|1|1|Visit_1|10|4|WASHOUT|2020-08-22|10
e|IS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|FEU|[?]|1|/10^4|BONE MARROW MONONUCLEAR CELL|LIQUID SCINTILLATION COUNTING|||1|2|Visit_2|25|5|SCREENING|2020-09-06|25
e|IS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BU|[?]|1|ug/min|AMNIOTIC FLUID|ACID FAST STAIN||Y|1|3|Visit_3|40|3|FOLLOW-UP|2020-09-21|40
e|IS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cL|[?]|1|ugEq/L|PROSTATIC FLUID|MOUSE PROTECTION ASSAY|||1|4|Visit_4|65|6|TREATMENT|2020-10-16|65
e|IS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|kat|[?]|1|ug/dL|SUPERNATANT, PLASMA|INDIRECT IMMUNOFLUORESCENCE|||1|5|Visit_5|90|2|SCREENING|2020-11-10|90
e|IS|3f75a463-1348-4c7f-8b29-7472d29628c8|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/beat|[?]|1|ks|CARDIAC MUSCLE TISSUE|DUCTOGRAPHY||Y|1|1|Visit_1|10|6|TREATMENT|2020-07-12|10
e|IS|3f75a463-1348-4c7f-8b29-7472d29628c8|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|min/day|[?]|1|mg/g/min|CORD SERUM|GRAM STAIN|||1|2|Visit_2|25|7|TREATMENT|2020-07-27|25
e|IS|3f75a463-1348-4c7f-8b29-7472d29628c8|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|s^-1(%O2)^-1|[?]|1|mol/day|RETICULOCYTES|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||1|3|Visit_3|40|1|TREATMENT|2020-08-11|40
e|IS|3f75a463-1348-4c7f-8b29-7472d29628c8|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/dose|[?]|1|g/m2/day|TISSUE|IMMUNODIFFUSION|||1|4|Visit_4|65|6|TREATMENT|2020-09-05|65
e|IS|3f75a463-1348-4c7f-8b29-7472d29628c8|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|deg|STRIATED MUSCLE TISSUE|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|5|Visit_5|90|1|WASHOUT|2020-09-30|90
e|IS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mAmp|[?]|1|mEq/ug|PLEURAL TISSUE|IMMUNOTURBIDIMETRY|||1|1|Visit_1|10|6|TREATMENT|2021-01-30|10
e|IS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 IU|[?]|1|mg/min|EXUDATE|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y||1|2|Visit_2|25|5|TREATMENT|2021-02-14|25
e|IS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/kg/min|[?]|1|PIXEL|ALVEOLAR AIR|DROPLET DIGITAL PCR||Y|1|3|Visit_3|40|3|TREATMENT|2021-03-01|40
e|IS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nmol/mL/min|[?]|1|uL/dose|PERSPIRATION|DROPLET DIGITAL PCR|||1|4|Visit_4|65|7|WASHOUT|2021-03-26|65
e|IS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Pack Year|[?]|1|%/min|SPUTUM|SEQUENCING|||1|5|Visit_5|90|5|TREATMENT|2021-04-20|90
e|IS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|JDF Unit|[?]|1|oz eq|EMESIS|CONTRAST ENHANCED CT SCAN|||1|1|Visit_1|10|6|SCREENING|2020-07-23|10
e|IS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6 organisms|[?]|1|ng/L|PLATELET RICH PLASMA|CLOT DETECTION||Y|1|2|Visit_2|25|3|WASHOUT|2020-08-07|25
e|IS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MET*h|[?]|1|U/g/min|FLUID|IMMUNOTURBIDIMETRY|||1|3|Visit_3|40|7|TREATMENT|2020-08-22|40
e|IS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cmH2O*s2/mL|[?]|1|mm3/mm2/year|SPUTUM|CELL BASED BIOASSAY|||1|4|Visit_4|65|2|FOLLOW-UP|2020-09-16|65
e|IS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|MAC50|[?]|1|PRESSOR UNITS|ISOLATE|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|5|Visit_5|90|3|FOLLOW-UP|2020-10-11|90
e|IS|a125efdf-aec8-47a1-b492-cdaf8b619a78|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|STEPS|[?]|1|mL/day|RETICULOCYTES|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y|1|1|Visit_1|10|5|TREATMENT|2020-09-30|10
e|IS|a125efdf-aec8-47a1-b492-cdaf8b619a78|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 IU|[?]|1|Ci/mL|INTERSTITIAL FLUID|IN VITRO GENE EXPRESSION ASSAY|||1|2|Visit_2|25|2|SCREENING|2020-10-15|25
e|IS|a125efdf-aec8-47a1-b492-cdaf8b619a78|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Bq/mg|[?]|1|ft2|DIALYSIS FLUID|MULTI-SLICE SPIRAL CT|||1|3|Visit_3|40|5|TREATMENT|2020-10-30|40
e|IS|a125efdf-aec8-47a1-b492-cdaf8b619a78|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|AU/mL|[?]|1|g/m2/day|SPERMATOZOON|ORCHIDOMETERY|||1|4|Visit_4|65|3|SCREENING|2020-11-24|65
e|IS|a125efdf-aec8-47a1-b492-cdaf8b619a78|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/kg|[?]|1|mm|PLATELET RICH PLASMA|ORCHIDOMETERY|Y||1|5|Visit_5|90|6|SCREENING|2020-12-19|90
e|IS|9171362e-0166-46f2-ab2d-2748d8c291d5|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|fmol/L/sec|[?]|1|mmol2/L2|DIALYSIS FLUID|DISK DIFFUSION|||1|1|Visit_1|10|6|WASHOUT|2021-01-12|10
e|IS|9171362e-0166-46f2-ab2d-2748d8c291d5|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|TRACE|[?]|1|dL|SUPERNATANT, SERUM|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||1|2|Visit_2|25|3|TREATMENT|2021-01-27|25
e|IS|9171362e-0166-46f2-ab2d-2748d8c291d5|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Absorbance U|[?]|1|mL/kg/day|SERUM OR PLASMA OR BLOOD|IVY INCISION METHOD|||1|3|Visit_3|40|5|WASHOUT|2021-02-11|40
e|IS|9171362e-0166-46f2-ab2d-2748d8c291d5|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Hz|[?]|1|beats/min|MUCUS|REVERSE TRANSCRIPTASE PCR|Y||1|4|Visit_4|65|6|WASHOUT|2021-03-08|65
e|IS|9171362e-0166-46f2-ab2d-2748d8c291d5|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uEq/L|[?]|1|P|BLOOD|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||1|5|Visit_5|90|1|TREATMENT|2021-04-02|90
e|IS|9b150e38-dc85-4a28-aad3-43f7620be460|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|GBq|[?]|1|ELISA unit/mL|MUSCLE TISSUE|GC/MS/MS|Y||1|1|Visit_1|10|4|SCREENING|2020-07-22|10
e|IS|9b150e38-dc85-4a28-aad3-43f7620be460|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/s|[?]|1|kBq/uL|VITREOUS HUMOR|BALLPOINT PEN TECHNIQUE|||1|2|Visit_2|25|6|FOLLOW-UP|2020-08-06|25
e|IS|9b150e38-dc85-4a28-aad3-43f7620be460|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|PIXELS/in|[?]|1|U/m2/h|CARDIAC MUSCLE TISSUE|CALIPER MEASUREMENT METHOD|||1|3|Visit_3|40|5|TREATMENT|2020-08-21|40
e|IS|9b150e38-dc85-4a28-aad3-43f7620be460|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uU/dL|[?]|1|s*kPa|HAIR|ICP-MS|||1|4|Visit_4|65|6|SCREENING|2020-09-15|65
e|IS|9b150e38-dc85-4a28-aad3-43f7620be460|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/m2|[?]|1|Bq/kg|AQUEOUS HUMOR|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|5|Visit_5|90|5|SCREENING|2020-10-10|90
e|IS|2a595fc0-7621-4ec9-bd77-74444886052e|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|min/day|[?]|1|U/g/min|CERUMEN|ELECTRONEUROGRAPHY|||1|1|Visit_1|10|5|SCREENING|2020-10-25|10
e|IS|2a595fc0-7621-4ec9-bd77-74444886052e|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|MPS U|[?]|1|uOsm|ADIPOSE TISSUE|INFRARED SPECTROMETRY|Y||1|2|Visit_2|25|2|FOLLOW-UP|2020-11-09|25
e|IS|2a595fc0-7621-4ec9-bd77-74444886052e|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Sv|[?]|1|Hz/s|SPERMATOZOON|CRYOSCOPY|||1|3|Visit_3|40|6|TREATMENT|2020-11-24|40
e|IS|2a595fc0-7621-4ec9-bd77-74444886052e|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^9 organisms/mg|[?]|1|/h|ARTERIAL CORD BLOOD|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|4|Visit_4|65|4|WASHOUT|2020-12-19|65
e|IS|2a595fc0-7621-4ec9-bd77-74444886052e|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^3/L|[?]|1|uV2|PERIPHERAL BLOOD MONONUCLEAR CELL|OPHTHALMOSCOPY|||1|5|Visit_5|90|5|TREATMENT|2021-01-13|90
e|IS|0bab89c8-cf57-4d19-9b95-884a2e9da523|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/kg/week|[?]|1|FFU|DIALYSIS FLUID|LINE PROBE ASSAY|||1|1|Visit_1|10|5|SCREENING|2020-12-20|10
e|IS|0bab89c8-cf57-4d19-9b95-884a2e9da523|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mEq/uL|[?]|1|DRINK|BONE MARROW MONONUCLEAR CELL|SLIT LAMP|||1|2|Visit_2|25|7|TREATMENT|2021-01-04|25
e|IS|0bab89c8-cf57-4d19-9b95-884a2e9da523|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|L|[?]|1|10^6/Ejaculate U|ARTERIALIZED CAPILLARY BLOOD|FLUOROSCOPY||Y|1|3|Visit_3|40|3|WASHOUT|2021-01-19|40
e|IS|0bab89c8-cf57-4d19-9b95-884a2e9da523|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Hz/s|[?]|1|uL|EPITHELIAL CELL|PERIPHERAL ANGIOGRAPHY|Y|Y|1|4|Visit_4|65|6|TREATMENT|2021-02-13|65
e|IS|0bab89c8-cf57-4d19-9b95-884a2e9da523|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|AU/mL|[?]|1|MONTHS|BONE MARROW MONONUCLEAR CELL|KLEIHAUER-BETKE|||1|5|Visit_5|90|4|TREATMENT|2021-03-10|90
e|IS|84edaa9d-ce48-4866-ab43-af91bee126ae|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nCi|[?]|1|mg/day|INTERSTITIAL FLUID|IVY INCISION METHOD|||1|1|Visit_1|10|7|TREATMENT|2020-05-11|10
e|IS|84edaa9d-ce48-4866-ab43-af91bee126ae|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^7 PFU|[?]|1|PFU/mL|SKELETAL MUSCLE TISSUE|POLYSOMNOGRAPHY||Y|1|2|Visit_2|25|6|TREATMENT|2020-05-26|25
e|IS|84edaa9d-ce48-4866-ab43-af91bee126ae|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GPL U/mL|[?]|1|/100 HPFs|INFRANATANT, PLEURAL FLUID|COLORIMETRY|Y||1|3|Visit_3|40|5|TREATMENT|2020-06-10|40
e|IS|84edaa9d-ce48-4866-ab43-af91bee126ae|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/m2/min|[?]|1|ug/m2/min|LEUKOCYTE|MICROPARTICLE ENZYME IMMUNOASSAY|Y|Y|1|4|Visit_4|65|5|FOLLOW-UP|2020-07-05|65
e|IS|84edaa9d-ce48-4866-ab43-af91bee126ae|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MdFI|[?]|1|U/m2/h|PLASMA ULTRAFILTRATE|APPLANATION TONOMETRY|Y|Y|1|5|Visit_5|90|3|WASHOUT|2020-07-30|90
e|IS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Mile|[?]|1|mmol/min/kPa|CARDIAC MUSCLE TISSUE|JAFFE REACTION|||1|1|Visit_1|10|6|SCREENING|2020-08-03|10
e|IS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|pmol/day|[?]|1|GPS U|AQUEOUS HUMOR|DC SHEATH FLOW|||1|2|Visit_2|25|3|TREATMENT|2020-08-18|25
e|IS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 IU|[?]|1|ug/L FEU|MIXED VENOUS BLOOD|SIZE EXCLUSION CHROMATOGRAPHY||Y|1|3|Visit_3|40|3|SCREENING|2020-09-02|40
e|IS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|log10 PFU|[?]|1|APPLICATION|VENOUS BLOOD|ENDPOINT DILUTION ASSAY|Y||1|4|Visit_4|65|4|FOLLOW-UP|2020-09-27|65
e|IS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|%/min|[?]|1|GPL U/mL|SUPERNATANT, PLEURAL FLUID|SCINTIGRAPHY|||1|5|Visit_5|90|5|SCREENING|2020-10-22|90
e|IS|9734ec2a-d06b-43e1-82a5-37764af17890|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pL|[?]|1|U/kg|CORD SERUM|MRI|||1|1|Visit_1|10|2|TREATMENT|2020-09-29|10
e|IS|9734ec2a-d06b-43e1-82a5-37764af17890|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|nmol|[?]|1|WEEKS|CAPILLARY PLASMA|NUCLEIC ACID SEQUENCING||Y|1|2|Visit_2|25|2|FOLLOW-UP|2020-10-14|25
e|IS|9734ec2a-d06b-43e1-82a5-37764af17890|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kg/cm2|[?]|1|pmol/dL|ENDOTRACHEAL FLUID|CLAUSS METHOD||Y|1|3|Visit_3|40|3|TREATMENT|2020-10-29|40
e|IS|9734ec2a-d06b-43e1-82a5-37764af17890|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|sec|[?]|1|U/animal|MENSTRUAL BLOOD|LC/MS|Y||1|4|Visit_4|65|1|FOLLOW-UP|2020-11-23|65
e|IS|9734ec2a-d06b-43e1-82a5-37764af17890|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|K|[?]|1|copies/ug|SMOOTH MUSCLE TISSUE|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|5|Visit_5|90|7|SCREENING|2020-12-18|90
e|IS|9a0ce525-7f10-4651-885a-f64bd9c8925e|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|AgU/mL|[?]|1|umol/mg/min|EPITHELIAL CELL|HEMAGGLUTINATION INHIBITION ASSAY|||1|1|Visit_1|10|3|TREATMENT|2020-11-28|10
e|IS|9a0ce525-7f10-4651-885a-f64bd9c8925e|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|tuberculin unit/mL|[?]|1|DIP|CAPILLARY BLOOD|FLUORIMETRY|||1|2|Visit_2|25|1|TREATMENT|2020-12-13|25
e|IS|9a0ce525-7f10-4651-885a-f64bd9c8925e|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uCi/L|[?]|1|CAPSULE|SEMINAL FLUID|LASER CAPTURE MICRODISSECTION|Y||1|3|Visit_3|40|6|FOLLOW-UP|2020-12-28|40
e|IS|9a0ce525-7f10-4651-885a-f64bd9c8925e|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kg/cm|[?]|1|ug/min|BONE|POLYSOMNOGRAPHY|||1|4|Visit_4|65|1|TREATMENT|2021-01-22|65
e|IS|9a0ce525-7f10-4651-885a-f64bd9c8925e|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|log10 CCID 50/dose|[?]|1|10^6 CFU|SMEGMA|IMMUNOFLUORESCENT STAIN|||1|5|Visit_5|90|2|TREATMENT|2021-02-16|90
e|IS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/g/h|[?]|1|L/min/m2|PLASMA|POPULATION SEQUENCING|Y||1|1|Visit_1|10|5|WASHOUT|2020-07-15|10
e|IS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|fmol/g|[?]|1|Rad|PLASMA ULTRAFILTRATE|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||1|2|Visit_2|25|2|WASHOUT|2020-07-30|25
e|IS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mmHg/L/min|[?]|1|CONTAINER|COLOSTRUM|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|Y|Y|1|3|Visit_3|40|6|SCREENING|2020-08-14|40
e|IS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mmol/min/kPa/L|[?]|1|PACK|EMOTIONAL TEAR|IMMUNOCHROMATOGRAPHY|||1|4|Visit_4|65|3|TREATMENT|2020-09-08|65
e|IS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SQU/mL|[?]|1|psec|SMOOTH MUSCLE TISSUE|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|Y||1|5|Visit_5|90|4|TREATMENT|2020-10-03|90
e|IS|4ba88073-0003-461a-a950-4504ef7680e7|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kN/cm2|[?]|1|days/wk|ALVEOLAR AIR|AMSLER GRID|||1|1|Visit_1|10|5|TREATMENT|2020-09-02|10
e|IS|4ba88073-0003-461a-a950-4504ef7680e7|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cmH2O*s2/mL|[?]|1|ka_u/dL|MUCUS|ALCIAN BLUE STAIN||Y|1|2|Visit_2|25|5|SCREENING|2020-09-17|25
e|IS|4ba88073-0003-461a-a950-4504ef7680e7|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Ci/mg|[?]|1|nmol/L|LUNG SURFACTANT|FLOCCULATION|Y|Y|1|3|Visit_3|40|3|WASHOUT|2020-10-02|40
e|IS|4ba88073-0003-461a-a950-4504ef7680e7|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ms/mmHg|[?]|1|ukat/L|SPERMATOZOON|IMMUNOASSAY|||1|4|Visit_4|65|1|FOLLOW-UP|2020-10-27|65
e|IS|4ba88073-0003-461a-a950-4504ef7680e7|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/animal/day|[?]|1|AU/mL|PUS|MICROBIAL BIOCHEMICAL IDENTIFICATION|||1|5|Visit_5|90|6|TREATMENT|2020-11-21|90
e|IS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3/L|[?]|1|mol/mol|EMOTIONAL TEAR|MICROBIAL CULTURE|Y||1|1|Visit_1|10|6|TREATMENT|2020-09-01|10
e|IS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|kg/mol|[?]|1|PIPE|CIRCULATING TUMOR CELL|BRDU CELLULAR PROLIFERATION ASSAY|||1|2|Visit_2|25|5|SCREENING|2020-09-16|25
e|IS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|DRUM|[?]|1|mg/min|HAIR FOLLICLE|COLORIMETRY|||1|3|Visit_3|40|1|TREATMENT|2020-10-01|40
e|IS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 U|[?]|1|AgU/mL|BLOOD|AGAR DILUTION|||1|4|Visit_4|65|5|TREATMENT|2020-10-26|65
e|IS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^4/L|[?]|1|LB|COLOSTRUM|FUNDUS PHOTOGRAPHY|||1|5|Visit_5|90|5|TREATMENT|2020-11-20|90
e|IS|f552fa78-d78f-44c5-9590-30a737e6652d|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^8/L|[?]|1|g/day|TISSUE|PERIPHERAL ANGIOGRAPHY||Y|1|1|Visit_1|10|5|FOLLOW-UP|2020-10-05|10
e|IS|f552fa78-d78f-44c5-9590-30a737e6652d|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/cage/wk|[?]|1|APPLICATION|ISOLATE|PET/SPECT SCAN||Y|1|2|Visit_2|25|3|TREATMENT|2020-10-20|25
e|IS|f552fa78-d78f-44c5-9590-30a737e6652d|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ELISA unit/mL|[?]|1|TRACE|SPERMATOZOON|IMMUNOCHEMILUMINOMETRIC ASSAY|||1|3|Visit_3|40|5|WASHOUT|2020-11-04|40
e|IS|f552fa78-d78f-44c5-9590-30a737e6652d|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Antibody Unit|[?]|1|log10 PFU|PLATELET POOR PLASMA|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||1|4|Visit_4|65|3|TREATMENT|2020-11-29|65
e|IS|f552fa78-d78f-44c5-9590-30a737e6652d|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log10 PFU|[?]|1|pmol/10^10 cells|ATHEROSCLEROTIC PLAQUE|MOUSE PROTECTION ASSAY|||1|5|Visit_5|90|3|TREATMENT|2020-12-24|90
e|IS|38d83f86-d8ce-461a-a288-95aebe498d22|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm/2h|[?]|1|USP U|PLATELET RICH PLASMA|ELECTRICAL IMPEDANCE MYOGRAPHY|||1|1|Visit_1|10|6|SCREENING|2020-08-25|10
e|IS|38d83f86-d8ce-461a-a288-95aebe498d22|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mU/g|[?]|1|MASK|CAPILLARY BLOOD|NON-INVASIVE DIELECTRIC SENSING|Y||1|2|Visit_2|25|3|TREATMENT|2020-09-09|25
e|IS|38d83f86-d8ce-461a-a288-95aebe498d22|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 organisms/g|[?]|1|mg/dose|ERYTHROCYTES|LC/MS/MS|Y||1|3|Visit_3|40|3|TREATMENT|2020-09-24|40
e|IS|38d83f86-d8ce-461a-a288-95aebe498d22|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|deg/mm|[?]|1|log10 CFU/g|EMOTIONAL TEAR|GC/FID||Y|1|4|Visit_4|65|5|SCREENING|2020-10-19|65
e|IS|38d83f86-d8ce-461a-a288-95aebe498d22|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mOsm|[?]|1|mV2/Hz|SYNOVIAL FLUID|ELASTOGRAPHY|||1|5|Visit_5|90|6|TREATMENT|2020-11-13|90
e|IS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/m2|[?]|1|QUANTITY SUFFICIENT|CORD SERUM|IMMUNOFLUORESCENT STAIN|||1|1|Visit_1|10|4|SCREENING|2020-08-13|10
e|IS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mMU/mL|[?]|1|um/day|URINE|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y||1|2|Visit_2|25|6|TREATMENT|2020-08-28|25
e|IS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|KALLIKREIN INHIBITOR UNIT|[?]|1|10^3 CFU|EPITHELIAL CELL|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||1|3|Visit_3|40|4|TREATMENT|2020-09-12|40
e|IS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Mile|[?]|1|g/L|GASTRIC FLUID|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y|Y|1|4|Visit_4|65|2|WASHOUT|2020-10-07|65
e|IS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|uL|[?]|1|mL/kg|CAPILLARY BLOOD|LANDOLT RING||Y|1|5|Visit_5|90|3|FOLLOW-UP|2020-11-01|90
e|IS|cf39d5bd-7682-4546-8495-5bcf48600a69|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|L/s|[?]|1|/4.0 mL|CAPILLARY BLOOD|DIFFUSION WEIGHTED MRI|||1|1|Visit_1|10|4|TREATMENT|2021-01-20|10
e|IS|cf39d5bd-7682-4546-8495-5bcf48600a69|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|DAYS|[?]|1|mkat|BONE MARROW|SPIRAL CT SCAN WITHOUT CONTRAST|||1|2|Visit_2|25|1|WASHOUT|2021-02-04|25
e|IS|cf39d5bd-7682-4546-8495-5bcf48600a69|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^5/hpf|[?]|1|kPa/L/sec|EXPIRED AIR|PHASE CONTRAST MICROSCOPY|||1|3|Visit_3|40|4|WASHOUT|2021-02-19|40
e|IS|cf39d5bd-7682-4546-8495-5bcf48600a69|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|pg|[?]|1|10^6 U|AQUEOUS HUMOR|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||Y|1|4|Visit_4|65|7|TREATMENT|2021-03-16|65
e|IS|cf39d5bd-7682-4546-8495-5bcf48600a69|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|umol/L|[?]|1|/5x10^4 WBC|MUSCLE TISSUE|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||1|5|Visit_5|90|7|WASHOUT|2021-04-10|90
e|IS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Siemens|[?]|1|WAFER|AMNIOTIC FLUID|RADIATION DOSIMETRY|Y||1|1|Visit_1|10|1|SCREENING|2020-11-24|10
e|IS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/kg/dose|[?]|1|uIU/dL|PLATELET RICH PLASMA|CONTACT SPECULAR MICROSCOPY|Y||1|2|Visit_2|25|6|FOLLOW-UP|2020-12-09|25
e|IS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|amol|[?]|1|cm/s|NAIL|AUTOMATED COUNT|||1|3|Visit_3|40|5|SCREENING|2020-12-24|40
e|IS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mol/mg|[?]|1|pt_us|URINE|IODINE STAIN|||1|4|Visit_4|65|2|TREATMENT|2021-01-18|65
e|IS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/mol|[?]|1|10^6 RNA copies/mL|BASAL TEAR|NUCLEIC ACID BASED METHOD|||1|5|Visit_5|90|6|FOLLOW-UP|2021-02-12|90
e|IS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|TROCHE|[?]|1|ug/kg/day|INFRANATANT, SERUM|KARYOTYPING|||1|1|Visit_1|10|3|TREATMENT|2021-01-27|10
e|IS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|BAU|[?]|1|Watt|SERUM OR PLASMA|COMPUTERIZED CORNEAL TOPOGRAPHY|||1|2|Visit_2|25|2|TREATMENT|2021-02-11|25
e|IS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|min*mg/mL|[?]|1|oz eq|URINE SEDIMENT|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|3|Visit_3|40|2|TREATMENT|2021-02-26|40
e|IS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|MPL U/mL|[?]|1|Log10 ELISA unit/dose|SUPERNATANT, PLASMA|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||Y|1|4|Visit_4|65|5|TREATMENT|2021-03-23|65
e|IS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/m2/min|[?]|1|gtt|PLASMA|TOTAL BODY RADIOGRAPHY|||1|5|Visit_5|90|2|FOLLOW-UP|2021-04-17|90
e|IS|2b25e1f9-929c-4bdc-8758-79f33b832026|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kBq|[?]|1|10^3 CFU/g|PLASMA ULTRAFILTRATE|HANSEL STAIN|||1|1|Visit_1|10|4|FOLLOW-UP|2020-10-19|10
e|IS|2b25e1f9-929c-4bdc-8758-79f33b832026|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|1/(s*kPa)|SUPERNATANT, PLEURAL FLUID|COMPUTERIZED CORNEAL TOPOGRAPHY||Y|1|2|Visit_2|25|2|FOLLOW-UP|2020-11-03|25
e|IS|2b25e1f9-929c-4bdc-8758-79f33b832026|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nmol/L/min|[?]|1|tsp|PROSTATIC FLUID|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|3|Visit_3|40|3|TREATMENT|2020-11-18|40
e|IS|2b25e1f9-929c-4bdc-8758-79f33b832026|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/g/h|[?]|1|AFU|LOCHIA|ANTIMICROBIAL COMBINATION TESTING|||1|4|Visit_4|65|3|WASHOUT|2020-12-13|65
e|IS|2b25e1f9-929c-4bdc-8758-79f33b832026|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^5/hpf|[?]|1|ug/kg/min|SKIN TISSUE|ICC|||1|5|Visit_5|90|4|FOLLOW-UP|2021-01-07|90
e|IS|d02c7553-17f5-44ec-8c24-469234d080e8|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|nmol/mL/min|[?]|1|mg/kg/day|SALIVA|SMEAR|Y||1|1|Visit_1|10|7|FOLLOW-UP|2021-01-26|10
e|IS|d02c7553-17f5-44ec-8c24-469234d080e8|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|SPRAY|[?]|1|FEU|GASTRIC CONTENTS|CENTRIFUGATION|||1|2|Visit_2|25|3|TREATMENT|2021-02-10|25
e|IS|d02c7553-17f5-44ec-8c24-469234d080e8|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Coulomb|[?]|1|mU/g|PLEURAL FLUID|BALLPOINT PEN TECHNIQUE|||1|3|Visit_3|40|1|SCREENING|2021-02-25|40
e|IS|d02c7553-17f5-44ec-8c24-469234d080e8|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|BU|[?]|1|mmol/s|EXHALED BREATH CONDENSATE|HPLC-FL|Y||1|4|Visit_4|65|6|WASHOUT|2021-03-22|65
e|IS|d02c7553-17f5-44ec-8c24-469234d080e8|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|pm|[?]|1|10^5/L|CORD SERUM|FUNDUS PHOTOGRAPHY|||1|5|Visit_5|90|3|TREATMENT|2021-04-16|90
e|IS|e819939e-548d-4e05-83e3-7976790de7e1|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|IU/kg/h|[?]|1|%/s|LYMPH|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y||1|1|Visit_1|10|4|SCREENING|2020-09-07|10
e|IS|e819939e-548d-4e05-83e3-7976790de7e1|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/m2|[?]|1|nkat/g Hb|STRIATED MUSCLE TISSUE|CONTRAST ENHANCED X-RAY|||1|2|Visit_2|25|4|FOLLOW-UP|2020-09-22|25
e|IS|e819939e-548d-4e05-83e3-7976790de7e1|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CIGAR|[?]|1|mV|SUPERNATANT, PLASMA|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|3|Visit_3|40|7|TREATMENT|2020-10-07|40
e|IS|e819939e-548d-4e05-83e3-7976790de7e1|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Frames/s|[?]|1|Bq/kg|SMOOTH MUSCLE TISSUE|TRANSTHORACIC ECHOCARDIOGRAPHY|||1|4|Visit_4|65|4|WASHOUT|2020-11-01|65
e|IS|e819939e-548d-4e05-83e3-7976790de7e1|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/cm|[?]|1|DAYS|SEBUM|DUKE INCISION METHOD||Y|1|5|Visit_5|90|5|WASHOUT|2020-11-26|90
e|IS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL|[?]|1|KALLIKREIN INHIBITOR UNIT|SUPERNATANT, SERUM|TRANSMISSION ELECTRON MICROSCOPY|||1|1|Visit_1|10|5|FOLLOW-UP|2020-08-18|10
e|IS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|EIA unit|[?]|1|ug/m2/h|PLEURAL TISSUE|RIA|||1|2|Visit_2|25|2|TREATMENT|2020-09-02|25
e|IS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|gpELISA unit/mL|[?]|1|mg/g/min|SYNOVIAL FLUID|NEXT GENERATION SEQUENCING|Y|Y|1|3|Visit_3|40|4|SCREENING|2020-09-17|40
e|IS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|100 IU/mL|[?]|1|ug/g/min|LOCHIA|FUNCTIONAL MRI|||1|4|Visit_4|65|3|FOLLOW-UP|2020-10-12|65
e|IS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|%/min|[?]|1|10^9 CFU/mL|EXPIRED AIR|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y||1|5|Visit_5|90|2|WASHOUT|2020-11-06|90
e|IS|ea5229ad-6469-4147-be40-546d27c04c4c|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|min/day|[?]|1|dL|LOCHIA|COMPUTERIZED CORNEAL TOPOGRAPHY||Y|1|1|Visit_1|10|6|TREATMENT|2020-06-09|10
e|IS|ea5229ad-6469-4147-be40-546d27c04c4c|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mEq/dL|[?]|1|h*%|MIXED VENOUS BLOOD|OLIGO ACGH|||1|2|Visit_2|25|5|TREATMENT|2020-06-24|25
e|IS|ea5229ad-6469-4147-be40-546d27c04c4c|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|breaths/min|[?]|1|10^9/dose|PLEURAL FLUID|DYNAMOMETRY|||1|3|Visit_3|40|3|TREATMENT|2020-07-09|40
e|IS|ea5229ad-6469-4147-be40-546d27c04c4c|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uL/mL|[?]|1|tuberculin unit|VITREOUS HUMOR|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||1|4|Visit_4|65|6|TREATMENT|2020-08-03|65
e|IS|ea5229ad-6469-4147-be40-546d27c04c4c|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|CONTAINER|[?]|1|ug/day|LYSATE|IMPEDANCE CONDUCTIVITY|||1|5|Visit_5|90|3|FOLLOW-UP|2020-08-28|90
e|IS|0a566742-0f71-4603-85f0-875e2c3395e7|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|OD Unit|[?]|1|10^6 organisms/g|CERUMEN|AGAR DILUTION|||1|1|Visit_1|10|4|TREATMENT|2021-01-08|10
e|IS|0a566742-0f71-4603-85f0-875e2c3395e7|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|fraction of 1|[?]|1|nmol|BONE|FLUORESCEIN STAIN|||1|2|Visit_2|25|4|FOLLOW-UP|2021-01-23|25
e|IS|0a566742-0f71-4603-85f0-875e2c3395e7|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^9 organisms/g|[?]|1|mL/sec/1.73m2|CERVICOVAGINAL SECRETION|SINGLE-MOLECULE ARRAY|||1|3|Visit_3|40|6|TREATMENT|2021-02-07|40
e|IS|0a566742-0f71-4603-85f0-875e2c3395e7|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/breath|[?]|1|/ms|EPITHELIAL CELL|CELL OF ORIGIN ASSAY|||1|4|Visit_4|65|6|FOLLOW-UP|2021-03-04|65
e|IS|0a566742-0f71-4603-85f0-875e2c3395e7|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uIU/L|[?]|1|10^9 CFU|ERYTHROCYTES|SLOAN LETTER EYE CHART 1.25%|||1|5|Visit_5|90|5|FOLLOW-UP|2021-03-29|90
e|IS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|DAgU/mL|[?]|1|m3|SKELETAL MUSCLE TISSUE|WESTERGREN|||1|1|Visit_1|10|2|TREATMENT|2020-05-14|10
e|IS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|DNA copies/ug|[?]|1|MESF|SERUM|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|1|2|Visit_2|25|2|WASHOUT|2020-05-29|25
e|IS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Antibody Unit|[?]|1|cpm|SOFT TISSUE|ANTIMICROBIAL COMBINATION TESTING|||1|3|Visit_3|40|2|WASHOUT|2020-06-13|40
e|IS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|kg/cm2|[?]|1|mEq/ug|PLATELET RICH PLASMA|NON-INVASIVE DIELECTRIC SENSING||Y|1|4|Visit_4|65|7|WASHOUT|2020-07-08|65
e|IS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|V|[?]|1|ms2|MECONIUM|SICKLE CELL SOLUBILITY TEST|Y||1|5|Visit_5|90|3|TREATMENT|2020-08-02|90
e|IS|48103500-0f3d-4108-9167-6afee1098773|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uU/L|[?]|1|ug/cm2|PROSTATIC FLUID|OPTICAL MAPPING|Y||1|1|Visit_1|10|7|TREATMENT|2020-05-15|10
e|IS|48103500-0f3d-4108-9167-6afee1098773|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PACKET|[?]|1|SFC/10^6 PBMC|BREAST MILK|EIA|||1|2|Visit_2|25|5|TREATMENT|2020-05-30|25
e|IS|48103500-0f3d-4108-9167-6afee1098773|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Linear ft*LB|[?]|1|AMPULE|ENDOTRACHEAL FLUID|DIGITAL PCR ARRAY|Y||1|3|Visit_3|40|5|SCREENING|2020-06-14|40
e|IS|48103500-0f3d-4108-9167-6afee1098773|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|dyn|[?]|1|fmol/g|PLASMA ULTRAFILTRATE|DISK DIFFUSION||Y|1|4|Visit_4|65|5|SCREENING|2020-07-09|65
e|IS|48103500-0f3d-4108-9167-6afee1098773|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/m2/day|[?]|1|/HPF|TISSUE|ARTERIAL SPIN LABELING FUNCTIONAL MRI||Y|1|5|Visit_5|90|7|TREATMENT|2020-08-03|90
e|IS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mg/mol|[?]|1|V|INFRANATANT, SERUM|OPTICAL DENSITY MEASUREMENT||Y|1|1|Visit_1|10|6|SCREENING|2020-07-25|10
e|IS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cal|[?]|1|MHz|HAIR FOLLICLE|AUSCULTATION||Y|1|2|Visit_2|25|4|TREATMENT|2020-08-09|25
e|IS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|GBq/ug|[?]|1|/100 WBC|VITREOUS HUMOR|CHROMATOGRAPHY|Y||1|3|Visit_3|40|1|TREATMENT|2020-08-24|40
e|IS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|rpm|[?]|1|Ci/mg|BILE|OLIGO ACGH||Y|1|4|Visit_4|65|4|TREATMENT|2020-09-18|65
e|IS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mCi/kg|[?]|1|Pack Year|NAIL|OLIGO ACGH|||1|5|Visit_5|90|3|WASHOUT|2020-10-13|90
e|IS|ceab42b0-3a7e-4aad-b599-5da311398148|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|APL U|[?]|1|cm/min|CALCULUS|FLUORESCENT SPOT TEST||Y|1|1|Visit_1|10|3|WASHOUT|2020-06-21|10
e|IS|ceab42b0-3a7e-4aad-b599-5da311398148|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/g/day|[?]|1|uL/mL|BUFFY COAT|DARK FIELD MICROSCOPY|||1|2|Visit_2|25|5|SCREENING|2020-07-06|25
e|IS|ceab42b0-3a7e-4aad-b599-5da311398148|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|log10 TCID 50/dose|[?]|1|BLOCKS|STOOL|MOUSE PROTECTION ASSAY|||1|3|Visit_3|40|4|WASHOUT|2020-07-21|40
e|IS|ceab42b0-3a7e-4aad-b599-5da311398148|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nmol/g|[?]|1|CYLINDER|VITREOUS HUMOR|GRAM STAIN||Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-08-15|65
e|IS|ceab42b0-3a7e-4aad-b599-5da311398148|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SCOOPFUL|[?]|1|keV|EXPIRED AIR|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|5|Visit_5|90|2|TREATMENT|2020-09-09|90
e|IS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|CCID 50/mL|[?]|1|/month|SOFT TISSUE|GEL ELECTROPHORESIS|||1|1|Visit_1|10|6|TREATMENT|2020-07-09|10
e|IS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ELISA unit/mL|[?]|1|Rad|SOFT TISSUE|IN VITRO GENE EXPRESSION ASSAY|Y||1|2|Visit_2|25|3|SCREENING|2020-07-24|25
e|IS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|/200 HPFs|[?]|1|EIA unit|BASAL TEAR|MASS SPECTROMETRY|||1|3|Visit_3|40|1|WASHOUT|2020-08-08|40
e|IS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Shock Wave|[?]|1|umol/L/sec|PLATELET RICH PLASMA|COMPUTERIZED CORNEAL TOPOGRAPHY|Y|Y|1|4|Visit_4|65|4|SCREENING|2020-09-02|65
e|IS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|titer|[?]|1|/cmH2O|SMEGMA|FARR ASSAY|||1|5|Visit_5|90|2|TREATMENT|2020-09-27|90
e|IS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/LSQN|[?]|1|mkat|BASAL TEAR|EPSILOMETER|Y||1|1|Visit_1|10|6|WASHOUT|2020-07-10|10
e|IS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|rpm|[?]|1|INHALATION|PLATELET POOR PLASMA|BRDU CELLULAR PROLIFERATION ASSAY|Y||1|2|Visit_2|25|2|TREATMENT|2020-07-25|25
e|IS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mL/s/m2|[?]|1|CONTAINER|ATHEROSCLEROTIC PLAQUE|FARNSWORTH-MUNSELL 100 HUE TEST|||1|3|Visit_3|40|1|WASHOUT|2020-08-09|40
e|IS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|GPL U|[?]|1|OI50|BILE|OPTICAL COHERENCE TOMOGRAPHY|Y||1|4|Visit_4|65|7|TREATMENT|2020-09-03|65
e|IS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MET*h|[?]|1|psi|SPUTUM|CONFOCAL MICROSCOPY|||1|5|Visit_5|90|4|FOLLOW-UP|2020-09-28|90
e|IS|36a54b72-6368-460e-ab4c-952923e0fd14|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|dpm/mL|[?]|1|cd/m2|SERUM|ENZYMATIC ULTRACENTRIFUGATION||Y|1|1|Visit_1|10|1|WASHOUT|2020-05-15|10
e|IS|36a54b72-6368-460e-ab4c-952923e0fd14|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|g/cage/day|[?]|1|gtt|ARTERIAL CORD BLOOD|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||1|2|Visit_2|25|5|FOLLOW-UP|2020-05-30|25
e|IS|36a54b72-6368-460e-ab4c-952923e0fd14|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kg/mol|[?]|1|kg/cm|SYNOVIAL FLUID|FARR ASSAY|Y||1|3|Visit_3|40|2|FOLLOW-UP|2020-06-14|40
e|IS|36a54b72-6368-460e-ab4c-952923e0fd14|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/h|[?]|1|yd|INFRANATANT, PLASMA|TRIPLE-PHASE SPIRAL CT SCAN|||1|4|Visit_4|65|2|SCREENING|2020-07-09|65
e|IS|36a54b72-6368-460e-ab4c-952923e0fd14|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 DNA copies/mL|[?]|1|foz_us|FLUID|ERGOSPIROMETRY|||1|5|Visit_5|90|7|WASHOUT|2020-08-03|90
e|IS|84e56692-9a33-472a-9ddc-545d3342da34|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|tuberculin unit/mL|[?]|1|/MBP|SERUM OR PLASMA|RADIATION DOSIMETRY||Y|1|1|Visit_1|10|4|WASHOUT|2020-12-19|10
e|IS|84e56692-9a33-472a-9ddc-545d3342da34|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/dose|[?]|1|U/kg/day|SEMINAL FLUID|IMPEDANCE CONDUCTIVITY|||1|2|Visit_2|25|7|TREATMENT|2021-01-03|25
e|IS|84e56692-9a33-472a-9ddc-545d3342da34|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^10/L|[?]|1|U/m2/h|WHITE MATTER TISSUE|ELECTRONEUROGRAPHY|Y||1|3|Visit_3|40|2|FOLLOW-UP|2021-01-18|40
e|IS|84e56692-9a33-472a-9ddc-545d3342da34|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|m/sec|[?]|1|CFU/g|URINE|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y||1|4|Visit_4|65|1|TREATMENT|2021-02-12|65
e|IS|84e56692-9a33-472a-9ddc-545d3342da34|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|dpm/0.5 mL|[?]|1|BAU/mL|CERVICOVAGINAL SECRETION|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||1|5|Visit_5|90|5|SCREENING|2021-03-09|90
e|IS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mm/h|[?]|1|mN|SEBUM|NO INFORMATION|||1|1|Visit_1|10|4|TREATMENT|2020-05-31|10
e|IS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|SYRINGE|[?]|1|pmol/10^9 cells|CORD SERUM|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||1|2|Visit_2|25|1|TREATMENT|2020-06-15|25
e|IS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|U/cL|[?]|1|ft|EPIDERMAL TISSUE|FLOW MICROSCOPY|Y||1|3|Visit_3|40|7|FOLLOW-UP|2020-06-30|40
e|IS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/cm2|[?]|1|DISK|PLASMA|MAGNETIC RESONANCE ENTEROGRAPHY|||1|4|Visit_4|65|7|WASHOUT|2020-07-25|65
e|IS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/mmHg|[?]|1|kHz|BLOOD|IVY INCISION METHOD|Y||1|5|Visit_5|90|2|WASHOUT|2020-08-19|90
e|IS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mmol/min/kPa|[?]|1|nmol BCE/nmol|RETICULOCYTES|CLIP|Y||1|1|Visit_1|10|7|WASHOUT|2020-06-10|10
e|IS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Enzyme U/m2|[?]|1|dram|GASTRIC CONTENTS|CLAUSS METHOD|||1|2|Visit_2|25|4|FOLLOW-UP|2020-06-25|25
e|IS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug|[?]|1|cd|CEREBROSPINAL FLUID|KARYOTYPING|Y||1|3|Visit_3|40|6|WASHOUT|2020-07-10|40
e|IS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^6 U|[?]|1|Linear ft*LB|DIALYSIS FLUID, PERITONEAL|FUNDUS PHOTOGRAPHY|||1|4|Visit_4|65|4|TREATMENT|2020-08-04|65
e|IS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/mg/min|[?]|1|uEq/L|CERVICOVAGINAL SECRETION|ELISA|||1|5|Visit_5|90|2|TREATMENT|2020-08-29|90
e|IS|ae0e05c1-3953-4406-bfae-299295c1fa4c|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/m2|[?]|1|ugEq/L|PERITONEAL FLUID|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||Y|1|1|Visit_1|10|4|TREATMENT|2021-01-12|10
e|IS|ae0e05c1-3953-4406-bfae-299295c1fa4c|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|DRINK|[?]|1|Roentgen|HAIR FOLLICLE|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||Y|1|2|Visit_2|25|7|TREATMENT|2021-01-27|25
e|IS|ae0e05c1-3953-4406-bfae-299295c1fa4c|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|oz eq|[?]|1|Watt|SWABBED MATERIAL|GRAM STAIN|||1|3|Visit_3|40|2|TREATMENT|2021-02-11|40
e|IS|ae0e05c1-3953-4406-bfae-299295c1fa4c|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|gtt|[?]|1|10^6 IU/mL|BREAST MILK|RYAN BLUE STAIN||Y|1|4|Visit_4|65|6|SCREENING|2021-03-08|65
e|IS|ae0e05c1-3953-4406-bfae-299295c1fa4c|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|TROCHE|[?]|1|ELISA unit/mL|SALIVA|ICC|||1|5|Visit_5|90|4|TREATMENT|2021-04-02|90
e|IS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|nmol/L|[?]|1|PACKAGE|SEBUM|OPTICAL MAPPING||Y|1|1|Visit_1|10|1|FOLLOW-UP|2021-01-16|10
e|IS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Arbitrary U|[?]|1|copies/ug|RETICULOCYTES|IMMUNOFLUORESCENT STAIN|||1|2|Visit_2|25|7|TREATMENT|2021-01-31|25
e|IS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MONTHS|[?]|1|BEAM BREAKS|GASTRIC FLUID|DYNAMOMETRY|Y||1|3|Visit_3|40|7|TREATMENT|2021-02-15|40
e|IS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/g|[?]|1|mCi|SMEGMA|DIGITAL PCR ARRAY|||1|4|Visit_4|65|7|FOLLOW-UP|2021-03-12|65
e|IS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|cy/cm|[?]|1|DNA copies/ug|LAVAGE FLUID|SXA SCAN||Y|1|5|Visit_5|90|7|TREATMENT|2021-04-06|90
e|IS|ab09e76d-8bbf-4126-a60d-08d6b5292836|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^3 organisms/mL|[?]|1|APS U|TISSUE|MULTI-SLICE SPIRAL CT|||1|1|Visit_1|10|7|WASHOUT|2020-12-25|10
e|IS|ab09e76d-8bbf-4126-a60d-08d6b5292836|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/cm3/min|[?]|1|mL/m2|PLATELET|DC SHEATH FLOW|||1|2|Visit_2|25|5|TREATMENT|2021-01-09|25
e|IS|ab09e76d-8bbf-4126-a60d-08d6b5292836|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|CARTRIDGE|[?]|1|mg/mL/min|ARTERIAL BLOOD|CYSTOMETRY||Y|1|3|Visit_3|40|1|TREATMENT|2021-01-24|40
e|IS|ab09e76d-8bbf-4126-a60d-08d6b5292836|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|U/animal|[?]|1|ks|VENOUS BLOOD|NON-INVASIVE DIELECTRIC SENSING|||1|4|Visit_4|65|5|TREATMENT|2021-02-18|65
e|IS|ab09e76d-8bbf-4126-a60d-08d6b5292836|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|BU|[?]|1|lx|CALCULUS|URANYL ACETATE STAIN|||1|5|Visit_5|90|1|FOLLOW-UP|2021-03-15|90
e|IS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/cm3/min|[?]|1|pmol/day|ATHEROSCLEROTIC PLAQUE|INDIA INK STAIN||Y|1|1|Visit_1|10|4|TREATMENT|2020-07-11|10
e|IS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^3 copies/mL|[?]|1|pt_us|BUFFY COAT|NUCLEIC ACID AMPLIFICATION TEST|||1|2|Visit_2|25|5|TREATMENT|2020-07-26|25
e|IS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cL|[?]|1|kg/cm2|CORD SERUM|ANTIMICROBIAL COMBINATION TESTING|Y||1|3|Visit_3|40|4|FOLLOW-UP|2020-08-10|40
e|IS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/mL/day|[?]|1|mL/sec/1.73m2|PLATELET|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||1|4|Visit_4|65|3|SCREENING|2020-09-04|65
e|IS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|pg|[?]|1|LB|TUMOR TISSUE|PET SCAN||Y|1|5|Visit_5|90|2|SCREENING|2020-09-29|90
e|IS|187b2279-526f-4978-89d4-d2da56cc2257|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^9 organisms/mg|[?]|1|mg/L|CERUMEN|PYROSEQUENCING||Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-06-21|10
e|IS|187b2279-526f-4978-89d4-d2da56cc2257|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|cP|[?]|1|mg/day|VENOUS PLASMA|OLIGO ACGH||Y|1|2|Visit_2|25|4|SCREENING|2020-07-06|25
e|IS|187b2279-526f-4978-89d4-d2da56cc2257|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nkat/L|[?]|1|BP|VENOUS CORD BLOOD|IMMUNORADIOMETRIC ASSAY|||1|3|Visit_3|40|5|TREATMENT|2020-07-21|40
e|IS|187b2279-526f-4978-89d4-d2da56cc2257|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|IU/kg/h|[?]|1|mg/cm2|MECONIUM|GC/MS-CI||Y|1|4|Visit_4|65|7|TREATMENT|2020-08-15|65
e|IS|187b2279-526f-4978-89d4-d2da56cc2257|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cmol|[?]|1|anti-Xa IU/mL|CORD SERUM|SNELLEN EYE CHART|||1|5|Visit_5|90|7|TREATMENT|2020-09-09|90
e|IS|53506a04-dedb-495b-8e35-0576cdf1b323|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|SACHET|[?]|1|F|LOCHIA|SLOAN LETTER EYE CHART 2.5%|||1|1|Visit_1|10|5|TREATMENT|2020-11-07|10
e|IS|53506a04-dedb-495b-8e35-0576cdf1b323|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cm2|[?]|1|Enzyme U|SEMINAL FLUID|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||1|2|Visit_2|25|5|TREATMENT|2020-11-22|25
e|IS|53506a04-dedb-495b-8e35-0576cdf1b323|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/g|[?]|1|mL*cmH2O|BONE MARROW|FREEZING POINT DEPRESSION||Y|1|3|Visit_3|40|1|SCREENING|2020-12-07|40
e|IS|53506a04-dedb-495b-8e35-0576cdf1b323|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/kg/dose|[?]|1|kUSP|HAIR FOLLICLE|HPLC-FL|||1|4|Visit_4|65|1|TREATMENT|2021-01-01|65
e|IS|53506a04-dedb-495b-8e35-0576cdf1b323|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|days/wk|[?]|1|HOMEOPATHIC DILUTION|CERUMEN|ELECTROMYOGRAPHY||Y|1|5|Visit_5|90|6|FOLLOW-UP|2021-01-26|90
e|IS|defa600c-4205-476e-a40c-690cb16769b3|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GBq|[?]|1|10^5/L|TRANSUDATE|PERCUSSION||Y|1|1|Visit_1|10|3|TREATMENT|2021-01-24|10
e|IS|defa600c-4205-476e-a40c-690cb16769b3|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/day|[?]|1|U/g Hb|MUCUS|WHOLE EXOME SEQUENCING|||1|2|Visit_2|25|7|TREATMENT|2021-02-08|25
e|IS|defa600c-4205-476e-a40c-690cb16769b3|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|L/min/m2|[?]|1|V|CERUMEN|CELL OF ORIGIN ASSAY||Y|1|3|Visit_3|40|1|FOLLOW-UP|2021-02-23|40
e|IS|defa600c-4205-476e-a40c-690cb16769b3|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|anti-Xa IU|[?]|1|10^3 CFU/mL|MECONIUM|RAJI CELL EIA|Y||1|4|Visit_4|65|6|TREATMENT|2021-03-20|65
e|IS|defa600c-4205-476e-a40c-690cb16769b3|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/beat|[?]|1|ELISA unit/mL|PLASMA ULTRAFILTRATE|BRDU CELLULAR PROLIFERATION ASSAY|Y|Y|1|5|Visit_5|90|4|TREATMENT|2021-04-14|90
e|IS|e5092583-4259-40ba-a6a2-eeef6607263b|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/g|[?]|1|hPa|SYNOVIAL FLUID|IMMUNOCHROMATOGRAPHY|||1|1|Visit_1|10|4|TREATMENT|2020-09-16|10
e|IS|e5092583-4259-40ba-a6a2-eeef6607263b|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|keV|[?]|1|IU/kg|SUPERNATANT, SERUM|VENTILATION PERFUSION LUNG SCAN|||1|2|Visit_2|25|1|SCREENING|2020-10-01|25
e|IS|e5092583-4259-40ba-a6a2-eeef6607263b|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|SACHET|[?]|1|g/cage/day|SUPERNATANT, PLEURAL FLUID|AGAR PROPORTION|||1|3|Visit_3|40|6|SCREENING|2020-10-16|40
e|IS|e5092583-4259-40ba-a6a2-eeef6607263b|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uIU/dL|[?]|1|10^3/L|MIXED VENOUS BLOOD|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y||1|4|Visit_4|65|7|WASHOUT|2020-11-10|65
e|IS|e5092583-4259-40ba-a6a2-eeef6607263b|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/animal/wk|[?]|1|10^7/L|WHITE MATTER TISSUE|LC-FL||Y|1|5|Visit_5|90|3|SCREENING|2020-12-05|90
e|IS|461196d1-1213-4e5f-9bac-71f097b6cfdb|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/dL|[?]|1|mEq/kg|INFRANATANT, PLEURAL FLUID|CALCULATION|||1|1|Visit_1|10|6|SCREENING|2020-11-13|10
e|IS|461196d1-1213-4e5f-9bac-71f097b6cfdb|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ag|[?]|1|mol|SMEGMA|WRIGHT STAIN|||1|2|Visit_2|25|6|TREATMENT|2020-11-28|25
e|IS|461196d1-1213-4e5f-9bac-71f097b6cfdb|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/500 WBC|[?]|1|cm/s|STOOL|IMMUNE REPERTOIRE DEEP SEQUENCING|Y||1|3|Visit_3|40|6|TREATMENT|2020-12-13|40
e|IS|461196d1-1213-4e5f-9bac-71f097b6cfdb|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/min|[?]|1|Sv|BASAL TEAR|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y|1|4|Visit_4|65|3|TREATMENT|2021-01-07|65
e|IS|461196d1-1213-4e5f-9bac-71f097b6cfdb|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^12/L|[?]|1|10^6 organisms/g|CAPILLARY PLASMA|AUSCULTATION|||1|5|Visit_5|90|2|TREATMENT|2021-02-01|90
e|IS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mm3/mm2/year|[?]|1|ug/day|DIALYSIS FLUID, PERITONEAL|SPIRAL CT SCAN WITHOUT CONTRAST|Y||1|1|Visit_1|10|7|TREATMENT|2020-12-09|10
e|IS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ag|[?]|1|dpm/mL|LOCHIA|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||1|2|Visit_2|25|5|TREATMENT|2020-12-24|25
e|IS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|amu|[?]|1|pmol/10^10 cells|CIRCULATING TUMOR CELL|SNELLEN EYE CHART|Y|Y|1|3|Visit_3|40|7|WASHOUT|2021-01-08|40
e|IS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|g/day|[?]|1|10^3 DNA copies/mL|ERYTHROCYTES|MAMMOGRAPHY|||1|4|Visit_4|65|6|TREATMENT|2021-02-02|65
e|IS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mm/2h|[?]|1|pmol/10^10 cells|PUS|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y||1|5|Visit_5|90|1|TREATMENT|2021-02-27|90
e|IS|57971bdc-14df-4d9e-a59a-2665703c12ab|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|m3|[?]|1|uEq|ARTERIAL BLOOD|LIGHT MICROSCOPY|||1|1|Visit_1|10|7|FOLLOW-UP|2020-05-30|10
e|IS|57971bdc-14df-4d9e-a59a-2665703c12ab|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DNA copies/ug|[?]|1|PA|MECONIUM|MICRONEUTRALIZATION ASSAY|||1|2|Visit_2|25|5|TREATMENT|2020-06-14|25
e|IS|57971bdc-14df-4d9e-a59a-2665703c12ab|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Bq/kg|[?]|1|pmol/dL|COLOSTRUM|IMMUNO-PET SCAN|||1|3|Visit_3|40|1|FOLLOW-UP|2020-06-29|40
e|IS|57971bdc-14df-4d9e-a59a-2665703c12ab|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/L|[?]|1|Pack Year|SYNOVIAL FLUID|CT SCAN WITHOUT CONTRAST|||1|4|Visit_4|65|1|TREATMENT|2020-07-24|65
e|IS|57971bdc-14df-4d9e-a59a-2665703c12ab|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^6 CFU/mL|[?]|1|mL*cmH2O|STOOL|CELL OF ORIGIN ASSAY|||1|5|Visit_5|90|2|SCREENING|2020-08-18|90
e|IS|dacea2da-9101-41e9-97aa-1cb8445b1320|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|OD Unit|[?]|1|g/g|ERYTHROCYTES|ERGOSPIROMETRY|Y||1|1|Visit_1|10|2|SCREENING|2020-10-09|10
e|IS|dacea2da-9101-41e9-97aa-1cb8445b1320|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|cd*s/m2|[?]|1|L/day|SPERMATOZOON|CONTRAST ENHANCED PET SCAN|||1|2|Visit_2|25|1|WASHOUT|2020-10-24|25
e|IS|dacea2da-9101-41e9-97aa-1cb8445b1320|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|bel|[?]|1|cmol/L|BONE MARROW|BALLPOINT PEN TECHNIQUE|||1|3|Visit_3|40|1|SCREENING|2020-11-08|40
e|IS|dacea2da-9101-41e9-97aa-1cb8445b1320|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|g/animal/day|[?]|1|QUANTITY SUFFICIENT|CARDIAC MUSCLE TISSUE|NUCLEAR RADIOLOGY|||1|4|Visit_4|65|3|TREATMENT|2020-12-03|65
e|IS|dacea2da-9101-41e9-97aa-1cb8445b1320|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log10 copies/mL|[?]|1|g/day|ERYTHROCYTES|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|Y|1|5|Visit_5|90|4|WASHOUT|2020-12-28|90
e|IS|cbf5d05e-e934-4946-b991-5fef63a01888|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mmol/s|[?]|1|pg/cell|EPITHELIAL CELL|MICRO BROTH DILUTION|||1|1|Visit_1|10|3|WASHOUT|2020-11-06|10
e|IS|cbf5d05e-e934-4946-b991-5fef63a01888|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mEq/dL|[?]|1|FFU|PLASMA ULTRAFILTRATE|CARDIAC THERMODILUTION|||1|2|Visit_2|25|4|TREATMENT|2020-11-21|25
e|IS|cbf5d05e-e934-4946-b991-5fef63a01888|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|v/v|[?]|1|RNA copies/mL|MENSTRUAL BLOOD|ACID FAST STAIN|||1|3|Visit_3|40|2|TREATMENT|2020-12-06|40
e|IS|cbf5d05e-e934-4946-b991-5fef63a01888|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/kg|[?]|1|mOsm|NAIL|ELECTROGASTROGRAPHY||Y|1|4|Visit_4|65|6|SCREENING|2020-12-31|65
e|IS|cbf5d05e-e934-4946-b991-5fef63a01888|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Weber|[?]|1|Bq/kg|CERUMEN|GRADIENT DIFFUSION||Y|1|5|Visit_5|90|6|TREATMENT|2021-01-25|90
e|IS|be18633c-0ff9-4775-9737-dc8a9524fd2c|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|PACKET|[?]|1|PUFF|ARTERIAL CORD BLOOD|MICROBIAL CULTURE|Y||1|1|Visit_1|10|5|TREATMENT|2020-10-18|10
e|IS|be18633c-0ff9-4775-9737-dc8a9524fd2c|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|BU/mL|[?]|1|pptr|CELL PELLET|MICROBIAL CULTURE, LIQUID|||1|2|Visit_2|25|5|SCREENING|2020-11-02|25
e|IS|be18633c-0ff9-4775-9737-dc8a9524fd2c|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ng/mol|[?]|1|uOsm|SKELETAL MUSCLE TISSUE|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y|1|3|Visit_3|40|7|TREATMENT|2020-11-17|40
e|IS|be18633c-0ff9-4775-9737-dc8a9524fd2c|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^5/hpf|[?]|1|/500 WBC|HAIR|WHOLE EXOME SEQUENCING|||1|4|Visit_4|65|1|FOLLOW-UP|2020-12-12|65
e|IS|be18633c-0ff9-4775-9737-dc8a9524fd2c|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/cm2|[?]|1|ug/min|LYMPH|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|5|Visit_5|90|6|TREATMENT|2021-01-06|90
e|IS|f7eba9b8-94fb-46b8-842a-0322eb68a355|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Hz|[?]|1|10^11/L|ALVEOLAR AIR|KLEIHAUER-BETKE|||1|1|Visit_1|10|5|TREATMENT|2020-05-12|10
e|IS|f7eba9b8-94fb-46b8-842a-0322eb68a355|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg2/dL2|[?]|1|MONTHS|INFRANATANT, PLASMA|CONTRAST ENHANCED PET SCAN|||1|2|Visit_2|25|5|TREATMENT|2020-05-27|25
e|IS|f7eba9b8-94fb-46b8-842a-0322eb68a355|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Osm|[?]|1|mm/2h|HAIR|PH METER MEASUREMENT METHOD|||1|3|Visit_3|40|4|TREATMENT|2020-06-11|40
e|IS|f7eba9b8-94fb-46b8-842a-0322eb68a355|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|log10 TCID 50/mL|[?]|1|AFU|NAIL|ELECTROCHEMILUMINESCENCE|||1|4|Visit_4|65|5|TREATMENT|2020-07-06|65
e|IS|f7eba9b8-94fb-46b8-842a-0322eb68a355|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/dL|[?]|1|IU/L|DIALYSIS FLUID, PERITONEAL|QUANTITATIVE ULTRASOUND||Y|1|5|Visit_5|90|3|TREATMENT|2020-07-31|90
e|IS|903199e2-56e1-41e4-8904-d33cc6846ee3|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|uCi|[?]|1|/10^3|SWABBED MATERIAL|IMMUNORADIOMETRIC ASSAY|Y||1|1|Visit_1|10|6|TREATMENT|2021-01-18|10
e|IS|903199e2-56e1-41e4-8904-d33cc6846ee3|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|APPLICATION|[?]|1|/7.5 mL|VENOUS CORD BLOOD|EIA|||1|2|Visit_2|25|2|FOLLOW-UP|2021-02-02|25
e|IS|903199e2-56e1-41e4-8904-d33cc6846ee3|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/mol|[?]|1|pmol/dL|CAPILLARY BLOOD|CELLULOSE TAPE|Y||1|3|Visit_3|40|1|WASHOUT|2021-02-17|40
e|IS|903199e2-56e1-41e4-8904-d33cc6846ee3|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|V/sec|[?]|1|uCi/kg|EPIDERMAL TISSUE|PULMONARY ANGIOGRAPHY|||1|4|Visit_4|65|3|TREATMENT|2021-03-14|65
e|IS|903199e2-56e1-41e4-8904-d33cc6846ee3|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|EID 50/dose|[?]|1|ug/L FEU|BLOOD|TRIPLE-PHASE SPIRAL CT SCAN||Y|1|5|Visit_5|90|5|WASHOUT|2021-04-08|90
e|IS|32567f8d-e746-44e1-a269-d95ba3bb0b11|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/40 HPFs|[?]|1|mOsm/kg|RETICULOCYTES|VIRUS PLAQUE ASSAY|||1|1|Visit_1|10|2|TREATMENT|2020-11-02|10
e|IS|32567f8d-e746-44e1-a269-d95ba3bb0b11|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mmol|[?]|1|MET*min|HAIR|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||1|2|Visit_2|25|5|TREATMENT|2020-11-17|25
e|IS|32567f8d-e746-44e1-a269-d95ba3bb0b11|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Henry|[?]|1|ELISA unit/mL|GASTRIC FLUID|RADIOIMMUNOPRECIPITATION ASSAY|||1|3|Visit_3|40|7|FOLLOW-UP|2020-12-02|40
e|IS|32567f8d-e746-44e1-a269-d95ba3bb0b11|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mm|[?]|1|g/mol|ERYTHROCYTES|CLINICAL EVALUATION|Y|Y|1|4|Visit_4|65|3|TREATMENT|2020-12-27|65
e|IS|32567f8d-e746-44e1-a269-d95ba3bb0b11|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|s^-1(%O2)^-1|[?]|1|/MBP|ISOLATE|MICRODENSITOMETRY|||1|5|Visit_5|90|3|WASHOUT|2021-01-21|90
e|IS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^9 organisms/mL|[?]|1|gMFI|HAIR FOLLICLE|CONTRAST ENHANCED CT SCAN|Y|Y|1|1|Visit_1|10|6|TREATMENT|2020-11-11|10
e|IS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|nkat/g Hb|[?]|1|ug/m2/day|SUPERNATANT, SERUM OR PLASMA|ELECTROPHORESIS|||1|2|Visit_2|25|3|FOLLOW-UP|2020-11-26|25
e|IS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Enzyme U|[?]|1|mL/mmHg|SUPERNATANT, SERUM|MICROBIAL BIOCHEMICAL IDENTIFICATION|||1|3|Visit_3|40|5|FOLLOW-UP|2020-12-11|40
e|IS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/LPF|[?]|1|mg/day|ATHEROSCLEROTIC PLAQUE|NEURAMINIDASE INHIBITION ASSAY|Y||1|4|Visit_4|65|1|TREATMENT|2021-01-05|65
e|IS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|pL|[?]|1|ng/day|CEREBROSPINAL FLUID|DYNAMIC LIGHT SCATTERING|Y||1|5|Visit_5|90|3|SCREENING|2021-01-30|90
e|IS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mV/sec|[?]|1|L/kg|PERSPIRATION|AMSLER GRID|Y||1|1|Visit_1|10|4|TREATMENT|2020-07-09|10
e|IS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|km|[?]|1|atm|CAPILLARY PLASMA|MUGA|||1|2|Visit_2|25|5|TREATMENT|2020-07-24|25
e|IS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|copies/mL|[?]|1|JAR|VENOUS BLOOD|LC/MS|||1|3|Visit_3|40|1|FOLLOW-UP|2020-08-08|40
e|IS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uL/mL|[?]|1|FIU|VITREOUS HUMOR|THERMAL IONIZATION MASS SPECTROMETRY|Y|Y|1|4|Visit_4|65|4|TREATMENT|2020-09-02|65
e|IS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/(min*100mL)|[?]|1|g/kg|INTERSTITIAL FLUID|MEDIASTINOSCOPY|Y||1|5|Visit_5|90|6|TREATMENT|2020-09-27|90
e|IS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/g|[?]|1|yd|HAIR|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|4|TREATMENT|2020-08-01|10
e|IS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ng/dL|[?]|1|Farad|TRANSUDATE|SMEAR|||1|2|Visit_2|25|4|FOLLOW-UP|2020-08-16|25
e|IS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/g/h|[?]|1|umol/h/mmol|FLUID|NEURAMINIDASE INHIBITION ASSAY|||1|3|Visit_3|40|6|TREATMENT|2020-08-31|40
e|IS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ngEq/L|[?]|1|10^3 organisms/g|CORD SERUM|NON-CONTACT SPECULAR MICROSCOPY||Y|1|4|Visit_4|65|4|FOLLOW-UP|2020-09-25|65
e|IS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|m2|[?]|1|U/dL|PERITONEAL FLUID|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||1|5|Visit_5|90|2|TREATMENT|2020-10-20|90
e|IS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ppm|[?]|1|QUANTITY SUFFICIENT|PLASMA|PELLI-ROBSON EYE CHART||Y|1|1|Visit_1|10|2|FOLLOW-UP|2020-06-01|10
e|IS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|log10 PFU|[?]|1|mg/cm2|LYSATE|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||1|2|Visit_2|25|5|TREATMENT|2020-06-16|25
e|IS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|aMFI|[?]|1|beats/min|INTERSTITIAL FLUID|GRAM STAIN|||1|3|Visit_3|40|2|TREATMENT|2020-07-01|40
e|IS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/kg/min|[?]|1|MET|EXHALED BREATH CONDENSATE|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|1|4|Visit_4|65|4|SCREENING|2020-07-26|65
e|IS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MPL U/mL|[?]|1|FIU|PLASMA ULTRAFILTRATE|BAC ACGH||Y|1|5|Visit_5|90|7|TREATMENT|2020-08-20|90
e|IS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mN|[?]|1|pmol/g|PLEURAL FLUID|IMMUNOFLUORESCENT STAIN|Y||1|1|Visit_1|10|4|SCREENING|2020-07-04|10
e|IS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|umol/min|[?]|1|dyn|SEMINAL FLUID|LIGHT SCATTERING SPECTROSCOPY|||1|2|Visit_2|25|2|TREATMENT|2020-07-19|25
e|IS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/10^4|[?]|1|m2|SUPERNATANT, CEREBROSPINAL FLUID|RADIOGRAPHY|Y||1|3|Visit_3|40|5|TREATMENT|2020-08-03|40
e|IS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mol/g|[?]|1|mU|NAIL|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||1|4|Visit_4|65|2|TREATMENT|2020-08-28|65
e|IS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/cm3/min|[?]|1|deg/mm|MUCUS|SLOAN LETTER EYE CHART 2.5%|||1|5|Visit_5|90|2|TREATMENT|2020-09-22|90
e|IS|a69c6182-9c35-4365-b732-b238e0584ba7|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|msec|[?]|1|mEq/g|EPIDERMAL TISSUE|IMPEDANCE CONDUCTIVITY|||1|1|Visit_1|10|4|TREATMENT|2020-08-07|10
e|IS|a69c6182-9c35-4365-b732-b238e0584ba7|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mmol2/L2|[?]|1|kN/cm2|TISSUE|CYSTOSCOPY|Y|Y|1|2|Visit_2|25|5|TREATMENT|2020-08-22|25
e|IS|a69c6182-9c35-4365-b732-b238e0584ba7|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U.CARR|[?]|1|PATCH|PROSTATIC FLUID|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||1|3|Visit_3|40|3|TREATMENT|2020-09-06|40
e|IS|a69c6182-9c35-4365-b732-b238e0584ba7|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|YEARS|[?]|1|BAU/mL|AQUEOUS HUMOR|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|1|4|Visit_4|65|2|SCREENING|2020-10-01|65
e|IS|a69c6182-9c35-4365-b732-b238e0584ba7|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|PACK|[?]|1|10^3 RNA copies/mL|SALIVA|RADIOGRAPHY|||1|5|Visit_5|90|4|FOLLOW-UP|2020-10-26|90
e|IS|1b9896cf-160e-4a56-8737-9759cd83e784|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Log10 ELISA unit|[?]|1|g/kg/day|SMEGMA|FISH|||1|1|Visit_1|10|1|TREATMENT|2020-12-11|10
e|IS|1b9896cf-160e-4a56-8737-9759cd83e784|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/beat|[?]|1|ohm|GASTRIC FLUID|PET/CT SCAN WITHOUT CONTRAST|||1|2|Visit_2|25|3|TREATMENT|2020-12-26|25
e|IS|1b9896cf-160e-4a56-8737-9759cd83e784|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|g|[?]|1|10^9 organisms/mL|PUS|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|3|Visit_3|40|6|WASHOUT|2021-01-10|40
e|IS|1b9896cf-160e-4a56-8737-9759cd83e784|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mV|[?]|1|fmol|SUPERNATANT, PLASMA|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||1|4|Visit_4|65|6|TREATMENT|2021-02-04|65
e|IS|1b9896cf-160e-4a56-8737-9759cd83e784|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|IU/mmol|[?]|1|mL/beat|MUSCLE TISSUE|MAGNETIC RESONANCE ANGIOGRAPHY|Y||1|5|Visit_5|90|6|SCREENING|2021-03-01|90
e|IS|ea87b553-e331-40cf-bd86-d2bd22694476|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|APL U/mL|[?]|1|ukat/10^12 RBC|SERUM OR PLASMA OR BLOOD|SANGER SEQUENCING|||1|1|Visit_1|10|1|SCREENING|2020-08-05|10
e|IS|ea87b553-e331-40cf-bd86-d2bd22694476|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol/dL|[?]|1|m/sec2|MIXED VENOUS BLOOD|MALDI-TOF||Y|1|2|Visit_2|25|3|WASHOUT|2020-08-20|25
e|IS|ea87b553-e331-40cf-bd86-d2bd22694476|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Torr|[?]|1|mg/cm2|CEREBROSPINAL FLUID|INTERRUPTER TECHNIQUE||Y|1|3|Visit_3|40|7|WASHOUT|2020-09-04|40
e|IS|ea87b553-e331-40cf-bd86-d2bd22694476|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/m2|[?]|1|oz eq|COLOSTRUM|FLUORIMETRY||Y|1|4|Visit_4|65|4|SCREENING|2020-09-29|65
e|IS|ea87b553-e331-40cf-bd86-d2bd22694476|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|v/v|[?]|1|10^6 organisms/mg|VITREOUS HUMOR|MODIFIED ACID FAST STAIN|Y|Y|1|5|Visit_5|90|5|WASHOUT|2020-10-24|90
e|IS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MHz|[?]|1|cmol/L|AQUEOUS HUMOR|ANTIMICROBIAL COMBINATION TESTING||Y|1|1|Visit_1|10|1|SCREENING|2020-07-30|10
e|IS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cg|[?]|1|mmol/g|SEBUM|PHOTOMETRIC CLOT DETECTION|Y|Y|1|2|Visit_2|25|3|SCREENING|2020-08-14|25
e|IS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/mL/min|[?]|1|mAmp|SPUTUM|MICRODENSITOMETRY|Y||1|3|Visit_3|40|4|FOLLOW-UP|2020-08-29|40
e|IS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmH2O*s2/mL|[?]|1|log10 copies/mL|SEMINAL FLUID|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||1|4|Visit_4|65|4|FOLLOW-UP|2020-09-23|65
e|IS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|cd*s/m2|[?]|1|pm|MUSCLE TISSUE|DIRECT SEQUENCING|||1|5|Visit_5|90|7|SCREENING|2020-10-18|90
e|IS|051dc064-be6f-43eb-aa51-7ed8634d6e23|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MAC50|[?]|1|Ci/L|PLASMA|CONTRAST ENHANCED SPIRAL CT SCAN|||1|1|Visit_1|10|3|TREATMENT|2020-07-08|10
e|IS|051dc064-be6f-43eb-aa51-7ed8634d6e23|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PATCH|[?]|1|ug/h|PLASMA|MANUAL CLOT DETECTION||Y|1|2|Visit_2|25|3|SCREENING|2020-07-23|25
e|IS|051dc064-be6f-43eb-aa51-7ed8634d6e23|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/2000 RBC|[?]|1|IU/day|FLUID|MAMMOGRAPHY||Y|1|3|Visit_3|40|4|FOLLOW-UP|2020-08-07|40
e|IS|051dc064-be6f-43eb-aa51-7ed8634d6e23|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mV*min|[?]|1|10^3 organisms/g|ARTERIAL BLOOD|HPLC/MS/MS|Y||1|4|Visit_4|65|7|TREATMENT|2020-09-01|65
e|IS|051dc064-be6f-43eb-aa51-7ed8634d6e23|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MnFI|[?]|1|uSiemens|MUSCLE TISSUE|FORCED OSCILLATION TECHNIQUE|||1|5|Visit_5|90|6|SCREENING|2020-09-26|90
e|IS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 CFU/g|[?]|1|/mm2|DERMAL TISSUE|DYNAMOMETRY|Y||1|1|Visit_1|10|2|SCREENING|2020-06-03|10
e|IS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mgEq|[?]|1|nL|PLATELET POOR PLASMA|IMMUNORADIOMETRIC ASSAY|||1|2|Visit_2|25|4|TREATMENT|2020-06-18|25
e|IS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cm H2O|[?]|1|10^6/hpf|LYMPH|PEAK FLOWMETRY|Y||1|3|Visit_3|40|6|WASHOUT|2020-07-03|40
e|IS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|WEEKS|[?]|1|mU/L|PLATELET|MEDIASTINOSCOPY|||1|4|Visit_4|65|6|TREATMENT|2020-07-28|65
e|IS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mEq/kg|[?]|1|pkat|MENSTRUAL BLOOD|X-RAY FLUORESCENCE SPECTROMETRY|||1|5|Visit_5|90|4|TREATMENT|2020-08-22|90
e|IS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|MnFI|[?]|1|CAPSULE|BUFFY COAT|DIRECT SEQUENCING|Y||1|1|Visit_1|10|5|FOLLOW-UP|2020-09-02|10
e|IS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MdFI|[?]|1|fL|PLASMA ULTRAFILTRATE|CALCOFLUOR WHITE STAIN||Y|1|2|Visit_2|25|6|WASHOUT|2020-09-17|25
e|IS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|lx|[?]|1|min/day|SERUM OR PLASMA OR BLOOD|PHOTOMETRY|Y||1|3|Visit_3|40|3|WASHOUT|2020-10-02|40
e|IS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|vg/dose|[?]|1|100 IU/mL|CALCULUS|LYMPHANGIOGRAPHY|||1|4|Visit_4|65|2|TREATMENT|2020-10-27|65
e|IS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|g/animal/wk|[?]|1|INHALATION|INFRANATANT, PLEURAL FLUID|AGAR PROPORTION|||1|5|Visit_5|90|3|TREATMENT|2020-11-21|90
e|IS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PA|[?]|1|cGy|LAVAGE FLUID|DIFFUSION TENSOR MRI|||1|1|Visit_1|10|4|TREATMENT|2021-01-20|10
e|IS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|anti-Xa IU/mL|[?]|1|U/10^12 RBC|PLATELET RICH PLASMA|HIGH RESOLUTION MELT ANALYSIS|||1|2|Visit_2|25|7|TREATMENT|2021-02-04|25
e|IS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|hPa|[?]|1|g/cage|SKIN TISSUE|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||1|3|Visit_3|40|1|WASHOUT|2021-02-19|40
e|IS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kV|[?]|1|pmol/g|LAVAGE FLUID|MICROBIAL CULTURE, LIQUID|||1|4|Visit_4|65|7|FOLLOW-UP|2021-03-16|65
e|IS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Enzyme U/m2|[?]|1|FEU|COLOSTRUM|THERMAL IONIZATION MASS SPECTROMETRY|||1|5|Visit_5|90|3|FOLLOW-UP|2021-04-10|90
e|IS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kg|[?]|1|10^3 DNA copies/mL|SERUM|IMMUNODIFFUSION||Y|1|1|Visit_1|10|4|TREATMENT|2020-06-23|10
e|IS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|pg|[?]|1|EIA unit|BILE|DNA MICROARRAY||Y|1|2|Visit_2|25|2|SCREENING|2020-07-08|25
e|IS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|g/cage/wk|[?]|1|dpm/mg|SERUM|IMMUNOFLUORESCENT STAIN|||1|3|Visit_3|40|3|WASHOUT|2020-07-23|40
e|IS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|MET*h|[?]|1|10^3 CFU|ISOLATE|KINYOUN STAIN|||1|4|Visit_4|65|5|TREATMENT|2020-08-17|65
e|IS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|CONTAINER|[?]|1|cmHg|CAPILLARY PLASMA|WESTERGREN|||1|5|Visit_5|90|3|TREATMENT|2020-09-11|90
e|IS|835594ab-e93c-402b-8129-6af659be5ae1|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cm/min|[?]|1|Tesla|STOOL|NEPHELOMETRY|||1|1|Visit_1|10|1|TREATMENT|2020-11-01|10
e|IS|835594ab-e93c-402b-8129-6af659be5ae1|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|U/mg|[?]|1|mL/dL|ERYTHROCYTES|ISHIHARA COLOR PLATES|||1|2|Visit_2|25|6|FOLLOW-UP|2020-11-16|25
e|IS|835594ab-e93c-402b-8129-6af659be5ae1|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug/g/day|[?]|1|mL/animal/wk|VENOUS CORD BLOOD|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y|1|3|Visit_3|40|2|WASHOUT|2020-12-01|40
e|IS|835594ab-e93c-402b-8129-6af659be5ae1|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mol/L|[?]|1|ECL unit|PLEURAL FLUID|ERGOSPIROMETRY||Y|1|4|Visit_4|65|2|FOLLOW-UP|2020-12-26|65
e|IS|835594ab-e93c-402b-8129-6af659be5ae1|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|V/sec|[?]|1|10^7 CFU|PLEURAL FLUID|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||1|5|Visit_5|90|4|SCREENING|2021-01-20|90
e|IS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|EU|[?]|1|GBq/mg|MIXED VENOUS BLOOD|MICROPARTICLE ENZYME IMMUNOASSAY|||1|1|Visit_1|10|4|SCREENING|2020-10-07|10
e|IS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|U/m2|[?]|1|L/day|BASAL TEAR|CONTRAST ENHANCED PET/CT SCAN|||1|2|Visit_2|25|5|TREATMENT|2020-10-22|25
e|IS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|JDF Unit|[?]|1|Ejaculate U|DIALYSIS FLUID, PERITONEAL|X-RAY|||1|3|Visit_3|40|5|TREATMENT|2020-11-06|40
e|IS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Absorbance U/mL|[?]|1|10^8/L|SEMEN|ACRIDINE ORANGE STAIN|||1|4|Visit_4|65|1|SCREENING|2020-12-01|65
e|IS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|ug|[?]|1|pkat|EXUDATE|FLOW CYTOMETRY|Y|Y|1|5|Visit_5|90|5|TREATMENT|2020-12-26|90
e|IS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|MESF|[?]|1|U/L|LYMPH|CONTRAST ENHANCED SPIRAL CT SCAN|||1|1|Visit_1|10|4|FOLLOW-UP|2020-11-15|10
e|IS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/mmHg|[?]|1|mmol/min/kPa|ALVEOLAR AIR|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||1|2|Visit_2|25|4|TREATMENT|2020-11-30|25
e|IS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|deg/mm|[?]|1|ug/dose|MUSCLE TISSUE|ENDPOINT DILUTION ASSAY|Y|Y|1|3|Visit_3|40|2|WASHOUT|2020-12-15|40
e|IS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|copies/mL|[?]|1|mol/mL|EMOTIONAL TEAR|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||1|4|Visit_4|65|6|TREATMENT|2021-01-09|65
e|IS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GBq/ug|[?]|1|PATCH|RETICULOCYTES|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y|1|5|Visit_5|90|4|WASHOUT|2021-02-03|90
e|IS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|sec|[?]|1|mL/cage|INFRANATANT, PLASMA|IN VITRO GENE EXPRESSION ASSAY|||1|1|Visit_1|10|3|FOLLOW-UP|2020-06-24|10
e|IS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|copies/uL|[?]|1|VOXEL|MIXED VENOUS BLOOD|PHOTOGRAPHY|Y||1|2|Visit_2|25|5|TREATMENT|2020-07-09|25
e|IS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|ECL unit|ENDOMETRIAL TISSUE|PERFUSION MRI|Y||1|3|Visit_3|40|6|TREATMENT|2020-07-24|40
e|IS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mEq/day|[?]|1|genEq|CORD BLOOD|CALCOFLUOR WHITE STAIN|||1|4|Visit_4|65|6|TREATMENT|2020-08-18|65
e|IS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/ms|[?]|1|kIU|DISCHARGE|TONOMETRY|||1|5|Visit_5|90|7|WASHOUT|2020-09-12|90
e|IS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PHERESIS UNIT|[?]|1|mL/g/min|PERITONEAL FLUID|MASS SPECTROMETRY|||1|1|Visit_1|10|1|WASHOUT|2020-08-13|10
e|IS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MnFI|[?]|1|mm|RETICULOCYTES|DIGITAL PCR ARRAY|||1|2|Visit_2|25|4|WASHOUT|2020-08-28|25
e|IS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|s*kPa|[?]|1|cmol|CAPILLARY PLASMA|IMMUNOASSAY||Y|1|3|Visit_3|40|4|WASHOUT|2020-09-12|40
e|IS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|PIXELS/cm|[?]|1|ukat/10^12 RBC|EMESIS|NEURAMINIDASE INHIBITION ASSAY|||1|4|Visit_4|65|1|FOLLOW-UP|2020-10-07|65
e|IS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|CIGARETTE|[?]|1|TRANSDUCING UNIT/mL|PROSTATIC FLUID|PET SCAN|||1|5|Visit_5|90|5|SCREENING|2020-11-01|90
e|IS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/10^4|[?]|1|uSiemens|MENSTRUAL BLOOD|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||1|1|Visit_1|10|2|SCREENING|2020-10-15|10
e|IS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nmol BCE/L|[?]|1|mol|TRANSUDATE|SISH||Y|1|2|Visit_2|25|1|FOLLOW-UP|2020-10-30|25
e|IS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|min|[?]|1|SQU/mL|PLEURAL TISSUE|STATIC PERIMETRY|||1|3|Visit_3|40|7|FOLLOW-UP|2020-11-14|40
e|IS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|mL/kg/min|PLASMA ULTRAFILTRATE|WHOLE GENOME SEQUENCING||Y|1|4|Visit_4|65|5|SCREENING|2020-12-09|65
e|IS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BU/mL|[?]|1|ng/mol|SUPERNATANT, PLASMA|EIA|||1|5|Visit_5|90|3|TREATMENT|2021-01-03|90
e|IS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/g|[?]|1|mL/kg/day|PERITONEAL FLUID|GRADIENT DIFFUSION||Y|1|1|Visit_1|10|1|TREATMENT|2020-06-01|10
e|IS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|nmol BCE/nmol|[?]|1|/2000 RBC|BONE|WHOLE TRANSCRIPTOME SEQUENCING|Y||1|2|Visit_2|25|1|TREATMENT|2020-06-16|25
e|IS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|umol/kg/min|[?]|1|POUCH|PUS|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y||1|3|Visit_3|40|2|TREATMENT|2020-07-01|40
e|IS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|AMPULE|[?]|1|PNU/mL|SOFT TISSUE|FLUORIMETRY|||1|4|Visit_4|65|5|SCREENING|2020-07-26|65
e|IS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|FINGERTIP UNIT|[?]|1|g/day|VENOUS PLASMA|SICKLE CELL SOLUBILITY TEST|||1|5|Visit_5|90|3|FOLLOW-UP|2020-08-20|90
e|IS|11b2b359-d4a1-411d-a676-075b26e1453c|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Linear ft*LB|[?]|1|mmol|PLEURAL FLUID|ELECTRONEUROGRAPHY|Y||1|1|Visit_1|10|5|FOLLOW-UP|2020-09-20|10
e|IS|11b2b359-d4a1-411d-a676-075b26e1453c|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^11/L|[?]|1|g/m2|BONE MARROW MONONUCLEAR CELL|COMPLEMENT FIXATION|Y||1|2|Visit_2|25|5|SCREENING|2020-10-05|25
e|IS|11b2b359-d4a1-411d-a676-075b26e1453c|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/mmHg|[?]|1|10^6 organisms/mL|BONE MARROW|MRI WITHOUT CONTRAST|Y||1|3|Visit_3|40|3|SCREENING|2020-10-20|40
e|IS|11b2b359-d4a1-411d-a676-075b26e1453c|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|kBq|[?]|1|tuberculin unit/mL|SPERMATOZOON|STATIC PERIMETRY||Y|1|4|Visit_4|65|1|WASHOUT|2020-11-14|65
e|IS|11b2b359-d4a1-411d-a676-075b26e1453c|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Bq/mL|[?]|1|um/s|LAVAGE FLUID|DYNAMIC LIGHT SCATTERING||Y|1|5|Visit_5|90|3|TREATMENT|2020-12-09|90
e|IS|293f673d-af6a-473e-8bce-118bb85bbd9e|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MAC50|[?]|1|oz|PUS|GRAM STAIN|||1|1|Visit_1|10|3|FOLLOW-UP|2020-10-19|10
e|IS|293f673d-af6a-473e-8bce-118bb85bbd9e|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/g|[?]|1|ug/L FEU|BLOOD|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|Y||1|2|Visit_2|25|5|SCREENING|2020-11-03|25
e|IS|293f673d-af6a-473e-8bce-118bb85bbd9e|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ppm|[?]|1|breaths/30s|LUNG SURFACTANT|SINGLE-SLICE SPIRAL CT|||1|3|Visit_3|40|3|WASHOUT|2020-11-18|40
e|IS|293f673d-af6a-473e-8bce-118bb85bbd9e|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 CFU/mL|[?]|1|Ci/g|AMNIOTIC FLUID|TRANSTHORACIC ECHOCARDIOGRAPHY|Y||1|4|Visit_4|65|6|TREATMENT|2020-12-13|65
e|IS|293f673d-af6a-473e-8bce-118bb85bbd9e|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ft2|[?]|1|Bq/g|TRANSUDATE|PHOTOGRAPHY|||1|5|Visit_5|90|6|WASHOUT|2021-01-07|90
e|IS|0f60ab31-ee13-4846-93d2-6bcac139006f|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mm3/mm2/year|[?]|1|STEPS|URINE SEDIMENT|ACRIDINE ORANGE STAIN||Y|1|1|Visit_1|10|7|WASHOUT|2020-07-02|10
e|IS|0f60ab31-ee13-4846-93d2-6bcac139006f|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|vg/dose|[?]|1|mg/g/h|CAPILLARY PLASMA|PYROSEQUENCING|Y|Y|1|2|Visit_2|25|6|TREATMENT|2020-07-17|25
e|IS|0f60ab31-ee13-4846-93d2-6bcac139006f|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mEq/mL|[?]|1|BEAM BREAKS|SMOOTH MUSCLE TISSUE|FLUORIMETRY|||1|3|Visit_3|40|7|TREATMENT|2020-08-01|40
e|IS|0f60ab31-ee13-4846-93d2-6bcac139006f|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|amu|[?]|1|DROP|SEMEN|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y|1|4|Visit_4|65|6|TREATMENT|2020-08-26|65
e|IS|0f60ab31-ee13-4846-93d2-6bcac139006f|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9/g|[?]|1|g/cage/day|PROSTATIC FLUID|BIOPSY|||1|5|Visit_5|90|2|TREATMENT|2020-09-20|90
e|IS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|%/s|[?]|1|GBq|CAPILLARY BLOOD|OLIGO ACGH|||1|1|Visit_1|10|3|TREATMENT|2020-08-31|10
e|IS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MPL U|[?]|1|ng/day|SPERMATOZOON|MAPH||Y|1|2|Visit_2|25|4|TREATMENT|2020-09-15|25
e|IS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug/kg/h|[?]|1|cmol/L|CIRCULATING TUMOR CELL|PHOTOGRAPHY|||1|3|Visit_3|40|1|WASHOUT|2020-09-30|40
e|IS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SPRAY|[?]|1|mU/L|SKIN TISSUE|MULTIPLE BREATH WASHOUT||Y|1|4|Visit_4|65|7|FOLLOW-UP|2020-10-25|65
e|IS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SACHET|[?]|1|U/kg/min|FLUID|ELLA||Y|1|5|Visit_5|90|3|FOLLOW-UP|2020-11-19|90
e|IS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Bq/L|[?]|1|mEq/uL|INFRANATANT, PLASMA|IMPEDANCE CONDUCTIVITY||Y|1|1|Visit_1|10|5|SCREENING|2020-07-06|10
e|IS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|MET*h|[?]|1|mmol/kg|LOCHIA|WESTERGREN|Y||1|2|Visit_2|25|1|SCREENING|2020-07-21|25
e|IS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/cage|[?]|1|BAR|MUCUS|FLUORIMETRY|Y||1|3|Visit_3|40|1|SCREENING|2020-08-05|40
e|IS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mmol/min/kPa|[?]|1|fmol/g|AQUEOUS HUMOR|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||1|4|Visit_4|65|6|TREATMENT|2020-08-30|65
e|IS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|hPa|[?]|1|ug/day|PLEURAL FLUID|TRYPAN BLUE STAIN||Y|1|5|Visit_5|90|3|WASHOUT|2020-09-24|90
e|IS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nkat/g Hb|[?]|1|Gy/min|PROSTATIC FLUID|PERIODIC ACID SCHIFF STAIN|||1|1|Visit_1|10|1|TREATMENT|2020-11-24|10
e|IS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Antibody Unit|[?]|1|mgEq|FLUID|DYNAMOMETRY|||1|2|Visit_2|25|6|SCREENING|2020-12-09|25
e|IS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|dmol|[?]|1|mm/sec|DIALYSIS FLUID|AUTOREFRACTION|Y||1|3|Visit_3|40|4|TREATMENT|2020-12-24|40
e|IS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|min/day|[?]|1|mCi|SPUTUM|NEPHELOMETRY|||1|4|Visit_4|65|1|FOLLOW-UP|2021-01-18|65
e|IS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|PFU|[?]|1|L/s|MECONIUM|POPULATION SEQUENCING|||1|5|Visit_5|90|4|TREATMENT|2021-02-12|90
e|IS|78778706-6b5b-4ad8-90af-f56d602863ae|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ugEq/L|[?]|1|tuberculin unit|CELL PELLET|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||1|1|Visit_1|10|4|TREATMENT|2020-05-13|10
e|IS|78778706-6b5b-4ad8-90af-f56d602863ae|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|APL U/mL|[?]|1|SUPPOSITORY|CARDIAC MUSCLE TISSUE|DIGITAL PCR||Y|1|2|Visit_2|25|3|FOLLOW-UP|2020-05-28|25
e|IS|78778706-6b5b-4ad8-90af-f56d602863ae|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|scm|[?]|1|nm|EPIDERMAL TISSUE|PHOTOGRAPHY|||1|3|Visit_3|40|5|WASHOUT|2020-06-12|40
e|IS|78778706-6b5b-4ad8-90af-f56d602863ae|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/dL|[?]|1|mmHg/sec|VENOUS BLOOD|IMMUNO-PET SCAN|||1|4|Visit_4|65|4|WASHOUT|2020-07-07|65
e|IS|78778706-6b5b-4ad8-90af-f56d602863ae|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/g|[?]|1|umol/mol|PERIPHERAL BLOOD MONONUCLEAR CELL|IMMUNOCHROMATOGRAPHY||Y|1|5|Visit_5|90|3|FOLLOW-UP|2020-08-01|90
e|IS|a6954aa1-4860-412a-b988-7f708aca2ab2|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ks|[?]|1|mol/mol|SUPERNATANT, SERUM OR PLASMA|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|1|TREATMENT|2020-09-17|10
e|IS|a6954aa1-4860-412a-b988-7f708aca2ab2|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/m2/h|[?]|1|mg/h|PERIPHERAL BLOOD MONONUCLEAR CELL|ELECTROMYOGRAPHY|||1|2|Visit_2|25|5|TREATMENT|2020-10-02|25
e|IS|a6954aa1-4860-412a-b988-7f708aca2ab2|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ug/mol|[?]|1|INHALATION|ALVEOLAR AIR|DOUBLE IMMUNODIFFUSION|Y||1|3|Visit_3|40|7|WASHOUT|2020-10-17|40
e|IS|a6954aa1-4860-412a-b988-7f708aca2ab2|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|VOXEL|[?]|1|U/kg|LOCHIA|OSCILLOMETRY||Y|1|4|Visit_4|65|7|TREATMENT|2020-11-11|65
e|IS|a6954aa1-4860-412a-b988-7f708aca2ab2|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|AFU|[?]|1|DAYS|ARTERIAL BLOOD|ANGIOGRAPHY||Y|1|5|Visit_5|90|1|TREATMENT|2020-12-06|90
e|IS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|m2|[?]|1|pg|CELL PELLET|CT SCAN WITHOUT CONTRAST||Y|1|1|Visit_1|10|4|TREATMENT|2020-05-14|10
e|IS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|min|[?]|1|/200 HPFs|SUPERNATANT, PLEURAL FLUID|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||1|2|Visit_2|25|5|TREATMENT|2020-05-29|25
e|IS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uV|[?]|1|10^7 CFU|PLEURAL TISSUE|THICK SMEAR|||1|3|Visit_3|40|5|TREATMENT|2020-06-13|40
e|IS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|FFU|[?]|1|/kg|PLATELET POOR PLASMA|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y|1|4|Visit_4|65|1|TREATMENT|2020-07-08|65
e|IS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mol/mol|[?]|1|kcal/day|STRIATED MUSCLE TISSUE|IMMUNOFLUORESCENT STAIN|Y||1|5|Visit_5|90|4|TREATMENT|2020-08-02|90
e|IS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^5/hpf|[?]|1|10^6 IU|MECONIUM|CONTRAST ENHANCED CT SCAN|Y|Y|1|1|Visit_1|10|1|WASHOUT|2021-01-26|10
e|IS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MBP|[?]|1|DAgU|DIALYSIS FLUID, PERITONEAL|TWO-COLOR MICROARRAY|Y|Y|1|2|Visit_2|25|6|FOLLOW-UP|2021-02-10|25
e|IS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|% INHIBITION|[?]|1|/200 HPFs|INFRANATANT, SERUM|CLINICAL EVALUATION|||1|3|Visit_3|40|7|FOLLOW-UP|2021-02-25|40
e|IS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/m2/day|[?]|1|INHALATION|WHITE MATTER TISSUE|CHROMATOGRAPHY|Y|Y|1|4|Visit_4|65|1|SCREENING|2021-03-22|65
e|IS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|nmol/day|[?]|1|mph|SALIVA|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y|1|5|Visit_5|90|5|TREATMENT|2021-04-16|90
e|IS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|grain|[?]|1|CCID 50/dose|INFRANATANT, PLEURAL FLUID|KINETIC CHROMOGENIC ASSAY|Y|Y|1|1|Visit_1|10|1|SCREENING|2020-08-24|10
e|IS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/LPF|[?]|1|mmol/s|MUSCLE TISSUE|IN VITRO GENE EXPRESSION ASSAY||Y|1|2|Visit_2|25|5|TREATMENT|2020-09-08|25
e|IS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|kBq|[?]|1|Gy/h|MONOCYTE|MAGNETIC RESONANCE ELASTOGRAPHY|||1|3|Visit_3|40|5|SCREENING|2020-09-23|40
e|IS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|pptr|[?]|1|g/g|COLOSTRUM|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||1|4|Visit_4|65|1|TREATMENT|2020-10-18|65
e|IS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|IU|[?]|1|Coulomb|DIALYSIS FLUID, PERITONEAL|MAGNETIC RESONANCE ANGIOGRAPHY|Y||1|5|Visit_5|90|4|TREATMENT|2020-11-12|90
e|IS|9b268a13-dc40-4eb6-8729-c131ac302dd3|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|RING|[?]|1|RFU|SUPERNATANT, SERUM|CONTRAST ENHANCED CT SCAN|Y||1|1|Visit_1|10|1|TREATMENT|2020-05-15|10
e|IS|9b268a13-dc40-4eb6-8729-c131ac302dd3|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PA|[?]|1|DAgU|SYNOVIAL FLUID|ZIEHL NEELSEN ACID FAST STAIN||Y|1|2|Visit_2|25|1|FOLLOW-UP|2020-05-30|25
e|IS|9b268a13-dc40-4eb6-8729-c131ac302dd3|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|pt_br|[?]|1|ms/mmHg|CERVICOVAGINAL SECRETION|MAMMOGRAPHY|||1|3|Visit_3|40|1|FOLLOW-UP|2020-06-14|40
e|IS|9b268a13-dc40-4eb6-8729-c131ac302dd3|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SYRINGE|[?]|1|ukat/10^12 RBC|ARTERIALIZED CAPILLARY BLOOD|LC-FL|Y|Y|1|4|Visit_4|65|6|TREATMENT|2020-07-09|65
e|IS|9b268a13-dc40-4eb6-8729-c131ac302dd3|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SFC/10^6 PBMC|[?]|1|10^3 CFU/mL|ISOLATE|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||1|5|Visit_5|90|6|TREATMENT|2020-08-03|90
e|IS|fa11534a-92f9-4887-828b-25b7637b8f57|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|gpELISA unit/mL|[?]|1|FIU|CEREBROSPINAL FLUID|FUNDUS PHOTOGRAPHY|||1|1|Visit_1|10|5|SCREENING|2020-12-13|10
e|IS|fa11534a-92f9-4887-828b-25b7637b8f57|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cycle/min|[?]|1|U/kg/min|SEMEN|IMMUNOFIXATION ELECTROPHORESIS|||1|2|Visit_2|25|6|SCREENING|2020-12-28|25
e|IS|fa11534a-92f9-4887-828b-25b7637b8f57|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|hPa|[?]|1|PA|INFRANATANT, PLEURAL FLUID|INTRAVASCULAR ULTRASOUND|Y||1|3|Visit_3|40|5|WASHOUT|2021-01-12|40
e|IS|fa11534a-92f9-4887-828b-25b7637b8f57|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/kg/dose|[?]|1|L/L|CAPILLARY PLASMA|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y|Y|1|4|Visit_4|65|7|TREATMENT|2021-02-06|65
e|IS|fa11534a-92f9-4887-828b-25b7637b8f57|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/animal|[?]|1|mEq/dL|PLATELET RICH PLASMA|LC/MS|||1|5|Visit_5|90|1|SCREENING|2021-03-03|90
e|IS|f305f7a3-8c8b-4eca-afb2-4a376f811170|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Ci|[?]|1|anti-Xa IU/mL|SPUTUM|IMPEDANCE CONDUCTIVITY|Y||1|1|Visit_1|10|4|TREATMENT|2020-10-04|10
e|IS|f305f7a3-8c8b-4eca-afb2-4a376f811170|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ug/m2/min|[?]|1|ug/mol|SKIN TISSUE|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|2|Visit_2|25|2|WASHOUT|2020-10-19|25
e|IS|f305f7a3-8c8b-4eca-afb2-4a376f811170|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|U/g|[?]|1|uCi/L|BILE|POLYGRAPHY|Y||1|3|Visit_3|40|3|SCREENING|2020-11-03|40
e|IS|f305f7a3-8c8b-4eca-afb2-4a376f811170|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^9 organisms/mg|[?]|1|nmol/mL/min|SOFT TISSUE|SIZE EXCLUSION CHROMATOGRAPHY||Y|1|4|Visit_4|65|5|WASHOUT|2020-11-28|65
e|IS|f305f7a3-8c8b-4eca-afb2-4a376f811170|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|IU/day|[?]|1|VOXEL|SEBUM|ENZYMATIC ULTRACENTRIFUGATION|||1|5|Visit_5|90|6|TREATMENT|2020-12-23|90
e|IS|6e4ed6b3-e419-464c-a40e-f100a6894baa|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mol/g|[?]|1|ug/kg/h|SMOOTH MUSCLE TISSUE|SMEAR|Y||1|1|Visit_1|10|1|WASHOUT|2020-06-07|10
e|IS|6e4ed6b3-e419-464c-a40e-f100a6894baa|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|mph|BLOOD|TOTAL BODY RADIOGRAPHY|||1|2|Visit_2|25|7|WASHOUT|2020-06-22|25
e|IS|6e4ed6b3-e419-464c-a40e-f100a6894baa|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PFU/animal|[?]|1|Absorbance U/min|SERUM|SCANNING ELECTRON MICROSCOPY|||1|3|Visit_3|40|1|TREATMENT|2020-07-07|40
e|IS|6e4ed6b3-e419-464c-a40e-f100a6894baa|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^6/g|[?]|1|GLOBULE|CALCULUS|MAGNETIC RESONANCE ANGIOGRAPHY|Y||1|4|Visit_4|65|5|WASHOUT|2020-08-01|65
e|IS|6e4ed6b3-e419-464c-a40e-f100a6894baa|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/day|[?]|1|kIU|ARTERIAL BLOOD|SPIRAL CT SCAN WITHOUT CONTRAST|Y||1|5|Visit_5|90|6|TREATMENT|2020-08-26|90
e|IS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/100g/min|[?]|1|PLUG|HAIR|HPLC|Y||1|1|Visit_1|10|1|WASHOUT|2020-08-08|10
e|IS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PIPE|[?]|1|Bq/kg|LAVAGE FLUID|BETA LACTAMASE|||1|2|Visit_2|25|7|SCREENING|2020-08-23|25
e|IS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/g|[?]|1|10^7 CFU/mL|SKELETAL MUSCLE TISSUE|TRIPLE-PHASE SPIRAL CT SCAN|Y|Y|1|3|Visit_3|40|1|FOLLOW-UP|2020-09-07|40
e|IS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|BAU|[?]|1|cmH2O*s2/mL|STOOL|U-HPLC/MS/MS|||1|4|Visit_4|65|5|TREATMENT|2020-10-02|65
e|IS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm2|[?]|1|m3|LOCHIA|LC/MS||Y|1|5|Visit_5|90|5|SCREENING|2020-10-27|90
e|IS|5d25ac6d-428d-41eb-9549-c23df035a54e|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|msec|[?]|1|BOWL|BLOOD|REBOUND TONOMETRY|||1|1|Visit_1|10|5|TREATMENT|2020-05-13|10
e|IS|5d25ac6d-428d-41eb-9549-c23df035a54e|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|lm|[?]|1|CYLINDER|DERMAL TISSUE|PET/CT SCAN WITHOUT CONTRAST|Y||1|2|Visit_2|25|4|WASHOUT|2020-05-28|25
e|IS|5d25ac6d-428d-41eb-9549-c23df035a54e|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PIXELS/in|[?]|1|mol/L|WHITE MATTER TISSUE|ORCHIDOMETERY||Y|1|3|Visit_3|40|4|SCREENING|2020-06-12|40
e|IS|5d25ac6d-428d-41eb-9549-c23df035a54e|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|HOMEOPATHIC DILUTION|[?]|1|ug/dose|ADIPOSE TISSUE|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|1|4|Visit_4|65|4|SCREENING|2020-07-07|65
e|IS|5d25ac6d-428d-41eb-9549-c23df035a54e|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Newton|[?]|1|HOURS|CORD SERUM|THIN SMEAR|Y||1|5|Visit_5|90|2|FOLLOW-UP|2020-08-01|90
e|IS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/animal/day|[?]|1|YEARS|NAIL|COMPLEMENT FIXATION||Y|1|1|Visit_1|10|6|TREATMENT|2020-10-30|10
e|IS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|m|[?]|1|log10 PFU/mL|BONE MARROW|PULMONARY ANGIOGRAPHY||Y|1|2|Visit_2|25|4|FOLLOW-UP|2020-11-14|25
e|IS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|uCi/kg|[?]|1|nkat/L|TUMOR TISSUE|SPIROMETRY|Y||1|3|Visit_3|40|4|FOLLOW-UP|2020-11-29|40
e|IS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|K|[?]|1|umol/kg/min|SALIVA|HPLC|Y|Y|1|4|Visit_4|65|5|TREATMENT|2020-12-24|65
e|IS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MHz|[?]|1|Antibody Unit|CERUMEN|MRS|Y||1|5|Visit_5|90|7|TREATMENT|2021-01-18|90
e|IS|173aea61-964d-4f4a-8d48-56a1a58de6d8|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|hPa|[?]|1|ng/dL|SERUM OR PLASMA OR BLOOD|CONFOCAL MICROSCOPY|||1|1|Visit_1|10|6|FOLLOW-UP|2020-10-13|10
e|IS|173aea61-964d-4f4a-8d48-56a1a58de6d8|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/day|[?]|1|DAgU/mL|FLUID|ACCELERATOR MASS SPECTROMETRY||Y|1|2|Visit_2|25|2|TREATMENT|2020-10-28|25
e|IS|173aea61-964d-4f4a-8d48-56a1a58de6d8|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ng/mol|[?]|1|10^9 CFU/g|PLASMA ULTRAFILTRATE|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y||1|3|Visit_3|40|5|TREATMENT|2020-11-12|40
e|IS|173aea61-964d-4f4a-8d48-56a1a58de6d8|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|log10 PFU/mL|[?]|1|C|CIRCULATING TUMOR CELL|TOTAL BODY RADIOGRAPHY||Y|1|4|Visit_4|65|5|FOLLOW-UP|2020-12-07|65
e|IS|173aea61-964d-4f4a-8d48-56a1a58de6d8|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 RNA copies/mL|[?]|1|P|INFRANATANT, SERUM|IMMUNOCHROMATOGRAPHY|Y||1|5|Visit_5|90|6|WASHOUT|2021-01-01|90
e|IS|45d1adb8-9b3b-4f06-87cb-740205448680|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmHg|[?]|1|dpm/mg|ADIPOSE TISSUE|HPLC-FL|||1|1|Visit_1|10|7|FOLLOW-UP|2020-07-17|10
e|IS|45d1adb8-9b3b-4f06-87cb-740205448680|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|EU|[?]|1|MET*min|ATHEROSCLEROTIC PLAQUE|STATIC PERIMETRY|Y|Y|1|2|Visit_2|25|3|TREATMENT|2020-08-01|25
e|IS|45d1adb8-9b3b-4f06-87cb-740205448680|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmol|[?]|1|aMFI|DISCHARGE|RULER MEASUREMENT METHOD|||1|3|Visit_3|40|5|WASHOUT|2020-08-16|40
e|IS|45d1adb8-9b3b-4f06-87cb-740205448680|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/10^5|[?]|1|km/h|STOOL|ELECTROGASTROGRAPHY|||1|4|Visit_4|65|2|SCREENING|2020-09-10|65
e|IS|45d1adb8-9b3b-4f06-87cb-740205448680|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|MET*min|[?]|1|OI50|PROSTATIC FLUID|ENDPOINT DILUTION ASSAY|Y||1|5|Visit_5|90|4|WASHOUT|2020-10-05|90
e|IS|7403ad67-7ed5-4716-a874-c360429845bc|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Farad|[?]|1|uV|SPERMATOZOON|MICROBIAL CULTURE, SOLID|||1|1|Visit_1|10|6|SCREENING|2020-05-30|10
e|IS|7403ad67-7ed5-4716-a874-c360429845bc|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Osm|[?]|1|%|FLUID|COULOMETRIC TITRATION|||1|2|Visit_2|25|3|TREATMENT|2020-06-14|25
e|IS|7403ad67-7ed5-4716-a874-c360429845bc|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|FFU|[?]|1|CONTAINER|CERUMEN|GC/MS-CI||Y|1|3|Visit_3|40|7|TREATMENT|2020-06-29|40
e|IS|7403ad67-7ed5-4716-a874-c360429845bc|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|L/h|[?]|1|%|RETICULOCYTES|FLUOROSCOPY|||1|4|Visit_4|65|7|TREATMENT|2020-07-24|65
e|IS|7403ad67-7ed5-4716-a874-c360429845bc|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/g/day|[?]|1|BLOCKS|CEREBROSPINAL FLUID|MAMMOGRAPHY|||1|5|Visit_5|90|4|TREATMENT|2020-08-18|90
e|IS|8be919ce-34da-4e49-ac7a-3679c7af632d|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/dose|[?]|1|/ms|CALCULUS|MIGET|||1|1|Visit_1|10|3|WASHOUT|2021-01-13|10
e|IS|8be919ce-34da-4e49-ac7a-3679c7af632d|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|beats/min|[?]|1|mL/beat|INTERSTITIAL FLUID|SPECT SCAN|Y||1|2|Visit_2|25|6|TREATMENT|2021-01-28|25
e|IS|8be919ce-34da-4e49-ac7a-3679c7af632d|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|m/sec|[?]|1|BU/mL|PERIPHERAL BLOOD MONONUCLEAR CELL|REFLECTANCE SPECTROSCOPY|||1|3|Visit_3|40|4|WASHOUT|2021-02-12|40
e|IS|8be919ce-34da-4e49-ac7a-3679c7af632d|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/L FEU|[?]|1|Bq/ug|MONOCYTE|SURFACE PLASMON RESONANCE|Y||1|4|Visit_4|65|3|FOLLOW-UP|2021-03-09|65
e|IS|8be919ce-34da-4e49-ac7a-3679c7af632d|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|BAR|[?]|1|10^6/L|ARTERIAL BLOOD|MALDI|||1|5|Visit_5|90|7|SCREENING|2021-04-03|90
e|IS|9c44967b-914e-43d5-be1e-6829804e04ab|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/U|[?]|1|L/L|URINE|POLYSOMNOGRAPHY|||1|1|Visit_1|10|7|TREATMENT|2021-01-24|10
e|IS|9c44967b-914e-43d5-be1e-6829804e04ab|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/wk|[?]|1|U/animal|BONE|PERCUSSION|||1|2|Visit_2|25|1|TREATMENT|2021-02-08|25
e|IS|9c44967b-914e-43d5-be1e-6829804e04ab|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/animal|[?]|1|dyn|TRANSUDATE|INDIRECT IMMUNOFLUORESCENCE|||1|3|Visit_3|40|4|SCREENING|2021-02-23|40
e|IS|9c44967b-914e-43d5-be1e-6829804e04ab|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|NEBULE|[?]|1|mJoule/cm2|DISCHARGE|BAC ACGH|||1|4|Visit_4|65|4|TREATMENT|2021-03-20|65
e|IS|9c44967b-914e-43d5-be1e-6829804e04ab|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mmol/kg|[?]|1|LB|CALCULUS|FREEZING POINT DEPRESSION|||1|5|Visit_5|90|4|TREATMENT|2021-04-14|90
e|IS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|IU/g|[?]|1|log10 CCID 50/dose|MUCUS|DIGITAL PCR ARRAY||Y|1|1|Visit_1|10|1|SCREENING|2020-07-31|10
e|IS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mPa|[?]|1|mgEq|PLATELET|IHC|||1|2|Visit_2|25|3|TREATMENT|2020-08-15|25
e|IS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|STEPS|[?]|1|mg/dL|ENDOMETRIAL TISSUE|EIA|||1|3|Visit_3|40|2|TREATMENT|2020-08-30|40
e|IS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|oz|[?]|1|Hz|SPUTUM|FLOCCULATION, CHARCOAL ENHANCED||Y|1|4|Visit_4|65|5|TREATMENT|2020-09-24|65
e|IS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mm2|[?]|1|mL/g/min|BREAST MILK|WHOLE EXOME SEQUENCING|||1|5|Visit_5|90|3|TREATMENT|2020-10-19|90
e|IS|cad8c553-739f-4046-a898-d939eb286dba|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^3/hpf|[?]|1|dyn|BONE|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||1|1|Visit_1|10|2|WASHOUT|2020-05-17|10
e|IS|cad8c553-739f-4046-a898-d939eb286dba|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ppb|[?]|1|aMFI|ENDOMETRIAL TISSUE|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|1|2|Visit_2|25|7|FOLLOW-UP|2020-06-01|25
e|IS|cad8c553-739f-4046-a898-d939eb286dba|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|breaths/30s|[?]|1|grain|ATHEROSCLEROTIC PLAQUE|POLYGRAPHY|Y||1|3|Visit_3|40|2|TREATMENT|2020-06-16|40
e|IS|cad8c553-739f-4046-a898-d939eb286dba|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|AU/mL|[?]|1|dpm/100mg|CERUMEN|RADIOGRAPHY|Y||1|4|Visit_4|65|5|FOLLOW-UP|2020-07-11|65
e|IS|cad8c553-739f-4046-a898-d939eb286dba|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Ejaculate U|[?]|1|mol|BUFFY COAT|JAEGER EYE CHART|||1|5|Visit_5|90|7|FOLLOW-UP|2020-08-05|90
e|IS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|um/s|[?]|1|vp/dose|CAPILLARY PLASMA|IMMUNODIFFUSION|||1|1|Visit_1|10|3|TREATMENT|2020-09-11|10
e|IS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^3 CFU/mL|[?]|1|uL/mL|PERSPIRATION|AGAR DILUTION|Y||1|2|Visit_2|25|6|TREATMENT|2020-09-26|25
e|IS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/kg/min|[?]|1|HOURS|SERUM OR PLASMA OR BLOOD|APPLANATION TONOMETRY||Y|1|3|Visit_3|40|6|TREATMENT|2020-10-11|40
e|IS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|GLOBULE|[?]|1|L/h|RETICULOCYTES|CLIP SEQUENCING|Y|Y|1|4|Visit_4|65|7|WASHOUT|2020-11-05|65
e|IS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|cycle/min|[?]|1|mAmp|SERUM OR PLASMA|ULTRASONOGRAPHIC ELASTOGRAPHY|Y||1|5|Visit_5|90|4|TREATMENT|2020-11-30|90
e|IS|81e934f8-7bcc-48d2-8d15-5270e51f2870|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|copies/ug|[?]|1|U/m2|SYNOVIAL FLUID|IMMUNOCHEMILUMINOMETRIC ASSAY|||1|1|Visit_1|10|5|SCREENING|2021-01-24|10
e|IS|81e934f8-7bcc-48d2-8d15-5270e51f2870|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Siemens|[?]|1|pmol/day|SUPERNATANT, SERUM OR PLASMA|FISH|Y||1|2|Visit_2|25|3|FOLLOW-UP|2021-02-08|25
e|IS|81e934f8-7bcc-48d2-8d15-5270e51f2870|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mol/mol|[?]|1|10^3 copies/mL|GASTRIC FLUID|TRYPAN BLUE STAIN|||1|3|Visit_3|40|5|SCREENING|2021-02-23|40
e|IS|81e934f8-7bcc-48d2-8d15-5270e51f2870|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|g/m2|[?]|1|ug/m2/day|SUPERNATANT, PLEURAL FLUID|FLOCCULATION, CHARCOAL ENHANCED|||1|4|Visit_4|65|1|TREATMENT|2021-03-20|65
e|IS|81e934f8-7bcc-48d2-8d15-5270e51f2870|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/40 HPFs|[?]|1|mmol/g|CAPILLARY BLOOD|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|1|5|Visit_5|90|2|WASHOUT|2021-04-14|90
e|IS|5713cabe-4d79-4f77-8ddc-daad1242a837|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|g/cage|[?]|1|kg|ALVEOLAR AIR|POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|7|FOLLOW-UP|2020-09-09|10
e|IS|5713cabe-4d79-4f77-8ddc-daad1242a837|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|K|[?]|1|Gy/min|SUPERNATANT, SERUM OR PLASMA|MALDI-TOF|||1|2|Visit_2|25|4|SCREENING|2020-09-24|25
e|IS|5713cabe-4d79-4f77-8ddc-daad1242a837|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|umol/L/sec|[?]|1|P|KERATINOCYTE|SPIROMETRY|||1|3|Visit_3|40|6|SCREENING|2020-10-09|40
e|IS|5713cabe-4d79-4f77-8ddc-daad1242a837|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cm H2O|[?]|1|mL/100g/min|MUCUS|ANTIMICROBIAL COMBINATION TESTING|||1|4|Visit_4|65|6|FOLLOW-UP|2020-11-03|65
e|IS|5713cabe-4d79-4f77-8ddc-daad1242a837|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^11/L|[?]|1|g/cage/wk|BLOOD|HPLC|Y||1|5|Visit_5|90|3|TREATMENT|2020-11-28|90
e|IS|414d20c7-8dc8-49ad-8ae9-f113b9610109|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|uCi/L|[?]|1|/MBP|COLOSTRUM|ELASTOGRAPHY|||1|1|Visit_1|10|4|FOLLOW-UP|2020-07-10|10
e|IS|414d20c7-8dc8-49ad-8ae9-f113b9610109|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^7/L|[?]|1|IU/mL|CORD BLOOD|RADIOIMMUNOPRECIPITATION ASSAY||Y|1|2|Visit_2|25|3|FOLLOW-UP|2020-07-25|25
e|IS|414d20c7-8dc8-49ad-8ae9-f113b9610109|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cmH2O*s/mL|[?]|1|DRINK|CERUMEN|QUANTITATIVE CORONARY ANGIOGRAPHY|||1|3|Visit_3|40|6|TREATMENT|2020-08-09|40
e|IS|414d20c7-8dc8-49ad-8ae9-f113b9610109|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|BU/mL|[?]|1|tsp eq|TISSUE|SCANNING ELECTRON MICROSCOPY|Y|Y|1|4|Visit_4|65|2|FOLLOW-UP|2020-09-03|65
e|IS|414d20c7-8dc8-49ad-8ae9-f113b9610109|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kN/cm2|[?]|1|mEq/mmol|SERUM OR PLASMA|NUCLEIC ACID SEQUENCING|||1|5|Visit_5|90|5|FOLLOW-UP|2020-09-28|90
e|IS|21e16094-23bd-4d20-b5f8-10d45858160e|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|NEEDLE GAUGE|[?]|1|BAU|ALVEOLAR AIR|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-09-17|10
e|IS|21e16094-23bd-4d20-b5f8-10d45858160e|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/kg/h|[?]|1|10^9/L|PUS|SPIROMETRY|||1|2|Visit_2|25|4|TREATMENT|2020-10-02|25
e|IS|21e16094-23bd-4d20-b5f8-10d45858160e|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq/kg|[?]|1|mmAL|AQUEOUS HUMOR|DNA MICROARRAY||Y|1|3|Visit_3|40|5|WASHOUT|2020-10-17|40
e|IS|21e16094-23bd-4d20-b5f8-10d45858160e|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|lx|[?]|1|Arbitrary U|HAIR FOLLICLE|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y||1|4|Visit_4|65|1|TREATMENT|2020-11-11|65
e|IS|21e16094-23bd-4d20-b5f8-10d45858160e|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|genEq|[?]|1|APL U/mL|SERUM OR PLASMA|GC/MS/MS|||1|5|Visit_5|90|2|SCREENING|2020-12-06|90
e|IS|2346613e-6734-476a-a414-511606c2d753|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MESF|[?]|1|BOX|INTERSTITIAL FLUID|SINGLE-MOLECULE ARRAY|Y||1|1|Visit_1|10|6|FOLLOW-UP|2020-09-22|10
e|IS|2346613e-6734-476a-a414-511606c2d753|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/breath|[?]|1|kg/mol|URINE|IMMUNOBLOT|||1|2|Visit_2|25|7|WASHOUT|2020-10-07|25
e|IS|2346613e-6734-476a-a414-511606c2d753|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/L FEU|[?]|1|kg|EMESIS|ROMANOWSKY STAIN|Y||1|3|Visit_3|40|7|TREATMENT|2020-10-22|40
e|IS|2346613e-6734-476a-a414-511606c2d753|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|tuberculin unit|[?]|1|Bq/mL|SEMINAL FLUID|MALDI|||1|4|Visit_4|65|5|TREATMENT|2020-11-16|65
e|IS|2346613e-6734-476a-a414-511606c2d753|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^4/L|[?]|1|mAnson U/mL|KERATINOCYTE|URANYL ACETATE STAIN|||1|5|Visit_5|90|6|TREATMENT|2020-12-11|90
e|IS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|g/cm2|[?]|1|ng/day|SUPERNATANT, PLEURAL FLUID|PHOTOGRAPHY|||1|1|Visit_1|10|7|SCREENING|2020-11-26|10
e|IS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/L|[?]|1|km/h|URINE SEDIMENT|ERGOSPIROMETRY||Y|1|2|Visit_2|25|7|FOLLOW-UP|2020-12-11|25
e|IS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MHz|[?]|1|L/h/m2|SOFT TISSUE|TOTAL BODY RADIOGRAPHY|||1|3|Visit_3|40|6|WASHOUT|2020-12-26|40
e|IS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|ks|[?]|1|deg/mm|VENOUS BLOOD|FLOCCULATION, CHARCOAL ENHANCED|||1|4|Visit_4|65|4|SCREENING|2021-01-20|65
e|IS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 organisms/mL|[?]|1|mL/dL|ADIPOSE TISSUE|ELECTROGASTROGRAPHY|Y||1|5|Visit_5|90|1|FOLLOW-UP|2021-02-14|90
e|IS|748ef401-3def-4674-8d5e-4a198709d672|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/animal|[?]|1|ohm|NAIL|TRIPLE-PHASE SPIRAL CT SCAN|||1|1|Visit_1|10|1|FOLLOW-UP|2020-06-08|10
e|IS|748ef401-3def-4674-8d5e-4a198709d672|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|breaths/30s|[?]|1|mg/kg/min|PLATELET|LANDOLT RING|Y|Y|1|2|Visit_2|25|5|TREATMENT|2020-06-23|25
e|IS|748ef401-3def-4674-8d5e-4a198709d672|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/animal/day|[?]|1|mEq|SERUM OR PLASMA|LANDOLT RING|||1|3|Visit_3|40|3|TREATMENT|2020-07-08|40
e|IS|748ef401-3def-4674-8d5e-4a198709d672|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|kHz|[?]|1|mg/mL/min|BUFFY COAT|MAPH|||1|4|Visit_4|65|3|TREATMENT|2020-08-02|65
e|IS|748ef401-3def-4674-8d5e-4a198709d672|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|kBq|[?]|1|nmol BCE/nmol|CERVICOVAGINAL SECRETION|LIGHT MICROSCOPY|Y||1|5|Visit_5|90|4|TREATMENT|2020-08-27|90
e|IS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/min/1.73m2|[?]|1|mL/h|SUPERNATANT, PLEURAL FLUID|REVERSE TRANSCRIPTASE PCR|Y||1|1|Visit_1|10|3|TREATMENT|2020-07-15|10
e|IS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|KIT|[?]|1|mg/min|CAPILLARY BLOOD|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||1|2|Visit_2|25|5|WASHOUT|2020-07-30|25
e|IS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SCOOPFUL|[?]|1|log10 IU/mL|TRANSUDATE|FLOW CYTOMETRY||Y|1|3|Visit_3|40|2|TREATMENT|2020-08-14|40
e|IS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|IU/g|[?]|1|PFU/dose|MUSCLE TISSUE|WESTERGREN||Y|1|4|Visit_4|65|4|TREATMENT|2020-09-08|65
e|IS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mEq|[?]|1|10^9 organisms/mL|VENOUS CORD BLOOD|FUNDUS PHOTOGRAPHY|Y||1|5|Visit_5|90|6|SCREENING|2020-10-03|90
e|IS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/L|[?]|1|Anson U|PLASMA ULTRAFILTRATE|TELLER ACUITY CARDS|Y||1|1|Visit_1|10|4|TREATMENT|2020-11-13|10
e|IS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|min*mg/mL|[?]|1|nmol/mol|PLATELET RICH PLASMA|SLOAN LETTER EYE CHART 1.25%|Y||1|2|Visit_2|25|1|SCREENING|2020-11-28|25
e|IS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|tuberculin unit/mL|[?]|1|OD Unit|BLOOD|SINGLE-MOLECULE ARRAY|||1|3|Visit_3|40|6|TREATMENT|2020-12-13|40
e|IS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|anti-Xa IU|[?]|1|fg|COLOSTRUM|PET/CT SCAN WITHOUT CONTRAST|Y|Y|1|4|Visit_4|65|5|SCREENING|2021-01-07|65
e|IS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|copies/mL|EXUDATE|TRANSMISSION ELECTRON MICROSCOPY||Y|1|5|Visit_5|90|7|TREATMENT|2021-02-01|90
e|IS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Enzyme U/g Hb|[?]|1|ug/animal|CERVICOVAGINAL SECRETION|FLUORESCENT IMMUNOASSAY|||1|1|Visit_1|10|6|TREATMENT|2020-11-28|10
e|IS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|aMFI|[?]|1|L/s|SERUM OR PLASMA OR BLOOD|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y|Y|1|2|Visit_2|25|2|WASHOUT|2020-12-13|25
e|IS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mPa|[?]|1|dmol|SALIVA|SPECULAR MICROSCOPY|||1|3|Visit_3|40|1|TREATMENT|2020-12-28|40
e|IS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^9 organisms/g|[?]|1|PACKET|PLASMA|LAPAROSCOPY|||1|4|Visit_4|65|5|TREATMENT|2021-01-22|65
e|IS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|MnFI|[?]|1|10^3 copies/mL|ALVEOLAR AIR|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||Y|1|5|Visit_5|90|4|FOLLOW-UP|2021-02-16|90
e|IS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mol/L|[?]|1|10^6 organisms/g|SEMINAL FLUID|DNA MICROARRAY||Y|1|1|Visit_1|10|2|TREATMENT|2020-06-30|10
e|IS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mmol/g|[?]|1|INHALATION|ARTERIAL BLOOD|SINGLE-SLICE SPIRAL CT|||1|2|Visit_2|25|6|TREATMENT|2020-07-15|25
e|IS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Torr|[?]|1|m2|INFRANATANT, SERUM|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|3|Visit_3|40|7|FOLLOW-UP|2020-07-30|40
e|IS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 CFU|[?]|1|DRINK|SKIN TISSUE|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|4|Visit_4|65|7|FOLLOW-UP|2020-08-24|65
e|IS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mCi/kg|[?]|1|QUANTITY SUFFICIENT|LYMPH|DYNAMOMETRY|||1|5|Visit_5|90|1|TREATMENT|2020-09-18|90
e|IS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|JDF Unit|[?]|1|mJoule/cm2|PERSPIRATION|IN VITRO GENE EXPRESSION ASSAY|||1|1|Visit_1|10|4|FOLLOW-UP|2020-12-09|10
e|IS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Bq|[?]|1|KALLIKREIN INHIBITOR UNIT|PLASMA|FLUOROSCOPY|||1|2|Visit_2|25|4|SCREENING|2020-12-24|25
e|IS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/100g/min|[?]|1|/4.0 mL|SEMINAL FLUID|REFRACTOMETRY|Y||1|3|Visit_3|40|2|TREATMENT|2021-01-08|40
e|IS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|PIXEL|[?]|1|Shock Wave|EMOTIONAL TEAR|NEPHELOMETRY|||1|4|Visit_4|65|6|FOLLOW-UP|2021-02-02|65
e|IS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kg|[?]|1|mmHg|BREAST MILK|CT SCAN WITHOUT CONTRAST|Y||1|5|Visit_5|90|2|WASHOUT|2021-02-27|90
e|IS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|atm|[?]|1|min/day|BREAST MILK|HEMATOXYLIN AND EOSIN STAIN|Y|Y|1|1|Visit_1|10|1|TREATMENT|2020-11-19|10
e|IS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|V/sec|[?]|1|mg/g/min|SERUM OR PLASMA|ICP-MS|||1|2|Visit_2|25|3|FOLLOW-UP|2020-12-04|25
e|IS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|kN/cm2|[?]|1|cal|URINE|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y||1|3|Visit_3|40|5|TREATMENT|2020-12-19|40
e|IS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/mL|[?]|1|pmol/10^10 cells|TISSUE|RADIOIMMUNOPRECIPITATION ASSAY|Y|Y|1|4|Visit_4|65|4|TREATMENT|2021-01-13|65
e|IS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|PUFF|[?]|1|STEPS|EXPIRED AIR|U-HPLC/MS/MS||Y|1|5|Visit_5|90|7|TREATMENT|2021-02-07|90
e|IS|bc71ddfa-c71c-447b-9684-005e4c112172|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PACKET|[?]|1|MnFI|ENDOMETRIAL TISSUE|LC-FL|||1|1|Visit_1|10|2|WASHOUT|2020-07-11|10
e|IS|bc71ddfa-c71c-447b-9684-005e4c112172|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|nU/cL|[?]|1|U/dL|INFRANATANT, PLASMA|PEAK FLOWMETRY|Y||1|2|Visit_2|25|4|SCREENING|2020-07-26|25
e|IS|bc71ddfa-c71c-447b-9684-005e4c112172|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|NEEDLE GAUGE|[?]|1|BAR|EXHALED BREATH CONDENSATE|MRI WITHOUT CONTRAST|||1|3|Visit_3|40|1|TREATMENT|2020-08-10|40
e|IS|bc71ddfa-c71c-447b-9684-005e4c112172|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/m2/day|[?]|1|10^3 organisms/mL|CALCULUS|SINGLE-SLICE SPIRAL CT|||1|4|Visit_4|65|1|TREATMENT|2020-09-04|65
e|IS|bc71ddfa-c71c-447b-9684-005e4c112172|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/g/min|[?]|1|LOZENGE|ENDOTRACHEAL FLUID|CT SCAN|Y||1|5|Visit_5|90|4|TREATMENT|2020-09-29|90
e|IS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|uV2|[?]|1|mmol|VENOUS BLOOD|TARGETED TRANSCRIPTOME SEQUENCING||Y|1|1|Visit_1|10|1|FOLLOW-UP|2020-12-09|10
e|IS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Gy/h|[?]|1|ng/day|DIALYSIS FLUID|PERIODIC ACID SCHIFF STAIN|Y|Y|1|2|Visit_2|25|2|FOLLOW-UP|2020-12-24|25
e|IS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|oz|[?]|1|10^7 TCID 50/dose|STRIATED MUSCLE TISSUE|ELLA|||1|3|Visit_3|40|3|TREATMENT|2021-01-08|40
e|IS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ks|[?]|1|umol/L|SMOOTH MUSCLE TISSUE|FLUORESCENT SPOT TEST|||1|4|Visit_4|65|2|SCREENING|2021-02-02|65
e|IS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/month|[?]|1|grain|PERSPIRATION|IRON HEMATOXYLIN STAIN|||1|5|Visit_5|90|3|FOLLOW-UP|2021-02-27|90
e|IS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mV/sec|[?]|1|cmol/L|CIRCULATING TUMOR CELL|SPECT SCAN||Y|1|1|Visit_1|10|3|TREATMENT|2020-09-06|10
e|IS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/m2/day|[?]|1|10^7 CFU|VENOUS CORD BLOOD|POLYGRAPHY|||1|2|Visit_2|25|4|WASHOUT|2020-09-21|25
e|IS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|MBq/uL|[?]|1|mg/kg/dose|CORD BLOOD|PET/CT SCAN WITHOUT CONTRAST|||1|3|Visit_3|40|1|SCREENING|2020-10-06|40
e|IS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kg/mol|[?]|1|g/day|CAPILLARY BLOOD|HPLC-FL|Y||1|4|Visit_4|65|2|WASHOUT|2020-10-31|65
e|IS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Siemens|[?]|1|Gravitational Unit|SUPERNATANT, PLEURAL FLUID|THIN SMEAR|||1|5|Visit_5|90|1|TREATMENT|2020-11-25|90
e|IS|b1b3e113-8c73-4446-8095-3341f8912bd7|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Bq/g|[?]|1|L/day|FLUID|ENZYMATIC COLORIMETRY|||1|1|Visit_1|10|2|SCREENING|2021-01-27|10
e|IS|b1b3e113-8c73-4446-8095-3341f8912bd7|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|HEP|[?]|1|m3|EPIDERMAL TISSUE|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|2|Visit_2|25|4|FOLLOW-UP|2021-02-11|25
e|IS|b1b3e113-8c73-4446-8095-3341f8912bd7|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|L/s/kPa|[?]|1|/2500 WBC|PUS|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|3|Visit_3|40|4|FOLLOW-UP|2021-02-26|40
e|IS|b1b3e113-8c73-4446-8095-3341f8912bd7|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|kg/cm|[?]|1|10^6 copies/mL|CERVICOVAGINAL SECRETION|FLUORESCENCE ANGIOGRAPHY|||1|4|Visit_4|65|7|WASHOUT|2021-03-23|65
e|IS|b1b3e113-8c73-4446-8095-3341f8912bd7|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|L/day|ALVEOLAR AIR|IHC|||1|5|Visit_5|90|2|WASHOUT|2021-04-17|90
e|IS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/g/min|[?]|1|V|CAPILLARY PLASMA|CARDIAC THERMODILUTION|||1|1|Visit_1|10|7|FOLLOW-UP|2020-11-22|10
e|IS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|lx|[?]|1|10^9 CFU/g|SUPERNATANT, PLEURAL FLUID|CELL BASED BIOASSAY||Y|1|2|Visit_2|25|1|FOLLOW-UP|2020-12-07|25
e|IS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|amu|[?]|1|/min|INTERSTITIAL FLUID|CELLULAR PROLIFERATION ASSAY|||1|3|Visit_3|40|6|TREATMENT|2020-12-22|40
e|IS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ka_u/dL|[?]|1|10^4 CFU/mL|BILE|X-RAY FLUORESCENCE SPECTROMETRY|||1|4|Visit_4|65|7|FOLLOW-UP|2021-01-16|65
e|IS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ks|[?]|1|ug/dL|FLUID|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||Y|1|5|Visit_5|90|7|WASHOUT|2021-02-10|90
e|IS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|FEU|[?]|1|JAR|PUS|MICROBIAL CULTURE, SOLID||Y|1|1|Visit_1|10|2|TREATMENT|2020-08-06|10
e|IS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cd*s/m2|[?]|1|/10^3|VENOUS BLOOD|WHOLE GENOME SEQUENCING|||1|2|Visit_2|25|6|WASHOUT|2020-08-21|25
e|IS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Farad|[?]|1|mV2/Hz|INFRANATANT, SERUM|SPECT/CT SCAN|Y||1|3|Visit_3|40|1|SCREENING|2020-09-05|40
e|IS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg/L FEU|[?]|1|mL/cage/wk|AQUEOUS HUMOR|FLUORIMETRY|||1|4|Visit_4|65|7|TREATMENT|2020-09-30|65
e|IS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|pg/cell|[?]|1|mmol/mol|INFRANATANT, PLEURAL FLUID|ACID FAST STAIN|||1|5|Visit_5|90|7|TREATMENT|2020-10-25|90
e|IS|3b83c7a0-e22b-45b1-b065-71971f014039|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|GPL U|[?]|1|/VF|EMOTIONAL TEAR|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|1|Visit_1|10|6|SCREENING|2020-09-01|10
e|IS|3b83c7a0-e22b-45b1-b065-71971f014039|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^9/dose|[?]|1|10^6/g|PLATELET|WHOLE EXOME SEQUENCING||Y|1|2|Visit_2|25|3|TREATMENT|2020-09-16|25
e|IS|3b83c7a0-e22b-45b1-b065-71971f014039|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Joule|[?]|1|BOLUS|EXHALED BREATH CONDENSATE|SPIRAL CT SCAN WITHOUT CONTRAST|||1|3|Visit_3|40|2|TREATMENT|2020-10-01|40
e|IS|3b83c7a0-e22b-45b1-b065-71971f014039|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|umol|[?]|1|um/day|GASTRIC FLUID|AGAR DILUTION|||1|4|Visit_4|65|4|TREATMENT|2020-10-26|65
e|IS|3b83c7a0-e22b-45b1-b065-71971f014039|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|amol|[?]|1|mCi/kg|STRIATED MUSCLE TISSUE|PANENDOSCOPY|||1|5|Visit_5|90|7|FOLLOW-UP|2020-11-20|90
e|IS|92c849ce-12b8-4c38-baab-f91c44a007b9|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|RNA copies/mL|[?]|1|APS U|ENDOTRACHEAL FLUID|SEQUENCING||Y|1|1|Visit_1|10|4|TREATMENT|2020-11-12|10
e|IS|92c849ce-12b8-4c38-baab-f91c44a007b9|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/m2/day|[?]|1|Weber|LAVAGE FLUID|MECHANICAL CLOT DETECTION|Y|Y|1|2|Visit_2|25|3|FOLLOW-UP|2020-11-27|25
e|IS|92c849ce-12b8-4c38-baab-f91c44a007b9|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|%(w/v)|[?]|1|10^6 IU/mL|MECONIUM|OPTICAL MAPPING|||1|3|Visit_3|40|3|TREATMENT|2020-12-12|40
e|IS|92c849ce-12b8-4c38-baab-f91c44a007b9|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/cm2|[?]|1|Bq/uL|ADIPOSE TISSUE|PHOTOGRAPHY||Y|1|4|Visit_4|65|7|FOLLOW-UP|2021-01-06|65
e|IS|92c849ce-12b8-4c38-baab-f91c44a007b9|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|min|[?]|1|dpm/0.5 mL|CORD SERUM|FLUORESCENT MICROSCOPY|Y|Y|1|5|Visit_5|90|6|TREATMENT|2021-01-31|90
e|IS|f2101018-c983-435e-a453-148f182388f7|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mL/cm|[?]|1|ug/g/h|EXPIRED AIR|PET SCAN|Y||1|1|Visit_1|10|6|SCREENING|2020-09-01|10
e|IS|f2101018-c983-435e-a453-148f182388f7|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Osm|[?]|1|Weber|ALVEOLAR AIR|WRIGHT-GIEMSA STAIN|Y|Y|1|2|Visit_2|25|7|SCREENING|2020-09-16|25
e|IS|f2101018-c983-435e-a453-148f182388f7|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uEq|[?]|1|mmAL|SMEGMA|DYNAMIC CONTRAST ENHANCED MRI||Y|1|3|Visit_3|40|2|TREATMENT|2020-10-01|40
e|IS|f2101018-c983-435e-a453-148f182388f7|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^7 CFU|[?]|1|nsec|MIXED VENOUS BLOOD|ULTRASOUND|Y||1|4|Visit_4|65|5|TREATMENT|2020-10-26|65
e|IS|f2101018-c983-435e-a453-148f182388f7|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ppth|[?]|1|ug/kg/h|STRIATED MUSCLE TISSUE|ETDRS EYE CHART|Y||1|5|Visit_5|90|5|WASHOUT|2020-11-20|90
e|IS|613284eb-edbe-446b-b4fe-f96f1510e626|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|DISK|[?]|1|ms2|PUS|IMMUNOASSAY|||1|1|Visit_1|10|4|TREATMENT|2020-11-07|10
e|IS|613284eb-edbe-446b-b4fe-f96f1510e626|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/LPF|[?]|1|mCi/kg|CAPILLARY PLASMA|DUCTOGRAPHY|Y||1|2|Visit_2|25|3|TREATMENT|2020-11-22|25
e|IS|613284eb-edbe-446b-b4fe-f96f1510e626|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|/HPF|[?]|1|mL/cage/day|ARTERIAL BLOOD|WESTERGREN|||1|3|Visit_3|40|3|WASHOUT|2020-12-07|40
e|IS|613284eb-edbe-446b-b4fe-f96f1510e626|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/sec|[?]|1|ft3|LUNG SURFACTANT|ELECTROMYOGRAPHY|Y||1|4|Visit_4|65|2|SCREENING|2021-01-01|65
e|IS|613284eb-edbe-446b-b4fe-f96f1510e626|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|scm|[?]|1|10^12/L|INTERSTITIAL FLUID|PEAK FLOWMETRY|||1|5|Visit_5|90|6|TREATMENT|2021-01-26|90
e|IS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ug/m2/h|[?]|1|kg/mol|ERYTHROCYTES|POLYSOMNOGRAPHY|||1|1|Visit_1|10|7|TREATMENT|2020-07-15|10
e|IS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|TRANSDUCING UNIT|[?]|1|mg/kg/week|FLUID|KARYOTYPING|||1|2|Visit_2|25|3|FOLLOW-UP|2020-07-30|25
e|IS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Watt|[?]|1|mEq/mmol|MIXED VENOUS BLOOD|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||1|3|Visit_3|40|4|TREATMENT|2020-08-14|40
e|IS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|breaths/min|[?]|1|nmol BCE/nmol|DIALYSIS FLUID|CALCOFLUOR WHITE STAIN|Y||1|4|Visit_4|65|3|TREATMENT|2020-09-08|65
e|IS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|kUSP|[?]|1|msec|PLATELET RICH PLASMA|BRDU CELLULAR PROLIFERATION ASSAY|||1|5|Visit_5|90|3|SCREENING|2020-10-03|90
e|IS|2350438a-0bc8-4da5-b6c9-99a6c012b454|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|breaths/min|[?]|1|ng/mol|LYSATE|CENTRIFUGATION|||1|1|Visit_1|10|6|TREATMENT|2020-08-21|10
e|IS|2350438a-0bc8-4da5-b6c9-99a6c012b454|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ka_u/dL|[?]|1|mL/beat|MIXED VENOUS BLOOD|NON-CONTACT SPECULAR MICROSCOPY||Y|1|2|Visit_2|25|6|FOLLOW-UP|2020-09-05|25
e|IS|2350438a-0bc8-4da5-b6c9-99a6c012b454|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|PIXELS/cm|[?]|1|copies/ug|MUSCLE TISSUE|SPIROMETRY|Y||1|3|Visit_3|40|2|TREATMENT|2020-09-20|40
e|IS|2350438a-0bc8-4da5-b6c9-99a6c012b454|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|GBq/ug|[?]|1|rpm|VENOUS BLOOD|SPIRAL CT SCAN WITHOUT CONTRAST|||1|4|Visit_4|65|4|WASHOUT|2020-10-15|65
e|IS|2350438a-0bc8-4da5-b6c9-99a6c012b454|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^6 CFU/g|[?]|1|ugEq/L|BONE|TRYPAN BLUE STAIN|||1|5|Visit_5|90|6|TREATMENT|2020-11-09|90
e|IS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|g/cage/wk|[?]|1|g/kg|AMNIOTIC FLUID|LIGHT MICROSCOPY|Y||1|1|Visit_1|10|5|TREATMENT|2020-11-16|10
e|IS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|gMFI|[?]|1|Arbitrary U|CAPILLARY BLOOD|DUCTOGRAPHY|||1|2|Visit_2|25|2|TREATMENT|2020-12-01|25
e|IS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Linear ft*LB|[?]|1|AU/mL|EXHALED BREATH CONDENSATE|QUANTITATIVE ULTRASOUND|||1|3|Visit_3|40|1|WASHOUT|2020-12-16|40
e|IS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|STRIP|[?]|1|pptr|SUPERNATANT, SERUM OR PLASMA|TONOMETRY|||1|4|Visit_4|65|5|FOLLOW-UP|2021-01-10|65
e|IS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|HOURS|[?]|1|vp/mL|SUPERNATANT, PLASMA|HEMAGGLUTINATION ASSAY||Y|1|5|Visit_5|90|1|FOLLOW-UP|2021-02-04|90
e|IS|416fe99b-1258-4e72-b1df-48b989f8f8ed|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|pkat|[?]|1|mEq/L|PERIPHERAL BLOOD MONONUCLEAR CELL|MICROBIAL CULTURE, LIQUID|||1|1|Visit_1|10|5|TREATMENT|2020-08-28|10
e|IS|416fe99b-1258-4e72-b1df-48b989f8f8ed|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|uL/kg/day|[?]|1|mm2|CAPILLARY PLASMA|ACID FAST STAIN|||1|2|Visit_2|25|7|TREATMENT|2020-09-12|25
e|IS|416fe99b-1258-4e72-b1df-48b989f8f8ed|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Hz/s|[?]|1|ukat/10^12 RBC|EPIDERMAL TISSUE|KARYOTYPING||Y|1|3|Visit_3|40|6|TREATMENT|2020-09-27|40
e|IS|416fe99b-1258-4e72-b1df-48b989f8f8ed|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Enzyme U/L|[?]|1|mmol/min/kPa|SEMEN|REVERSE TRANSCRIPTASE PCR|||1|4|Visit_4|65|6|TREATMENT|2020-10-22|65
e|IS|416fe99b-1258-4e72-b1df-48b989f8f8ed|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|BOWL|[?]|1|uV2|PROSTATIC FLUID|MICROPARTICLE ENZYME IMMUNOASSAY||Y|1|5|Visit_5|90|5|TREATMENT|2020-11-16|90
e|IS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IU/L|[?]|1|vp/mL|SEBUM|RADIAL IMMUNODIFFUSION|Y||1|1|Visit_1|10|5|TREATMENT|2020-05-26|10
e|IS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|/500 WBC|[?]|1|PUFF|SALIVA|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y||1|2|Visit_2|25|7|WASHOUT|2020-06-10|25
e|IS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|pg/L|[?]|1|mAmp|PLATELET|IRON HEMATOXYLIN STAIN|||1|3|Visit_3|40|3|TREATMENT|2020-06-25|40
e|IS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|GPS U|[?]|1|OD Unit|CAPILLARY BLOOD|MANUAL CLOT DETECTION||Y|1|4|Visit_4|65|6|TREATMENT|2020-07-20|65
e|IS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|breaths/min|[?]|1|ag|STRIATED MUSCLE TISSUE|PERIODIC ACID SCHIFF STAIN|Y||1|5|Visit_5|90|3|TREATMENT|2020-08-14|90
e|IS|1497a00d-55b1-4e02-a957-cf15e3d15512|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|kBq/uL|[?]|1|mmol|GASTRIC CONTENTS|FUNDUS PHOTOGRAPHY|||1|1|Visit_1|10|7|WASHOUT|2021-01-25|10
e|IS|1497a00d-55b1-4e02-a957-cf15e3d15512|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|JAR|[?]|1|nmol/L|LYMPH|MICROBIAL CULTURE|||1|2|Visit_2|25|7|FOLLOW-UP|2021-02-09|25
e|IS|1497a00d-55b1-4e02-a957-cf15e3d15512|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|APPLICATION|[?]|1|mV|SERUM OR PLASMA|RADIATION DOSIMETRY|||1|3|Visit_3|40|7|WASHOUT|2021-02-24|40
e|IS|1497a00d-55b1-4e02-a957-cf15e3d15512|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|atm|[?]|1|pkat/L|STRIATED MUSCLE TISSUE|SINGLE-SLICE SPIRAL CT||Y|1|4|Visit_4|65|3|TREATMENT|2021-03-21|65
e|IS|1497a00d-55b1-4e02-a957-cf15e3d15512|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|umol/L|[?]|1|ug/day|PLEURAL TISSUE|CELL OF ORIGIN ASSAY|||1|5|Visit_5|90|1|TREATMENT|2021-04-15|90
e|IS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mJoule/cm2|[?]|1|anti-Xa IU/mL|SUPERNATANT, SERUM OR PLASMA|CT SCAN||Y|1|1|Visit_1|10|2|TREATMENT|2020-07-21|10
e|IS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|TUBE|[?]|1|ug/L DDU|ISOLATE|SPECULAR MICROSCOPY|||1|2|Visit_2|25|6|SCREENING|2020-08-05|25
e|IS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/dose|[?]|1|cL|PLATELET|FARR ASSAY|||1|3|Visit_3|40|5|TREATMENT|2020-08-20|40
e|IS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|pkat|[?]|1|vg/mL|BILE|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||1|4|Visit_4|65|1|TREATMENT|2020-09-14|65
e|IS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|5|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Bq|[?]|1|PACKET|URINE|NEURAMINIDASE INHIBITION ASSAY|Y||1|5|Visit_5|90|1|SCREENING|2020-10-09|90
e|IS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MPL U/mL|[?]|1|mg/L FEU|SMOOTH MUSCLE TISSUE|PLETHYSMOGRAPHY|Y||1|1|Visit_1|10|7|FOLLOW-UP|2020-12-09|10
e|IS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Absorbance U/mL|[?]|1|kcal|BONE MARROW|EIA|||1|2|Visit_2|25|3|WASHOUT|2020-12-24|25
e|IS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|DDU|[?]|1|IU/day|CIRCULATING TUMOR CELL|DYNAMIC CONTRAST ENHANCED MRI|||1|3|Visit_3|40|5|TREATMENT|2021-01-08|40
e|IS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/mL/min|[?]|1|L/s/kPa|CAPILLARY PLASMA|FLUORESCENT SPOT TEST||Y|1|4|Visit_4|65|4|TREATMENT|2021-02-02|65
e|IS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|fmol/g|[?]|1|pL|EMESIS|SPECT SCAN|||1|5|Visit_5|90|1|TREATMENT|2021-02-27|90
e|IS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|fraction of 1|[?]|1|ug/mL/h|SOFT TISSUE|OPTICAL DENSITY MEASUREMENT||Y|1|1|Visit_1|10|1|WASHOUT|2020-11-05|10
e|IS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|FEU|[?]|1|ft2|CIRCULATING TUMOR CELL|OPTICAL MAPPING|Y||1|2|Visit_2|25|2|WASHOUT|2020-11-20|25
e|IS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MESF|[?]|1|OI50|MONOCYTE|PET SCAN|||1|3|Visit_3|40|5|TREATMENT|2020-12-05|40
e|IS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Gravitational Unit|[?]|1|ug/dose|STOOL|MODIFIED ACID FAST STAIN|||1|4|Visit_4|65|4|TREATMENT|2020-12-30|65
e|IS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|LENS|[?]|1|mg/h|SPUTUM|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|1|5|Visit_5|90|3|SCREENING|2021-01-24|90
e|IS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|U/m2|[?]|1|mg/mL/day|ENDOTRACHEAL FLUID|POLYMERASE CHAIN REACTION||Y|1|1|Visit_1|10|6|WASHOUT|2020-05-27|10
e|IS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mL/kg/day|[?]|1|L/L|ALVEOLAR AIR|FLAME PHOTOMETRY|||1|2|Visit_2|25|6|FOLLOW-UP|2020-06-11|25
e|IS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|U/mmol|[?]|1|nkat/L|PERIPHERAL BLOOD MONONUCLEAR CELL|ISHIHARA COLOR PLATES|||1|3|Visit_3|40|5|WASHOUT|2020-06-26|40
e|IS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|h*%|[?]|1|GBq/g|SERUM OR PLASMA|PHOTOMETRIC CLOT DETECTION||Y|1|4|Visit_4|65|7|TREATMENT|2020-07-21|65
e|IS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|INHALATION|[?]|1|BOLUS|MONOCYTE|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||1|5|Visit_5|90|7|FOLLOW-UP|2020-08-15|90
e|IS|2216086b-197e-4780-8e10-28123eb090c5|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|10^9/g|[?]|1|10^6/g|CERVICOVAGINAL SECRETION|MICROSCOPY|Y||1|1|Visit_1|10|2|FOLLOW-UP|2020-12-12|10
e|IS|2216086b-197e-4780-8e10-28123eb090c5|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|JAR|[?]|1|uEq|TISSUE|SPIRAL CT SCAN WITHOUT CONTRAST||Y|1|2|Visit_2|25|6|SCREENING|2020-12-27|25
e|IS|2216086b-197e-4780-8e10-28123eb090c5|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cm/s|[?]|1|nmol/L|BILE|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y|1|3|Visit_3|40|3|SCREENING|2021-01-11|40
e|IS|2216086b-197e-4780-8e10-28123eb090c5|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|kPa|[?]|1|dpm/mL|SEMEN|OPHTHALMOSCOPY|Y||1|4|Visit_4|65|3|TREATMENT|2021-02-05|65
e|IS|2216086b-197e-4780-8e10-28123eb090c5|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|MONTHS|[?]|1|pkat/L|SUPERNATANT, PLEURAL FLUID|TWO-COLOR MICROARRAY|Y||1|5|Visit_5|90|1|FOLLOW-UP|2021-03-02|90
e|IS|7280f69c-a0f4-48b5-b714-1e272193168c|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL*cmH2O|[?]|1|/HPF|GASTRIC FLUID|MICRODENSITOMETRY|||1|1|Visit_1|10|7|TREATMENT|2020-08-19|10
e|IS|7280f69c-a0f4-48b5-b714-1e272193168c|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mg/L FEU|[?]|1|msec|DIALYSIS FLUID, PERITONEAL|RULER MEASUREMENT METHOD|||1|2|Visit_2|25|2|TREATMENT|2020-09-03|25
e|IS|7280f69c-a0f4-48b5-b714-1e272193168c|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nmol/L/h|[?]|1|Tesla|SWABBED MATERIAL|LISSAMINE GREEN STAIN|||1|3|Visit_3|40|1|SCREENING|2020-09-18|40
e|IS|7280f69c-a0f4-48b5-b714-1e272193168c|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|HOURS|[?]|1|10^12 IU/L|CAPILLARY BLOOD|WHOLE EXOME SEQUENCING|||1|4|Visit_4|65|3|TREATMENT|2020-10-13|65
e|IS|7280f69c-a0f4-48b5-b714-1e272193168c|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|10^3 organisms/mL|[?]|1|dram|SERUM OR PLASMA OR BLOOD|REFRACTOMETRY|Y||1|5|Visit_5|90|3|SCREENING|2020-11-07|90
e|IS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|kDa|[?]|1|days/month|LEUKOCYTE|MALDI-TOF|Y|Y|1|1|Visit_1|10|1|SCREENING|2020-08-01|10
e|IS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mm|[?]|1|cpm|TRANSUDATE|QUANTITATIVE COMPUTED TOMOGRAPHY|||1|2|Visit_2|25|4|SCREENING|2020-08-16|25
e|IS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|/sec|[?]|1|EVENTS|LUNG SURFACTANT|INDIRECT IMMUNOFLUORESCENCE|||1|3|Visit_3|40|6|TREATMENT|2020-08-31|40
e|IS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/mmol|[?]|1|TRANSDUCING UNIT/mL|PLEURAL FLUID|AUTOMATED COUNT|||1|4|Visit_4|65|7|TREATMENT|2020-09-25|65
e|IS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uIU/L|[?]|1|mEq/uL|PROSTATIC FLUID|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||1|5|Visit_5|90|6|FOLLOW-UP|2020-10-20|90
e|IS|25c6812b-9200-4dc4-a954-6879183a2c54|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|SPRAY|[?]|1|mm/2h|NAIL|CHROMOGENIC ASSAY|Y|Y|1|1|Visit_1|10|3|SCREENING|2020-12-24|10
e|IS|25c6812b-9200-4dc4-a954-6879183a2c54|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|breaths/min|[?]|1|Ci/mL|PERITONEAL FLUID|FARNSWORTH-MUNSELL 100 HUE TEST|||1|2|Visit_2|25|6|SCREENING|2021-01-08|25
e|IS|25c6812b-9200-4dc4-a954-6879183a2c54|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|dpm/0.5 mL|[?]|1|kg|ALVEOLAR AIR|TOTAL BODY IRRADIATION|Y|Y|1|3|Visit_3|40|5|TREATMENT|2021-01-23|40
e|IS|25c6812b-9200-4dc4-a954-6879183a2c54|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|FFU|[?]|1|mEq/g|MONOCYTE|MRS|||1|4|Visit_4|65|3|TREATMENT|2021-02-17|65
e|IS|25c6812b-9200-4dc4-a954-6879183a2c54|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/min|[?]|1|mmol/mol|BONE MARROW MONONUCLEAR CELL|INDIRECT IMMUNOFLUORESCENCE|Y||1|5|Visit_5|90|4|FOLLOW-UP|2021-03-14|90
e|IS|10dca475-f364-42f3-9192-faf762832adf|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mCi|[?]|1|fmol/L/sec|VITREOUS HUMOR|TOTAL BODY IRRADIATION|||1|1|Visit_1|10|3|TREATMENT|2020-09-25|10
e|IS|10dca475-f364-42f3-9192-faf762832adf|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DNA copies/mL|[?]|1|Enzyme U/L|BILE|ELECTROMYOGRAPHY||Y|1|2|Visit_2|25|5|SCREENING|2020-10-10|25
e|IS|10dca475-f364-42f3-9192-faf762832adf|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|BOTTLE|[?]|1|ugEq|TRANSUDATE|OPTICAL COHERENCE TOMOGRAPHY|||1|3|Visit_3|40|5|SCREENING|2020-10-25|40
e|IS|10dca475-f364-42f3-9192-faf762832adf|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/4.0 mL|[?]|1|mEq/day|SPUTUM|MALDI|Y||1|4|Visit_4|65|7|WASHOUT|2020-11-19|65
e|IS|10dca475-f364-42f3-9192-faf762832adf|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Coulomb|[?]|1|Joule|HAIR|THERMAL IONIZATION MASS SPECTROMETRY|Y||1|5|Visit_5|90|7|TREATMENT|2020-12-14|90
e|IS|caf54095-56c3-428f-8342-ce45c6c9a287|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|umol/mol|[?]|1|L/h|SUPERNATANT, SERUM OR PLASMA|ANTIMICROBIAL COMBINATION TESTING|Y||1|1|Visit_1|10|4|SCREENING|2020-12-20|10
e|IS|caf54095-56c3-428f-8342-ce45c6c9a287|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/cm2|[?]|1|mPa|LAVAGE FLUID|ELECTROPHORESIS|||1|2|Visit_2|25|6|SCREENING|2021-01-04|25
e|IS|caf54095-56c3-428f-8342-ce45c6c9a287|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|dB|[?]|1|10^6 DNA copies/mL|PERIPHERAL BLOOD MONONUCLEAR CELL|GIEMSA STAIN|Y||1|3|Visit_3|40|2|FOLLOW-UP|2021-01-19|40
e|IS|caf54095-56c3-428f-8342-ce45c6c9a287|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|BE/mL|[?]|1|U/mmol|TUMOR TISSUE|BRDU CELLULAR PROLIFERATION ASSAY|||1|4|Visit_4|65|6|FOLLOW-UP|2021-02-13|65
e|IS|caf54095-56c3-428f-8342-ce45c6c9a287|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Pa|[?]|1|10^3/hpf|PLASMA ULTRAFILTRATE|PET/MRI SCAN|||1|5|Visit_5|90|6|TREATMENT|2021-03-10|90
e|IS|f833ca56-d426-420b-a6d3-fedeabc02734|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|days/month|[?]|1|10^3 organisms|SKELETAL MUSCLE TISSUE|REFLECTANCE SPECTROSCOPY|||1|1|Visit_1|10|1|TREATMENT|2020-06-20|10
e|IS|f833ca56-d426-420b-a6d3-fedeabc02734|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|PFU/mL|[?]|1|mL/sec/1.73m2|STRIATED MUSCLE TISSUE|MULTI-SLICE SPIRAL CT||Y|1|2|Visit_2|25|6|SCREENING|2020-07-05|25
e|IS|f833ca56-d426-420b-a6d3-fedeabc02734|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PNU/mL|[?]|1|mm2|DERMAL TISSUE|IMMUNE REPERTOIRE DEEP SEQUENCING|||1|3|Visit_3|40|6|SCREENING|2020-07-20|40
e|IS|f833ca56-d426-420b-a6d3-fedeabc02734|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ug/L FEU|[?]|1|kg/L|DIALYSIS FLUID, PERITONEAL|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y|Y|1|4|Visit_4|65|1|WASHOUT|2020-08-14|65
e|IS|f833ca56-d426-420b-a6d3-fedeabc02734|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Ci/g|[?]|1|nmol/mL/min|MIXED VENOUS BLOOD|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|Y|1|5|Visit_5|90|3|TREATMENT|2020-09-08|90
e|IS|03c8e2c7-b70d-4d46-8064-c99370eab232|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ng/dL|[?]|1|gpELISA unit/mL|CAPILLARY PLASMA|SISH|||1|1|Visit_1|10|4|TREATMENT|2020-11-29|10
e|IS|03c8e2c7-b70d-4d46-8064-c99370eab232|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|yd|[?]|1|ug/m2|VENOUS PLASMA|SPIROMETRY|||1|2|Visit_2|25|5|TREATMENT|2020-12-14|25
e|IS|03c8e2c7-b70d-4d46-8064-c99370eab232|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^6 RNA copies/mL|[?]|1|U/m2/day|VENOUS BLOOD|OSCILLOMETRY|||1|3|Visit_3|40|4|FOLLOW-UP|2020-12-29|40
e|IS|03c8e2c7-b70d-4d46-8064-c99370eab232|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Hz|[?]|1|nmol/g|DIALYSIS FLUID|PHASE CONTRAST MICROSCOPY|||1|4|Visit_4|65|5|WASHOUT|2021-01-23|65
e|IS|03c8e2c7-b70d-4d46-8064-c99370eab232|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|IU/g Hb|[?]|1|SUPPOSITORY|MENSTRUAL BLOOD|SPIROMETRY|||1|5|Visit_5|90|7|TREATMENT|2021-02-17|90
e|IS|944617c7-c5e6-4e06-b114-499c3020dbbd|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|g/cm2|[?]|1|U/mL|EPITHELIAL CELL|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y|1|1|Visit_1|10|3|TREATMENT|2020-10-22|10
e|IS|944617c7-c5e6-4e06-b114-499c3020dbbd|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|TRANSDUCING UNIT/mL|[?]|1|Gauss|AMNIOTIC FLUID|MULTIPLEXED BEAD BASED IMMUNOASSAY|||1|2|Visit_2|25|7|FOLLOW-UP|2020-11-06|25
e|IS|944617c7-c5e6-4e06-b114-499c3020dbbd|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|DISK|[?]|1|%(v/v)|SKELETAL MUSCLE TISSUE|IMPEDANCE CONDUCTIVITY|||1|3|Visit_3|40|5|WASHOUT|2020-11-21|40
e|IS|944617c7-c5e6-4e06-b114-499c3020dbbd|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/100 HPFs|[?]|1|mmol/min/kPa|AQUEOUS HUMOR|ANGIOGRAPHY|Y|Y|1|4|Visit_4|65|1|TREATMENT|2020-12-16|65
e|IS|944617c7-c5e6-4e06-b114-499c3020dbbd|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|v/v|[?]|1|ft3|SMEGMA|ANTIBIOTIC AGAR SCREEN|Y||1|5|Visit_5|90|6|FOLLOW-UP|2021-01-10|90
e|IS|e4878c66-1e2b-49bb-838e-85139d160dd4|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|U/g|[?]|1|MBq|INFRANATANT, PLASMA|NON-CONTACT SPECULAR MICROSCOPY|||1|1|Visit_1|10|2|TREATMENT|2020-10-21|10
e|IS|e4878c66-1e2b-49bb-838e-85139d160dd4|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|SYRINGE|[?]|1|mg/kg/day|CERUMEN|TOTAL BODY RADIOGRAPHY|Y||1|2|Visit_2|25|4|TREATMENT|2020-11-05|25
e|IS|e4878c66-1e2b-49bb-838e-85139d160dd4|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|umol/L|[?]|1|10^4/L|CERUMEN|MASS SPECTROMETRY|||1|3|Visit_3|40|5|FOLLOW-UP|2020-11-20|40
e|IS|e4878c66-1e2b-49bb-838e-85139d160dd4|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|keV|[?]|1|min/day|SWABBED MATERIAL|CHROMATOGRAPHY||Y|1|4|Visit_4|65|7|TREATMENT|2020-12-15|65
e|IS|e4878c66-1e2b-49bb-838e-85139d160dd4|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|cGy|[?]|1|uIU/L|BLOOD|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||1|5|Visit_5|90|5|TREATMENT|2021-01-09|90
e|IS|6873e227-baef-4d6e-8600-0bb61d60fe49|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|ag|[?]|1|/500 WBC|WHITE MATTER TISSUE|CELLULOSE TAPE|Y|Y|1|1|Visit_1|10|6|TREATMENT|2020-06-06|10
e|IS|6873e227-baef-4d6e-8600-0bb61d60fe49|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Osm|[?]|1|psec|PLATELET|SCINTIGRAPHY|||1|2|Visit_2|25|6|TREATMENT|2020-06-21|25
e|IS|6873e227-baef-4d6e-8600-0bb61d60fe49|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|BLOCKS|[?]|1|kcal/day|SMEGMA|IN VITRO GENE EXPRESSION ASSAY|||1|3|Visit_3|40|3|WASHOUT|2020-07-06|40
e|IS|6873e227-baef-4d6e-8600-0bb61d60fe49|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|%/s|[?]|1|PLUG|EXPIRED AIR|RAJI CELL EIA|||1|4|Visit_4|65|6|TREATMENT|2020-07-31|65
e|IS|6873e227-baef-4d6e-8600-0bb61d60fe49|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|uL|[?]|1|copies/uL|CEREBROSPINAL FLUID|DUKE INCISION METHOD|||1|5|Visit_5|90|4|TREATMENT|2020-08-25|90
e|IS|bad01879-9b97-4d9c-9eec-58871168bd57|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|GBq/ug|[?]|1|K|BONE MARROW|THICK SMEAR|||1|1|Visit_1|10|6|TREATMENT|2020-10-15|10
e|IS|bad01879-9b97-4d9c-9eec-58871168bd57|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|Hz|[?]|1|10^6 CFU/mL|ENDOMETRIAL TISSUE|WRIGHT-GIEMSA STAIN||Y|1|2|Visit_2|25|1|TREATMENT|2020-10-30|25
e|IS|bad01879-9b97-4d9c-9eec-58871168bd57|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/mol|[?]|1|uCi/L|LUNG SURFACTANT|BIOPSY|||1|3|Visit_3|40|7|TREATMENT|2020-11-14|40
e|IS|bad01879-9b97-4d9c-9eec-58871168bd57|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|WEEKS|SUPERNATANT, SERUM|LIQUID SCINTILLATION COUNTING|Y||1|4|Visit_4|65|7|TREATMENT|2020-12-09|65
e|IS|bad01879-9b97-4d9c-9eec-58871168bd57|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mL/animal/day|[?]|1|m|VENOUS PLASMA|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||1|5|Visit_5|90|7|FOLLOW-UP|2021-01-03|90
e|IS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|L/L|[?]|1|PELLET|ISOLATE|CINEANGIOGRAPHY|Y|Y|1|1|Visit_1|10|6|WASHOUT|2020-11-05|10
e|IS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|damol/L|[?]|1|amol|SOFT TISSUE|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|2|Visit_2|25|4|TREATMENT|2020-11-20|25
e|IS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|IU/L|[?]|1|nmol/day|MENSTRUAL BLOOD|ANALYTICAL ULTRACENTRIFUGATION|||1|3|Visit_3|40|7|TREATMENT|2020-12-05|40
e|IS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Pack Year|[?]|1|mL/cm H2O|ISOLATE|CENTRIFUGATION|Y||1|4|Visit_4|65|1|WASHOUT|2020-12-30|65
e|IS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|L/s/kPa|[?]|1|pg/cell|INFRANATANT, PLEURAL FLUID|ACCELERATOR MASS SPECTROMETRY|||1|5|Visit_5|90|6|SCREENING|2021-01-24|90
e|IS|0df77775-6e65-4f77-9f8f-7faaa1471141|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|days/wk|[?]|1|mL|ADIPOSE TISSUE|TWO-COLOR MICROARRAY|Y||1|1|Visit_1|10|4|TREATMENT|2020-08-24|10
e|IS|0df77775-6e65-4f77-9f8f-7faaa1471141|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|JDF Unit|[?]|1|foz_br|EMESIS|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|2|Visit_2|25|7|TREATMENT|2020-09-08|25
e|IS|0df77775-6e65-4f77-9f8f-7faaa1471141|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/wk|[?]|1|mEq/g|TUMOR TISSUE|SLOAN LETTER EYE CHART 100%|||1|3|Visit_3|40|3|WASHOUT|2020-09-23|40
e|IS|0df77775-6e65-4f77-9f8f-7faaa1471141|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol/L/min|[?]|1|gtt|SEBUM|HIGH RESOLUTION MELT ANALYSIS|||1|4|Visit_4|65|7|TREATMENT|2020-10-18|65
e|IS|0df77775-6e65-4f77-9f8f-7faaa1471141|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/s/m2|[?]|1|10^6 RNA copies/mL|COLOSTRUM|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||1|5|Visit_5|90|6|TREATMENT|2020-11-12|90
e|IS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/cm3/min|[?]|1|copies/mL|ARTERIAL CORD BLOOD|CONTRAST ENHANCED CT SCAN|||1|1|Visit_1|10|3|TREATMENT|2020-08-22|10
e|IS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^5/hpf|[?]|1|POINT|ARTERIALIZED CAPILLARY BLOOD|SPIRAL CT SCAN WITHOUT CONTRAST|Y||1|2|Visit_2|25|7|TREATMENT|2020-09-06|25
e|IS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|10^6/L|INFRANATANT, SERUM|IMMUNO-PET SCAN|||1|3|Visit_3|40|7|WASHOUT|2020-09-21|40
e|IS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq/g|[?]|1|mL*cmH2O|DIALYSIS FLUID, PERITONEAL|HEMAGGLUTINATION INHIBITION ASSAY|||1|4|Visit_4|65|1|WASHOUT|2020-10-16|65
e|IS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|m2|[?]|1|MASK|CAPILLARY BLOOD|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||1|5|Visit_5|90|1|FOLLOW-UP|2020-11-10|90
e|IS|cd68296c-95d4-489e-8b64-b2404f16316c|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|log EID 50/dose|[?]|1|Mile|INFRANATANT, SERUM|TRANSTHORACIC ECHOCARDIOGRAPHY|Y|Y|1|1|Visit_1|10|6|WASHOUT|2020-12-20|10
e|IS|cd68296c-95d4-489e-8b64-b2404f16316c|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|ELISA unit/dose|[?]|1|Coulomb|PLATELET POOR PLASMA|AUTOMATED COUNT|||1|2|Visit_2|25|2|TREATMENT|2021-01-04|25
e|IS|cd68296c-95d4-489e-8b64-b2404f16316c|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|MHz|[?]|1|ug/dL|CAPILLARY BLOOD|MAMMOGRAPHY|||1|3|Visit_3|40|6|SCREENING|2021-01-19|40
e|IS|cd68296c-95d4-489e-8b64-b2404f16316c|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|TAMPON|[?]|1|uL|EMOTIONAL TEAR|MICROBIAL CULTURE, LIQUID|Y||1|4|Visit_4|65|3|WASHOUT|2021-02-13|65
e|IS|cd68296c-95d4-489e-8b64-b2404f16316c|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|uOsm|[?]|1|pg/cell|MIXED VENOUS BLOOD|CLAUSS METHOD|||1|5|Visit_5|90|1|TREATMENT|2021-03-10|90
e|IS|fe137506-d1ce-4b08-a043-9366d86c421e|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/40 HPFs|[?]|1|cP|FLUID|WRIGHT-GIEMSA STAIN|||1|1|Visit_1|10|7|SCREENING|2020-07-03|10
e|IS|fe137506-d1ce-4b08-a043-9366d86c421e|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/mL|[?]|1|U/mg|SKELETAL MUSCLE TISSUE|PET/CT SCAN|||1|2|Visit_2|25|3|SCREENING|2020-07-18|25
e|IS|fe137506-d1ce-4b08-a043-9366d86c421e|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ngEq/L|[?]|1|mg/kg|ALVEOLAR AIR|SNP ARRAY|Y|Y|1|3|Visit_3|40|7|SCREENING|2020-08-02|40
e|IS|fe137506-d1ce-4b08-a043-9366d86c421e|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ug/day|[?]|1|g/g/day|SUPERNATANT, PLASMA|CYSTOMETRY|||1|4|Visit_4|65|2|FOLLOW-UP|2020-08-27|65
e|IS|fe137506-d1ce-4b08-a043-9366d86c421e|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|deg/s|[?]|1|LENS|BONE MARROW|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||Y|1|5|Visit_5|90|5|SCREENING|2020-09-21|90
e|IS|b112c524-42c8-4e9e-8699-209e739972a7|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|TRANSDUCING UNIT|[?]|1|10^3 CFU/g|GASTRIC CONTENTS|ALCIAN BLUE STAIN|||1|1|Visit_1|10|6|TREATMENT|2021-01-03|10
e|IS|b112c524-42c8-4e9e-8699-209e739972a7|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|%/min|[?]|1|kIU|SERUM OR PLASMA OR BLOOD|MAGNETIC RESONANCE ANGIOGRAPHY|||1|2|Visit_2|25|1|WASHOUT|2021-01-18|25
e|IS|b112c524-42c8-4e9e-8699-209e739972a7|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|g/cage/day|[?]|1|psec|HAIR FOLLICLE|REFRACTOMETRY|Y||1|3|Visit_3|40|4|FOLLOW-UP|2021-02-02|40
e|IS|b112c524-42c8-4e9e-8699-209e739972a7|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|SQU/mL|[?]|1|pmol|URINE|NUCLEIC ACID BASED METHOD|||1|4|Visit_4|65|6|WASHOUT|2021-02-27|65
e|IS|b112c524-42c8-4e9e-8699-209e739972a7|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6/g|[?]|1|TUBE|TUMOR TISSUE|EIA|||1|5|Visit_5|90|6|FOLLOW-UP|2021-03-24|90
e|IS|e6e32df8-8b66-49a5-a626-fd385297dd6f|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mL/m2/day|[?]|1|aMFI|VITREOUS HUMOR|FLUORIMETRY|||1|1|Visit_1|10|3|TREATMENT|2020-09-02|10
e|IS|e6e32df8-8b66-49a5-a626-fd385297dd6f|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|U/g Hb|[?]|1|log10 TCID 50/uL|ISOLATE|KARYOTYPING|Y|Y|1|2|Visit_2|25|5|SCREENING|2020-09-17|25
e|IS|e6e32df8-8b66-49a5-a626-fd385297dd6f|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|10^6 CFU/mL|[?]|1|L/min|ABSCESS FLUID|EEG||Y|1|3|Visit_3|40|7|TREATMENT|2020-10-02|40
e|IS|e6e32df8-8b66-49a5-a626-fd385297dd6f|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/7.5 mL|[?]|1|IU/mL|GASTRIC CONTENTS|INTRAVASCULAR ULTRASOUND|Y||1|4|Visit_4|65|3|TREATMENT|2020-10-27|65
e|IS|e6e32df8-8b66-49a5-a626-fd385297dd6f|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ms/mmHg|[?]|1|CONTAINER|INFRANATANT, PLASMA|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||1|5|Visit_5|90|3|TREATMENT|2020-11-21|90
e|IS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^3 copies/mL|[?]|1|min/day|SEBUM|HPLC|Y|Y|1|1|Visit_1|10|2|WASHOUT|2020-09-18|10
e|IS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|10^9 organisms/g|MUSCLE TISSUE|FARNSWORTH-MUNSELL 100 HUE TEST||Y|1|2|Visit_2|25|7|TREATMENT|2020-10-03|25
e|IS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^3 CFU/g|[?]|1|PFU/animal|PROSTATIC FLUID|CAPILLARY ELECTROPHORESIS|||1|3|Visit_3|40|2|SCREENING|2020-10-18|40
e|IS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/kg/day|[?]|1|ukat/10^12 RBC|EMESIS|CONTRAST ENHANCED PET/CT SCAN|Y|Y|1|4|Visit_4|65|5|TREATMENT|2020-11-12|65
e|IS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|IU/mL|[?]|1|g/m2|CEREBROSPINAL FLUID|SCANNING ELECTRON MICROSCOPY|||1|5|Visit_5|90|2|FOLLOW-UP|2020-12-07|90
e|IS|5002de57-45df-4525-a6b7-b6cc33c22229|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|vp/mL|[?]|1|ms2|TISSUE|ENZYMATIC COLORIMETRY||Y|1|1|Visit_1|10|1|TREATMENT|2021-01-12|10
e|IS|5002de57-45df-4525-a6b7-b6cc33c22229|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|uCi|[?]|1|mL/g/day|FLUID|ECHOCARDIOGRAPHY|||1|2|Visit_2|25|4|WASHOUT|2021-01-27|25
e|IS|5002de57-45df-4525-a6b7-b6cc33c22229|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/mmHg/min/L|[?]|1|log10 TCID 50/mL|PLATELET RICH PLASMA|CONTACT SPECULAR MICROSCOPY|Y|Y|1|3|Visit_3|40|3|SCREENING|2021-02-11|40
e|IS|5002de57-45df-4525-a6b7-b6cc33c22229|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|K|[?]|1|kat|BONE|RAJI CELL EIA|Y||1|4|Visit_4|65|7|TREATMENT|2021-03-08|65
e|IS|5002de57-45df-4525-a6b7-b6cc33c22229|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|copies/mL|[?]|1|g/L|SKELETAL MUSCLE TISSUE|TURBIDIMETRY||Y|1|5|Visit_5|90|1|TREATMENT|2021-04-02|90
e|IS|298f2081-bb11-4856-9e88-4be3b9b2250d|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|pkat/L|[?]|1|g|PLEURAL TISSUE|PELLI-ROBSON EYE CHART|||1|1|Visit_1|10|5|SCREENING|2020-10-05|10
e|IS|298f2081-bb11-4856-9e88-4be3b9b2250d|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|MAC50|[?]|1|10^11/L|EMESIS|TRYPAN BLUE STAIN||Y|1|2|Visit_2|25|3|TREATMENT|2020-10-20|25
e|IS|298f2081-bb11-4856-9e88-4be3b9b2250d|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|uV|[?]|1|Bq/mL|ADIPOSE TISSUE|PHOTOMETRIC CLOT DETECTION|Y||1|3|Visit_3|40|6|TREATMENT|2020-11-04|40
e|IS|298f2081-bb11-4856-9e88-4be3b9b2250d|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|AU/mL|[?]|1|km/h|AQUEOUS HUMOR|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y|1|4|Visit_4|65|3|WASHOUT|2020-11-29|65
e|IS|298f2081-bb11-4856-9e88-4be3b9b2250d|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mAnson U/mL|[?]|1|U/cL|LUNG SURFACTANT|PHOTOMETRIC CLOT DETECTION|Y||1|5|Visit_5|90|1|TREATMENT|2020-12-24|90
e|IS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|TROCHE|[?]|1|USP U|SMEGMA|AGAR PROPORTION|||1|1|Visit_1|10|5|SCREENING|2020-12-29|10
e|IS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|EU|[?]|1|10^10/L|NAIL|GC/FID||Y|1|2|Visit_2|25|3|WASHOUT|2021-01-13|25
e|IS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|fraction of 1|[?]|1|mmol2/L2|PERITONEAL FLUID|CAPILLARY ELECTROPHORESIS|||1|3|Visit_3|40|1|TREATMENT|2021-01-28|40
e|IS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|VIAL|[?]|1|m|STOOL|SPIRAL CT SCAN WITHOUT CONTRAST|||1|4|Visit_4|65|6|WASHOUT|2021-02-22|65
e|IS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/m2/min|[?]|1|mN|ABSCESS FLUID|MUGA|||1|5|Visit_5|90|3|TREATMENT|2021-03-19|90
e|IS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|FEU|[?]|1|10^6 organisms/mg|PERSPIRATION|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||1|1|Visit_1|10|1|WASHOUT|2020-05-12|10
e|IS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Enzyme U/m2|[?]|1|10^6 RNA copies/mL|STOOL|KINETIC MICROPARTICLE IMMUNOASSAY|||1|2|Visit_2|25|7|FOLLOW-UP|2020-05-27|25
e|IS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|foz_br|[?]|1|BE/mL|PLATELET RICH PLASMA|SINGLE-SLICE SPIRAL CT||Y|1|3|Visit_3|40|2|TREATMENT|2020-06-11|40
e|IS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/10^4|[?]|1|mL/(min*100mL)|MUSCLE TISSUE|IMMUNOCHROMATOGRAPHY||Y|1|4|Visit_4|65|4|TREATMENT|2020-07-06|65
e|IS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/h/mmol|[?]|1|pmol/10^10 cells|PLASMA ULTRAFILTRATE|AGAR DILUTION|||1|5|Visit_5|90|2|WASHOUT|2020-07-31|90
e|IS|18c21176-db5e-4650-a1af-beb2042c31d8|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|PRESSOR UNITS|[?]|1|U/10^12 RBC|CARDIAC MUSCLE TISSUE|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y||1|1|Visit_1|10|3|TREATMENT|2020-08-30|10
e|IS|18c21176-db5e-4650-a1af-beb2042c31d8|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|Bq/mL|[?]|1|tsp|PLATELET POOR PLASMA|ACID FAST STAIN||Y|1|2|Visit_2|25|4|FOLLOW-UP|2020-09-14|25
e|IS|18c21176-db5e-4650-a1af-beb2042c31d8|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pptr|[?]|1|GPL U|BILE|PANENDOSCOPY|||1|3|Visit_3|40|5|TREATMENT|2020-09-29|40
e|IS|18c21176-db5e-4650-a1af-beb2042c31d8|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|ka_u/dL|[?]|1|IU|PLASMA ULTRAFILTRATE|MYELOPEROXIDASE STAIN|||1|4|Visit_4|65|4|WASHOUT|2020-10-24|65
e|IS|18c21176-db5e-4650-a1af-beb2042c31d8|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|umol/L|[?]|1|log10 IU/mL|SERUM OR PLASMA OR BLOOD|AGAR PROPORTION|||1|5|Visit_5|90|4|TREATMENT|2020-11-18|90
e|IS|7808abd1-7d6f-4090-aa08-916a804c95f5|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|FFU|[?]|1|L/min/m2|PLASMA ULTRAFILTRATE|PULMONARY ANGIOGRAPHY|||1|1|Visit_1|10|4|TREATMENT|2020-06-20|10
e|IS|7808abd1-7d6f-4090-aa08-916a804c95f5|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|GPL U/mL|[?]|1|pmol/L|MUSCLE TISSUE|SEQUENCING||Y|1|2|Visit_2|25|6|WASHOUT|2020-07-05|25
e|IS|7808abd1-7d6f-4090-aa08-916a804c95f5|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|Newton|[?]|1|s^-1(%O2)^-1|MUSCLE TISSUE|BIOPSY|||1|3|Visit_3|40|2|TREATMENT|2020-07-20|40
e|IS|7808abd1-7d6f-4090-aa08-916a804c95f5|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|atm|[?]|1|10^10/L|LEUKOCYTE|PERFUSION MRI|Y|Y|1|4|Visit_4|65|5|TREATMENT|2020-08-14|65
e|IS|7808abd1-7d6f-4090-aa08-916a804c95f5|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|in2|[?]|1|kN/cm2|ARTERIAL CORD BLOOD|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y|1|5|Visit_5|90|5|FOLLOW-UP|2020-09-08|90
e|IS|57553b78-e761-4577-aae2-5c693a2dc303|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|umol/mg/min|[?]|1|ug/kg/min|SKELETAL MUSCLE TISSUE|MANUAL CLOT DETECTION|Y||1|1|Visit_1|10|2|SCREENING|2021-01-01|10
e|IS|57553b78-e761-4577-aae2-5c693a2dc303|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^12/L|[?]|1|CFU/g|PLASMA|TWO-COLOR MICROARRAY||Y|1|2|Visit_2|25|4|TREATMENT|2021-01-16|25
e|IS|57553b78-e761-4577-aae2-5c693a2dc303|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|yd|[?]|1|nm|SYNOVIAL FLUID|IRON HEMATOXYLIN STAIN|Y|Y|1|3|Visit_3|40|7|TREATMENT|2021-01-31|40
e|IS|57553b78-e761-4577-aae2-5c693a2dc303|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|pmol/L/h|[?]|1|%|ARTERIAL BLOOD|ICC|||1|4|Visit_4|65|2|SCREENING|2021-02-25|65
e|IS|57553b78-e761-4577-aae2-5c693a2dc303|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ng/mol|[?]|1|TRANSDUCING UNIT|KERATINOCYTE|VENTILATION PERFUSION LUNG SCAN||Y|1|5|Visit_5|90|6|TREATMENT|2021-03-22|90
e|IS|40883550-4627-4f92-974a-7eeb5bde74c5|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|km|[?]|1|mL/m2|TRANSUDATE|AUDIOMETRY|||1|1|Visit_1|10|5|WASHOUT|2020-10-13|10
e|IS|40883550-4627-4f92-974a-7eeb5bde74c5|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|GBq|[?]|1|L/min/m2|VITREOUS HUMOR|THERMAL IONIZATION MASS SPECTROMETRY|||1|2|Visit_2|25|3|FOLLOW-UP|2020-10-28|25
e|IS|40883550-4627-4f92-974a-7eeb5bde74c5|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mL/kg/min|[?]|1|L/kg|INFRANATANT, PLASMA|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||1|3|Visit_3|40|7|TREATMENT|2020-11-12|40
e|IS|40883550-4627-4f92-974a-7eeb5bde74c5|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SCOOPFUL|[?]|1|lx|BILE|HEMAGGLUTINATION INHIBITION ASSAY|||1|4|Visit_4|65|2|TREATMENT|2020-12-07|65
e|IS|40883550-4627-4f92-974a-7eeb5bde74c5|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|mm2|[?]|1|pL|PLATELET|CELLULOSE TAPE||Y|1|5|Visit_5|90|5|TREATMENT|2021-01-01|90
e|IS|4199b549-d021-4bfd-97e6-95630d407183|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|min/day|[?]|1|L/kg|BUFFY COAT|TRANSCRIPTION-MEDIATED AMPLIFICATION|||1|1|Visit_1|10|7|FOLLOW-UP|2020-12-02|10
e|IS|4199b549-d021-4bfd-97e6-95630d407183|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|WAFER|[?]|1|L/s|CAPILLARY BLOOD|SCINTIGRAPHY|||1|2|Visit_2|25|3|FOLLOW-UP|2020-12-17|25
e|IS|4199b549-d021-4bfd-97e6-95630d407183|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|ug/L|[?]|1|uL/dose|INFRANATANT, PLEURAL FLUID|NEPHELOMETRY||Y|1|3|Visit_3|40|2|TREATMENT|2021-01-01|40
e|IS|4199b549-d021-4bfd-97e6-95630d407183|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|mg/L FEU|[?]|1|Tesla|SUPERNATANT, SERUM OR PLASMA|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|1|4|Visit_4|65|6|WASHOUT|2021-01-26|65
e|IS|4199b549-d021-4bfd-97e6-95630d407183|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ng/L|[?]|1|Henry|KERATINOCYTE|POLYGRAPHY|||1|5|Visit_5|90|2|TREATMENT|2021-02-20|90
e|IS|6366647f-62fa-48dc-9d77-1677fce62fc7|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|amol|[?]|1|U/g|PLEURAL FLUID|SCANNING ELECTRON MICROSCOPY|Y|Y|1|1|Visit_1|10|4|TREATMENT|2020-07-14|10
e|IS|6366647f-62fa-48dc-9d77-1677fce62fc7|2|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|10^6 organisms/mL|[?]|1|10^6 CFU/mL|LAVAGE FLUID|RIA||Y|1|2|Visit_2|25|2|TREATMENT|2020-07-29|25
e|IS|6366647f-62fa-48dc-9d77-1677fce62fc7|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Tbsp|[?]|1|uL/kg/day|EMESIS|LC/MS|||1|3|Visit_3|40|1|FOLLOW-UP|2020-08-13|40
e|IS|6366647f-62fa-48dc-9d77-1677fce62fc7|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|um/s|[?]|1|nkat/L|SYNOVIAL FLUID|FARNSWORTH-MUNSELL 100 HUE TEST|Y||1|4|Visit_4|65|2|WASHOUT|2020-09-07|65
e|IS|6366647f-62fa-48dc-9d77-1677fce62fc7|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|LB|[?]|1|mN|LAVAGE FLUID|DIRECT SEQUENCING||Y|1|5|Visit_5|90|1|TREATMENT|2020-10-02|90
e|IS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|vg/mL|[?]|1|mL/day|SEBUM|NON-CONTACT SPECULAR MICROSCOPY||Y|1|1|Visit_1|10|5|WASHOUT|2020-05-13|10
e|IS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|ft3|[?]|1|lx|LOCHIA|IN VITRO GENE EXPRESSION ASSAY|||1|2|Visit_2|25|4|TREATMENT|2020-05-28|25
e|IS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Mile|[?]|1|Gravitational Unit|CERUMEN|FREEZING POINT DEPRESSION||Y|1|3|Visit_3|40|5|TREATMENT|2020-06-12|40
e|IS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|CFU/g|[?]|1|Farad|SMEGMA|MANUAL CLOT DETECTION|Y||1|4|Visit_4|65|1|FOLLOW-UP|2020-07-07|65
e|IS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|damol/L|[?]|1|log10 TCID 50/mL|TISSUE|HPLC-FL|||1|5|Visit_5|90|3|WASHOUT|2020-08-01|90
e|IS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Mile|[?]|1|mEq/mL|MUCUS|APPLANATION TONOMETRY|||1|1|Visit_1|10|1|TREATMENT|2020-06-03|10
e|IS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/dose|[?]|1|mL/sec/1.73m2|PLEURAL FLUID|SPIRAL CT|Y||1|2|Visit_2|25|4|WASHOUT|2020-06-18|25
e|IS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|U/cL|[?]|1|Joule|BONE MARROW|ICP-MS|Y||1|3|Visit_3|40|1|FOLLOW-UP|2020-07-03|40
e|IS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|cmH2O*s/mL|[?]|1|10^6 DNA copies/mL|AQUEOUS HUMOR|SNP ARRAY||Y|1|4|Visit_4|65|4|TREATMENT|2020-07-28|65
e|IS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/animal/wk|[?]|1|U/g/h|AQUEOUS HUMOR|NUCLEIC ACID HYBRIDIZATION|||1|5|Visit_5|90|5|FOLLOW-UP|2020-08-22|90
e|IS|696cd04a-cde7-4481-b5e2-fad1877ec284|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Enzyme U/L|[?]|1|10^6 organisms|ENDOMETRIAL TISSUE|FARR ASSAY|||1|1|Visit_1|10|5|TREATMENT|2020-08-31|10
e|IS|696cd04a-cde7-4481-b5e2-fad1877ec284|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|pkat/L|[?]|1|log10 copies/mL|PLATELET POOR PLASMA|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||1|2|Visit_2|25|3|WASHOUT|2020-09-15|25
e|IS|696cd04a-cde7-4481-b5e2-fad1877ec284|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|F|[?]|1|Enzyme U/m2|GASTRIC CONTENTS|SLOAN LETTER EYE CHART 1.25%|Y|Y|1|3|Visit_3|40|5|FOLLOW-UP|2020-09-30|40
e|IS|696cd04a-cde7-4481-b5e2-fad1877ec284|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL*cmH2O|[?]|1|F|LUNG SURFACTANT|AGAR PROPORTION|||1|4|Visit_4|65|7|TREATMENT|2020-10-25|65
e|IS|696cd04a-cde7-4481-b5e2-fad1877ec284|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|DRUM|[?]|1|kg/cm|FLUID|ENZYMATIC ULTRACENTRIFUGATION|||1|5|Visit_5|90|5|TREATMENT|2020-11-19|90
e|IS|ce4699cb-66f1-4c13-8428-84064255b765|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mg2/dL2|[?]|1|ug/g/h|SPUTUM|GC/FID||Y|1|1|Visit_1|10|3|FOLLOW-UP|2020-12-02|10
e|IS|ce4699cb-66f1-4c13-8428-84064255b765|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|DNA copies/mL|[?]|1|ug/kg/day|STRIATED MUSCLE TISSUE|SPECTROPHOTOMETRY|||1|2|Visit_2|25|3|FOLLOW-UP|2020-12-17|25
e|IS|ce4699cb-66f1-4c13-8428-84064255b765|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mV/sec|[?]|1|mEq/mmol|MONOCYTE|CALIPER MEASUREMENT METHOD||Y|1|3|Visit_3|40|7|WASHOUT|2021-01-01|40
e|IS|ce4699cb-66f1-4c13-8428-84064255b765|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/animal|[?]|1|POUCH|CAPILLARY BLOOD|PATHOLOGICAL EVALUATION|||1|4|Visit_4|65|2|TREATMENT|2021-01-26|65
e|IS|ce4699cb-66f1-4c13-8428-84064255b765|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|umol/L/sec|[?]|1|mmol/g|INFRANATANT, SERUM|RAJI CELL EIA|||1|5|Visit_5|90|1|SCREENING|2021-02-20|90
e|IS|015b391b-23c7-478d-b9d1-226d3cb9edcf|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/7.5 mL|[?]|1|ka_u/dL|ABSCESS FLUID|SLIT LAMP|||1|1|Visit_1|10|5|TREATMENT|2020-11-29|10
e|IS|015b391b-23c7-478d-b9d1-226d3cb9edcf|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|vp/mL|[?]|1|breaths/min|SERUM|MICRODENSITOMETRY|||1|2|Visit_2|25|1|TREATMENT|2020-12-14|25
e|IS|015b391b-23c7-478d-b9d1-226d3cb9edcf|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mmAL|[?]|1|g/g|ENDOMETRIAL TISSUE|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||1|3|Visit_3|40|4|WASHOUT|2020-12-29|40
e|IS|015b391b-23c7-478d-b9d1-226d3cb9edcf|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|10^7 CFU/mL|[?]|1|genEq|SEMEN|SEQUENCING|Y||1|4|Visit_4|65|5|FOLLOW-UP|2021-01-23|65
e|IS|015b391b-23c7-478d-b9d1-226d3cb9edcf|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|/ms|[?]|1|Bq|URINE|IMMUNOFLUORESCENT STAIN|||1|5|Visit_5|90|7|SCREENING|2021-02-17|90
e|IS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|PHERESIS UNIT|[?]|1|eq|EXUDATE|IHC|Y|Y|1|1|Visit_1|10|7|SCREENING|2020-06-07|10
e|IS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|%|[?]|1|HOURS|DERMAL TISSUE|TOTAL BODY RADIOGRAPHY|Y||1|2|Visit_2|25|5|SCREENING|2020-06-22|25
e|IS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9 CFU/mL|[?]|1|U/mg|BREAST MILK|ANTIMICROBIAL COMBINATION TESTING|Y|Y|1|3|Visit_3|40|5|FOLLOW-UP|2020-07-07|40
e|IS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|mEq/mmol|[?]|1|psi|CAPILLARY BLOOD|MIGET||Y|1|4|Visit_4|65|4|SCREENING|2020-08-01|65
e|IS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|ng/day|[?]|1|SACHET|ATHEROSCLEROTIC PLAQUE|GEL ELECTROPHORESIS|Y|Y|1|5|Visit_5|90|6|SCREENING|2020-08-26|90
e|IS|9e9acf6b-d29a-4c11-96d6-b580c721f462|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Mile|[?]|1|/10^4|CALCULUS|PUPILLOMETRY|||1|1|Visit_1|10|6|TREATMENT|2020-08-20|10
e|IS|9e9acf6b-d29a-4c11-96d6-b580c721f462|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|PLUG|[?]|1|ug/mL/h|PLASMA|EPSILOMETER||Y|1|2|Visit_2|25|2|FOLLOW-UP|2020-09-04|25
e|IS|9e9acf6b-d29a-4c11-96d6-b580c721f462|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|Gravitational Unit|[?]|1|Coulomb|EPITHELIAL CELL|DUCTOGRAPHY|||1|3|Visit_3|40|4|SCREENING|2020-09-19|40
e|IS|9e9acf6b-d29a-4c11-96d6-b580c721f462|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|Ci/uL|[?]|1|mmHg|INFRANATANT, PLEURAL FLUID|NEXT GENERATION TARGETED SEQUENCING||Y|1|4|Visit_4|65|5|WASHOUT|2020-10-14|65
e|IS|9e9acf6b-d29a-4c11-96d6-b580c721f462|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|AMPULE|[?]|1|Enzyme U/L|PLEURAL TISSUE|TEST STRIP|||1|5|Visit_5|90|5|FOLLOW-UP|2020-11-08|90
e|IS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|uCi/L|[?]|1|OD Unit|AMNIOTIC FLUID|SPECT/CT SCAN|Y||1|1|Visit_1|10|5|FOLLOW-UP|2020-07-18|10
e|IS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mm|[?]|1|ug/kg/h|CALCULUS|INTRAVASCULAR ULTRASOUND|||1|2|Visit_2|25|6|WASHOUT|2020-08-02|25
e|IS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|/cmH2O|[?]|1|cy/cm|INTERSTITIAL FLUID|HPLC-UV|||1|3|Visit_3|40|1|FOLLOW-UP|2020-08-17|40
e|IS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|deg/s|[?]|1|BAU|EXHALED BREATH CONDENSATE|TEMPLATE INCISION METHOD|Y||1|4|Visit_4|65|1|TREATMENT|2020-09-11|65
e|IS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|5|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|s*kPa|[?]|1|/40 HPFs|CARDIAC MUSCLE TISSUE|TRIPLE-PHASE SPIRAL CT SCAN||Y|1|5|Visit_5|90|7|SCREENING|2020-10-06|90
e|IS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|aMFI|[?]|1|mL/kg/min|BUFFY COAT|PEAK FLOWMETRY|||1|1|Visit_1|10|2|WASHOUT|2020-05-29|10
e|IS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cy/cm|[?]|1|GPL U|PLEURAL FLUID|GRADIENT DIFFUSION|||1|2|Visit_2|25|4|FOLLOW-UP|2020-06-13|25
e|IS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|VIAL|[?]|1|nsec|CORD SERUM|CYSTOMETRY|Y||1|3|Visit_3|40|3|TREATMENT|2020-06-28|40
e|IS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|fg|[?]|1|/200 HPFs|TUMOR TISSUE|CARDIAC THERMODILUTION|||1|4|Visit_4|65|6|SCREENING|2020-07-23|65
e|IS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmHg|[?]|1|deg/mm|RETICULOCYTES|ELECTROMYOGRAPHY|||1|5|Visit_5|90|5|SCREENING|2020-08-17|90
e|IS|77c97d1e-e223-4485-b2de-59daa4e5b01f|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|tsp|FLUID|SURFACE PLASMON RESONANCE|Y|Y|1|1|Visit_1|10|4|TREATMENT|2020-06-19|10
e|IS|77c97d1e-e223-4485-b2de-59daa4e5b01f|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mg/L FEU|[?]|1|kV|BONE|PALM METHOD|||1|2|Visit_2|25|1|TREATMENT|2020-07-04|25
e|IS|77c97d1e-e223-4485-b2de-59daa4e5b01f|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|U/L|[?]|1|mmol/g|PERIPHERAL BLOOD MONONUCLEAR CELL|CELLULAR PROLIFERATION ASSAY|||1|3|Visit_3|40|1|TREATMENT|2020-07-19|40
e|IS|77c97d1e-e223-4485-b2de-59daa4e5b01f|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ELISA unit/dose|[?]|1|log10 TCID 50/uL|CEREBROSPINAL FLUID|LAPAROSCOPY||Y|1|4|Visit_4|65|2|TREATMENT|2020-08-13|65
e|IS|77c97d1e-e223-4485-b2de-59daa4e5b01f|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|vp/mL|[?]|1|g/dL|SALIVA|INTRAVASCULAR ULTRASOUND|Y||1|5|Visit_5|90|2|TREATMENT|2020-09-07|90
e|IS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ngEq/L|[?]|1|10^7 CFU|PLEURAL TISSUE|CELLULOSE TAPE|Y||1|1|Visit_1|10|1|TREATMENT|2020-10-14|10
e|IS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|pm|[?]|1|Enzyme U/L|SUPERNATANT, PLASMA|TOLUIDINE BLUE STAIN||Y|1|2|Visit_2|25|3|SCREENING|2020-10-29|25
e|IS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|m/sec2|[?]|1|U/kg|URINE SEDIMENT|VIRUS PLAQUE ASSAY|||1|3|Visit_3|40|3|TREATMENT|2020-11-13|40
e|IS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|RFU|[?]|1|km/h|URINE SEDIMENT|ERGOSPIROMETRY|||1|4|Visit_4|65|4|TREATMENT|2020-12-08|65
e|IS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^9/dose|[?]|1|ks|LEUKOCYTE|MICROBIAL CULTURE, SOLID|||1|5|Visit_5|90|7|TREATMENT|2021-01-02|90
e|IS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|kBq/uL|[?]|1|DAgU|BONE|CONTACT SPECULAR MICROSCOPY|||1|1|Visit_1|10|2|TREATMENT|2020-11-01|10
e|IS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|U/cL|[?]|1|Gy/min|PERITONEAL FLUID|IMMUNOFLUORESCENT STAIN||Y|1|2|Visit_2|25|7|SCREENING|2020-11-16|25
e|IS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|um2|[?]|1|MBq/uL|ENDOTRACHEAL FLUID|NEURAMINIDASE INHIBITION ASSAY|||1|3|Visit_3|40|1|TREATMENT|2020-12-01|40
e|IS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|U/m2/h|[?]|1|mV/sec|EPIDERMAL TISSUE|BETA LACTAMASE|Y||1|4|Visit_4|65|4|TREATMENT|2020-12-26|65
e|IS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^6 organisms/mL|[?]|1|mg2/dL2|ATHEROSCLEROTIC PLAQUE|IMMUNOBLOT|||1|5|Visit_5|90|4|SCREENING|2021-01-20|90
e|IS|9eb6e591-d266-4e05-85b6-230e8a02d494|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mg/kg/min|[?]|1|mEq/kg|BASAL TEAR|FREEZING POINT DEPRESSION|||1|1|Visit_1|10|6|SCREENING|2020-06-28|10
e|IS|9eb6e591-d266-4e05-85b6-230e8a02d494|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/day|[?]|1|BP|PLASMA ULTRAFILTRATE|HANSEL STAIN|||1|2|Visit_2|25|2|FOLLOW-UP|2020-07-13|25
e|IS|9eb6e591-d266-4e05-85b6-230e8a02d494|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|uU/L|[?]|1|mL/sec/1.73m2|ARTERIAL BLOOD|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||1|3|Visit_3|40|4|SCREENING|2020-07-28|40
e|IS|9eb6e591-d266-4e05-85b6-230e8a02d494|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|%/min|[?]|1|ng/dL|SEMINAL FLUID|THERMAL IONIZATION MASS SPECTROMETRY|Y|Y|1|4|Visit_4|65|1|FOLLOW-UP|2020-08-22|65
e|IS|9eb6e591-d266-4e05-85b6-230e8a02d494|5|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|DPM|[?]|1|GPL U/mL|GASTRIC CONTENTS|LISSAMINE GREEN STAIN|||1|5|Visit_5|90|4|SCREENING|2020-09-16|90
e|IS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|nU/cL|[?]|1|umol/mg/min|REFLEX TEAR|SLOAN LETTER EYE CHART 100%|Y|Y|1|1|Visit_1|10|2|WASHOUT|2020-06-30|10
e|IS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|/HPF|[?]|1|nL|ISOLATE|MULTI-SLICE SPIRAL CT|Y||1|2|Visit_2|25|7|TREATMENT|2020-07-15|25
e|IS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mmol/g|[?]|1|K|PROSTATIC FLUID|MAMMOGRAPHY||Y|1|3|Visit_3|40|2|TREATMENT|2020-07-30|40
e|IS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|fmol/L|[?]|1|cm H2O|SERUM OR PLASMA|AUSCULTATION|||1|4|Visit_4|65|5|WASHOUT|2020-08-24|65
e|IS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|umol/L/sec|[?]|1|mmol/min/kPa/L|EPITHELIAL CELL|CELLULAR PROLIFERATION ASSAY|Y|Y|1|5|Visit_5|90|6|SCREENING|2020-09-18|90
e|IS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|U/m2|[?]|1|GPL U|URINE|SNP ARRAY|||1|1|Visit_1|10|2|FOLLOW-UP|2020-08-17|10
e|IS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|2|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|L/L|[?]|1|um2|INTERSTITIAL FLUID|DYNAMIC CONTRAST ENHANCED MRI|||1|2|Visit_2|25|5|TREATMENT|2020-09-01|25
e|IS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|10^9 organisms|[?]|1|cmol/L|DISCHARGE|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|Y|1|3|Visit_3|40|4|TREATMENT|2020-09-16|40
e|IS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|4|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/animal/day|[?]|1|10^9/dose|FLUID|DYNAMIC CONTRAST ENHANCED MRI|||1|4|Visit_4|65|3|SCREENING|2020-10-11|65
e|IS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|g/cage|[?]|1|Hounsfield Unit|CERUMEN|ENZYMATIC ULTRACENTRIFUGATION|||1|5|Visit_5|90|4|FOLLOW-UP|2020-11-05|90
e|IS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|1|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|/min|[?]|1|pmol/g|LAVAGE FLUID|TRANSTHORACIC ECHOCARDIOGRAPHY|||1|1|Visit_1|10|6|FOLLOW-UP|2021-01-19|10
e|IS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mEq|[?]|1|cal|GASTRIC CONTENTS|ENZYMATIC ULTRACENTRIFUGATION|||1|2|Visit_2|25|4|TREATMENT|2021-02-03|25
e|IS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|dpm/mL|[?]|1|10^9/g|SKELETAL MUSCLE TISSUE|HPLC/IEX|||1|3|Visit_3|40|5|TREATMENT|2021-02-18|40
e|IS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|4|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|/mm|[?]|1|mg/animal|PUS|LANDOLT RING|Y||1|4|Visit_4|65|6|TREATMENT|2021-03-15|65
e|IS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ng/L|[?]|1|um/day|PLEURAL FLUID|IVY INCISION METHOD|||1|5|Visit_5|90|6|TREATMENT|2021-04-09|90
e|IS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|1|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|fL|[?]|1|grain|SALIVA|MRS|||1|1|Visit_1|10|7|TREATMENT|2020-05-12|10
e|IS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|DNA copies/mL|[?]|1|bel|FLUID|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||1|2|Visit_2|25|3|SCREENING|2020-05-27|25
e|IS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|MBP|[?]|1|mmol/day|INTERSTITIAL FLUID|SINGLE-MOLECULE ARRAY|||1|3|Visit_3|40|1|TREATMENT|2020-06-11|40
e|IS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|pm|[?]|1|mmAL|DERMAL TISSUE|SINGLE-MOLECULE ARRAY||Y|1|4|Visit_4|65|7|SCREENING|2020-07-06|65
e|IS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|m/sec2|[?]|1|dpm/100mg|CAPILLARY BLOOD|OSCILLOMETRY|||1|5|Visit_5|90|3|TREATMENT|2020-07-31|90
e|IS|ba99022a-d398-4c60-828c-876f119459e1|1|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|10^9/L|[?]|1|SUPPOSITORY|ERYTHROCYTES|MANUAL COUNT|||1|1|Visit_1|10|7|SCREENING|2020-12-01|10
e|IS|ba99022a-d398-4c60-828c-876f119459e1|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|EID 50/mL|[?]|1|Pa|BASAL TEAR|SLIT LAMP||Y|1|2|Visit_2|25|2|SCREENING|2020-12-16|25
e|IS|ba99022a-d398-4c60-828c-876f119459e1|3|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|km/h|[?]|1|g/animal|CERUMEN|OBSERVATION||Y|1|3|Visit_3|40|2|WASHOUT|2020-12-31|40
e|IS|ba99022a-d398-4c60-828c-876f119459e1|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mm3/mm2/year|[?]|1|10^6/g|CORD SERUM|HPLC/IEX||Y|1|4|Visit_4|65|3|TREATMENT|2021-01-25|65
e|IS|ba99022a-d398-4c60-828c-876f119459e1|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|cm/s|[?]|1|mL/animal/day|URINE|ALCIAN BLUE STAIN|||1|5|Visit_5|90|6|FOLLOW-UP|2021-02-19|90
e|IS|d713869e-061c-4e95-8a50-da2e1ec47b3c|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^6 IU/mL|[?]|1|SACHET|LAVAGE FLUID|ANTIMICROBIAL COMBINATION TESTING|||1|1|Visit_1|10|1|WASHOUT|2020-06-06|10
e|IS|d713869e-061c-4e95-8a50-da2e1ec47b3c|2|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|AMPULE|[?]|1|10^7 PFU|EMESIS|DYNAMIC LIGHT SCATTERING|||1|2|Visit_2|25|5|WASHOUT|2020-06-21|25
e|IS|d713869e-061c-4e95-8a50-da2e1ec47b3c|3|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|Bq/ug|[?]|1|usec|CORD SERUM|MEDIASTINOSCOPY||Y|1|3|Visit_3|40|5|FOLLOW-UP|2020-07-06|40
e|IS|d713869e-061c-4e95-8a50-da2e1ec47b3c|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|L/h/m2|[?]|1|deg/s|PLEURAL FLUID|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y|1|4|Visit_4|65|2|TREATMENT|2020-07-31|65
e|IS|d713869e-061c-4e95-8a50-da2e1ec47b3c|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/cage|[?]|1|IU/g Hb|CEREBROSPINAL FLUID|IMMUNO-PET SCAN||Y|1|5|Visit_5|90|4|TREATMENT|2020-08-25|90
e|IS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|oz eq|[?]|1|BISCUIT|VITREOUS HUMOR|HPLC|||1|1|Visit_1|10|2|WASHOUT|2020-07-11|10
e|IS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|2|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|pkat/L|[?]|1|U/10^12 RBC|URINE SEDIMENT|PELLI-ROBSON EYE CHART|||1|2|Visit_2|25|7|FOLLOW-UP|2020-07-26|25
e|IS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|in|[?]|1|mol/L|BREAST MILK|COMPLEMENT FIXATION|||1|3|Visit_3|40|7|TREATMENT|2020-08-10|40
e|IS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|COAT|[?]|1|U/kg/h|REFLEX TEAR|IN VITRO GENE EXPRESSION ASSAY|||1|4|Visit_4|65|6|TREATMENT|2020-09-04|65
e|IS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|sec|[?]|1|mOsm/L|SEMEN|RADIATION DOSIMETRY|||1|5|Visit_5|90|6|TREATMENT|2020-09-29|90
e|IS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|V/sec|[?]|1|mU/g|AQUEOUS HUMOR|QUANTITATIVE COMPUTED TOMOGRAPHY||Y|1|1|Visit_1|10|7|TREATMENT|2021-01-01|10
e|IS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mg/m2/h|[?]|1|SYRINGE|KERATINOCYTE|FARNSWORTH-MUNSELL 100 HUE TEST|||1|2|Visit_2|25|1|WASHOUT|2021-01-16|25
e|IS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/dose|[?]|1|ECL unit|DERMAL TISSUE|CONTRAST ENHANCED SPIRAL CT SCAN|||1|3|Visit_3|40|5|WASHOUT|2021-01-31|40
e|IS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/m2/h|[?]|1|mg/kg/day|CARDIAC MUSCLE TISSUE|WEBER GREEN STAIN|Y||1|4|Visit_4|65|5|TREATMENT|2021-02-25|65
e|IS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mOsm/L|[?]|1|QUANTITY SUFFICIENT|TISSUE|SCINTIGRAPHY|||1|5|Visit_5|90|6|TREATMENT|2021-03-22|90
e|IS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|DRINK|[?]|1|mEq/uL|ISOLATE|LISSAMINE GREEN STAIN||Y|1|1|Visit_1|10|6|TREATMENT|2020-06-22|10
e|IS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ppth|[?]|1|rpm|ARTERIAL CORD BLOOD|IMMUNORADIOMETRIC ASSAY|||1|2|Visit_2|25|4|TREATMENT|2020-07-07|25
e|IS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|CAN|[?]|1|pg/dL|LEUKOCYTE|SLOAN LETTER EYE CHART 1.25%|Y||1|3|Visit_3|40|4|TREATMENT|2020-07-22|40
e|IS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Ci/g|[?]|1|in2|LAVAGE FLUID|SPECT/CT SCAN|||1|4|Visit_4|65|4|FOLLOW-UP|2020-08-16|65
e|IS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|U/dL|[?]|1|ELISA unit/mL|LYMPH|PANENDOSCOPY|||1|5|Visit_5|90|7|TREATMENT|2020-09-10|90
e|IS|8a2147b1-2deb-410e-a298-d028a5efc555|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|Bq/g|[?]|1|TUBE|SPUTUM|FLUORESCENT IMMUNOASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-10-30|10
e|IS|8a2147b1-2deb-410e-a298-d028a5efc555|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|ug/m2/h|[?]|1|Roentgen|MENSTRUAL BLOOD|CELL BASED BIOASSAY||Y|1|2|Visit_2|25|3|TREATMENT|2020-11-14|25
e|IS|8a2147b1-2deb-410e-a298-d028a5efc555|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/sec/1.73m2|[?]|1|mm/min|CAPILLARY BLOOD|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||1|3|Visit_3|40|7|SCREENING|2020-11-29|40
e|IS|8a2147b1-2deb-410e-a298-d028a5efc555|4|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|MONTHS|[?]|1|Bq/L|CALCULUS|CELLULOSE TAPE|||1|4|Visit_4|65|3|SCREENING|2020-12-24|65
e|IS|8a2147b1-2deb-410e-a298-d028a5efc555|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^6 organisms/g|[?]|1|umol/kg/min|BILE|IMMUNOTURBIDIMETRY|Y||1|5|Visit_5|90|3|WASHOUT|2021-01-18|90
e|IS|033db3bf-17fb-4872-afdb-1eea3dac6d85|1|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|g/m2|[?]|1|ug/kg/h|EPIDERMAL TISSUE|ELLA|||1|1|Visit_1|10|4|TREATMENT|2020-07-05|10
e|IS|033db3bf-17fb-4872-afdb-1eea3dac6d85|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|FEU|[?]|1|kcal/day|SPUTUM|WHOLE GENOME SEQUENCING|||1|2|Visit_2|25|7|SCREENING|2020-07-20|25
e|IS|033db3bf-17fb-4872-afdb-1eea3dac6d85|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|mL/breath|[?]|1|10^7 CFU|SWABBED MATERIAL|PANENDOSCOPY|||1|3|Visit_3|40|6|TREATMENT|2020-08-04|40
e|IS|033db3bf-17fb-4872-afdb-1eea3dac6d85|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|/VF|[?]|1|ug/h|PLATELET POOR PLASMA|CRYOSCOPY|Y||1|4|Visit_4|65|1|TREATMENT|2020-08-29|65
e|IS|033db3bf-17fb-4872-afdb-1eea3dac6d85|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/beat|[?]|1|10^9 organisms/g|SKELETAL MUSCLE TISSUE|FARR ASSAY|Y||1|5|Visit_5|90|3|WASHOUT|2020-09-23|90
e|IS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|kg/cm|[?]|1|Weber|CORD BLOOD|HPLC/IEX|||1|1|Visit_1|10|6|TREATMENT|2020-06-19|10
e|IS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|KALLIKREIN INHIBITOR UNIT|[?]|1|TABLET|URINE SEDIMENT|PET/SPECT SCAN|||1|2|Visit_2|25|3|SCREENING|2020-07-04|25
e|IS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|3|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|POUCH|[?]|1|genEq/mL|PROSTATIC FLUID|FLAME PHOTOMETRY|Y||1|3|Visit_3|40|7|SCREENING|2020-07-19|40
e|IS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|4|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|DRINK|[?]|1|mN|BUFFY COAT|SIZE EXCLUSION CHROMATOGRAPHY|Y||1|4|Visit_4|65|4|TREATMENT|2020-08-13|65
e|IS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|/VF|[?]|1|uU/dL|PLASMA ULTRAFILTRATE|PULSE OXIMETRY|||1|5|Visit_5|90|4|FOLLOW-UP|2020-09-07|90
e|IS|8dd493b7-a892-4cab-8f69-701471c51d99|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|EID 50/dose|[?]|1|titer|CELL PELLET|CELL OF ORIGIN ASSAY|||1|1|Visit_1|10|2|TREATMENT|2021-01-12|10
e|IS|8dd493b7-a892-4cab-8f69-701471c51d99|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|BAU|[?]|1|BU|SERUM|CONTRAST ENHANCED SPIRAL CT SCAN|||1|2|Visit_2|25|1|TREATMENT|2021-01-27|25
e|IS|8dd493b7-a892-4cab-8f69-701471c51d99|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|SPRAY|[?]|1|Bq/ug|SERUM OR PLASMA OR BLOOD|IMMUNOFLUORESCENT STAIN|||1|3|Visit_3|40|7|TREATMENT|2021-02-11|40
e|IS|8dd493b7-a892-4cab-8f69-701471c51d99|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Absorbance U/min|[?]|1|10^9 CFU/mL|GASTRIC FLUID|MRI|||1|4|Visit_4|65|1|TREATMENT|2021-03-08|65
e|IS|8dd493b7-a892-4cab-8f69-701471c51d99|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|U/cL|[?]|1|MPL U|BONE MARROW MONONUCLEAR CELL|AGAR PROPORTION||Y|1|5|Visit_5|90|3|SCREENING|2021-04-02|90
e|IS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|1|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|copies/ug|[?]|1|BU/mL|EXPIRED AIR|INDIA INK STAIN|||1|1|Visit_1|10|2|TREATMENT|2020-11-07|10
e|IS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/cage/wk|[?]|1|mmol|INFRANATANT, PLASMA|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y||1|2|Visit_2|25|5|FOLLOW-UP|2020-11-22|25
e|IS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|PIXELS/in|[?]|1|10^12 IU/L|PLATELET POOR PLASMA|IMMUNOFLUORESCENT STAIN|||1|3|Visit_3|40|2|TREATMENT|2020-12-07|40
e|IS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|10^8 PFU|[?]|1|10^7 TCID 50/dose|ALVEOLAR AIR|COULOMETRIC TITRATION||Y|1|4|Visit_4|65|4|WASHOUT|2021-01-01|65
e|IS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|pmol/L|[?]|1|mL/g/day|INTERSTITIAL FLUID|KINETIC CHROMOGENIC ASSAY|Y||1|5|Visit_5|90|7|TREATMENT|2021-01-26|90
e|IS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/kg/day|[?]|1|g/cage|VENOUS PLASMA|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y||1|1|Visit_1|10|4|WASHOUT|2020-09-04|10
e|IS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mL/cage/day|[?]|1|VIRTUAL PIXEL|MONOCYTE|PAP STAIN|Y||1|2|Visit_2|25|4|WASHOUT|2020-09-19|25
e|IS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ug/kg/day|[?]|1|/ms|VENOUS PLASMA|ICC|||1|3|Visit_3|40|2|SCREENING|2020-10-04|40
e|IS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|nmol/L|[?]|1|CIGARETTE|EXUDATE|PERIODIC ACID SCHIFF STAIN|Y||1|4|Visit_4|65|6|WASHOUT|2020-10-29|65
e|IS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|5|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|kg/m2|[?]|1|PFU|SEBUM|SIZE EXCLUSION CHROMATOGRAPHY|||1|5|Visit_5|90|7|TREATMENT|2020-11-23|90
e|IS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|g/U|[?]|1|umol/mg/min|MONOCYTE|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||1|1|Visit_1|10|4|TREATMENT|2020-11-20|10
e|IS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|2|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mmol/day|[?]|1|cP|SOFT TISSUE|PEAK FLOWMETRY|||1|2|Visit_2|25|1|SCREENING|2020-12-05|25
e|IS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|3|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|g/g|[?]|1|tsp eq|LOCHIA|JAFFE REACTION||Y|1|3|Visit_3|40|1|FOLLOW-UP|2020-12-20|40
e|IS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|4|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|SCOOPFUL|[?]|1|dpm/mg|CELL PELLET|IN SITU HYBRIDIZATION|||1|4|Visit_4|65|1|WASHOUT|2021-01-14|65
e|IS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|mL/kg|[?]|1|mL/cage|SERUM OR PLASMA OR BLOOD|TONOMETRY|||1|5|Visit_5|90|3|WASHOUT|2021-02-08|90
e|IS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|CCID 50/dose|[?]|1|ng/day|CERVICOVAGINAL SECRETION|PHYSICAL EXAMINATION|Y||1|1|Visit_1|10|4|TREATMENT|2021-01-05|10
e|IS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^4/L|[?]|1|m3|PROSTATIC FLUID|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||1|2|Visit_2|25|2|FOLLOW-UP|2021-01-20|25
e|IS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|3|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|mkat|[?]|1|mOsm/kg|BUFFY COAT|ULTRASONOGRAPHIC ELASTOGRAPHY|||1|3|Visit_3|40|1|SCREENING|2021-02-04|40
e|IS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|Henry|[?]|1|DNA copies/mL|ENDOTRACHEAL FLUID|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y||1|4|Visit_4|65|3|TREATMENT|2021-03-01|65
e|IS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|aMFI|[?]|1|ug/dose|MIXED VENOUS BLOOD|ISHIHARA COLOR PLATES|||1|5|Visit_5|90|7|FOLLOW-UP|2021-03-26|90
e|IS|df041193-ee4e-4835-8db9-5be9b832ded0|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|V/sec|[?]|1|mm2|PROSTATIC FLUID|TRYPAN BLUE STAIN|Y||1|1|Visit_1|10|4|SCREENING|2020-11-25|10
e|IS|df041193-ee4e-4835-8db9-5be9b832ded0|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|vg/dose|[?]|1|PACKET|KERATINOCYTE|GEL ELECTROPHORESIS|Y||1|2|Visit_2|25|2|TREATMENT|2020-12-10|25
e|IS|df041193-ee4e-4835-8db9-5be9b832ded0|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|/4.0 mL|[?]|1|nkat|EXHALED BREATH CONDENSATE|FLAME PHOTOMETRY|||1|3|Visit_3|40|3|TREATMENT|2020-12-25|40
e|IS|df041193-ee4e-4835-8db9-5be9b832ded0|4|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|L/h/m2|[?]|1|MET|CAPILLARY PLASMA|IMMUNOASSAY||Y|1|4|Visit_4|65|4|TREATMENT|2021-01-19|65
e|IS|df041193-ee4e-4835-8db9-5be9b832ded0|5|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|umol/L/sec|[?]|1|AgU/mL|EXUDATE|NEPHELOMETRY||Y|1|5|Visit_5|90|6|TREATMENT|2021-02-13|90
e|IS|e41a4505-a5aa-4cac-895b-04fe85737ca9|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|ug/day|[?]|1|g/mol|AMNIOTIC FLUID|COMPLEMENT FIXATION|||1|1|Visit_1|10|3|TREATMENT|2021-01-13|10
e|IS|e41a4505-a5aa-4cac-895b-04fe85737ca9|2|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|JDF Unit|[?]|1|/7.5 mL|SYNOVIAL FLUID|SIZE EXCLUSION CHROMATOGRAPHY|Y||1|2|Visit_2|25|6|TREATMENT|2021-01-28|25
e|IS|e41a4505-a5aa-4cac-895b-04fe85737ca9|3|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|GBq/ug|[?]|1|L|PLATELET POOR PLASMA|TARGETED GENOME SEQUENCING|Y||1|3|Visit_3|40|3|WASHOUT|2021-02-12|40
e|IS|e41a4505-a5aa-4cac-895b-04fe85737ca9|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mJoule/cm2|[?]|1|usec|PROSTATIC FLUID|LEAD CITRATE STAIN||Y|1|4|Visit_4|65|7|TREATMENT|2021-03-09|65
e|IS|e41a4505-a5aa-4cac-895b-04fe85737ca9|5|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nmol/mL/min|[?]|1|VIRTUAL PIXEL|DERMAL TISSUE|CALCOFLUOR WHITE STAIN|Y||1|5|Visit_5|90|1|TREATMENT|2021-04-03|90
e|IS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|1|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|/sec|[?]|1|cpm|SUPERNATANT, SERUM|ANALYTICAL ULTRACENTRIFUGATION|||1|1|Visit_1|10|6|TREATMENT|2021-01-15|10
e|IS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|2|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|cm H2O|[?]|1|%(w/w)|MECONIUM|MEDIASTINOSCOPY|||1|2|Visit_2|25|7|TREATMENT|2021-01-30|25
e|IS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|3|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|mg/animal|[?]|1|LB|SPUTUM|MICRODENSITOMETRY|||1|3|Visit_3|40|7|TREATMENT|2021-02-14|40
e|IS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|4|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|NEBULE|[?]|1|umol/kg/min|DERMAL TISSUE|CALCOFLUOR WHITE STAIN||Y|1|4|Visit_4|65|7|FOLLOW-UP|2021-03-11|65
e|IS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|5|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|ppth|[?]|1|eq|LYSATE|GRAM STAIN||Y|1|5|Visit_5|90|6|FOLLOW-UP|2021-04-05|90
e|IS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|1|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|Ci/uL|[?]|1|mmHg/sec|SALIVA|SCINTIGRAPHY||Y|1|1|Visit_1|10|4|WASHOUT|2020-12-12|10
e|IS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|mL/g/day|[?]|1|s/h|CIRCULATING TUMOR CELL|MULTI-SLICE SPIRAL CT|||1|2|Visit_2|25|3|SCREENING|2020-12-27|25
e|IS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|Roentgen|[?]|1|cGy|EXUDATE|HANSEL STAIN|||1|3|Visit_3|40|3|TREATMENT|2021-01-11|40
e|IS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|4|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|cal|[?]|1|USP U|DIALYSIS FLUID, PERITONEAL|CISH|Y|Y|1|4|Visit_4|65|3|TREATMENT|2021-02-05|65
e|IS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|L/L|[?]|1|Coulomb|PLATELET RICH PLASMA|FUNDUS PHOTOGRAPHY|||1|5|Visit_5|90|7|SCREENING|2021-03-02|90
e|IS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|ppb|[?]|1|umol/mol|PLATELET POOR PLASMA|DIGITAL PCR ARRAY|Y|Y|1|1|Visit_1|10|1|TREATMENT|2021-01-25|10
e|IS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|gtt|[?]|1|10^3 CFU/mL|TISSUE|WHOLE GENOME SEQUENCING||Y|1|2|Visit_2|25|7|FOLLOW-UP|2021-02-09|25
e|IS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|deg/mm|[?]|1|titer|PLATELET POOR PLASMA|CALCOFLUOR WHITE STAIN|Y||1|3|Visit_3|40|6|SCREENING|2021-02-24|40
e|IS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|gtt|[?]|1|/2500 WBC|REFLEX TEAR|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||1|4|Visit_4|65|2|TREATMENT|2021-03-21|65
e|IS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|5|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|cmHg|[?]|1|/month|PLATELET POOR PLASMA|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|||1|5|Visit_5|90|2|WASHOUT|2021-04-15|90
e|IS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|1|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|g/kg|[?]|1|%/min|VENOUS PLASMA|ORCHIDOMETERY||Y|1|1|Visit_1|10|5|TREATMENT|2020-05-20|10
e|IS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|2|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|eq|[?]|1|RATIO|EMESIS|MANUAL CLOT DETECTION|Y|Y|1|2|Visit_2|25|4|SCREENING|2020-06-04|25
e|IS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|3|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mL/h|[?]|1|MPS U|SYNOVIAL FLUID|RAJI CELL RIA|||1|3|Visit_3|40|2|TREATMENT|2020-06-19|40
e|IS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|L/s/kPa|[?]|1|g/cage/wk|LYSATE|ELISPOT|||1|4|Visit_4|65|1|SCREENING|2020-07-14|65
e|IS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|5|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|Gauss|[?]|1|IU/mg|PLASMA|ELISPOT||Y|1|5|Visit_5|90|2|TREATMENT|2020-08-08|90
e|IS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|STRIP|[?]|1|um/day|INFRANATANT, SERUM|COULOMETRIC TITRATION|||1|1|Visit_1|10|5|FOLLOW-UP|2020-09-03|10
e|IS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|2|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|BISCUIT|[?]|1|dpm/mL|GASTRIC FLUID|PELLI-ROBSON EYE CHART|||1|2|Visit_2|25|3|FOLLOW-UP|2020-09-18|25
e|IS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|3|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|mAmp|[?]|1|h/wk|NAIL|PET/SPECT SCAN|||1|3|Visit_3|40|7|TREATMENT|2020-10-03|40
e|IS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|4|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|cd*s/m2|[?]|1|uU/L|SKIN TISSUE|ENZYMATIC ULTRACENTRIFUGATION|Y||1|4|Visit_4|65|2|FOLLOW-UP|2020-10-28|65
e|IS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|5|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|hPa|[?]|1|/10^4|SEMINAL FLUID|MAMMOGRAPHY|||1|5|Visit_5|90|5|TREATMENT|2020-11-22|90
e|IS|e515b916-5d28-4236-8835-2ff43b498ab3|1|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|FIU|[?]|1|mOsm|INFRANATANT, PLEURAL FLUID|WRIGHT STAIN|||1|1|Visit_1|10|6|TREATMENT|2020-05-23|10
e|IS|e515b916-5d28-4236-8835-2ff43b498ab3|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|h/wk|[?]|1|/min|MUCUS|PAP STAIN|||1|2|Visit_2|25|2|TREATMENT|2020-06-07|25
e|IS|e515b916-5d28-4236-8835-2ff43b498ab3|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|pmol/10^10 cells|[?]|1|Log10 ELISA unit|DISCHARGE|ELECTROPHORESIS||Y|1|3|Visit_3|40|1|SCREENING|2020-06-22|40
e|IS|e515b916-5d28-4236-8835-2ff43b498ab3|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|nmol BCE/L|[?]|1|MASK|SMEGMA|ENDPOINT DILUTION ASSAY|Y||1|4|Visit_4|65|7|TREATMENT|2020-07-17|65
e|IS|e515b916-5d28-4236-8835-2ff43b498ab3|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|log10 TCID 50/dose|[?]|1|DPM|DERMAL TISSUE|FUNDUS PHOTOGRAPHY||Y|1|5|Visit_5|90|1|TREATMENT|2020-08-11|90
e|IS|158af2a8-d447-45e5-8c58-3b950f1bd889|1|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|g/day|[?]|1|SFC/10^6 PBMC|EMOTIONAL TEAR|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||1|1|Visit_1|10|7|TREATMENT|2020-05-30|10
e|IS|158af2a8-d447-45e5-8c58-3b950f1bd889|2|H3IGGASC|H3 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|dL|[?]|1|um/s|INFRANATANT, PLEURAL FLUID|LAPAROSCOPY|||1|2|Visit_2|25|1|TREATMENT|2020-06-14|25
e|IS|158af2a8-d447-45e5-8c58-3b950f1bd889|3|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|mg/kg/dose|[?]|1|Absorbance U/mL|SUPERNATANT, SERUM OR PLASMA|NO INFORMATION|Y||1|3|Visit_3|40|3|WASHOUT|2020-06-29|40
e|IS|158af2a8-d447-45e5-8c58-3b950f1bd889|4|ADA_NAB|Neutralizing Binding Antidrug Antibody|SEROLOGY|[?]|%|[?]|1|mU/g|SEMEN|PLETHYSMOGRAPHY|||1|4|Visit_4|65|7|FOLLOW-UP|2020-07-24|65
e|IS|158af2a8-d447-45e5-8c58-3b950f1bd889|5|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|fraction of 1|[?]|1|mmHg/sec|SALIVA|AUDIOMETRY|||1|5|Visit_5|90|5|TREATMENT|2020-08-18|90
e|IS|e9a930d5-ca57-4069-8251-c164273df082|1|HIV1SR|HIV-1 Seroreactivity|SEROLOGY|[?]|V/sec|[?]|1|pmol/L/h|PERIPHERAL BLOOD MONONUCLEAR CELL|MECHANICAL CLOT DETECTION||Y|1|1|Visit_1|10|4|TREATMENT|2020-05-21|10
e|IS|e9a930d5-ca57-4069-8251-c164273df082|2|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|mg/g/h|[?]|1|mL/kg/day|SEBUM|CELLULAR PROLIFERATION ASSAY|Y||1|2|Visit_2|25|2|SCREENING|2020-06-05|25
e|IS|e9a930d5-ca57-4069-8251-c164273df082|3|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|nCi|[?]|1|/HPF|BREAST MILK|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||1|3|Visit_3|40|2|FOLLOW-UP|2020-06-20|40
e|IS|e9a930d5-ca57-4069-8251-c164273df082|4|EVIGGASC|EBOV Specific IgG AB Secreting Cells|SEROLOGY|[?]|rpm|[?]|1|U/kg/h|PUS|HPLC-UV|||1|4|Visit_4|65|3|WASHOUT|2020-07-15|65
e|IS|e9a930d5-ca57-4069-8251-c164273df082|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mOsm|[?]|1|CCID 50/mL|VENOUS BLOOD|EEG|Y|Y|1|5|Visit_5|90|1|SCREENING|2020-08-09|90
e|IS|e654e37e-1c95-4f25-83b1-9233186626c6|1|TLYMPIDX|T-Lymphocyte Proliferation Index|SEROLOGY|[?]|10^6 copies/mL|[?]|1|mPa|COLOSTRUM|ATOMIC ABSORPTION SPECTROMETRY|Y||1|1|Visit_1|10|5|TREATMENT|2020-08-04|10
e|IS|e654e37e-1c95-4f25-83b1-9233186626c6|2|H1IGGASC|H1 Specific IgG Antibody Secreting Cells|SEROLOGY|[?]|g/cage/wk|[?]|1|MET|CARDIAC MUSCLE TISSUE|AUDIOMETRY|||1|2|Visit_2|25|1|FOLLOW-UP|2020-08-19|25
e|IS|e654e37e-1c95-4f25-83b1-9233186626c6|3|EVIGMASC|EBOV Specific IgM AB Secreting Cells|SEROLOGY|[?]|cs|[?]|1|log EID 50/dose|SUPERNATANT, PLASMA|HILLMEN COLOR CHART|||1|3|Visit_3|40|2|SCREENING|2020-09-03|40
e|IS|e654e37e-1c95-4f25-83b1-9233186626c6|4|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|BOTTLE|[?]|1|U|MIXED VENOUS BLOOD|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||1|4|Visit_4|65|6|TREATMENT|2020-09-28|65
e|IS|e654e37e-1c95-4f25-83b1-9233186626c6|5|ADA_NX|Neutraliz Cross-React Bind Antidrug AB|SEROLOGY|[?]|mol/day|[?]|1|NEEDLE GAUGE|GASTRIC CONTENTS|GC/MS||Y|1|5|Visit_5|90|6|TREATMENT|2020-10-23|90
e|IS|808ee0ac-e668-4e8e-aa0a-889476cbe631|1|ADA_BAB|Binding Antidrug Antibody|SEROLOGY|[?]|10^6 organisms/mg|[?]|1|mg/kg/dose|MIXED VENOUS BLOOD|PERCUSSION||Y|1|1|Visit_1|10|3|WASHOUT|2020-06-19|10
e|IS|808ee0ac-e668-4e8e-aa0a-889476cbe631|2|HIV2SR|HIV-2 Seroreactivity|SEROLOGY|[?]|10^9/L|[?]|1|copies/mL|ARTERIAL BLOOD|CYSTOMETRY|Y||1|2|Visit_2|25|5|TREATMENT|2020-07-04|25
e|IS|808ee0ac-e668-4e8e-aa0a-889476cbe631|3|TIGGASC|Total IgG Antibody Secreting Cells|SEROLOGY|[?]|USP U|[?]|1|oz|SEMEN|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y||1|3|Visit_3|40|2|TREATMENT|2020-07-19|40
e|IS|808ee0ac-e668-4e8e-aa0a-889476cbe631|4|IGMABSC|IgM Antibody Secreting Cells|SEROLOGY|[?]|deg2|[?]|1|fg|ABSCESS FLUID|LIGHT SCATTERING SPECTROSCOPY|Y||1|4|Visit_4|65|3|TREATMENT|2020-08-13|65
e|IS|808ee0ac-e668-4e8e-aa0a-889476cbe631|5|ADA_X|Cross-Reactive Binding Antidrug Antibody|SEROLOGY|[?]|10^9 organisms|[?]|1|lm|SALIVA|HILLMEN COLOR CHART|||1|5|Visit_5|90|2|WASHOUT|2020-09-07|90
